PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Beecham, L				Beecham, L			Junior doctors call for ballot on industrial action	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					62	62						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617549				2022-12-28	WOS:000084621600060
J	Roggla, G; Moser, B; Roggla, M				Roggla, G; Moser, B; Roggla, M			Effect of temazepam on ventilatory response at moderate altitude	BRITISH MEDICAL JOURNAL			English	Letter							TRIAL		Municipal Hosp Neunkirchen, Dept Internal Med, Neunkirchen, Austria; Univ Vienna, Dept Emergency Med, Vienna, Austria	University of Vienna	Roggla, G (corresponding author), Municipal Hosp Neunkirchen, Dept Internal Med, Neunkirchen, Austria.		Moser, Berthold/AAA-4849-2021	Moser, Berthold/0000-0001-8200-1194				Dubowitz G, 1998, BRIT MED J, V316, P587, DOI 10.1136/bmj.316.7131.587; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; ROGGLA G, 1994, WIEN KLIN WOCHENSCHR, V106, P649; ROGGLA G, 1995, ANN INTERN MED, V122, P925; SPIRO SG, 1976, BRIT J DIS CHEST, V70, P263, DOI 10.1016/0007-0971(76)90042-5	5	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					56	56		10.1136/bmj.320.7226.56	http://dx.doi.org/10.1136/bmj.320.7226.56			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617541				2022-12-28	WOS:000084621600040
J	Stewart, M				Stewart, M			Paediatrics on the peace line	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1648	1648		10.1136/bmj.319.7225.1648	http://dx.doi.org/10.1136/bmj.319.7225.1648			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600981	Green Published			2022-12-28	WOS:000084562600032
J	Sachdev, S; Buragohain, C; Vojta, M				Sachdev, S; Buragohain, C; Vojta, M			Quantum impurity in a nearly critical two-dimensional antiferromagnet	SCIENCE			English	Article							SPIN-PEIERLS CUPRATE; SI-DOPED CUGEO3; NONMAGNETIC IMPURITIES; KONDO MODEL; ZN; TRANSITION; STATE; SUBSTITUTION; SYSTEMS; POINTS	The spin dynamics of an arbitrary Localized impurity in an insulating two-dimensional antiferromagnet, across the host transition from a paramagnet with a spin gap to a Neel state, is described. The impurity spin susceptibility has a Curie-like divergence at the quantum-critical coupling, but with a universal effective spin that is neither an integer nor a half-odd integer. In the Neel state, the transverse impurity susceptibility is a universal number divided by the host spin stiffness (which determines the energy cost to slow twists in the orientation of the Neel order). These and numerous other results for the thermodynamics, Knight shift, and magnon damping have important applications in experiments on Layered transition metal oxides.	Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Sachdev, S (corresponding author), Yale Univ, Dept Phys, POB 208120, New Haven, CT 06520 USA.		Sachdev, Subir/Y-3037-2019; Sachdev, Subir/A-8781-2013; Vojta, Matthias/B-2298-2012	Sachdev, Subir/0000-0002-2432-7070; Sachdev, Subir/0000-0002-2432-7070; Vojta, Matthias/0000-0002-5740-831X				AFFLECK I, 1991, NUCL PHYS B, V360, P641, DOI 10.1016/0550-3213(91)90419-X; AFFLECK I, DMR9623181 NSF; ALLOUL H, 1991, PHYS REV LETT, V67, P3140, DOI 10.1103/PhysRevLett.67.3140; ANDERSON PW, 1961, PHYS REV, V124, P41, DOI 10.1103/PhysRev.124.41; Barzykin V, 1998, PHYS REV B, V57, P432, DOI 10.1103/PhysRevB.57.432; BREZIN E, 1976, PHASE TRANSITIONS CR, V6, P127; CARDY J, 1996, SCALING RENORMALIZAT, pCH7; CHUBUKOV AV, 1993, PHYS REV LETT, V71, P169, DOI 10.1103/PhysRevLett.71.169; Dagotto E, 1996, SCIENCE, V271, P618, DOI 10.1126/science.271.5249.618; Diehl H. W., 1986, Phase transition and critical phenomena. Vol.10, P75; DIEHL HW, 1981, Z PHYS B CON MAT, V42, P65, DOI 10.1007/BF01298293; FINKELSTEIN AM, 1990, PHYSICA C, V168, P370, DOI 10.1016/0921-4534(90)90532-J; Fong HF, 1999, PHYS REV LETT, V82, P1939, DOI 10.1103/PhysRevLett.82.1939; HASE M, 1993, PHYS REV LETT, V71, P4059, DOI 10.1103/PhysRevLett.71.4059; Imada M, 1997, J PHYS SOC JPN, V66, P568, DOI 10.1143/JPSJ.66.568; KATOH N, 1994, J PHYS SOC JPN, V63, P4529, DOI 10.1143/JPSJ.63.4529; Kojima KM, 1997, PHYS REV LETT, V79, P503, DOI 10.1103/PhysRevLett.79.503; MAHAJAN AV, 1994, PHYS REV LETT, V72, P3100, DOI 10.1103/PhysRevLett.72.3100; Masuda T, 1998, PHYS REV LETT, V80, P4566, DOI 10.1103/PhysRevLett.80.4566; NOZIERES P, 1980, J PHYS-PARIS, V41, P193, DOI 10.1051/jphys:01980004103019300; OSEROFF SB, 1995, PHYS REV LETT, V74, P1450, DOI 10.1103/PhysRevLett.74.1450; Parcollet O, 1998, PHYS REV B, V58, P3794, DOI 10.1103/PhysRevB.58.3794; READ N, 1991, PHYS REV LETT, V66, P1773, DOI 10.1103/PhysRevLett.66.1773; READ N, 1989, PHYS REV LETT, V62, P1694, DOI 10.1103/PhysRevLett.62.1694; REGNAULT LP, 1995, EUROPHYS LETT, V32, P579, DOI 10.1209/0295-5075/32/7/007; Sachdev S, 1997, PHYS REV B, V55, P142, DOI 10.1103/PhysRevB.55.142; Sachdev S, 1999, PHYS WORLD, V12, P33; SACHDEV S, 1993, PHYS REV LETT, V70, P3339, DOI 10.1103/PhysRevLett.70.3339; Sachdev S., 1999, QUANTUM PHASE TRANSI; Sandvik AW, 1997, PHYS REV B, V56, P11701, DOI 10.1103/PhysRevB.56.11701; Smith JL, 1999, EUROPHYS LETT, V45, P228, DOI 10.1209/epl/i1999-00151-4; Tworzydlo J, 1999, PHYS REV B, V59, P115, DOI 10.1103/PhysRevB.59.115; Uchiyama Y, 1999, PHYS REV LETT, V83, P632, DOI 10.1103/PhysRevLett.83.632	33	146	146	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2479	2482		10.1126/science.286.5449.2479	http://dx.doi.org/10.1126/science.286.5449.2479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617456	Green Submitted			2022-12-28	WOS:000084429700039
J	Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD				Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD			The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C-elegans	CELL			English	Article							RECEPTOR TYROSINE KINASES; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE LIGANDS; NERVOUS-SYSTEM; CELL LINEAGE; ATTACHMENT; ZEBRAFISH; FAMILY; EXPRESSION; HYPODERMIS	The Eph receptor VAB-1 is required in neurons for epidermal morphogenesis during C. elegans embryogenesis. Two models were proposed for the nonautonomous role of VAB-1: neuronal VAB-1 might signal directly to epidermis, or VAB-1 signaling between neurons might be required for epidermal development. We show that the ephrin VAB-2 (also known as EFN-1) is a ligand for VAB-1 and can function in neurons to regulate epidermal morphogenesis. In the absence of VAB-1 signaling, ephrin-expressing neurons are disorganized. vab-2/efn-1 mutations synergize with vab-1 kinase alleles, suggesting that VAB-2/EFN-1 may partly function in a kinase-independent VAB-1 pathway. Our data indicate that ephrin signaling between neurons is required nonautonomously for epidermal morphogenesis in C. elegans.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537; Chin-Sang, Ian/0000-0001-7480-9775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araujo M, 1998, DEVELOPMENT, V125, P4195; BARD JB, 1992, MORPHOGENESIS; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cerretti DP, 1998, GENOMICS, V47, P131, DOI 10.1006/geno.1997.5088; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Conway G, 1997, P NATL ACAD SCI USA, V94, P3082, DOI 10.1073/pnas.94.7.3082; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GUARENTE L, 1993, TRENDS GENET, V9, P395; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Hodgkin Jonathan, 1997, V33, P881; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Kane DA, 1996, DEVELOPMENT, V123, P47; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; MADURO M, 1995, GENETICS, V141, P977; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452	46	125	131	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					781	790		10.1016/S0092-8674(00)81675-X	http://dx.doi.org/10.1016/S0092-8674(00)81675-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619431	Bronze			2022-12-28	WOS:000084488200011
J	Charney, P; Walsh, J; Nattinger, AB				Charney, P; Walsh, J; Nattinger, AB			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Review							BREAST-CANCER; TAMOXIFEN; TRIAL		Jacobi Med Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Bronx, NY 10461 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; Medical College of Wisconsin	Charney, P (corresponding author), Jacobi Med Ctr, Dept Med, 1400 Pelham Pkwy S, Bronx, NY 10461 USA.			Nattinger, Ann/0000-0002-8189-3300				Altkorn D, 1999, ANN INTERN MED, V131, P199, DOI 10.7326/0003-4819-131-3-199908030-00007; Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776; Powles T, 1998, LANCET, V352, P98; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Veronesi U, 1998, LANCET, V352, P93	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					952	958		10.7326/0003-4819-131-12-199912210-00008	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610647				2022-12-28	WOS:000084374400007
J	Borgstein, J				Borgstein, J			The end of the clinical anecdote	LANCET			English	Editorial Material											Borgstein, J (corresponding author), Calle Hercules 9,Col Credito Constructor,Del Beni, Mexico City 03940, DF, Mexico.								0	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2151	2152		10.1016/S0140-6736(99)08445-7	http://dx.doi.org/10.1016/S0140-6736(99)08445-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609833				2022-12-28	WOS:000084318200044
J	Gurdon, JB; Colman, A				Gurdon, JB; Colman, A			The future of cloning	NATURE			English	Editorial Material							NUCLEAR TRANSPLANTATION; CELLS; MESODERM; XENOPUS; OOCYTES; MICE		Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; PPL Therapeut, Roslin Inst, Edinburgh EH25 9PP, Midlothian, Scotland	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Gurdon, JB (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			GURDON, JOHN/0000-0002-5621-3799				Ashworth D, 1998, NATURE, V394, P329, DOI 10.1038/28521; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BLASCO MA, 1997, CELL, V91, P24; BRIGGS ROBERT, 1957, J MORPH, V100, P269, DOI 10.1002/jmor.1051000204; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Burley J, 1999, J MED ETHICS, V25, P108, DOI 10.1136/jme.25.2.108; Burley J, 1999, SEMIN CELL DEV BIOL, V10, P287, DOI 10.1006/scdb.1999.0313; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; Chan APY, 1996, INT J DEV BIOL, V40, P441; DEROBERTIS EM, 1977, J EMBRYOL EXP MORPH, V40, P199; DIBERARDINO MA, 1983, SCIENCE, V219, P862, DOI 10.1126/science.6600520; Dominko T, 1999, BIOL REPROD, V60, P1496, DOI 10.1095/biolreprod60.6.1496; ELSDALE TR, 1960, J EMBRYOL EXP MORPH, V8, P437; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1975, J EMBRYOL EXP MORPH, V34, P93; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; GURDON JB, 1966, NATURE, V210, P1240, DOI 10.1038/2101240a0; GURDON JB, 1977, PROC R SOC SER B-BIO, V198, P211, DOI 10.1098/rspb.1977.0095; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; SIGNER E, 1995, NATURE, V394, P329; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Stennard F, 1997, CURR OPIN GENET DEV, V7, P620, DOI 10.1016/S0959-437X(97)80009-3; SUN FZ, 1995, CURR TOP DEV BIOL, V30, P145; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0	34	87	98	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					743	746		10.1038/45429	http://dx.doi.org/10.1038/45429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617195				2022-12-28	WOS:000084330500042
J	Tonks, L				Tonks, L			Registering clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNPUBLISHED TRIALS; PUBLICATION BIAS; AMNESTY					atonks@bmj.com						Blum J, 1998, BRIT MED J, V316, P312, DOI 10.1136/bmj.316.7127.312; Horton R, 1999, BRIT MED J, V319, P865, DOI 10.1136/bmj.319.7214.865; Roberts I, 1998, BRIT MED J, V317, P763, DOI 10.1136/bmj.317.7161.763; SAVULESCU J, 1996, BRIT MED J, V13, P1390; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Smith R, 1997, BRIT MED J, V315, P622, DOI 10.1136/bmj.315.7109.622; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Yamey G, 1999, BRIT MED J, V319, P939, DOI 10.1136/bmj.319.7215.939a; 1999, NATL FORUM, V79, P19	9	49	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1565	1568		10.1136/bmj.319.7224.1565	http://dx.doi.org/10.1136/bmj.319.7224.1565			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591727	Green Published			2022-12-28	WOS:000084245600031
J	Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R				Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R			Geomicrobiology of subglacial ice above Lake Vostok, Antarctica	SCIENCE			English	Article							PCR	Data from ice 3590 meters below Vostok Station indicate that the ice was accreted from liquid water associated with Lake Vostok. Microbes were observed at concentrations ranging from 2.8 x 10(3) to 3.6 x 10(4) cells per milliliter; no biological incorporation of selected organic substrates or bicarbonate was detected. Bacterial 16S ribosomal DNA genes revealed Low diversity in the gene population. The phylotypes were closely related to extant members of the alpha- and beta-Proteobacteria and the Actinomycetes. Extrapolation of the data from accretion ice to Lake Vostok implies that Lake Vostok may support a microbial population, despite more than 10(6) years of isolation from the atmosphere.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Montana State Univ, Dept Earth Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Phys, Bozeman, MT 59717 USA; Univ Alabama, Dept Geol, Tuscaloosa, AL 35487 USA; US Geol Survey, Reston, VA 20192 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; University of Alabama System; University of Alabama Tuscaloosa; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Welch, Kathleen/0000-0003-1028-3086				ABYZOV SS, 1993, ANTARCTIC MICROBIOLO, P265; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brunk CF, 1996, APPL ENVIRON MICROB, V62, P872, DOI 10.1128/AEM.62.3.872-879.1996; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; DREVER JI, 1988, GEOCHMISTRY NATURAL; HYNDMAN DW, 1985, PETROLOGY IGNEOUS ME; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; Kawamura K, 1996, GEOPHYS RES LETT, V23, P2665, DOI 10.1029/96GL02428; Killawee JA, 1998, GEOCHIM COSMOCHIM AC, V62, P3637, DOI 10.1016/S0016-7037(98)00268-3; LANGWAY CC, 1959, 62 SIPRE ARM COLD RE; LIESACK W, 1991, MICROBIAL ECOL, V21, P191, DOI 10.1007/BF02539153; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; *NAT SCI FDN WORKS, 1998, LAK VOST STUD CUR FO; ONEIL JR, 1968, J PHYS CHEM-US, V72, P3683, DOI 10.1021/j100856a060; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; TWICKLER MS, 1986, NATURE, V320, P156, DOI 10.1038/320156a0; VOYTEK MA, 1995, APPL ENVIRON MICROB, V56, P2430; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2; Welch KA, 1996, J CHROMATOGR A, V739, P257, DOI 10.1016/0021-9673(96)00044-1	24	289	317	4	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2141	2144		10.1126/science.286.5447.2141	http://dx.doi.org/10.1126/science.286.5447.2141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591642				2022-12-28	WOS:000084157300047
J	Hall, WJ				Hall, WJ			Update in geriatrics	ANNALS OF INTERNAL MEDICINE			English	Review							CONVERTING ENZYME-INHIBITORS; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; CONTROLLED TRIAL; OLDER PATIENTS; DOUBLE-BLIND; BONE LOSS; MORTALITY; DISEASE; UNDERUTILIZATION		Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester	Hall, WJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Box MED,601 Elmwood Ave, Rochester, NY 14642 USA.							Aronow WS, 1998, J AM GERIATR SOC, V46, P615, DOI 10.1111/j.1532-5415.1998.tb01079.x; Brass LM, 1998, ARCH INTERN MED, V158, P2093, DOI 10.1001/archinte.158.19.2093; FANTL JA, 1996, AHCPR PUBLICATION; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Havranek EP, 1998, ARCH INTERN MED, V158, P2024, DOI 10.1001/archinte.158.18.2024; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lemaitre RN, 1998, ARCH INTERN MED, V158, P1761, DOI 10.1001/archinte.158.16.1761; Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140-6736(97)09528-7; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; Mendelson G, 1998, J AM GERIATR SOC, V46, P751, DOI 10.1111/j.1532-5415.1998.tb03811.x; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; Pereira MA, 1998, ARCH INTERN MED, V158, P1695, DOI 10.1001/archinte.158.15.1695; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rowe JW, 1998, SUCCESSFUL AGING; Shaywitz SE, 1999, JAMA-J AM MED ASSOC, V281, P1197, DOI 10.1001/jama.281.13.1197; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	19	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					842	849		10.7326/0003-4819-131-11-199912070-00008	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610630				2022-12-28	WOS:000084053200007
J	Lee, ST; Peng, HY; Zhou, XT; Wang, N; Lee, CS; Bello, I; Lifshitz, Y				Lee, ST; Peng, HY; Zhou, XT; Wang, N; Lee, CS; Bello, I; Lifshitz, Y			A nucleation site and mechanism leading to epitaxial growth of diamond films	SCIENCE			English	Article							CHEMICAL-VAPOR-DEPOSITION; BIAS-ENHANCED NUCLEATION; SILICON	A diamond nucleation site responsible for epitaxial growth of diamond on silicon by chemical vapor deposition (CVD) is identified in high-resolution transmission electron microscopic images. Other sites in the same sample Leading to polycrystalline growth, but deleterious to epitaxial CVD growth, are also described. A mechanism for the heteroepitaxial growth of diamond is suggested, in which etching of the nondiamond carbon binder exposes and removes nonadherent nanodiamond nuclei, leaving intact only those directly nucleated on the silicon substrate. This work enhances our understanding of diamond nucleation and heteroepitaxial growth and its potential applications.	City Univ Hong Kong, Dept Phys & Mat Sci, Hong Kong, Peoples R China; City Univ Hong Kong, Ctr Super Diamond & Adv Films, Hong Kong, Peoples R China	City University of Hong Kong; City University of Hong Kong	Lee, ST (corresponding author), City Univ Hong Kong, Dept Phys & Mat Sci, Hong Kong, Peoples R China.	apannale@cityu.edu.hk	Lifshitz, Yeshayahu/E-6043-2011; LEE, Chun-Sing/B-6254-2013; Lee, Shuit-Tong/Q-7552-2018; Wang, Ning/B-5436-2011	LEE, Chun-Sing/0000-0001-6557-453X; Wang, Ning/0000-0002-4902-5589				ANGUS JC, 1988, SCIENCE, V241, P913, DOI 10.1126/science.241.4868.913; Butler JE, 1998, MRS BULL, V23, P22, DOI 10.1557/S0883769400029316; Gerber J, 1996, J APPL PHYS, V79, P4388, DOI 10.1063/1.361864; GRUEN DM, 1998, MAT RES SOC B, V23; Jiang X, 1998, PHYS REV B, V58, P7064, DOI 10.1103/PhysRevB.58.7064; Kawarada H, 1997, P INT SCH PHYS, V135, P505; LAMBRECHT WRL, 1993, NATURE, V364, P607, DOI 10.1038/364607a0; LIFSHITZ Y, 1989, PHYS REV LETT, V62, P1290, DOI 10.1103/PhysRevLett.62.1290; MORISH AA, 1991, APPL PHYS LETT, V59, P417; Paoletti A., 1997, PHYSICS DIAMOND INT, P135; Stockel R, 1998, J APPL PHYS, V83, P531, DOI 10.1063/1.366667; STONER BR, 1992, PHYS REV B, V45, P11067, DOI 10.1103/PhysRevB.45.11067; Yugo S, 1998, DIAM RELAT MATER, V7, P1017, DOI 10.1016/S0925-9635(98)00154-X; YUGO S, 1991, APPL PHYS LETT, V58, P1036, DOI 10.1063/1.104415; ZHOU XT, IN PRESS DIAMOND REL	15	120	128	9	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					104	106		10.1126/science.287.5450.104	http://dx.doi.org/10.1126/science.287.5450.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615039				2022-12-28	WOS:000084578400044
J	Ram, PT; Horvath, CM; Iyengar, R				Ram, PT; Horvath, CM; Iyengar, R			Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L G alpha(o) protein	SCIENCE			English	Article							MAP KINASE KINASE; PC12 CELLS; NEURITE OUTGROWTH; V-SRC; STAT3; ACTIVATION; DIFFERENTIATION; INTERLEUKIN-6; LOCALIZATION; ASSOCIATION	Expression of Q205L G alpha(o) (G alpha(o)*), an alpha subunit of heterotrimeric guanine nucleotide-binding proteins (G proteins) that lacks guanosine triphosphatase (GTPase) activity in NIH-3T3 cells, results in transformation. Expression of G alpha(o)* in NIH-3T3 cells activated signal transducer and activator of transcription 3 (Stat3) but not mitogen-activated protein (MAP) kinases 1 or 2, Coexpression of dominant negative Stat3 inhibited G alpha(o)*-induced transformation of NIH-3T3 cells and activation of endogenous Stat3, Furthermore, G alpha(o)* expression increased activity of the tyrosine kinase c-Src, and the G alpha(o)*-induced activation of Stat3 was blocked by expression of Csk (carboxyl-terminal Src kinase), which inactivates c-Src. The results indicate that Stat3 can function as a downstream effector for G alpha(o)* and mediate its biological effects.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Ram, PT (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	ramp01@doc.mssm.edu		Horvath, Curt/0000-0003-2449-225X; Ram, Prahlad/0000-0003-4739-3166	NATIONAL CANCER INSTITUTE [F32CA079134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NCI NIH HHS [1F32 CA79134-01] Funding Source: Medline; NIDDK NIH HHS [DK-38671] Funding Source: Medline; NIGMS NIH HHS [GM-54508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1996, MOL CELL BIOCHEM, V127, P201; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nusse O, 1996, J CELL SCI, V109, P221; RAM P, UNPUB; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	25	89	89	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					142	144		10.1126/science.287.5450.142	http://dx.doi.org/10.1126/science.287.5450.142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615050				2022-12-28	WOS:000084578400055
J	Strube, G				Strube, G			For and against - Should steroids be the first line treatment for asthma? For	BRITISH MEDICAL JOURNAL			English	Editorial Material											Strube, G (corresponding author), 33 Goffs Pk Rd, Crawley RH11 8AX, W Sussex, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Morice AH, 1999, ASTHMA GEN PRACTICE, V7, P7; O'Byrne P, 1996, CAN RESPIR J, V3, P169; PRICE D, 1999, ASTHMA J, V4, P74; Price D. B., 1995, European Respiratory Journal, V8, p463S; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310; SEARS MR, 1991, LANCET, V338, P1331, DOI 10.1016/0140-6736(91)92627-E; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; 1997, THORAX S1, V52, pS1	13	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					47	48		10.1136/bmj.320.7226.47	http://dx.doi.org/10.1136/bmj.320.7226.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617533	Green Published			2022-12-28	WOS:000084621600028
J	Rees, G; Russell, C; Frith, CD; Driver, J				Rees, G; Russell, C; Frith, CD; Driver, J			Inattentional blindness versus inattentional amnesia for fixated but ignored words	SCIENCE			English	Article							SELECTIVE ATTENTION; PICTURES; PERCEPTION; HUMANS; LOAD; TASK	People often are unable to report the content of ignored in Formation, but it is unknown whether this reflects a complete failure to perceive it (inattentional blindness) or merely that it is rapidly forgotten (inattentional amnesia). Here functional imaging is used to address this issue by measuring brain activity for unattended words. When attention is fully engaged with other material, the brain no Longer differentiates between meaningful words and random letters, even when they are looked at directly. These results demonstrate true inattentional blindness for words and show that visual recognition wholly depends on attention even for highly familiar and meaningful stimuli at the center of gaze.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA; UCL, Dept Psychol, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; California Institute of Technology; University of London; University College London	Rees, G (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	geraint@klab.caltech.edu	Frith, Chris D/A-2171-2009; Driver, Jon/A-4779-2010; Rees, Geraint/C-1493-2008	Frith, Chris D/0000-0002-8665-0690; Rees, Geraint/0000-0002-9623-7007; Russell, Charlotte/0000-0002-8194-8033	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D.E., 1958, PERCEPTION COMMUNICA; Buchel C, 1998, NATURE, V394, P274, DOI 10.1038/28389; Cherry C., 1957, HUMAN COMMUNICATION, DOI [10.2307/1292231, DOI 10.2307/1292231]; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEUTSCH JA, 1963, PSYCHOL REV, V70, P80, DOI 10.1037/h0039515; DRIVER J, 1995, CURR OPIN NEUROBIOL, V5, P191, DOI 10.1016/0959-4388(95)80026-3; Fiez JA, 1998, P NATL ACAD SCI USA, V95, P914, DOI 10.1073/pnas.95.3.914; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; JOHNSTON WA, 1986, ANNU REV PSYCHOL, V37, P43, DOI 10.1146/annurev.ps.37.020186.000355; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, IN PRESS J EXP PSYCH; LEWIS JL, 1970, J EXP PSYCHOL, V85, P225, DOI 10.1037/h0029518; Luck SJ, 1996, NATURE, V383, P616, DOI 10.1038/383616a0; Mack A., 1998, INATTENTIONAL BLINDN; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Menard MT, 1996, NEUROPSYCHOLOGIA, V34, P185, DOI 10.1016/0028-3932(95)00099-2; Pashler HE, 1998, PSYCHOL ATTENTION; Posner M.I., 1978, CHRONOMETRIC EXPLORA; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1998, TRENDS COGN SCI, V2, P281, DOI 10.1016/S1364-6613(98)01201-7; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; ROCK I, 1981, J EXP PSYCHOL HUMAN, V7, P275, DOI 10.1037/0096-1523.7.2.275; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; TIPPER SP, 1988, MEM COGNITION, V16, P64, DOI 10.3758/BF03197746; TREISMAN A, 1974, MEM COGNITION, V2, P641, DOI 10.3758/BF03198133; Treisman A., 1996, ATTENTION PERFORM, VXVI, P15; TREISMAN AM, 1969, PSYCHOL REV, V76, P282, DOI 10.1037/h0027242; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; Vandenberghe R, 1996, NATURE, V383, P254, DOI 10.1038/383254a0; VANORDEN GC, 1988, J EXP PSYCHOL LEARN, V14, P371, DOI 10.1037/0278-7393.14.3.371; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; Wolfe JM, 1999, MIT BRAD COGN PSYCH, P71	37	185	190	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2504	2507		10.1126/science.286.5449.2504	http://dx.doi.org/10.1126/science.286.5449.2504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617465				2022-12-28	WOS:000084429700048
J	Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S				Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S			Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL ACTIVATION; HORMONE RECEPTORS; RETINOIC ACID; LIGAND; GENE; THIAZOLIDINEDIONES; IDENTIFICATION; PPAR-GAMMA-2	Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes(1). Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR gamma), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis(2). Here we report two different heterozygous mutations in the ligand-binding domain of PPAR gamma in three subjects with severe insulin resistance. In the PPAR gamma crystal structure, the mutations destabilize helix 12 which mediates transactivation. Consistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPAR gamma in a dominant negative manner. In addition to insulin resistance, all three subjects developed type 2 diabetes mellitus and hypertension at an unusually early age. Our findings represent the first germline loss-of-function mutations in PPAR gamma and provide compelling genetic evidence that this receptor is important in the control of insulin sensitivity, glucose homeostasis and blood pressure in man.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2QQ, England; Incyte Europe Ltd, Cambridge CB4 0WA, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Prince Philip Hosp, Llanelli SA14 8QF, Wales; Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Incyte; MRC Laboratory Molecular Biology	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	kkcl@mole.bio.cam.ac.uk; sorahill@hgmp.mrc.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Schwabe, John WR/A-9132-2008	O'Rahilly, Stephen/0000-0003-2199-4449; Schwabe, John WR/0000-0003-2865-4383; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Barroso, Ines/0000-0001-5800-4520; Maslen, Gareth/0000-0001-7318-3678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Beamer BA, 1998, DIABETES, V47, P1806, DOI 10.2337/diabetes.47.11.1806; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Doi K, 1998, CIRCULATION, V98, P39; FLIER JS, 1992, DIABETES, V41, P1207, DOI 10.2337/diabetes.41.9.1207; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Iijima K, 1998, BIOCHEM BIOPH RES CO, V247, P353, DOI 10.1006/bbrc.1998.8794; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIBBY P, 1999, ARTEROISCLER THROMB, V19, P546; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nakamura Y, 1998, BRIT J PHARMACOL, V123, P675, DOI 10.1038/sj.bjp.0701669; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Whitehead JP, 1998, DIABETES, V47, P837, DOI 10.2337/diabetes.47.5.837; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	30	1031	1083	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					880	883		10.1038/47254	http://dx.doi.org/10.1038/47254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622252				2022-12-28	WOS:000084482000034
J	Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ				Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ			p53 inhibition by the LANA protein of KSHV protects against cell death	NATURE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; DNA-SEQUENCES; NUCLEAR ANTIGEN; EXPRESSION; HUMAN-HERPESVIRUS-8; IDENTIFICATION; COACTIVATORS	Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, has been implicated in the development of Kaposi's sarcoma (KS) and several B-cen lymphoproliferative diseases(1-3) Most cells in lesions derived from these malignancies are latently infected, and different viral gene products have been identified in association with lytic or latent infection by KSHV4,5. The latency-associated nuclear antigen (LANA), encoded by open reading frame 73 of the KSHV genome, is a highly immunogenic protein that is expressed predominantly during viral latency, in most KS spindle cells and in cell lines established from body-cavity-based lymphomas(6,7). Antibodies to LANA can be detected in a high percentage of HIV-infected individuals who subsequently develop KS8,9, although its role in disease pathogenesis is not completely understood. p53 is a potent transcriptional regulator of cell growth whose induction leads either to cell-cycle arrest or apoptosis. Loss of p53 function correlates with cell transformation and oncogenesis(10,11), and several viral oncoproteins interact with p53 and modulate its biological activity(12-13). Here we show that LANA interacts with the tumour suppressor protein p53 and represses its transcriptional activity. This viral gene product further inhibits the ability of p53 to induce cell death. We propose that LANA contributes to viral persistence and oncogenesis in KS through its ability to promote cell survival by altering p53 function.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr,MSC 3005, Bethesda, MD 20892 USA.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JJ, 1997, AM J DERMATOPATH, V19, P373, DOI 10.1097/00000372-199708000-00009; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NOEL JC, 1997, AM J DERMATOPATH, V19, P322; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255	30	539	558	1	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					889	894		10.1038/47266	http://dx.doi.org/10.1038/47266			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622254				2022-12-28	WOS:000084482000036
J	Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y				Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y			Impaired immunoproteasome assembly and immune responses in PA28(-/-) mice	SCIENCE			English	Article							PROTEASOME REGULATOR PA28; REG-ALPHA; PEPTIDE; BETA; PA28-ALPHA; ACTIVATOR; COMPLEXES; CELLS	In vitro PA28 binds and activates proteasomes. It is shown here that mice with a disrupted PA28b gene Lack PA28a and PA28b polypeptides, demonstrating that PA28 functions as a hetero-oligomer in vivo. Processing of antigenic epitopes derived from exogenous or endogenous antigens is altered in PA28(-/-) mice. Cytotoxic T Lymphocyte responses are impaired, and assembly of immunoproteasomes is greatly inhibited in mice lacking PA28. These results show that PA28 is necessary for immunoproteasome assembly and is required for efficient antigen processing, thus demonstrating the importance of PA28-mediated proteasome function in immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Fruh, K (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.		Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045; Frueh, Klaus/0000-0001-8014-3877; winqvist, Ola/0000-0003-0842-4441; Fung-Leung, Wai-Ping/0000-0001-7013-8855; Angulo, Ana/0000-0002-5792-1164				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Borrow Persephone, 1997, P593; BUCHMEIER MJ, 1999, PERSISTENT VIRAL INF, P575; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Flad T, 1998, CANCER RES, V58, P5803; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Ho M., 1991, CYTOMEGALOVIRUS BIOL; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Li YH, 1999, IMMUNOGENETICS, V49, P149, DOI 10.1007/s002510050476; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; PRECKEL T, UNPUB; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Vitiello A, 1997, EUR J IMMUNOL, V27, P671, DOI 10.1002/eji.1830270315; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	26	143	147	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2162	2165		10.1126/science.286.5447.2162	http://dx.doi.org/10.1126/science.286.5447.2162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591649				2022-12-28	WOS:000084157300054
J	Hampson, RE; Simeral, JD; Deadwyler, SA				Hampson, RE; Simeral, JD; Deadwyler, SA			Distribution of spatial and nonspatial information in dorsal hippocampus	NATURE			English	Article							TO-SAMPLE PERFORMANCE; SHORT-TERM-MEMORY; ENSEMBLE ACTIVITY; PLACE CELLS; SEMANTIC MEMORY; AMPAKINE CX516; ORGANIZATION; NAVIGATION; BRAIN; RATS	The hippocampus in the mammalian brain is required for the encoding of current and the retention of past experience, Previous studies have shown that the hippocampus contains neurons that encode information required to perform spatial and nonspatial short-term memory tasks. A more detailed understanding of the functional anatomy of the hippocampus would provide important insight into how such encoding occurs. Here we show that hippocampal neurons in the rat are distributed anatomically in distinct segments along the length of the hippocampus. Each longitudinal segment contains clusters of neurons that become active when the animal performs a task with spatial attributes. Within these same segments are ordered arrangements of neurons that encode the nonspatial aspects of the task appropriate to those spatial features. Thus, anatomical segregation of spatial information, together with the interleaved representation of nonspatial information, represents a structural framework that may help to resolve conflicting views of hippocampal function.	Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Wake Forest University	Hampson, RE (corresponding author), Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.		Simeral, John/CCI-2624-2022					AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; Burgess N, 1996, HIPPOCAMPUS, V6, P749; Burwell RD, 1995, HIPPOCAMPUS, V5, P390, DOI 10.1002/hipo.450050503; Cohen N J, 1991, Hippocampus, V1, P265, DOI 10.1002/hipo.450010312; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; Colombo M, 1998, J NEUROPHYSIOL, V80, P1002, DOI 10.1152/jn.1998.80.2.1002; Deadwyler SA, 1996, J NEUROSCI, V16, P354; DEADWYLER SA, 1995, SCIENCE, V270, P1316, DOI 10.1126/science.270.5240.1316; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; EICHENBAUM H, 1993, SCIENCE, V261, P993, DOI 10.1126/science.8351525; Gabrieli JDE, 1998, NEUROBIOL LEARN MEM, V70, P275, DOI 10.1006/nlme.1998.3853; Gothard KM, 1996, J NEUROSCI, V16, P823; Hampson RE, 1996, P NATL ACAD SCI USA, V93, P13487, DOI 10.1073/pnas.93.24.13487; Hampson RE, 1996, HIPPOCAMPUS, V6, P281, DOI 10.1002/(SICI)1098-1063(1996)6:3<281::AID-HIPO6>3.0.CO;2-Q; Hampson RE, 1998, J NEUROSCI, V18, P2740; Hampson RE, 1998, J NEUROSCI, V18, P2748; Hampson RE, 1999, J NEUROSCI, V19, P1492; Hirsch JA, 1998, J NEUROSCI, V18, P9517; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Kohonen T, 1999, TRENDS NEUROSCI, V22, P135, DOI 10.1016/S0166-2236(98)01342-3; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; LI XM, 1994, POTENTIAL ANAL, V3, P339, DOI 10.1007/BF01049807; McClelland JL, 1998, ANN NY ACAD SCI, V843, P153, DOI 10.1111/j.1749-6632.1998.tb08212.x; MORRIS RG, 1997, PHIL T R SOC LOND B, V29, P1489; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Moser MB, 1998, J NEUROSCI, V18, P7535; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; Rawlins JNP, 1999, NATURE, V397, P561, DOI 10.1038/17481; RAWLINS JNP, 1982, BEHAV BRAIN RES, V5, P331, DOI 10.1016/0166-4328(82)90039-0; Samsonovich A, 1997, J NEUROSCI, V17, P5900; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Shapiro ML, 1997, HIPPOCAMPUS, V7, P624, DOI 10.1002/(SICI)1098-1063(1997)7:6<624::AID-HIPO5>3.0.CO;2-E; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Touretzky DS, 1996, HIPPOCAMPUS, V6, P247; Tulving E, 1997, CURR OPIN NEUROBIOL, V7, P209, DOI 10.1016/S0959-4388(97)80009-8; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wallenstein GV, 1998, TRENDS NEUROSCI, V21, P317, DOI 10.1016/S0166-2236(97)01220-4; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	48	234	240	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					610	614		10.1038/45154	http://dx.doi.org/10.1038/45154			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604466				2022-12-28	WOS:000084189800053
J	Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH				Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH			Evolution - Conservation of a sex-determining gene	NATURE			English	Article									Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Smith, CA (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia.		Sinclair, Andrew H/A-3598-2010	Sinclair, Andrew H/0000-0003-2741-7992; Western, Patrick/0000-0002-7587-8227; Smith, Craig/0000-0002-1670-5545				Bull J.J., 1983, EVOLUTION SEX DETERM; Flejter WL, 1998, AM J HUM GENET, V63, P794, DOI 10.1086/302016; Guioli S, 1998, AM J HUM GENET, V63, P905, DOI 10.1086/302017; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Nanda I, 1999, NAT GENET, V21, P258, DOI 10.1038/6769; Raymond CS, 1999, HUM MOL GENET, V8, P989, DOI 10.1093/hmg/8.6.989; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	8	304	332	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					601	602		10.1038/45130	http://dx.doi.org/10.1038/45130			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604464				2022-12-28	WOS:000084189800045
J	Egolf, DA				Egolf, DA			Equilibrium regained: From nonequilibrium chaos to statistical mechanics	SCIENCE			English	Article							RAYLEIGH-BENARD CONVECTION; SPIRAL-DEFECT CHAOS; SPATIOTEMPORAL CHAOS; TRANSITION; COMPETITION; TURBULENCE	Far-from-equilibrium, spatially extended chaotic systems have generally eluded analytical solution, leading researchers to consider theories based on a statistical rather than a detailed knowledge of the microscopic Length scales. Building on the recent discovery of a separation of length scales between macroscopic behavior and microscopic chaos, a simple far-from-equilibrium spatially extended chaotic system has been studied computationally at intermediate, coarse-grained scales. Equilibrium properties such as Gibbs distributions and detailed balance are recovered at these scales, which suggests that the macroscopic behavior of some far-from-equilibrium systems might be understood in terms of equilibrium statistical mechanics.	Los Alamos Natl Lab, Ctr Nonlinear Studies MS B258, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Egolf, DA (corresponding author), Los Alamos Natl Lab, Ctr Nonlinear Studies MS B258, Div Theoret, POB 1663, Los Alamos, NM 87545 USA.	egolf@cnls.lanl.gov						Bajaj KMS, 1997, PHYS REV E, V55, pR4869, DOI 10.1103/PhysRevE.55.R4869; BOHR T, 1994, NATURE, V372, P48, DOI 10.1038/372048a0; Bunimovich LA, 1988, NONLINEARITY, V1, P491, DOI 10.1088/0951-7715/1/4/001; Cakmur RV, 1997, PHYS REV LETT, V79, P1853, DOI 10.1103/PhysRevLett.79.1853; CROSS MC, 1993, REV MOD PHYS, V65, P851, DOI 10.1103/RevModPhys.65.851; CROSS MC, 1994, SCIENCE, V263, P1569, DOI 10.1126/science.263.5153.1569; Durr D, 1998, NATURE, V394, P831, DOI 10.1038/29650; ECKE RE, 1995, SCIENCE, V269, P1704, DOI 10.1126/science.269.5231.1704; Egolf DA, 1998, PHYS REV LETT, V80, P3228, DOI 10.1103/PhysRevLett.80.3228; EGOLF DA, 1994, NATURE, V369, P129, DOI 10.1038/369129a0; EGOLF DA, 1995, PHYS REV LETT, V74, P1751, DOI 10.1103/PhysRevLett.74.1751; FOWLER RH, 1955, STAT MECH THEORY PRO, P659; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; Gaspard P, 1998, NATURE, V394, P865, DOI 10.1038/29721; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; Lee KJ, 1996, PHYS REV LETT, V76, P1174, DOI 10.1103/PhysRevLett.76.1174; Marcq P, 1996, PHYS REV LETT, V77, P4003, DOI 10.1103/PhysRevLett.77.4003; MILLER J, 1993, PHYS REV E, V48, P2528, DOI 10.1103/PhysRevE.48.2528; MORRIS SW, 1993, PHYS REV LETT, V71, P2026, DOI 10.1103/PhysRevLett.71.2026; OHern CS, 1996, PHYS REV E, V53, P3374, DOI 10.1103/PhysRevE.53.3374; Ouyang Q, 1996, NATURE, V379, P143, DOI 10.1038/379143a0; Qu ZL, 1997, PHYS REV LETT, V78, P1387, DOI 10.1103/PhysRevLett.78.1387; SHRAIMAN BI, 1992, PHYSICA D, V57, P241, DOI 10.1016/0167-2789(92)90001-4; Xi HW, 1997, PHYS REV LETT, V78, P1046, DOI 10.1103/PhysRevLett.78.1046	24	78	80	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					101	104		10.1126/science.287.5450.101	http://dx.doi.org/10.1126/science.287.5450.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615038				2022-12-28	WOS:000084578400043
J	Goverde, AJ; McDonnell, J; Vermeiden, JPW; Schats, R; Rutten, FFH; Schoemaker, J				Goverde, AJ; McDonnell, J; Vermeiden, JPW; Schats, R; Rutten, FFH; Schoemaker, J			Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis	LANCET			English	Article							HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING-HORMONE SURGE; ESHRE MULTICENTER TRIAL; CLOMIPHENE CITRATE; INFERTILITY; PREGNANCY; CYCLES; OLIGOASTHENOSPERMIA; OVULATION; PATIENT	Background Couples affected by idiopathic subfertility or male subfertility have an estimated spontaneous conception rate of about 2% per cycle. Although various infertility treatments are available, counselling of a couple in their choice of treatment is difficult because of the lack of consistent data from good-quality comparative studies. We compared the results of treatment with intrauterine insemination (IUI) with those of in-vitro fertilisation (IVF), and did a cost-effectiveness analysis. Methods In a prospective, randomised, parallel trial, 258 couples with idiopathic subfertility or male subfertility were treated for a maximum of six cycles of either IUI in the spontaneous cycle (IUI alone), IUI after mild ovarian hyperstimulation, or IVF. The primary endpoint was a pregnancy resulting in at least one livebirth after treatment. Cost-effectiveness based on real costs was studied by Markov chain analysis. Findings 86 couples were assigned IUI alone, 85 IUI plus ovarian hyperstimulation, and 87 IVF. Ten couples dropped out before treatment began. Although the pregnancy rate per cycle was higher in the IVF group than in the IUI groups (12.2% vs 7.4% and 8.7%, respectively; p=0.09), the cumulative pregnancy rate for IVF was not significantly better than that for IUI. Couples in the IVF group were more likely than those in the IUI groups to give up treatment before their maximum of six attempts (37 [42%] dropouts vs 13 [15%] and 14 [16%], respectively; p<0.01). The woman's age was the only factor that influenced a couple's chance of success, IUI was a more cost-effective treatment than IVF (costs per pregnancy resulting in at least one livebirth 8423-10 661 Dutch guilders [US$4511-5710] for IUI vs 27 409 Dutch guilders [US$14 679] for IVF). Interpretation Couples with idiopathic or male subfertility should be counselled that IUI offers the same likelihood of successful pregnancy as IVF, and is a more cost-effective approach. IUI in the spontaneous cycle carries fewer health risks than does IUI after mild hormonal stimulation and is therefore the first-choice treatment.	Vrije Univ Amsterdam, Med Ctr, Inst Endocrinol Reprod & Metab, Div Reprod Endocrinol & Fertil, Amsterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Erasmus University Rotterdam	Goverde, AJ (corresponding author), Free Univ Amsterdam Hosp, Dept Obstet & Gynaecol, Postbus 7057, NL-1007 MB Amsterdam, Netherlands.							ARICI A, 1994, FERTIL STERIL, V61, P314; BALASCH J, 1994, HUM REPROD, V9, P1863, DOI 10.1093/oxfordjournals.humrep.a138349; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; CROSIGNANI PG, 1991, HUM REPROD, V6, P953, DOI 10.1093/oxfordjournals.humrep.a137468; CROSIGNANI PG, 1994, HUM REPROD, V9, P1112, DOI 10.1093/oxfordjournals.humrep.a138642; Dawood MY, 1996, AM J OBSTET GYNECOL, V174, P1208, DOI 10.1016/S0002-9378(96)70663-4; Diczfalusy E, 1996, HUM REPROD, V11, P1775; Guzick DS, 1999, NEW ENGL J MED, V340, P177, DOI 10.1056/NEJM199901213400302; HO PC, 1989, FERTIL STERIL, V51, P682; Hughes EG, 1997, HUM REPROD, V12, P1865, DOI 10.1093/humrep/12.9.1865; HUGHES EG, 1987, FERTIL STERIL, V48, P278; KERIN JFP, 1984, LANCET, V1, P533; Land JA, 1997, FERTIL STERIL, V68, P278, DOI 10.1016/S0015-0282(97)81515-4; Martinez A R, 1993, Obstet Gynecol Surv, V48, P811, DOI 10.1097/00006254-199312000-00007; MARTINEZ AR, 1994, GYNECOL ENDOCRINOL, V8, P1, DOI 10.3109/09513599409028450; MARTINEZ AR, 1991, ACTA ENDOCRINOL-COP, V124, P357, DOI 10.1530/acta.0.1240357; MARTINEZ AR, 1990, THESIS VRIJE U AMSTE; MCINTOSH JEA, 1980, FERTIL STERIL, V34, P125; MUENZ LR, 1985, BIOMETRICS, V41, P91, DOI 10.2307/2530646; NULSEN JC, 1993, OBSTET GYNECOL, V82, P780; ODONOVAN PA, 1993, HUM REPROD, V8, P1209, DOI 10.1093/oxfordjournals.humrep.a138230; PETERSON CM, 1994, FERTIL STERIL, V62, P353; Roseboom TJ, 1995, HUM REPROD, V10, P3035, DOI 10.1093/oxfordjournals.humrep.a135842; THOMAS EJ, 1986, LANCET, V2, P693; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361	26	297	306	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					13	18		10.1016/S0140-6736(99)04002-7	http://dx.doi.org/10.1016/S0140-6736(99)04002-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615885				2022-12-28	WOS:000085049200010
J	Lilford, RJ; Braunholtz, DA; Greenhalgh, R; Edwards, SJL				Lilford, RJ; Braunholtz, DA; Greenhalgh, R; Edwards, SJL			Trials and fast changing technologies: the case for tracker studies	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; RANDOMIZED TRIALS; CANCER; MEDICINE; DESIGN		Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, London W6 8RF, England	University of Birmingham; Imperial College London	Braunholtz, DA (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.							Banta H D, 1978, J Community Health, V3, P245, DOI 10.1007/BF01349387; Berry D A, 1995, Cancer Treat Res, V75, P125; BRUNIER HC, 1994, STAT MED, V13, P2493, DOI 10.1002/sim.4780132312; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Carlin BP, 1996, STAT MED, V15, P1093, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1093::AID-SIM231>3.0.CO;2-0; CHALMERS TC, 1968, LANCET, V1, P858; EDWARDS SJL, 1999, 1998215 NHS HTA; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FREEDMAN LS, 1994, STAT MED, V13, P1371, DOI 10.1002/sim.4780131312; GEORGE SL, 1994, STAT MED, V13, P1313, DOI 10.1002/sim.4780131305; GRANT A, 1991, LANCET, V337, P1491; GRANT A, 1999, ASSESSING LEARNING C; GRAY RJ, 1994, BIOMETRICS, V50, P244, DOI 10.2307/2533216; GREEN SJ, 1987, J CLIN ONCOL, V5, P1477, DOI 10.1200/JCO.1987.5.9.1477; LAZARO P, 1998, 14 ANN M INT SOC TEC; Lilford R, 1999, J Health Serv Res Policy, V4, P164; LILFORD R, 1994, BMJ-BRIT MED J, V308, P111, DOI 10.1136/bmj.308.6921.111; Lilford RJ, 1996, BRIT MED J, V313, P603; LILFORD RJ, 1992, J ROY COLL PHYS LOND, V26, P400; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; *NHS CTR REV DISS, 1997, MAN STABL ANG 1997; OQUIGLEY J, 1990, BIOMETRICS, V46, P33, DOI 10.2307/2531628; PARMAR MKB, 1994, STAT MED, V13, P1297, DOI 10.1002/sim.4780131304; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PRESCOTT RJ, 1979, CONTROVERSIES CANC D, P55; RUSSELL I, 1995, BRIT MED J, V311, P1243, DOI 10.1136/bmj.311.7015.1243; SPODICK DH, 1982, AM J MED, V73, P420, DOI 10.1016/0002-9343(82)90746-X; STRAUSS N, 1995, STAT MED, V14, P1479, DOI 10.1002/sim.4780141308; Thornton JG, 1996, BRIT J OBSTET GYNAEC, V103, P611, DOI 10.1111/j.1471-0528.1996.tb09826.x; Varlan E, 1996, THERAPIE, V51, P348; Warden J, 1998, BRIT MED J, V316, P1851; Yao TJ, 1996, BIOMETRICS, V52, P992, DOI 10.2307/2533060	32	76	77	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					43	46		10.1136/bmj.320.7226.43	http://dx.doi.org/10.1136/bmj.320.7226.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617532	Green Published			2022-12-28	WOS:000084621600027
J	Kemeny, N; Huang, Y; Cohen, AM; Shi, WJ; Conti, JA; Brennan, MF; Bertino, JR; Turnbull, ADM; Sullivan, D; Stockman, J; Blumgart, LH; Fong, YM				Kemeny, N; Huang, Y; Cohen, AM; Shi, WJ; Conti, JA; Brennan, MF; Bertino, JR; Turnbull, ADM; Sullivan, D; Stockman, J; Blumgart, LH; Fong, YM			Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 13-18, 1999	ATLANTA, GA	Amer Soc Clin Oncol			PROSPECTIVE RANDOMIZED TRIAL; LIVER METASTASES; INTRAARTERIAL FLOXURIDINE; SURGICAL RESECTION; CARCINOMA; SURVIVAL; FLUORODEOXYURIDINE; 5-FLUOROURACIL; LIFE	Background: Two years after undergoing resection of liver metastases from colorectal cancer, about 65 percent of patients are alive and 25 percent are free of detectable disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection. Methods: We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone. Patients were stratified according to previous treatment and the number of liver metastases identified at operation. The study end points were overall survival, survival without recurrence of hepatic metastases, and survival without any metastases at two years. Results: The actuarial rate of overall survival at two years was 86 percent in the group treated with combined therapy and 72 percent in the group given monotherapy alone (P = 0.03). The median survival was 72.2 months in the combined-therapy group and 59.3 months in the monotherapy group, with a median follow-up of 62.7 months. After two years, the rates of survival free of hepatic recurrence were 90 percent in the combined-therapy group and 60 percent in the monotherapy group (P < 0.001), and the respective rates of progression-free survival were 57 percent and 42 percent (P = 0.07). At two years, the risk ratio for death was 2.34 among patients treated with systemic therapy alone, as compared with patients who received combined therapy (95 percent confidence interval, 1.10 to 4.98; P = 0.027), after adjustment for important variables. The rates of adverse effects of at least moderate severity were similar in the two groups, except for a higher frequency of diarrhea and hepatic effects in the combined-therapy group. Conclusions: For patients who undergo resection of liver metastases from colorectal cancer, postoperative treatment with a combination of hepatic arterial infusion of floxuridine and intravenous fluorouracil improves the outcome at two years. (N Engl J Med 1999;341:2039-48.) (C)1999, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kemeny, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [R01 CA61524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN NB, 1974, SURGERY, V75, P589; ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647; ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; AUGUST DA, 1985, ANN SURG, V201, P210, DOI 10.1097/00000658-198502000-00013; CADY B, 1992, ARCH SURG-CHICAGO, V127, P561; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; COX DR, 1972, J R STAT SOC B, V34, P187; DOCI R, 1991, BRIT J SURG, V78, P797, DOI 10.1002/bjs.1800780711; ENSMINGER WD, 1983, SEMIN ONCOL, V10, P176; FEGIZ G, 1991, J SURG ONCOL, P144; Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; FORTNER JG, 1988, AM J SURG, V155, P378, DOI 10.1016/S0002-9610(88)80086-2; FOSTER JH, 1978, AM J SURG, V135, P389, DOI 10.1016/0002-9610(78)90072-7; GILBERT HA, 1976, FUNDAMENTAL ASPECTS, P385; Gorlick R, 1998, J CLIN ONCOL, V16, P1465, DOI 10.1200/JCO.1998.16.4.1465; HOHN DC, 1989, J CLIN ONCOL, V7, P1646, DOI 10.1200/JCO.1989.7.11.1646; HUGHES K, 1989, SURG CLIN N AM, V69, P339; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMENY MM, 1999, P AN M AM SOC CLIN, V18, P1012; KEMENY N, 1992, CANCER, V69, P327, DOI 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U; KEMENY N, 1993, CANCER-AM CANCER SOC, V71, P1964, DOI 10.1002/1097-0142(19930315)71:6<1964::AID-CNCR2820710607>3.0.CO;2-T; KEMENY N, 1987, ANN INTERN MED, V107, P459, DOI 10.7326/0003-4819-107-4-459; KEMENY N, 1994, SURG LIVER BILIARY T, V2, P1473; KEMENY NE, 1999, CURRENT CLIN ONCOLOG, P5; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEICHMAN L, 1995, EUR J CANCER, V31A, P1306, DOI 10.1016/0959-8049(95)00326-E; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; SCHEELE J, 1990, BRIT J SURG, V77, P1241, DOI 10.1002/bjs.1800771115; SIGURDSON ER, 1991, P AN M AM SOC CLIN, V10, P140; VANOOIJEN B, 1992, CANCER-AM CANCER SOC, V70, P28, DOI 10.1002/1097-0142(19920701)70:1<28::AID-CNCR2820700105>3.0.CO;2-9; WAGMAN LD, 1990, J CLIN ONCOL, V8, P1885, DOI 10.1200/JCO.1990.8.11.1885; YOUNES RN, 1991, ANN SURG, V214, P107, DOI 10.1097/00000658-199108000-00003	36	686	701	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2039	2048		10.1056/NEJM199912303412702	http://dx.doi.org/10.1056/NEJM199912303412702			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	271BR	10615075				2022-12-28	WOS:000084573300002
J	Bourdon, B; Turner, S; Allegre, C				Bourdon, B; Turner, S; Allegre, C			Melting dynamics beneath the Tonga-Kermadec Island are inferred from Pa-231-U-235 systematics	SCIENCE			English	Article							SERIES DISEQUILIBRIA; ELEMENT CHEMISTRY; ARC MAGMAS; FLUX RATES; MANTLE; TH; CONSTRAINTS; BASALTS; LAVAS; GEOCHEMISTRY	Measurement of Pa-231-U-235 disequilibrium in Tonga-Kermadec island are Lavas (north of New Zealand) permits discrimination of the time scales and mechanisms of fluid addition and partial melting. For Tonga Lavas, the (Pa-231/U-235) ratios are less than 1 and can be explained by fluid addition from the subducting plate around 60,000 years ago. In contrast, the effects of partial melting overprinted those of fluid addition in the Kermadec Lavas resulting in (Pa-231/U-235) ratios greater than 1.	Inst Phys Globe, CNRS, UMR 7579, Lab Geochim & Cosmochim, F-75252 Paris 05, France; Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Open University - UK	Bourdon, B (corresponding author), Inst Phys Globe, CNRS, UMR 7579, Lab Geochim & Cosmochim, 4 Pl Jussieu, F-75252 Paris 05, France.		Bourdon, Bernard/A-3303-2008; Turner, Simon/0000-0002-6426-6495	Turner, Simon/0000-0002-6426-6495				ALLEGRE CJ, 1982, NATURE, V299, P21, DOI 10.1038/299021a0; BEVIS M, 1995, NATURE, V374, P249, DOI 10.1038/374249a0; Bourdon B, 1999, CHEM GEOL, V157, P147, DOI 10.1016/S0009-2541(98)00198-3; Bourdon B, 1998, EARTH PLANET SC LETT, V164, P119, DOI 10.1016/S0012-821X(98)00227-1; BRENAN JM, 1995, GEOCHIM COSMOCHIM AC, V59, P3331, DOI 10.1016/0016-7037(95)00215-L; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; Elliott T, 1997, J GEOPHYS RES-SOL EA, V102, P14991, DOI 10.1029/97JB00788; EWART A, 1987, J PETROL, V28, P495, DOI 10.1093/petrology/28.3.495; Ewart A, 1998, J PETROL, V39, P331, DOI 10.1093/petrology/39.3.331; GUILLAUMONT R, 1968, ACTIN REV, V1, P135; Hawkesworth CJ, 1997, SCIENCE, V276, P551, DOI 10.1126/science.276.5312.551; JAQUES AL, 1980, CONTRIB MINERAL PETR, V73, P287, DOI 10.1007/BF00381447; Keppler H, 1996, NATURE, V380, P237, DOI 10.1038/380237a0; Lundstrom CC, 1998, EARTH PLANET SC LETT, V157, P167, DOI 10.1016/S0012-821X(98)00039-9; LUNDSTROM CC, 1994, EARTH PLANET SC LETT, V128, P407, DOI 10.1016/0012-821X(94)90159-7; MILLER DM, 1994, NATURE, V368, P514, DOI 10.1038/368514a0; Pearce J.A., 1993, GEOL SOC SPEC PUBL, V76, P373, DOI 10.1144/GSL.SP.1993.076.01.19; Pickett DA, 1997, EARTH PLANET SC LETT, V148, P259, DOI 10.1016/S0012-821X(97)00037-X; PLANK T, 1988, EARTH PLANET SC LETT, V90, P349, DOI 10.1016/0012-821X(88)90135-5; Regelous M, 1997, EARTH PLANET SC LETT, V150, P291, DOI 10.1016/S0012-821X(97)00107-6; Robinson JAC, 1998, EARTH PLANET SC LETT, V164, P277, DOI 10.1016/S0012-821X(98)00213-1; SPIEGELMAN M, 1993, EARTH PLANET SC LETT, V118, P1, DOI 10.1016/0012-821X(93)90155-3; STOLPER E, 1994, EARTH PLANET SC LETT, V121, P293, DOI 10.1016/0012-821X(94)90074-4; Turner S, 1997, GEOCHIM COSMOCHIM AC, V61, P4855, DOI 10.1016/S0016-7037(97)00281-0; Turner S, 1997, NATURE, V389, P568, DOI 10.1038/39257; WASYLENKI LE, 1996, EOS T AM GEOPHYS UN, V77, pF847; Wood Barbara, COMMUNICATION	27	49	49	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2491	2493		10.1126/science.286.5449.2491	http://dx.doi.org/10.1126/science.286.5449.2491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617460				2022-12-28	WOS:000084429700043
J	Davis, SJ; Vener, AV; Vierstra, RD				Davis, SJ; Vener, AV; Vierstra, RD			Bacteriophytochromes: Phytochrome-like photoreceptors from nonphotosynthetic eubacteria	SCIENCE			English	Article							DEINOCOCCUS-RADIODURANS	Phytochromes are a family of photoreceptors used by green plants to entrain their development to the light environment. The distribution of these chromoproteins has been expanded beyond photoautotrophs with the discovery of phytochrome-like proteins in the nonphotosynthetic eubacteria Deinococcus radiodurans and Pseudomonas aeruginosa. Like plant phytochromes, the D. radiodurans receptor covalently binds Linear tetrapyrroles autocatalytically to generate a photochromic holoprotein. However, the attachment site is distinct, using a histidine to potentially form a Schiff base Linkage. Sequence homology and mutational analysis suggest that D. radiodurans bacteriophytochrome functions as a Light-regulated histidine kinase, which helps protect the bacterium from visible Light.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vierstra, RD (corresponding author), Univ Wisconsin, Genet Lab, 1575 Linden Dr, Madison, WI 53706 USA.							Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Davis S.M, UNPUB; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gupta RS, 1998, J MOL EVOL, V46, P716, DOI 10.1007/PL00006352; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Lemee L, 1997, TETRAHEDRON, V53, P919, DOI 10.1016/S0040-4020(96)01036-8; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; VIERSTRA RD, 1983, BIOCHEMISTRY-US, V22, P2498, DOI 10.1021/bi00279a029; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	18	276	293	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2517	2520		10.1126/science.286.5449.2517	http://dx.doi.org/10.1126/science.286.5449.2517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617469				2022-12-28	WOS:000084429700052
J	Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K				Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K			Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells	CELL			English	Article							DROSOPHILA-MELANOGASTER; SONIC HEDGEHOG; TRANSDUCING HEDGEHOG; GENE-EXPRESSION; PATCHED HOMOLOG; EGF RECEPTOR; PATTERN; POLARITY; INDUCTION; MUTATIONS	Members of the Hedgehog (Hh) family of secreted signaling proteins function as potent short-range organizers in animal development. Their range of action is limited by a C-terminal cholesterol tether and the upregulation of Patched (Ptc) receptor levels. Here we identify a novel segment-polarity gene in Drosophila, dispatched (disp), and demonstrate that its product is required in sending cells for normal Hh function. In the absence of Disp, cholesterol-modified but not cholesterol-free Hh is retained in these cells, indicating that Disp functions to release cholesterol-anchored Hh. Despite their opposite roles, Disp and Ptc share structural homology in the form of a sterol-sensing domain, suggesting that release and sequestration of cholesterol-modified Hh may be based on related molecular pathways.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Senti, Kirsten-Andre/AAB-3036-2020; Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X; Burke, Richard/0000-0003-0086-0767; Senti, Kirsten-Andre/0000-0002-7208-7593; Basler, Konrad/0000-0003-3534-1529				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chou TB, 1996, GENETICS, V144, P1673; COUSO JP, 1994, DEVELOPMENT, V120, P621; Deak P, 1997, GENETICS, V147, P1697; FORBES AJ, 1993, DEVELOPMENT, P115; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Golembo M, 1996, DEVELOPMENT, V122, P3363; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Marigo V, 1996, DEVELOPMENT, V122, P1225; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; NEWSOME TP, 2000, IN PRESS DEVELOPMENT; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pignoni F, 1997, DEVELOPMENT, V124, P271; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SLUSARSKI DC, 1995, GENETICS, V139, P229; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	54	414	434	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					803	815		10.1016/S0092-8674(00)81677-3	http://dx.doi.org/10.1016/S0092-8674(00)81677-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619433	Bronze, Green Accepted			2022-12-28	WOS:000084488200013
J	Grines, CL; Cox, DA; Stone, GW; Garcia, E; Mattos, LA; Giambartolomei, A; Brodie, BR; Madonna, O; Eijgelshoven, M; Lansky, AJ; O'Neill, WW; Morice, MC				Grines, CL; Cox, DA; Stone, GW; Garcia, E; Mattos, LA; Giambartolomei, A; Brodie, BR; Madonna, O; Eijgelshoven, M; Lansky, AJ; O'Neill, WW; Morice, MC		Stent Primary Angioplasty Myocardi	Coronary angioplasty with or without stent implantation for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALMAZ-SCHATZ STENTS; INTRAVENOUS STREPTOKINASE; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; THERAPY; ARTERIES; REOCCLUSION; PAMI	Background: Coronary-stent implantation is frequently performed for treatment of acute myocardial infarction. However, few studies have compared stent implantation with primary angioplasty alone. Methods: We designed a multicenter study to compare primary angioplasty with angioplasty accompanied by implantation of a heparin-coated Palmaz-Schatz stent. Patients with acute myocardial infarction underwent emergency catheterization and angioplasty. Those with vessels suitable for stenting were randomly assigned to undergo angioplasty with stenting (452 patients) or angioplasty alone (448 patients). Results: The mean (+/-SD) minimal luminal diameter was larger after stenting than after angioplasty alone (2.56+/-0.44 mm vs. 2.12+/-0.45 mm, P<0.001), although fewer patients assigned to stenting had grade 3 blood flow (according to the classification of the Thrombolysis in Myocardial Infarction trial) (89.4 percent, vs. 92.7 percent in the angioplasty group; P=0.10). After six months, fewer patients in the stent group than in the angioplasty group had angina (11.3 percent vs. 16.9 percent, P=0.02) or needed target-vessel revascularization because of ischemia (7.7 percent vs. 17.0 percent, P<0.001). In addition, the combined primary end point of death, reinfarction, disabling stroke, or target-vessel revascularization because of ischemia occurred in fewer patients in the stent group than in the angioplasty group (12.6 percent vs. 20.1 percent, P<0.01). The decrease in the combined end point was due entirely to the decreased need for target-vessel revascularization. The six-month mortality rates were 4.2 percent in the stent group and 2.7 percent in the angioplasty group (P=0.27). Angiographic follow-up at 6.5 months demonstrated a lower incidence of restenosis in the stent group than in the angioplasty group (20.3 percent vs. 33.5 percent, P<0.001). Conclusions: In patients with acute myocardial infarction, routine implantation of a stent has clinical benefits beyond those of primary coronary angioplasty alone. (N Engl J Med 1999;341:1949-56.) (C)1999, Massachusetts Medical Society.	William Beaumont Hosp, Cardiac Catheterizat Lab, Div Cardiol, Royal Oak, MI 48073 USA; Washington Hosp Ctr, Washington, DC 20010 USA; Mid Carolina Cardiol, Charlotte, NC USA; Hosp Gen Gregorio Maranon, E-28007 Madrid, Spain; Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; St Josephs Hosp, Syracuse, NY USA; LeBauer Hlth Care, Greensboro, NC USA; Cordis Johnson & Johnson, Paris, France; Cardialysis, Rotterdam, Netherlands; Inst Cardiovasc Paris Sud, Antony, France	Beaumont Health; MedStar Washington Hospital Center; General University Gregorio Maranon Hospital; Instituto Dante Pazzanese de Cardiologia; LeBauer-Brodie Center for Cardiovascular Research & Education; Johnson & Johnson; Cardialysis; UDICE-French Research Universities; Universite Paris Saclay	Grines, CL (corresponding author), William Beaumont Hosp, Cardiac Catheterizat Lab, Div Cardiol, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.							Antoniucci D, 1998, J AM COLL CARDIOL, V31, P1234, DOI 10.1016/S0735-1097(98)00097-7; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; GRINES C, 1995, CIRCULATION S1, V92, P146; Grines CL, 1997, J AM COLL CARDIOL, V29, P1122; Grines CL, 1997, J INVASIVE CARDIOL, V9, pB44; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GRONENSCHILD E, 1994, CATHETER CARDIO DIAG, V33, P61, DOI 10.1002/ccd.1810330116; Hardhammar PA, 1996, CIRCULATION, V93, P423, DOI 10.1161/01.CIR.93.3.423; Lansky A, 1999, TXB INTERVENTIONAL C, P725; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; Monassier Jean Pierre, 1996, Journal of the American College of Cardiology, V27, p68A; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Rodriguez A, 1998, AM J CARDIOL, V81, P1286, DOI 10.1016/S0002-9149(98)00154-4; Serruys P, 1998, LANCET, V352, P1478; Serruys PW, 1998, Int J Cardiovasc Intervent, V1, P19; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; Stone GW, 1997, J AM COLL CARDIOL, V29, P1459, DOI 10.1016/S0735-1097(97)00088-0; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Tcheng JE, 1997, LANCET, V349, P1422; Tommaso CL, 1997, CATHETER CARDIO DIAG, V42, P257, DOI 10.1002/(SICI)1097-0304(199711)42:3<257::AID-CCD3>3.0.CO;2-B; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Weaver WD, 1998, JAMA-J AM MED ASSOC, V279, P1876; WHITE HD, 1995, J AM COLL CARDIOL, V25, P218, DOI 10.1016/0735-1097(94)00331-J; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	29	698	743	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1949	1956		10.1056/NEJM199912233412601	http://dx.doi.org/10.1056/NEJM199912233412601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607811				2022-12-28	WOS:000084399400001
J	Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P				Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P			CD46 is a cellular receptor for human herpesvirus 6	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COFACTOR PROTEIN CD46; ACCELERATING FACTOR CD55; MEASLES-VIRUS; MARROW TRANSPLANTATION; FATAL ENCEPHALITIS; EXANTHEM-SUBITUM; DOWN-REGULATION; VARIANT-A; INFECTION	Human herpesvirus 6 (HHV-6) is the etiologic agent of exanthema subitum, causes opportunistic infections in immunocompromised patients, and has been implicated in multiple sclerosis and in the progression of AIDS. Here, we show that the two major HHV-6 subgroups (A and B) use human CD46 as a cellular receptor. Downregulation of surface CD46 was documented during the course of HHV-6 infection. Both acute infection and cell fusion mediated by HHV-6 were specifically inhibited by a monoclonal antibody to CD46; fusion was also blocked by soluble CD46. Nonhuman cells that were resistant to HHV-6 fusion and entry became susceptible upon expression of recombinant human CD46. The use of a ubiquitous immunoregulatory receptor opens novel perspectives for understanding the tropism and pathogenicity of HHV-6.	San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy; Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy; NIAID, Viral Dis Lab, Bethesda, MD 20894 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lusso, P (corresponding author), San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy.		Malnati, Mauro/AAN-4207-2020	Malnati, mauro/0000-0001-5355-1680	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000733, ZIAAI000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; BRODER CC, 1993, J VIROL, V67, P913, DOI 10.1128/JVI.67.2.913-926.1993; Buckland R, 1997, VIRUS RES, V48, P1, DOI 10.1016/S0168-1702(96)01421-9; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; CORBELLINO M, 1993, LANCET, V342, P1242, DOI 10.1016/0140-6736(93)92226-J; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorig Ruth E., 1994, Trends in Microbiology, V2, P312, DOI 10.1016/0966-842X(94)90447-2; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905; Emery VC, 1999, J MED VIROL, V57, P278, DOI 10.1002/(SICI)1096-9071(199903)57:3&lt;278::AID-JMV11&gt;3.0.CO;2-3; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Ghali M, 1998, J NEUROVIROL, V4, P521, DOI 10.3109/13550289809113496; Gobbi A, 1999, J EXP MED, V189, P1953, DOI 10.1084/jem.189.12.1953; Hall CB, 1998, CLIN INFECT DIS, V26, P132, DOI 10.1086/516280; Hirano A, 1999, J VIROL, V73, P4776, DOI 10.1128/JVI.73.6.4776-4785.1999; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; JARVIS JN, 1995, J ACQ IMMUN DEF SYND, V9, P249; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KNOX KK, 1995, CLIN INFECT DIS, V20, P406, DOI 10.1093/clinids/20.2.406; KNOX KK, 1994, LANCET, V343, P577, DOI 10.1016/S0140-6736(94)91524-5; KNOX KK, 1995, J MED VIROL, V45, P288, DOI 10.1002/jmv.1890450309; Kositanont U, 1999, J INFECT DIS, V180, P50, DOI 10.1086/314826; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; LUSSO P, 1989, LANCET, V1, P730; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; QAVI HB, 1992, CURR EYE RES, V11, P315, DOI 10.3109/02713689209001785; Randhawa PS, 1997, AM J SURG PATHOL, V21, P847, DOI 10.1097/00000478-199707000-00014; Sakata H, 1998, BIOL PHARM BULL, V21, P1121; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SEYA T, 1995, MICROBIOL IMMUNOL, V39, P295, DOI 10.1111/j.1348-0421.1995.tb02205.x; Tsujimura A, 1998, BIOCHEM J, V330, P163, DOI 10.1042/bj3300163; Tufaro F, 1997, TRENDS MICROBIOL, V5, P257, DOI 10.1016/S0966-842X(97)01057-3; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; YAMANISHI K, 1988, LANCET, V1, P1065; YEFENOF E, 1976, INT J CANCER, V17, P693, DOI 10.1002/ijc.2910170602	60	394	413	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					817	827		10.1016/S0092-8674(00)81678-5	http://dx.doi.org/10.1016/S0092-8674(00)81678-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619434	Bronze			2022-12-28	WOS:000084488200014
J	Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH				Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH			Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							ARTHRITIS; SERODIAGNOSIS; FIBROMYALGIA; POPULATION; FEATURES; CHILDREN	Background: Previous follow-up studies of patients with Lyme disease suggest that disseminated infection may be associated with long-term neurologic and musculoskeletal morbidity. Objective: To determine clinical and functional outcomes in persons who were treated for Lyme disease in the late 1980s. Design: Population-based, retrospective cohort study. Setting: Nantucket Island, Massachusetts. Participants: 186 persons who had a history of Lyme disease (case-patients) and 167 persons who did not (controls). Measurements: Standardized medical history, physical examination, functional status measure (Medical Outcomes Study 36-item Short Form Health Survey [SF-36]), mood state assessment (Profile of Mood States), neurocognitive tests, and serologic examination. Results: The prevalence of Lyme disease among adults on Nantucket Island was estimated to be 14.3% (95% CI, 9.3% to 19.1%). In multivariate analyses, persons with previous Lyme disease (mean time from infection to study evaluation, 6.0 years) had more joint pain (odds ratio for having joint pain in any joint, 2.1 [CI, 1.2 to 3.5]; P = 0.007), more symptoms of memory impairment (odds ratio for having any memory problem, 1.9 [CI, 1.1 to 3.5]; P = 0.003), and poorer functional status due to pain (odds ratio for 1 point on the SF-36 scale, 1.02 [CI, 1.01 to 1.03]; P < 0.001) than persons without previous Lyme disease. However, on physical examination, case-patients and controls did not differ in musculoskeletal abnormalities, neurologic abnormalities, or neurocognitive performance. Persons with previous Lyme disease who had persistent symptoms after receiving treatment (n = 67) were more likely than those who had completely recovered to have had fever, headache, photosensitivity, or neck stiffness during their acute illness (87% compared with 13%; odds ratio, 2.4 [CI, 1.0 to 5.5]; P = 0.045); however, the performance of the two groups on neurocognitive tests did not significantly differ. Conclusions: Because persons with previous Lyme disease exhibited no sequelae on physical examination and neurocognitive tests a mean of 6.0 years after infection, musculoskeletal and neurocognitive outcomes seem to be favorable. However, long-term impairment of functional status can occur.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Univ Munich, Bavarian Publ Hlth Res Ctr, Sch Med, Munich, Germany; Univ Connecticut, Ctr Hlth, Farmington, CT USA; IMUGEN Inc, Norwood, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Rochester; University of Munich; University of Connecticut	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR36308] Funding Source: Medline; PHS HHS [02033] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*ACR GLOSS COMM, 1982, DICT RHEUM DIS, V1; [Anonymous], 1978, MAIL TELEPHONE SURVE; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; BROADBENT DE, 1992, BR J CLIN PSYCHOL, V21, P1; Bujak DI, 1996, J RHEUMATOL, V23, P1392; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DELIS D, 1988, PSYCHOL CORPORATION; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HERMAN D, 1988, CLIN NEUROPSYCHOL, V2, P102; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kaplan RF, 1997, SEMIN NEUROL, V17, P31, DOI 10.1055/s-2008-1040910; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; MCNAIR DM, 1996, MANUAL PROFILE MOOD; MILLER GL, 1992, 5 INT C LYM BORR ARL; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; *PURD RES FDN, 1948, EX MAN PURD PEGB; S.A.S. Institute, 1990, SAS STAT US GUID; Sangha O, 1998, ANN INTERN MED, V128, P346, DOI 10.7326/0003-4819-128-5-199803010-00002; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; *STAT CT DEP PUBL, 1995, CONNECTICUT EPIDEMIO, V15, P185; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; US Army, 1944, ARM IND TEST BATT MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; 1996, MMWR MORB MORTAL WKL, V45, P481; 1990, MMWR MORB MORTAL WKL, V39, P19	37	114	114	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					919	+		10.7326/0003-4819-131-12-199912210-00003	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610642				2022-12-28	WOS:000084374400002
J	Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS				Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS			Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta	SCIENCE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; TARGETED DISRUPTION; SERTOLI CELLS; MOUSE; GENE; EXPRESSION; HORMONE; DIFFERENTIATION; TESTIS; DIETHYLSTILBESTROL	Mice lacking estrogen receptors alpha and beta were generated to clarify the roles of each receptor in the physiology of estrogen target tissues. Both sexes of alpha beta estrogen receptor knockout (alpha beta ERKO) mutants exhibit normal reproductive tract development but are infertile. Ovaries of adult alpha beta ERKO females exhibit follicle transdifferentiation to structures resembling seminiferous tubules of the testis, including Sertoli-like cells and expression of Mullerian inhibiting substance, sulfated glycoprotein-2, and Sox9, Therefore, Loss of both receptors Leads to an ovarian phenotype that is distinct from that of the individual ERKO mutants, which indicates that both receptors are required for the maintenance of germ and somatic cells in the postnatal ovary.	NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell Biol, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Korach, KS (corresponding author), NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	korach@niehs.nih.gov	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Korach, Kenneth/0000-0002-7765-418X; Bunch, Donna/0000-0002-3638-0522				BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; FITZPATRICK L, 1990, ENDOCRINOLOGY, V140, P2581; Flaws JA, 1997, BIOL REPROD, V57, P1233, DOI 10.1095/biolreprod57.5.1233; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; GUERRIER D, 1990, J REPROD FERTIL, V88, P695; GURAYA SS, 1995, INT REV CYTOL, V160, P163, DOI 10.1016/S0074-7696(08)61555-7; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; JOST A, 1970, MAMMALIAN REPRODUCTI, P4; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KURODA T, 1991, ENDOCRINOLOGY, V129, P2985, DOI 10.1210/endo-129-6-2985; Lindzey J, 1998, ENDOCRINOLOGY, V139, P4092, DOI 10.1210/en.139.10.4092; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Robertson KM, 1999, P NATL ACAD SCI USA, V96, P7986, DOI 10.1073/pnas.96.14.7986; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; TAKETO T, 1991, ANN NY ACAD SCI, V637, P74, DOI 10.1111/j.1749-6632.1991.tb27302.x; VIGIER B, 1987, DEVELOPMENT, V100, P43; Visser JA, 1998, ENDOCRINOLOGY, V139, P4244, DOI 10.1210/en.139.10.4244; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WENIGER JP, 1990, J DEV PHYSIOL, V14, P303; Whitworth DJ, 1998, TRENDS ENDOCRIN MET, V9, P2, DOI 10.1016/S1043-2760(98)00002-2; WU TCJ, 1992, MOL REPROD DEV, V33, P407, DOI 10.1002/mrd.1080330406; WU TCJ, 1993, FERTIL STERIL, V59, P54; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	28	429	447	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2328	2331		10.1126/science.286.5448.2328	http://dx.doi.org/10.1126/science.286.5448.2328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600740	Green Submitted			2022-12-28	WOS:000084318500057
J	Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC				Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC			Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana	NATURE			English	Article							REPETITIVE DNA; MITOCHONDRIAL GENOME; REGIONS; LIBRARY; MAP; RNA; CONSTRUCTION; DUPLICATION; PREDICTION; CENTROMERE	Arabidopsis thaliana (Arabidopsis) is unique among plant model organisms in having a small genome (130-140 Mb), excellent physical and genetic maps, and little repetitive DNA. Here we report the sequence of chromosome 2 from the Columbia ecotype in two gap-free assemblies (contigs) of 3.6 and 16 megabases (Mb). The latter represents the longest published stretch of uninterrupted DNA sequence assembled from any organism to date. Chromosome 2 represents 15% of the genome and encodes 4,037 genes, 49% of which have no predicted function. Roughly 250 tandem gene duplications were found in addition to large-scale duplications of about 0.5 and 4.5 Mb between chromosomes 2 and 1 and between chromosomes 2 and 4, respectively. Sequencing of nearly 2 Mb within the genetically defined centromere revealed a low density of recognizable genes, and a high density and diverse range of vestigial and presumably inactive mobile elements. More unexpected is what appears to be a recent insertion of a continuous stretch of 75% of the mitochondrial genome into chromosome 2.	Inst Genom Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Venter, JC (corresponding author), Cereon Genom, 270 Albany St, Cambridge, MA 02139 USA.	jcventer@celera.com	Copenhaver, Gregory P/A-7549-2014; Copenhaver, Gregory/AAH-2031-2022; Somerville, Christopher R/A-4048-2009; Salzberg, Steven L/F-6162-2011; Eisen, Jonathan A./H-2706-2019; Copenhaver, Gregory/AFL-9831-2022; Salzberg, Steven/Q-6514-2019	Copenhaver, Gregory P/0000-0002-7962-3862; Copenhaver, Gregory/0000-0002-7962-3862; Somerville, Christopher R/0000-0003-4647-0094; Salzberg, Steven L/0000-0002-8859-7432; Eisen, Jonathan A./0000-0002-0159-2197; Copenhaver, Gregory/0000-0002-7962-3862; Salzberg, Steven/0000-0002-8859-7432; Buell, C Robin/0000-0002-6727-4677; Fraser, Claire/0000-0003-1462-2428				Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; BEVAN M, 1998, NATURE, V391, P485; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; COPENHAVER GP, 1995, PLANT J, V7, P273, DOI 10.1046/j.1365-313X.1995.7020273.x; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; COPENHAVER GP, IN PRESS SCIENCE; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; KLEIN M, 1994, PLANT J, V6, P447, DOI 10.1046/j.1365-313X.1994.06030447.x; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; LIU YG, 1995, PLANT J, V7, P351, DOI 10.1046/j.1365-313X.1995.7020351.x; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; Schweizer D, 1987, Results Probl Cell Differ, V14, P235; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Terryn N, 1999, FEBS LETT, V445, P237, DOI 10.1016/S0014-5793(99)00097-6; Thompson H, 1996, MOL GEN GENET, V253, P247, DOI 10.1007/s004380050319; Thompson HL, 1996, NUCLEIC ACIDS RES, V24, P3017, DOI 10.1093/nar/24.15.3017; Thompson HL, 1996, PLANT MOL BIOL, V32, P553, DOI 10.1007/BF00019109; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamada Y., 1990, SECONDARY PRODUCTS P, P227; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	50	535	3223	5	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					761	+		10.1038/45471	http://dx.doi.org/10.1038/45471			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617197	Bronze			2022-12-28	WOS:000084330500053
J	Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I				Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I		European Union Arabidopsis Genome; Washington Univ; PE Biosystems Arabidopsis Sequenci	Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana	NATURE			English	Article							FISSION YEAST; DNA-SEQUENCES; GENOMIC DNA; MODEL-PLANT; REGIONS; RFLP; RNA; RECOMBINATION; PREDICTION; TELOMERE	The higher plant Arabidopsis thaliana (Arabidopsis) is an important model for identifying plant genes and determining their function. To assist biological investigations and to define chromosome structure, a coordinated effort to sequence the Arabidopsis genome was initiated in late 1996, Here we report one of the first milestones of this project, the sequence of chromosome 4. Analysis of 17.38 megabases of unique sequence, representing about 17% of the genome, reveals 3,744 protein coding genes, 81 transfer RNAs and numerous repeat elements. Heterochromatic regions surrounding the putative centromere, which has not yet been completely sequenced, are characterized by an increased frequency of a variety of repeats, new repeats, reduced recombination, lowered gene density and lowered gene expression. Roughly 60% of the predicted protein-coding genes have been functionally characterized on the basis of their homology to known genes. Many genes encode predicted proteins that are homologous to human and Caenorhabditis elegans proteins.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequences, Max Planck Inst Biochem, D-82152 Munich, Germany; AGOWA GmbH, D-12489 Berlin, Germany; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; GATC GmbH, D-78467 Constance, Germany; QIAGEN GmbH, D-40724 Hilden, Germany; DLO, CPRO, NL-6700 AA Wageningen, Netherlands; SRD GmbH, D-61440 Oberursel, Germany; Univ Ghent, Dept Genet, B-3000 Louvain, Belgium; Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; GBF, D-38124 Braunschweig, Germany; Univ Amsterdam, Mol Biol Sect, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; MWG AG Biotech, D-85554 Ebersberg, Germany; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Naples Federico II, CEINGE, I-80131 Naples, Italy; MediGenomix GmbH, DNA Analyt & Genom, D-82152 Planegg Martinsried, Germany; Univ Grenoble 1, Lab Plastes & Differenciat Cellulaire, UMR5575, F-38041 Grenoble, France; CNRS, F-38041 Grenoble, France; Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Paris Sud, UMR CNRS 8618, Inst Biotechnol Plantes, F-91405 Orsay, France; Univ Perpignan, UMR CNRS 5545, Lab Physiol & Biol Mol Plantes, F-66860 Perpignan, France; CSIC, Inst Biol Mol Barcelona, Dept Mol Genet, Barcelona, Spain; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Microsynth GmbH, CH-9436 Balgach, Switzerland; Baseclear, Leiden, Netherlands; Fac Univ Sci Agronom, Microbiol Unit, B-5030 Gembloux, Belgium; Univ Valencia, Dept Genet, Valencia 46100, Spain; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Keygene NV, NL-6700 AE Wageningen, Netherlands; Deutsch Krebsforschungszentrum, Funct Genome Anal, D-69120 Heidelberg, Germany; Inst Plant Genet & Crop Plant Res IPK, D-06466 Gatersleben, Germany; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Lita Annenberg Hazen Genome Ctr, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Cold Spring Harbor Plant Biol Grp, Cold Spring Harbor, NY 11724 USA; Appl Biosyst Inc, Foster City, CA 94494 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; KU Leuven; QIAGEN GmbH; Ghent University; Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Helmholtz-Center for Infection Research; University of Amsterdam; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Vienna Biocenter (VBC); UDICE-French Research Universities; Universite Paris Saclay; Universite Perpignan Via Domitia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Durham University; University of Valencia; Universite Catholique Louvain; Keygene N.V.; Helmholtz Association; German Cancer Research Center (DKFZ); Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Washington University (WUSTL); Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Thermo Fisher Scientific; Applied Biosystems	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.	bevan@bbsrc.ac.uk	Frishman, Dmitrij/AAT-7815-2020; Marra, Marco A/B-5987-2008; Pérez-Alonso, Manuel/M-3333-2014; Ansorge, Wilhelm/AAN-8780-2020; Mayer, Klaus FX/M-7941-2015; Monfort, Amparo/K-1356-2015; Mardis, Elaine/W-2202-2019; Wilson, Richard K./AAF-4139-2019; Entian, Karl-Dieter/D-3080-2011; Terol, Javier/H-6401-2013; Quail, michael/ABE-6131-2020; Klein Lankhorst, René/HGD-0360-2022; Bancroft, Ian/AAH-3831-2020; Muendlein, Axel/AAS-5313-2021; Mewes, Hans-Werner/A-8204-2019	Marra, Marco A/0000-0001-7146-7175; Pérez-Alonso, Manuel/0000-0002-3266-0340; Mayer, Klaus FX/0000-0001-6484-1077; Monfort, Amparo/0000-0001-7106-7745; Wilson, Richard K./0000-0002-1992-1358; Terol, Javier/0000-0003-3345-0078; Bancroft, Ian/0000-0001-7707-1171; Muendlein, Axel/0000-0002-5582-4125; Benes, Vladimir/0000-0002-0352-2547; Sander, Peters/0000-0002-2663-5149; Argiriou, Anagnostis/0000-0002-9164-632X; Kay, Mike/0000-0002-3282-0834; Van den Daele, Hilde/0000-0002-4271-6694; Casacuberta, Elena/0000-0002-8203-8357; Boutry, Marc/0000-0002-2315-6900; Mewes, Hans-Werner/0000-0002-9713-6398; Schmidt, Wolfgang/0000-0002-6944-2443				ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; BEVAN M, 1998, NATURE, V391, P485; BORODOVSKY M, 1994, COMPUT CHEM, V18, P259, DOI 10.1016/0097-8485(94)85022-4; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; *C EL SEQ CONS, 1998, SCIENCE, V282, P2012; CHOI S, 1995, WEEDS WORLD, V2, P17; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Gamas P, 1996, MOL PLANT MICROBE IN, V9, P233, DOI 10.1094/MPMI-9-0233; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gerstein M, 1997, J MOL BIOL, V274, P562, DOI 10.1006/jmbi.1997.1412; Grewal SIS, 1997, GENETICS, V146, P1221; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Jensen RB, 1998, FEBS LETT, V436, P283, DOI 10.1016/S0014-5793(98)01143-0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kotani H, 1997, DNA Res, V4, P291, DOI 10.1093/dnares/4.4.291; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 1999, NUCLEIC ACIDS RES, V27, P44, DOI 10.1093/nar/27.1.44; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mizutani M, 1998, PLANT MOL BIOL, V37, P39, DOI 10.1023/A:1005921406884; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Richards EJ, 1998, CURR OPIN PLANT BIOL, V1, P130, DOI 10.1016/S1369-5266(98)80014-9; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHAFFER AA, IN PRESS BIOINFORMAT; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Xu XJ, 1995, PLANT CELL, V7, P2151, DOI 10.1105/tpc.7.12.2151	50	291	2757	4	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					769	+		10.1038/47134	http://dx.doi.org/10.1038/47134			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617198				2022-12-28	WOS:000084330500054
J	Ford, CA; Bearman, PS; Moody, J				Ford, CA; Bearman, PS; Moody, J			Foregone health care among adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE; SCHOOL-STUDENTS; UNITED-STATES; MEDICAL-CARE; ACCESS; PERCEPTIONS; SERVICES; CHILDREN; CONFIDENTIALITY; WILLINGNESS	Context No annual national population estimates exist of the numbers of adolescents who think they need but do not receive health care or their risk of health problems. Objective To describe the proportion of adolescents who report foregone health care each year and the influence of sociodemographic factors, insurance status, past health care, and health risks/behaviors on foregone care. Design Cross-sectional analyses of data from wave 1 of the National Longitudinal Study of Adolescent Health, conducted during 1995. Setting In-home interviews conducted throughout the United States. Participants Of 27 000 adolescents in grades 7 through 12 who were invited to participate, 20 746 (76.8%) completed the in-home interview. Main Outcome Measure Reported foregone health care in the preceding year by individual and family characteristics, insurance status, past health care, health/ behavior risk factors, and symptoms. Results On average, 2268 (18.7%) of 12 079 adolescents reported foregone health care within the past year. Factors associated with decreased risk of foregone care included continuous private or public insurance (adjusted relative risk [95% confidence interval], 0.64 [0.50-0.82] to 0.82 [0.70-0.96]), and having a physical examination within the past year (0.87 [0.78-0.97] for male and 0.79 [0.70-0.88] for female adolescents). Factors associated with increased risk of foregone care included older age (1.12 [1.06-1.15] for male), minority race/ethnicity (1.25 [1.06-1.46] to 1.50 [1.30-1.73]), single-parent home (1.31 [1.18-1.46] for female), and disability (2.03 [1.61-2.52] for male and 1.66 [1.20-2.10] for female). Adolescents participating in the following behaviors were more likely to report foregone care than those who did not: daily cigarette use (26.0% vs 16.8%; 1.34 [1.16-1.55]), frequent alcohol use (30.3% vs 18.1%; 1.34 [1.11-1.62] for male), and sexual intercourse (25.1% vs 15.1%; 1.23 [1.09-1.39] for male and 1.39 [1.23-1.56] for female). From 32.4% to 38.2% of adolescents with symptoms suggesting health problems reported foregone care (1.61 [1.13-2.26] to 2.03 [1.81-2.28]). Conclusions Our study suggests that adolescents who forego care are at increased risk of physical and mental health problems. Efforts to improve adolescent health through health care should address factors influencing foregone care.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Sociol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ford, CA (corresponding author), Univ N Carolina, Dept Med, CB 7225, Chapel Hill, NC 27599 USA.			bearman, peter/0000-0002-3745-3164	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD031921] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD31921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAY LA, 1975, DEV INDICES ACCESS M, P306; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Bartman BA, 1997, J HEALTH CARE POOR U, V8, P214; BEARMAN PS, 1998, NATL LONGITUDINAL ST; CHAMIE M, 1982, FAM PLANN PERSPECT, V14, P126, DOI 10.2307/2134710; Chantala K, 1999, STRATEGIES PERFORM D; CHENG TL, 1993, JAMA-J AM MED ASSOC, V269, P1404, DOI 10.1001/jama.269.11.1404; COBLE YD, 1993, JAMA-J AM MED ASSOC, V269, P1420, DOI 10.1001/jama.1993.03500110088042; DUBOW EF, 1990, J CLIN CHILD PSYCHOL, V19, P44, DOI 10.1207/s15374424jccp1901_6; Dunn L.M., 2007, PEABODY PICTURE VOCA; Ellen, 1997, Adolesc Med, V8, P385; Elster AB, 1998, ARCH PEDIAT ADOL MED, V152, P193; English A., 1995, STATE MINOR CONSENT; Ford CA, 1997, JAMA-J AM MED ASSOC, V278, P1029, DOI 10.1001/jama.278.12.1029; FRIEDMAN E, 1994, JAMA-J AM MED ASSOC, V271, P1535, DOI 10.1001/jama.271.19.1535; GANS JE, 1993, POLICY COMPENDIUM CO; GINSBURG KR, 1995, JAMA-J AM MED ASSOC, V273, P1913, DOI 10.1001/jama.273.24.1913; HODGSON C, 1986, ADOLESCENCE, V21, P383; Kennedy P., 1994, GUIDE ECONOMETRICS, V3; KLEIN JD, 1992, J ADOLESCENT HEALTH, V13, P162, DOI 10.1016/1054-139X(92)90084-O; MARKS A, 1983, J PEDIATR-US, V102, P456, DOI 10.1016/S0022-3476(83)80677-5; MILLMAN M, 1993, ACCESS HLTH CARE AM, P229; NEWACHECK PW, 1989, PEDIATRICS, V84, P1056; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; NEWACHECK PW, 1997, HLTH CARE CHILDREN W, P53; OZER EM, 1997, AM ADOLESCENTS ARE T; SCHOEN C, 1997, COMMONWEALTH FUND SU, P43; SCHOEN C, 1998, HLTH ADOLESCENT BOYS, P45; Sells CW, 1996, AM J PUBLIC HEALTH, V86, P513, DOI 10.2105/AJPH.86.4.513; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; WEISSMAN JS, 1994, FALLING SAFETY NET I, P192; WINSHIP C, 1994, SOCIOL METHOD RES, V23, P230, DOI 10.1177/0049124194023002004; WOOD DL, 1990, PEDIATRICS, V86, P666; Young TL, 1998, ARCH PEDIAT ADOL MED, V152, P1137; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZimmerGembeck MJ, 1997, J ADOLESCENT HEALTH, V21, P388, DOI 10.1016/S1054-139X(97)00167-5	38	244	245	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2227	2234		10.1001/jama.282.23.2227	http://dx.doi.org/10.1001/jama.282.23.2227			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605974	Green Published			2022-12-28	WOS:000084138600030
J	Josefson, D				Josefson, D			Patients dialysed at for-profit centres do worse	BRITISH MEDICAL JOURNAL			English	News Item																		Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; Levinsky NG, 1999, NEW ENGL J MED, V341, P1691, DOI 10.1056/NEJM199911253412212	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1517	1517		10.1136/bmj.319.7224.1517	http://dx.doi.org/10.1136/bmj.319.7224.1517			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591694	Green Published			2022-12-28	WOS:000084245600005
J	Levi, M; Cromheecke, ME; de Jonge, E; Prins, MH; de Mol, BJM; Briet, E; Buller, HR				Levi, M; Cromheecke, ME; de Jonge, E; Prins, MH; de Mol, BJM; Briet, E; Buller, HR			Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints	LANCET			English	Review							LOW-DOSE APROTININ; EPSILON-AMINOCAPROIC ACID; ARTERY BYPASS OPERATIONS; PROPHYLACTIC TRANEXAMIC ACID; INDUCED PLATELET DYSFUNCTION; PATIENTS RECEIVING ASPIRIN; PLACEBO-CONTROLLED TRIAL; BLIND RANDOMIZED TRIAL; OPEN-HEART-SURGERY; CARDIOPULMONARY BYPASS	Background Excessive bleeding may complicate cardiac surgery, and is associated with increased morbidity and mortality. Pharmacological strategies to decrease perioperative bleeding have been investigated in a large number of controlled trials, most of which have shown a decrease in blood loss. However, most studies lacked sufficient power to detect a beneficial effect on clinically more relevant outcomes. We did a meta-analysis of all randomised, controlled trials of the three most frequently used pharmacological strategies to decrease perioperative blood loss (aprotinin, lysine analogues [aminocaproic acid and tranexamic acid], and desmopressin). Methods Studies were included if they reported at least one clinically relevant outcome (mortality, rethoracotomy, proportion of patients receiving a transfusion, or perioperative myocardial infarction) in addition to perioperative blood loss. In addition, a separate meta-analysis was done for studies concerning complicated cardiac surgery. Findings We identified 72 trials (8409 patients) that met the inclusion criteria. Treatment with aprotinin decreased mortality almost two-fold (odds ratio 0.55 [95% CI 0.34-0.90]) compared with placebo. Treatment with aprotinin and with lysine analogues decreased the frequency of surgical re-exploration (0.37 [0.25-0.55] and 0.44 [0.22-0.90], respectively). These two treatments also significantly decreased the proportion of patients receiving any allogeneic blood transfusion. By contrast, the use of desmopressin resulted in a small decrease in perioperative blood loss, but was not associated with a beneficial effect on other clinical outcomes. Aprotinin and lysine analogues did not increase the risk of perioperative myocardial infarction; however, desmopressin was associated with a 2.4-fold increase in the risk of this complication. Studies in patients undergoing complicated cardiac surgery showed similar results. Interpretation Pharmacological strategies that decrease perioperative blood loss in cardiac surgery, in particular aprotinin and lysine analogues, also decrease mortality, the need for rethoracotomy, and the proportion of patients receiving a blood transfusion.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiopulm Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr F4, Dept Vasc Med Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020	de Mol, Bastian/0000-0001-6888-9430				Alderman EL, 1998, J THORAC CARDIOV SUR, V116, P716, DOI 10.1016/S0022-5223(98)00431-0; ALVAREZ JM, 1995, J CARDIOTHOR VASC AN, V9, P29, DOI 10.1016/S1053-0770(05)80052-7; ANDERSSON TLG, 1990, CIRCULATION, V81, P872, DOI 10.1161/01.CIR.81.3.872; ANSELL J, 1992, J THORAC CARDIOV SUR, V104, P117; Baele P L, 1992, Acta Anaesthesiol Belg, V43, P103; BAILEY CR, 1994, BRIT HEART J, V71, P349; BAILEY CR, 1994, BRIT J SURG, V81, P969, DOI 10.1002/bjs.1800810713; BennettGuerrero E, 1997, ANESTHESIOLOGY, V87, P1373, DOI 10.1097/00000542-199712000-00017; BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; BIDSTRUP BP, 1993, J THORAC CARDIOV SUR, V105, P147, DOI 10.1016/S0022-5223(19)33859-0; BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958; BOLDT J, 1993, J THORAC CARDIOV SUR, V105, P705; Brown M R, 1989, J Cardiothorac Anesth, V3, P726, DOI 10.1016/S0888-6296(89)94790-X; Brown RS, 1997, ANESTH ANALG, V85, P963, DOI 10.1097/00000539-199711000-00003; CARREL T, 1991, LANCET, V337, P673, DOI 10.1016/0140-6736(91)92485-K; Carrera A, 1994, Rev Esp Anestesiol Reanim, V41, P13; CATTANEO M, 1995, THROMB HAEMOSTASIS, V74, P1064; CHUANG HI, 1993, ACTA ANESTHESIOL SIN, V31, P35; Cicek S, 1996, ANN THORAC SURG, V61, P1372, DOI 10.1016/0003-4975(96)00058-6; COFFEY A, 1995, AM SURGEON, V61, P566; CORBEAU JJ, 1995, ANN FR ANESTH, V14, P154, DOI 10.1016/S0750-7658(95)70013-2; COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; Dacey LJ, 1998, ARCH SURG-CHICAGO, V133, P442, DOI 10.1001/archsurg.133.4.442; DAILY PO, 1994, J THORAC CARDIOV SUR, V108, P99; DELEUZE P, 1991, ARCH MAL COEUR VAISS, V84, P1797; DELROSSI AJ, 1989, CHEST, V96, P27, DOI 10.1378/chest.96.1.27; DEPEPPO AP, 1995, TEX HEART I J, V22, P231; DEPROST D, 1992, THROMB HAEMOSTASIS, V68, P106; DIETRICH W, 1990, ANESTHESIOLOGY, V73, P1119, DOI 10.1097/00000542-199012000-00009; DIETRICH W, 1995, ANESTHESIOLOGY, V83, P679, DOI 10.1097/00000542-199510000-00006; DIETRICH W, 1989, THORAC CARDIOV SURG, V37, P92, DOI 10.1055/s-2007-1013915; Dilthey G, 1993, J Cardiothorac Vasc Anesth, V7, P425, DOI 10.1016/1053-0770(93)90164-G; Dryden PJ, 1997, CAN J ANAESTH, V44, P934, DOI 10.1007/BF03011964; Eberle B, 1998, ANN THORAC SURG, V65, P667, DOI 10.1016/S0003-4975(97)01424-0; FRANKVILLE DD, 1991, ANESTHESIOLOGY, V74, P988, DOI 10.1097/00000542-199106000-00004; FREMES SE, 1994, ANN THORAC SURG, V58, P1580, DOI 10.1016/0003-4975(94)91636-5; Gherli T, 1992, Minerva Cardioangiol, V40, P121; GRATZ I, 1992, J THORAC CARDIOV SUR, V104, P1417; GREEN D, 1995, J THORAC CARDIOV SUR, V110, P963, DOI 10.1016/S0022-5223(05)80163-1; Gschossmann J, 1994, Cardiovasc Surg, V2, P716; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HARDER MP, 1991, ANN THORAC SURG, V51, P936, DOI 10.1016/0003-4975(91)91009-K; Hardy JF, 1998, ANN THORAC SURG, V65, P371, DOI 10.1016/S0003-4975(97)01016-3; Hardy JF, 1997, J CARDIAC SURG, V12, P15, DOI 10.1111/j.1540-8191.1997.tb00083.x; HARDY JF, 1993, CAN J ANAESTH, V40, P625, DOI 10.1007/BF03009699; HARKER LA, 1986, NEW ENGL J MED, V314, P1446, DOI 10.1056/NEJM198605293142209; HAVEL M, 1994, J THORAC CARDIOV SUR, V107, P807; HAVEL M, 1991, J THORAC CARDIOV SUR, V101, P968; HEDDERICH GS, 1990, CAN J SURG, V33, P33; HORROW JC, 1990, J THORAC CARDIOV SUR, V99, P70; HORROW JC, 1991, CIRCULATION, V84, P2063, DOI 10.1161/01.CIR.84.5.2063; Jamieson WRE, 1997, CIRCULATION, V96, P96; KALANGOS A, 1994, EUR J CARDIO-THORAC, V8, P651, DOI 10.1016/S1010-7940(05)80140-X; KAWASUJI M, 1993, ANN THORAC SURG, V55, P1205, DOI 10.1016/0003-4975(93)90035-G; Klein M, 1998, EUR J CARDIO-THORAC, V14, P360, DOI 10.1016/S1010-7940(98)00192-4; Lambert W, 1998, CAN J ANAESTH, V45, P571, DOI 10.1007/BF03012711; Landymore RW, 1997, EUR J CARDIO-THORAC, V11, P798; Lass M, 1997, Cardiovasc Surg, V5, P604, DOI 10.1016/S0967-2109(97)00079-3; LAUB GW, 1994, CHEST, V106, P1370, DOI 10.1378/chest.106.5.1370; Laupacis A, 1997, ANESTH ANALG, V85, P1258, DOI 10.1097/00000539-199712000-00014; LAZENBY WD, 1990, CIRCULATION, V82, P413; LEMMER JH, 1994, J THORAC CARDIOV SUR, V107, P543, DOI 10.1016/S0022-5223(94)70101-6; Lemmer JH, 1996, ANN THORAC SURG, V62, P1659, DOI 10.1016/S0003-4975(96)00451-1; LEVY JH, 1995, CIRCULATION, V92, P2236, DOI 10.1161/01.CIR.92.8.2236; LIU B, 1993, SCAND J THORAC CARD, V27, P149, DOI 10.3109/14017439309099103; Mannucci PM, 1998, NEW ENGL J MED, V339, P245, DOI 10.1056/NEJM199807233390407; Marquez J, 1992, J Cardiothorac Vasc Anesth, V6, P674, DOI 10.1016/1053-0770(92)90049-D; MASTROROBERTO P, 1995, EUR J CARDIO-THORAC, V9, P143, DOI 10.1016/S1010-7940(05)80061-2; Menichetti A, 1996, J CARDIOVASC SURG, V37, P401; Miller BE, 1998, ANN THORAC SURG, V66, P535, DOI 10.1016/S0003-4975(98)00469-X; Minohara S, 1997, Nihon Kyobu Geka Gakkai Zasshi, V45, P821; MOHR R, 1992, CIRCULATION, V86, P405; MONGAN PD, 1992, ANESTHESIOLOGY, V77, P38, DOI 10.1097/00000542-199207000-00007; Mongan PD, 1998, ANESTH ANALG, V87, P258, DOI 10.1097/00000539-199808000-00005; MURKIN JM, 1994, J THORAC CARDIOV SUR, V107, P554, DOI 10.1016/S0022-5223(12)70102-2; Nakashima A, 1993, ASAIO J, V39, pM185; ORCHARD MA, 1993, BRIT J HAEMATOL, V85, P533; OSAKA M, 1998, NIPPON KYOBU GEKA GA, V46, P846; Pinosky ML, 1997, J CARDIAC SURG, V12, P330, DOI 10.1111/j.1540-8191.1997.tb00147.x; PUGH SC, 1995, J CARDIOTHOR VASC AN, V9, P240, DOI 10.1016/S1053-0770(05)80314-3; Ray MJ, 1997, ANN THORAC SURG, V63, P57; Reich D L, 1991, J Cardiothorac Vasc Anesth, V5, P142, DOI 10.1016/1053-0770(91)90327-P; REYNOLDS LM, 1993, J THORAC CARDIOV SUR, V106, P954, DOI 10.1016/S0022-5223(19)33965-0; ROCHA E, 1994, CIRCULATION, V90, P921, DOI 10.1161/01.CIR.90.2.921; ROCHA E, 1988, CIRCULATION, V77, P1319, DOI 10.1161/01.CIR.77.6.1319; Rodrigus IE, 1996, PERFUSION-UK, V11, P313, DOI 10.1177/026765919601100403; Rossi M, 1997, J CARDIOTHOR VASC AN, V11, P835, DOI 10.1016/S1053-0770(97)90116-6; Royston D, 1992, J Cardiothorac Vasc Anesth, V6, P76, DOI 10.1016/1053-0770(91)90052-U; ROYSTON D, 1987, LANCET, V2, P1289; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SEEAR MD, 1989, J THORAC CARDIOV SUR, V98, P217; SHERIDAN DP, 1994, CAN J SURG, V37, P33; ShoreLesserson L, 1996, ANESTH ANALG, V83, P18, DOI 10.1097/00000539-199607000-00005; Smith PK, 1996, ANN THORAC SURG, V62, P1575; SPEEKENBRINK RGH, 1995, ANN THORAC SURG, V59, P438, DOI 10.1016/0003-4975(94)00865-5; Speekenbrink RGH, 1996, J THORAC CARDIOV SUR, V112, P523, DOI 10.1016/S0022-5223(96)70281-7; SPYT T J, 1990, Perfusion (London), V5, P57; SWART MJ, 1994, ANAESTH INTENS CARE, V22, P529, DOI 10.1177/0310057X9402200505; TEMECK BK, 1994, SOUTHERN MED J, V87, P611, DOI 10.1097/00007611-199406000-00006; UNSWORTHWHITE MJ, 1995, ANN THORAC SURG, V59, P664; vanderMeer J, 1996, THROMB HAEMOSTASIS, V75, P1; VanderSalm TJ, 1996, J THORAC CARDIOV SUR, V112, P1098, DOI 10.1016/S0022-5223(96)70112-5; VANDERSALM TJ, 1996, J THORAC CARDIOVASC, V112, P1125; Vedrinne C, 1992, J Cardiothorac Vasc Anesth, V6, P319, DOI 10.1016/1053-0770(92)90149-2; Zonis Z, 1996, J THORAC CARDIOV SUR, V111, P982, DOI 10.1016/S0022-5223(96)70374-4	105	357	371	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1940	1947		10.1016/S0140-6736(99)01264-7	http://dx.doi.org/10.1016/S0140-6736(99)01264-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622296				2022-12-28	WOS:000084034700010
J	Redmond, T				Redmond, T			How do you eat an elephant?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Hosp Pristina, Kosovo, Yugoslavia		Redmond, T (corresponding author), Univ Hosp Pristina, Kosovo, Yugoslavia.								0	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1652	1653		10.1136/bmj.319.7225.1652	http://dx.doi.org/10.1136/bmj.319.7225.1652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600985	Green Published			2022-12-28	WOS:000084562600036
J	Andrews, NC				Andrews, NC			Medical progress: Disorders of iron metabolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEONATAL HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR; AFRICAN-AMERICANS; CONGENITAL ATRANSFERRINEMIA; LIVER-TRANSPLANTATION; MICROCYTIC ANEMIA; GENE; OVERLOAD; DEFICIENCY		Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Andrews, NC (corresponding author), Childrens Hosp, Div Hematol & Oncol, Enders 720,300 Longwood Ave, Boston, MA 02115 USA.	nandrews@rascal.med.harvard.edu		Andrews, Nancy/0000-0003-0243-4462	NHLBI NIH HHS [HL51057] Funding Source: Medline; NIDDK NIH HHS [R01 DK053813-10, DK53813, R01 DK053813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051057, R01HL051057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053813] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; Ajioka RS, 1997, AM J HUM GENET, V60, P1439, DOI 10.1086/515466; ANDREWS NC, 1998, NATHAN OSKIS HEMATOL, V1, P423; AUERBACH M, 1988, J LAB CLIN MED, V111, P566; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; Baer D, 1996, AM J MED, V101, P5, DOI 10.1016/S0002-9343(96)00157-X; Baker SS, 1999, PEDIATRICS, V104, P119; BANNERMAN RM, 1981, J PEDIATR-US, V98, P760, DOI 10.1016/S0022-3476(81)80838-4; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Barton JC, 1999, BLOOD CELL MOL DIS, V25, P146; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; Blaud P., 1832, REV MED FR ETRANG, V45, P357; BLISARD KS, 1986, HUM PATHOL, V17, P376, DOI 10.1016/S0046-8177(86)80461-0; Bothwell T.H., 1962, IRON METABOLISM; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; Brugnara C, 1999, JAMA-J AM MED ASSOC, V281, P2225, DOI 10.1001/jama.281.23.2225; BUCHANAN GR, 1981, J PEDIATR-US, V98, P723, DOI 10.1016/S0022-3476(81)80831-1; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; COOK JD, 1973, AM J PATHOL, V72, P337; DALHOJ J, 1990, AM J MED GENET, V37, P342, DOI 10.1002/ajmg.1320370310; DANKS D, 1963, ARCH DIS CHILD, V38, P378, DOI 10.1136/adc.38.200.378; DAVIS WD, 1950, J LAB CLIN MED, V36, P814; DRISCOLL S G, 1988, American Journal of Human Genetics, V43, pA232; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Eisenstein RS, 1998, NUTR REV, V56, P356, DOI 10.1111/j.1753-4887.1998.tb01679.x; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; FINCH C, 1994, BLOOD, V84, P1697; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; FRIEDEN E, 1976, ADV ENZYMOL RAMB, V44, P187; Galanello R, 1998, BLOOD, V92, p669A; Gangaidzo IT, 1999, GUT, V45, P278, DOI 10.1136/gut.45.2.278; GOLDFISCHER S, 1981, HEPATOLOGY, V1, P58, DOI 10.1002/hep.1840010110; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; GORDEUK VR, 1992, BAILLIERE CLIN HAEM, V5, P169, DOI 10.1016/S0950-3536(11)80040-5; Gordeuk VR, 1996, BLOOD, V87, P3470, DOI 10.1182/blood.V87.8.3470.bloodjournal8783470; Gordeuk VR, 1998, BLOOD, V91, P2175, DOI 10.1182/blood.V91.6.2175.2175_2175_2179; GOYA N, 1972, BLOOD-J HEMATOL, V40, P239, DOI 10.1182/blood.V40.2.239.239; GUGGENHEIM KY, 1995, J NUTR, V125, P1822, DOI 10.1093/jn/125.7.1822; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hahn PF, 1943, J EXP MED, V78, P169, DOI 10.1084/jem.78.3.169; HAMILL RL, 1991, AM J CLIN PATHOL, V96, P215, DOI 10.1093/ajcp/96.2.215; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hartman KR, 1996, AM J HEMATOL, V51, P269, DOI 10.1002/(SICI)1096-8652(199604)51:4<269::AID-AJH4>3.0.CO;2-U; HAYASHI A, 1993, AM J HUM GENET, V53, P201; HEILMEYER L, 1961, GERM MED MONTHLY, V6, P385; HOOGSTRATEN J, 1990, GASTROENTEROLOGY, V98, P1699, DOI 10.1016/0016-5085(90)91110-R; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Knisely A S, 1992, Adv Pediatr, V39, P383; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Levy JE, 1999, BLOOD, V94, P9, DOI 10.1182/blood.V94.1.9.413a43_9_11; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; LUND DP, 1993, TRANSPLANT P, V25, P1068; McKie AT, 1998, BIOCHEM SOC T, V26, pS264, DOI 10.1042/bst026s264; McNamara L, 1998, BRIT J HAEMATOL, V102, P1176; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Monaghan KG, 1998, AM J HEMATOL, V58, P213, DOI 10.1002/(SICI)1096-8652(199807)58:3<213::AID-AJH9>3.0.CO;2-U; MOORE DF, 1994, AM J MED, V97, P390, DOI 10.1016/0002-9343(94)90309-3; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; Moyo V. M., 1997, Central African Journal of Medicine, V43, P334; Moyo VM, 1998, BLOOD, V91, P1076; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; OSKI FA, 1982, MAJOR PROBLEMS CLIN, V4, P32; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; POLLITT E, 1993, ANNU REV NUTR, V13, P521, DOI 10.1146/annurev.nu.13.070193.002513; RAND EB, 1992, J PEDIATR GASTR NUTR, V15, P325, DOI 10.1097/00005176-199210000-00017; RIEDEL HD, 1995, BIOCHEM J, V309, P745, DOI 10.1042/bj3090745; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Sigurdsson L, 1998, J PEDIATR GASTR NUTR, V26, P85, DOI 10.1097/00005176-199801000-00015; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; Trousseau A, 1865, CLIN MED HOTEL PARIS, V2, P663; von Recklinghausen FD, 1889, TAGEBL VERSAMML NATU, V62, P324; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Wallace DF, 1999, GASTROENTEROLOGY, V116, P1409, DOI 10.1016/S0016-5085(99)70505-6; WITZLEBEN CL, 1989, HUM PATHOL, V20, P335, DOI 10.1016/0046-8177(89)90042-7; Wurapa RK, 1996, AM J MED, V101, P9, DOI 10.1016/S0002-9343(96)00053-8; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	86	1295	1359	7	147	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1986	1995		10.1056/NEJM199912233412607	http://dx.doi.org/10.1056/NEJM199912233412607			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607817				2022-12-28	WOS:000084399400007
J	Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE				Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE			Improved clinical outcome after widespread use of coronary-artery stenting in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WAVE MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; BYPASS-SURGERY; ADMINISTRATIVE DATA; COMORBIDITY INDEX; FOLLOW-UP; DISEASE; PLACEMENT; THROMBOLYSIS	Background: The introduction and refinement of coronary-artery stenting dramatically changed the practice of percutaneous coronary revascularization in the mid-1990s. We analyzed one-year follow-up data for all percutaneous coronary interventions performed in a large, unselected population in Canada to determine whether the use of coronary stenting has been associated with improved outcomes. Methods: Prospectively collected data on all percutaneous coronary interventions performed on residents of British Columbia, Canada, between April 1994 and June 1997 were linked to province-wide health care data bases to provide the date of the following end points: subsequent target-vessel revascularization, myocardial infarction, and death. Base-line characteristics and procedural variables were identified and Kaplan-Meier survival curves were generated for 9594 procedures divided into seven groups, one for each sequential half-year period. Results: The overall burden of coexisting illnesses remained stable throughout the study period. A large increase in the rate of coronary stenting (from 14.2 percent in the period from April to June 1994 to 58.7 percent in the period from January to June 1997) was associated with a significant reduction in the rate of adverse cardiac events at one year (from 28.8 percent to 22.8 percent; adjusted relative risk, 0.79; 95 percent confidence interval, 0.69 to 0.90; P<0.001). This reduction in adverse events was exclusively due to a large reduction in subsequent target-vessel revascularization (from 24.4 percent to 17.0 percent; adjusted relative risk, 0.72; 95 percent confidence interval, 0.62 to 0.83; P<0.001) without significant changes in the overall rates of myocardial infarction (5.4 percent, P=0.28) or death (3.9 percent, P=0.65). Conclusions: The need for target-vessel revascularization during one year of follow-up after percutaneous coronary intervention decreased during the mid-1990s. The reduction was coincident with the introduction and subsequent widespread use of coronary stenting. (N Engl J Med 1999;341:1957-65.) (C)1999, Massachusetts Medical Society.	Vancouver Gen Hosp, Vancouver, BC, Canada; British Columbian Cardiac Registries, Vancouver, BC, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Royal Jubilee Hosp, Victoria, BC, Canada; Royal Columbian Hosp, New Westminster, BC, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Buller, CE (corresponding author), Intervent Cardiol Res, 865 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.		Spinelli, John J./B-6210-2013	Spinelli, John J./0000-0002-9119-3287				Alderman EL, 1996, NEW ENGL J MED, V335, P217; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Buller CE, 1999, CIRCULATION, V100, P236, DOI 10.1161/01.CIR.100.3.236; *BYP ANG REV INV I, 1996, NEW ENGL J MED, V336, P147; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Gruntzig A, 1980, G Ital Cardiol, V10, P261; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Landon B, 1996, INQUIRY-J HEALTH CAR, V33, P155; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Pitt B, 1998, CIRCULATION, V98, P636; *PRINC INV CASS TH, 1981, CIRCULATION S1, V63, P1; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys P, 1998, LANCET, V352, P1478; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; TERRIN ML, 1993, J AM COLL CARDIOL, V22, P1763, DOI 10.1016/0735-1097(93)90755-P; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 1998, NEW ENGL J MED, V339, P1702, DOI 10.1056/NEJM199812033392311; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Williams JI, 1996, 9603TR I CLIN EV SCI	37	102	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1957	1965		10.1056/NEJM199912233412602	http://dx.doi.org/10.1056/NEJM199912233412602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607812				2022-12-28	WOS:000084399400002
J	Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN				Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN			Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; STRAIN DIFFERENTIATION; TRANSMISSION; POLYMORPHISM; ELEMENT; IS6110; PROBE	Context Typing of Mycobacterium tuberculosis could provide a more sensitive means of identifying outbreaks than use of conventional surveillance techniques alone. Variants of the New York City W strain of M tuberculosis were identified in New Jersey. Objective To describe the spread of the W family of M tuberculosis strains in New Jersey identified by molecular typing and surveillance data. Design Population-based cross-sectional study. Setting and Subjects All incident culture-positive tuberculosis cases reported in New Jersey from January 1996 to September 1998, for which the W family was defined by insertion sequence (IS) IS6110 DNA fingerprinting, polymorph ic GC-rich repetitive sequence (PGRS) typing, spacer oligotyping (spoligotyping), and variable number tandem repeat (VNTR) analysis. Main Outcome Measure Identification and characterization of W family clones supplemented by surveillance data. Results Isolates from 1207 cases were analyzed, of which 68 isolates (6%) belonged to the W family based on IS6110 and spoligotype hybridization patterns. The IS6110 hybridization patterns or fingerprints revealed that 43 patients (designated group A) shared a unique banding motif not present in other W family isolates. Strains collected from the remaining 25 patients (designated group B), while related to W, displayed a variety of IS6110 patterns and did not share this motif, The PGRS and VNTR typing confirmed the division of the W family into groups A and B and again showed group A strains to be closely related and group B strains to be more diverse. The demographic characteristics of individuals from groups A and B were specific and defined. Group A patients were more likely than group B patients to be US born (91% vs 24%, P < .001), black (76% vs 16%, P < .001), human immunodeficiency virus positive (40% vs 0%, P = .007), and residents of urban northeast New Jersey counties (P < .001), Patients with group B strains were primarily non-US born, of Asian descent, and more dispersed throughout New Jersey. No outbreak had been detected using conventional surveillance alone. Conclusions The implementation of multiple molecular techniques in conjunction with surveillance data enabled us to identify a previously undetected outbreak in a defined geographical setting. The outbreak isolates comprise members of a distinct branch of the W family phylogenetic lineage. The use of molecular strain typing provides a proactive approach that may be used to initiate, and not just augment, traditional surveillance outbreak investigations.	Publ Hlth Res Inst City New York Inc, TB Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY USA; New Jersey Dept Hlth & Senior Serv, Div Communicable Dis, Trenton, NJ USA; Univ Washington, Dept Geog, Seattle, WA 98195 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Baylor Coll Med, Dept Pathol, Inst Study Human Bacterial Pathogenesis, Houston, TX 77030 USA	New York University; New York University; New Jersey Department of Health & Senior Services; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; Wadsworth Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Baylor College of Medicine	Kreiswirth, BN (corresponding author), Publ Hlth Res Inst City New York Inc, TB Ctr, 455 1st Ave, New York, NY 10016 USA.			Bifani, Pablo/0000-0001-9651-6439; Tempalski, Barbara/0000-0002-6128-2510; Mathema, Barun/0000-0003-2772-479X	NIAID NIH HHS [AI27742] Funding Source: Medline; NIDA NIH HHS [DA09238] Funding Source: Medline; PHS HHS [NL51517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; Frothingham R, 1998, MICROBIOL-UK, V144, P1189, DOI 10.1099/00221287-144-5-1189; GROENEN PMA, 1993, MOL MICROBIOL, V10, P1057, DOI 10.1111/j.1365-2958.1993.tb00976.x; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; KREISWIRTH BN, 1996, TUBERCULOSIS, P199; Kurepina N. E., 1998, Tubercle and Lung Disease, V79, P31, DOI 10.1054/tuld.1998.0003; LIN R, 1996, INT J INFECT DIS, V1, P18; Moss AR, 1997, INT J TUBERC LUNG D, V1, P115; Palittapongarnpim P, 1997, INT J TUBERC LUNG D, V1, P370; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; TORREA G, 1995, J CLIN MICROBIOL, V33, P1899, DOI 10.1128/JCM.33.7.1899-1904.1995; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991	27	138	151	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2321	2327		10.1001/jama.282.24.2321	http://dx.doi.org/10.1001/jama.282.24.2321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612319				2022-12-28	WOS:000084261700025
J	Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE				Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE			Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study	ANNALS OF INTERNAL MEDICINE			English	Article							STROKE PREVENTION; PHYSICIAN ATTITUDES; NATIONAL PATTERNS; COMMUNITY; PROPHYLAXIS; PREVALENCE; HOSPITALS; ASPIRIN	Background: Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied. Objective: To assess the rates and predictors of warfarin use in ambulatory patients with nonvalvular atrial fibrillation. Design: Cross-sectional study. Setting: Large health maintenance organization. Patients: 13428 patients with a confirmed ambulatory diagnosis of nonvalvular atrial fibrillation and known warfarin status between 1 July 1996 and 31 December 1997. Measurements: Data from automated pharmacy, laboratory, and clinical-administrative databases were used to determine the prevalence and determinants of warfarin use in the 3 months before or after the identified diagnosis of atrial fibrillation. Results: Of 11082 patients with nonvalvular atrial fibrillation and no known contraindications, 55% received warfarin. Warfarin use was substantially lower in patients who were younger than 55 years of age (44.3%) and those who were 85 years of age or older (35.4%). Only 59.3% of patients with one or more risk factors for stroke and no contraindications were receiving warfarin. Among a subset of "ideal" candidates to receive warfarin (persons 65 to 74 years of age who had no contraindications and had previous stroke, hypertension, or both), 62.1% had evidence of warfarin use. Among our entire cohort, the strongest predictors of receiving warfarin were previous stroke (adjusted odds ratio, 2.55 [95% CI, 2.23 to 2.92]), heart failure (odds ratio, 1.63 [CI, 1.51 to 1.77]), previous intracranial hemorrhage (odds ratio, 0.33 [CI, 0.21 to 0.52]), age 85 years or older (odds ratio, 0.35 [CI, 0.31 to 0.40]), and previous gastrointestinal hemorrhage (odds ratio, 0.47 [CI, 0.40 to 0.57]). Conclusions: In a large, contemporary cohort of ambulatory patients with atrial fibrillation who received care within a health maintenance organization, warfarin use was considerably higher than in other reported studies. Although the reasons why physicians did not prescribe warfarin could not be elucidated, many apparently eligible patients with atrial fibrillation and at least one additional risk factor for stroke, especially hypertension, did not receive anticoagulation. Interventions are needed to increase the use of warfarin for stroke prevention among appropriate candidates.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Kaiser Permanente; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Go, AS (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway St,12th Floor, Oakland, CA 94611 USA.	axg@dor.kaiser.org	Go, Alan S./AAE-7745-2019	Hylek, Elaine/0000-0001-8263-8304	NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; *AM SOC HLTH SYST, 1998, AM J HEALTH-SYST PH, V55, P376; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; Arnsten JH, 1997, AM J MED, V103, P11, DOI 10.1016/S0002-9343(97)90048-6; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; Blackshear JL, 1996, LANCET, V348, P633; Brass LM, 1998, ARCH INTERN MED, V158, P2093, DOI 10.1001/archinte.158.19.2093; Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382; Cleves M A, 1997, Jt Comm J Qual Improv, V23, P550; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Diggle PJ, 1994, ANAL LONGITUDINAL DA; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Flaker GC, 1999, AM HEART J, V137, P307, DOI 10.1053/hj.1999.v137.91403; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Greenberg MK, 1998, NEUROLOGY, V51, P671; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Gurwitz JH, 1997, ARCH INTERN MED, V157, P978, DOI 10.1001/archinte.157.9.978; Kerr C, 1996, EUR HEART J, V17, P48, DOI 10.1093/eurheartj/17.suppl_C.48; Kerr CR, 1998, AM J CARDIOL, V82, p82N, DOI 10.1016/S0002-9149(98)00589-X; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; Lackner T E, 1995, Arch Fam Med, V4, P1017, DOI 10.1001/archfami.4.12.1017; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; Munschauer FE, 1997, STROKE, V28, P72, DOI 10.1161/01.STR.28.1.72; PETERSEN P, 1989, LANCET, V1, P175; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Smith NL, 1999, ARCH INTERN MED, V159, P1574, DOI 10.1001/archinte.159.14.1574; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Teo K, 1998, CAN J CARDIOL, V14, P695; White RH, 1999, AM J MED, V106, P165, DOI 10.1016/S0002-9343(98)00389-1; Whittle J, 1997, ARCH INTERN MED, V157, P441, DOI 10.1001/archinte.157.4.441	48	495	508	2	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					927	+		10.7326/0003-4819-131-12-199912210-00004	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610643				2022-12-28	WOS:000084374400003
J	Tyrer, P				Tyrer, P			Borderline personality disorder: a motley diagnosis in need of reform	LANCET			English	Editorial Material							AXIS-II		Univ London Imperial Coll Sci Technol & Med, Dept Publ Mental Hlth, Div Neurosci & Psychol Med, London W2 1PD, England	Imperial College London	Tyrer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Publ Mental Hlth, Div Neurosci & Psychol Med, London W2 1PD, England.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bateman A, 1999, AM J PSYCHIAT, V156, P1563, DOI 10.1176/ajp.156.10.1563; Blais MA, 1999, J NERV MENT DIS, V187, P167, DOI 10.1097/00005053-199903000-00006; Herpertz SC, 1999, AM J PSYCHIAT, V156, P1550, DOI 10.1176/ajp.156.10.1550; Hooley JM, 1999, AM J PSYCHIAT, V156, P1557, DOI 10.1176/ajp.156.10.1557; Kernberg O.F., 1975, BORDERLINE CONDITION; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Links PS, 1998, CAN J PSYCHIAT, V43, P265, DOI 10.1177/070674379804300305; SALZMAN C, 1995, J CLIN PSYCHOPHARM, V15, P23, DOI 10.1097/00004714-199502000-00005; Tyrer P, 1996, AM J PSYCHIAT, V153, P1593; Westen D, 1997, AM J PSYCHIAT, V154, P895; WHO, 2012, ICD 10 CLASS MENT BE; ZANARINI MC, 1989, COMPR PSYCHIAT, V30, P18, DOI 10.1016/0010-440X(89)90114-4; Zimmerman M, 1999, AM J PSYCHIAT, V156, P1570, DOI 10.1176/ajp.156.10.1570; Zimmerman M, 1999, COMPR PSYCHIAT, V40, P245, DOI 10.1016/S0010-440X(99)90123-2	15	44	45	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2095	2096		10.1016/S0140-6736(99)00401-8	http://dx.doi.org/10.1016/S0140-6736(99)00401-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609809				2022-12-28	WOS:000084318200003
J	Ramos, L; Lubensky, TC; Dan, N; Nelson, P; Weitz, DA				Ramos, L; Lubensky, TC; Dan, N; Nelson, P; Weitz, DA			Surfactant-mediated two-dimensional crystallization of colloidal crystals	SCIENCE			English	Article							NEUTRON-SCATTERING; MEMBRANES; COMPLEXES; PHASE	Colloidal particles can form unexpected two-dimensional ordered colloidal crystals when they interact with surfactants of the opposite charge. Coulomb interactions Lead to self-limited adsorption of the particles on the surface of vesicles formed by the surfactants. The adsorbed particles form ordered but fluid rafts on the vesicle surfaces, and these ultimately form robust two-dimensional crystals. This use of attractive Coulomb interaction between colloidal particles and surfactant structures offers a potential new route to self-assembly of ordered colloidal structures.	Drexel Univ, Dept Phys & Astron, Philadelphia, PA 19104 USA; Drexel Univ, Dept Chem Engn, Philadelphia, PA 19104 USA	Drexel University; Drexel University; University of Pennsylvania	Weitz, DA (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.		ramos, laurence/C-4610-2013; Nelson, Philip C/I-6251-2015	Nelson, Philip C/0000-0002-1782-3076				Aranda-Espinoza H, 1999, SCIENCE, V285, P394, DOI 10.1126/science.285.5426.394; BEYER K, 1982, J COLLOID INTERF SCI, V86, P73, DOI 10.1016/0021-9797(82)90042-X; DUBOIS M, 1993, LANGMUIR, V9, P673, DOI 10.1021/la00027a011; GOULIAN M, 1993, EUROPHYS LETT, V22, P145, DOI 10.1209/0295-5075/22/2/012; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Koltover I, 1999, PHYS REV LETT, V82, P1991, DOI 10.1103/PhysRevLett.82.1991; Oberdisse J, 1996, LANGMUIR, V12, P1212, DOI 10.1021/la950313l; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; WONG K, 1989, LANGMUIR, V5, P1346, DOI 10.1021/la00090a014; Yang PD, 1998, SCIENCE, V282, P2244, DOI 10.1126/science.282.5397.2244; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897	13	113	114	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2325	2328		10.1126/science.286.5448.2325	http://dx.doi.org/10.1126/science.286.5448.2325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600739				2022-12-28	WOS:000084318500056
J	Kemp, M				Kemp, M			Slanted evidence	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2BE, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 59 George St, Oxford OX1 2BE, England.								0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					727	727		10.1038/45392	http://dx.doi.org/10.1038/45392			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617190	Bronze			2022-12-28	WOS:000084330500029
J	Staszewski, S; Morales-Ramirez, J; Tashima, KT; Rachlis, A; Skiest, D; Stanford, J; Stryker, R; Johnson, P; Labriola, DF; Farina, D; Manion, DJ; Ruiz, NM				Staszewski, S; Morales-Ramirez, J; Tashima, KT; Rachlis, A; Skiest, D; Stanford, J; Stryker, R; Johnson, P; Labriola, DF; Farina, D; Manion, DJ; Ruiz, NM		Study 006 Team	Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; REVERSE-TRANSCRIPTASE INHIBITORS; HIGH-DOSE NEVIRAPINE; PROTEASE INHIBITORS; ANTIRETROVIRAL THERAPY; TYPE-1 RNA; COMBINATION THERAPY; INSULIN-RESISTANCE; CONTROLLED TRIAL; PLASMA	Background: Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). We compared two regimens containing efavirenz, one with a protease inhibitor and the other with two nucleoside reverse-transcriptase inhibitors, with a standard three-drug regimen. Methods: The study subjects were 450 patients who had not previously been treated with lamivudine or any nonnucleoside reverse-transcriptase inhibitor or protease inhibitor. In this open-label study, patients were randomly assigned to one of three regimens: efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily); the protease inhibitor indinavir (800 mg every eight hours) plus zidovudine and lamivudine; or efavirenz plus indinavir (1000 mg every eight hours). Results: Suppression of plasma HIV-1 RNA to undetectable levels was achieved in more patients in the group given efavirenz plus nucleoside reverse-transcriptase inhibitors than in the group given indinavir plus nucleoside reverse-transcriptase inhibitors (70 percent vs. 48 percent, P<0.001). The efficacy of the regimen of efavirenz plus indinavir was similar (53 percent) to that of the regimen of indinavir, zidovudine, and lamivudine. CD4 cell counts increased significantly with all combinations (range of increases, 180 to 201 cells per cubic millimeter). More patients discontinued treatment because of adverse events in the group given indinavir and two nucleoside reverse-transcriptase inhibitors than in the group given efavirenz and two nucleoside reverse-transcriptase inhibitors (43 percent vs. 27 percent, P=0.005). Conclusions: As antiretroviral therapy in HIV-1-infected adults, the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity and is better tolerated than the combination of indinavir, zidovudine, and lamivudine. (N Engl J Med 1999;341:1865-73.) (C)1999, Massachusetts Medical Society.	JW Goethe Univ Klinikum, Frankfurt, Germany; Clin Res Puerto Rico, San Juan, PR USA; Miriam Hosp, Providence, RI 02906 USA; Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON, Canada; Univ Texas, Hlth Sci Ctr, SW Med Sch, Dallas, TX 75235 USA; Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA; Kansas City AIDS Res Consortium, Kansas City, MO 64110 USA; Pacific Oaks Res, Beverly Hills, CA USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19805 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Lifespan Health Rhode Island; Miriam Hospital; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health Science Center Houston; DuPont	Manion, DJ (corresponding author), Dupont Merck Pharmaceut Co, Rm HR 2003,974 Ctr Rd,Chestnut Run Plaza, Wilmington, DE 19805 USA.							Bourezane Y, 1998, CLIN INFECT DIS, V27, P1321, DOI 10.1086/517713; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chene G, 1998, CONTROL CLIN TRIALS, V19, P233, DOI 10.1016/S0197-2456(97)00145-1; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; deJong MD, 1997, J INFECT DIS, V175, P966, DOI 10.1086/514002; Demeter LM, 1997, J ACQ IMMUN DEF SYND, V14, P136, DOI 10.1097/00042560-199702010-00006; *DIV CANC TREATM, 1988, GUID REP ADV DRUG RE; ERICKSONVIITANE.S, 1999, 6 C RETR OPP INF CHI; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Floridia M, 1999, J ACQ IMMUN DEF SYND, V20, P11, DOI 10.1097/00042560-199901010-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HASHIDA S, 1996, J VIROL METHODS, V62, P4; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Katzenstein D A, 1997, J Assoc Nurses AIDS Care, V8 Suppl, P10, DOI 10.1016/S1055-3290(97)80003-9; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; KILBY JM, 1994, INFECT AGENT DIS, V3, P313; Kleinman KP, 1998, BIOMETRICS, V54, P265, DOI 10.2307/2534013; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Malaty LI, 1999, DRUG SAFETY, V20, P147, DOI 10.2165/00002018-199920020-00005; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, SCIENCE, V275, P14; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; *PAN CLIN PRACT TR, 1998, J INT ASS PHYSICI S2, V5, P4; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Segondy M, 1998, J CLIN MICROBIOL, V36, P3392, DOI 10.1128/JCM.36.11.3392-3395.1998; Silva M, 1998, AIDS, V12, P1645, DOI 10.1097/00002030-199813000-00012; Stone VE, 1998, J GEN INTERN MED, V13, P586, DOI 10.1046/j.1525-1497.1998.00180.x; Striker R, 1998, CLIN INFECT DIS, V27, P218, DOI 10.1086/517682; Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998; Sutherland SE, 1997, J UROLOGY, V158, P31, DOI 10.1097/00005392-199707000-00007; TSIATIS A, 1990, J ACQ IMMUN DEF SYND, V3, pS120; VanCleef GF, 1997, PHARMACOTHERAPY, V17, P774; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Yeh KC, 1998, ANTIMICROB AGENTS CH, V42, P1308, DOI 10.1128/AAC.42.5.1308; YOULE M, 1999, AIDS S4, V12, pS63; 1996, MMWR MORB MORTAL WKL, V45, P921	46	796	827	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1865	1873		10.1056/NEJM199912163412501	http://dx.doi.org/10.1056/NEJM199912163412501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601505	Bronze			2022-12-28	WOS:000084210200001
J	Longworth, C; Honey, G; Sharma, T				Longworth, C; Honey, G; Sharma, T			Science, medicine, and the future - Functional magnetic resonance imaging in neuropsychiatry	BRITISH MEDICAL JOURNAL			English	Review							ALZHEIMERS-DISEASE; SCHIZOPHRENIA; MRI; ACTIVATION; LATERALIZATION; BRAIN; FMRI		Inst Psychiat, Dept Psychol Med, Sect Cognit Psychopharmacol, London SE5 8AF, England	University of London; King's College London	Sharma, T (corresponding author), Inst Psychiat, Dept Psychol Med, Sect Cognit Psychopharmacol, London SE5 8AF, England.		Ford, Catherine/AAW-4008-2021	Ford, Catherine/0000-0002-8646-9402				Beauregard M, 1998, NEUROREPORT, V9, P3253, DOI 10.1097/00001756-199810050-00022; Bookheimer SY, 1996, NEUROIMAGE, V4, pS139, DOI 10.1006/nimg.1996.0064; Buchbinder B R, 1998, Magn Reson Imaging Clin N Am, V6, P67; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; Bullmore ET, 1999, HUM BRAIN MAPP, V7, P38, DOI 10.1002/(SICI)1097-0193(1999)7:1<38::AID-HBM4>3.3.CO;2-H; Curtis VA, 1998, AM J PSYCHIAT, V155, P1056, DOI 10.1176/ajp.155.8.1056; GEORGE JS, 1995, J CLIN NEUROPHYSIOL, V12, P406, DOI 10.1097/00004691-199509010-00002; Harris GJ, 1996, AM J PSYCHIAT, V153, P721; Honey GD, 1998, SCHIZOPHR RES, V29, P65, DOI 10.1016/S0920-9964(97)88459-9; Honey GD, 1998, SCHIZOPHR RES, V29, P70, DOI 10.1016/S0920-9964(97)88471-X; Honey GD, 1999, SCHIZOPHR RES, V36, P223; Howard R, 1997, DEMENT GERIATR COGN, V8, P73, DOI 10.1159/000106610; Kotchoubey B, 1997, NEUROREPORT, V8, P1867, DOI 10.1097/00001756-199705260-00015; Mattay VS, 1997, NEUROREPORT, V8, P2977, DOI 10.1097/00001756-199709080-00034; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; PAULESU E, 1995, FUNCT NEUROIMAGING, V5, P207; Sandson TA, 1996, NEUROLOGY, V47, P1339, DOI 10.1212/WNL.47.5.1339; VANMUISWINKLE AMC, 1999, NEUROIMAGE, V9, pS212; WENZ F, 1994, MAGN RESON IMAGING, V12, P975, DOI 10.1016/0730-725X(94)91227-N; Woodruff PWR, 1997, AM J PSYCHIAT, V154, P1676, DOI 10.1176/ajp.154.12.1676	21	11	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1551	1554		10.1136/bmj.319.7224.1551	http://dx.doi.org/10.1136/bmj.319.7224.1551			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591721	Green Published			2022-12-28	WOS:000084245600027
J	Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ				Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ			Possible ancient oceans on Mars: Evidence from Mars Orbiter Laser Altimeter data	SCIENCE			English	Article							TOPOGRAPHY; UTOPIA	High-resolution altimetric data define the detailed topography of the northern lowlands of Mars, and a range of data is consistent with the hypothesis that a Lowland-encircling geologic contact represents the ancient shoreline of a Large standing body of water present in middle Mars history. The contact altitude is close to an equipotential Line, the topography is smoother at all scales below the contact than above it, the volume enclosed by this contact is within the range of estimates of available water on Mars, and a series of extensive terraces parallel the contact in many places.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Russian Acad Sci, Vernadsky Inst, Moscow 117975, Russia; Kharkov State Univ, Kharkov Astron Observ, UA-310022 Kharkov, Ukraine	Brown University; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National University	Head, JW (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Thomson, Bradley/AAA-3496-2022; Kreslavsky, Mikhail/J-3425-2013	Thomson, Bradley/0000-0001-8635-8932; Ivanov, Mikhail/0000-0001-5696-8131; Kreslavsky, Mikhail/0000-0002-1900-826X				Aharonson O, 1998, GEOPHYS RES LETT, V25, P4413, DOI 10.1029/1998GL900057; Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; BANIN A., 2000, MARS, P594; BIRD EC, 1976, BEACH PROCESSES SEDI; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CLIFFORD SM, 1999, LUNAR PLANET SCI, V30, P1619; Garvin JB, 1999, GEOPHYS RES LETT, V26, P381, DOI 10.1029/1998GL900309; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1987, US GEOL SUR VMISC IN; HEARD JW, 1998, GEOPHYS RES LETT, V25, P4401; IVANOV MA, 1999, 5 INT C MARS; Kreslavsky MA, 1999, J GEOPHYS RES-PLANET, V104, P21911, DOI 10.1029/1999JE001051; KUZMIN RO, 1988, SOLAR SYST RES, V22, P195; LUCCHITTA BK, 1986, J GEOPHYS RES, V91, P166; Malin MC, 1999, GEOPHYS RES LETT, V26, P3049, DOI 10.1029/1999GL002342; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MCGILL GE, 1986, GEOPHYS RES LETT, V13, P705, DOI 10.1029/GL013i008p00705; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; McSween HY, 1999, J GEOPHYS RES-PLANET, V104, P8679, DOI 10.1029/98JE02551; MUTCH TA, 1976, SCIENCE, V194, P1277, DOI 10.1126/science.194.4271.1277; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; ROTTO S, 1995, US GEOL SURV MISC IN; SCOTT DH, 1992, P LUNAR PLANET SCI, V22, P53; SCOTT DH, 1995, US GEOL SURV MISC IN; SCOTT DH, 1986, US GEOL SURV MISC IN; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; Squyres S. W., 1992, MARS, P523; Tanaka KL, 1997, J GEOPHYS RES-PLANET, V102, P4131, DOI 10.1029/96JE02862; TANAKA KL, 1992, US GEOL SURV MISC IN; TANAKA KL, 1987, US GEOL SURV MISC IN; Thomas P., 1992, MARS, P767; THOMSON BJ, 1999, LUNAR PLANET SCI C, V30, P1894; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	41	292	294	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2134	2137		10.1126/science.286.5447.2134	http://dx.doi.org/10.1126/science.286.5447.2134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591640				2022-12-28	WOS:000084157300045
J	Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA				Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA			Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, messenger; colorectal neoplasms; guanylate cyclase; neoplasm recurrence, local; lymph nodes	STABLE ENTEROTOXIN RECEPTORS; LYMPH-NODES; CARCINOEMBRYONIC ANTIGEN; ADJUVANT THERAPY; COLON-CANCER; OCCULT MICROMETASTASES; CARCINOMA; TUMORS; BREAST; FLUOROURACIL	Background: Patients with stage II colorectal cancer and no histologic evidence of lymph node invasion develop recurrent disease, presumably because of undetected micrometastases. Guanylyl cyclase C is expressed by intestinal and colorectal cancer cells but not by extraintestinal tissues or tumors. Objective: To examine the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer who did and did not have recurrent disease. Design: Case-control study. Setting: Tertiary care academic medical center. Patients: Paraffin-embedded lymph nodes were obtained from 21 patients with histologically confirmed node-negative colorectal cancer who had undergone resection. Controls included 11 patients without disease recurrence 6 or more yea rs after resection, a nd case-patients included 10 patients whose disease recurred up to 3 years after resection. Measurements: Sections of paraffin-embedded lymph nodes were obtained from each patient and were pooled, and their RNA was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Results: Guanylyl cyclase C mRNA was expressed in lymph nodes from all patients with recurrent disease but not in those from patients without recurrent disease (P = 0.004). Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1 of 10 patients with recurrent disease and those from 0 of 11 patients without recurrent disease. The odds ratio for death associated with expression of guanylyl cyclase C mRNA in regional lymph nodes was 15.0 (95% Cl, 1.1 to 756.7). Conclusions: Expression of guanylyl cyclase C mRNA in lymph nodes is associated with recurrence of colorectal cancer in patients with stage II disease. Analysis of guanylyl cyclase mRNA expression by RT-PCR may be useful for colorectal cancer staging.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg, Div Colorectal Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol & Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Div Gastroenterol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University	Waldman, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, 132 S 10th St,1170 Main, Philadelphia, PA 19107 USA.	scott.waldman@mail.tju.edu		Waldman, Scott/0000-0001-6619-175X; Park, Jason/0000-0001-6797-4000	NATIONAL CANCER INSTITUTE [R21CA079663, R01CA075123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008562] Funding Source: NIH RePORTER; NCI NIH HHS [CA79663, CA75123] Funding Source: Medline; NIGMS NIH HHS [5T32 GM08562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abati A, 1996, CANCER, V78, P1; ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; BEATTY JD, 1992, CANCER PHILA S5, V75, P1425; BORDES M, 1973, DIGESTION, V9, P106, DOI 10.1159/000197436; Bostick PJ, 1998, NEW ENGL J MED, V339, P1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; CARRITHERS SL, 1994, GASTROENTEROLOGY, V107, P1653, DOI 10.1016/0016-5085(94)90804-4; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; Carrithers SL, 1996, DIS COLON RECTUM, V39, P171, DOI 10.1007/BF02068072; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; CRESANTA JL, 1992, PRIMARY CARE, V19, P419; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUCHS CS, 1995, SEMIN ONCOL, V22, P472; Ghossein RA, 1998, NEW ENGL J MED, V339, P1642; GOLDENBERG DM, 1978, CANCER, V42, P1546, DOI 10.1002/1097-0142(197809)42:3+<1546::AID-CNCR2820420829>3.0.CO;2-D; Goldstein NS, 1996, AM J CLIN PATHOL, V106, P209; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; GREENWALD P, 1992, CANCER, V70, P1206, DOI 10.1002/1097-0142(19920901)70:3+<1206::AID-CNCR2820701504>3.0.CO;2-J; GUARINO A, 1987, DIGEST DIS SCI, V32, P1017, DOI 10.1007/BF01297193; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KROCZEK RA, 1993, J CHROMATOGR-BIOMED, V618, P133, DOI 10.1016/0378-4347(93)80031-X; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; Merrie AEH, 1998, NEW ENGL J MED, V339, P1642; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; RUBIO CA, 1977, SURG GYNECOL OBSTET, V145, P682; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLOANE JP, 1995, LANCET, V345, P1255, DOI 10.1016/S0140-6736(95)90921-4; Waldman SA, 1998, CANCER EPIDEM BIOMAR, V7, P505; Waldman SA, 1998, DIS COLON RECTUM, V41, P310, DOI 10.1007/BF02237484; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Zippelius A, 1997, J CLIN ONCOL, V15, P2701, DOI 10.1200/JCO.1997.15.7.2701	36	89	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					805	+		10.7326/0003-4819-131-11-199912070-00002	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610624				2022-12-28	WOS:000084053200001
J	Wessner, DR				Wessner, DR			Planning plasmids	SCIENCE			English	Software Review									Davidson Coll, Dept Biol, Davidson, NC 28036 USA	Davidson College	Wessner, DR (corresponding author), Davidson Coll, Dept Biol, POB 1719, Davidson, NC 28036 USA.								0	3	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1495	1496		10.1126/science.286.5444.1495	http://dx.doi.org/10.1126/science.286.5444.1495			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610552				2022-12-28	WOS:000083768300036
J	Venkitaraman, AR				Venkitaraman, AR			Cancer - Breast cancer genes and DNA repair	SCIENCE			English	Editorial Material							MEIOTIC CELLS; BRCA1; DAMAGE; RAD51; MICE; ATM; PHOSPHORYLATION; RADIATION; ACTIVATION; ACCUMULATE		Univ Cambridge, Dept Oncol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, Dept Oncol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; EASTON DF, 1994, INT J RADIAT BIOL, V66, P5177; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	33	48	50	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1100	1102		10.1126/science.286.5442.1100	http://dx.doi.org/10.1126/science.286.5442.1100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10610523				2022-12-28	WOS:000083534200029
J	Conroy, S; Choonara, I; Impicciatore, P; Mohn, A; Arnell, H; Rane, AR; Knoeppel, C; Seyberth, H; Pandolfini, C; Raffaelli, MP; Rocchi, F; Bonati, M; 't Jong, G; de Hoog, M; van den Anker, J				Conroy, S; Choonara, I; Impicciatore, P; Mohn, A; Arnell, H; Rane, AR; Knoeppel, C; Seyberth, H; Pandolfini, C; Raffaelli, MP; Rocchi, F; Bonati, M; 't Jong, G; de Hoog, M; van den Anker, J		European Network Drug Invest Child	Survey of unlicensed and off label drug use in paediatric wards in European countries	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the extent of use of unlicensed and off label drugs in children in hospital in five European countries. Design Prospective study of drugs administered to children in general paediatric medical wards over four weeks. Setting Children's wards in five hospitals tone each in the United Kingdom, Sweden, Germany, Italy, and the Netherlands). Subjects Children aged 4 days to 16 years admitted to general paediatric medical wards. Main outcome measure Proportion of drugs that were used in an unlicensed or off label manner. Results 2262 drug prescriptions were administered to 624 children in the five hospitals. Almost half of all drug prescriptions (1036; 46%) were either unlicensed or off label. Of these 1036, 872 were off label and 164 were unlicensed. Over half of the patients (421; 67%) received an unlicensed or off label drug prescription. Conclusions Use of off label or unlicensed drugs to treat children is widespread. This problem is likely to affect children throughout Europe and requires European action.	Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ Nottingham, Derbushire Childrens Hosp, Acad Div Child Hlth, Derby DE22 3NE, England; Univ Uppsala Hosp, Uppsala, Sweden; Univ Marburg, Childrens Hosp, Marburg, Germany; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; University of Nottingham; Uppsala University; Uppsala University Hospital; Philipps University Marburg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Choonara, I (corresponding author), Univ Nottingham, Derbushire Childrens Hosp, Acad Div Child Hlth, Derby DE22 3NE, England.		Pandolfini, Chiara/K-5693-2016; Bonati, Maurizio/K-8980-2016; de Hoog, Matthijs/A-3882-2013; Choonara, Imti/I-3559-2019	Pandolfini, Chiara/0000-0001-9809-2991; Bonati, Maurizio/0000-0003-3997-3726; Choonara, Imti/0000-0002-3069-6323				Bonati M, 1999, LANCET, V353, P1625, DOI 10.1016/S0140-6736(05)75752-4; BONATI M, 1994, J CLIN PHARMACOL, V34, P300, DOI 10.1002/j.1552-4604.1994.tb01997.x; Choonara I, 1998, ARCH DIS CHILD, V78, P402, DOI 10.1136/adc.78.5.402; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Cote CJ, 1996, PEDIATRICS, V98, P118; *EMEA, 1997, NOT GUID CLIN INV ME; Impicciatore P, 1999, BRIT J CLIN PHARMACO, V48, P15, DOI 10.1046/j.1365-2125.1999.00981.x; NAHATA MC, 1997, PAEDIAT PERINAT DRUG, V1, P50; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Turner S, 1996, LANCET, V347, P549, DOI 10.1016/S0140-6736(96)91182-4; Turner S, 1999, ACTA PAEDIATR, V88, P965, DOI 10.1080/08035259950168469; Turner S, 1998, BRIT MED J, V316, P343, DOI 10.1136/bmj.316.7128.343; TURNER S, 1997, PAEDIAT PERINAT DRUG, V1, P152	13	487	521	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					79	82		10.1136/bmj.320.7227.79	http://dx.doi.org/10.1136/bmj.320.7227.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625257	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000084746600014
J	Buser, R				Buser, R			The formation and early evolution of the Milky Way Galaxy	SCIENCE			English	Review							PROPER-MOTION STARS; ON SPIRAL GALAXIES; INTERMEDIATE-BAND PHOTOMETRY; GLOBULAR-CLUSTER SYSTEMS; HORIZONTAL-BRANCH STARS; GALACTIC HALO; STELLAR POPULATIONS; SURFACE PHOTOMETRY; THICK DISK; 3-DIMENSIONAL DISTRIBUTION				Buser, R (corresponding author), Univ Basel, Dept Astron, Venusstr 7, CH-4102 Binningen, Switzerland.	Roland.Buser@unibas.ch						AGUILAR L, 1988, ASTROPHYS J, V335, P720, DOI 10.1086/166961; Alcock C, 2000, SCIENCE, V287, P74, DOI 10.1126/science.287.5450.74; Arnett D, 1997, SCIENCE, V276, P1359, DOI 10.1126/science.276.5317.1359; ARNOLD R, 1992, MON NOT R ASTRON SOC, V257, P225, DOI 10.1093/mnras/257.2.225; Baade W, 1944, ASTROPHYS J, V100, P137, DOI 10.1086/144650; BATTRICK B, 1997, ESA SPEC PUBL, V402, P52; BECKER W, 1972, Q J ROY ASTRON SOC, V13, P226; BECKER W, 1980, ASTRON ASTROPHYS, V87, P80; BEERS TC, 1995, ASTROPHYS J SUPPL S, V96, P175, DOI 10.1086/192117; Blaauw A., 1965, GALACTIC STRUCTURE; Bland-Hawthorn J, 2000, SCIENCE, V287, P79, DOI 10.1126/science.287.5450.79; BULGARELLA D, 1997, SCIENCE, V276, P1370; BURSTEIN D, 1979, ASTROPHYS J, V234, P829, DOI 10.1086/157563; Buser R, 1999, ASTRON ASTROPHYS, V348, P98; BUSER R, 1992, ASTRON ASTROPHYS, V264, P557; Buser R, 1998, ASTRON ASTROPHYS, V331, P934; Carney BW, 1996, PUBL ASTRON SOC PAC, V108, P900, DOI 10.1086/133811; CARNEY BW, 1989, ASTRON J, V97, P423, DOI 10.1086/114992; Carney BW, 1996, ASTRON J, V112, P668, DOI 10.1086/118042; CARNEY BW, IN PRESS SAAS FEE AD, V28; Chaboyer B, 1996, ASTROPHYS J, V459, P558, DOI 10.1086/176921; Chiba M, 1998, ASTRON J, V115, P168, DOI 10.1086/300177; CUDWORTH KM, 1993, ASTRON J, V105, P168, DOI 10.1086/116417; DACOSTA GS, 1995, ASTRON J, V109, P2533, DOI 10.1086/117469; Dinescu DI, 1997, ASTRON J, V114, P1014, DOI 10.1086/118532; Dinescu DI, 1999, ASTRON J, V117, P277, DOI 10.1086/300699; DOINIDIS SP, 1989, ASTROPHYS J, V340, pL57, DOI 10.1086/185438; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; EGGEN OJ, 1977, ASTROPHYS J, V215, P812, DOI 10.1086/155418; EGGEN OJ, 1978, ASTROPHYS J, V221, P881, DOI 10.1086/156091; EGGEN OJ, 1962, ASTROPHYS J, V136, P748, DOI 10.1086/147433; EGRET D, 1999, ASTRON SOC PACIFIC C, V167; FREEMAN KC, 1995, IAU S, V164, P119; FREEMAN KC, 1991, DYNAMICS DISC GALAXI, P15; FREEMAN KC, 1996, IAU S, V171, P3; GILMORE G, 1995, ASTRON J, V109, P1095, DOI 10.1086/117344; GILMORE G, 1987, GALAXY, P211; GILMORE G, 1995, IAU S, V164, P99; Gnedin OY, 1997, ASTROPHYS J, V474, P223, DOI 10.1086/303441; HARRIS WE, IN PRESS SAAS FEE AD, V28; HARTKOPF WI, 1982, ASTRON J, V87, P1679, DOI 10.1086/113261; HARTWICK FDA, 1996, IAU S, V169, P669; Henry RBC, 1999, PUBL ASTRON SOC PAC, V111, P919, DOI 10.1086/316403; IBATA RA, 1994, NATURE, V370, P194, DOI 10.1038/370194a0; IBATA RA, 1999, IAU S, V186, P39; KINMAN TD, 1996, ASTRON J, V111, P1165; Kovalevsky J, 1998, ANNU REV ASTRON ASTR, V36, P99, DOI 10.1146/annurev.astro.36.1.99; LANCE CM, 1988, ASTROPHYS J, V334, P927, DOI 10.1086/166887; LYNDENBELL D, 1995, MON NOT R ASTRON SOC, V275, P429, DOI 10.1093/mnras/275.2.429; MAJEWSKI SR, 1994, ASTROPHYS J, V431, pL17, DOI 10.1086/187462; MAJEWSKI SR, 1993, ANNU REV ASTRON ASTR, V31, P575; MAJEWSKI SR, 1997, ASTRON J, V113, P311; MAJEWSKI SR, 1992, ASTROPHYS J SUPPL, V87, P78; McWilliam A, 1997, ANNU REV ASTRON ASTR, V35, P503, DOI 10.1146/annurev.astro.35.1.503; Murali C, 1997, MON NOT R ASTRON SOC, V288, P749, DOI 10.1093/mnras/288.3.749; NORRIS J, 1987, ASTROPHYS J, V314, pL39, DOI 10.1086/184847; OCONNELL J, 1958, SPECOLA ASTRONOMICA, V5; Odenkirchen M, 1997, NEW ASTRON, V2, P477, DOI 10.1016/S1384-1076(97)00035-3; OJHA DK, 1994, ASTRON ASTROPHYS, V290, P771; PECCI FF, 1995, ASTRON J, V110, P1664, DOI 10.1086/117639; PHELPS RL, 1995, FORMATION MILKY WAY, P187; PRESTON GW, 1994, ASTRON J, V108, P538, DOI 10.1086/117089; QUINN PJ, 1993, ASTROPHYS J, V403, P74, DOI 10.1086/172184; Robin AC, 1996, ASTRON ASTROPHYS, V305, P125; RODGERS AW, 1981, ASTROPHYS J, V244, P912, DOI 10.1086/158766; RODGERS AW, 1971, ASTROPHYS J, V165, P581, DOI 10.1086/150923; RONG JX, UNPUB ASTRON ASTROPH; SANDAGE A, 1987, ASTRON J, V93, P74, DOI 10.1086/114291; SARAJEDINI A, 1995, ASTRON J, V109, P1086, DOI 10.1086/117343; Sarajedini A, 1997, PUBL ASTRON SOC PAC, V109, P1321, DOI 10.1086/134013; SEARLE L, 1978, ASTROPHYS J, V225, P357, DOI 10.1086/156499; SMECKERHANE TA, 1994, ASTRON J, V108, P507, DOI 10.1086/117087; SOUBIRAN C, 1993, ASTRON ASTROPHYS, V274, P181; Stromgren B., 1987, GALAXY, P229; TSIKOUDI V, 1980, ASTROPHYS J SUPPL S, V43, P365, DOI 10.1086/190672; TSIKOUDI V, 1979, ASTROPHYS J, V234, P842, DOI 10.1086/157565; Unavane M, 1996, MON NOT R ASTRON SOC, V278, P727, DOI 10.1093/mnras/278.3.727; van den Bergh S, 1999, ASTRON ASTROPHYS REV, V9, P273, DOI 10.1007/s001590050019; VANDERKRUIT PC, 1982, ASTRON ASTROPHYS, V110, P61; VANDERKRUIT PC, 1981, ASTRON ASTROPHYS, V95, P105; WIELEN R, 1977, ASTRON ASTROPHYS, V60, P263; WOOD MA, 1995, B AM ASTRON SOC, V27, P1310; WYSE RFG, 1992, ASTRON J, V104, P144, DOI 10.1086/116226; Wyse RFG, 1995, ASTRON J, V110, P2771, DOI 10.1086/117729; YOSS KM, 1987, ASTRON J, V94, P1600, DOI 10.1086/114591; Yusef-Zadeh F, 2000, SCIENCE, V287, P85, DOI 10.1126/science.287.5450.85; 1997, SCIENCE, V276, P1350	90	20	22	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					69	74		10.1126/science.287.5450.69	http://dx.doi.org/10.1126/science.287.5450.69			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615051				2022-12-28	WOS:000084578400037
J	Juszkiewicz, R; Ferreira, PG; Feldman, HA; Jaffe, AH; Davis, M				Juszkiewicz, R; Ferreira, PG; Feldman, HA; Jaffe, AH; Davis, M			Evidence for a low-density universe from the relative velocities of galaxies	SCIENCE			English	Article							DISTANCE DATA; TULLY-FISHER; PECULIAR; CALIBRATION; EVOLUTION; SAMPLES; FIELDS	The motions of galaxies can be used to constrain the cosmological density parameter Omega and the clustering amplitude of matter on Large scales. The mean relative velocity of galaxy pairs, estimated from the Mark III survey, indicates that n = 0.35(-0.25)(+0.35). if the clustering of galaxies is unbiased on large scales, Omega = 0.35 +/- 0.15, so that an unbiased Einstein-de Sitter model (Omega = 1) is inconsistent with the data.	Univ Geneva, Dept Phys Theor, CH-1211 Geneva, Switzerland; CERN, Theory Grp, CH-1211 Geneva 23, Switzerland; Inst Super Tecn, CENTRA, P-1096 Lisbon, Portugal; Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA; Univ Calif Berkeley, Ctr Particle Astrophys, Berkeley, CA 94720 USA	University of Geneva; European Organization for Nuclear Research (CERN); Universidade de Lisboa; Instituto Superior Tecnico; University of Kansas; University of California System; University of California Berkeley	Ferreira, PG (corresponding author), Univ Geneva, Dept Phys Theor, CH-1211 Geneva, Switzerland.		Jaffe, Andrew/D-3526-2009					da Costa LN, 1998, MON NOT R ASTRON SOC, V299, P425, DOI 10.1046/j.1365-8711.1998.01802.x; DAVIS M, 1977, ASTROPHYS J SUPPL S, V34, P425, DOI 10.1086/190456; Davis M, 1996, ASTROPHYS J, V473, P22, DOI 10.1086/178124; Doroshkevich A. G., 1978, Soviet Astronomy, V22, P523; EFSTATHIOU G, 1996, HOUCH SESS 60 COSM L, P107; Ferreira PG, 1999, ASTROPHYS J, V515, pL1, DOI 10.1086/311959; FISHER KB, 1994, MON NOT R ASTRON SOC, V267, P927, DOI 10.1093/mnras/267.4.927; Fry JN, 1996, ASTROPHYS J, V461, pL65, DOI 10.1086/310006; GORSKI KM, 1989, ASTROPHYS J, V344, P1, DOI 10.1086/167771; GROTH EJ, 1989, ASTROPHYS J, V346, P558, DOI 10.1086/168038; Hubble E, 1929, P NATL ACAD SCI USA, V15, P168, DOI 10.1073/pnas.15.3.168; Jain B, 1997, MON NOT R ASTRON SOC, V287, P687, DOI 10.1093/mnras/287.3.687; Jenkins A, 1998, ASTROPHYS J, V499, P20, DOI 10.1086/305615; Juszkiewicz R, 1999, ASTROPHYS J, V518, pL25, DOI 10.1086/312055; Kauffmann G, 1999, MON NOT R ASTRON SOC, V303, P188, DOI 10.1046/j.1365-8711.1999.02202.x; LYNDENBELL D, 1988, ASTROPHYS J, V326, P19, DOI 10.1086/166066; Peebles P. J. E., 1980, LARGE SCALE STRUCTUR, P266; PEEBLES PJE, 1993, PRINCIPLES PHYSICAL, P340; SHAYA EJ, 1995, ASTROPHYS J, V454, P15, DOI 10.1086/176460; SIGAD Y, 1997, ASTROPHYS J SUPPL SE, V109, P516; STRAUSS MA, 1995, PHYS REP, V261, P271, DOI 10.1016/0370-1573(95)00013-7; Willick JA, 1997, ASTROPHYS J, V486, P629, DOI 10.1086/304551; Willick JA, 1998, ASTROPHYS J, V507, P64, DOI 10.1086/306314; Willick JA, 1996, ASTROPHYS J, V457, P460, DOI 10.1086/176746; Willick JA, 1997, ASTROPHYS J SUPPL S, V109, P333, DOI 10.1086/312983; WILLICK JA, 1995, ASTROPHYS J, V446, P12, DOI 10.1086/175762	26	50	50	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					109	112		10.1126/science.287.5450.109	http://dx.doi.org/10.1126/science.287.5450.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615041	Green Submitted			2022-12-28	WOS:000084578400046
J	van den Hoogen, PCW; Feskens, EJM; Nagelkerke, NJD; Menotti, A; Nissinen, A; Kromhout, D				van den Hoogen, PCW; Feskens, EJM; Nagelkerke, NJD; Menotti, A; Nissinen, A; Kromhout, D		Seven Countries Study Res Grp	The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM; FOLLOW-UP; REGRESSION DILUTION; RISK-FACTORS; HYPERTENSION; PREVENTION; FINLAND	Background: Elevated blood pressure is known to be a risk factor for death from coronary heart disease (CHD). However, it is unclear whether the risk of death from CHD in relation to blood pressure varies among populations. Methods: In six populations in different parts of the world, we examined systolic and diastolic blood pressures and hypertension in relation to long-term mortality from CHD, both with and without adjustment for variability in blood pressure within individual subjects. Blood pressure was measured at base line in 12,031 men (age range, 40 to 59 years) who were free of CHD. During 25 years of follow-up, 1291 men died from CHD. Results: At systolic and diastolic blood pressures of about 140 and 85 mm Hg, respectively, 25-year rates of mortality from CHD (standardized for age) varied by a factor of more than three among the populations. Rates in the United States and northern Europe were high (approximately 70 deaths per 10,000 person-years), but rates in Japan and Mediterranean southern Europe were low (approximately 20 deaths per 10,000 person-years). However, the relative increase in 25-year mortality from CHD for a given increase in blood pressure was similar among the populations. The overall unadjusted relative risk of death due to CHD was 1.17 (95 percent confidence interval, 1.14 to 1.20) per 10 mm Hg increase in systolic pressure and 1.13 (95 percent confidence interval, 1.10 to 1.15) per 5 mm Hg increase in diastolic pressure, and it was 1.28 for each of these increments after adjustment for within-subject variability in blood pressure. Conclusions: Among the six populations we studied, the relative increase in long-term mortality due to CHD for a given increase in blood pressure is similar, whereas the absolute risk at the same level of blood pressure varies substantially. These findings may have implications for antihypertensive therapy in different parts of the world. (N Engl J Med 2000;342:1-8.).	Natl Inst Publ Hlth & Environm, Dept Chron Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands; Netherlands Inst Hlth Sci, Rotterdam, Netherlands; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	Netherlands National Institute for Public Health & the Environment; University of Minnesota System; University of Minnesota Twin Cities; University of Eastern Finland	van den Hoogen, PCW (corresponding author), Natl Inst Publ Hlth & Environm, Dept Chron Dis Epidemiol, POB 1, NL-3720 BA Bilthoven, Netherlands.	peggy.van.den.hoogen@rivm.nl	Kromhout, Daan/A-8566-2014; Feskens, Edith/ABI-1446-2020; Feskens, Edith JM/A-3757-2012	Feskens, Edith/0000-0001-5819-2488; 				[Anonymous], 1994, TXB HYPERTENSION; CUPPLES LA, 1992, CIRCULATION, V85, P11; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; GORDON T, 1976, INT J EPIDEMIOL, V5, P327, DOI 10.1093/ije/5.4.327; GRAVLEE GP, 1990, J CLIN MONITOR, V6, P284, DOI 10.1007/BF02842488; HUGHES MD, 1992, J CLIN EPIDEMIOL, V45, P985, DOI 10.1016/0895-4356(92)90114-3; Kannel WB, 1996, JAMA-J AM MED ASSOC, V275, P1571, DOI 10.1001/jama.275.20.1571; Keys A, 1966, Acta Med Scand Suppl, V460, P1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Klungel OH, 1998, J HYPERTENS, V16, P1371, DOI 10.1097/00004872-199816090-00018; Knuiman MW, 1998, ANN EPIDEMIOL, V8, P56, DOI 10.1016/S1047-2797(97)00107-5; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Menotti A, 1996, J Cardiovasc Risk, V3, P69, DOI 10.1097/00043798-199602000-00010; Pietinen P, 1996, PREV MED, V25, P243, DOI 10.1006/pmed.1996.0053; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSNER B, 1992, AM J EPIDEMIOL, V136, P1400, DOI 10.1093/oxfordjournals.aje.a116453; SELMER R, 1992, AM J EPIDEMIOL, V136, P428, DOI 10.1093/oxfordjournals.aje.a116516; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8; WHITTEMORE AS, 1989, AM STAT, V43, P226, DOI 10.2307/2685366; *WHO, 1967, MAN INT STAT CLASS D, V1; Wood D, 1998, EUR HEART J, V19, P1434; [No title captured]	28	374	384	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					1	8		10.1056/NEJM200001063420101	http://dx.doi.org/10.1056/NEJM200001063420101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620642				2022-12-28	WOS:000084575600001
J	Cox, NH				Cox, NH			Permethrin treatment in scabies infestation: importance of the correct formulation	BRITISH MEDICAL JOURNAL			English	Review							HEAD LICE		Cumberland Infirm, Dept Dermatol, Carlisle CA2 7HY, England		Cox, NH (corresponding author), Cumberland Infirm, Dept Dermatol, Carlisle CA2 7HY, England.							BROWN S, 1995, CLIN INFECT DIS, V20, pS104, DOI 10.1093/clinids/20.Supplement_1.S104; BURGESS IF, 1995, BRIT MED J, V311, P752, DOI 10.1136/bmj.311.7007.752; Burkhart CG, 1998, J AM ACAD DERMATOL, V38, P979, DOI 10.1016/S0190-9622(98)70163-X; COX NH, 1991, LANCET, V337, P1547, DOI 10.1016/0140-6736(91)93239-6; TAPLIN D, 1986, J AM ACAD DERMATOL, V15, P995; TAPLIN D, 1990, ARCH DERMATOL, V126, P213, DOI 10.1001/archderm.126.2.213	6	6	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					37	38		10.1136/bmj.320.7226.37	http://dx.doi.org/10.1136/bmj.320.7226.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617528	Green Published			2022-12-28	WOS:000084621600025
J	Wade, OL				Wade, OL			Prisoner of war camps - memories of a remarkable evening	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Birmingham, Stratford Upon Avon CV37 6DN, Warwick, England	University of Birmingham	Wade, OL (corresponding author), Univ Birmingham, 26 West St, Stratford Upon Avon CV37 6DN, Warwick, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1649	1650		10.1136/bmj.319.7225.1649	http://dx.doi.org/10.1136/bmj.319.7225.1649			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600982	Green Published			2022-12-28	WOS:000084562600033
J	Watnick, RS; Gottesman, ME				Watnick, RS; Gottesman, ME			Binding of transcription termination protein nun to nascent RNA and template DNA	SCIENCE			English	Article							ESCHERICHIA-COLI; ANTITERMINATION; POLYMERASE	The amino-terminal arginine-rich motif of coliphage HK022 Nun binds phage lambda nascent transcript, whereas the carboxyl-terminal domain interacts with RNA polymerase (RNAP) and blocks transcription elongation. RNA binding is inhibited by zinc (Zn2+) and stimulated by Escherichia coli NusA, To study these interactions. the Nun carboxyl terminus was extended by a cysteine residue conjugated to a photochemical cross-linker. The carboxyl terminus contacted NusA and made Zn2+-dependent intramolecular contacts. When Nun was added to a paused transcription elongation complex, it cross-linked to the DNA template. Nun may arrest transcription by anchoring RNAP to DNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Columbia University; Columbia University	Gottesman, ME (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.							BULLARD JM, 1995, J MOL BIOL, V252, P572, DOI 10.1006/jmbi.1995.0521; Burova E, 1999, MOL MICROBIOL, V31, P1783, DOI 10.1046/j.1365-2958.1999.01315.x; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Hung SC, 1997, GENE DEV, V11, P2670, DOI 10.1101/gad.11.20.2670; HUNG SC, 1995, J MOL BIOL, V247, P428; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; WATNICK R, UNPUB; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546	12	24	24	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2337	2339		10.1126/science.286.5448.2337	http://dx.doi.org/10.1126/science.286.5448.2337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600743				2022-12-28	WOS:000084318500060
J	Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L				Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L			Implication of tubby proteins as transcription factors by structure-based functional analysis	SCIENCE			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; GENE FAMILY; MOLECULAR CHARACTERIZATION; ANOMALOUS DIFFRACTION; RETINAL DEGENERATION; MOUSE; MUTATIONS; TULP1; ACTIVATOR; SUGGESTS	Tubby-like proteins (TULPs) are found in a broad range of multicellular organisms. In mammals, genetic mutation of tubby or other TULPs can result in one dr more of three disease phenotypes: obesity (from which the name "tubby" is derived), retinal degeneration, and hearing loss. These disease phenotypes indicate a vital role for tubby proteins; however, no biochemical function has yet been ascribed to any member of this protein family. A structure-directed approach was employed to investigate the biological function of these proteins. The crystal structure of the core domain from mouse tubby was determined at a resolution of 1.9 angstroms. From primarily structural clues, experiments were devised, the results of which suggest that TULPs are a unique family of bipartite transcription factors.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Shapiro, L (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Berg OG, 1990, BIOL NONSPECIFIC DNA, P71; BRUGER AT, 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; *DNASTAR, 1996, MOL BIOTECHNOL, V5, P185; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goslin K., 1991, CULTURING NERVE CELL, P251; Gu SM, 1998, LANCET, V351, P1103, DOI 10.1016/S0140-6736(05)79384-3; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ikeda S, 1999, INVEST OPHTH VIS SCI, V40, P2706; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kim SH, 1998, NAT STRUCT BIOL, V5, P643, DOI 10.1038/1334; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis CA, 1999, INVEST OPHTH VIS SCI, V40, P2106; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishina PM, 1998, GENOMICS, V54, P215, DOI 10.1006/geno.1998.5567; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; Ohlemiller KK, 1997, AUDIOL NEURO-OTOL, V2, P175, DOI 10.1159/000259242; Ohlemiller KK, 1998, CELL TISSUE RES, V291, P489, DOI 10.1007/s004410051018; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; PORSCH P, 1993, ANAL BIOCHEM, V211, P133; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; Rost B, 1996, METHOD ENZYMOL, V266, P525; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shapiro L, 1998, STRUCTURE, V6, P265, DOI 10.1016/S0969-2126(98)00030-6; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Terwilliger TC, 1998, PROTEIN SCI, V7, P1851, DOI 10.1002/pro.5560070901; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	47	152	168	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2119	2125		10.1126/science.286.5447.2119	http://dx.doi.org/10.1126/science.286.5447.2119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591637				2022-12-28	WOS:000084157300042
J	Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P				Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P			Three-dimensional structures of the TAF(II)-containing complexes TFIID and TFTC	SCIENCE			English	Article							RNA-POLYMERASE-II; ACETYLASE COMPLEX; HISTONE OCTAMER; TRANSCRIPTION; DISTINCT; CORE; TAFS; MICROSCOPY; SIMILARITY; SUBUNITS	TBP (TATA-binding protein)-associated factors (TAF(II)s) are components of Large multiprotein complexes such as TFIID, TFTC, STAGA, PCAF/GCN5, and SAGA, which play a key role in the regulation of gene expression by RNA polymerase II. The structures of TFIID and TFTC have been determined at 3.5-nanometer resolution by electron microscopy and digital image analysis of single particles. Human TFIID resembles a macromolecular clamp that contains four globular domains organized around a solvent-accessible groove of a size suitable to bind DNA. TFTC is Larger and contains five domains, four of which are similar to TFIID.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schultz, P (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Boite Postale 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; schultz, patrick/0000-0002-7310-6186				Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; GANGLOFF YG, IN PRESS MOL CELL BI; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	31	102	106	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2151	2153		10.1126/science.286.5447.2151	http://dx.doi.org/10.1126/science.286.5447.2151			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591645				2022-12-28	WOS:000084157300050
J	Curran, LM; Caniago, I; Paoli, GD; Astianti, D; Kusneti, M; Leighton, M; Nirarita, CE; Haeruman, H				Curran, LM; Caniago, I; Paoli, GD; Astianti, D; Kusneti, M; Leighton, M; Nirarita, CE; Haeruman, H			Impact of El Nino and logging on canopy tree recruitment in Borneo	SCIENCE			English	Article							SOUTHERN OSCILLATION; CLIMATE-CHANGE; EVOLUTIONARY ECOLOGY; RAIN-FOREST; INDONESIA; KALIMANTAN; EVENT; VARIABILITY; POLLINATION; BIOMASS	Dipterocarpaceae, the dominant family of Bornean canopy trees, display the unusual reproductive strategy of strict interspecific mast-fruiting. During 1986-99, more than 50 dipterocarp species dispersed seed only within a 1- to 2-month period every 3 to 4 years during El Nino-Southern Oscillation events. Synchronous seed production occurred across extensive areas and was essential. for satiating seed predators. Logging of dipterocarps reduced the extent and intensity of these reproductive episodes and exacerbated Local El Nino conditions. Viable seed and seedling establishment have declined as a result of climate, Logging, and predators. Since 1991, dipterocarps have experienced recruitment failure within a national park, now surrounded by logged forest.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; US Agcy Int Dev, Nat Resource Management, Pontianak 78121, West Kalimantan, Indonesia; Univ Tanjungpura, Dept Forestry, Pontianak 78121, West Kalimantan, Indonesia; WWF Indonesia, World Wide Fund Nat, Samarinda 75117, East Kalimantan, Indonesia; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Wetlands Int Indonesia, Bogor 16002, Java, Indonesia; Natl Dev Planning Agcy, Jakarta 10310, Java, Indonesia	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; United States Agency for International Development (USAID); Universitas Tanjungpura; World Wildlife Fund; Harvard University	Curran, LM (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	lcurran@umich.edu						Allan RJ, 1999, HOLOCENE, V9, P101, DOI 10.1191/095968399669125102; APPANAH S, 1993, J BIOSCIENCES, V18, P457, DOI 10.1007/BF02703079; Asdak C, 1998, J HYDROL, V206, P237, DOI 10.1016/S0022-1694(98)00108-5; *BAPPEDA KALBAR PO, 1992, RENC STRUKT TAT RUAN, V1; Bertault JG, 1997, FOREST ECOL MANAG, V94, P209, DOI 10.1016/S0378-1127(96)03974-6; Bove MC, 1998, B AM METEOROL SOC, V79, P2477, DOI 10.1175/1520-0477(1998)079<2477:EOENOO>2.0.CO;2; BRUENIG E, 1996, CONSERVATION MANAGEM; Condit R, 1996, J TROP ECOL, V12, P231, DOI 10.1017/S0266467400009433; Corlett RT, 1998, CLIMATIC CHANGE, V39, P439, DOI 10.1023/A:1005328124567; CRAWLEY MJ, 1995, J ECOL, V83, P683, DOI 10.2307/2261636; Curran Lisa, 1994, THESIS PRINCETON U; Curran LM, 2000, ECOL MONOGR, V70, P129, DOI 10.1890/0012-9615(2000)070[0129:ETOTSS]2.0.CO;2; CURRAN LM, 1992, PRODUCTION FOREST MA; CURRAN LM, 1992, APPL RES RECOMMENDAT; CURRAN LM, 2000, ECOL MONOGR, V70, P151; *DEP KEH, 1986, STAT KEH IND; ELNERS JB, 1999, J CLIMAT, V12, P427; Fang M, 1998, INT J REMOTE SENS, V19, P387, DOI 10.1080/014311698214532; Folkins I, 1997, J GEOPHYS RES-ATMOS, V102, P13291, DOI 10.1029/96JD03711; GRANT BR, 1993, PHILOS T R SOC LON B, V336, P111; HARGER JRE, 1995, ATMOS ENVIRON, V29, P1919, DOI 10.1016/1352-2310(95)00017-S; Herrera CM, 1998, AM NAT, V152, P576, DOI 10.1086/286191; Hunt AG, 1999, B AM METEOROL SOC, V80, P297, DOI 10.1175/1520-0477-80.2.297; JANZEN D H, 1974, Biotropica, V6, P69, DOI 10.2307/2989823; JANZEN DH, 1976, ANNU REV ECOL SYST, V7, P347, DOI 10.1146/annurev.es.07.110176.002023; Kajita T, 1998, MOL PHYLOGENET EVOL, V10, P202, DOI 10.1006/mpev.1998.0516; KELLY D, 1994, TRENDS ECOL EVOL, V9, P465, DOI 10.1016/0169-5347(94)90310-7; Koenig WD, 1998, NATURE, V396, P225, DOI 10.1038/24293; KOENIG WD, 1994, ECOLOGY, V75, P99, DOI 10.2307/1939386; LAFRANKIE JV, 1991, BIOTROPICA, V23, P200, DOI 10.2307/2388308; Latif M, 1997, J CLIMATE, V10, P2221, DOI 10.1175/1520-0442(1997)010<2221:GWDVOE>2.0.CO;2; LYAL CHC, IN PRESS J NAT HIST; McField MD, 1999, B MAR SCI, V64, P155; McPhaden MJ, 1999, SCIENCE, V283, P950, DOI 10.1126/science.283.5404.950; Nichol J, 1997, ATMOS ENVIRON, V31, P1209, DOI 10.1016/S1352-2310(96)00260-9; Norton DA, 1988, FUNCT ECOL, V2, P399, DOI 10.2307/2389413; Pinard MA, 1996, BIOTROPICA, V28, P278, DOI 10.2307/2389193; Rosenfeld D, 1998, B AM METEOROL SOC, V79, P2457, DOI 10.1175/1520-0477(1998)079<2457:SBIIPF>2.0.CO;2; Salafsky N, 1998, CLIMATIC CHANGE, V39, P601, DOI 10.1023/A:1005334204308; SALAFSKY N, 1994, CLIMATIC CHANGE, V27, P373, DOI 10.1007/BF01096268; SILVERTOWN JW, 1980, BIOL J LINN SOC, V14, P235, DOI 10.1111/j.1095-8312.1980.tb00107.x; Sist P, 1998, FOREST ECOL MANAG, V108, P251, DOI 10.1016/S0378-1127(98)00228-X; SMITH CC, 1990, AM NAT, V136, P154, DOI 10.1086/285089; SORK VL, 1993, ECOLOGY, V74, P528, DOI 10.2307/1939313; Stahle DW, 1998, B AM METEOROL SOC, V79, P2137, DOI 10.1175/1520-0477(1998)079<2137:EDROTS>2.0.CO;2; *TIMB CONC, 1986, STAT KEH TAH; Trenberth KE, 1997, GEOPHYS RES LETT, V24, P3057, DOI 10.1029/97GL03092; Webster PJ, 1997, NATURE, V390, P562, DOI 10.1038/37499; WOLTER K, 1987, J CLIM APPL METEOROL, V26, P540, DOI 10.1175/1520-0450(1987)026<0540:TSOISC>2.0.CO;2; [No title captured]	50	230	250	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2184	2188		10.1126/science.286.5447.2184	http://dx.doi.org/10.1126/science.286.5447.2184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591655				2022-12-28	WOS:000084157300060
J	Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P				Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P			Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; CAMP-REGULATED PHOSPHOPROTEIN; PROTEIN-KINASE; INHIBITOR; SCAFFOLD; SUBUNIT; POTENT	The physiological state of the cell is controlled by signal transduction mechanisms which regulate the balance between protein kinase and protein phosphatase activities(1). Here we report that a single protein can, depending on which particular amino-acid residue is phosphorylated, function either as a kinase or phosphatase inhibitor. DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34 (refs 2, 3), We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5), Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells. Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Kurume Univ, Sch Med, Dept Physiol, Fukuoka 8300011, Japan; CNRS, Biol Stn, F-29682 Roscoff, France; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Coll France, INSERM, U114, F-75231 Paris 05, France; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Rockefeller University; Kurume University; Centre National de la Recherche Scientifique (CNRS); Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Howard Hughes Medical Institute; Johns Hopkins University; Cornell University; Cornell University	Greengard, P (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; , laurent/0000-0003-3511-4916; Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CAPORASO G, IN PRESS NEUROPHARMA; Czernik A. J., 1997, REGULATORY PROTEIN M, V30, P219; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1989, J BIOL CHEM, V264, P7726; HORIUCHI A, 1990, J BIOL CHEM, V265, P9476; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; NICOLA SM, IN PRESS ANN REV NEU; Nishi A, 1997, J NEUROSCI, V17, P8147; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	23	460	481	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					669	671		10.1038/45251	http://dx.doi.org/10.1038/45251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604473				2022-12-28	WOS:000084189800067
J	Maini, R; St Clair, EW; Breedveld, F; Furst, D; Kalden, J; Weisman, M; Smolen, J; Emery, P; Harriman, G; Feldmann, M; Lipsky, P				Maini, R; St Clair, EW; Breedveld, F; Furst, D; Kalden, J; Weisman, M; Smolen, J; Emery, P; Harriman, G; Feldmann, M; Lipsky, P		ATTRACT Study Grp	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial	LANCET			English	Article							THERAPY; COMBINATION; DISEASE; CA2	Background Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNF alpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNF alpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. Methods In an international double-blind placebo-controlled phase III clinical trial, 428 patients who had active rheumatoid arthritis, who had received continuous methotrexate for at least 3 months and at a stable dose for at least 4 weeks, were randomised to placebo (n=88) or one of four regimens of infliximab at weeks 0, 2, and 6. Additional infusions of the same dose were given every 4 or 8 weeks thereafter on a background of a stable dose of methotrexate (median 15 mg/week for greater than or equal to 6 months; range 10-35 mg/wk). Patients were assessed every 4 weeks for 30 weeks. Findings At 30 weeks, the American College of Rheumatology (20) response criteria, representing a 20% improvement from baseline, were achieved in 53, 50, 58, and 52% of patients receiving 3 mg/kg every 4 or 8 weeks or 10 mg/kg every 4 or 8 weeks, respectively, compared with 20% of patients receiving placebo plus methotrexate (p<0.001 for each of the four infliximab regimens vs placebo). A 50% improvement was achieved in 29, 27, 26, and 31% of infliximab plus methotrexate in the same treatment groups, compared with 5% of patients on placebo plus methotrexate (p<0.001). Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group. Interpretation During 30 weeks, treatment with infliximab plus methotrexate was more efficacious than methotrexate alone in patients with active rheumatoid arthritis not previously responding to methotrexate.	Kennedy Inst Rheumatol, London W8 8LH, England; Charing Cross Hosp, Imperial Coll, Sch Med, London W8 8LH, England; Duke Univ, Durham, NC USA; Leiden Univ, Leiden, Netherlands; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Inst Clin Immunol & Rheumatol, Erlangen, Germany; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Vienna, A-1010 Vienna, Austria; Univ Leeds, Rheumatol & Rehabil Res Unit, Leeds LS2 9JT, W Yorkshire, England; Centocor Inc, Malvern, PA 19355 USA; Univ Texas, SW Med Ctr, Dallas, TX USA	University of Oxford; Imperial College London; Duke University; Leiden University; Leiden University - Excl LUMC; Virginia Mason Medical Center; University of Erlangen Nuremberg; University of California System; University of California San Diego; University of Vienna; University of Leeds; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Maini, R (corresponding author), Kennedy Inst Rheumatol, London W8 8LH, England.		emery, paul/B-3560-2013					Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FRIES JF, 1982, J RHEUMATOL, V9, P789; HOCHBERG MC, 1991, ARTHRITIS RHEUM, V35, P498; Jones M, 1996, BRIT J RHEUMATOL, V35, P738; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Maetzel A, 1998, J RHEUMATOL, V25, P2331; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; *NCI, 1997, SURV EP END RES SEER; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; WEINBLATT ME, 1994, ARTHRITIS RHEUM, V37, P1492, DOI 10.1002/art.1780371013; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Williams C A, 1996, J Clin Rheumatol, V2, P64, DOI 10.1097/00124743-199604000-00002; WOLFE F, 1990, J RHEUMATOL, V17, P994	23	1981	2074	2	82	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1932	1939		10.1016/S0140-6736(99)05246-0	http://dx.doi.org/10.1016/S0140-6736(99)05246-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622295				2022-12-28	WOS:000084034700009
J	Hayden, GF				Hayden, GF			Alliteration in medicine: a puzzling profusion of p's	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAPULES; CHILDREN; PURPURA; DISEASE; PRIORITIES; PREGNANCY; OUTCOMES; FOLLOW; PAIN	Problem Puzzling, progressive profusion of alliterative "p's" in published papers. Purpose To depict this particular "p" predominance with pinpoint precision. Plan Periodic, painstaking perusal of periodicals by a professor of paediatrics. Proposal The "p" plethora is positively perplexing and potentially perturbing.	Univ Virginia, Childrens Med Ctr, Dept Pediat, Charlottesville, VA 22908 USA	University of Virginia	Hayden, GF (corresponding author), Univ Virginia, Childrens Med Ctr, Dept Pediat, Charlottesville, VA 22908 USA.	gfh@virginia.edu						ABECK D, 1992, J AM ACAD DERMATOL, V27, P123, DOI 10.1016/S0190-9622(08)80826-2; *AM AC PED VA CHAP, 1994, VIRGINIA PEDIAT  SUM; *AM AUT MAN ASS, 1994, PROGR REP AUT POLL P, P1; ANDERS KH, 1992, ARCH DERMATOL, V128, P105; Anderson KR, 1999, PEDIATRICS, V103, P662, DOI 10.1542/peds.103.3.662; [Anonymous], 1990, STEDMANS MED DICT; BARTON PG, 1993, PEDIATR DERMATOL, V10, P129, DOI 10.1111/j.1525-1470.1993.tb00037.x; Belcher HME, 1998, ARCH PEDIAT ADOL MED, V152, P952; BLAUVELT A, 1992, J AM ACAD DERMATOL, V27, P111, DOI 10.1016/S0190-9622(08)80819-5; BURNS DA, 1991, BRIT MED J, V303, P1611, DOI 10.1136/bmj.303.6817.1611; CANO LR, 1994, J PEDIATR-US, V125, P914, DOI 10.1016/S0022-3476(05)82008-6; Craig JE, 1998, J PEDIATR-US, V133, P727, DOI 10.1016/S0022-3476(98)70140-4; Detsky AS, 1998, NEW ENGL J MED, V339, P402, DOI 10.1056/NEJM199808063390611; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; DUSDIEKER LB, 1993, AM J DIS CHILD, V147, P146, DOI 10.1001/archpedi.1993.02160260036018; EISENBERG L, 1987, PEDIATRICS, V80, P415; EPPS RP, 1994, CONT PEDIAT, V11, P24; Fehder WP, 1998, CLIN DIAGN LAB IMMUN, V5, P303, DOI 10.1128/CDLI.5.3.303-307.1998; FRANKENBURG WK, 1994, PEDIATRICS, V93, P586; GEBAUER KA, 1992, ARCH DERMATOL, V128, P105, DOI 10.1001/archderm.128.1.107; GRAY D, 1990, PEDIAT PERCEPTIONS M; GREEN M, 1999, CONT PEDIAT, V16, P118; Greenhalgh T, 1997, BRIT MED J, V315, P1482, DOI 10.1136/bmj.315.7121.1482; HALL CB, 1991, NEW ENGL J MED, V325, P57, DOI 10.1056/NEJM199107043250110; HARRIS WH, 1975, NEW COLUMBIA ENCY, P71; HOLM AR, 1994, J PEDIATR, V125, P368; KAHANA M, 1983, PEDIAT DERMATOL, V3, P45; KALB RE, 1986, JAMA-J AM MED ASSOC, V256, P1170, DOI 10.1001/jama.256.9.1170; KANZAKI T, 1992, Journal of Dermatology (Tokyo), V19, P109; KESSLER KM, 1988, J AM COLL CARDIOL, V11, P48, DOI 10.1016/0735-1097(88)90165-9; Kirby D., 1999, CONT PEDIAT, V16, P83; KLEIN R, 1995, BRIT MED J, V311, P761, DOI 10.1136/bmj.311.7008.761; Klein R, 1998, BMJ-BRIT MED J, V317, P959, DOI 10.1136/bmj.317.7164.959; Kone-Paut I, 1999, J PEDIATR-US, V135, P89, DOI 10.1016/S0022-3476(99)70333-1; LAING VB, 1991, J AM ACAD DERMATOL, V24, P415, DOI 10.1016/0190-9622(91)70062-7; LESTRINGANT GG, 1989, ARCH DERMATOL, V125, P816, DOI 10.1001/archderm.125.6.816; Levy D, 1998, NEW ENGL J MED, V339, P915, DOI 10.1056/NEJM199809243391309; LUCKY AW, 1989, PEDIATR DERMATOL, V6, P254, DOI 10.1111/j.1525-1470.1989.tb00826.x; MAIBACH E, 1998, CHILDR VACC IN CONS; MARKEL H, 1992, PORTABLE PEDIAT; MCGRATH PJ, 1993, J PEDIATR-US, V122, pS2, DOI 10.1016/S0022-3476(11)80002-8; MCMILLAN JA, 1999, CONT PEDIAT, V16, P9; MEHREGAN DR, 1992, ARCH DERMATOL, V128, P414, DOI 10.1001/archderm.128.3.414; Moake JL, 1998, NEW ENGL J MED, V339, P1629, DOI 10.1056/NEJM199811263392210; MOSER KM, 1992, J RESP DIS, V13, P1037; NEINSTEIN LS, 1984, J PEDIATR-US, V105, P594, DOI 10.1016/S0022-3476(84)80427-8; Nurse D S, 1968, Australas J Dermatol, V9, P258, DOI 10.1111/j.1440-0960.1968.tb01616.x; OLK DG, 1992, CONT PEDIAT, V9, P63; OSKI FA, 1994, PRINCIPLES PRACTICE; Pasternak GW, 1998, P NATL ACAD SCI USA, V95, P10354, DOI 10.1073/pnas.95.18.10354; RESNICK SD, 1989, PEDIATR DERMATOL, V6, P206, DOI 10.1111/j.1525-1470.1989.tb00819.x; Richards T, 1998, BMJ-BRIT MED J, V316, P85; Richards T, 1999, BRIT MED J, V318, P277, DOI 10.1136/bmj.318.7179.277; Routledge P, 1998, BRIT MED J, V317, P1609; Schoenberg D G, 1978, South Med J, V71, P956; SCHOENBERG DG, 1979, SOUTHERN MED J, V72, P1590, DOI 10.1097/00007611-197912000-00028; SCHOENBERG DG, 1977, SOUTHERN MED J, V70, P1465, DOI 10.1097/00007611-197712000-00027; SHAH AS, 1992, PEDIATR DERMATOL, V9, P251, DOI 10.1111/j.1525-1470.1992.tb00341.x; SHIPMAN JJ, 1981, MNEMONICS TACTICS SU; Sibert JR, 1999, BRIT MED J, V318, P1595, DOI 10.1136/bmj.318.7198.1595; Simmons D, 1997, BRIT MED J, V315, P263, DOI 10.1136/bmj.315.7103.263; Sokol RJ, 1999, J PEDIATR-US, V134, P136, DOI 10.1016/S0022-3476(99)70403-8; SOLIS J, 1991, ARCH DERMATOL, V127, P1219; TAMAKI K, 1992, ARCH DERMATOL, V128, P1277, DOI 10.1001/archderm.1992.01680190137022; Topol EJ, 1998, NEW ENGL J MED, V339, P1702, DOI 10.1056/NEJM199812033392311; Tosti A, 1998, PEDIATR DERMATOL, V15, P259, DOI 10.1046/j.1525-1470.1998.1998015259.x; VANSTRAATEN EA, 1991, PEDIATR DERMATOL, V8, P277; WEISS R, 1992, J AM ACAD DERMATOL, V26, P715, DOI 10.1016/0190-9622(92)70098-Z; WERNER JH, 1994, CONT PEDIAT, V11, P57; WHITE KP, 1994, PEDIATR DERMATOL, V11, P1, DOI 10.1111/j.1525-1470.1994.tb00063.x; YALISOVE BL, 1991, ARCH DERMATOL, V127, P722; 1994, MERRIAMWEBSTER DICT	72	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1605	1608		10.1136/bmj.319.7225.1605	http://dx.doi.org/10.1136/bmj.319.7225.1605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600957	Bronze, Green Published			2022-12-28	WOS:000084562600011
J	Milgrom, H; Fick, RB; Su, JQ; Reimann, JD; Bush, RK; Watrous, ML; Metzger, WJ				Milgrom, H; Fick, RB; Su, JQ; Reimann, JD; Bush, RK; Watrous, ML; Metzger, WJ		rhuMAb-E25 Study Grp	Treatment of allergic asthma with monoclonal anti-IgE antibody	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; LATE-PHASE; COMPLEX-FORMATION; IMMUNOGLOBULIN-E; CHILDREN; RESPONSIVENESS; HISTAMINE; AFFINITY; DISEASE; CELLS	Background: Immune responses mediated by IgE are important in the pathogenesis of allergic asthma. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE and blocks its interaction with mast cells and basophils. We studied the efficacy of rhuMAb-E25 as a treatment for moderate-to-severe allergic asthma. Methods: After a 4-week run-in period, we randomly assigned 317 subjects (age range, 11 to 50 years) who required inhaled or oral corticosteroids (or both) to receive either placebo or one of two regimens of rhuMAb-E25: high-dose rhuMAb-E25 (5.8 microg per kilogram of body weight per nanogram of IgE per milliliter) or low-dose rhuMAb-E25 (2.5 microg per kilogram per nanogram of IgE per milliliter) intravenously on days 0 (half a dose), 4 (half a dose), and 7 (full dose) and then once every 2 weeks thereafter for 20 weeks. For the first 12 weeks of the study, the subjects continued the regimen of corticosteroids they had received before enrollment. During the following eight weeks, the doses of corticosteroids were tapered in an effort to discontinue this therapy. The primary outcome measure was an improvement in the asthma symptom score at 12 weeks, according to a 7-point scale, in which a score of 1 indicated no symptoms and a score of 7 the most severe symptoms. Results: A total of 106 subjects were assigned to receive a high dose of rhuMAb-E25, 106 were assigned to receive a low dose, and 105 were assigned to receive placebo. At base line, the mean asthma symptom score was 4.0. After 12 weeks of therapy, the mean (+/-SE) scores were 2.8+/-0.1 in the high-dose group (P=0.008) and 2.8+/-0.1 in the low-dose group (P=0.005), as compared with 3.1+/-0.1 in the placebo group. At 20 weeks, the mean scores were 2.7+/-0.1 in both the high-dose group (P=0.048) and the low-dose group (P=0.14), as compared with 2.9+/-0.1 in the placebo group. More subjects in the two rhuMAb-E25 groups were able to decrease or discontinue their use of corticosteroids than in the placebo group, but only some of the differences were significant. After 20 weeks, serum free IgE concentrations decreased by a mean of more than 95 percent in both rhuMAb-E25 groups. The therapy was well tolerated. After 20 weeks, none of the subjects had antibodies against rhuMAb-E25. Conclusions: A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma. (N Engl J Med 1999;341:1966-73.) (C)1999, Massachusetts Medical Society.	E Carolina Univ, Sch Med, Dept Med, Sect Allergy Immunol, Greenville, NC 27858 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Genentech Inc, San Francisco, CA USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA	University of North Carolina; East Carolina University; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roche Holding; Genentech; University of Wisconsin System; University of Wisconsin Madison	Metzger, WJ (corresponding author), E Carolina Univ, Sch Med, Dept Med, Sect Allergy Immunol, Greenville, NC 27858 USA.							Adkinson NF, 1999, NEW ENGL J MED, V341, P522, DOI 10.1056/NEJM199908123410710; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Barnes PJ, 1996, NEW ENGL J MED, V334, P531, DOI 10.1056/NEJM199602223340811; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Cacia J, 1996, BIOCHEMISTRY-US, V35, P1897, DOI 10.1021/bi951526c; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Demoly, 1997, AM J RESP CRIT CARE, V156, P1707; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825, DOI 10.1164/ajrccm.155.6.9196081; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; Galli SJ, 1997, INT ARCH ALLERGY IMM, V113, P14, DOI 10.1159/000237497; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; *INT ASTHM MAN PRO, 1992, INT CONS REP DIAGN T; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; KALINER MA, 1986, NEW ENGL REG ALLERGY, V7, P236; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; LOZEWICZ S, 1988, BRIT MED J, V297, P1515, DOI 10.1136/bmj.297.6662.1515; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; *NAT ASTHM ED PREV, 1997, NIH PUBL; NIVED O, 1994, J RHEUMATOL, V21, P1537; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SABAN R, 1994, J ALLERGY CLIN IMMUN, V94, P836, DOI 10.1016/0091-6749(94)90151-1; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Senn S., 2021, THE BLIND DAT; SHALABY MR, 1992, J EXP MED, V175, P217, DOI 10.1084/jem.175.1.217; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P412, DOI 10.1159/000237058; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; WARNER JO, 1978, LANCET, V2, P912; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	37	521	630	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1966	1973		10.1056/NEJM199912233412603	http://dx.doi.org/10.1056/NEJM199912233412603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607813				2022-12-28	WOS:000084399400003
J	Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R				Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R			Inhibition of SNARE complex assembly differentially affects kinetic components of exocytosis	CELL			English	Article							ADRENAL CHROMAFFIN CELLS; MEMBRANE-FUSION; SYNAPTIC EXOCYTOSIS; NEUROTRANSMITTER RELEASE; FLASH-PHOTOLYSIS; CAGED CA2+; SECRETION; SYNTAXIN; VESICLES; PROTEINS	In chromaffin cells, an increase in intracellular Ca2+ leads to an exocytotic burst followed by sustained secretion. The burst can be further resolved into two kinetically distinct components, which suggests the presence of two separate pools of vesicles. To investigate how these components relate to SNARE complex formation, we introduced an antibody that blocks SNARE assembly but not disassembly. In the presence of the antibody, the sustained component was largely blocked, the burst was slightly reduced, and one of its kinetic components was eliminated. We conclude that SNARE complexes form before Ca2+-triggered membrane fusion and exist in a dynamic equilibrium between a loose and a tight state, both of which support exocytosis. Interaction of the antibody with preformed SNARE complexes favors the loose state.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Am Fassberg 2, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Oka, Yoshitaka/C-9670-2010; Neher, Erwin/A-2109-2013; Artalejo, Antonio R./H-4378-2015; Margittai, Martin/D-5039-2014; Artalejo, Antonio R./ABG-2009-2020	Oka, Yoshitaka/0000-0002-3482-3051; Artalejo, Antonio R./0000-0001-9720-9190; Margittai, Martin/0000-0003-1903-5927; Artalejo, Antonio R./0000-0001-9720-9190; Jahn, Reinhard/0000-0003-1542-3498				Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Bruns D, 1997, J NEUROSCI, V17, P1898; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gillis Kevin D., 1995, P155; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Ryan TA, 1998, NAT NEUROSCI, V1, P175, DOI 10.1038/621; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terrian DM, 1997, EUR J CELL BIOL, V73, P198; THEAN ET, 1989, ANAL BIOCHEM, V177, P256, DOI 10.1016/0003-2697(89)90048-1; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293	58	243	254	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					713	722		10.1016/S0092-8674(00)81669-4	http://dx.doi.org/10.1016/S0092-8674(00)81669-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619425	Bronze			2022-12-28	WOS:000084488200005
J	Collins, MW; Lovell, MR; Mckeag, DB				Collins, MW; Lovell, MR; Mckeag, DB			Current issues in managing sports-related concussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Henry Ford Hlth Syst, Div Neuropsychol, Detroit, MI 48202 USA; Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA	Henry Ford Health System; Henry Ford Hospital; Indiana University System; Indiana University-Purdue University Indianapolis	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, 1 Ford Pl 1E, Detroit, MI 48202 USA.	mcollin1@hfhs.org						CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 1999, P MIDW AM COLL SPORT; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, IN PRESS CLIN J SPOR; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCKEAG DB, 1999, P ANN M AM MED SOC S; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1; RICE SG, 1998, HEAD INJURED ATHLETE; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	15	87	89	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2283	2285		10.1001/jama.282.24.2283	http://dx.doi.org/10.1001/jama.282.24.2283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612307				2022-12-28	WOS:000084261700001
J	Porta, M; Malats, N; Jariod, M; Grimalt, JO; Rifa, J; Carrato, A; Guarner, L; Salas, A; Santiago-Silva, M; Corominas, JM; Andreu, M; Real, FX				Porta, M; Malats, N; Jariod, M; Grimalt, JO; Rifa, J; Carrato, A; Guarner, L; Salas, A; Santiago-Silva, M; Corominas, JM; Andreu, M; Real, FX		PANKRAS II Study Grp	Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer	LANCET			English	Article							POLYCHLORINATED-BIPHENYLS; EXPRESSION; RISK; PCBS; DDT	Background Organochlorine compounds such as 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane (p,p'-DDT), 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (p,p'-DDE), and same polychlorinated biphenyls (PCBs) are carcinogenic to animals and possibly also to human beings. Occupational exposure to DDT may increase the risk of pancreas cancer. The high frequency of K-ras mutations in pancreatic cancer remains unexplained. We analysed the relation between serum concentrations of selected organochlorine compounds and mutations in codon 12 of the K-ras gene in patients with exocrine pancreatic cancer. Methods Cases were prospectively identified in five hospitals. Mutations in K-ras were analysed by PCR and artificial restriction fragment length polymorphism. Cases of pancreatic cancer with wild-type K-ras (n=17) were frequency matched for age and sex to cases of pancreatic cancer with a K-ras mutation (n=34, case-case study). These 51 cases were further compared with 26 hospital controls (case-control comparison). Serum organochlorine concentrations measured by high-resolution gas chromatography with electron-capture detection and negative ion chemical ionisation mass spectrometry. Findings Serum concentrations of p,p'-DDT were significantly higher in pancreatic cancer cases with a K-ras mutation than in cases without a mutation (odds ratio for upper tertile 8.7 [95% CI 1.6-48.5], p for trend=0.005). For p,p'-DDE the corresponding figures were 5.3 (1.1-25.2, p for trend=0.031). These estimates held after adjusting for total lipids, other covariates, and total PCBs, A specific association was observed between a glycine to valine substitution at codon 12 and both p,p'-DDT and p,p'-DDE concentrations (odds ratio 15.9, p=0.044 and odds ratio 24.1, p=0.028; respectively). A similar pattern was shown for the major di-ortho-chlorinated PCBs (congeners 138, 153, and 180), even after adjustment for p,p'-DDE, but without a specific association with spectrum, Concentrations of p,p'-DDT and p,p'-DDE were similar among wild-type cases and controls, but significantly higher for K-ras mutated cases than for controls (p<0.01). Interpretation Organochlorine compounds such as p,p'-DDT, p,p'-DDE, and some PCBs could play a part in the pathogenesis of exocrine pancreatic cancer through modulation of K-ras activation. The results require replication, but they suggest new roles for organochlorines in the development of several cancers in human beings.	Univ Autonoma Barcelona, Inst Municipal Invest Med, E-08003 Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; CSIC, Cid, Dept Environm Chem, Inst Chem & Environm Res, ES-08034 Barcelona, Spain; Hosp Son Dureta, Dept Oncol, Mallorca, Spain; Hosp Univ Elche, Dept Oncol, Alicante, Spain; Hosp Gen Valle Hebron, Dept Gastroenterol, Barcelona, Spain; Hosp Mutua de Terrassa, Dept Pathol, Terrassa, Spain; Hosp del Mar, Dept Pathol, Barcelona, Spain; Hosp del Mar, Dept Gastroenterol, Barcelona, Spain	Autonomous University of Barcelona; Pompeu Fabra University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Hospital Universitari Vall d'Hebron; Hospital Universitario Mutua Terrassa; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Porta, M (corresponding author), Univ Autonoma Barcelona, Inst Municipal Invest Med, Carrer Dr Aiguader 80, E-08003 Barcelona, Spain.	mporta@imim.es	Arribas, Francisco X Real/H-5275-2015; Andreu, Montserrat/D-9911-2015; Grimalt, Joan O/E-2073-2011; Porta, Miquel/AAD-5371-2020; Porta, Miquel/B-5787-2008; Marchi, Mary R R/F-3316-2012; Malats, Nuria/H-7041-2015	Arribas, Francisco X Real/0000-0001-9501-498X; Andreu, Montserrat/0000-0003-4286-1098; Grimalt, Joan O/0000-0002-7391-5768; Porta, Miquel/0000-0003-1684-7428; Porta, Miquel/0000-0003-1684-7428; Marchi, Mary R R/0000-0001-5381-249X; CARRATO, ALFREDO/0000-0001-7749-8140; Malats, Nuria/0000-0003-2538-3784				Anderson KE PJ, 1996, CANC EPIDEMIOLOGY PR, P725; ARINO A, 1995, FOOD ADDIT CONTAM, V12, P559, DOI 10.1080/02652039509374344; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; CHUANG LF, 1991, TOXICOLOGY, V70, P283, DOI 10.1016/0300-483X(91)90003-J; Cogliano VJ, 1998, ENVIRON HEALTH PERSP, V106, P317, DOI 10.2307/3434037; COOPER GM, 1995, ONCOGENES, P169; Davis DL, 1998, ENVIRON HEALTH PERSP, V106, P523, DOI 10.2307/3434225; GARABRANT DH, 1993, J NATL CANCER I, V85, P328, DOI 10.1093/jnci/85.4.328-a; Gribaldo L, 1998, J TOXICOL ENV HEAL A, V55, P121, DOI 10.1080/009841098158557; Hesketh R., 1994, ONCOGENE HDB, P378; *INT AG RES CANC, 1987, IARC MON EV CARC S7, V1, P186; *INT AG RES CANC, 1991, IARC MON EV CARC RIS, V53; Lazaro R, 1999, J FOOD PROTECT, V62, P1054, DOI 10.4315/0362-028X-62.9.1054; LI HC, 1995, J BIOCHEM TOXICOL, V10, P51; Longnecker Daniel S., 1993, P551; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; Malats N, 1997, INT J CANCER, V70, P661, DOI 10.1002/(SICI)1097-0215(19970317)70:6<661::AID-IJC6>3.0.CO;2-T; MCCORMICK CSF, 1998, PANCREAS, V2, P907; MCKINNEY JD, 1994, ENVIRON HEALTH PERSP, V102, P290, DOI 10.1289/ehp.94102290; Moysich KB, 1999, AM J IND MED, V35, P223, DOI 10.1002/(SICI)1097-0274(199903)35:3<223::AID-AJIM2>3.0.CO;2-L; Otero R, 1997, J CHROMATOGR A, V778, P87, DOI 10.1016/S0021-9673(97)00339-7; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; Porta M, 1999, J EPIDEMIOL COMMUN H, V53, P702, DOI 10.1136/jech.53.11.702; Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3; Smith A.G., 1991, HDB PESTICIDE TOXICO, V2, P731; Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2; *US DEPT HHS, 1998, 8 US DEP HLTH HUM SE; Warshawsky D, 1999, ENV HLTH PERSPECT, V107, P317, DOI [10.1289/ehp.99107317, DOI 10.1289/EHP.99107317, DOI 10.1289/ehp.99107317]; Weiderpass E, 1998, SCAND J WORK ENV HEA, V24, P165, DOI 10.5271/sjweh.295	29	138	145	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1999	354	9196					2125	2129		10.1016/S0140-6736(99)04232-4	http://dx.doi.org/10.1016/S0140-6736(99)04232-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609819				2022-12-28	WOS:000084318200015
J	Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS				Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS			Deflection of the local interstellar dust flow by solar radiation pressure	SCIENCE			English	Article							INTER-STELLAR GRAINS; ULYSSES; GALILEO; PARTICLES; FORCES; SYSTEM; CLOUD; GAS	Interstellar dust grains intercepted by the dust detectors on the Ulysses and Galileo spacecrafts at heliocentric distances from 2 to 4 astronomical units show a deficit of grains with masses from 1 x 10(-17) to 3 x 10(-16) kilograms relative to grains intercepted outside 4 astronomical units. To divert grains out of the 2- to 4-astronomical unit region, the solar radiation pressure must be 1.4 to 1.8 times the force of solar gravity. These figures are consistent with the optical properties of spherical or elongated grains that consist of astronomical silicates or organic refractory material. Pure graphite grains with diameters of 0.2 to 0.4 micrometer experience a solar radiation pressure force as much as twice the force of solar gravity.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; ESA, European Space Operat Ctr, D-64293 Darmstadt, Germany; Royal Inst Technol, Dept Comp Sci & Syst, S-16440 Kista, Sweden; Stockholm Univ, S-16440 Kista, Sweden; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Univ Florida, Dept Astron, Gainesville, FL 32661 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; European Space Agency; Royal Institute of Technology; Stockholm University; Max Planck Society; State University System of Florida; University of Florida	Landgraf, M (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mailcode SN2, Houston, TX 77058 USA.	mlandgra@esoc.esa.de	Gustafson, Bo/B-9526-2011					Baguhl M, 1996, SPACE SCI REV, V78, P165, DOI 10.1007/BF00170803; BAGUHL M, 1995, SCIENCE, V268, P1016, DOI 10.1126/science.268.5213.1016; BEHANNON KW, 1989, J GEOPHYS RES-SPACE, V94, P1245, DOI 10.1029/JA094iA02p01245; BERTAUX JL, 1985, ASTRON ASTROPHYS, V150, P1; BERTAUX JL, 1976, NATURE, V262, P263, DOI 10.1038/262263a0; Bradley JP, 1999, SCIENCE, V285, P1716, DOI 10.1126/science.285.5434.1716; BREITSCHWERDT D, 1998, LECT NOTE PHYS, V506, P381; BROWNLEE DE, 1975, P LUNAR PLANET SCI C, P3409; BURNS JA, 1979, ICARUS, V40, P1, DOI 10.1016/0019-1035(79)90050-2; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; Frisch PC, 1999, ASTROPHYS J, V525, P492, DOI 10.1086/307869; GREENBERG JM, 1995, ASTROPHYS J, V455, pL177, DOI 10.1086/309834; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; Grun E, 1997, ICARUS, V129, P270, DOI 10.1006/icar.1997.5789; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, ASTRON ASTROPHYS SUP, V92, P411; GUSTAFSON BAS, 1994, ANNU REV EARTH PL SC, V22, P553, DOI 10.1146/annurev.ea.22.050194.003005; GUSTAFSON BAS, 1979, NATURE, V282, P276, DOI 10.1038/282276a0; Gustafson BAS, 1996, ASTR SOC P, V104, P35; JONES AP, 1994, ASTROPHYS J, V433, P797, DOI 10.1086/174689; LALLEMENT R, 1992, ASTRON ASTROPHYS, V266, P479; Landgraf M, 1999, PLANET SPACE SCI, V47, P1029, DOI 10.1016/S0032-0633(99)00031-8; LANDGRAF M, 1997, P IAU C, V166; LEVY EH, 1976, NATURE, V264, P423, DOI 10.1038/264423a0; Li AG, 1997, ASTRON ASTROPHYS, V323, P566; MCDONNELL JAM, 1975, SPACE RES, V15, P555; MORFILL GE, 1979, PLANET SPACE SCI, V27, P1283, DOI 10.1016/0032-0633(79)90106-5; MUKAI T, 1992, ASTRON ASTROPHYS, V262, P315; MUKAI T, 1981, ASTRON ASTROPHYS, V99, P1; WELLER CS, 1974, ASTROPHYS J, V193, P471, DOI 10.1086/153182; WITTE M, 1993, ADV SPACE RES-SERIES, V13, P121, DOI 10.1016/0273-1177(93)90401-V; Xu YL, 1999, ASTROPHYS J, V513, P894, DOI 10.1086/306892; Zook HA, 1996, SCIENCE, V274, P1501, DOI 10.1126/science.274.5292.1501; [No title captured]	36	65	66	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2319	2322		10.1126/science.286.5448.2319	http://dx.doi.org/10.1126/science.286.5448.2319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600737				2022-12-28	WOS:000084318500054
J	Linke, H; Humphrey, TE; Lofgren, A; Sushkov, AO; Newbury, R; Taylor, RP; Omling, P				Linke, H; Humphrey, TE; Lofgren, A; Sushkov, AO; Newbury, R; Taylor, RP; Omling, P			Experimental tunneling ratchets	SCIENCE			English	Article							MOTION; TRANSPORT; PARTICLES; SERIES	Adiabatically rocked electron ratchets, defined by quantum confinement in semiconductor heterostructures, were experimentally studied in a regime where tunneling contributed to the particle flow. The rocking-induced electron flow reverses direction as a function of temperature. This result confirms a recent prediction of fundamentally different behavior of classical versus quantum ratchets. A wave-mechanical model reproduced the temperature-induced current reversal and provides an intuitive explanation.	Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia; Lund Univ, Div Solid State Phys, S-22100 Lund, Sweden	University of New South Wales Sydney; Lund University	Linke, H (corresponding author), Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia.	hl@phys.unsw.edu.au	Taylor, Richard P/P-9908-2016; Omling, Par/A-8267-2010; Linke, Heiner/A-5825-2010; Sushkov, Alexander/AAJ-1720-2021	Linke, Heiner/0000-0003-4451-4006; Taylor, Richard/0000-0002-5248-4524				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; BEENAKKER CWJ, 1989, PHYS REV B, V39, P10445, DOI 10.1103/PhysRevB.39.10445; Datta S., 1997, ELECT TRANSPORT MESO; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Gorre L, 1996, EUROPHYS LETT, V33, P267, DOI 10.1209/epl/i1996-00331-2; Goychuk I, 1998, EUROPHYS LETT, V43, P503, DOI 10.1209/epl/i1998-00389-2; Haenggi P., 1996, Nonlinear physics of complex systems. Current status and future trends, P294; Hanggi P, 1999, PHYS WORLD, V12, P21; Julicher F, 1997, REV MOD PHYS, V69, P1269, DOI 10.1103/RevModPhys.69.1269; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Leff H., 1990, MAXWELLS DEMON ENTRO; LEIBLER S, 1994, NATURE, V370, P412, DOI 10.1038/370412a0; Linke H, 1998, EUROPHYS LETT, V44, P341, DOI 10.1209/epl/i1998-00562-1; Linke H, 1999, EUROPHYS LETT, V45, P406, DOI 10.1209/epl/i1999-00179-4; Lorke A, 1998, PHYSICA B, V249, P312, DOI 10.1016/S0921-4526(98)00121-5; MADDOX J, 1994, NATURE, V369, P181, DOI 10.1038/369181a0; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; Mennerat-Robilliard C, 1999, PHYS REV LETT, V82, P851, DOI 10.1103/PhysRevLett.82.851; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652; Reimann P, 1997, PHYS REV LETT, V79, P10, DOI 10.1103/PhysRevLett.79.10; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; STARING AAM, 1990, PHYS REV B, V41, P8461, DOI 10.1103/PhysRevB.41.8461; XU HQ, 1993, PHYS REV B, V47, P15630, DOI 10.1103/PhysRevB.47.15630	24	273	276	4	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2314	2317		10.1126/science.286.5448.2314	http://dx.doi.org/10.1126/science.286.5448.2314			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600735				2022-12-28	WOS:000084318500052
J	Schulz, R; Beach, SR				Schulz, R; Beach, SR			Caregiving as a risk factor for mortality - The caregiver health effects study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPOUSAL CAREGIVERS; IMMUNE-RESPONSE; SPECIAL ISSUE; STRESS; ADULTS	Context There is strong consensus that caring for an elderly individual with disability is burdensome and stressful to many family members and contributes to psychiatric morbidity. Researchers have also suggested that the combination of loss, prolonged distress, the physical demands of caregiving, and biological vulnerabilities of older caregivers may compromise their physiological functioning and increase their risk for physical health problems, leading to increased mortality. Objective To examine the relationship between caregiving demands among older spousal caregivers and 4-year all-cause mortality, controlling for sociodemographic factors, prevalent clinical disease, and subclinical disease at baseline. Design Prospective population-based cohort study, from 1993 through 1998 with an average of 4.5 years of follow-up. Setting Four US communities. Participants A total of 392 caregivers and 427 noncaregivers aged 66 to 96 years who were living with their spouses. Main Outcome Measure Four-year mortality, based on level of caregiving: (1) spouse not disabled; (2) spouse disabled and not helping; (3) spouse disabled and helping with no strain reported; or(4) spouse disabled and helping with mental or emotional strain reported. Results After 4 years of follow-up, 103 participants (12.6%) died. After adjusting for sociodemographic factors, prevalent disease, and subclinical cardiovascular disease, participants who were providing care and experiencing caregiver strain had mortality risks that were 63% higher than noncaregiving controls (relative risk [RR], 1.63; 95% confidence interval [CI], 1.00-2.65). Participants who were providing care but not experiencing strain (RR, 1.08; 95% CI, 0.61-1.90) and those with a disabled spouse who were not providing care (RR, 1.37; 95% CI, 0.73-2.58) did not have elevated adjusted mortality rates relative to the noncaregiving controls. Conclusions Our study suggests that being a caregiver who is experiencing mental or emotional strain is an independent risk factor for mortality among elderly spousal caregivers. Caregivers who report strain associated with caregiving are more likely to die than noncaregiving controls.	Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schulz, R (corresponding author), Univ Pittsburgh, Dept Psychiat, 121 Univ Pl, Pittsburgh, PA 15260 USA.				NIMH NIH HHS [R01 MH 46015, T32 MH19986, R01 MH52247] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019986, R01MH046015] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Glaser R, 1997, ANN BEHAV MED, V19, P78, DOI 10.1007/BF02883323; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; ORY MG, IN PRESS GERONTOLOGI; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 1998, HEALTH PSYCHOL, V17, P107, DOI 10.1037/h0092707; Shaw WS, 1997, ANN BEHAV MED, V19, P101, DOI 10.1007/BF02883326; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Vitaliano PP, 1997, ANN BEHAV MED, V19, P75, DOI 10.1007/BF02883322; [No title captured]	13	2136	2174	5	167	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2215	2219		10.1001/jama.282.23.2215	http://dx.doi.org/10.1001/jama.282.23.2215			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605972	Bronze			2022-12-28	WOS:000084138600028
J	Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF				Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF			Mouse tumor model for neurofibromatosis type 1	SCIENCE			English	Article							MICE DEFICIENT; NEURAL CREST; COLORECTAL-CANCER; GENE; RAS; P53; MUTATION; CELL; NF1; GAP	Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by increased incidence of benign and malignant tumors of neural crest origin. Mutations that activate the protooncogene ras, such as Loss of Nf1, cooperate with inactivating mutations at the p53 tumor suppressor gene during malignant transformation, One hundred percent of mice harboring null Nf1 and p53 alleles in cis synergize to develop soft tissue sarcomas between 3 and 7 months of age. These sarcomas exhibit Loss of heterozygosity at both gene loci and express phenotypic traits characteristic of neural crest derivatives and human NF1 malignancies.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.	parada@utsw.swmed.edu	Parada, luis F/B-9400-2014	Klesse, Laura/0000-0003-1323-7720	NINDS NIH HHS [NS34296, R01 NS034296-04, R01 NS034296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Bernardis V, 1999, DIGESTION, V60, P82, DOI 10.1159/000007594; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Halling KC, 1996, AM J CLIN PATHOL, V106, P282; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ISHIZAKI Y, 1992, SURGERY, V111, P706; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JHANWAR SC, 1994, CANCER GENET CYTOGEN, V78, P138, DOI 10.1016/0165-4608(94)90081-7; Kamijo T, 1999, CANCER RES, V59, P2217; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Orlow I, 1999, INT J ONCOL, V15, P17; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; RICCARDI VM, 1994, AM J PATHOL, V145, P994; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TANAKA M, 1994, J SURG ONCOL, V57, P57, DOI 10.1002/jso.2930570115; Vogel KS, 1998, MOL CELL NEUROSCI, V11, P19, DOI 10.1006/mcne.1998.0670; VOGEL KS, UNPUB; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	40	260	264	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2176	2179		10.1126/science.286.5447.2176	http://dx.doi.org/10.1126/science.286.5447.2176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591653	Green Accepted			2022-12-28	WOS:000084157300058
J	Bartel, N; Bietenholz, MF; Rupen, MP; Beasley, AJ; Graham, DA; Altunin, VI; Venturi, T; Umana, G; Cannon, WH; Conway, JE				Bartel, N; Bietenholz, MF; Rupen, MP; Beasley, AJ; Graham, DA; Altunin, VI; Venturi, T; Umana, G; Cannon, WH; Conway, JE			The changing morphology and increasing deceleration of supernova 1993J in M81	SCIENCE			English	Article							SN 1993J; GALAXY M81; RADIO; SN-1993J; EXPANSION; SUPERGIANT; DISCOVERY; DISTANCE; SN1993J; EJECTA	Twenty consecutive Very Long Baseline Interferometry images of supernova 1993J from the time of explosion to the present show the dynamic evolution of the expanding radio shell of an exploded star. High-precision astrometry reveals that the supernova expands isotropically from its explosion center. Systematic changes in the images may reflect a pattern of anisotropies and inhomogeneities in the material left over from the progenitor star. As the shock front sweeps up the material in the surrounding medium, it is increasingly decelerated and influenced by the material. After 5 years, the supernova has slowed to half of its original expansion velocity and may have entered the early stages of the adiabatic phase common in much older supernova remnants in the Milky Way Galaxy.	York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada; Natl Radio Astron Observ, Socorro, NM 87801 USA; Max Planck Inst Radioastron, D-53121 Bonn, Germany; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CNR, Inst Radioastron, I-40129 Bologna, Italy; CNR, Inst Radioastron, I-96017 Noto, Italy; Space Geodynam Lab CRESTech, Toronto, ON M3J 3K1, Canada; Chalmers, Onsala Space Observ, S-43992 Onsala, Sweden	York University - Canada; National Radio Astronomy Observatory (NRAO); Max Planck Society; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); Consiglio Nazionale delle Ricerche (CNR); Chalmers University of Technology	Bartel, N (corresponding author), York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada.	bartel@york.u.ca		Venturi, Tiziana/0000-0002-8476-6307; Umana, Grazia/0000-0002-6972-8388				BANDIERA R, 1984, ASTROPHYS J, V285, P134, DOI 10.1086/162484; BARTEL N, 1995, P NATL ACAD SCI USA, V92, P11374, DOI 10.1073/pnas.92.25.11374; BARTEL N, 1994, NATURE, V368, P610, DOI 10.1038/368610a0; BARTEL N, UNPUB; Bietenholz MF, 1996, ASTROPHYS J, V457, P604, DOI 10.1086/176756; BIETENHOLZ MF, IN PRESS ASTROPHYS J; CHEVALIER RA, 1982, ASTROPHYS J, V259, P302, DOI 10.1086/160167; CHEVALIER RA, 1982, ASTROPHYS J, V258, P790, DOI 10.1086/160126; Fransson C, 1996, ASTROPHYS J, V461, P993, DOI 10.1086/177119; Fransson C, 1998, ASTROPHYS J, V509, P861, DOI 10.1086/306531; FREEDMAN WL, 1994, ASTROPHYS J, V427, P628, DOI 10.1086/174172; Gaensler BM, 1997, ASTROPHYS J, V479, P845, DOI 10.1086/303917; HOFLICH P, 1993, ASTRON ASTROPHYS, V275, pL29; Houck JC, 1996, ASTROPHYS J, V456, P811, DOI 10.1086/176699; KUNDT W, 1998, FUNDAMENTALS COSMIC, V20, P1; LEWIS JM, 1994, MON NOT R ASTRON SOC, V266, pL29; LUNDQVIST P, 1994, CIRCUMSTELLAR MEDIA IN LATE STAGES OF STELLAR EVOLUTION, P213, DOI 10.1017/CBO9780511564628.028; Marcaide JM, 1997, ASTROPHYS J, V486, pL31, DOI 10.1086/310830; MARCAIDE JM, 1995, NATURE, V373, P44, DOI 10.1038/373044a0; MARCAIDE JM, 1995, SCIENCE, V270, P1475, DOI 10.1126/science.270.5241.1475; Nomoto K, 1996, IAU SYMP, P119; NUSSBAUMER H, 1993, ASTRON ASTROPHYS, V278, P209; PHILLIPS JA, 1993, IAU CIRC, V5775, P1; PODSIADLOWSKI P, 1993, NATURE, V364, P509, DOI 10.1038/364509a0; POOLEY GG, 1993, MON NOT R ASTRON SOC, V264, pL17, DOI 10.1093/mnras/264.1.L17; RIPERO J, 1993, IAU CIRC, V5731, P1; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P25; RUPEN MP, 1998, IAU C, V164, P355; Sandage A., 1961, HUBBLE ATLAS GALAXIE; SUZUKI T, 1995, ASTROPHYS J, V455, P658, DOI 10.1086/176613; TRAMMELL SR, 1993, ASTROPHYS J, V414, pL21, DOI 10.1086/186986; VANDYK SD, 1994, ASTROPHYS J, V432, pL115, DOI 10.1086/187525; WEILER KW, 1993, IAU CIRC, V5752, P1; WHEELER JC, 1993, ASTROPHYS J, V417, pL71, DOI 10.1086/187097; WOOSLEY SE, 1994, ASTROPHYS J, V429, P300, DOI 10.1086/174319	35	55	55	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					112	116		10.1126/science.287.5450.112	http://dx.doi.org/10.1126/science.287.5450.112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615042				2022-12-28	WOS:000084578400047
J	Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N				Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N			Psychiatric illness and risk factors for suicide in Denmark	LANCET			English	Article							PREVENTING SUICIDE; ATTRIBUTABLE RISK; SWEDISH SUICIDE; UNEMPLOYMENT; MORTALITY	Background Several risk factors for suicide have been identified, We assessed the relative risks and population attributable risks of suicide associated with various socioeconomic factors and with previous mental illness that necessitated hospital admission. Our aim was to assist in the choice of potential strategies for preventing suicide in the general population. Methods We did a population-based nested case-control study based on register data. Data were collected on a random 5% sample of the Danish population aged 16-78 years during a 15-year period (1980-94) and analysed with conditional logistic regression. Findings 811 cases of suicide were found and 79 871 controls were chosen in this population. Unemployment, tow income, being single, and a history of mental illness necessitating hospital admission were associated With increased risk of suicide. However, in the multivariate analysis, the strongest risk factor was mental illness necessitating hospital admission; risk of suicide was especially high during admission (relative risk 62.6 [95% CI 41.1-95.4]) and during the year after discharge (6.51 [5.03-8.44]). The effect of socioeconomic variables decreased after adjustment for history of mental illness. The population attributable risk associated with mental illness necessitating admission to hospital was 44.6% (43.6-45.5); the attributable risks associated with the other factors were 3.0% (1.4-6.6) for unemployment and 10.3% (6.13-16.9) for being single. Interpretation Suicide prevention aimed at patients who are admitted to hospital with mental disorders and improved detection and treatment of mental disorders in the general population may be the most efficient strategy to decrease risk of suicide. Reports of high relative risk and attributable risk associated with unemployment and other socioeconomic risk factors may be confounded and overestimated owing to the lack of adjustment for the association with mental disorders.	Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Univ Aarhus, Ctr Labour Market & Social Res, Aarhus, Denmark	Aarhus University; Aarhus University	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark.		Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012	Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; Eriksson, Tor/0000-0001-9309-5499				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; BARNDORFFNIELSE.OE, 1989, ASYMPTOMATIC TECHNIQ; BARNERASMUSSEN P, 1986, ACTA PSYCHIAT SCAND, V73, P449, DOI 10.1111/j.1600-0447.1986.tb02710.x; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; FerradaNoli M, 1997, ACTA PSYCHIAT SCAND, V96, P108, DOI 10.1111/j.1600-0447.1997.tb09914.x; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldberg DP., 1992, COMMON MENTAL DISORD; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hills, 1993, STAT MODELS EPIDEMIO; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; Johansson LM, 1997, SOC PSYCH PSYCH EPID, V32, P165; KREITMAN N, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P73; KURITZ SJ, 1988, BIOMETRICS, V44, P355, DOI 10.2307/2531850; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Lewis G, 1997, BRIT J PSYCHIAT, V171, P351, DOI 10.1192/bjp.171.4.351; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Rosenman SJ, 1998, MED J AUSTRALIA, V169, P100, DOI 10.5694/j.1326-5377.1998.tb140193.x; *SUNDH, 1992, DODS 1990 CAUS DEATH; WESTERGARDNIELS.N, 1984, STUDIES LABOR MARKET, P267; *WHO, 1967, MAN INT CLASS DIS IC; WILKINSON G, 1994, BRIT MED J, V309, P860, DOI 10.1136/bmj.309.6958.860; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; 1993, LANCET, V342, P381	30	253	260	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					9	12		10.1016/S0140-6736(99)06376-X	http://dx.doi.org/10.1016/S0140-6736(99)06376-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279MU	10615884				2022-12-28	WOS:000085049200009
J	Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS				Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS			Underrepresentation of patients 65 years of age or older in cancer-treatment trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST-ONCOLOGY-GROUP; ACUTE MYELOID-LEUKEMIA; CLINICAL-TRIALS; BREAST-CANCER; WOMEN; CHEMOTHERAPY; REPRESENTATION; HEALTH	Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P < 0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P < 0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. (N Engl J Med 1999;341:2061-7.) (C)1999, Massachusetts Medical Society.	Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA; Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA; Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX 78284 USA; Loyola Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Maywood, IL 60153 USA	University of Arkansas System; University of Arkansas Medical Sciences; Fred Hutchinson Cancer Center; Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; Loyola University Chicago	Hutchins, LF (corresponding author), SW Oncol Grp, Operat Off, 4980 Omicron Dr, San Antonio, TX 78245 USA.		Unger, Joseph/O-7457-2019		NATIONAL CANCER INSTITUTE [U10CA032102, U10CA037981, U10CA038926] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102, CA37981, CA38926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P271, DOI 10.1056/NEJM199307223290409; Baquet C, 1986, Prog Clin Biol Res, V216, P215; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; BONADONNA G, 1992, CANCER RES, V52, P2127; Chamberlain RM, 1998, INT J RADIAT ONCOL, V40, P9, DOI 10.1016/S0360-3016(97)00833-X; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; COTTON P, 1993, JAMA-J AM MED ASSOC, V269, P2067; CRIVELLARI D, 1998, P AN M AM SOC CLIN, V17, pA102; DEES EC, 1998, P AN M AM SOC CLIN, V17, pA103; Dignam JJ, 1997, CANCER-AM CANCER SOC, V80, P80, DOI 10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B; FELDMAN EJ, 1995, SEMIN ONCOL, V22, P21; Food and Drug Administration, 1993, FED REG, V58, P39406; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GIOVANAZZIBANNON S, 1994, J CLIN ONCOL, V12, P2447, DOI 10.1200/JCO.1994.12.11.2447; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; Gotay C C, 1993, Oncology (Williston Park), V7, P67; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; HAYUNGA EG, 1997, APPL CLIN TRIALS, V6, P41; Hutchins L F, 1987, Clin Geriatr Med, V3, P483; JOHNSON PRE, 1993, BRIT J HAEMATOL, V83, P1, DOI 10.1111/j.1365-2141.1993.tb04622.x; Leith CP, 1997, BLOOD, V89, P3323; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MARLIN SM, 1996, CLIN INVEST MED S, V19, pA50; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P418, DOI 10.1001/jama.279.6.418; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; PINN VW, 1992, AM J PREV MED, V8, P399; RYAN DH, 1992, AM J CLIN ONCOL-CANC, V15, P69, DOI 10.1097/00000421-199202000-00013; SCHMUCKER DL, 1993, CLIN PHARMACOL THER, V54, P11, DOI 10.1038/clpt.1993.102; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; YANCIK R, 1986, AM J OBSTET GYNECOL, V154, P639, DOI 10.1016/0002-9378(86)90623-X	32	1677	1695	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2061	2067		10.1056/NEJM199912303412706	http://dx.doi.org/10.1056/NEJM199912303412706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615079				2022-12-28	WOS:000084573300006
J	Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J				Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J			Long-term follow-up of idiopathic chronic pericardial effusion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY CHYLOPERICARDIUM; CARDIAC-TAMPONADE; EXPERIENCE; SERIES	Background: A large idiopathic chronic pericardial effusion is a collection of pericardial fluid that persists for more than three months and has no apparent cause. We conducted a prospective study of the natural history and treatment of this disorder. Methods: Between 1977 and 1992, we prospectively evaluated and enrolled patients with large idiopathic chronic pericardial effusion. We performed pericardiocentesis in most of the patients. We performed pericardiectomy when large pericardial effusion reappeared after pericardiocentesis. Follow-up ranged from 18 months to 20 years (median, 7 years). Results: During the study period, we evaluated a total of 1108 patients with pericarditis, 461 of whom had large pericardial effusion. Twenty-eight of these patients (age range, 7 to 85 years; median, 61) had large idiopathic chronic effusion and were included in the study. The duration of effusion ranged from 6 months to 15 years (median, 3 years). At the initial evaluation, 13 patients were asymptomatic. Overt tamponade was found in eight patients (29 percent). Therapeutic pericardiocentesis, performed in 24 patients, was followed by the disappearance of or marked reduction in the effusion in 8. Five of the 24 patients underwent early pericardiectomy, and in 11 large pericardial effusion reappeared. Cardiac catheterization, performed in 16 patients, showed elevated intrapericardial pressure (mean [+/-SD], 4.75+/-3.79 mm Hg) and reduced transmural pressure (1.0+/-2.50 mm Hg) before pericardiocentesis. Both of these abnormalities in pressure improved significantly after pericardiocentesis. Pericardiectomy, performed in 20 patients, yielded excellent long-term results. At the end of the follow-up period, 10 patients had died, but none had died from pericardial disease. Conclusions: Large idiopathic chronic pericardial effusion is well tolerated for long periods in most patients, but severe tamponade can develop unexpectedly at any time. Pericardiocentesis alone frequently results in the resolution of large effusions, but recurrence is common and pericardiectomy should be considered whenever a large effusion recurs after pericardiocentesis. (N Engl J Med 1999;341:2054-9.) (C)1999, Massachusetts Medical Society.	Hosp Gen Univ Vall Dhebron, Serv Cardiol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Sagrista-Sauleda, J (corresponding author), Hosp Gen Univ Vall Dhebron, Serv Cardiol, Passeig Vall Dhebron 119-129, Barcelona 08035, Spain.							BARKER PS, 1950, CIRCULATION, V2, P134, DOI 10.1161/01.CIR.2.1.134; BEDFORD DE, 1964, BRIT HEART J, V26, P499; BENDAYAN P, 1991, ARCH MAL COEUR VAISS, V84, P127; BOUVRAIN Y, 1957, Sem Hop, V33, P3353; BROWN AK, 1966, BRIT HEART J, V28, P609; COLOMBO A, 1988, CLIN CARDIOL, V11, P389, DOI 10.1002/clc.4960110606; CONNOLLY DC, 1959, CIRCULATION, V20, P1095, DOI 10.1161/01.CIR.20.6.1095; CONTRO S, 1955, CIRCULATION, V11, P844, DOI 10.1161/01.CIR.11.6.844; DRESSLER W, 1966, J AMER MED ASSOC, V195, P1064, DOI 10.1001/jama.195.12.1064; DUNN RP, 1975, AM HEART J, V89, P369, DOI 10.1016/0002-8703(75)90088-5; FOWLER NO, 1985, PERICARDIUM HLTH DIS, P217; GHOSH SC, 1985, INT SURG, V70, P5; GONIN A, 1956, REV LYON MED, V5, P741; GUIDOTTI P L, 1954, Arch Mal Coeur Vaiss, V47, P1001; HOUSEHAM C, 1982, S AFR MED J, V62, P293; JAFFE RJ, 1959, ANN INTERN MED, V51, P363, DOI 10.7326/0003-4819-51-2-363; KANE G C, 1988, Chest, V93, P434, DOI 10.1378/chest.93.2.434; KLOPFENSTEIN HS, 1990, PERICARDIAL DIS NEW, P47; Loire R, 1996, ARCH MAL COEUR VAISS, V89, P835; MARION MMJ, 1979, BORDEAUX MED, V12, P1449; MASK WK, 1990, J THORAC CARDIOV SUR, V99, P569; MUSEMECHE CA, 1990, J PEDIATR SURG, V25, P840, DOI 10.1016/0022-3468(90)90187-E; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; PUIGMASSANA M, 1972, BRIT HEART J, V34, P431; REDDY PS, 1990, AM J CARDIOL, V66, P1487, DOI 10.1016/0002-9149(90)90540-H; RIVAS JJ, 1985, MED CLIN-BARCELONA, V84, P102; SAGRISTASAULEDA J, 1988, J AM COLL CARDIOL, V11, P724, DOI 10.1016/0735-1097(88)90203-3; SAGRISTASAULEDA J, 1982, CIRCULATION, V66, P895, DOI 10.1161/01.CIR.66.4.895; SAINTPIERRE A, 1966, ACTUAL CARDIOVASC, P300; SANCHEZ MAG, 1982, MONOCARDIO, V3, P24; SCHEUER J, 1960, CIRCULATION, V21, P41, DOI 10.1161/01.CIR.21.1.41; SHABETAI R, 1981, PERICARDIUM, P108; Soler-Soler J, 1990, PERICARDIAL DIS NEW, P217; SOULIE P, 1960, ARCH MAL COEUR, V53, P1248; Suzman S, 1943, BRIT HEART J, V5, P19; TAVARES S, 1981, MD STATE MED J, V30, P64; WEITZMAN LB, 1984, CIRCULATION, V69, P506, DOI 10.1161/01.CIR.69.3.506; WOOD P, 1968, WOODS DIS HEART CIRC, P762; YU PNG, 1953, ANN INTERN MED, V39, P928, DOI 10.7326/0003-4819-39-4-928; ZISKIND AA, 1993, J AM COLL CARDIOL, V21, P1, DOI 10.1016/0735-1097(93)90710-I	40	122	132	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2054	2059		10.1056/NEJM199912303412704	http://dx.doi.org/10.1056/NEJM199912303412704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615077				2022-12-28	WOS:000084573300004
J	Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR				Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR			Shaken, not stirred: bioanalytical study of the antioxidant activities of martinis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; RISK; ALCOHOL	Background Moderate consumption of alcoholic drinks seems to reduce the risks of developing cardiovascular disease, stroke, and cataracts, perhaps through antioxidant actions of their alcohol, flavonoid, ur polyphenol contents. "Shaken, not stirred" routinely identifies the way the famous secret agent James Bond requires his martinis. Objectives As Mr Bond is not afflicted by cataracts or cardiovascular disease, an investigation was conducted to determine whether the mode of preparing martinis has an influence on their antioxidant capacity. Design Stir-red and shaken martinis were assayed for their ability to quench luminescence by a luminescent procedure in which hydrogen peroxide reacts with luminol bound to albumin. Student's t test was used for statistical analysis. Results Shaken martinis were more effective in deactivating hydrogen peroxide than the stirred variety, and both were more effective than gin or vermouth alone (0.072% of peroxide control for shaken martini, 0.157% for stirred v 58.3% for gin and 1.90% for vermouth). The reason for this is not clear, but it may well not involve the facile oxidation of reactive martini components: control martinis through which either oxygen or nitrogen was bubbled did not differ in their ability to deactivate hydrogen peroxide (0.061% v 0.057%) and did not differ from the shaken martini. Moreover, preliminary experiments indicate that martinis are less well endowed with polyphenols than Sauvignon white wine or Scotch whisky (0.056 mmol/l (catechin equivalents) shaken, 0.060 mmol/l stirred v 0.0592 mmol/l wine, 0.575 mmol/l whisky). Conclusions 007's profound state of health may be due, at least in part, to compliant bartenders.	Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Trevithick, JR (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.	trevjohn@julian.uwo.ca		Chartrand, Michelle/0000-0003-3398-7246				CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SASAKI H, 1997, US JAP COOP CAT RES, P66; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Trevithick CC, 1999, REDOX REP, V4, P89, DOI 10.1179/135100099101534765; Trevithick JR, 1997, BIOCHEM MOL BIOL INT, V41, P695; TREVITHICK JR, 1994, BIOCHEM MOL BIOL INT, V33, P1179	13	11	11	2	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1600	1602		10.1136/bmj.319.7225.1600	http://dx.doi.org/10.1136/bmj.319.7225.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600955	Bronze, Green Published			2022-12-28	WOS:000084562600008
J	Planesas, P; Martin-Pintado, J; Neri, R; Colina, L				Planesas, P; Martin-Pintado, J; Neri, R; Colina, L			Gas-rich galaxy pair unveiled in the lensed quasar 0957+561	SCIENCE			English	Article							GRAVITATIONAL LENS	Molecular gas in the host galaxy of the Lensed quasar 0957+561 (QSO 0957+561) at the redshift of 1.41 has been detected in the carbon monoxide (CO) Line. This detection shows the extended nature of the molecular gas distribution in the host galaxy and the pronounced lensing effects due to the differentially magnified CO Luminosity at different velocities. The estimated mass of molecular gas is about 4 x 10(9) solar masses, a molecular gas mass typical of a spiral galaxy Like the Milky Way. A second, weaker component of CO is interpreted as arising from a close companion galaxy that is rich in molecular gas and has remained undetected so far. Its estimated molecular gas mass is 1.4 x 10(9) solar masses, and its velocity relative to the main galaxy is 660 kilometers per second. The ability to probe the molecular gas distribution and kinematics of galaxies associated with high-redshift Lensed quasars can be used to improve the determination of the Hubble constant H-0.	Observ Astron Nacl IGN, E-28800 Alcala De Henares, Spain; Inst Radio Astron Millimetr, F-38460 St Martin Dheres, France; Univ Cantabria, CSIC, Fac Ciencias, Inst Fis Cantabria, E-39005 Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Fisica de Cantabria (IFCA)	Planesas, P (corresponding author), Observ Astron Nacl IGN, Apartado 1143, E-28800 Alcala De Henares, Spain.		Martin-Pintado, Jesus/H-6107-2015; Planesas, Pere/G-7950-2015; Colina, Luis/C-2823-2017	Martin-Pintado, Jesus/0000-0003-4561-3508; Planesas, Pere/0000-0002-7808-3040; Colina, Luis/0000-0002-9090-4227				Bahcall JN, 1997, ASTROPHYS J, V479, P642, DOI 10.1086/303926; Barkana R, 1999, ASTROPHYS J, V520, P479, DOI 10.1086/307469; Combes F, 1999, ASTRON ASTROPHYS, V345, P369; Downes D, 1999, ASTROPHYS J, V513, pL1, DOI 10.1086/311896; GREENFIELD PE, 1980, SCIENCE, V208, P495, DOI 10.1126/science.208.4443.495; HAEHNELT MG, 1993, MON NOT R ASTRON SOC, V263, P168, DOI 10.1093/mnras/263.1.168; Harvanek M, 1997, ASTRON J, V114, P2240, DOI 10.1086/118644; HEWITT JN, 1988, NATURE, V333, P537, DOI 10.1038/333537a0; Hutchings JB, 1999, ASTRON J, V117, P1109, DOI 10.1086/300787; KORMENDY J, 1992, ASTROPHYS J, V390, pL53, DOI 10.1086/186370; RADFORD SJE, 1991, ASTROPHYS J, V368, pL15, DOI 10.1086/185937; Sakamoto K, 1999, ASTROPHYS J, V514, P68, DOI 10.1086/306951; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; SANDERS DB, 1988, APJ, V328, P35; SCOVILLE NZ, 1993, ASTROPHYS J, V415, pL75, DOI 10.1086/187036; SOIFER BT, 1980, NATURE, V285, P91, DOI 10.1038/285091a0; STOCKTON A, 1980, ASTROPHYS J, V242, pL141, DOI 10.1086/183419; WALSH D, 1979, NATURE, V279, P381, DOI 10.1038/279381a0	18	15	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2493	2495		10.1126/science.286.5449.2493	http://dx.doi.org/10.1126/science.286.5449.2493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617461				2022-12-28	WOS:000084429700044
J	Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA				Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA			Evolution of shape complementarity and catalytic efficiency from a primordial antibody template	SCIENCE			English	Article							DIELS-ALDER REACTION; AUTOMATED DOCKING; RATE ACCELERATIONS; CROSS-REACTIVITY; PROTEINS; COMPLEXES; INSIGHTS; ENERGY	The crystal structure of an efficient Diels-Alder antibody catalyst at 1.9 angstrom resolution reveals almost perfect shape complementarity with its transition state analog. Comparison with highly related progesterone and Diels-Alderase antibodies that arose from the same primordial germ Line template shows the relatively subtle mutational steps that were able to evolve both structural complementarity and catalytic efficiency.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Swiss Fed Inst Technol, ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; Swiss Federal Institutes of Technology Domain; ETH Zurich	Xu, JA (corresponding author), Mol Simulat Inc, 9685 Scranton Rd, San Diego, CA 92121 USA.		Bartek, Jiri/G-5870-2014	Xu, Jian/0000-0002-4251-6895	NCI NIH HHS [CA27489] Funding Source: Medline; NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Badger J, 1999, PROTEINS, V35, P25, DOI 10.1002/(SICI)1097-0134(19990401)35:1<25::AID-PROT3>3.3.CO;2-M; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; Cossi M, 1996, CHEM PHYS LETT, V255, P327, DOI 10.1016/0009-2614(96)00349-1; Frisch M.J., GAUSSIAN; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1997, SCIENCE, V275, P1140; Haynes MR, 1996, ISRAEL J CHEM, V36, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Heine A, 1998, SCIENCE, V279, P1934, DOI 10.1126/science.279.5358.1934; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, 1999, TOP STEREOCHEM, V22, P83; Hollfelder F, 1996, NATURE, V383, P60, DOI 10.1038/383060a0; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES S, 1996, P NATL ACAD SCI USA, V93, P1320; Kabat EA, 1991, SEQUENCES PROTEINS I; Kikuchi K, 1996, J AM CHEM SOC, V118, P8184, DOI 10.1021/ja9617395; Laschat S, 1996, ANGEW CHEM INT EDIT, V35, P289, DOI 10.1002/anie.199602891; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; MEEKEL AAP, 1995, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39950000571; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PAULING L, 1948, Am Sci, V36, P51; PEARLMAN DA, 1995, AMBER 4 1; Pitt AR, 1996, ISRAEL J CHEM, V36, P171; Romesberg FE, 1999, BIOORG MED CHEM LETT, V9, P1741, DOI 10.1016/S0960-894X(99)00281-4; RORNESBERG FE, 1998, SCIENCE, V279, P1929; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seelig B, 1999, CHEM BIOL, V6, P167, DOI 10.1016/S1074-5521(99)89008-5; Stura E. A., 1993, IMMUNOMETHODS, V3, P164; Tarasow TM, 1997, NATURE, V389, P54, DOI 10.1038/37950; THORN SN, 1995, NATURE, V373, P228, DOI 10.1038/373228a0; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Warshel A, 1998, P NATL ACAD SCI USA, V95, P5950, DOI 10.1073/pnas.95.11.5950; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001	50	106	107	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2345	2348		10.1126/science.286.5448.2345	http://dx.doi.org/10.1126/science.286.5448.2345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600746				2022-12-28	WOS:000084318500063
J	Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G				Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G			T-cell co-stimulation through B7RP-1 and ICOS	NATURE			English	Article							CONTACT HYPERSENSITIVITY; MOLECULAR-CLONING; EFFICIENCY; EXPRESSION; RESPONSES; TOLERANCE; BLOCKADE; SYSTEM; MEMORY; CTLA-4	T-cell activation requires co-stimulation through receptors such as CD28 (refs 1-3) and antigen-specific signalling through the T-cell antigen receptor. Here we describe a new murine costimulatory receptor-ligand pair. The receptor, which is related to CD28 and is the homologue of the human protein ICOS4, is expressed on activated T cells and resting memory T cells. The ligand, which has homology to B7 molecules and is called B7-related protein-1 (B7RP-1), is expressed on B cells and macrophages. ICOS and B7RP-1 do not interact with proteins in the CD28-B7 pathway, and B7RP-1 co-stimulates T cells in vitro independently of CD28. Transgenic mice expressing a B7RP-1-Fc fusion protein show lymphoid hyperplasia in the spleen, lymph nodes and Peyer's patches. Presensitized mice treated with B7RP-1-Fc during antigen challenge show enhanced hypersensitivity. Therefore, B7RP-1 exhibits co-stimulatory activities in vitro and in vivo. ICOS and B7RP-1 define a new and distinct receptor-ligand pair that is structurally related to CD28-B7 and is involved in the adaptive immune response.	Amgen Inc, Thousand Oaks, CA 91320 USA; Amgen Inc, Res Inst, Toronto, ON M5G 2C1, Canada	Amgen	Yoshinaga, SK (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bajorath J, 1999, J MOL MODEL, V5, P169, DOI 10.1007/s008940050116; Beverley PCL, 1996, CURR OPIN IMMUNOL, V8, P327, DOI 10.1016/S0952-7915(96)80120-8; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Greene RME, 1998, EUR RADIOL, V8, P359, DOI 10.1007/s003300050394; GROSS JA, 1990, J IMMUNOL, V144, P3201; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; McHale JF, 1999, J IMMUNOL, V162, P1648; Schulte M, 1998, OXID MET, V49, P33, DOI 10.1023/A:1018818021754; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Tang AM, 1996, J IMMUNOL, V157, P117; Tang AM, 1997, EUR J IMMUNOL, V27, P3143, DOI 10.1002/eji.1830271210; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419	23	643	752	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					827	832		10.1038/45582	http://dx.doi.org/10.1038/45582			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617205				2022-12-28	WOS:000084330500069
J	Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L				Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L			Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; COST-EFFECTIVENESS; CARDIAC PROCEDURES; ELDERLY PATIENTS; CERVICAL-CANCER; HEALTH-CARE; OUTCOMES; MEDICINE; POLICY; ANGIOPLASTY	Context Expert panels and decision-analytic techniques are increasingly used to determine the appropriateness of medical interventions, but these 2 approaches use different methods to process evidence. Objective To compare expert panel appropriateness ratings of coronary angiography after myocardial infarction (from the time of hospital discharge to 12 weeks after infarction) with the health gains and cost-effectiveness predicted by a decision-analytic model. Design Comparison of the degree of importance of the clinical variables considered in expert panel appropriateness ratings vs a previously published decision-analytic model. Identification of 36 clinical scenarios from the expert panel that could be simulated by the decision-analytic model. Main Outcome Measures Appropriateness score and appropriateness classification (expert panel) vs gain in quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (decision-analytic model). Results The most important clinical variables were similar in the 2 approaches, with the exercise tolerance test result exerting the greatest leverage on strength of recommendation for angiography. Among the expert panel clinical scenarios considered to be appropriate for coronary angiography that could be simulated in the decision-analysis model, the median (interquartile range) health gain and incremental cost-effectiveness ratio were 0.59 (0.41-0.76) QALYs and $27 000 ($23 000-$35 000) per QALY gained, respectively. Among the clinical scenarios that expert panels considered inappropriate, the corresponding medians (interquartile ranges) were 0.24 (0.19-0.34) QALYs and $54 000 ($36 000-$58 000) per QALY gained. The Spearman rank correlation between appropriateness score and QALY gain was 0.58 (P<.001) and between appropriateness score and estimated incremental cost-effectiveness ratios was -0.66 (P<.001). Conclusions For the 36 expert panel scenarios that could be simulated by the decision; analytic model, there was moderate to good agreement between the appropriateness score and both the health gain and the incremental cost-effectiveness ratio of coronary angiography compared with no angiography in the convalescent phase of acute myocardial infarction, but several scenarios judged as inappropriate by the expert panel approach had cost-effectiveness ratios comparable with many generally recommended medical interventions. Formal synthesis of expert judgment and decision modeling is warranted in future efforts at guideline development.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA; Univ San Francisco, Sch Med, Dept Med, San Francisco, CA 94117 USA	Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of San Francisco	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA.				AHRQ HHS [R01-HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], CORONARY ANGIOGRAPHY; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; Bernstein SJ, 1997, INT J QUAL HEALTH C, V9, P255, DOI 10.1093/intqhc/9.4.255; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHURCHILL DN, 1984, MED DECIS MAKING, V4, P489, DOI 10.1177/0272989X8400400411; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Field MJ, 1990, CLIN PRACTICE GUIDEL; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Gold MR, 1996, COST EFFECTIVENESS H; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Hawkes AP, 1996, AM J PREV MED, V12, P342; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; Landrum MB, 1999, STAT MED, V18, P117, DOI 10.1002/(SICI)1097-0258(19990130)18:2<117::AID-SIM8>3.0.CO;2-7; LEAPE LL, 1990, QRB QUAL REV B, V16, P24; *NAT CTR HLTH STAT, 1991, MORTALITY A, V2; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Weinstein MC, 1980, CLIN DECISION ANAL; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	31	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2246	2251		10.1001/jama.282.23.2246	http://dx.doi.org/10.1001/jama.282.23.2246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605977				2022-12-28	WOS:000084138600033
J	Bloom, BS; Iannacone, RC				Bloom, BS; Iannacone, RC			Internet availability of prescription pharmaceuticals to the public	ANNALS OF INTERNAL MEDICINE			English	Article						Internet; prescriptions, drug; health services accessibility; costs and cost analysis; conflict of interest		Background: The Internet holds great but uncertain promise for increased access and cost control in health care. Objective: To determine access to and cost of prescription pharmaceuticals over the Internet. Design: An Internet search conducted during February and March 1999. Setting: The Philadelphia region. Measurements: Data were collected on availability and cost of medications and physician Internet visits, requirements for physician prescriptions, and geographic location of Web-based companies and consulting physicians. Costs of comparable physician visits were obtained from Medicare and managed care organizations in the Philadelphia region. Costs of medications came from five Philadelphia community pharmacies. Results: Forty-six Web sites were identified. Thirty-seven sites (33 based in the United States and 4 based outside the United States) required a prescription from a personal physician or from an Internet physician consultation. Nine sites based outside of the United States did not require a prescription or physician consultation. The median cost of an Internet physician visit was $70 (range, $20 to $90), more than 15% higher than that for a genera I practice visit in the Philadelphia region. Quality of physician consultation, physician qualifications and specialty, and geographic location were unknown. Median price per pill of the two most commonly offered medications was 10% higher on the Internet (before shipping charges) than at Philadelphia pharmacies ($5.49 and $4.50 for sildenafil; $1.94 and $1.83 for finasteride). Conclusions: The Internet may expand patient access to health-related services but at overall increased cost. In addition, the quality of physician Internet care is uncertain, and potential for serious abuse exists. Patients can easily provide incorrect or false information to obtain medications. Furthermore, conflict of interest exists for Web-based firms because they profit from selling medications and physician consultations.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Bloom, BS (corresponding author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA.								0	57	58	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					830	+		10.7326/0003-4819-131-11-199912070-00005	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610627				2022-12-28	WOS:000084053200004
J	Hillis, DM				Hillis, DM			Perspectives: Evolutionary biology - Predictive evolution	SCIENCE			English	Editorial Material							INFLUENZA		Univ Texas, Sch Biol Sci, Sect Integrat Biol, Austin, TX 78712 USA; Univ Texas, Sch Biol Sci, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hillis, DM (corresponding author), Univ Texas, Sch Biol Sci, Sect Integrat Biol, Austin, TX 78712 USA.		Hillis, David/L-5421-2019; Hillis, David M/B-4278-2008					Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	5	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1866	1867		10.1126/science.286.5446.1866	http://dx.doi.org/10.1126/science.286.5446.1866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10610576				2022-12-28	WOS:000084003400030
J	Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH				Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH			A mammalian H+ channel generated through alternative splicing of the NADPH oxidase homolog NOH-1	SCIENCE			English	Article							HYDROGEN-ION CURRENTS; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; INTRACELLULAR PH; PROTON CURRENT; MEMBRANE; CONDUCTANCE; LEUKOCYTES	Voltage-gated proton (H+) channels are found in many human and animal tissues and play an important role in cellular defense against acidic stress. However, a molecular identification of these unique ion conductances has so far not been achieved. A 191-amino acid protein is described that, upon heterologous expression, has properties indistinguishable from those of native H+ channels. This protein is generated through alternative splicing of messenger RNA derived from the gene NOH-1 (NADPH oxidase homolog 1, where NADPH is the reduced form of nicotinamide adenine dinucleotide phosphate).	Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Dept Geriatr, Biol Aging Lab, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Fdn Rech Med, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Semmelweis Univ, Dept Physiol, H-1444 Budapest 8, Hungary	University of Geneva; University of Geneva; University of Geneva; University of Geneva; Semmelweis University	Demaurex, N (corresponding author), Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Sinha, Bhanu/0000-0003-1634-0010; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; BANFI B, UNPUB; BERNHEIM L, 1993, J PHYSIOL-LONDON, V470, P313, DOI 10.1113/jphysiol.1993.sp019860; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DECOURSEY TE, 1994, J MEMBRANE BIOL, V141, P203; Decoursey Thomas E., 1998, Frontiers in Bioscience, V3, pD477; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Hille B., 1992, IONIC CHANNELS EXCIT; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Kuno M, 1997, J GEN PHYSIOL, V109, P731, DOI 10.1085/jgp.109.6.731; NANDA A, 1994, J BIOL CHEM, V269, P27280; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Roos D, 1986, Methods Enzymol, V132, P250; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	26	240	252	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					138	142		10.1126/science.287.5450.138	http://dx.doi.org/10.1126/science.287.5450.138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615049				2022-12-28	WOS:000084578400054
J	de Boer, WA; Tytgat, GNJ				de Boer, WA; Tytgat, GNJ			Regular review - Treatment of Helicobacter pylori infection	BRITISH MEDICAL JOURNAL			English	Review							PEPTIC-ULCER DISEASE; RANITIDINE BISMUTH CITRATE; TRIPLE THERAPY; ERADICATION; CLARITHROMYCIN; OMEPRAZOLE; EFFICACY; RESISTANCE		St Anna Hosp, Dept Internal Med, NL-5340 BE Oss, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	de Boer, WA (corresponding author), St Anna Hosp, Dept Internal Med, Postbus 10, NL-5340 BE Oss, Netherlands.							Benitez JH, 1998, GUT, V43, pA86; Bodger K, 1997, ALIMENT PHARM THER, V11, P273, DOI 10.1046/j.1365-2036.1997.145321000.x; Borda F, 1998, GUT, V43, pA81; Borody TJ, 1996, HELICOBACTER PYLORI, P357; Breuer T, 1998, AM J GASTROENTEROL, V93, P553; Buckley MJM, 1997, DIGEST DIS SCI, V42, P2111, DOI 10.1023/A:1018882804607; Buda A, 1997, GUT, V41, pA92; Chiba N., 1996, Gut, V39, pA36; DEBOER W, 1995, LANCET, V345, P817, DOI 10.1016/S0140-6736(95)92962-2; DEBOER WA, 1995, SCAND J GASTROENTERO, V30, P401, DOI 10.3109/00365529509093298; deBoer WA, 1996, EUR J GASTROEN HEPAT, V8, P709; DeKoster E, 1997, GASTROENTEROLOGY, V112, pA99; Goddard AF, 1997, GUT, V41, pA96; Graham DY, 1996, AM J GASTROENTEROL, V91, P1072; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Huang JQ, 1997, GUT, V41, pA90; Katelaris PH, 1997, AM J GASTROENTEROL, V92, P1245; Kist M, 1997, GUT, V41, pA90; Kolkman JJ, 1997, ALIMENT PHARM THERAP, V11, P1123, DOI 10.1046/j.1365-2036.1997.00254.x; Lamouliatte H, 1997, GUT, V41, pA93; Lee JM, 1997, GASTROENTEROLOGY, V112, pA195; Lerang F, 1997, AM J GASTROENTEROL, V92, P653; Lind T, 1999, GASTROENTEROLOGY, V116, P248, DOI 10.1016/S0016-5085(99)70119-8; Malfertheiner P, 1997, GUT, V41, P8; Megraud F, 1997, GUT, V41, pA92; Misiewicz JJ, 1997, GUT, V41, P735, DOI 10.1136/gut.41.6.735; Neil GA, 1997, AM J GASTROENTEROL, V92, P387; Pare P, 1997, GASTROENTEROLOGY, V112, pA251; Peitz U, 1997, GUT, V41, pA104; Penston JG, 1996, ALIMENT PHARM THERAP, V10, P139, DOI 10.1046/j.1365-2036.1996.745128000.x; Penston JG, 1996, ALIMENT PHARM THER, V10, P469, DOI 10.1046/j.1365-2036.1996.40182000.x; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; THYS JC, 1997, ALIMENT PHARM THERAP, V11, P305; Treiber G, 1996, AM J GASTROENTEROL, V91, P246; van der Hulst R W, 1996, Helicobacter, V1, P6; vanderHulst RWM, 1997, J INFECT DIS, V176, P196, DOI 10.1086/514023; Wilhelmsen I, 1996, SCAND J GASTROENTERO, V31, P18, DOI 10.3109/00365529609095546	37	147	152	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					31	34		10.1136/bmj.320.7226.31	http://dx.doi.org/10.1136/bmj.320.7226.31			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617524	Green Published			2022-12-28	WOS:000084621600023
J	McCarron, P; Harvey, I; Brogan, R; Peters, TJ				McCarron, P; Harvey, I; Brogan, R; Peters, TJ			Self reported health of people in an area contaminated by chromium waste: interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY EXPOSURE; SITES	Objectives To compare the self reported health of a group of individuals living in an area contaminated by chromium (chromium group) wtih a group living in an uncontaminated area (control group), and to assess the effects of perception of risk from exposure to chromium ori health. Design Cross sectional study using the SF-36 validated quality of life questionnaire. Further questions were added to examine the relations between perceptions about living on or near land contaminated with chromium and the effects on self reported health. Setting An area contaminated with chromium (Cambuslang, Carmyle, and Rutherglen) and a control area (Barrmulloch and Pollok). Participants Residents of an area containing chromium landfill and residents of an uncontaminated control area. Main outcome measures Scores on SF-36. Results Little difference was found in health scores between the two groups, and only for general health was there a significantly higher score in the chromium group. Health scores for the chromium group were significantly worse across all dimensions for chose who believed that chromium adversely affected health. Most of the chromium group (68%) would prefer money to be spent on improving amenities rather than on chromium remediation. Conclusions Similar self reported health among residents of the chromium and control groups indicates that there is no evidence of harm to health from exposure to chromium in this setting. Noticeably lower scores in participants who believed chromium to be harmful to health point to the potential importance of perception and possible anxiety. Given the overall greater desire for better amenities rather than remedial action, policy makers and planners should discuss with residents how best to spend resources before instigating expensive cleaning up programmes.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich R4 7TJ, Norfolk, England; Greater Glasgow Hlth Board, Glasgow G3 8YZ, Lanark, Scotland	University of Bristol; University of East Anglia	McCarron, P (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	P.McCarron@bristol.ac.uk						ANDERSON RA, 1993, J TOXICOL ENV HEALTH, V40, P555, DOI 10.1080/15287399309531819; Barnhart J, 1997, REGUL TOXICOL PHARM, V26, pS3, DOI 10.1006/rtph.1997.1132; BIDSTRUP P L, 1956, Br J Ind Med, V13, P260; BIDSTRUP PL, 1951, BRIT J IND MED, V8, P302; BIDSTRUP PL, 1983, ENCY OCCUPATIONAL HL; Carstairs V., 1991, DEPRIVATION HLTH SCO; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; *DEP PUBL HLTH, 1991, ASS RISK HUM HLTH LA; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; EIZAGUIRRE D, 1993, USE ROUTINE HLTH DAT; EIZAGUIRRE D, 1996, THESIS U GLASGOW GLA; EIZAGUIRRE D, 1999, IN PRESS J PUBLIC HL; Fagliano JA, 1997, REGUL TOXICOL PHARM, V26, pS13, DOI 10.1006/rtph.1997.1134; HUGHES K, 1994, ENVIRON CARCIN ECO R, V12, P237; *INT AG RES CANC, 1990, IARC MON EV CARC RIS, V38, P49; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LANGARD S, 1975, HDB TOXICOLOGY METAL; PASTIDES H, 1994, AM J IND MED, V25, P663, DOI 10.1002/ajim.4700250506; *PUBL AN STRATHCL, 1989, SOILS RUTH SIT INV; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; SHUSTERMAN D, 1991, ENVIRON HEALTH PERSP, V94, P25, DOI 10.2307/3431288; SLOVIC P, 1997, ENV HLTH, V54, P22; Ware JE, 1993, SF36 HLTH SURVEY MAN	23	30	30	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2000	320	7226					11	15		10.1136/bmj.320.7226.11	http://dx.doi.org/10.1136/bmj.320.7226.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617516	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000084621600013
J	Acheson, D				Acheson, D			Conflict in Bosnia 1992-3	BRITISH MEDICAL JOURNAL			English	Article									UCL, Int Ctr Hlth & Soc, London WC1E 6BT, England	University of London; University College London	Acheson, D (corresponding author), UCL, Int Ctr Hlth & Soc, Mortimer St, London WC1E 6BT, England.								0	2	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1639	1642		10.1136/bmj.319.7225.1639	http://dx.doi.org/10.1136/bmj.319.7225.1639			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600978	Green Published			2022-12-28	WOS:000084562600029
J	Cowen, P				Cowen, P			The price of coffins: specious arguments by eminent doctors against the dangers of tobacco	BRITISH MEDICAL JOURNAL			English	Article											Cowen, P (corresponding author), 22 Congreve Way, Leeds LS17 9BG, W Yorkshire, England.							Chambers J, 1999, BMJ-BRIT MED J, V318, P1; COWEN PN, 1961, CHEST HEART B, V25, P129; DEMOULIN D, 1983, SHORT HIST BREAST CA; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; EYSENCK HJ, 1961, FAM DOCTOR, V6, P420; *MED RES COUNC, 1957, TOB SMOK CANC LUNG; 1959, CHEST HEART B, V22, P101; 1959, BMJ, V2, P1465	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1621	1623		10.1136/bmj.319.7225.1621	http://dx.doi.org/10.1136/bmj.319.7225.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600970	Green Published			2022-12-28	WOS:000084562600022
J	Sgro, CM; Partridge, L				Sgro, CM; Partridge, L			A delayed wave of death from reproduction in Drosophila	SCIENCE			English	Article							MORTALITY-RATES; LIFE-HISTORY; MELANOGASTER; LONGEVITY; SENESCENCE; EVOLUTION; SELECTION; COST; EXPOSURE; MALES	Mortality rates typically increase rapidly at the onset of aging but can decelerate at Later ages. Reproduction increases the death rate in many organisms. To test the idea that a delayed impact of earlier reproduction contributes to both an increase in death rates and a Later deceleration in mortality, the timing of the surplus mortality produced by an increased Level of egg production was measured in female Drosophila. Reproduction produced a delayed wave of mortality, coincident with the sharp increase in death rates at the onset of aging and the subsequent deceleration of mortality. These results suggest that aging has evolved primarily because of the damaging effects of reproduction earlier in Life, rather than because of mutations that have detrimental effects only at Late ages.	UCL, Dept Biol, London NW1 2HE, England	University of London; University College London	Partridge, L (corresponding author), UCL, Dept Biol, 4 Stephenson Way, London NW1 2HE, England.	l.partridge@ucl.ac.uk	Partridge, Linda/E-7342-2015; Sgro, Carla M/G-5166-2010; Sgro, Carla/A-2495-2010; Partridge, Linda/A-5501-2010	Partridge, Linda/0000-0001-9615-0094; Sgro, Carla/0000-0001-7950-2246				Ashburner M., 1989, DROSOPHILA LAB HDB; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BROOKS A, 1994, SCIENCE, V263, P668, DOI 10.1126/science.8303273; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HOULE D, 1994, GENETICS, V138, P773; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; LAMB MJ, 1964, J INSECT PHYSIOL, V10, P487, DOI 10.1016/0022-1910(64)90072-1; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; Medawar P., 1952, UNSOLVED PROBLEM BIO; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; Miller R. G., 1981, SURVIVAL ANAL; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Partridge L, 1999, P ROY SOC B-BIOL SCI, V266, P255, DOI 10.1098/rspb.1999.0630; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; Pletcher SD, 1998, GENETICS, V148, P287; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROSE MR, 1981, GENETICS, V97, P187; SMITH JM, 1958, J EXP BIOL, V35, P832; TATAR M, 1993, EVOLUTION, V47, P1302, DOI [10.1111/j.1558-5646.1993.tb02156.x, 10.2307/2410149]; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.2307/2410318	33	197	205	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2521	2524		10.1126/science.286.5449.2521	http://dx.doi.org/10.1126/science.286.5449.2521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617470	Green Submitted			2022-12-28	WOS:000084429700053
J	Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A				Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A			EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; DIPHTHERIA-TOXIN RECEPTOR; KINASE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; SECRETION; DOMAIN; ALPHA; CELLS	Cross-communication between different signalling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. The transactivation of epidermal growth factor receptor (EGFR)-dependent signalling pathways upon stimulation of G-protein-coupled receptors (GPCRs), which are critical for the mitogenic activity of ligands such as lysophosphatidic acid, endothelin, thrombin, bombesin and carbachol, provides evidence for such an interconnected communication network(1-4). Here we show that EGFR transactivation upon GPCR stimulation involves proHB-EGF and a metalloproteinase activity that is rapidly induced upon GPCR-ligand interaction. We show that inhibition of proHB-EGF processing blocks GPCR-induced EGFR transactivation and downstream signals, The pathophysiological significance of this mechanism is demonstrated by inhibition of constitutive EGFR activity upon treatment of PC3 prostate carcinoma cells with the metalloproteinase inhibitor batimastat. Together, our results establish a new mechanistic concept for cross-communication among different signalling systems.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	Ullrich@biochem.mpg.de						BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHING KZ, 1993, MOL CELL BIOCHEM, V126, P151, DOI 10.1007/BF00925693; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; GOLSHI K, 1995, MOL BIOL CELL, V6, P967; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	29	1445	1492	2	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					884	888		10.1038/47260	http://dx.doi.org/10.1038/47260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622253				2022-12-28	WOS:000084482000035
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 44-year-old woman with severe pain at the end of life, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Parker RA, 1999, JAMA-J AM MED ASSOC, V281, P1937, DOI 10.1001/jama.281.20.1937	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2354	2354		10.1001/jama.282.24.2354	http://dx.doi.org/10.1001/jama.282.24.2354			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612324				2022-12-28	WOS:000084261700030
J	Kraman, SS; Hamm, G				Kraman, SS; Hamm, G			Risk management: Extreme honesty may be the best policy	ANNALS OF INTERNAL MEDICINE			English	Article							MALPRACTICE CLAIMS; MISTAKES	This paper reviews a humanistic risk management policy that includes early injury review, steadfast maintenance of the relationship between the hospital and the patient, proactive full disclosure to patients who have been injured because of accidents or medical negligence, and fair compensation for injuries. The financial consequences of this type of policy are not yet known; however, one Veterans Affairs medical center, which has been using humanistic risk management since 1987, has had encouragingly moderate liability payments. The Department of Veterans Affairs now requires such a policy for all of its facilities; therefore, comprehensive experience may be only a few years away.	Vet Adm Med Ctr, Lexington, KY 40511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	Kraman, SS (corresponding author), Vet Adm Med Ctr, 2210 Leestown Rd, Lexington, KY 40511 USA.							DEFRANCES CJ, 1995, NCJ154346 US DEP JUS, P1; *DEP VET AFF VHA, 1998, DEP VET AFF VHA MAN, V1051; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; PENCHANSKY R, 1994, MED CARE, V32, P813, DOI 10.1097/00005650-199408000-00005; PETERKIN A, 1990, CAN MED ASSOC J, V142, P984; PRESS AH, 1997, NCJ165810 US DEP JUS; RUBIN B, 1978, HOSPITALS, V52, P86; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x	10	279	283	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					963	967		10.7326/0003-4819-131-12-199912210-00010	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610649				2022-12-28	WOS:000084374400009
J	Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ				Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ			Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut	SCIENCE			English	Article							ENCEPHALITIS	West Nile (WN) virus, a mosquito-transmitted virus native to Africa. Asia. and Europe, was isolated from two species of mosquitoes, Culex pipiens and Aedes vexans, and from brain tissues of 28 American crows, Corvus brachyrhynchos, and one Cooper's hawk, Accipiter cooperii, in Connecticut. A portion of the genome of virus isolates from four different hosts was sequenced and analyzed by comparative phylogenetic analysis. Our isolates from Connecticut were similar to one another and most closely related to two WN isolates from Romania (2.8 and 3.6 percent difference). If established in North America, WN virus will likely have severe effects on human health and on the health of populations of birds.	Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA; Connecticut Agr Expt Stn, Dept Soil & Water, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06512 USA; Univ Connecticut, Dept Pathobiol, Storrs, CT 06269 USA	Connecticut Agricultural Experiment Station; Connecticut Agricultural Experiment Station; Yale University; University of Connecticut	Anderson, JF (corresponding author), Connecticut Agr Expt Stn, Dept Entomol, POB 1106, New Haven, CT 06504 USA.	john.f.anderson@po.state.ct.us; theodore.andreadis@po.state.ct.us; charles.vossbrinck@po.state.ct.us			NIAID NIH HHS [P01-AI-30548] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030548] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreadis TG, 1998, J MED ENTOMOL, V35, P296, DOI 10.1093/jmedent/35.3.296; ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P845; CHAYES CG, 1989, ARBOVIRUSES EPIDEMIO, V5, pCH49; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; KITAOKA MASAMI, 1950, JAPANESE MED JOUR, V3, P77; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Philip CB, 1943, P SOC EXP BIOL MED, V53, P49, DOI 10.3181/00379727-53-14180; Savage HM, 1999, AM J TROP MED HYG, V61, P600, DOI 10.4269/ajtmh.1999.61.600; Sibley CG, 1990, DISTRIBUTION TAXONOM; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872; WORK TH, 1953, P SOC EXP BIOL MED, V84, P719, DOI 10.3181/00379727-84-20764	19	267	299	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2331	2333		10.1126/science.286.5448.2331	http://dx.doi.org/10.1126/science.286.5448.2331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600741				2022-12-28	WOS:000084318500058
J	Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD				Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD			Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons	SCIENCE			English	Article							NERVE GROWTH-FACTOR; C-FOS; BCL-2; DEATH; PHOSPHORYLATION; MECHANISM; PROTEIN	Nerve growth factor (NGF) and other neurotrophins support survival of neurons through processes that are incompletely understood. The transcription factor CREB is a critical mediator of NGF-dependent gene expression, but whether CREB family transcription factors regulate expression of genes that contribute to NGF-dependent survival of sympathetic neurons is unknown. CREB-mediated gene expression was both necessary for NGF-dependent survival and sufficient on its own to promote survival of sympathetic neurons, Moreover, expression of Bcl-2 was activated by NGF and other neurotrophins by a CREB-dependent transcriptional mechanism. Overexpression of Bcl-2 reduced the death-promoting effects of CREB inhibition. Together, these data support a model in which neurotrophins promote survival of neurons, in part through a mechanism involving CREB family transcription factor-dependent expression of genes encoding prosurvival factors.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA	Johns Hopkins University; University of Pennsylvania	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Davenport, Christopher/0000-0003-2639-6392	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034814, R37NS034814, R29NS034814] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34814-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Lanahan A, 1997, J NEUROSCI, V17, P2876; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RICCIO A, UNPUB; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	23	663	682	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2358	2361		10.1126/science.286.5448.2358	http://dx.doi.org/10.1126/science.286.5448.2358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600750				2022-12-28	WOS:000084318500067
J	Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E				Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E			Functional characterization of a potassium-selective prokaryotic glutamate receptor	NATURE			English	Article							ACID-BINDING PROTEINS; AMPA RECEPTORS; EXPRESSION; CHANNELS; FAMILY; DESENSITIZATION; CONDUCTION; SEQUENCE; MUTATION; KAINATE	Ion channels are molecular pores that facilitate the passage of ions across cell membranes and participate in a range of biological processes, from excitatory signal transmission in the mammalian nervous system to the modulation of swimming behaviour in the protozoan Paramecium(1). Two particularly important families of ion channels are ionotropic glutamate receptors (GluRs)(2) and potassium channels(3,4). GluRs are permeable to Na+, K+ and Ca2+ are gated by glutamate, and have previously been found only in eukaryotes(2), In contrast, potassium channels are selective for K+, are gated by a range of stimuli, and are found in both prokaryotes and eukaryotes(3,4). Here we report the discovery and functional characterization of GluR0 from Synechocystis PCC 6803, which is the first GluR found in a prokaryote. GluR0 binds glutamate, forms potassium-selective channels and is related in amino-acid sequence to both eukaryotic GluRs and potassium channels. On the basis of amino-acid sequence and functional relationships between GluR0 and eukaryotic GluRs, we propose that a prokaryotic GluR was the precursor to eukaryotic GluRs. GluR0 provides evidence for the missing link between potassium channels and GluRs, and we suggest that their ion channels have a similar architecture, that GluRs are tetramers and that the gating mechanisms of GluRs and potassium channels have some essential features in common.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; NICHHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Mayer, Mark L/H-5500-2013; Mayer, Mark/AAE-7356-2019; Gouaux, Eric/Y-4370-2019	Mayer, Mark/0000-0003-4378-8451; Gouaux, Eric/0000-0002-8549-2360				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Baro DJ, 1996, GENE, V170, P267, DOI 10.1016/0378-1119(95)00876-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Kaneko T, 1996, DNA Res, V3, P109; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEINANEN K, 1994, BIO-TECHNOL, V12, P802, DOI 10.1038/nbt0894-802; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lam HM, 1998, NATURE, V396, P125, DOI 10.1038/24066; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	30	269	282	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					817	821		10.1038/45568	http://dx.doi.org/10.1038/45568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617203				2022-12-28	WOS:000084330500067
J	Kyriacou, DN; Anglin, D; Taliaferro, E; Stone, S; Tubb, T; Linden, JA; Muelleman, R; Barton, E; Kraus, JF				Kyriacou, DN; Anglin, D; Taliaferro, E; Stone, S; Tubb, T; Linden, JA; Muelleman, R; Barton, E; Kraus, JF			Risk factors for injury to women from domestic violence	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALCOHOL-CONSUMPTION; AGGRESSION; SELECTION; SPOUSE; MEN; QUESTIONS; EMERGENCY; DRINKING; BATTER; AUDIT	Background: Domestic violence is the most common cause of nonfatal injury to women in the United States. To identify risk factors for such injuries, we examined the socioeconomic and behavioral characteristics of women who were victims of domestic violence and the men who injured them. Methods: We conducted a case-control study at eight large, university-affiliated emergency departments. The 256 intentionally injured women had acute injuries resulting from a physical assault by a male partner. The 659 controls were women treated for other conditions in the emergency department. Information was collected with a standardized questionnaire; no information was obtained directly from the male partners. Results: The 256 intentionally injured women had a total of 434 contusions and abrasions, 89 lacerations, and 41 fractures and dislocations. In a multivariate analysis, the characteristics of the partners that were most closely associated with an increased risk of inflicting injury as a result of domestic violence were alcohol abuse (adjusted relative risk, 3.6; 95 percent confidence interval, 2.2 to 5.9); drug use (adjusted relative risk, 3.5; 95 percent confidence interval, 2.0 to 6.4); intermittent employment (adjusted relative risk, 3.1; 95 percent confidence interval, 1.1 to 8.8); recent unemployment (adjusted relative risk, 2.7; 95 percent confidence interval, 1.2 to 6.5); having less than a high-school education (adjusted relative risk, 2.5; 95 percent confidence interval, 1.4 to 4.4); and being a former husband, estranged husband, or former boyfriend (adjusted relative risk, 3.5; 95 percent confidence interval, 1.5 to 8.3). Conclusions: Women at greatest risk for injury from domestic violence include those with male partners who abuse alcohol or use drugs, are unemployed or intermittently employed, have less than a high-school education, and are former husbands, estranged husbands, or former boyfriends of the women. (N Engl J Med 1999;341:1892-8.) (C)1999, Massachusetts Medical Society. (C)1999, Massachusetts Medical Society.	Olive View UCLA Med Ctr, Dept Emergency Med, Sylmar, CA 91342 USA; Univ Calif Los Angeles, Sch Med, Dept Epidemiol, So Calif Injury Publ Hlth, Los Angeles, CA USA; Univ So Calif, Los Angeles Cty Med Ctr, Dept Emergency Med, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Div Emergency Med, Dallas, TX USA; NYU, Bellevue Hosp, Emergency Med Serv, New York, NY USA; Univ Mississippi, Med Ctr, Dept Emergency Med, Jackson, MS 39216 USA; Boston Med Ctr, Dept Emergency Med, Boston, MA USA; Univ Missouri, Truman Med Ctr, Dept Emergency Med, Kansas City, MO 64108 USA; Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bellevue Hospital Center; New York University; University of Mississippi; University of Mississippi Medical Center; Boston Medical Center; University of Missouri System; University of Missouri Kansas City; Harvard University; Brigham & Women's Hospital	Anglin, D (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Emergency Med, Rm 1011,1200 N State St, Los Angeles, CA 90033 USA.			Linden, Judith/0000-0002-2677-3410				Bookwala J, 1992, Violence Vict, V7, P297; BRANCHEY MH, 1988, PSYCHIAT RES, V25, P49, DOI 10.1016/0165-1781(88)90157-6; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; Coleman D H, 1986, Violence Vict, V1, P141; CONNER KR, 1994, J FAM VIOLENCE, V9, P143, DOI 10.1007/BF01531960; Crowell N. A., 1996, UNDERSTANDING VIOLEN; Dutton D G, 1987, Violence Vict, V2, P145; Ellis D, 1989, Violence Vict, V4, P235; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Fink A., 1995, DESIGN SURVEYS; Fink Arlene., 1995, ASK SURVEY QUESTIONS; GANTNER AB, 1992, AGGRESSIVE BEHAV, V18, P29, DOI 10.1002/1098-2337(1992)18:1<29::AID-AB2480180104>3.0.CO;2-1; GAZMARARIAN JA, 1995, OBSTET GYNECOL, V85, P1031, DOI 10.1016/0029-7844(95)00057-X; GELLES RJ, 1979, CONT THEORIES FAMILY, V1; Golden CJ, 1996, AGGRESS VIOLENT BEH, V1, P3, DOI 10.1016/1359-1789(95)00002-X; GRAHAM P, 1993, AM J EPIDEMIOL, V138, P443, DOI 10.1093/oxfordjournals.aje.a116876; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; Grunfeld A F, 1994, J Emerg Nurs, V20, P271; GUSTAFSON R, 1992, AGGRESSIVE BEHAV, V18, P21, DOI 10.1002/1098-2337(1992)18:1<21::AID-AB2480180103>3.0.CO;2-S; GUSTAFSON R, 1986, PSYCHOL REP, V58, P303, DOI 10.2466/pr0.1986.58.1.303; Hastings J E, 1988, Violence Vict, V3, P31; HOLTZWORTHMUNROE A, 1994, PSYCHOL BULL, V116, P476, DOI 10.1037/0033-2909.116.3.476; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hotaling G T, 1986, Violence Vict, V1, P101; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; Kyriacou DN, 1998, ANN EMERG MED, V31, P502, DOI 10.1016/S0196-0644(98)70261-6; Lee W V, 1997, Recent Dev Alcohol, V13, P337; LERCHEN ML, 1986, AM J EPIDEMIOL, V123, P481, DOI 10.1093/oxfordjournals.aje.a114263; LINDMAN R, 1992, AGGRESSIVE BEHAV, V18, P393, DOI 10.1002/1098-2337(1992)18:6<393::AID-AB2480180602>3.0.CO;2-N; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; McLaughlin J K, 1990, Epidemiology, V1, P408, DOI 10.1097/00001648-199009000-00013; MCLEOD JD, 1993, ALCOHOL CLIN EXP RES, V17, P1146, DOI 10.1111/j.1530-0277.1993.tb05220.x; MIETTINEN OS, 1990, J CLIN EPIDEMIOL, V43, P1017, DOI 10.1016/0895-4356(90)90092-4; OFARRELL TJ, 1995, J CONSULT CLIN PSYCH, V63, P256, DOI 10.1037/0022-006X.63.2.256; ROBERTS AR, 1988, J SUBST ABUSE TREAT, V5, P83, DOI 10.1016/0740-5472(88)90017-7; Robins J, 1990, Epidemiology, V1, P273; Rothman K., 1998, MODERN EPIDEMIOLOGY; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAVITZ DA, 1988, AM J EPIDEMIOL, V127, P1109; Sorenson SB, 1996, AM J PUBLIC HEALTH, V86, P35, DOI 10.2105/AJPH.86.1.35; STARK E, 1986, SURG GEN WORKSH VIOL, pSA1; Starzomski A. J., 1993, VIOLENCE VICTIMS, V8, P327, DOI DOI 10.1891/0886-6708.8.4.327; Tontodonato P, 1992, Violence Vict, V7, P3; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Wilt S, 1996, J Am Med Womens Assoc (1972), V51, P77; Woolson RF, 1987, STAT METHODS ANAL BI; 1996, MMWR MORB MORTAL WKL, V45, P765; 1990, MMWR MORB MORTAL WKL, V39, P525	50	284	295	2	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1892	1898		10.1056/NEJM199912163412505	http://dx.doi.org/10.1056/NEJM199912163412505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	264XZ	10601509				2022-12-28	WOS:000084210200005
J	Zorio, DAR; Blumenthal, T				Zorio, DAR; Blumenthal, T			Both subunits of U2AF recognize the 3 ' splice site in Caenorhabditis elegans	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; FUNCTIONAL-ANALYSIS; RNA; CLONING; DOMAIN; GENE	Introns are defined by sequences that bind components of the splicing machinery. The branchpoint consensus, polypyrimidine (poly(Y)) tract, and AG at the splice boundary comprise the mammalian 3' splice site(1), Although the AG is crucial for the recognition of introns with relatively short poly(Y) tracts, which are termed 'AG-dependent introns'(2), the molecule responsible for AG recognition has never been identified. A key player in 3' splice site definition is the essential heterodimeric splicing factor U2AF, which facilitates the interaction of the U2 small nuclear ribonucleoprotein particle with the branch point. The U2AF subunit with a relative molecular mass (M-r 65K) of 65,000 (U2AF(65)) binds to the poly(Y) tract(3-7), whereas the role of the 35K subunit (U2AF(35))(8) has not been clearly defined. It is not required for splicing in vitro(4) but it plays a critical role in vivo(9,10) Caenorhabiditis elegans introns have a highly conserved U(4)CAG/R at their 3' splice sites instead of branch-point and poly(Y) consensus sequences(11). Nevertheless, C. elegans has U2AF (refs 10, 12). Here we show that both U2AF subunits crosslink to the 3' splice site. Our results suggest that the U2AF(65)-U2AF(35) complex identifies the U(4)CAG/R, with U2AF35 being responsible for recognition of the canonical AG.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Indiana University System; Indiana University Bloomington	Blumenthal, T (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.							BLUMENTHAL T, 1997, C ELEGANS, V2, P117; CONRAD R, 1993, NUCLEIC ACIDS RES, V21, P913, DOI 10.1093/nar/21.4.913; JONES D, 1986, J BIOL CHEM, V261, P2006; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MacMorris MA, 1999, P NATL ACAD SCI USA, V96, P3813, DOI 10.1073/pnas.96.7.3813; Moore M., 1993, RNA WORLD, P303; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; Rudner DZ, 1998, MOL CELL BIOL, V18, P4004, DOI 10.1128/MCB.18.7.4004; RUSKIN B, 1988, CELL, V52, P201; STROEHER VL, 1994, DEV BIOL, V163, P367, DOI 10.1006/dbio.1994.1155; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAMORE PD, 1991, EMBO J, V10, P210; Zhang HB, 1996, RNA, V2, P380; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1997, MOL CELL BIOL, V17, P946, DOI 10.1128/MCB.17.2.946; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225	20	195	221	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					835	838		10.1038/45597	http://dx.doi.org/10.1038/45597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617207				2022-12-28	WOS:000084330500071
J	Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM				Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM			Control of early viral and bacterial distribution and disease by natural antibodies	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CELL-DEFICIENT MICE; B-CELLS; ANTIVIRAL PROTECTION; IMMUNE-RESPONSE; CRUCIAL ROLE; COMPLEMENT; INFECTION; MEMORY	Natural antibodies are often dismissed from immunological analysis as "background," but they may play an important role in conferring immunity against infections. In antibody-free mice infected with various viruses or with Listeria monocytogenes, viral or bacterial titers in peripheral organs, including the kidney and brain, were 10 to 100 times greater than in antibody-competent mice (and enhanced their susceptibility to some infections), and titers in secondary Lymphoid organs were 10 to 100 times lower than in antibody-competent mice. Thus, natural antibodies play a crucial role by preventing pathogen dissemination to vital organs and by improving immunogenicity through enhanced antigen-trapping in secondary Lymphoid organs.	Univ Hosp Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Max Planck Inst Immunobiol, Freiburg, Germany; Univ Zurich, Inst Virol, CH-8006 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	University of Zurich; University Zurich Hospital; Max Planck Society; University of Zurich; University of Cape Town	Ochsenbein, AF (corresponding author), Univ Hosp Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Fehr, Thomas/AFQ-9308-2022	Fehr, Thomas/0000-0003-1668-1800; Ochsenbein, Adrian/0000-0003-1773-5436				AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COUTINHO A, 1989, IMMUNOL REV, V110, P63, DOI 10.1111/j.1600-065X.1989.tb00027.x; DIETZSCHOLD B, 1995, VIROLOGY, P1137; Ehrenstein MR, 1998, P NATL ACAD SCI USA, V95, P10089, DOI 10.1073/pnas.95.17.10089; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; Fehr T, 1998, J EXP MED, V188, P145, DOI 10.1084/jem.188.1.145; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; FREI PC, 1968, J IMMUNOL, V101, P605; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; GOBET R, 1988, EXP CELL BIOL, V56, P175; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LAMERS MC, 1981, EUR J IMMUNOL, V11, P764, DOI 10.1002/eji.1830111006; Lutz C, 1998, NATURE, V393, P797, DOI 10.1038/31716; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Reid RR, 1997, J IMMUNOL, V159, P970; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; Thomsen AR, 1996, J IMMUNOL, V157, P3074; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; THORNTON BP, 1994, J IMMUNOL, V152, P1727; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; WAGNER RR, 1987, RHABDOVIRUSES; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WILSON GS, 1961, PRINCIPLES BACTERIOL, P1223	39	702	739	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2156	2159		10.1126/science.286.5447.2156	http://dx.doi.org/10.1126/science.286.5447.2156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591647				2022-12-28	WOS:000084157300052
J	Mimoz, O; Karim, A; Mercat, A; Cosseron, M; Falissard, B; Parker, F; Richard, C; Samii, K; Nordmann, P				Mimoz, O; Karim, A; Mercat, A; Cosseron, M; Falissard, B; Parker, F; Richard, C; Samii, K; Nordmann, P			Chlorhexidine compared with povidone-iodine as skin preparation before blood culture - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							CATHETER COLONIZATION; PREVENTION; ANTISEPSIS; INFECTION; FLORA	Background: Chlorhexidine is better than povidone-iodine for care of catheter sites, but it is not known whether chlorhexidine is superior in reducing blood culture contamination. Objective: To determine whether alcoholic chlorhexidine is a more effective skin antiseptic for collection of blood cultures than aqueous povidone-iodine, Design: Randomized, controlled trial. Setting: Three adult intensive care units in a French university hospital. Patients: 403 adults who had at least one blood culture drawn through a peripheral vein. I nterventions: Patients were randomly assigned to receive skin preparation with an aqueous solution of 10% povidone-iodine or an alcoholic solution of 0.5% chlorhexidine before phlebotomy. Measurements: Contamination rates of blood cultures. Results: Of 2041 blood cultures collected in 403 patients, 124 yielded pathogens. Chlorhexidine reduced the incidence of blood culture contamination more than povidone-iodine (14 of 1019 cultures [1.4%] compared with 34 of 1022 cultures [3.3%]; odds ratio, 0.40 [95% Cl, 0.21 to 0.75]; P = 0.004). Conclusion: Skin preparation with alcoholic chlorhexidine is more efficacious than skin preparation with aqueous povidone-iodine in reducing contamination of blood cultures.	Hop Paul Brousse, Serv Anesthesie Reanimat, F-94809 Villejuif, France; Hop Bicetre, Serv Bacteriol Virol, F-94275 Le Kremlin Bicetre, France; Hop Bicetre, Serv Reanimat Med, F-94275 Le Kremlin Bicetre, France; INSERM U472, Hop Paul Brousse, F-94807 Villejuif, France; Hop Bicetre, Serv Neurochirugie, F-94275 Le Kremlin Bicetre, France; Hop Bicetre, Serv Anaesthesie Reanimat Chirugicale, F-94275 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Mimoz, O (corresponding author), Hop Paul Brousse, Serv Anesthesie Reanimat, 10 Ave Paul Vaillant Couturier, F-94809 Villejuif, France.		Mercat, Alain/AFU-4426-2022	mimoz, olivier/0000-0003-1737-7915				ALY R, 1976, APPL ENVIRON MICROB, V31, P931, DOI 10.1128/AEM.31.6.931-935.1976; Baquero F, 1997, J ANTIMICROB CHEMOTH, V39, P1, DOI 10.1093/jac/39.suppl_1.1; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; CHAMPAGNE S, 1984, INFECT CONT HOSP EP, V5, P489, DOI 10.1017/S0195941700060902; DUNAGAN WC, 1989, AM J MED, V87, P253; GARLAND JS, 1995, PEDIATR INFECT DIS J, V14, P510, DOI 10.1097/00006454-199506000-00008; Kunisada T, 1997, DERMATOLOGY, V195, P14, DOI 10.1159/000246025; LOWBURY EJL, 1974, BRIT J SURG, V61, P19, DOI 10.1002/bjs.1800610106; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; SAKURAGI T, 1995, ANESTH ANALG, V81, P555, DOI 10.1097/00000539-199509000-00023; Sato S, 1996, ANESTHESIOLOGY, V85, P1276, DOI 10.1097/00000542-199612000-00008; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Souvenir D, 1998, J CLIN MICROBIOL, V36, P1923, DOI 10.1128/JCM.36.7.1923-1926.1998; STICKLER DJ, 1983, BRIT J CLIN PRACT, V25, P23; STRAND CL, 1993, JAMA-J AM MED ASSOC, V269, P1004, DOI 10.1001/jama.269.8.1004; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; WIDMER AF, 1994, INTENS CARE MED, V20, pS7, DOI 10.1007/BF01713976; 1995, INFECT CONTROL HOSP, V16, P105	20	111	120	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					834	837		10.7326/0003-4819-131-11-199912070-00006	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610628				2022-12-28	WOS:000084053200005
J	Horwitz, AR; Parsons, JT				Horwitz, AR; Parsons, JT			Cell biology - Cell migration - Movin' on	SCIENCE			English	Editorial Material									Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Horwitz, AR (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA.	horwitz@virginia.edu; jtp@virginia.edu						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Pelham RJ, 1999, MOL BIOL CELL, V10, P935, DOI 10.1091/mbc.10.4.935; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8	14	331	338	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1102	1103		10.1126/science.286.5442.1102	http://dx.doi.org/10.1126/science.286.5442.1102			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10610524				2022-12-28	WOS:000083534200030
J	Davis, RC; Hobbs, FDR; Lip, GYH				Davis, RC; Hobbs, FDR; Lip, GYH			ABC of heart failure - History and epidemiology	BRITISH MEDICAL JOURNAL			English	Review							POPULATION		Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Davis, RC (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.			hobbs, richard/0000-0001-7976-7172				CLARKE KW, 1994, BRIT HEART J, V71, P584; CLELAND JG, 1995, EUR HEART J, V16, P741; Cowie MR, 1997, EUR HEART J, V18, P208; Cowie MR, 1999, EUR HEART J, V20, P421, DOI 10.1053/euhj.1998.1280; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Lip GYH, 1997, INT J CLIN PRACT, V51, P223; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X	8	102	109	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					39	42		10.1136/bmj.320.7226.39	http://dx.doi.org/10.1136/bmj.320.7226.39			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617530	Green Published			2022-12-28	WOS:000084621600026
J	Mays, N; Pope, C				Mays, N; Pope, C			Qualitative research in health care - Assessing quality in qualitative research	BMJ-BRITISH MEDICAL JOURNAL			English	Article									The Treasury, Social Policy Branch, Wellington, New Zealand; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Mays, N (corresponding author), The Treasury, Social Policy Branch, POB 3724, Wellington, New Zealand.	nicholas.mays@treasury.govt.nz		Pope, Catherine/0000-0002-8935-6702				Blaxter M., 1996, MED SOCIOLOGY NEWS, V22, P68; Bloor M, 1997, CONTEXT METHOD QUALI, P37; Boulton M., 1994, QUAL HEALTH CARE, V3, P107, DOI [10.1136/qshc.3.2.107, DOI 10.1136/QSHC.3.2.107]; Dingwall R, 1998, J Health Serv Res Policy, V3, P167; Hammersley M., 1992, WHATS WRONG ETHNOGRA; Hammersley M., 1990, READING ETHNOGRAPHIC; Harding G, 1998, FAM PRACT, V15, P76, DOI 10.1093/fampra/15.1.76; Kirk J., 1986, QUALITATIVE RES METH, V1; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Mays N, 1996, QUALITATIVE RES HLTH; Murphy E, 1998, HLTH TECHNOL ASSESS, V2; Secker J., 1995, HEALTH EDUC J, V54, P74, DOI [10.1177/001789699505400108, DOI 10.1177/001789699505400108]	12	2092	2117	4	176	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2000	320	7226					50	52		10.1136/bmj.320.7226.50	http://dx.doi.org/10.1136/bmj.320.7226.50			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617534	Green Published			2022-12-28	WOS:000084621600031
J	Jones, E; Wessely, S				Jones, E; Wessely, S			Case of chronic fatigue syndrome after Crimean war and Indian mutiny	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England	University of London; King's College London	Jones, E (corresponding author), Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929; Jones, Edgar/0000-0002-4610-9584				CLOWES GG, 1958, COMMUNICATION   1112; DEAN ET, 1998, SHOOK HELL POSTTRAUM, P131; FORREST GW, 1912, INDIAN MUTINY SELECT, V3, P156; FORTESCUE JW, 1930, HIST BRIT ARMY, V13, P396; HIBBERT C, 1978, GREAT MUTINY INDIA 1, P385; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; MURRAY RH, 1928, HIST 8 KINGS ROYAL I, V2, P457; POORE R, 1858, COMMUNICATION   0415; *PUBL REC OFF, PIN712260 PUBL REC O; *PUBL REC OFF, PIN71 PUBL REC OFF; RICHARDS F, 1936, OLD SOLDIER SAHIB, P73; WESSELY S, 1994, CHRONIC FATIGUE SYND, P41; Wessely S, 1998, CHRONIC FATIGUE ITS; 1956, LANCET, V1, P789; 1858, LANCET, V2, P77; 1909, BMJ, V2, P97	16	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1645	1647		10.1136/bmj.319.7225.1645	http://dx.doi.org/10.1136/bmj.319.7225.1645			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600980	Green Published, Green Submitted			2022-12-28	WOS:000084562600031
J	Zeldin, T				Zeldin, T			How work can be made less frustrating and conversation less boring	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford St Antonys Coll, Oxford OX2 6JF, England	University of Oxford	Zeldin, T (corresponding author), Univ Oxford St Antonys Coll, Oxford OX2 6JF, England.							ZELDIN T, 1998, CONVERSION; Zeldin Theodore, 1995, INTIMATE HIST HUMANI	2	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1633	1635		10.1136/bmj.319.7225.1633	http://dx.doi.org/10.1136/bmj.319.7225.1633			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600975	Green Published			2022-12-28	WOS:000084562600027
J	Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE				Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE			Structure of a transiently phosphorylated switch in bacterial signal transduction	NATURE			English	Article							RESPONSE REGULATOR; 3-DIMENSIONAL STRUCTURE; RECEIVER DOMAIN; NMR STRUCTURE; PROTEIN CHEY; CHEMOTAXIS; ACTIVATION; CONFORMATION; MECHANISM; DYNAMICS	Receiver domains are the dominant molecular switches in bacterial signalling(1,2), Although several structures of non-phosphorylated receiver domains have been reported(3-8), a detailed structural understanding of the activation arising from phosphorylation has been impeded by the very short half-lives of the aspartyl-phosphate linkages. Here we present the first structure of a receiver domain in its active state, the phosphorylated receiver domain of the bacterial enhancer-binding protein NtrC (nitrogen regulatory protein C), Nuclear magnetic resonance spectra were taken during steady-state autophosphorylation/dephosphorylation, and three-dimensional spectra from multiple samples were combined. Phosphorylation induces a large conformational change involving a displacement of beta-strands 4 and 5 and alpha-helices 3 and 4 away from the active site, a register shift and an axial rotation in helix 4, This creates an exposed hydrophobic surface that is likely to transmit the signal to the transcriptional activation domain.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Sci, Berkeley, CA 94720 USA	Brandeis University; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kern, D (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.		Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; Hwang I, 1999, P NATL ACAD SCI USA, V96, P4880, DOI 10.1073/pnas.96.9.4880; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Nohaile M, 1997, J MOL BIOL, V273, P299, DOI 10.1006/jmbi.1997.1296; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMBEL L, 1998, COLD SPRING HARB SYM, P157; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANTORO J, 1995, J MOL BIOL, V247, P717, DOI 10.1006/jmbi.1995.0175; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001	29	174	177	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					894	898		10.1038/47273	http://dx.doi.org/10.1038/47273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622255				2022-12-28	WOS:000084482000037
J	Grisso, JA; Schwarz, DF; Hirschinger, N; Sammel, M; Brensinger, C; Santanna, J; Lowe, RA; Anderson, E; Shaw, LM; Bethel, CA; Teeple, L				Grisso, JA; Schwarz, DF; Hirschinger, N; Sammel, M; Brensinger, C; Santanna, J; Lowe, RA; Anderson, E; Shaw, LM; Bethel, CA; Teeple, L			Violent injuries among women in an urban area	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; PREGNANCY; ABUSE; URINE; QUANTITATION; EMERGENCY; ASSAY	Background: Although the rate of death from injuries due to violent acts is much higher among black women than among white women in the United States, little is known about the nature and correlates of violent injuries among black women living in urban areas. Methods: In this case-control study conducted at three emergency departments in one inner-city community (in west Philadelphia), we studied 405 adolescent girls and women who had been intentionally injured and 520 adolescent girls and women (control subjects) who had health problems not related to violent injury. Data were collected by conducting standardized interviews with use of questionnaires and by screening urine for illicit drugs. Individual logistic-regression models were constructed to identify factors associated with violent injuries inflicted by partners and those inflicted by persons other than the partners of the victims. Results: The male partners of the injured women were much more likely than the male partners of control subjects to use cocaine (odds ratio, 4.4; 95 percent confidence interval, 2.3 to 8.4) and to have been arrested in the past (odds ratio, 3.1; 95 percent confidence interval, 1.8 to 5.2). Fifty-three percent of violent injuries to the women had been perpetrated by persons other than their partners. Women's use of illicit drugs and alcohol abuse were factors associated with both violence on the part of partners and violence on the part of other persons. Neighborhood characteristics, including low median income, a high rate of change of residence, and poor education, were independently associated with the risk of violent injuries among women. Conclusions: Women in this urban, low-income community face violence from both partners and other persons. Substance abuse, particularly cocaine use, is a significant correlate of violent injuries. Standard Census data may help identify neighborhoods where women are at high risk for such violence and that would benefit from community-level interventions. (N Engl J Med 1999;341:1899-905.) (C)1999, Massachusetts Medical Society.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Presbyterian Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Mercy Catholic Med Ctr, Misericordia Hosp Div, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Social Sci, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Grisso, JA (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Gen Internal Med, 920 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Lowe, Robert A/A-4926-2008	Lowe, Robert A/0000-0002-4732-9634; Sammel, Mary/0000-0003-1248-4199	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052234] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52234] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN JP, 1995, NIAAA TREATMENT HDB, V4, P540; Anderson E., 2000, CODE STREET DECENCY; BELENKO S, 1996, COMP MODELS TREATMEN; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CAMPBELL JC, 1992, RES NURS HEALTH, V15, P219, DOI 10.1002/nur.4770150308; CAMPBELL JC, 1989, NURS RES, V38, P18; CAPLAN YH, 1987, J FORENSIC SCI, V32, P55; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; *DEP HHS, 1998, DHHS PUBL, P251; *DEP JUST, 1998, 167237 NCJ; Fagan J. A., 1994, UNDERSTANDING PREVEN, V3, P115; GAQUIN DA, 1977, VICTIMOLOGY, V2, P632; GIST NE, 1997, 166821 NCJ; Grisso JA, 1996, AM J PUBLIC HEALTH, V86, P67, DOI 10.2105/AJPH.86.1.67; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; KARLSSON L, 1988, J ANAL TOXICOL, V12, P319, DOI 10.1093/jat/12.6.319; KELLERMANN AL, 1994, JAMA-J AM MED ASSOC, V271, P1953, DOI 10.1001/jama.271.24.1953; Kruttschnitt C, 1993, Violence Vict, V8, P253; Landenburger K M, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P378; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; MICKEY RM, 1989, AM J EPIDEMIOL, V130, P1066; Muelleman RL, 1998, AM J EMERG MED, V16, P128, DOI 10.1016/S0735-6757(98)90028-6; MULE SJ, 1988, J ANAL TOXICOL, V12, P153, DOI 10.1093/jat/12.3.153; MYERS JK, 1980, AM J PSYCHIAT, V137, P1081; PAUL BD, 1985, J ANAL TOXICOL, V9, P222, DOI 10.1093/jat/9.5.222; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSENBERG M, 1965, SOC ADOLESCENT SELFI; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; Scholle SH, 1998, J GEN INTERN MED, V13, P607, DOI 10.1046/j.1525-1497.1998.00183.x; SCHWARZ DF, 1994, JAMA-J AM MED ASSOC, V271, P755, DOI 10.1001/jama.271.10.755; SHAW LM, 1991, CLIN CHEM, V37, P2062; SILBER E, 1965, PSYCHOL REP, V16, P1017, DOI 10.2466/pr0.1965.16.3c.1017; STARK E, 1991, VIOLENCE AM PUBLIC H, P123; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; Sutherland C, 1998, Womens Health, V4, P41; TJADEN P, 1998, 172837 NCJ; Toothaker L. E., 1991, MULTIPLE COMPARISONS; WARSHAW C, 1993, J WOMENS HEALTH, V2, P73; Wolfe L R, 1994, Womens Health Issues, V4, P109, DOI 10.1016/S1049-3867(05)80044-1	41	134	138	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1899	1905		10.1056/NEJM199912163412506	http://dx.doi.org/10.1056/NEJM199912163412506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	264XZ	10601510	Green Submitted			2022-12-28	WOS:000084210200006
J	Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A				Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A		Swiss HIV Cohort Study	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; COMBINATION; DISEASE; HAART; RECOVERY; COUNT	Context Acquired immunodeficiency syndrome-related opportunistic illnesses (Ols) continue to occur after initiation of potent antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection, Risk factors for clinical progression to Ols during potent therapy are not well defined, Objective To examine the incidence of and risk factors for Ols among patients treated with potent antiretroviral therapy in a population-based study, Design The Swiss HIV Cohort Study, a prospective cohort study of adult HIV-infected persons. Setting Seven study centers throughout Switzerland. Patients A total of 2410 cohort study participants with a potential follow-up of at least 15 months after starting potent therapy between September 1995 and December 1997. Main Outcome Measures Disease-specific incidence of Ols during the 6 months preceding potent antiretroviral therapy and at 3 intervals after initiating therapy; risk factors for development of Ols during therapy. Results Of the 2410 participants, 143 developed 186 Ols after initiation of potent antiretroviral therapy, Incidence of any OI decreased from 15.1 per 100 person-years in the 6 months before therapy to 7.7 in the first 3 months after starting treatment, 2.6 in the following 6 months, and 2.2 per 100 person-years between 9 and 15 months. Reductions in incidence ranged from 38% per month for Kaposi sarcoma (P<.001) to 5% per month for non-Hodgkin lymphoma (P =.31). Baseline CD4 cell count continued to predict the risk of disease progression after initiating potent therapy, Compared with CD4 cell counts above 200 x 10(6)/L, the hazard ratio for developing Ols was 2.5 (95% confidence interval [CI], 1.4-4.5) for counts between 51 and 200 x 10(6)/L and 5.8 (95% CI, 3.2-10.5) for counts below 51 x 10(6)/L at baseline, Independent of baseline CD4 cell count, a rise in CD4 cell count by 50 x 10(6)/L or more and undetectable HIV-1 RNA in plasma (<400 copies/mL) by 6 months reduced risk of subsequent events, with hazard ratios of 0.32 (95% CI, 0.20-0.52) and 0.39 (0.24-0.65), respectively, Conclusions Our data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy, Baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy. Individuals with CD4 cell counts of 50 x 10(6)/L or below may need close clinical surveillance after initiation of potent therapy.	Univ Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Hosp, Div Infect Dis, Lausanne, Switzerland; Univ Hosp, Div Infect Dis, Geneva, Switzerland; Univ Bern, Inselspital, Med Policlin, CH-3010 Bern, Switzerland; Univ Basel, Cantonal Hosp, Med Policlin, Basel, Switzerland; Cantonal Hosp, Internal Med Clin A, St Gall, Switzerland; Reg Hosp, Infect Dis Ambulatorium, Lugano, Switzerland	University of Zurich; University Zurich Hospital; University of Bristol; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Bern; University Hospital of Bern; University of Basel	Telenti, A (corresponding author), CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Ledergerber, Bruno/B-5656-2009; Telenti, Amalio/AAY-1674-2021; Furrer, Hansjakob/G-6768-2013; Weber, Rainer/D-5175-2012	Ledergerber, Bruno/0000-0002-6881-4401; Furrer, Hansjakob/0000-0002-1375-3146; Egger, Matthias/0000-0001-7462-5132				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114; Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1997, LANCET, V350, P589, DOI 10.1016/S0140-6736(05)63175-3; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Feinberg J, 1999, LANCET, V353, P1287, DOI 10.1016/S0140-6736(99)00123-3; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Furrer H, 1999, AM J MED, V106, P371, DOI 10.1016/S0002-9343(99)00015-7; Hengge UR, 1998, AIDS, V12, pF225, DOI 10.1097/00002030-199817000-00003; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Perry CM, 1998, DRUGS, V55, P461, DOI 10.2165/00003495-199855030-00014; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2	32	375	386	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2220	2226		10.1001/jama.282.23.2220	http://dx.doi.org/10.1001/jama.282.23.2220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605973				2022-12-28	WOS:000084138600029
J	Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC				Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC			Relationship between modifiable health risks and short-term health care charges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; LIFE-STYLE; COST; DISEASE; MORTALITY; DATABASE; SMOKING; MEMBERS; IMPACT; MEN	Context If physical inactivity, obesity, and smoking status prove to contribute significantly to increased health care charges within a short period of time, health plans and payers may wish to invest in strategies to modify these risk factors. However, few data are available to guide such resource allocation decisions. Objective To examine the relationship of modifiable health risks to subsequent health care charges after controlling for age, race, sex, and chronic conditions. Design, Setting, and Participants Cohort study of a stratified random sample of 5689 adults (75.5% of total sample of 7535) aged 40 years or older who were enrolled in a Minnesota health plan and completed a 60-item questionnaire. Main Outcome Measure Resource use as measured by billed health care charges from July 1, 1995, to December 31, 1996, compared by health risk (physical activity, body mass index [BMI], and smoking status). Results The mean annual per patient charge in the total study population was $3570 (median, $600), and 15% of patients had no charges during the study period. After adjustment for age, race, sex,and chronic disease status, physical activity (4.7% lower health care charges per active day per week), BMI (1.9% higher charges per BMI unit), current smoking status (18% higher charges), and history of tobacco use (25.8% higher charges) were prospectively related to health care charges over 18 months. Never-smokers with a BMI of 25 kg/m(2) and who participated in physical activity 3 days per week had mean annual health care charges that were approximately 49% lower than physically inactive smokers with a BMI of 27.5 kg/m(2), Conclusions Our data suggest that adverse health risks translate into significantly higher health care charges within 18 months. Health plans or payers seeking to minimize health care charges may wish to consider strategic investments in interventions that effectively modify adverse health risks.	Healthpartners Res Fdn, Minneapolis, MN 55440 USA; Healthpartners Ctr Hlth Promot, Minneapolis, MN USA	HealthPartners Institute for Education & Research	O'Connor, PJ (corresponding author), Healthpartners Res Fdn, 8100 34th Ave S, Minneapolis, MN 55440 USA.	Patrick.J.Oconnor@HealthPartners.com	Martinson, Brian C/AAX-2860-2020; O'Connor, Patrick/HII-2987-2022	Martinson, Brian C/0000-0002-4255-5595; O'Connor, Patrick/0000-0002-2324-6228				Ainsworth B., 1992, MED EXERCISE NUTR HL, V1, P75; BAUM WP, 1986, J OCCUP MED, V28, P18; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Boyle RG, 1998, AM J HEALTH PROMOT, V12, P170, DOI 10.4278/0890-1171-12.3.170; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Edington DW, 1997, J OCCUP ENVIRON MED, V39, P1037, DOI 10.1097/00043764-199711000-00004; GILMER T, 1998, MINN HLTH SERV RES C; Gilmer TG, 1998, DIABETES, V47, pA190; Goetzel RZ, 1998, J OCCUP ENVIRON MED, V40, P843, DOI 10.1097/00043764-199810000-00003; Goetzel RZ, 1996, AM J HEALTH PROMOT, V10, P340, DOI 10.4278/0890-1171-10.5.340; Hornbrook MC, 1996, HEALTH SERV RES, V31, P283; HORNBROOK MC, 1995, INQUIRY-J HEALTH CAR, V32, P56; HOSMER D, 1989, WILEY SERIES PROBABI, V13, P307; KAMAN RL, 1995, WORKSITE HLTH PROMOT; KEELER EB, 1989, AM J PUBLIC HEALTH, V79, P975, DOI 10.2105/AJPH.79.8.975; Kortt MA, 1998, CLIN THER, V20, P772, DOI 10.1016/S0149-2918(98)80140-9; MANNING W, 1991, COSTS POOR HLTH HABI, P223; O'Connor P J, 1996, HMO Pract, V10, P17; O'Connor P J, 1997, Fam Med, V29, P424; O'Connor PJ, 1998, AM J MANAG CARE, V4, P335; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pelletier KR, 1997, J OCCUP ENVIRON MED, V39, P1154, DOI 10.1097/00043764-199712000-00009; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; PRONK N, IN PRESS MED SCI SPO; Pronk N P, 1997, J Ambul Care Manage, V20, P24; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; SHEPHARD RJ, 1992, AM J HLTH PROMOT, V17, P475; STEIN AD, 1993, AM J PUBLIC HEALTH, V83, P1768, DOI 10.2105/AJPH.83.12.1768; VELICER WF, 1993, TOB CONTROL, V2, P95	33	202	204	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2235	2239		10.1001/jama.282.23.2235	http://dx.doi.org/10.1001/jama.282.23.2235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605975	Bronze			2022-12-28	WOS:000084138600031
J	Bhalla, P; Eaton, FE; Coulter, JBS; Amegavie, FL; Sills, JA; Abernethy, LJ				Bhalla, P; Eaton, FE; Coulter, JBS; Amegavie, FL; Sills, JA; Abernethy, LJ			Lesson of the week - Hyponatraemic seizures and excessive intake of hypotonic fluids in young children	BRITISH MEDICAL JOURNAL			English	Review							SQUASH DRINKING SYNDROME; HIGH-ENERGY FLUIDS; WATER-INTOXICATION; NORMAL INFANTS; MORBIDITY		Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England; Whiston Hosp, Prescot, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Whiston Hospital	Coulter, JBS (corresponding author), Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England.							Arieff AI, 1999, PEDIATRICS, V103, P1292, DOI 10.1542/peds.103.6.1292; Corneli H M, 1985, Pediatr Emerg Care, V1, P190, DOI 10.1097/00006565-198512000-00005; CRUMPACK.RW, 1973, NEUROLOGY, V23, P1251, DOI 10.1212/WNL.23.11.1251; DAVID R, 1981, PEDIATRICS, V68, P349; DUGAN S, 1967, PEDIATRICS, V39, P418; EASTON J, 1992, LANCET, V339, P808; FINBERG L, 1991, AM J DIS CHILD, V145, P981, DOI 10.1001/archpedi.1991.02160090033016; GORDILLO G, 1957, PEDIATRICS, V20, P303; HOPE SA, 1995, ARCH DIS CHILD, V73, P277, DOI 10.1136/adc.73.3.277-b; HOURIHANE JOB, 1995, ARCH DIS CHILD, V72, P141, DOI 10.1136/adc.72.2.141; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; NICKMAN SL, 1968, PEDIATRICS, V41, P149; PARTRIDGE JC, 1981, AM J DIS CHILD, V135, P38, DOI 10.1001/archpedi.1981.02130250026009; PETTER LPM, 1995, ARCH DIS CHILD, V72, P137, DOI 10.1136/adc.72.2.137; ROWE JW, 1979, KIDNEY INT, V16, P729, DOI 10.1038/ki.1979.189; Sandhu BK, 1997, J PEDIATR GASTR NUTR, V24, P522, DOI 10.1097/00005176-199705000-00006; SCHAEFFER AV, 1991, AM J DIS CHILD, V145, P27, DOI 10.1001/archpedi.1991.02160010029006; Schwartz ID, 1998, ARCH PEDIAT ADOL MED, V152, P1037; Sharf R E, 1993, Arch Fam Med, V2, P647, DOI 10.1001/archfami.2.6.647; 1992, LANCET, V339, P153	20	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1554	1557		10.1136/bmj.319.7224.1554	http://dx.doi.org/10.1136/bmj.319.7224.1554			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591722	Green Published			2022-12-28	WOS:000084245600028
J	Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA				Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA			Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand	NATURE			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAIN; INHIBITORY RECEPTOR; 3-DIMENSIONAL STRUCTURE; LY-49A RECOGNIZES; H-2D(D); PEPTIDE; COMPLEX; SPECIFICITY; MOLECULES	Natural killer (NK) cell function is regulated by NK receptors that interact with MHC class I (MHC-I) molecules on target cells. The murine NK receptor Ly49A inhibits NK cell activity by interacting with H-2D(d) through its G-type-lectin-like NK receptor domain. Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d), The Ly49A dimer interacts extensively with two H-2D(d) molecules at distinct sites, At one interface, a single Ly49A subunit contacts one side of the MHC-I peptide-binding platform, presenting an open cavity towards the conserved glycosylation site on the H-2D(d) alpha 2 domain, At a second, larger interface, the Ly49A dimer binds in a region overlapping the CD8-binding site. The smaller interface probably represents the interaction between Ly49A on the NK cell and MHC-I on the target cell, whereas the larger one suggests an interaction between Ly49A and MHC-I on the NK cell itself. Both Ly49A binding sites on MHC-I are spatially distinct from that of the T-cell receptor.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; NIAID, Mol Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Marluzza, RA (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9,600 Gudelsky Dr, Rockville, MD 20850 USA.	dhm@nih.gov; mariuzza@carb.nist.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000394, Z01AI000394] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; Andersson M, 1998, J IMMUNOL, V161, P6475; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CS, 1998, J IMMUNOL, V160, P4367; Chung Y, 1999, J IMMUNOL, V163, P3692; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Franksson L, 1999, EUR J IMMUNOL, V29, P2748, DOI 10.1002/(SICI)1521-4141(199909)29:09<2748::AID-IMMU2748>3.0.CO;2-C; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kase A, 1998, J IMMUNOL, V161, P6133; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; Lian RH, 1998, J IMMUNOL, V161, P2301; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Orihuela M, 1996, P NATL ACAD SCI USA, V93, P11792, DOI 10.1073/pnas.93.21.11792; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Sundback J, 1998, J IMMUNOL, V160, P5971; Vales-Gomez M, 1999, EMBO J, V18, P4250, DOI 10.1093/emboj/18.15.4250; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Yokoyama W. M., 1999, FUNDAMENTAL IMMUNOLO, P575	49	231	238	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					623	631		10.1038/45170	http://dx.doi.org/10.1038/45170			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604468				2022-12-28	WOS:000084189800055
J	Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP				Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP			Evidence of a chronic systemic cause of instability of atherosclerotic plaques	LANCET			English	Article							CAROTID STENOSIS; 1001 ANGIOGRAMS; ULCERATION; REPRODUCIBILITY; INFARCTION; MECHANISMS; DISEASE; LINK	Background Major thrombotic and embolic complications of atherosclerosis are closely associated with irregularity and rupture of atheromatous plaques in both the carotid and coronary arteries. Plaque instability is partly determined by local factors, but systemic factors, such as infection, autoimmunity, or genes, may also be important. If plaque stability is influenced by systemic factors that are present in only a proportion of patients, some individuals should be more prone to rupture of plaques than others-ie, irregular plaques should occur in multiple vascular beds in some individuals more frequently than would be expected by chance alone. Methods We studied 5393 carotid bifurcation angiograms from 3007 patients with a recently symptomatic carotid stenosis. We assessed the extent to which plaque-surface irregularity at the symptomatic carotid artery was associated with irregularity at a distant site, the contralateral carotid artery, and the extent to which plaque irregularity at these sites was associated with previous myocardial infarction or subsequent non-stroke vascular death (due mainly to coronary-artery disease). Findings Patients with plaque-surface irregularity (n=1897) in the symptomatic carotid artery were more likely than those with smooth plaque (n=110) to have irregularity in the contralateral carotid artery (odds ratio 2.21 [95% CI 1.62-3.01], p<0.001). Patients with irregular plaques in both arteries were more likely to have had a previous myocardial infarction than patients with smooth plaques (hazard ratio 1.82 [1.23-2.64], p<0.001), and were more likely to have a non-stroke vascular death on follow-up (hazard ratio 1.67 [1.15-2.44], p=0.007). However, there was no difference in the risk of non-vascular death (hazard ratio 0.92 [0.57-1.45], p=0.5). These associations were not explicable on the basis of differences in traditional vascular risk factors. Interpretation These data suggest that some individuals have a systemic predisposition to irregularity and rupture of atherosclerotic plaques that is independent of traditional vascular risk factors. This finding supports the hypothesis that other systemic factors are important in the cause of plaque instability.	Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Radcliffe Infirmary; University of Edinburgh	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020; Donders, A.R.T./L-4277-2015	Rothwell, Peter/0000-0001-9739-9211; Donders, A.R.T./0000-0002-0484-1419				Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EIKELBOOM BC, 1983, STROKE, V14, P882, DOI 10.1161/01.STR.14.6.882; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; EPSTEIN SE, 1996, LANCET S, V348, P13; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER M, 1987, ANGIOLOGY, V38, P116, DOI 10.1177/000331978703800204; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; JULIAN OC, 1963, ARCH SURG-CHICAGO, V86, P131; Lammie GA, 1999, STROKE, V30, P1319, DOI 10.1161/01.STR.30.7.1319; LIBBY P, 1996, LANCET, V348, P4; RICHARDSON PD, 1989, LANCET, V2, P941; ROSS R, 1992, OXFORD TXB PATHOLOGY; Rothwell P. M., 1996, CEREBROVASC DIS, V6, P1; ROTHWELL PM, 1994, STROKE, V25, P2440, DOI 10.1161/01.STR.25.12.2440; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; Rothwell PM, 1998, CLIN RADIOL, V53, P439, DOI 10.1016/S0009-9260(98)80273-0; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SITZER M, 1995, STROKE, V26, P1231, DOI 10.1161/01.STR.26.7.1231; STREIFLER JY, 1994, STROKE, V25, P1130, DOI 10.1161/01.STR.25.6.1130; THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5; TOUBOUL PJ, 1994, CEREBROVASC DIS, V4, P8, DOI 10.1159/000108544; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X	23	179	184	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					19	24		10.1016/S0140-6736(99)04470-0	http://dx.doi.org/10.1016/S0140-6736(99)04470-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615886				2022-12-28	WOS:000085049200011
J	Estevez, AG; Crow, JP; Sampson, JB; Reiter, C; Zhuang, YX; Richardson, GJ; Tarpey, MM; Barbeito, L; Beckman, JS				Estevez, AG; Crow, JP; Sampson, JB; Reiter, C; Zhuang, YX; Richardson, GJ; Tarpey, MM; Barbeito, L; Beckman, JS			Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; LINKED SUPEROXIDE-DISMUTASE-1 MUTANT; TYROSINE NITRATION; OXIDATIVE DAMAGE; SPINAL-CORD; IN-VITRO; PEROXYNITRITE; NEUROFILAMENT; MUTATIONS; COPPER	Mutations in copper, tint superoxide dismutase (SOD) have been implicated in the selective death of motor neurons in 2 percent of amyotrophic lateral sclerosis (ALS) patients. The loss of zinc from either wild-type or ALS-mutant SODs was sufficient to induce apoptosis in cultured motor neurons. Toxicity required that copper be bound to SOD and depended on endogenous production of nitric oxide. When replete with zinc, neither ALS-mutant nor wild-type copper, zinc SODs were toxic, and both protected motor neurons from trophic factor withdrawal. Thus, zinc-deficient SOD may participate in both sporadic and familiar ALS by an oxidative mechanism involving nitric oxide.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Mol Genet & Biochem, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Univ Republica, Fac Ciencias, Inst Invest Biol Clemente Estable, Div Neurobiol Celular & Mol,Secc Neurociencias, Montevideo 11600, Uruguay	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Instituto de Investigaciones Biologicas Clemente Estable Uruguay; Universidad de la Republica, Uruguay	Beckman, JS (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA.	joe.beckman@ccc.uab.edu		Barbeito, Luis/0000-0002-3047-232X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036761, R01NS033291] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58209] Funding Source: Medline; NINDS NIH HHS [R01 NS36761, R01 NS33291] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE K, 1995, NEUROSCI LETT, V199, P152, DOI 10.1016/0304-3940(95)12039-7; BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Beckman J., 1994, BIOCHEMIST, V16, P8; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Chou SM, 1996, J CHEM NEUROANAT, V10, P249, DOI 10.1016/0891-0618(96)00137-8; Couillard-Despres S, 1998, P NATL ACAD SCI USA, V95, P9626, DOI 10.1073/pnas.95.16.9626; Crow J. P., UNPUB; Crow JP, 1997, J NEUROCHEM, V69, P1936; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Estevez AG, 1998, J NEUROSCI, V18, P923; Estevez AG, 1998, J NEUROSCI, V18, P3708; ESTEVEZ AG, IN PRESS FREE RADICA; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GURNEY ME, 1997, NEURON, V18, P327; HERDEGEN T, 1994, MOL BRAIN RES, V22, P245, DOI 10.1016/0169-328X(94)90053-1; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kooy NW, 1997, FREE RADICAL RES, V27, P245, DOI 10.3109/10715769709065763; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Marklund SL, 1997, J NEUROCHEM, V69, P675; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shaw CE, 1998, ANN NEUROL, V43, P390, DOI 10.1002/ana.410430319; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; VIGLINO P, 1986, BIOCHEM J, V237, P305, DOI 10.1042/bj2370305; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631; WINTERBOURN CC, 1995, FEBS LETT, V368, P449, DOI 10.1016/0014-5793(95)00708-H	39	499	512	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2498	2500		10.1126/science.286.5449.2498	http://dx.doi.org/10.1126/science.286.5449.2498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617463				2022-12-28	WOS:000084429700046
J	Bjornsdottir, US; Smith, D				Bjornsdottir, US; Smith, D			South African religious leader with hyperventilation, hypophosphataemia, and respiratory arrest	LANCET			English	Article									Univ Hosp Vifilstadir, Dept Pulm Med, Reykjavik, Iceland; Univ Wisconsin, Ctr Clin Canc, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Bjornsdottir, US (corresponding author), Univ Hosp Vifilstadir, Dept Pulm Med, 210 Gardabae, Reykjavik, Iceland.							CLIFFORD NJ, 1989, JAMA-J AM MED ASSOC, V262, P2035; ELSEVIEW M, 1988, MED TOXICOL, P1071; GORMAN JM, 1986, ARCH GEN PSYCHIAT, V43, P1067; GRAVELYN TR, 1988, AM J MED, V84, P870, DOI 10.1016/0002-9343(88)90065-4; 1990, NY TIMES        0306, pA3	5	2	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2130	2130		10.1016/S0140-6736(99)03522-9	http://dx.doi.org/10.1016/S0140-6736(99)03522-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609820				2022-12-28	WOS:000084318200016
J	Ong, PJL; Dean, TS; Hayward, CS; Della Monica, PL; Sanders, TAB; Collins, P				Ong, PJL; Dean, TS; Hayward, CS; Della Monica, PL; Sanders, TAB; Collins, P			Effect of fat and carbohydrate consumption on endothelial function	LANCET			English	Article							DIET	Consumption of a meal high in monounsaturated fat was associated with acute impairment of endothelial function when compared with a carbohydrate-rich meal. Such a divergent response in endothelial function may be important in the modulation of vascular function in health and disease.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, Sch Med, London SW3 6LY, England; Univ London Kings Coll, Nutr Food & Hlth Res Ctr, London WC2R 2LS, England	Imperial College London; University of London; King's College London	Collins, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, Sch Med, London SW3 6LY, England.			Sanders, Thomas/0000-0001-9529-095X				BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Starling RD, 1997, J APPL PHYSIOL, V82, P1185, DOI 10.1152/jappl.1997.82.4.1185; Vogel RA, 1997, AM J CARDIOL, V79, P350, DOI 10.1016/S0002-9149(96)00760-6	5	74	77	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2134	2134		10.1016/S0140-6736(99)03374-7	http://dx.doi.org/10.1016/S0140-6736(99)03374-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609824				2022-12-28	WOS:000084318200020
J	Wu, SP; Romfo, CM; Nilsen, TW; Green, MR				Wu, SP; Romfo, CM; Nilsen, TW; Green, MR			Functional recognition of the 3 ' splice site AG by the splicing factor U2AF(35)	NATURE			English	Article							PRE-MESSENGER-RNA; SMALL-SUBUNIT; BRANCH POINT; IDENTIFICATION; U2AF(65); PROTEIN; DROSOPHILA; SEQUENCES	In metazoans, spliceosome assembly is initiated through recognition of the 5' splice site by U1 snRNP and the polypyrimidine tract by the U2 small nuclear ribonucleoprotein particle (snRNP) auxiliary factor, U2AF (refs 1, 2), U2AF is a heterodimer comprising a large subunit, U2AF(65), and a small subunit, U2AF(35) (ref. 3). U2AF65 directly contacts the polypyrimidine tract and is required for splicing in vitro(4). In comparison, the role of U2AF35 has been puzzling: U2AF(35) is highly conserved(5-7) and is required for viabilit(6,7), but can be dispensed with for splicing in vitro(4,8,9). Here we use sire-specific crosslinking to show that very early during spliceosome assembly U2AF directly contacts the 3' splice site. Mutational analysis and in vitro genetic selection indicate that U2AF35 has a sequence-specific RNA-binding activity that recognizes the 3'-splice-site consensus, AG/G. We show that for introns with weak polypyrimidine tracts, the U2AF(35)-3'-splice-site interaction is critical for U2AF binding and splicing. Our results demonstrate a new biochemical activity of U2AF(35) identify the factor that initially recognizes the 3' splice site, and explain why the AG dinucleotide is required for the first step of splicing for some but not all introns.	Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, 373 Plantat St, Worcester, MA 01605 USA.	michael.green@umassmed.edu						Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NILSEN TW, 1997, TRANSSPLICING EUKARY, P310; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, SPLICEOSOME ASSEMBLY, P103; Romfo CM, 1997, NUCLEIC ACIDS RES, V25, P4658, DOI 10.1093/nar/25.22.4658; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	21	322	331	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					832	835		10.1038/45590	http://dx.doi.org/10.1038/45590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617206				2022-12-28	WOS:000084330500070
J	Jones, J; Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Parker, G				Jones, J; Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Parker, G			Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY DISCHARGE; MINIMIZATION ANALYSIS; SCHEME; HIP	Objectives To compare the costs of admission to a hospital at home scheme with those of acute hospital admission. Design Cost minimisation analysis within a pragmatic randomised controlled trial. Setting Hospital at home scheme in Leicester and the city's three acute hospitals. Participants 199 consecutive patients assessed as being suitable for admission to hospital at home for acute care during the 18 month trial period (median age 84 years). Intervention Hospital at home or hospital inpatient care. Main outcome measures Costs to NHS, social services, patients, and families during the initial episode of treatment and the three months after admission. Results Mean (median) costs per episode (including any transfer from hospital at home to hospital) were similar when analysed by intention to treat-hospital at home pound f2569 (pound 1655), hospital ward pound 2881 (pound 2031), bootstrap mean difference -305 (95% confidence interval -1112 to 448). When analysis was restricted to those who accepted their allocated place of care, hospital at home was significantly cheaper-hospital at home pound 2557 (pound 1710), hospital ward pound 3660 (pound 2903), bootstrap mean difference - 1071 (-1843 to -246). At thee months the cost differences were sustained. Costs with all cases included were hospital at home pound 3671 (pound 2491), hospital ward pound 3877 (pound 3405), bootstrap mean difference -210 (-1025 to 635). When only those accepting allocated care were included the costs were hospital at home pound 3698 (pound 2493), hospital ward pound 4761 (pound 3940), bootstrap mean difference -1063 (-2044 to -163); P = 0.009. About 25% of the costs for episodes of hospital at home were incurred through transfer to hospital. Costs per day of care were higher in the hospital at home arm (mean pound 207 v pound 134 in the hospital arm, excluding refusers, P < 0.001). Conclusions Hospital at home can deliver care at similar or lower cost than an equivalent admission to an acute hospital.	Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England; Univ Leicester, Nuffield Community Care Studies Unit, Leicester LE1 6TP, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester; University of Leicester	Wilson, A (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England.	AW7@le.ac.uk		Jagger, Carol/0000-0002-6377-9926; Parker, Gillian Mary/0000-0002-2221-6748				Briggs AH, 1999, HLTH TECHNOLOGY ASSE, V3, P1, DOI DOI 10.3310/hta3020; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, IN PRESS J HLTH SERV; Edwards N, 1998, BRIT MED J, V317, P135, DOI 10.1136/bmj.317.7151.135; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; FARNWORTH MG, 1994, AGE AGEING, V23, P190, DOI 10.1093/ageing/23.3.190; Hensher M, 1999, BRIT MED J, V319, P1127, DOI 10.1136/bmj.319.7217.1127; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; Lilford RJ, 1998, BRIT MED J, V317, P1651; NETTEN A, 1996, PERSONAL SOCIAL SERV; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; Wilson A, 1999, BRIT MED J, V319, P1542, DOI 10.1136/bmj.319.7224.1542	15	71	79	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1547	1550		10.1136/bmj.319.7224.1547	http://dx.doi.org/10.1136/bmj.319.7224.1547			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591720	Bronze, Green Published			2022-12-28	WOS:000084245600026
J	Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F				Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F			More than 200 meters of lake ice above subglacial lake Vostok, Antarctica	SCIENCE			English	Article							CENTRAL EAST-ANTARCTICA; ISOTOPIC COMPOSITION; AIR CONTENT; DELTA-O-18; WATER	Isotope studies show that the Vostok ice core consists of ice refrozen from Lake Vostok water, from 3539 meters below the surface of the Antarctic ice sheet to its bottom at about 3750 meters. Additional evidence comes from the total gas content, crystal size, and electrical conductivity of the ice. The Vostok site is a likely place for water freezing at the Lake-ice interface, because this interface occurs at a higher Level here than anywhere else above the Lake. Isotopic data suggest that subglacial Lake Vostok is an open system with an efficient circulation of water that was formed during periods that were slightly warmer than those of the past 420,000 years. Lake ice recovered by deep drilling is of interest for preliminary investigations of Lake chemistry and bedrock properties and for the search for indigenous lake microorganisms. This latter aspect is of potential importance for the exploration of icy planets and moons.	CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France; Lab Glaciol & Geophys Environm, CNRS, F-38402 St Martin Dheres, France; Free Univ Brussels, Fac Sci, Dept Sci Terre, B-1050 Brussels, Belgium; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia; St Petersburg Min Inst, St Petersburg 199026, Russia	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Arctic & Antarctic Research Institute; Saint Petersburg Mining University	Jouzel, J (corresponding author), CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France.		Raynaud, Dominique/H-9626-2016; raynaud, dominique/ABG-4718-2020; Lipenkov, Vladimir Y/Q-8262-2016; Vasilyev, Nikolay I./AAS-2261-2020	Lipenkov, Vladimir Y/0000-0003-4221-5440; Vasilyev, Nikolay I./0000-0002-2279-699X				CARSEY F, 1998, NAT SCI FDN WORKSH L, P21; CRAIG H, 1961, SCIENCE, V133, P1702, DOI 10.1126/science.133.3465.1702; JOUZEL J, 1982, J GLACIOL, V28, P35, DOI 10.3189/S0022143000011771; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; KERN RG, 1998, NAT SCI FDN WORKSH L, P24; LIPENKOV V, 1995, J GLACIOL, V41, P423, DOI 10.3189/S0022143000016294; LIPENKOV V, 1998, P INT WORKSH LAK VOS, P31; MARTINERIE P, 1994, J GEOPHYS RES-ATMOS, V99, P10565, DOI 10.1029/93JD03223; Paillard D, 1998, NATURE, V391, P378, DOI 10.1038/34891; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; SALAMATIN A, 1998, DATA GLACIOL STUD, V85, P233; Siegert MJ, 1998, J GEOPHYS RES-SOL EA, V103, P10195, DOI 10.1029/98JB00390; SOUCHEZ R, 1987, GEOPHYS RES LETT, V14, P599, DOI 10.1029/GL014i006p00599; SOUCHEZ RA, 1984, J GLACIOL, V30, P369, DOI 10.3189/S0022143000006249; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TIEDJIE JM, 1998, NAT SCI FDN WORKSH L, P19; Vimeux F, 1999, NATURE, V398, P410, DOI 10.1038/18860; WHITE DC, 1998, NAT SCI FDN WORKSH L, P22; 1998, NAT SCI FDN WORKSH L	21	139	144	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2138	2141		10.1126/science.286.5447.2138	http://dx.doi.org/10.1126/science.286.5447.2138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591641				2022-12-28	WOS:000084157300046
J	Tonks, NK; Myers, MP				Tonks, NK; Myers, MP			Cancer - Structural assets of a tumor suppressor	SCIENCE			English	Editorial Material							PHOSPHATASE; PTEN; GENE		Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.							Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; FUNARI FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292	11	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2096	2097		10.1126/science.286.5447.2096	http://dx.doi.org/10.1126/science.286.5447.2096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617421				2022-12-28	WOS:000084157300037
J	Keen, RW				Keen, RW			Effects of lifestyle interventions on bone health	LANCET			English	Editorial Material							OSTEOPOROTIC FRACTURES; RISK-FACTORS; WOMEN; MASS; EXERCISE; DENSITY		UCL, Bone & Mineral Ctr, London WC1E 6JJ, England	University of London; University College London	Keen, RW (corresponding author), UCL, Bone & Mineral Ctr, London WC1E 6JJ, England.							COMPSTON JE, 1992, CLIN SCI, V82, P429, DOI 10.1042/cs0820429; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Heinonen A, 1996, LANCET, V348, P1343, DOI 10.1016/S0140-6736(96)04214-6; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; Ralston SH, 1997, BMJ-BRIT MED J, V315, P469, DOI 10.1136/bmj.315.7106.469; REID IR, 1995, J CLIN ENDOCR METAB, V80, P1764, DOI 10.1210/jc.80.6.1764; Royal College of Physicians, 1999, OST CLIN GUID PREV T; Salamone LM, 1999, AM J CLIN NUTR, V70, P97; TORGERSON DJ, 1995, BRIT J RHEUMATOL, V34, P620	12	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1923	1924		10.1016/S0140-6736(99)00406-7	http://dx.doi.org/10.1016/S0140-6736(99)00406-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622292				2022-12-28	WOS:000084034700006
J	Laubichler, MD				Laubichler, MD			Frankenstein in the land of Dichter and Denker	SCIENCE			English	Editorial Material									Princeton Univ, Program Hist Sci, Princeton, NJ 08544 USA; Max Planck Inst Hist Sci, Berlin, Germany	Princeton University; Max Planck Society	Laubichler, MD (corresponding author), Princeton Univ, Program Hist Sci, 129 Dickinson Hall, Princeton, NJ 08544 USA.							GOETHE, FAUST; HUXLEY A, BRAVE NEW WORLD; JURGEN P, 1995, HISTORIKERSTREIT SUC; LEICHT R, 1998, ZEIT, P1; NIETZSCHE, THUS SPOKE ZARATHUST; NUSSLEINVOLHARD C, 1999, TAGESSPIEGEL    0927; ROSS J, 1998, ZEIT, P3; SHELLEY MW, FRANKENSTEIN; Sloterdijk P., 1999, REGELN MENSCHENPARK; WATSON JD, 1997, SCIENCE, V276, P892	10	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1859	1860						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10610575				2022-12-28	WOS:000084003400026
J	Brown, ME; Calvin, WM				Brown, ME; Calvin, WM			Evidence for crystalline water and ammonia ices on Pluto's satellite Charon	SCIENCE			English	Article							SURFACE-COMPOSITION; SPECTROSCOPY; IRRADIATION; VOLCANISM; SYSTEM; FLOW	Observations have resolved the satellite Charon from its parent planet Pluto, giving separate spectra of the two objects from 1.0 to 2.5 micrometers. The spectrum of Charon is found to be different from that of Pluto, with water ice in crystalline form covering most of the surface of the satellite. In addition, an absorption feature in Charon's spectrum suggests the presence of ammonia ices. Ammonia ice-water ice mixtures have been proposed as the cause of flowlike features observed on the surfaces of many icy satellites. The existence of such ices on Charon may indicate geological activity in the satellite's past.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Nevada, Dept Geol Sci, Reno, NV 89557 USA	California Institute of Technology; Nevada System of Higher Education (NSHE); University of Nevada Reno	Brown, ME (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.			Brown, Michael E./0000-0002-8255-0545				BROWN RH, 1988, ICARUS, V74, P262, DOI 10.1016/0019-1035(88)90041-3; BULE MW, 1987, NATURE, V329, P522; CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; CHRISTY JW, 1978, IAU CIRC, V3241, P1; CROFT SK, 1997, URANUS, P561; Cruikshank D.P., 1997, PLUTO CHARON, P221; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; DURHAM WB, 1993, J GEOPHYS RES-SOL EA, V98, P17667, DOI 10.1029/93JB01564; Fanale FP, 1999, ICARUS, V139, P179, DOI 10.1006/icar.1999.6117; FINK U, 1982, COMETS, P172; Grundy WM, 1998, J GEOPHYS RES-PLANET, V103, P25809, DOI 10.1029/98JE00738; GRUNDY WM, IN PRESS ICARUS; HAPKE B, 1981, J GEOPHYS RES, V86, P3039, DOI 10.1029/JB086iB04p03039; KARGEL JS, 1991, ICARUS, V89, P93, DOI 10.1016/0019-1035(91)90090-G; KHARE BN, 1989, ICARUS, V79, P350, DOI 10.1016/0019-1035(89)90082-1; KOUCHI A, 1990, NATURE, V344, P134, DOI 10.1038/344134a0; LANCON A, 1992, ASTRON ASTROPHYS SUP, V96, P593; LANZEROTTI LJ, 1984, NATURE, V312, P139, DOI 10.1038/312139a0; LEWIS JS, 1971, ICARUS, V15, P174, DOI 10.1016/0019-1035(71)90072-8; LIDE DR, 1996, CRC HDB CHEM PHYSICS, P77; MARCIALIS RL, 1987, SCIENCE, V237, P1349, DOI 10.1126/science.237.4820.1349; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; ROUSH TL, 1994, ICARUS, V108, P243, DOI 10.1006/icar.1994.1059; Roush TL, 1996, ICARUS, V119, P214, DOI 10.1006/icar.1996.0014; SCHENK PM, 1991, J GEOPHYS RES-SOLID, V96, P1887, DOI 10.1029/90JB01604; Schmitt B, 1998, ASTROPHYS SPACE SC L, V227, P199, DOI 10.1007/978-94-011-5252-5_9; STEVENSON DJ, 1982, NATURE, V298, P142, DOI 10.1038/298142a0	27	149	150	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					107	109		10.1126/science.287.5450.107	http://dx.doi.org/10.1126/science.287.5450.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615040				2022-12-28	WOS:000084578400045
J	Mari, G				Mari, G		Collaborative Grp Doppler Assessme	Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAUTERINE TRANSFUSION; ISOIMMUNIZED PREGNANCY; FLOW-VELOCITY; SENSITIZATION; HEMORRHAGE; HEMATOCRIT; ULTRASOUND	Background: Invasive techniques such as amniocentesis and cordocentesis are used for diagnosis and treatment in fetuses at risk for anemia due to maternal red-cell alloimmunization. The purpose of our study was to determine the value of noninvasive measurements of the velocity of blood flow in the fetal middle cerebral artery for the diagnosis of fetal anemia. Methods: We measured the hemoglobin concentration in blood obtained by cordocentesis and also the peak velocity of systolic blood flow in the middle cerebral artery in 111 fetuses at risk for anemia due to maternal red-cell alloimmunization. Peak systolic velocity was measured by Doppler velocimetry. To identify the fetuses with anemia, the hemoglobin values of those at risk were compared with the values in 265 normal fetuses. Results: Fetal hemoglobin concentrations increased with increasing gestational age in the 265 normal fetuses. Among the 111 fetuses at risk for anemia, 41 fetuses did not have anemia; 35 had mild anemia; 4 had moderate anemia; and 31, including 12 with hydrops, had severe anemia. The sensitivity of an increased peak velocity of systolic blood flow in the middle cerebral artery for the prediction of moderate or severe anemia was 100 percent either in the presence or in the absence of hydrops (95 percent confidence interval, 86 to 100 percent for the 23 fetuses without hydrops), with a false positive rate of 12 percent. Conclusions: In fetuses without hydrops that are at risk because of maternal red-cell alloimmunization, moderate and severe anemia can be detected noninvasively by Doppler ultrasonography on the basis of an increase in the peak velocity of systolic blood flow in the middle cerebral artery. (N Engl J Med 2000;342:9-14.).	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA; Baylor Coll Med, Houston, TX 77030 USA; King Faisal Hosp & Specialist Ctr, Riyadh, Saudi Arabia; Univ Spital Zurich, Klin & Poliklin Geburtshilfe, Zurich, Switzerland; Univ N Carolina, Chapel Hill, NC USA; Penn Hosp, Philadelphia, PA 19107 USA; Catholic Univ Chile, Hosp Dr Sotero del Rio, Santiago, Chile; Yale Univ, Sch Med, New Haven, CT USA; Wayne State Univ, Hutzel Hosp, Detroit, MI USA	Yale University; Baylor College of Medicine; King Faisal Specialist Hospital & Research Center; University of Zurich; University Zurich Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; Pontificia Universidad Catolica de Chile; Universidad de Chile; Yale University; Wayne State University	Mari, G (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.	giancarlo.mari@yale.edu						*ACOG, 1996, ACOG ED B, V227; Bahado-Singh R, 1998, OBSTET GYNECOL, V92, P828, DOI 10.1016/S0029-7844(98)00250-6; Bowman J.M., 1999, MATERNAL FETAL MED, P736; BOWMAN JM, 1985, OBSTET GYNECOL, V66, P749; CAINE ME, 1986, AM J OBSTET GYNECOL, V154, P85, DOI 10.1016/0002-9378(86)90398-4; COPEL JA, 1989, AM J OBSTET GYNECOL, V161, P341, DOI 10.1016/0002-9378(89)90516-4; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; ERICKSON JD, 1993, TERATOLOGY, V48, P545, DOI 10.1002/tera.1420480602; FAN FC, 1980, AM J PHYSIOL, V238, pH545, DOI 10.1152/ajpheart.1980.238.4.H545; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1339, DOI 10.1016/S0002-9378(11)90761-3; HECHER K, 1995, OBSTET GYNECOL, V85, P122, DOI 10.1016/0029-7844(94)00331-7; LILEY AW, 1961, AM J OBSTET GYNECOL, V82, P1359; MACGREGOR SN, 1991, AM J OBSTET GYNECOL, V165, P382, DOI 10.1016/0002-9378(91)90098-C; MARI G, 1995, ULTRASOUND OBST GYN, V5, P400, DOI 10.1046/j.1469-0705.1995.05060400.x; Mari G, 1997, J Matern Fetal Med, V6, P206; MARI G, 1990, 37 ANN M SOC GYN INV, P253; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MOISE KJ, 1990, AM J OBSTET GYNECOL, V163, P776, DOI 10.1016/0002-9378(90)91067-M; NICOLAIDES KH, 1986, AM J OBSTET GYNECOL, V155, P90, DOI 10.1016/0002-9378(86)90085-2; NICOLAIDES KH, 1988, LANCET, V1, P1073; NICOLAIDES KH, 1988, AM J OBSTET GYNECOL, V158, P920, DOI 10.1016/0002-9378(88)90095-6; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; Rahman F, 1998, ACTA OBSTET GYN SCAN, V77, P804, DOI 10.1034/j.1600-0412.1998.770804.x; ROSENKRANTZ TS, 1982, J PEDIATR-US, V101, P94, DOI 10.1016/S0022-3476(82)80194-7; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; VYAS S, 1990, AM J OBSTET GYNECOL, V162, P1066, DOI 10.1016/0002-9378(90)91317-6	26	734	813	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					9	14		10.1056/NEJM200001063420102	http://dx.doi.org/10.1056/NEJM200001063420102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620643				2022-12-28	WOS:000084575600002
J	Bliss, MR				Bliss, MR			Is an apology called for?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					67	67		10.1136/bmj.320.7226.67	http://dx.doi.org/10.1136/bmj.320.7226.67			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617556	Green Published			2022-12-28	WOS:000084621600068
J	Kaldjian, LC; Wu, BJ; Jekel, JF; Kaldjian, EP; Duffy, TP				Kaldjian, LC; Wu, BJ; Jekel, JF; Kaldjian, EP; Duffy, TP			Insertion of femoral-vein catheters for practice by medical house officers during cardiopulmonary resuscitation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEWLY DEAD; CONSENT; EMERGENCY; SKILLS; TEACH		Yale Univ, Sch Med, New Haven, CT 06520 USA; Hosp St Raphael, New Haven, CT 06511 USA; Griffin Hosp, Derby, CT 06418 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48109 USA	Yale University; Hospital Saint Raphael; Pfizer	Kaldjian, LC (corresponding author), St Marys Hosp, Dept Med, 56 Franklin St, Waterbury, CT 06706 USA.			Kaldjian, Lauris/0000-0002-9170-6986				ABRAMSON NS, 1981, JAMA-J AM MED ASSOC, V246, P2828; ABRAMSON NS, 1985, CRIT CARE MED, V13, P930, DOI 10.1097/00003246-198511000-00020; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P125; BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BURNS JP, 1994, NEW ENGL J MED, V331, P1652, DOI 10.1056/NEJM199412153312411; CUMMINS RO, 1997, ADV CARDIAC LIFE SUP, pI25; GOLDBLATT AD, 1995, ANN EMERG MED, V25, P86, DOI 10.1016/S0196-0644(95)70361-6; Hundert EM, 1996, ACAD MED, V71, P624, DOI 10.1097/00001888-199606000-00014; ISERSON KV, 1993, J MED ETHICS, V19, P92, DOI 10.1136/jme.19.2.92; Kant Immanuel, 1964, GROUNDWORK METAPHYSI, P101; LEVINE RJ, 1981, ETHICS REGULATION CL, P71; MCNAMARA RM, 1995, JAMA-J AM MED ASSOC, V273, P310, DOI 10.1001/jama.273.4.310; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; NELSON MS, 1990, ANN EMERG MED, V19, P333, DOI 10.1016/S0196-0644(05)82058-X; OLSON CM, 1994, JAMA-J AM MED ASSOC, V271, P1445, DOI 10.1001/jama.271.18.1445; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; PELLEGRINO ED, 1995, ENCY BIOETHICS, V3, P1435	17	15	15	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2088	2091		10.1056/NEJM199912303412711	http://dx.doi.org/10.1056/NEJM199912303412711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615084				2022-12-28	WOS:000084573300011
J	Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ				Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ			Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Maternal-Fetal Medicine	JAN 18-23, 1999	SAN FRANCISCO, CALIFORNIA	Soc Maternal Fetal Med			ALPHA-FETOPROTEIN; FETAL GROWTH; 2ND-TRIMESTER; HCG; PREECLAMPSIA; MANAGEMENT	Background: Maternal serum chorionic gonadotropin is measured to screen for fetal chromosomal abnormalities. Whether the results can also be used to predict the risk of complications or an adverse outcome of pregnancy is not known. Methods: We reviewed the medical records of 28,743 girls and women in whom chorionic gonadotropin was measured during the second trimester of pregnancy (between July 1, 1995, and January 31, 1997), seeking information about the complications and outcome of their pregnancies. We excluded girls and women who had preexisting risk factors for complications or an adverse outcome of pregnancy. Results: Higher serum chorionic gonadotropin concentrations were associated with higher rates of stillbirth (odds ratio for every increase in chorionic gonadotropin of 1 multiple of the median, 1.4; 95 percent confidence interval, 1.1 to 1.9). There was no relation between higher serum chorionic gonadotropin concentrations and the risk of gestational diabetes, premature rupture of membranes, or intrauterine growth retardation or small size for gestational age (odds ratio, 1.1; 95 percent confidence interval, 0.9 to 1.2). Higher serum chorionic gonadotropin concentrations were associated with a risk of placental abnormalities (odds ratio, 1.5; 95 percent confidence interval, 1.3 to 1.7), pregnancy-induced hypertension (odds ratio, 1.4; 95 percent confidence interval, 1.3 to 1.5), and preterm delivery without pregnancy-induced hypertension (odds ratio, 1.1; 95 percent confidence interval, 1.0 to 1.2). Inclusion in certain racial or ethnic categories (black, Filipino or Pacific Islander, unknown race or ethnic group, and "other,'' which included those of Middle Eastern descent and Native Americans) was a better predictor of the risk of an adverse outcome than serum chorionic gonadotropin values. Conclusions: Measurements of serum chorionic gonadotropin are of little clinical value for predicting the risk of complications and the outcome of pregnancy. (N Engl J Med 1999;341:2033-8.) (C) 1999, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Dept Obstet, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Schoen, EJ (corresponding author), Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, 280 W MacArthur Blvd, Oakland, CA 94611 USA.			Walton, David/0000-0002-8461-2551				ABUELO DN, 1991, PRENATAL DIAG, V11, P381, DOI 10.1002/pd.1970110607; Ashour AMN, 1997, AM J OBSTET GYNECOL, V176, P438, DOI 10.1016/S0002-9378(97)70512-X; Benn PA, 1996, OBSTET GYNECOL, V87, P217, DOI 10.1016/0029-7844(95)00390-8; Bodegard G, 1983, Acta Paediatr Scand Suppl, V304, P1; Chalmers I, 1989, EFFECTIVE CARE PREGN; FREEMAN RK, 1982, AM J OBSTET GYNECOL, V143, P771, DOI 10.1016/0002-9378(82)90008-4; GANT NF, 1994, SEMIN PERINATOL, V18, P94; GLANTZ JC, 1993, CLIN OBSTET GYNECOL, V36, P279, DOI 10.1097/00003081-199306000-00009; GONEN R, 1992, OBSTET GYNECOL, V80, P83; GRAVETT CP, 1992, AM J MED GENET, V44, P485, DOI 10.1002/ajmg.1320440420; Heinonen S, 1996, AM J PERINAT, V13, P437, DOI 10.1055/s-2007-994384; *INT CLASS DIS, 1997, ICD9CM; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; MORSSINK LP, 1995, PRENATAL DIAG, V15, P1041, DOI 10.1002/pd.1970151109; Onderoglu LS, 1997, INT J GYNECOL OBSTET, V56, P245, DOI 10.1016/S0020-7292(96)02830-5; SORENSEN TK, 1993, AM J OBSTET GYNECOL, V169, P834, DOI 10.1016/0002-9378(93)90013-9; TANAKA M, 1993, OBSTET GYNECOL, V81, P341; VASILENKO P, 1995, 43 ACOG ANN M SAN FR; VORHERR H, 1975, AM J OBSTET GYNECOL, V123, P67, DOI 10.1016/0002-9378(75)90951-5; Wilkins-Haug L, 1998, CURR OPIN OBSTET GYN, V10, P469, DOI 10.1097/00001703-199812000-00007; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624	22	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2033	2038		10.1056/NEJM199912303412701	http://dx.doi.org/10.1056/NEJM199912303412701			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615074				2022-12-28	WOS:000084573300001
J	Katz, LC				Katz, LC			What's critical for the critical period in visual cortex?	CELL			English	Review							OCULAR DOMINANCE COLUMNS; EXPERIENCE-DEPENDENT PLASTICITY; QUANTAL AMPLITUDE; SYNAPSES; KITTENS; NEURONS		Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Katz, LC (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.							ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; Antonini A, 1999, J NEUROSCI, V19, P4388; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Gordon JA, 1996, J NEUROSCI, V16, P3274; Hata Y, 1999, NEURON, V22, P375, DOI 10.1016/S0896-6273(00)81097-1; Hensch TK, 1998, J NEUROSCI, V18, P2108; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; KASAMATSU T, 1976, SCIENCE, V194, P206, DOI 10.1126/science.959850; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; Marty S, 1996, J NEUROSCI, V16, P675; MOWER GD, 1985, J COMP NEUROL, V235, P448, DOI 10.1002/cne.902350404; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103	20	35	37	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					673	676		10.1016/S0092-8674(00)81665-7	http://dx.doi.org/10.1016/S0092-8674(00)81665-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619421	Bronze			2022-12-28	WOS:000084488200001
J	Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD				Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD			Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study	LANCET			English	Article							DIAGNOSIS; EPIDEMIOLOGY; ULTRASOUND; MOTILITY; OLIVE	Background In February, 1999, a local US health department identified a cluster of pertussis cases among neonates born at a community hospital and recommended oral erythromycin for post-exposure prophylaxis for about 200 neonates born at that hospital between Feb 1 and Feb 24, 1999, We investigated a cluster of seven cases of infantile hypertrophic pyloric stenosis (IHPS) that occurred the following month among the neonates who had received erythromycin. Methods We obtained a masked, independent review of the IHPS ultrasonography diagnoses, calculated the monthly IHPS incidence, and compared index and historical (1998-99) IHPS cases with respect to several characteristics including erythromycin exposure. We used a retrospective cohort of infants born in January and February, 1999, to investigate further erythromycin exposure and development of IHPS. Findings An independent review confirmed the ultrasonographic diagnoses of all seven index IHPS cases. All index cases versus none of the historical IHPS cases had been given erythromycin for pertussis prophylaxis. The IHPS rate for infants born in the hospital in February, 1999, was 323 per 1000 liveborn infants, representing nearly a seven-fold increase over 1997-98 (relative risk 6.8 [95% CI 3.0-15.7]). Among infants born in January and February, 1999, erythromycin was associated with IHPS (absolute risk 4.5%, relative risk infinity [1.7-infinity]). Interpretation Neonates receiving oral erythromycin may have an increased risk of IHPS. The risks and benefits of erythromycin for neonatal pertussis prophylaxis should be re-evaluated, and caution should be used in defining risk groups for prophylaxis.	Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Knox Cty Hlth Dept, Knoxville, TN USA; Johns Hopkins Sch Med, Baltimore, MD USA; E Tennessee Childrens Hosp, Knoxville, TN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Medicine	Honein, MA (corresponding author), Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, MS F-45,4770 Buford Highway NE, Atlanta, GA 30341 USA.							Abbas AE, 1999, AM SURGEON, V65, P73; Ali KI, 1996, EUR J PEDIATR SURG, V6, P233, DOI 10.1055/s-2008-1066516; APPLEGATE MS, 1995, ARCH PEDIAT ADOL MED, V149, P1123, DOI 10.1001/archpedi.1995.02170230077011; Boiron M, 1997, ARCH PHYSIOL BIOCHEM, V105, P591, DOI 10.1076/apab.105.6.591.3281; Coulie B, 1998, GUT, V43, P395, DOI 10.1136/gut.43.3.395; DILORENZO C, 1994, DIGEST DIS SCI, V39, P1399; Godbole P, 1996, ARCH DIS CHILD, V75, P335, DOI 10.1136/adc.75.4.335; HERNANZSCHULMAN M, 1994, RADIOLOGY, V193, P771, DOI 10.1148/radiology.193.3.7972822; HITCHCOCK NE, 1987, ARCH DIS CHILD, V62, P512, DOI 10.1136/adc.62.5.512; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Jadcherla SR, 1997, PEDIATR RES, V42, P365, DOI 10.1203/00006450-199709000-00018; Misra D, 1997, EUR J PEDIATR SURG, V7, P328, DOI 10.1055/s-2008-1071185; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; PERITI P, 1993, DRUG SAFETY, V9, P346, DOI 10.2165/00002018-199309050-00004; PETER G, 1997, 1997 RED BOOK REPORT, P397; Poon TSC, 1996, J PEDIATR SURG, V31, P1611, DOI 10.1016/S0022-3468(96)90032-9; RASMUSSEN L, 1989, INT J EPIDEMIOL, V18, P413, DOI 10.1093/ije/18.2.413; Rohrschneider WK, 1998, PEDIATR RADIOL, V28, P429, DOI 10.1007/s002470050377; ROLLINS MD, 1989, ARCH DIS CHILD, V64, P138, DOI 10.1136/adc.64.1.138; SANFILIPPO JA, 1976, J PEDIATR SURG, V11, P177; Schechter R, 1997, PAEDIATR PERINAT EP, V11, P407, DOI 10.1046/j.1365-3016.1997.d01-32.x; SCHWARTZ MZ, 1998, PEDIAT SURG, P1111; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STANG H, 1986, MINN MED, V69, P669; STANG H, 1986, MINN MED, V69, P682; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; TEELE RL, 1977, NEW ENGL J MED, V296, P1149, DOI 10.1056/NEJM197705192962006; White MC, 1998, J PEDIATR SURG, V33, P913, DOI 10.1016/S0022-3468(98)90673-X; ZEIDAN B, 1988, ARCH DIS CHILD, V63, P1060, DOI 10.1136/adc.63.9.1060	29	118	124	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2101	2105		10.1016/S0140-6736(99)10073-4	http://dx.doi.org/10.1016/S0140-6736(99)10073-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609814				2022-12-28	WOS:000084318200010
J	Tsai, E				Tsai, E			Why the Republic of China should be included in WHO	LANCET			English	Editorial Material									Taipei Representat Off UK, Informat Div, London SW1W 0EB, England		Tsai, E (corresponding author), Taipei Representat Off UK, Informat Div, 50 Grosvenor Gardens, London SW1W 0EB, England.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2157	2157		10.1016/S0140-6736(99)07062-2	http://dx.doi.org/10.1016/S0140-6736(99)07062-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609836				2022-12-28	WOS:000084318200047
J	Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT				Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT			Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study	LANCET			English	Article							HORMONE-BINDING GLOBULIN; EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; ISOFLAVONOID PHYTOESTROGENS; CARDIOVASCULAR RISK; LIPID-PEROXIDATION; PHYTO-ESTROGENS; BREAST-CANCER	Background The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been implicated in protection against cancer. We investigated the association of serum enterolactone concentration with the risk of acute coronary events in a prospective nested case-control study in middle-aged men from eastern Finland. Methods Enterolactone was measured by time-resolved fluoroimmunoassay in serum from 167 men who had an average 7.7 years of follow-up to an acute coronary event and from 167 control men. Both cases and controls were from a cohort of 2005 men who had no clinical coronary heart disease (CHD) at baseline. The controls were matched for age, examination year, and residence. Acute coronary events were registered prospectively. Findings The mean baseline serum enterolactone concentration was lower among the cases than the controls (18.2 [SD 21.1] vs 23.5 [18.2] nmol/L, p=0.001). The men in the highest quarter of the enterolactone distribution (>30.1 nmol/L) had a 58.8% (95% CI 24.1-77.6, p=0.005) lower risk of acute coronary events than men in the lowest quarter. After adjustment for the nine most strongly predictive risk factors, men in the highest enterolactone quarter had a 65.3% (11.9-86.3, p=0.03) lower risk than men in the lowest quarter. Interpretation Healthy men with high serum concentrations of enterolactone had a lower risk of acute coronary events than men with lower concentrations. These findings support the hypothesis that plant-dominated fibre-rich food lowers the risk of CHD.	Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Univ Helsinki, Folkhalsan Res Ctr, Inst Prevent Med Nutr & Canc, Helsinki, Finland; Univ Helsinki, Dept Clin Chem, Helsinki, Finland	University of Eastern Finland; University of Eastern Finland; Folkhalsan Research Center; University of Helsinki; University of Helsinki	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, PO 1627, FIN-70211 Kuopio, Finland.			Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL 44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; Adlercreutz H, 1998, ANAL BIOCHEM, V265, P208, DOI 10.1006/abio.1998.2886; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; Haffner SM, 1996, J CLIN ENDOCR METAB, V81, P3697, DOI 10.1210/jc.81.10.3697; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; KUMAR KV, 1993, FREE RADICAL RES COM, V19, P59, DOI 10.3109/10715769309056499; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAPIDUS L, 1986, CLIN CHEM, V32, P146; Martin M E, 1996, Life Sci, V58, P429; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PUGEAT M, 1995, J STEROID BIOCHEM, V53, P567, DOI 10.1016/0960-0760(95)00102-6; PUHAKAINEN EVJ, 1987, CLIN CHIM ACTA, V170, P255, DOI 10.1016/0009-8981(87)90135-5; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; Steinberg FM, 1998, AM J CLIN NUTR, V68, P319, DOI 10.1093/ajcn/68.2.319; TOUMILEHTO J, 1992, EUR HEART J, V13, P577; Zeleniuch-Jacquotte A, 1998, CANCER EPIDEM BIOMAR, V7, P885	30	185	190	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2112	2115		10.1016/S0140-6736(99)05031-X	http://dx.doi.org/10.1016/S0140-6736(99)05031-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609816				2022-12-28	WOS:000084318200012
J	Blavette, D; Cadel, E; Fraczkiewicz, A; Menand, A				Blavette, D; Cadel, E; Fraczkiewicz, A; Menand, A			Three-dimensional atomic-scale imaging of impurity segregation to line defects	SCIENCE			English	Article							DISLOCATIONS; PROBE; FEAL	Clouds of impurity atoms near Line defects are believed to affect the plastic deformation of alloys. Three-dimensional atom probe techniques were used to image these so-tailed Cottrell atmospheres directly. Ordered iron-aluminum alloys (40 atomic percent aluminum) doped with boron (400 atomic parts per million) were investigated on an atomic scale along the (001) direction. A boron enrichment was observed in the vicinity of an (001) edge dislocation, The enriched region appeared as a three-dimensional pipe 5 nanometers in diameter, tangent to the dislocation Line. The dislocation was found to be boron-enriched by a factor of 50 (2 atomic percent) relative to the bulk. The Local boron enrichment is accompanied by a strong aluminum depletion of 20 atomic percent.	Univ Rouen, Fac Sci, CNRS, UMR 6634,Grp Met Phys, F-76821 Mont St Aignan, France; Ecole Mines St Etienne, Ctr SMS, F-42100 St Etienne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Rouen Normandie; IMT - Institut Mines-Telecom; Mines Saint-Etienne	Blavette, D (corresponding author), Univ Rouen, Fac Sci, CNRS, UMR 6634,Grp Met Phys, F-76821 Mont St Aignan, France.	blavette@univ-rouen.fr	Blavette, Didier/J-9488-2013; CADEL, Emmanuel/D-7037-2015					BLAVETTE D, 1993, NATURE, V363, P432, DOI 10.1038/363432a0; Blavette D, 1998, ULTRAMICROSCOPY, V70, P115, DOI 10.1016/S0304-3991(97)00085-5; CEREZO A, 1927, REV SCI INSTRUM, V862, P88; CHANG L, 1992, FUNDAMENTALS AGING T, P19; COTTRELL AH, 1949, P PHYS SOC LOND A, V62, P49, DOI 10.1088/0370-1298/62/1/308; CRIMP MA, 1986, MATER SCI ENG, V78, P193, DOI 10.1016/0025-5416(86)90323-X; Fraczkiewicz A, 1999, J PHYS IV, V9, P75, DOI 10.1051/jp4:1999410; JAYARAM R, 1995, SCRIPTA METALL MATER, V33, P19, DOI 10.1016/0956-716X(95)00036-U; Miller M.K., 1996, ATOM PROBE FIELD ION; Morris MA, 1998, SCRIPTA MATER, V38, P509, DOI 10.1016/S1359-6462(97)00468-5; NANDEDKAR AS, 1982, ACTA METALL MATER, V30, P2055, DOI 10.1016/0001-6160(82)90108-0; WOLFER WG, 1985, ACTA METALL MATER, V33, P2005, DOI 10.1016/0001-6160(85)90123-3	12	238	244	2	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2317	2319		10.1126/science.286.5448.2317	http://dx.doi.org/10.1126/science.286.5448.2317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600736				2022-12-28	WOS:000084318500053
J	Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S				Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S			Requirement of yeast SGS1 and SRS2 genes for replication and transcription	SCIENCE			English	Article							WERNER-SYNDROME PROTEIN; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; BLOOMS-SYNDROME; HOMOLOG; PRODUCT; PURIFICATION; EXONUCLEASE; INTERACTS	The SGS1 gene of the yeast Saccharomyces cerevisiae encodes a DNA helicase with homology to the human Bloom's syndrome gene BLM and the Werner's syndrome gene WRN. The SRS2 gene of yeast also encodes a DNA helicase. Simultaneous deletion of SGS1 and SRS2 is Lethal in yeast. Here, using a conditional mutation of SGS1, it is shown that DNA replication and RNA polymerase I transcription are drastically inhibited in the srs2 Delta sgs1-ts strain at the restrictive temperature. Thus, SGS1 and SRS2 function in DNA replication and RNA polymerase I transcription. These functions may contribute to the various defects observed in Werner's and Bloom's syndromes.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA80882] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; Lee S. A., UNPUB; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	28	121	121	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2339	2342		10.1126/science.286.5448.2339	http://dx.doi.org/10.1126/science.286.5448.2339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600744				2022-12-28	WOS:000084318500061
J	Bodenheimer, T; Casalino, L				Bodenheimer, T; Casalino, L			Executives with white coats - The work and world view of managed-care medical directors - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INSURANCE COMPANIES; PHYSICIANS; COMPETENCES; CAPITATION; CALIFORNIA; NECESSITY; COVERAGE		Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Stanford Coastside Med Clin, Half Moon Bay, CA USA	University of California System; University of California San Francisco; Stanford University	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				BODENHEIMER T, 1998, UNDERSTANDING HLTH P, P47; Halbert RJ, 1998, AM J PREV MED, V15, P65, DOI 10.1016/S0749-3797(98)00020-8; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; Jacobson PD, 1997, INQUIRY-J HEALTH CAR, V34, P143; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LIGHT DW, 1994, NEW ENGL J MED, V330, P498, DOI 10.1056/NEJM199402173300711; Ottensmeyer D J, 1991, Health Care Manage Rev, V16, P21; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; Quinn C, 1997, AM J MANAG C, V3, P883; REINER S, 1997, CALIF MED, V8, P36; Reinertsen JL, 1998, ANN INTERN MED, V128, P833, DOI 10.7326/0003-4819-128-10-199805150-00007; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Scutchfield FD, 1998, AM J PREV MED, V15, P71; SHLIAN D, 1998, SEARCH PHYSICIAN LEA, P39; SIPKOFF M, 1998, PHYSICAN PRACTIC APR, P1; Steiner CA, 1997, MED CARE, V35, P472, DOI 10.1097/00005650-199705000-00005; VOLZ D, 1999, PHYSICIANS FINA 0228, P14; VOLZ D, 1999, PHYSICIANS FINA 0228, P19	18	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1945	1948		10.1056/NEJM199912163412521	http://dx.doi.org/10.1056/NEJM199912163412521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601517				2022-12-28	WOS:000084210200027
J	Starr, SE; Fletcher, CV; Spector, SA; Yong, FH; Fenton, T; Brundage, RC; Manion, D; Ruiz, NM; Gersten, M; Becker, M; McNamara, J; Mofenson, LM				Starr, SE; Fletcher, CV; Spector, SA; Yong, FH; Fenton, T; Brundage, RC; Manion, D; Ruiz, NM; Gersten, M; Becker, M; McNamara, J; Mofenson, LM		Pediat AIDS Clinical Trials Grp 38	Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIDANOSINE; ZIDOVUDINE; INDINAVIR; GROWTH	Background: Consistent long-term viral suppression has been difficult to achieve in children with human immunodeficiency virus type 1 (HIV-1) infection. We tested the safety and antiviral efficacy of a novel combination consisting of efavirenz, nelfinavir, and one or more nucleoside reverse-transcriptase inhibitors in 57 children previously treated with only nucleoside reverse-transcriptase inhibitors. Methods: The children were monitored for 48 weeks after the initiation of therapy. We assessed plasma concentrations of efavirenz and nelfinavir, plasma HIV-1 RNA levels, and lymphocyte subpopulations. Results: At base line, the 57 HIV-1-infected children (age range, 3.8 to 16.8 years) had a median of 699 CD4 cells per cubic millimeter and 10,000 copies of HIV-1 RNA per milliliter of plasma. The most common treatment-related effects of at least moderate severity were rash (in 30 percent of children), diarrhea (in 18 percent), neutropenia (in 12 percent), and biochemical abnormalities (in 12 percent). Serious side effects were uncommon. The mean values for the area under the curve for efavirenz and nelfinavir corresponded to expected values. In an intention-to-treat analysis, 76 percent of children had plasma HIV-1 RNA levels of less than 400 copies per milliliter after 48 weeks of therapy and 63 percent had levels of less than 50 copies per milliliter. A high plasma HIV-1 RNA level at base line significantly decreased the likelihood that plasma levels of HIV-1 RNA would become undetectable during treatment. Conclusions: In HIV-1-infected children who were previously treated with nucleoside reverse-transcriptase inhibitors, the combination of efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors was generally well tolerated and had a potent and sustained antiviral effect. (N Engl J Med 1999;341:1874-81.) (C)1999, Massachusetts Medical Society.	Childrens Hosp Philadelphia, Div Infect Dis & Immunol, Philadelphia, PA 19104 USA; Univ Minnesota, Minneapolis, MN USA; Univ San Diego, San Diego, CA 92110 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Frontier Sci & Technol Res Fdn, Brookline, MA USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA; Agourou Pharmaceut, La Jolla, CA USA; NIAID, Rockville, MD USA; NICHHD, Rockville, MD USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Minnesota System; University of Minnesota Twin Cities; University of San Diego; Harvard University; Harvard T.H. Chan School of Public Health; Frontier Science Foundation; DuPont; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Starr, SE (corresponding author), Childrens Hosp Philadelphia, Div Infect Dis & Immunol, 34th St & Civic Ctr blvd, Philadelphia, PA 19104 USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041110, R01AI033835] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41110, AI33835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; BERHANE R, 1997, PEDIATRICS, V100, P126; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; COX DR, 1972, J R STAT SOC B, V34, P187; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; *DUP PHARM, 1998, SUST EF CAPS; FISKE WD, 1997, 37 INT C ANT AG CHEM, P275; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kline MW, 1998, J PEDIATR-US, V132, P543, DOI 10.1016/S0022-3476(98)70039-3; Krogstad P, 1999, CLIN INFECT DIS, V28, P1109, DOI 10.1086/514759; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MCKINNEY RE, 1994, J PEDIATR-US, V125, P728, DOI 10.1016/S0022-3476(94)70065-6; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Rutstein RM, 1997, AIDS, V11, pF107, DOI 10.1097/00002030-199712000-00004; WEI LJ, 1985, BIOMETRIKA, V72, P359; Wintergerst U, 1998, PEDIATR INFECT DIS J, V17, P495, DOI 10.1097/00006454-199806000-00012; YOGEV R, 1997, 37 INT C ANT AG CHEM; YONG FH, 1998, 38 INT C ANT AG CHEM, P364; YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602; ZAR JH, 1984, BIOSTAT ANAL, P113; 1998, MMWR MORB MORTAL WKL, V47, P315	24	182	183	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1874	1881		10.1056/NEJM199912163412502	http://dx.doi.org/10.1056/NEJM199912163412502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601506				2022-12-28	WOS:000084210200002
J	Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K				Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K			Ghrelin is a growth-hormone-releasing acylated peptide from stomach	NATURE			English	Article							NATRIURETIC PEPTIDE; RECEPTOR; PITUITARY; RAT; SECRETAGOGUE; BRAIN; NEUROPEPTIDES	Small synthetic molecules called growth-hormone secretagogues (GHSs)(1-3) stimulate the release of growth hormone (GH) from the pituitary(4,5). They act through GHS-R, a G-protein-coupled receptor for which the ligand is unknown. Recent cloning of GHS-R-6,R-7 strongly suggests that an endogenous ligand for the receptor does exist and that there is a mechanism for regulating GH release that is distinct from its regulation by hypothalamic growth-hormone-releasing hormone (GHRH)(4,5). We now report the purification and identification in rat stomach of an endogenous ligand specific for GHS-R. The purified ligand is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated. The acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation at serine 3 is essential for the activity. We designate the GH-releasing peptide 'ghrelin' (ghre is the Proto-Indo-European root of the word 'grow'). Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin.	Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan; Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	Kangawa, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan.							AKMAN MS, 1993, ENDOCRINOLOGY, V132, P1286, DOI 10.1210/en.132.3.1286; ALONSO G, 1988, BRAIN RES, V453, P191, DOI 10.1016/0006-8993(88)90158-8; BERGHE GV, 1999, J CLIN ENDOCR METAB, V84, P1311; Bisi G, 1999, J ENDOCRINOL INVEST, V22, P266, DOI 10.1007/BF03343555; Bowers CY, 1998, CELL MOL LIFE SCI, V54, P1316, DOI 10.1007/s000180050257; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Date Y, 1999, ENDOCRINOLOGY, V140, P2398, DOI 10.1210/en.140.5.2398; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; JONATHAN NB, 1983, METHOD ENZYMOL, V103, P249; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KOJIMA M, 1994, J BIOL CHEM, V269, P13136; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; Smith GD, 1997, EUR HEART J, V18, P6; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0	27	6582	7089	9	332	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					656	660		10.1038/45230	http://dx.doi.org/10.1038/45230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604470				2022-12-28	WOS:000084189800064
J	Grafman, J; Litvan, I				Grafman, J; Litvan, I			Importance of deficits in executive functions	LANCET			English	Editorial Material							DEMENTIA; MANAGEMENT		NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; Henry M Jackson Fdn, Def & Vet Head Injury Program, Cognit Neuropharmacol Unit, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA.		Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445; Grafman, Jordan H./0000-0001-8645-4457				CARLSON DL, 1995, MAYO CLIN PROC, V70, P1108, DOI 10.4065/70.11.1108; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Eccles M, 1998, BMJ-BRIT MED J, V317, P802, DOI 10.1136/bmj.317.7161.802; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Litvan I, 1997, NEUROLOGY, V49, P62, DOI 10.1212/WNL.49.1.62; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; Swartz JR, 1997, J CLIN PSYCHIAT, V58, P212, DOI 10.4088/JCP.v58n0506	11	94	98	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1921	1923		10.1016/S0140-6736(99)90438-5	http://dx.doi.org/10.1016/S0140-6736(99)90438-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622291				2022-12-28	WOS:000084034700005
J	Castro, A				Castro, A			Commentary: increase in caesarean sections may reflect medical control not women's choice	BRITISH MEDICAL JOURNAL			English	Editorial Material							DELIVERY; MEXICO		Harvard Univ, Sch Publ Hlth, Ctr Populat & Dev Studies, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health	Castro, A (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Populat & Dev Studies, Cambridge, MA 02138 USA.		Castro, Arachu/L-6664-2014	Castro, Arachu/0000-0003-0428-9174				BOBADILLA JL, 1991, AM J OBSTET GYNECOL, V164, P22, DOI 10.1016/0002-9378(91)90616-Y; Campero L, 1998, SOC SCI MED, V47, P395, DOI 10.1016/S0277-9536(98)00077-X; CASTRO A, 1998, CESAREAN SECTIONS ME	3	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1401	1402						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10610165				2022-12-28	WOS:000083995200025
J	Smitt, PS; Kinoshita, A; De Leeuw, B; Moll, W; Coesmans, M; Jaarsma, D; Henzen-Logmans, S; Vecht, C; De Zeeuw, C; Sekiyama, N; Nakanishi, S; Shigemoto, R				Smitt, PS; Kinoshita, A; De Leeuw, B; Moll, W; Coesmans, M; Jaarsma, D; Henzen-Logmans, S; Vecht, C; De Zeeuw, C; Sekiyama, N; Nakanishi, S; Shigemoto, R			Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; ENCEPHALOMYELITIS ANTIGEN; SIGNAL TRANSDUCTION; HODGKINS-DISEASE; PURKINJE-CELLS; MGLUR1; MICE; DEGENERATION; EXPRESSION		Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Neurooncol, Rotterdam, Netherlands; Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Pathol, Rotterdam, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Anat, NL-3000 DR Rotterdam, Netherlands; Kyoto Univ, Fac Med, Dept Morphol Brain Sci, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 606, Japan; Natl Inst Physiol Sci, Lab Cerebral Struct, Okazaki, Aichi 444, Japan	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus University Rotterdam; Kyoto University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Smitt, PS (corresponding author), Dr Daniel Den Hoed Canc Ctr, Dept Neurooncol, POB 5201, NL-3008 AE Rotterdam, Netherlands.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				ABE T, 1992, J BIOL CHEM, V267, P13361; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BRUNNER RL, 1973, BEHAV BIOL, V9, P169, DOI 10.1016/S0091-6773(73)80154-3; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; FOTUHI M, 1993, J NEUROSCI, V13, P2001; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; GRAUS F, 1991, J NEUROL SCI, V106, P82, DOI 10.1016/0022-510X(91)90198-G; Graus F, 1997, J NEUROIMMUNOL, V74, P55, DOI 10.1016/S0165-5728(96)00205-6; HAMMACK J, 1992, NEUROLOGY, V42, P1938; Henson RA., 1982, CANC NERVOUS SYSTEM, P346; KOBAYASHI K, 1995, P NATL ACAD SCI USA, V92, P1132, DOI 10.1073/pnas.92.4.1132; LANG B, 1981, LANCET, V2, P224; Lang B, 1996, CURR OPIN IMMUNOL, V8, P865, DOI 10.1016/S0952-7915(96)80017-3; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; MOLL JWB, 1995, NEUROLOGY, V45, P1937, DOI 10.1212/WNL.45.10.1937; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SMITT PAES, 1995, NEUROLOGY, V45, P1873; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TOYKA KV, 1975, SCIENCE, V190, P397, DOI 10.1126/science.1179220; WELSH JP, 1995, NATURE, V374, P453, DOI 10.1038/374453a0	28	292	299	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					21	27		10.1056/NEJM200001063420104	http://dx.doi.org/10.1056/NEJM200001063420104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620645				2022-12-28	WOS:000084575600004
J	Ferguson, H				Ferguson, H			Body piercing	BRITISH MEDICAL JOURNAL			English	Article											Ferguson, H (corresponding author), POB 32, Great Yarmouth NR29 5RD, Norfolk, England.							Ferguson H, 1994, BODY ART, V20, P24; 1994, BODY ART, V20, P39; 1994, BODY ART, V19, P34	3	57	59	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1627	1629		10.1136/bmj.319.7225.1627	http://dx.doi.org/10.1136/bmj.319.7225.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600973	Green Published			2022-12-28	WOS:000084562600024
J	Froggatt, P				Froggatt, P			Medicine in Ulster in relation to the great famine and "the troubles"	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	BMA Annual Representative Meeting	JUL   07, 1999	BELFAST, NORTH IRELAND						Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast	Froggatt, P (corresponding author), 3 Strangford Ave, Belfast BT9 6PG, Antrim, North Ireland.							CROCKARD HA, 1974, ANN ROY COLL SURG, V55, P111; CUSACK JW, 1848, DUBLIN J MED SCI, V5, P111; Froggatt P, 1995, J Ir Coll Physicians Surg, V24, P291; FROGGATT P, 1985, ULSTER MED J, V54, P89; FROGGATT P, 1989, FAMINE : THE IRISH EXPERIENCE 900-1900, P134; Johnstone R J, 1937, Br Med J, V2, P151; MCARTHUR WP, 1956, GREAT FAMINE STUDIES, P263; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; WHITLA W, 1909, BRIT MED J, V2, P249; Wilde WR, 1849, DUBLIN J MED SCI, V7, P64; Wilde WR, 1849, DUBLIN J MED SCI, V7, P340	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1636	1639		10.1136/bmj.319.7225.1636	http://dx.doi.org/10.1136/bmj.319.7225.1636			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600977	Green Published			2022-12-28	WOS:000084562600028
J	Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E				Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E			Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal	BRITISH MEDICAL JOURNAL			English	Article								Objective To find out whether taking images of the male and female genitals during coitus is feasible and to find out whether former and current ideas about the anatomy during sexual intercourse and during female sexual arousal are based on assumptions or on facts. Design Observational study Setting University hospital in the Netherlands. Methods Magnetic resonance imaging was used to study are female sexual response and the male and female genitals during coitus. Thirteen experiments were performed with eight couples and three single women. Results The images obtained showed that during intercourse in the "missionary position" the penis has the shape of a boomerang and 1/3 of its length consists of the root of the penis. During female sexual arousal without intercourse the uterus was raised and the anterior vaginal wall lengthened. The size of the uterus did not increase during sexual arousal. Conclusion Taking magnetic resonance images of the male and female genitals during coitus is feasible and contributes to understanding of anatomy.	Univ Groningen Hosp, Dept Gynaecol, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Lab Cell Biol & Electron Microscopy, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Dept Radiol, NL-9700 RB Groningen, Netherlands; Dept Business Anthropol VU, NL-1081 HV Amsterdam, Netherlands	University of Groningen; University of Groningen; University of Groningen	Schultz, WW (corresponding author), Univ Groningen Hosp, Dept Gynaecol, POB 30 001, NL-9700 RB Groningen, Netherlands.	w.c.m.weymar.schultz@oprit.rug.nl	Sabelis, Ida/F-8893-2013; Sabelis, Ida/G-4830-2013	Sabelis, Ida/0000-0003-0109-0127; Sabelis, Ida/0000-0003-0109-0127				ALZATE H, 1984, J SEX MARITAL THER, V10, P49, DOI 10.1080/00926238408405789; CHIANCHI M, 1998, LEONARDO ANATOMY, P56; Clark K, 1968, CATALOGUE DRAWINGS L, V2nd; Dickinson RL, 1949, HUMAN SEX ANATOMY TO, P84; FLECK L, 1979, GENESIS DEV SCI FACT, P35; HILLIGES M, 1995, ACTA ANAT, V153, P119; HOCH Z, 1986, ACTA OBSTET GYN SCAN, V65, P767, DOI 10.3109/00016348609161498; Johnson Virginia E., 1964, MANUAL CONTRACEPTIVE, P138; KRANTZ KE, 1958, OBSTET GYNECOL, V12, P382; LEVIN RJ, 1998, INT J IMPOT RES S1, V10, P14; Masters WH., 1966, HUMAN SEXUAL RESPONS; MINH MH, 1981, CAHIERS SEXUOL CLIN, V7, P169; O'Connell HE, 1998, J UROLOGY, V159, P1892, DOI 10.1016/S0022-5347(01)63188-4; RILEY AJ, 1992, INT CONGR SER, P29; SCHULTZ WCMW, 1989, ARCH SEX BEHAV, V18, P87, DOI 10.1007/BF01543115; SOHN MH, 1991, IMPOTENCE RES, V3, P36; VANANDEL P, 1994, BRIT J PHILOS SCI, V45, P631	17	74	75	6	87	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1596	1600		10.1136/bmj.319.7225.1596	http://dx.doi.org/10.1136/bmj.319.7225.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600954	Bronze, Green Published			2022-12-28	WOS:000084562600007
J	Bloj, MG; Kersten, D; Hurlbert, AC				Bloj, MG; Kersten, D; Hurlbert, AC			Perception of three-dimensional shape influences colour perception through mutual illumination	NATURE			English	Article							BRIGHTNESS; CONSTANCY	Objects in the natural world possess different visual attributes, including shape, colour, surface texture and motion. Previous perceptual studies have assumed that the brain analyses the colour of a surface independently of its three-dimensional shape and viewing geometry(1,2), although there are neural connections between colour and two-dimensional form processing early in the visual pathway(3,4). Here we show that colour perception is strongly influenced by three-dimensional shape perception in a novel, chromatic version of the Mach Card-a concave folded card with one side made of magenta paper and the other of white paper. The light reflected from the magenta paper casts a pinkish glow on the white side. The perceived colour of the white side changes from pale pink to deep magenta when the perceived shape of the card flips from concave to convex. The effect demonstrates that the human visual system incorporates knowledge of mutual illumination-the physics of light reflection between surfaces-at an early stage in colour perception.	Med Sch Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA	Newcastle University - UK; University of Minnesota System; University of Minnesota Twin Cities	Hurlbert, AC (corresponding author), Med Sch Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Hurlbert, Anya/I-5243-2012; Bloj, Marina/F-1081-2010	Hurlbert, Anya/0000-0002-9879-5758; Bloj, Marina/0000-0001-9251-0750	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELSON EH, 1993, SCIENCE, V262, P2042, DOI 10.1126/science.8266102; AREND L, 1986, J OPT SOC AM A, V3, P1743, DOI 10.1364/JOSAA.3.001743; BECK J, 1965, J EXP PSYCHOL, V69, P170, DOI 10.1037/h0021571; Bloj M. G., 1999, IOVS, V40, pS981; BLOJ MG, 1995, INVEST OPHTH VIS SCI, V36, P5639; Efron B., 1994, MONOGRAPHS STAT APPL; FORSYTH D, 1990, IMAGE VISION COMPUT, V8, P42, DOI 10.1016/0262-8856(90)90055-A; FREEMAN WT, 1994, NATURE, V368, P542, DOI 10.1038/368542a0; FUNT BV, 1991, INT J COMPUT VISION, V6, P5, DOI 10.1007/BF00127123; Gegenfurtner KR, 1996, VISUAL NEUROSCI, V13, P161, DOI 10.1017/S0952523800007203; GILCHRIST A, 1983, PERCEPT PSYCHOPHYS, V33, P425, DOI 10.3758/BF03202893; GILCHRIST AL, 1977, SCIENCE, V195, P185, DOI 10.1126/science.831266; KNILL DC, 1991, NATURE, V351, P228, DOI 10.1038/351228a0; Knill DC, 1996, PERCEPTION BAYESIAN; Kraft JM, 1999, P NATL ACAD SCI USA, V96, P307, DOI 10.1073/pnas.96.1.307; Mach E., 1959, ANAL SENSATIONS; NAYAR SK, 1991, INT J COMPUT VISION, V6, P173, DOI 10.1007/BF00115695; NUBERG ND, 1971, BIOPHYSICS-USSR, V16, P285; RAMACHANDRAN VS, 1988, NATURE, V331, P163, DOI 10.1038/331163a0; TROOST JM, 1998, PERCEPTUAL CONSTANCY; Williams SM, 1998, P NATL ACAD SCI USA, V95, P13296, DOI 10.1073/pnas.95.22.13296; Wyszecki G., 2000, COLOR SCI CONCEPTS M, V2nd ed., P117; ZEKI S, 1989, EUR J NEUROSCI, V1, P494, DOI 10.1111/j.1460-9568.1989.tb00356.x	23	189	189	1	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					877	879		10.1038/47245	http://dx.doi.org/10.1038/47245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622251				2022-12-28	WOS:000084482000033
J	DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ				DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ			Transport-dependent proteolysis of SREBP: Relocation of Site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi	CELL			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; BOUND TRANSCRIPTION FACTOR; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; STEROL RESISTANCE; MEMBRANE-PROTEIN; BREFELDIN-A; IDENTIFICATION; SECRETION	Cholesterol homeostasis in animal cells is achieved by regulated cleavage of membrane-bound transcription factors, designated SREBPs. Proteolytic release of the active domains of SREBPs from membranes requires a sterol-sensing protein, SCAP, which forms a complex with SREBPs. In sterol-depleted cells, SCAP escorts SREBPs from ER to Golgi, where SREBPs are cleaved by Site-1 protease (S1P). Sterols block this transport and abolish cleavage. Relocating active S1P from Golgi to ER by treating cells with brefeldin A or by fusing the ER retention signal KDEL to S1P obviates the SCAP requirement and renders cleavage insensitive to sterols. Transport-dependent proteolysis may be a common mechanism to regulate the processing of membrane proteins.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Nohturfft, Axel/0000-0001-9484-3209	NHLBI NIH HHS [HL-09993, HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL009993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLLAG DM, 1991, PROTEIN METHODS, P1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Harlow E., 1999, USING ANTIBODIES LAB, P1; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KOMFELD R, 1985, ANNU REV BIOCHEM, V54, P631; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PELHAM HRB, 1992, P ROY SOC B-BIOL SCI, V250, P1, DOI 10.1098/rspb.1992.0123; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	37	244	250	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					703	712		10.1016/S0092-8674(00)81668-2	http://dx.doi.org/10.1016/S0092-8674(00)81668-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619424	Bronze			2022-12-28	WOS:000084488200004
J	Appelboom, T; Struyven, J				Appelboom, T; Struyven, J			Medical imaging of the Peruvian mummy Rascar Capac	LANCET			English	Editorial Material									Erasme Univ Hosp, Div Rheumatol, B-1070 Brussels, Belgium; Erasme Univ Hosp, Dept Radiol, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Appelboom, T (corresponding author), Erasme Univ Hosp, Div Rheumatol, 808 Route Lennik, B-1070 Brussels, Belgium.							ASSOULINE Pierre, 1996, HERGE BIOGRAPHIE; CHARLES C, 1987, MED PRECOLOMBIENNE; Cockburn A., 1998, MUMMIES DIS ANCIENT; Gaber O, 1998, EXP GERONTOL, V33, P655, DOI 10.1016/S0531-5565(98)00048-5; HERGE, 1949, TEMPLE SOLEIL; MICHEL G, 1997, B SEANCES ARSOM KAOW, V43, P269; WIENER C, 1880, RECIT VOYAGES; 1938, NAT GEOGR MAG, V73, P224	8	20	20	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2153	2155		10.1016/S0140-6736(99)07113-5	http://dx.doi.org/10.1016/S0140-6736(99)07113-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609834				2022-12-28	WOS:000084318200045
J	Foley, D				Foley, D			Sorting out sleep in patients with Alzheimer's disease	LANCET			English	Editorial Material									NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Foley, D (corresponding author), NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA.							ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; Bliwise DL, 1996, J AM GERIATR SOC, V44, P1407; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Foley DJ, 1999, J AM GERIATR SOC, V47, P524, DOI 10.1111/j.1532-5415.1999.tb02564.x; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; McCurry SM, 1999, J GERIATR PSYCH NEUR, V12, P53, DOI 10.1177/089198879901200203; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; Redline S, 1998, SLEEP, V21, P759; Taylor, 1997, Semin Clin Neuropsychiatry, V2, P113; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; VITIELLO MV, 1992, NEUROLOGY, V42, P83; Wilcox S, 1999, J GERONTOL B-PSYCHOL, V54, pP189, DOI 10.1093/geronb/54B.3.P189	12	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2098	2099		10.1016/S0140-6736(99)00413-4	http://dx.doi.org/10.1016/S0140-6736(99)00413-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609812				2022-12-28	WOS:000084318200006
J	Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD				Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD			A structural change in the kinesin motor protein that drives motility	NATURE			English	Article							CRYSTAL-STRUCTURE; DIMERIC KINESIN; MYOSIN MOTOR; CRYOELECTRON MICROSCOPY; ATP HYDROLYSIS; MICROTUBULE; DOMAIN; MECHANISM; COMPLEX; NCD	Kinesin motors power many motile processes by converting ATP energy into unidirectional motion along microtubules, The force-generating and enzymatic properties of conventional kinesin have been extensively studied; however, the structural basis of movement is unknown. Here we have detected and visualized a large conformational change of a similar to 15-amino-acid region (the neck linker) in kinesin using electron paramagnetic resonance, fluorescence resonance energy transfer, pre-steady state kinetics and cryo-electron microscopy, This region becomes immobilized and extended towards the microtubule 'plus' end when kinesin binds microtubules and ATP, and reverts to a more mobile conformation when gamma-phosphate is released after nucleotide hydrolysis, This conformational change explains both the direction of kinesin motion and processive movement by the kinesin dimer.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Washington State Univ, Dept Pure & Appl Math, Pullman, WA 99164 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute; University of Pennsylvania; University of Illinois System; University of Illinois Urbana-Champaign; University of Chicago; Washington State University	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.uscf.edu	Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Carragher, Bridget/0000-0002-0624-5020				AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BARNETT VA, 1986, BIOPHYS J, V49, P144, DOI 10.1016/S0006-3495(86)83628-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; HOENGER A, 1998, CURR BIOL, V8, P191; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Marx A, 1998, EUR BIOPHYS J BIOPHY, V27, P455, DOI 10.1007/s002490050156; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 1997, BIOCHEMISTRY-US, V36, P9681, DOI 10.1021/bi9706881; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Safer D, 1999, J STRUCT BIOL, V127, P101, DOI 10.1006/jsbi.1999.4110; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; THOMAS DD, 1995, BIOPHYS J, V68, pS135; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	50	618	642	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					778	784		10.1038/45483	http://dx.doi.org/10.1038/45483			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617199				2022-12-28	WOS:000084330500055
J	Crescentini, L; Amoruso, A; Scarpa, R				Crescentini, L; Amoruso, A; Scarpa, R			Constraints on slow earthquake dynamics from a swarm in central Italy	SCIENCE			English	Article							MACQUARIE RIDGE EARTHQUAKE; SAN-ANDREAS FAULT; STRESS REDISTRIBUTION; CALIFORNIA; PRECURSOR; SEQUENCE	Several clustered slow earthquakes have been recorded by a geodetic interferometer in central Italy. The strain rise times of the events range from tens to thousands of seconds, and the seismic moment scales with the square root of the rise time. This scaling law contrasts with the conservative assumption of constant rupture velocity in fault modeling but is consistent with the occurrence of a slow rupture propagation analogous to heat diffusion in a slab.	Univ Camerino, Dipartimento Sci Terra, I-62032 Camerino, MC, Italy; Ist Nazl Fis Nucl, Lab Nazl Gran Sasso, Laquila, Italy; Univ Aquila, Dipartimento Fis, I-67100 Laquila, Italy	University of Camerino; Gran Sasso Science Institute (GSSI); Istituto Nazionale di Fisica Nucleare (INFN); University of L'Aquila	Crescentini, L (corresponding author), Univ Camerino, Dipartimento Sci Terra, I-62032 Camerino, MC, Italy.		Crescentini, Luca/AAU-6323-2020; Amoruso, Antonella/AAS-1771-2020; Scarpa, Roberto/AAE-9877-2019	Crescentini, Luca/0000-0002-6877-0074; Amoruso, Antonella/0000-0002-1108-8365; 				Amato A, 1998, GEOPHYS RES LETT, V25, P2861, DOI 10.1029/98GL51842; Amoruso A, 1998, J GEOPHYS RES-SOL EA, V103, P29989, DOI 10.1029/98JB02849; AMORUSO A, IN PRESS GEOPHYS J I; CAPUTO M, 1977, ANN GEOPHYS, V130, P125; Crescentini L, 1997, REV SCI INSTRUM, V68, P3206, DOI 10.1063/1.1148268; DENATALE G, 1988, GEOPHYS J INT, V95, P285, DOI 10.1111/j.1365-246X.1988.tb00467.x; GLADWIN MT, 1994, J GEOPHYS RES-SOL EA, V99, P4559, DOI 10.1029/93JB02877; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; IHMLE PF, 1994, SCIENCE, V266, P1547, DOI 10.1126/science.266.5190.1547; IHMLE PF, 1993, SCIENCE, V261, P177, DOI 10.1126/science.261.5118.177; JORDAN TH, 1991, GEOPHYS RES LETT, V18, P2019, DOI 10.1029/91GL02414; KANAMORI H, 1992, B SEISMOL SOC AM, V82, P2087; KASAHARA K, 1981, EARTHQUAKE MECH, P28; KAWASAKI I, 1995, J PHYS EARTH, V43, P105, DOI 10.4294/jpe1952.43.105; KEDAR S, 1994, J GEOPHYS RES-SOL EA, V99, P17893, DOI 10.1029/94JB01251; LIENHARD JH, 1981, HEAT TRANSFER TXB, P152; Linde AT, 1996, NATURE, V383, P65, DOI 10.1038/383065a0; MANTOVANI E, 1986, PHYS EARTH PLANET IN, V44, P264, DOI 10.1016/0031-9201(86)90075-0; Marone C, 1998, ANNU REV EARTH PL SC, V26, P643, DOI 10.1146/annurev.earth.26.1.643; MARZOCCHI W, 1995, GEOPHYS RES LETT, V22, P29, DOI 10.1029/94GL02792; McGuire JJ, 1996, SCIENCE, V274, P82, DOI 10.1126/science.274.5284.82; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; ROMANOWICZ B, 1993, B SEISMOL SOC AM, V83, P1294; SACKS IS, 1982, TECTONOPHYSICS, V81, P311, DOI 10.1016/0040-1951(82)90135-4; SACKS IS, 1978, NATURE, V275, P599, DOI 10.1038/275599a0; SACKS IS, 1981, M EWING SERIES, V4, P617; SCARPA R, 1985, EARTHQ PREDICT RES, V1, P81; Scholz CH, 1998, NATURE, V391, P37, DOI 10.1038/34097	28	55	56	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2132	2134		10.1126/science.286.5447.2132	http://dx.doi.org/10.1126/science.286.5447.2132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591639				2022-12-28	WOS:000084157300044
J	Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR				Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR			The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder	CELL			English	Article							FIELD GEL-ELECTROPHORESIS; ACTIVATED PROTEIN-KINASE; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; HUMAN FIBROBLASTS; HUMAN MRE11; CELLS; YEAST; IDENTIFICATION	We show that hypomorphic mutations in hMRE11, but not in ATM, are present in certain individuals with an ataxia-telangiectasia-like disorder (ATLD). The cellular features resulting from these hMRE11 mutations are similar to those seen in A-T as well as NBS and include hypersensitivity to ionizing radiation, radioresistant DNA synthesis, and abrogation of ATM-dependent events, such as the activation of Jun kinase following exposure to gamma irradiation. Although the mutant hMre11 proteins retain some ability to interact with hRad50 and Nbs1, formation of ionizing radiation-induced hMre11 and Nbs1 fool was absent in hMRE11 mutant cells. These data demonstrate that ATM and the hMre11/h Rad50/Nbs1 protein complex act in the same DNA damage response pathway and link hMre11 to the complex pathology of A-T.	Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Wisconsin, Sch Med, Madison, WI 53706 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of Birmingham; University of Wisconsin System; University of Wisconsin Madison; Erasmus University Rotterdam	Taylor, AMR (corresponding author), Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	jpetrini@facstaff.wisc.edu; a.m.r.taylor@bham.ac.uk	Maser, Richard/B-2970-2012	Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056888, R01GM059413, R37GM059413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59413, GM56888] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGER DD, 1990, INT J RADIAT BIOL, V58, P249, DOI 10.1080/09553009014551601; AJIMURA M, 1993, GENETICS, V133, P51; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel FM, 1988, MOL REPROD DEV; Bressan DA, 1998, GENETICS, V150, P591; BRESSAN DA, 1999, IN PRESS MOL CELL BI; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; JASPERS NGJ, 1982, CANCER RES, V42, P335; Jorgensen TJ, 1996, INT J RADIAT BIOL, V69, P527, DOI 10.1080/095530096145535; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLEIJER WJ, 1994, INT J RADIAT BIOL, V66, pS167, DOI 10.1080/09553009414552001; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McConville CM, 1996, AM J HUM GENET, V59, P320; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; NOVE J, 1986, MUTAT RES, V163, P255, DOI 10.1016/0027-5107(86)90023-0; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; RYDBERG B, 1994, RADIAT RES, V139, P133, DOI 10.2307/3578657; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Taylor A. M. R., 1996, P138; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamazaki V, 1998, CANCER RES, V58, P2316; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	46	777	793	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					577	587		10.1016/S0092-8674(00)81547-0	http://dx.doi.org/10.1016/S0092-8674(00)81547-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612394	Bronze			2022-12-28	WOS:000084278700005
J	Ren, SL; Liang, P; Zu, GA				Ren, SL; Liang, P; Zu, GA			Scientific publications - The challenge for Chinese scientific journals	SCIENCE			English	Article									Natl Nat Sci Fdn China, Dept Publicat, Beijing 100083, Peoples R China	National Natural Science Foundation of China (NSFC)	Ren, SL (corresponding author), Natl Nat Sci Fdn China, Dept Publicat, 35 Huayang Beilu,E Gate,Haidian Dist, Beijing 100083, Peoples R China.							Butler D, 1999, NATURE, V398, P735, DOI 10.1038/19570; Butler D, 1999, NATURE, V400, P97, DOI 10.1038/21948; Butler D, 1999, NATURE, V399, P292, DOI 10.1038/20511; MACILWAIN C, 1999, NATURE, V399, P8; REN SL, 1998, ACTA EDITOL, V10, P152; Saegusa A, 1999, NATURE, V400, P491, DOI 10.1038/22835; Seglen PO, 1997, BRIT MED J, V314, P498; SHI CX, 1997, CHINESE SCI BULL, V42, P888; Strauss E, 1999, SCIENCE, V285, P1466; TESTA J, ISI DATABASE J SELEC; ZHANG BH, 1999, COMPLETE COLLECTION; ZOU CL, 1998, CHINESE SCI TIM 0518, P3; 1998, J ISI J CITATION REP	13	12	15	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1683	1683		10.1126/science.286.5445.1683	http://dx.doi.org/10.1126/science.286.5445.1683			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10610564				2022-12-28	WOS:000083912200019
J	Kinra, S; Okasha, M				Kinra, S; Okasha, M			Unsafe sax: cohort study of the impact of too much sax on the mortality of famous jazz musicians	BRITISH MEDICAL JOURNAL			English	Article									S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England	University of Bristol	Kinra, S (corresponding author), S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England.							CARR I, 1998, JAZZ ROUGH GUIDE; COOK R, 1994, PENGUIN GUIDE JAZZ; FORDHAM J, 1993, ANATOMY INSTRUMENTS, P60	3	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1612	1613		10.1136/bmj.319.7225.1612	http://dx.doi.org/10.1136/bmj.319.7225.1612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600961	Green Published, Bronze			2022-12-28	WOS:000084562600015
J	Bodenheimer, T; Casalino, L				Bodenheimer, T; Casalino, L			Executives with white coats - The work and world view of managed-care medical directors (second of two parts)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Stanford Coastside Med Clin, Half Moon Bay, CA USA	University of California System; University of California San Francisco; Stanford University	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				Bindman AB, 1998, JAMA-J AM MED ASSOC, V279, P675, DOI 10.1001/jama.279.9.675; Bindman AB, 1999, JAMA-J AM MED ASSOC, V281, P2142, DOI 10.1001/jama.281.22.2142; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; *HARV U SCH PUBL H, SURV PHYS NURS; PEENO L, 1998, US NEWS WORLD R 0309; PITURRO M, 1999, MANAGED HEALTHCARE N, V15, P22	6	13	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					2029	2032		10.1056/NEJM199912233412623	http://dx.doi.org/10.1056/NEJM199912233412623			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607824				2022-12-28	WOS:000084399400028
J	Gale, CR; Braidwood, EA; Winter, PD; Martyn, CN				Gale, CR; Braidwood, EA; Winter, PD; Martyn, CN			Mortality from Parkinson's disease and other causes in men who were prisoners of war in the Far East	LANCET			English	Article							FORMER PRISONERS; FOLLOW-UP; RISK; JAPANESE	Background During World War II, more than 140 000 Allied prisoners of war (POWs) were held captive by the Japanese in conditions of extreme privation. There have been concerns that the survivors are at increased risk of degenerative neurological disorders, especially Parkinson's disease. We assembled a cohort of British ex-POWs and analysed their mortality in a 46-year follow-up study. Methods Using records held by the War Pensions Agency, we abstracted data on 11915 British former POWs. 11134 men were traced, and observed numbers of deaths between 1952 and 1997 were compared with those expected from national rates for the male population of England and Wales. Standardised mortality ratios (SMR) were calculated. Findings Overall, mortality was lower than expected (7474 deaths vs 8796.2 expected; SMR 0.85 [95% CI 0.83-0.87]). Death rates from Parkinson's disease among the former POWs were slightly below the national average, though this difference was not statistically significant (35 deaths vs 43.2 expected; SMR 0.81 [0.56-1.13]). A similar pattern was seen for other degenerative neurological disorders (motorneuron disease 0.62 [0.31-1.11], multiple sclerosis 0.88 [0.42-1.61], and dementia 0.88 [0.68-1.11]). The former POWs had significantly lower than expected mortality from all major causes of death (ischaemic heart disease 0.81 [0.78-0.85], cerebrovascular disease 0.88 [0.81-0.95], all malignant neoplasms 0.92 [0.88-0.95], and respiratory disease 0.79 [0.74-0.85]). They also had below average rates of death from tuberculosis (0.44 [0.26-0.71]) and suicide (0.77 [0.57-1.02]), though the latter relation was not statistically significant. Mortality from diseases of the liver was increased (chronic liver disease and cirrhosis 1.68 [1.28-2.17], primary carcinoma of the liver 2.42 [1.75-3.26]). Interpretation There is little evidence that men who were POWs in the Far East have higher rates of death than the male population generally. The only exception is diseases of the liver, which may be due to infection with hepatitis B or C virus during captivity. Death-certification data cannot provide a complete picture of physical and mental health, but the period of severe malnutrition, frequent infections, exhaustion, and intense psychological stress seems not to have increased susceptibility to neurodegenerative disease.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Dept Social Secur, Blackpool, Lancs, England	University of Southampton	Martyn, CN (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	cnm@mrc.soton.ac.uk	Gale, Catharine R/B-1653-2012					BEEBE GW, 1975, AM J EPIDEMIOL, V101, P400, DOI 10.1093/oxfordjournals.aje.a112108; BURGESS RC, 1946, LANCET, V251, P411; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; Creasey H, 1999, J AM GERIATR SOC, V47, P60, DOI 10.1111/j.1532-5415.1999.tb01901.x; DENNYBROWN D, 1947, MEDICINE, V26, P41, DOI 10.1097/00005792-194702000-00002; FREED G, 1968, AUST REPAT DEPT MED, V2, P1; GIBBERD FB, 1980, LANCET, V2, P135; Gill G, 1997, LANCET, V350, P1247, DOI 10.1016/S0140-6736(05)63478-2; GILL GV, 1981, PRACTITIONER, V225, P531; GILL GV, 1991, POSTGRAD MED J, V67, P39, DOI 10.1136/pgmj.67.783.39; GILL GV, 1982, J NEUROL NEUROSUR PS, V45, P861, DOI 10.1136/jnnp.45.10.861; GUEST CS, 1992, MED J AUSTRALIA, V157, P132, DOI 10.5694/j.1326-5377.1992.tb137048.x; HILL ID, 1972, BRIT J PREV SOC MED, V26, P132; KEEHN RJ, 1980, AM J EPIDEMIOL, V111, P194, DOI 10.1093/oxfordjournals.aje.a112887; PAGE WF, 1991, J NERV MENT DIS, V179, P670, DOI 10.1097/00005053-199111000-00004; Phillips NJ, 1999, J EPIDEMIOL COMMUN H, V53, P587, DOI 10.1136/jech.53.9.587; SMITH CI, 1987, MED J AUSTRALIA, V147, P229, DOI 10.5694/j.1326-5377.1987.tb133414.x; SPENCER PS, 1987, CAN J NEUROL SCI, V14, P347, DOI 10.1017/S0317167100037732; STERLING TD, 1986, J OCCUP ENVIRON MED, V28, P348; TENNANT C, 1986, PSYCHOL MED, V16, P833, DOI 10.1017/S0033291700011843; WATSON P, 1982, STUDY POST CAPITIVIT	22	29	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1999	354	9196					2116	2118		10.1016/S0140-6736(99)06264-9	http://dx.doi.org/10.1016/S0140-6736(99)06264-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609817				2022-12-28	WOS:000084318200013
J	Thursz, M; Yallop, R; Goldin, R; Trepo, C; Thomas, HC				Thursz, M; Yallop, R; Goldin, R; Trepo, C; Thomas, HC		HENCORE Grp	Influence of MHC class II genotype on outcome of infection with hepatitis C virus	LANCET			English	Article							NONSTRUCTURAL PROTEIN-3; NATURAL-HISTORY; B VIRUS; HLA; CLEARANCE; ANTIGENS; ASSOCIATION; ALLELES; DISEASE; GENES	Background The outcome of infection with hepatitis C virus (HCV) varies substantially among individuals. Host genetic factors are likely to give rise to some of this variability. Polymorphisms in the MHC class II loci may influence the outcome of HCV infection; however, reports of MHC class II allele associations have been inconsistent. We aimed to confirm these associations in a cohort of European patients with different clinical outcomes. Methods The distribution of MHC class II alleles was compared between patients with self-limiting infection (n=85) and matched patients with persistent infection (n=170); between patients with mild (n=321) and severe (n=321) histological injury; and between patients who responded to interferon (n=96) and those who did not (n=192). The results of these comparisons were confirmed with a second-stage study of self-limiting infection (n=52) versus persistent infection (n=152), Findings Self-limiting HCV infection was associated with HLA-DRB1*1101 (odds ratio 2.14 [95% CI 1.11-4.12]; p=0.013) and HLA-DQB1*0301 (2.22 [1.24-3.96], p=0.004). Persistent HCV infection was associated with HLA-DRB1*0701 (2.04 [1.03-4.17], p=0.027), and HLA-DRB4*0101 (2.38 [1.29-4.35], p=0.002), These results were confirmed in the second-stage study. No significant associations (p<0.05 after Bonferroni correction) were found between MHC class II alleles and severe histological injury or response to interferon therapy. Interpretation Specific MHC class II alleles influence susceptibility or resistance to persistent HCV infection.	St Marys Hosp, Sch Med, Hepatol Sect, Div Med A,Imperial Coll, London W2 1NY, England; Hop Lyon, Lyon, France	Imperial College London; CHU Lyon	Thursz, M (corresponding author), St Marys Hosp, Sch Med, Hepatol Sect, Div Med A,Imperial Coll, London W2 1NY, England.	m.thurz@ic.ac.uk	Thomas, Howard C/A-3152-2009; Yang, Chen/G-1379-2010	Thursz, Mark/0000-0002-8218-192X; Goldin, Robert/0000-0001-5184-4519				Aikawa T, 1996, J MED VIROL, V49, P274, DOI 10.1002/(SICI)1096-9071(199608)49:4&lt;274::AID-JMV3&gt;3.0.CO;2-0; ALMARRI A, 1994, LANCET, V344, P1194, DOI 10.1016/S0140-6736(94)90510-X; Alric L, 1997, GASTROENTEROLOGY, V113, P1675, DOI 10.1053/gast.1997.v113.pm9352872; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Bismuth H, 1992, Clin Transpl, P161; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Chen DF, 1996, LIVER, V16, P384; Colantoni A, 1996, BAILLIERE CLIN GASTR, V10, P375, DOI 10.1016/S0950-3528(96)90011-1; Congia M, 1996, HEPATOLOGY, V24, P1338, DOI 10.1002/hep.510240603; Cramp M. E., 1998, Journal of Hepatology, V28, P94, DOI 10.1016/S0168-8278(98)80573-4; Cramp ME, 1998, J HEPATOL, V29, P207, DOI 10.1016/S0168-8278(98)80005-6; Czaja AJ, 1996, J HEPATOL, V24, P666, DOI 10.1016/S0168-8278(96)80261-3; Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Higashi Y, 1996, J GASTROEN HEPATOL, V11, P241, DOI 10.1111/j.1440-1746.1996.tb00069.x; HOFFMANN RM, 1995, HEPATOLOGY, V21, P632, DOI 10.1002/hep.1840210305; Hohler T, 1997, J HEPATOL, V27, P259, DOI 10.1016/S0168-8278(97)80169-9; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JUNG MC, 1994, EUR J CLIN INVEST, V24, P641, DOI 10.1111/j.1365-2362.1994.tb01055.x; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Kuzushita N, 1996, J MED VIROL, V48, P1; McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57; Minton EJ, 1998, J INFECT DIS, V178, P39, DOI 10.1086/514258; PEANO G, 1994, ARCH INTERN MED, V154, P2733, DOI 10.1001/archinte.1994.00420230126015; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Simmonds P, 1998, CURR STUD HEMATOL BL, P38; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; Thursz MR, 1997, NAT GENET, V17, P11, DOI 10.1038/ng0997-11; Tibbs C, 1996, HEPATOLOGY, V24, P1342, DOI 10.1002/hep.510240604; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; VITTE RL, 1995, TISSUE ANTIGENS, V45, P356, DOI 10.1111/j.1399-0039.1995.tb02467.x; Zavaglia C, 1996, J HEPATOL, V24, P658, DOI 10.1016/S0168-8278(96)80260-1	33	243	258	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1999	354	9196					2119	2124		10.1016/S0140-6736(99)91443-5	http://dx.doi.org/10.1016/S0140-6736(99)91443-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609818				2022-12-28	WOS:000084318200014
J	Weller, R; O'Callaghan, CJ; MacSween, RM; White, MI				Weller, R; O'Callaghan, CJ; MacSween, RM; White, MI			Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation	BRITISH MEDICAL JOURNAL			English	Article									Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England; Royal Infirm, Dept Dermatol, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England; Aberdeen Royal Infirm, Dept Dermatol, Aberdeen AB25 2ZN, Scotland	University of Nottingham; Royal Infirmary of Edinburgh; University of Warwick; University of Aberdeen	MacSween, RM (corresponding author), Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England.		Weller, Richard/B-4954-2010	Weller, Richard/0000-0003-2550-9586				FIELD LM, 1980, JAMA-J AM MED ASSOC, V243, P2526; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HAWLEY T G, 1970, Journal of Hygiene, V68, P631; POSTLETH.R, 1970, ARCH ENVIRON HEALTH, V21, P432, DOI 10.1080/00039896.1970.10667262; SMITH EB, 1982, MED CLIN N AM, V66, P807, DOI 10.1016/S0025-7125(16)31395-5	5	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1540	1540		10.1136/bmj.319.7224.1540	http://dx.doi.org/10.1136/bmj.319.7224.1540			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591712	Bronze, Green Published			2022-12-28	WOS:000084245600023
J	Roth, MG				Roth, MG			Inheriting the Golgi	CELL			English	Review							CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM; MITOTIC FRAGMENTATION; BREFELDIN-A; HELA-CELLS; MITOSIS; STACKS; MEMBRANES; APPARATUS; PROTEINS		Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roth, MG (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA.			Roth, Michael/0000-0002-9056-332X				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Farmaki T, 1999, J CELL SCI, V112, P589; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	20	28	28	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					559	562		10.1016/S0092-8674(00)81544-5	http://dx.doi.org/10.1016/S0092-8674(00)81544-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612391	Bronze			2022-12-28	WOS:000084278700002
J	Zhou, JM; Levine, M				Zhou, JM; Levine, M			A novel cis-regulatory element, the PTS, mediates an anti-insulator activity in the Drosophila embryo	CELL			English	Article							CHROMATIN DOMAIN BOUNDARY; BITHORAX COMPLEX; ABDOMINAL-B; MOLECULAR ANALYSIS; GENE-EXPRESSION; MELANOGASTER; ENHANCER; REPRESSION; PROTEIN; FAB-7	The Abd-B Hox gene contains an extended 3' cis-regulatory region that is subdivided into a series of separate lab domains. The iab-7 domain activates Abd-B in parasegment 12 (ps12), whereas iab-8 controls expression in ps13. iab-7 is flanked by two insulators, Fab-7 and Fab-8, which are thought to prevent regulatory factors, such as Polycomb silencers, from influencing neighboring iab domains. This organization poses a potential paradox, since insulator DNAs can work in a dominant fashion to block enhancer-promoter interactions over long distances. Here, we present evidence for a novel cia-regulatory sequence located within iab-7, the promoter targeting sequence (PTS), which permits distal enhancers to overcome the blocking effects of Fab-8 and the heterologous su(Hw) insulator. We propose that the PTS converts dominant, long-range insulators into local regulatory elements that separate neighboring iab domains.	Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA.	mlevine@uclink4.berkeley.edu		Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34431, GM 19329] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARGES S, 2000, IN PRESS DEVELOPMENT; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BOULET AM, 1991, DEVELOPMENT, V111, P393; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Busturia A, 1997, DEVELOPMENT, V124, P4343; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CASTRILLON DH, 1993, GENETICS, V135, P489; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; DORSETT D, 1993, GENETICS, V134, P1135; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; HENDRICKSON JE, 1995, GENETICS, V139, P835; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; HOPMANN R, 1995, GENETICS, V139, P815; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; Mallin DR, 1998, GENETICS, V148, P331; MCCALL K, 1994, GENETICS, V138, P387; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; PARO R, 1998, NOVART FDN SYMP, V214, P61; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SCHIER AF, 1993, P NATL ACAD SCI USA, V90, P1450, DOI 10.1073/pnas.90.4.1450; Sipos L, 1998, GENETICS, V149, P1031; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; Wu XL, 1998, DEVELOPMENT, V125, P3765; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; Zhou JM, 1999, DEVELOPMENT, V126, P3057	56	105	107	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					567	575		10.1016/S0092-8674(00)81546-9	http://dx.doi.org/10.1016/S0092-8674(00)81546-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612393	Bronze			2022-12-28	WOS:000084278700004
J	Le Feuvre, Y; Fenelon, VS; Meyrand, P				Le Feuvre, Y; Fenelon, VS; Meyrand, P			Central inputs mask multiple adult neural networks within a single embryonic network	NATURE			English	Article							LOBSTER STOMATOGASTRIC GANGLION; CENTRAL PATTERN GENERATOR; LONG-TERM POTENTIATION; MUSCARINIC MODULATION; GASTRIC RHYTHM; NERVOUS-SYSTEM; MOTOR PATTERN; NEURONS; CIRCUIT; CONSTRUCTION	It is usually assumed that, after construction of basic network architecture in embryos(1), immature networks undergo progressive maturation to acquire their adult properties(2-4), We examine this assumption in the context of the lobster stomatogastric nervous system. In the lobster, the neuronal population(5) that will form this system is at first organized into a single embryonic network that generates a single rhythmic pattern(6). The system then splits into different functional adult networks(6) controlled by central descending systems(7,8); these adult networks produce multiple motor programmes, distinctively different from the single output of the embryonic network. We show here that the single embryonic network can produce multiple adult-like programmes. This occurs after the embryonic network is silenced by removal of central inputs, then pharmacologically stimulated to restore rhythmicity, Furthermore, restoration of the flow of descending information reversed the adult-like pattern to an embryonic pattern. This indicates that the embryonic network possesses the ability to express adult-like network characteristics, but descending information prevents it from doing so. Functional adult networks may therefore not necessarily be derived from progressive ontogenetic changes in networks themselves, but may result from maturation of descending systems that unmask preexisting adult networks in an embryonic system.	CNRS, Lab Neurobiol Reseaux, F-33405 Talence, France; Univ Bordeaux 1, UMR 5816, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Meyrand, P (corresponding author), CNRS, Lab Neurobiol Reseaux, Batiment B2,Ave Fac, F-33405 Talence, France.			Fenelon, Valerie/0000-0001-8023-0049; Le Feuvre, Yves/0000-0002-2646-4028				Angulo MC, 1999, J NEUROSCI, V19, P1566; BAL T, 1994, J NEUROSCI, V14, P3019; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; CASASNOVAS B, 1995, J NEUROSCI, V15, P5703; Clemens S, 1998, J NEUROSCI, V18, P2788; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ELSON RC, 1992, J NEUROPHYSIOL, V68, P890, DOI 10.1152/jn.1992.68.3.890; Faumont S, 1998, J NEUROPHYSIOL, V80, P2776, DOI 10.1152/jn.1998.80.5.2776; Fenelon VS, 1999, J COMP NEUROL, V408, P335, DOI 10.1002/(SICI)1096-9861(19990607)408:3<335::AID-CNE3>3.0.CO;2-W; Fenelon VS, 1998, CURR OPIN NEUROBIOL, V8, P705, DOI 10.1016/S0959-4388(98)80111-6; Fenelon VS, 1998, J COMP NEUROL, V399, P289, DOI 10.1002/(SICI)1096-9861(19980928)399:3<289::AID-CNE1>3.0.CO;2-X; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P847, DOI 10.1152/jn.1986.55.5.847; Harris -Warrick R.M., 1992, DYNAMIC BIOL NETWORK; HOOPER SL, 1984, BRAIN RES, V305, P186, DOI 10.1016/0006-8993(84)91138-7; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kilman V, 1999, J COMP NEUROL, V408, P318, DOI 10.1002/(SICI)1096-9861(19990607)408:3<318::AID-CNE2>3.0.CO;2-S; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MASABUAU JC, 1996, J NEUROSCI, V16, P3950; MCCORMICK DA, 1995, J NEUROSCI, V15, P2739; MEYRAND P, 1991, NATURE, V351, P60, DOI 10.1038/351060a0; MOULINS M, 1982, J NEUROBIOL, V5, P447; Nick TA, 1996, J NEUROSCI, V16, P7583; ROBERTSON RM, 1984, J COMP PHYSIOL, V154, P473, DOI 10.1007/BF00610162; Sillar Keith T., 1994, Current Opinion in Neurobiology, V4, P101, DOI 10.1016/0959-4388(94)90038-8; SPITZER NC, 1994, PROG BRAIN RES, V102, P169; Sun QQ, 1998, J PHYSIOL-LONDON, V507, P257, DOI 10.1111/j.1469-7793.1998.257bu.x; TURRIGIANO GG, 1989, J NEUROSCI, V9, P2486; Warren RA, 1997, J NEUROSCI, V17, P277, DOI 10.1523/JNEUROSCI.17-01-00277.1997	28	41	41	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					660	664		10.1038/45238	http://dx.doi.org/10.1038/45238			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604471				2022-12-28	WOS:000084189800065
J	Alcock, C				Alcock, C			The dark halo of the Milky Way	SCIENCE			English	Review							LARGE-MAGELLANIC-CLOUD; MICROLENSING EVENTS; ROTATION CURVE; GALACTIC HALO; GALAXY; MATTER; MASS; STARS	Most of the matter in the Milky Way is invisible to astronomers. Precise numbers are elusive, but it appears that the dark component is 20 times as massive as the visible disk of stars and gas. This dark matter is distributed in space differently than the stars, forming a vast, diffuse halo, more spherical than disklike, which occupies more than 1000 times the volume of the disk of stars. The composition of this dark halo is unknown, but it may comprise a mixture of ancient, degenerate dwarf stars and exotic, hypothetical elementary particles.	Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Alcock, C (corresponding author), Lawrence Livermore Natl Lab, 700 East Ave,Mail Code L-051, Livermore, CA 94550 USA.	alcock@igpp.llnl.gov						ALARD C, 1995, ASTRON ASTROPHYS, V300, pL17; Alcock C, 1998, ASTROPHYS J, V499, pL9, DOI 10.1086/311355; Alcock C, 1997, ASTROPHYS J, V486, P697, DOI 10.1086/304535; ALCOCK C, UNPUB; ASHMAN KM, 1992, PUBL ASTRON SOC PAC, V104, P1109, DOI 10.1086/133099; BECKER A, UNPUB; CARNEY BW, 1994, ASTRON J, V107, P2240, DOI 10.1086/117035; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; EVANS N, PREPRINT; Evans NW, 1998, ASTROPHYS J, V501, pL45, DOI 10.1086/311451; FICH M, 1991, ANNU REV ASTRON ASTR, V29, P409; GATES E, 1994, PHYS REV LETT, V72, P2520, DOI 10.1103/PhysRevLett.72.2520; Gould A, 1999, ASTROPHYS J, V517, P719, DOI 10.1086/307214; Hagmann C, 1998, PHYS REV LETT, V80, P2043, DOI 10.1103/PhysRevLett.80.2043; Hansen BMS, 1998, NATURE, V394, P860, DOI 10.1038/29710; Ibata RA, 1999, ASTROPHYS J, V524, pL95, DOI 10.1086/312310; JAFFE W, 1983, MON NOT R ASTRON SOC, V202, P995, DOI 10.1093/mnras/202.4.995; KAHN FD, 1959, ASTROPHYS J, V130, P705, DOI 10.1086/146762; Kochanek CS, 1996, ASTROPHYS J, V457, P228, DOI 10.1086/176724; LITTLE B, 1987, ASTROPHYS J, V320, P493, DOI 10.1086/165567; MENDEZ RA, PREPRINT; MERRIFIELD MR, 1992, ASTRON J, V103, P1552, DOI 10.1086/116168; Mihalas D., 1981, GALACTIC ASTRONOMY; Navarro JF, 1996, ASTROPHYS J, V462, P563, DOI 10.1086/177173; Olling RP, 1998, MON NOT R ASTRON SOC, V297, P943, DOI 10.1046/j.1365-8711.1998.01577.x; PACZYNSKI B, 1986, ASTROPHYS J, V304, P1, DOI 10.1086/164140; Paczynski B, 1996, ANNU REV ASTRON ASTR, V34, P419, DOI 10.1146/annurev.astro.34.1.419; Palanque-Delabrouille N, 1998, ASTRON ASTROPHYS, V332, P1; PECCEI RD, 1977, PHYS REV LETT, V38, P1440, DOI 10.1103/PhysRevLett.38.1440; PEEBLES PJE, 1993, PRINCIPLES PHYSICAL; Persic M, 1996, MON NOT R ASTRON SOC, V281, P27, DOI 10.1093/mnras/278.1.27; Roulet E, 1997, PHYS REP, V279, P68; SACKETT PD, 1990, ASTROPHYS J, V361, P408, DOI 10.1086/169206; Sadoulet B, 1999, REV MOD PHYS, V71, pS197, DOI 10.1103/RevModPhys.71.S197; SAHU KC, 1994, NATURE, V370, P275, DOI 10.1038/370275a0; SIKIVIE P, 1983, PHYS REV LETT, V51, P1415, DOI 10.1103/PhysRevLett.51.1415; SILK J, 1999, P 3 STROML S, P27; STUBBS C, 1999, P 3 STROML S, P503; TURNER M, 1999, P 3 STROML S, P431; UDALSKI A, 1993, ACTA ASTRONOM, V43, P289; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; Wilkinson MI, 1999, MON NOT R ASTRON SOC, V310, P645, DOI 10.1046/j.1365-8711.1999.02964.x; Williams RE, 1996, ASTRON J, V112, P1335, DOI 10.1086/118105; Zaritsky D, 1997, ASTRON J, V114, P2545, DOI 10.1086/118666; ZARITSKY D, 1999, P 3 STROML S, P34; ZHAO HS, 1999, P 3 STROML S, P125	46	17	17	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					74	79		10.1126/science.287.5450.74	http://dx.doi.org/10.1126/science.287.5450.74			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615052				2022-12-28	WOS:000084578400038
J	Edelman, M; Mckitrick, J				Edelman, M; Mckitrick, J			Histoplasma capsulatum in a peripheral-blood smear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Montefiore Med Ctr, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Edelman, M (corresponding author), Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.								0	3	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					28	28		10.1056/NEJM200001063420105	http://dx.doi.org/10.1056/NEJM200001063420105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620646				2022-12-28	WOS:000084575600005
J	Rigotti, A; Krieger, M				Rigotti, A; Krieger, M			Clinical implications of basic research - Getting a handle on "Good" cholesterol with the high-density lipoprotein receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Pontificia Univ Catolica Chile, Santiago, Chile; MIT, Cambridge, MA 02139 USA	Pontificia Universidad Catolica de Chile; Massachusetts Institute of Technology (MIT)	Rigotti, A (corresponding author), Pontificia Univ Catolica Chile, Alameda 340, Santiago, Chile.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Acton S, 1999, ARTERIOSCL THROM VAS, V19, P1734, DOI 10.1161/01.ATV.19.7.1734; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; KOZARSKY KF, IN PRESS ARTERIOSCLE; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Spady DK, 1999, J LIPID RES, V40, P1384; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322	8	27	30	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					2011	2013		10.1056/NEJM199912233412612	http://dx.doi.org/10.1056/NEJM199912233412612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607822				2022-12-28	WOS:000084399400032
J	Emery, P; Zeidler, H; Kvien, TK; Guslandi, M; Naudin, R; Stead, H; Verburg, KM; Isakson, PC; Hubbard, RC; Geis, GS				Emery, P; Zeidler, H; Kvien, TK; Guslandi, M; Naudin, R; Stead, H; Verburg, KM; Isakson, PC; Hubbard, RC; Geis, GS			Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SERIOUS GASTROINTESTINAL COMPLICATIONS; ENDOPEROXIDE-H SYNTHASE-1; PROSTAGLANDIN SYNTHASE; SELECTIVE-INHIBITION; SYNOVIAL TISSUES; PHORBOL ESTER; MESSENGER-RNA; CYCLOOXYGENASE-2; EXPRESSION	Background Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated production of gastrointestinal-protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safely, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor. Methods 655 patients with adult-onset rheumatoid arthritis of at least 6 months' duration were randomly assigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks. Anti-inflammatory and analgesic activity and tolerability were assessed at baseline, every 4 weeks, and at week 24. We assessed gastrointestinal safety by upper-gastrointestinal endoscopy within 7 days of the last treatment dose at centres where the procedure was available. Analysis was by intention-to-treat, Findings 430 patients underwent endoscopy (celecoxib n=212, diclofenac n=218). The two drugs were similar in management of rheumatoid arthritis pain and inflammation. Gastroduodenal ulcers were detected endoscopically in 33 (15%) patients treated with diclofenac and in eight (4%) in the celecoxib group (p<0.001). The rate of withdrawal for any gastrointestinal-related adverse event, most commonly abdominal pain, diarrhoea, and dyspepsia, was nearly three times higher in the diclofenac-treated group than in the celecoxib group (16 vs 6%; p<0.001). Interpretation Celecoxib showed sustained anti-inflammatory and analgesic activity similar to diclofenac, with a lower frequency of upper gastrointestinal ulceration or gastrointestinal adverse events, and tolerability was better.	GD Searle & Co, Res & Dev, Skokie, IL 60077 USA; Univ Leeds, Dept Rheumatol & Rehabil, Leeds, W Yorkshire, England; Med Hsch Hannover, Div Rheumatol, Hannover, Germany; Diakinhjemmet Hosp, Oslo City Dept Rheumatol, Oslo, Norway; St Raffaele Hosp, Gastroenterol Unit, Milan, Italy; Searle European Clin Res & Dev, Paris, France; Searle Med Dept, High Wycombe, Bucks, England	Pfizer; University of Leeds; Hannover Medical School; Diakonhjemmet Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Pfizer	Geis, GS (corresponding author), GD Searle & Co, Res & Dev, Skokie, IL 60077 USA.		emery, paul/B-3560-2013		Arthritis Research UK [18475] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		AGRAWAL NM, 1995, DIGEST DIS SCI, V40, P1125, DOI 10.1007/BF02064210; AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; *ARA GLOSS COMM, 1988, DICT RHEUM DIS, V1; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEANDRADE J R, 1965, Arthritis Rheum, V8, P302; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; IHMAKI T, 1979, SCAND J GASTROENTERO, V14, P801; Kargman S, 1996, GASTROENTEROLOGY, V111, P445, DOI 10.1053/gast.1996.v111.pm8690211; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; KOLODNY AL, 1988, J RHEUMATOL, V15, P1205; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; ROTH SH, 1995, CLIN DRUG INVEST, V9, P171, DOI 10.2165/00044011-199509030-00007; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Singh G, 1998, J RHEUMATOL, V25, P8; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	32	417	434	0	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2106	2111		10.1016/S0140-6736(99)02332-6	http://dx.doi.org/10.1016/S0140-6736(99)02332-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609815				2022-12-28	WOS:000084318200011
J	Blau, J; Young, MW				Blau, J; Young, MW			Cycling vrille expression is required for a functional Drosophila clock	CELL			English	Article							NERVOUS-SYSTEM; CIRCADIAN-RHYTHMS; TRANSCRIPTION FACTORS; GENE-PRODUCT; BZIP FAMILY; DOUBLE-TIME; PERIOD; MELANOGASTER; PROTEIN; CRYPTOCHROME	We identified a novel regulatory loop within Drosophila's circadian clock. A screen for clock-controlled genes recovered vrille (vri), a transcription factor essential for embryonic development. vri iss expressed in circadian pacemaker cells in larval and adult brains. vri RNA levels oscillate with a circadian rhythm. Cycling is directly regulated by the transcription factors dCLOCK and CYCLE, which are also required for oscillations of period and timeless RNA. Eliminating the normal vri cycle suppresses period and timeless expression and causes long-period behavioral rhythms and arrhythmicity, indicating that cycling vri is required for a functional Drosophila clock. We also show that dCLOCK and VRI independently regulate levels of a neuropeptide, pigment dispersing factor, which appears to regulate overt behavior.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA	Rockefeller University	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cheng YZ, 1998, J NEUROSCI, V18, P741; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; George H, 1997, GENETICS, V146, P1345; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; NEWBY LM, 1993, GENETICS, V135, P1077; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	45	332	340	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					661	671		10.1016/S0092-8674(00)81554-8	http://dx.doi.org/10.1016/S0092-8674(00)81554-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612401	Bronze			2022-12-28	WOS:000084278700012
J	Leventhal, LJ				Leventhal, LJ			Management of fibromyalgia	ANNALS OF INTERNAL MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; PITUITARY-ADRENAL AXIS; DOUBLE-BLIND CROSSOVER; COGNITIVE-BEHAVIORAL TREATMENT; DISORDER FIBROSITIS SYNDROME; CEREBRAL BLOOD-FLOW; CLINICAL-TRIAL; S-ADENOSYLMETHIONINE; AEROBIC EXERCISE; SKELETAL-MUSCLE	Despite extensive clinical study, there is no distinct consensus on the optimal management of fibromyalgia. The cause of fibromyalgia has not been clearly defined, but several mechanisms may be involved. Abnormalities in sleep patterns, muscle structure, and cerebral blood flow have been associated with the syndrome, but it is unclear whether a causal relation exists between these abnormalities and fibromyalgia. Recent evidence suggests that alterations in the metabolism and function of the neurotransmitters serotonin, norepinephrine, and substance P may contribute to the development of fibromyalgia. No pharmacologic agents are indicated specifically for the treatment of fibromyalgia in the United States, and most pharmacologic therapies show only limited success, although drugs that affect serotonin or norepinephrine at the receptor site (such as antidepressants or tramadol) seem to generate the most consistent results. Tricyclic antidepressants may diminish the sleep disturbance and pain caused by fibromyalgia, whereas selective serotonin reuptake inhibitors may be more useful for sleep and coexistent depression only. Among the commonly used analgesics, preliminary data suggest that tramadol may be useful for treatment of fibromyalgia pain and that trigger-point injections may be helpful. Controlled trials of antiinflammatory agents have demonstrated little usefulness of these drugs, and oral opioids have not been studied for this condition. Miscellaneous agents, such as growth hormone, tropisetron or ondansetron, 5-hydroxytryptophan, gamma-hydroxybutyrate, and S-adenosyl-L-methionine, have also shown promising preliminary results, but their clinical roles remain to be defined. Nonpharmacologic interventions (such as exercise, biofeedback, and electroacupuncture) have likewise shown some success. Therefore, a multidisciplinary approach that includes both pharmacologic and nonpharmacologic strategies is recommended.	Grad Hosp Philadelphia, Philadelphia, PA 19146 USA	University of Pennsylvania; Pennsylvania Medicine	Leventhal, LJ (corresponding author), Grad Hosp Philadelphia, Pepper Pavil,Suite 801,1800 Lombard St, Philadelphia, PA 19146 USA.							Adler GK, 1999, AM J MED, V106, P534, DOI 10.1016/S0002-9343(99)00074-1; BACKMAN E, 1988, ACTA NEUROL SCAND, V77, P187; BARTELS EM, 1986, LANCET, V1, P755; BENGTSSON A, 1986, ARTHRITIS RHEUM, V29, P817, DOI 10.1002/art.1780290701; BENGTSSON A, 1986, SCAND J RHEUMATOL, V15, P1; Bennett RM, 1998, AM J MED, V104, P227, DOI 10.1016/S0002-9343(97)00351-3; BENNETT RM, 1988, ARTHRITIS RHEUM, V31, P1535, DOI 10.1002/art.1780311210; BENNETT RM, 1992, ARTHRITIS RHEUM-US, V35, P1113, DOI 10.1002/art.1780351002; Bennett RM, 1996, J RHEUMATOL, V23, P521; Bessette L, 1998, SCAND J RHEUMATOL, V27, P112; Biasi G, 1998, INT J CLIN PHARM RES, V18, P13; Bradley DS, 1996, ARTHRITIS RHEUM, V39, P1210; Buckelew SP, 1998, ARTHRIT CARE RES, V11, P196, DOI 10.1002/art.1790110307; CARETTE S, 1986, ARTHRITIS RHEUM-US, V29, P655, DOI 10.1002/art.1780290510; CARETTE S, 1994, ARTHRITIS RHEUM, V37, P32, DOI 10.1002/art.1780370106; CARLSSON CPO, 1994, CLIN J PAIN, V10, P290, DOI 10.1097/00002508-199412000-00008; CARUSO I, 1990, J INT MED RES, V18, P201, DOI 10.1177/030006059001800304; CHASE TN, 1983, ANN REV PHARM TOXICO, V13, P181; CLARK S, 1985, J RHEUMATOL, V12, P980; CORTET B, 1992, REV RHUM, V59, P497; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Dwight MM, 1998, PSYCHOSOMATICS, V39, P14, DOI 10.1016/S0033-3182(98)71375-1; ELERT JE, 1992, SCAND J RHEUMATOL, V21, P28, DOI 10.3109/03009749209095059; FELSON DT, 1986, ARTHRITIS RHEUM, V29, P1522, DOI 10.1002/art.1780291216; FERRACCIOLI G, 1987, J RHEUMATOL, V14, P820; Figuerola MD, 1998, FUNCT NEUROL, V13, P291; FINESTONE DH, 1990, JAMA-J AM MED ASSOC, V264, P2869, DOI 10.1001/jama.1990.03450220031017; GELLER SA, 1989, AM J MED, V87, P594; Goldenberg D, 1996, ARTHRITIS RHEUM, V39, P1852, DOI 10.1002/art.1780391111; GOLDENBERG DL, 1989, RHEUM DIS CLIN N AM, V15, P61; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; Goldenberg DL, 1994, J MUSCULOSKELET PAIN, V2, P53, DOI [10.1300/J094v02n02_05, DOI 10.1300/J094V02N02_05]; GOLDSTEIN JA, 1993, ARTHRITIS RHEUM-US, V36, pS222; Griep EN, 1998, J RHEUMATOL, V25, P1374; GRIEP EN, 1993, J RHEUMATOL, V20, P469; GUPTA MA, 1986, CAN J PSYCHIAT, V31, P608, DOI 10.1177/070674378603100702; HAANEN HCM, 1991, J RHEUMATOL, V18, P72; Haddox JD, 1997, CLIN J PAIN, V13, P6; HENRIKSSON KG, 1982, LANCET, V2, P1395; Hong CZ, 1996, ARCH PHYS MED REHAB, V77, P1161, DOI 10.1016/S0003-9993(96)90141-0; Hrycaj P, 1996, J RHEUMATOL, V23, P1418; JACOBSEN S, 1991, SCAND J RHEUMATOL, V20, P294, DOI 10.3109/03009749109096803; JACOBSEN S, 1991, SCAND J RHEUMATOL, V20, P336, DOI 10.3109/03009749109096809; JAESCHKE R, 1991, J RHEUMATOL, V18, P447; JUBRIAS SA, 1994, ARTHRITIS RHEUM-US, V37, P801, DOI 10.1002/art.1780370604; JUNNILA SYT, 1987, ACUPUNCTURE ELECTRO, V12, P23, DOI 10.3727/036012987816358977; Katz WA, 1996, DRUGS, V52, P39, DOI 10.2165/00003495-199600523-00007; Keel PJ, 1998, CLIN J PAIN, V14, P232, DOI 10.1097/00002508-199809000-00010; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Leventhal L, 1995, J Clin Rheumatol, V1, P110, DOI 10.1097/00124743-199504000-00009; LEWIS PJ, 1993, BRIT MED J, V306, P393, DOI 10.1136/bmj.306.6874.393; Ling SM, 1996, J AM GERIATR SOC, V44, pP135; LUND N, 1986, SCAND J RHEUMATOL, V15, P165, DOI 10.3109/03009748609102084; Martin L, 1996, J RHEUMATOL, V23, P1050; Martinez-Lavin Manuel, 1997, Current Opinion in Rheumatology, V9, P83, DOI 10.1097/00002281-199701000-00016; Maurizio S J, 1997, Nurse Pract, V22, P18; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; MENGSHOEL AM, 1992, CLIN EXP RHEUMATOL, V10, P345; MENGSHOEL AM, 1995, CLIN RHEUMATOL, V14, P165, DOI 10.1007/BF02214937; MOLDOFSKY H, 1978, PAIN, V5, P65, DOI 10.1016/0304-3959(78)90025-8; MOLDOFSKY H, 1989, RHEUM DIS CLIN N AM, V15, P91; MOLDOFSKY H, 1975, PSYCHOSOM MED, V37, P341, DOI 10.1097/00006842-197507000-00008; MOLDOFSKY H, 1989, Journal of Rheumatology, V16, P47; MOLDOFSKY H, 1980, ELECTROEN CLIN NEURO, V50, P71, DOI 10.1016/0013-4694(80)90324-7; Moldofsky H, 1982, Adv Neurol, V33, P51; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; NICHOLS DS, 1994, PHYS THER, V74, P327, DOI 10.1093/ptj/74.4.327; NIELSON WR, 1992, J RHEUMATOL, V19, P98; Norregaard J, 1997, J MUSCULOSKELET PAIN, V5, P71, DOI 10.1300/J094v05n01_05; NORREGAARD J, 1995, PAIN, V61, P445, DOI 10.1016/0304-3959(94)00218-4; Park JH, 1998, ARTHRITIS RHEUM, V41, P406, DOI 10.1002/1529-0131(199803)41:3<406::AID-ART5>3.3.CO;2-C; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; QuijadaCarrera J, 1996, PAIN, V65, P221, DOI 10.1016/0304-3959(95)00199-9; RAUCK RL, 1994, CURR THER RES CLIN E, V55, P1417, DOI 10.1016/S0011-393X(05)80748-9; RUSSELL I J, 1989, Arthritis and Rheumatism, V32, pS70; Russell I. J., 1997, Arthritis and Rheumatism, V40, pS117; Russell IJ, 1996, B RHEUM DIS, V45, P1; RUSSELL IJ, 1995, J RHEUMATOL, V22, P953; RUSSELL IJ, 1986, AM J MED, V81, P50, DOI 10.1016/0002-9343(86)90874-0; RUSSELL IJ, 1992, ARTHRITIS RHEUM, V35, P550, DOI 10.1002/art.1780350509; RUSSELL IJ, 1994, ARTHRITIS RHEUM-US, V37, P1593, DOI 10.1002/art.1780371106; RUSSELL IJ, 1992, J RHEUMATOL, V19, P104; RUSSELL IJ, 1993, ARTHRITIS RHEUM, V36, pS223; RUSSELL IJ, 1991, ARTHRITIS RHEUM-US, V34, P552, DOI 10.1002/art.1780340507; RUSSELL IJ, 1998, J MUSCULOSKELET P S2, V6, P147; Samborski Wlodzimierz, 1996, Materia Medica Polona, V28, P17; Sarnoch H, 1997, PERCEPT MOTOR SKILL, V84, P1043, DOI 10.2466/pms.1997.84.3.1043; SASKIN P, 1986, PSYCHOSOM MED, V48, P319, DOI 10.1097/00006842-198605000-00002; Scharf MB, 1998, J RHEUMATOL, V25, P1986; Scudds R A, 1989, J Rheumatol Suppl, V19, P98; Simms R W, 1996, Arthritis Care Res, V9, P315, DOI 10.1002/1529-0131(199608)9:4<315::AID-ANR1790090417>3.0.CO;2-F; Simms RW, 1998, AM J MED SCI, V315, P346, DOI 10.1097/00000441-199806000-00002; SIMMS RW, 1994, ARTHRITIS RHEUM, V37, P794, DOI 10.1002/art.1780370603; SIMMS RW, 1995, J MUSCULOSKELET PAIN, V3, P127; Singh BB, 1998, ALTERN THER HEALTH M, V4, P67; Sprott H, 1998, RHEUMATOL INT, V18, P35, DOI 10.1007/s002960050051; TAVONI A, 1987, AM J MED, V83, P107, DOI 10.1016/0002-9343(87)90862-X; Tavoni A, 1998, CLIN EXP RHEUMATOL, V16, P106; Turk DC, 1998, ARTHRIT CARE RES, V11, P186, DOI 10.1002/art.1790110306; VAEROY H, 1988, PAIN, V32, P21, DOI 10.1016/0304-3959(88)90019-X; VANDENDEREN JC, 1992, SCAND J RHEUMATOL, V21, P35, DOI 10.3109/03009749209095060; Vlaeyen JWS, 1996, J RHEUMATOL, V23, P1237; Volkmann H, 1997, SCAND J RHEUMATOL, V26, P206, DOI 10.3109/03009749709065682; Wallace DJ, 1997, ANN MED, V29, P9, DOI 10.3109/07853899708998739; Waylonis G W, 1977, Ohio State Med J, V73, P299; Welin M, 1995, J MUSCULOSKELETAL S1, V3, P4; WHITE KP, 1995, J RHEUMATOL, V22, P717; Wigers SH, 1996, SCAND J RHEUMATOL, V25, P77, DOI 10.3109/03009749609069212; WOLFE F, 1989, RHEUM DIS CLIN N AM, V15, P1; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WOLFE F, 1994, SCAND J RHEUMATOL, V23, P255, DOI 10.3109/03009749409103725; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1560, DOI 10.1002/art.1780400904; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS M B, 1990, Arthritis and Rheumatism, V33, pS55; YUNUS MB, 1989, J RHEUMATOL, V16, P527	118	74	79	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					850	858		10.7326/0003-4819-131-11-199912070-00009	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610631				2022-12-28	WOS:000084053200008
J	Wilson, IA				Wilson, IA			Perspectives: Protein structure - Class-conscious TCR?	SCIENCE			English	Editorial Material							T-CELL RECEPTOR; PEPTIDE; COMPLEX; RECOGNITION; PROGRAM; ACIDS		Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.							BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Hare BJ, 1999, NAT STRUCT BIOL, V6, P574; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5	16	22	22	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1867	1868		10.1126/science.286.5446.1867	http://dx.doi.org/10.1126/science.286.5446.1867			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10610577				2022-12-28	WOS:000084003400031
J	Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G				Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G			Assessment of impact on health of residents living near the Nant-y-Gwyddon landfill site: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objectives To compare indices of health in a population living near a landfill site with a population matched for socioeconomic status and to review environmental monitoring data. Design Ecological study with small area statistics and environmental reports. Setting Electoral wards in valleys of South Wales. Subjects Populations in the five wards near the landfill site who had formally complained of odours (exposed population), and comparison populations in 22 wards in the same unitary authority within the same fifth of Townsend score. Outcome measures Mortality, rates of hospital admission, measures of reproductive health (proportion of all births and stillbirths of infants weighing < 2500 g; rates of admissions for spontaneous abortion; rates of all reported congenital malformations). Environmental data on site emissions. Results There were no consistent differences in mortality, rates of hospital admissions, or proportion of low birthweight infants between the two populations. There was an increased maternal risk of having a baby with a congenital abnormality in residents near the site, both before its opening (relative risk 1.9; 95% confidence interval 1.3 to 2.85; P < 0.001) and after (1.9; 1.23 to 2.95; P = 0.003). Environmental monitoring showed that hydrogen sulphide from the site was probably responsible for odours. Conclusions The area surrounding the landfill site has an increased rate of reported congenital malformations,which predated the opening of the landfill, although the cluster of cases of gastroschisis postdated its opening. Several chemicals emitted from the site, including hydrogen sulphide and benzene, were found in air samples in the nearby community. Further studies of the reproductive risk in such communities are needed to examine the safety of waste disposal sites.	Univ Wales Coll Med, Div Publ Hlth, Cardiff CF14 4XN, S Glam, Wales; Bro Taf Hlth Author, Temple Peace & Hlth, Dept Informat, Cardiff CF1 3NW, S Glam, Wales; Univ Wales Inst, WHO, Collaborating Ctr Chem Incidents, Cardiff CG5 2YB, S Glam, Wales	Cardiff University; World Health Organization	Fielder, HMP (corresponding author), Welsh Combined Ctr Publ Hlth, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.							*AG TOX SUBST DIS, 1994, ENV NEED PUBL HLTH A; BOTTING B, 1998, POP TRENDS, V3, P19; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; GARDNER MJ, 1992, CONFIDENCE INTERVAL; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; GOLDBERG MS, 1995, ENVIRON RES, V69, P37, DOI 10.1006/enrs.1995.1023; HADDOW JE, 1993, TERATOLOGY, V47, P225, DOI 10.1002/tera.1420470306; HERTZMAN C, 1987, ENVIRON HEALTH PERSP, V75, P173, DOI 10.2307/3430589; NEAVE HR, 1989, ELEMENTARY STAT TABL; RAMSEY TL, 1994, MANAGING HAZARDOUS I, V3; SCOTT PE, 1998, INVESTIGATION ODOUR; Tan KH, 1996, BRIT MED J, V313, P903; *WORK GROUP REG GE, 1995, 43 OFF POP CENS SURV	13	69	72	2	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					19	22		10.1136/bmj.320.7226.19	http://dx.doi.org/10.1136/bmj.320.7226.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617518	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000084621600016
J	Brondello, JM; Pouyssegur, J; McKenzie, FR				Brondello, JM; Pouyssegur, J; McKenzie, FR			Reduced MAP kinase phosphatase-1 degradation after p42/p44(MAPK)-dependent phosphorylation	SCIENCE			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-TYROSINE-PHOSPHATASE; FIBROBLAST PROLIFERATION; SUBSTRATE RECOGNITION; C-JUN; EXPRESSION; CELLS; IDENTIFICATION; PATHWAY; TRANSDUCTION	The mitogen-activated protein (MAP) kinase cascade is inactivated at the level of MAP kinase by members of the MAP kinase phosphatase (MKP) family, including MKP-1. MKP-1 was a labile protein in CCL39 hamster fibroblasts; its degradation was attenuated by inhibitors of the ubiquitin-directed proteasome complex; MKP-1 was a target in vivo and in vitro for p42(MAPK) or p44(MAPK), which phosphorylates MKP-1 on two carboxyl-terminal serine residues, Serine 359 and Serine 364. This phosphorylation did not modify MKP-1's intrinsic ability to dephosphorylate p44(MAPK) but led to stabilization of the protein. These results illustrate the importance of regulated protein degradation in the control of mitogenic signaling.	Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	McKenzie, FR (corresponding author), Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026939] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26939] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRONDELLO JM, 1991, NATURE, V350, P359; CHARLES CH, 1992, ONCOGENE, V7, P197; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SEGER R, 1992, J BIOL CHEM, V267, P14373; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	38	353	365	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2514	2517		10.1126/science.286.5449.2514	http://dx.doi.org/10.1126/science.286.5449.2514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617468				2022-12-28	WOS:000084429700051
J	Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH				Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH			A pdf neuropeptide gene mutation and ablation of PDF neurons each cause severe abnormalities of behavioral circadian rhythms in Drosophila	CELL			English	Article							HORMONE-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; SUPRACHIASMATIC NUCLEUS; VISUAL-SYSTEM; DARK CYCLES; CLOCK GENE; MELANOGASTER; PERIOD; MUTANTS; CELLS	The mechanisms by which circadian pacemaker systems transmit timing information to control behavior are largely unknown. Here, we define two critical features of that mechanism in Drosophila. We first describe animals mutant for the pdf neuropeptide gene, which is expressed by most of the candidate pacemakers (LN, neurons). Next, we describe animals in which pdf neurons were selectively ablated. Both sets of animals produced similar behavioral phenotypes. Both sets entrained to light, but both were largely arrhythmic under constant conditions. A minority of each pdf variant exhibited weak to moderate free-running rhythmicity. These results confirm the assignment of LN, neurons as the principal circadian pacemakers controlling daily locomotion in Drosophila. They also implicate PDF as the principal circadian transmitter.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Natl Sci Fdn Biol Timing, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Washington University (WUSTL); Brandeis University; Brandeis University; National Science Foundation (NSF); Brandeis University; Howard Hughes Medical Institute	Taghert, PH (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.			Park, Jae/0000-0002-4846-2197	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33205] Funding Source: Medline; NIMH NIH HHS [F32MH-1196] Funding Source: Medline; NINDS NIH HHS [NS-21749] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; Benveniste RJ, 1999, J NEUROBIOL, V38, P507, DOI 10.1002/(SICI)1097-4695(199903)38:4<507::AID-NEU7>3.0.CO;2-X; Boer GJ, 1999, NEUROSCIENCE, V89, P375, DOI 10.1016/S0306-4522(98)00300-5; BRAND A, 1993, DEVELOPMENT, V118, P410; CASSONE VM, 1984, J EXP ZOOL, V232, P539, DOI 10.1002/jez.1402320321; CASSONE VM, 1983, BRAIN RES, V272, P311, DOI 10.1016/0006-8993(83)90578-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DIRCKSEN H, 1987, CELL TISSUE RES, V250, P377; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; DUSHAY MS, 1990, GENETICS, V125, P557; Elekes K, 1999, CELL TISSUE RES, V295, P339, DOI 10.1007/s004410051240; Hamblen MJ, 1998, GENETICS, V149, P165; HAMBLEN MJ, 1966, J NEUROGENET, V3, P249; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Harrington ME, 1999, J NEUROSCI, V19, P6637; Helfrich-Forster C, 1998, CHRONOBIOL INT, V15, P567, DOI 10.3109/07420529808993195; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HOMBERG U, 1991, CELL TISSUE RES, V266, P343, DOI 10.1007/BF00318190; Inouye SIT, 1996, PROG BRAIN RES, V111, P75, DOI 10.1016/S0079-6123(08)60401-X; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Li XD, 1998, CURR OPIN NEUROBIOL, V8, P648, DOI 10.1016/S0959-4388(98)80094-9; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Loros JJ, 1998, CURR OPIN MICROBIOL, V1, P698, DOI 10.1016/S1369-5274(98)80118-5; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; MENAKER M, 1976, AM ZOOL, V16, P45; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; NASSEL DR, 1991, CELL TISSUE RES, V266, P511, DOI 10.1007/BF00318593; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Pyza E, 1996, J COMP PHYSIOL A, V178, P33, DOI 10.1007/BF00189588; RAO KR, 1993, ANN NY ACAD SCI, V680, P78, DOI 10.1111/j.1749-6632.1993.tb19676.x; SCHNEIDER LE, 1993, NEURON, V10, P279, DOI 10.1016/0896-6273(93)90318-L; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	45	831	838	1	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					791	802		10.1016/S0092-8674(00)81676-1	http://dx.doi.org/10.1016/S0092-8674(00)81676-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619432	Bronze			2022-12-28	WOS:000084488200012
J	Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D				Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D			An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing	CELL			English	Article							MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; POLY(ADP-RIBOSE) POLYMERASE; TELOMERIC HETEROCHROMATIN; ESCHERICHIA-COLI; ADP-RIBOSYLATION; BINDING-PROTEIN; COMPLEX; DNA; TRANSCRIPTION	Despite its conservation in organisms from bacteria to human and its general requirement for transcriptional silencing in yeast, the function of the Sir2 protein is unknown. Here we show that Sir:! can transfer labeled phosphate from nicotinamide adenine dinucleotide to itself and histones in vitro. A modified form of Sir2, which results from its automodification activity, is specifically recognized by anti-mono-ADP-ribose antibodies, suggesting that Sir2 is an ADP-ribosyltransferase. Mutation of a phylogenetically invariant histidine residue in Sir2 abolishes both its enzymatic activity in vitro and its silencing functions in vivo. However, the mutant protein is associated with chromatin and other silencing factors in a manner similar to wild-type Sir2. These findings suggest that Sir2 contains an ADP-ribosyltransferase activity that is essential for its silencing function.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Molekularbiol, D-20246 Hamburg, Germany	Harvard University; Harvard Medical School; University of Hamburg	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BISERCIC M, 1991, J BACTERIOL, V173, P3894; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GOLDERER G, 1991, BIOCHEM J, V277, P607, DOI 10.1042/bj2770607; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Holmes SG, 1997, GENETICS, V145, P605; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KLAR AJS, 1979, GENETICS, V93, P37; KUN E, 1976, P NATL ACAD SCI USA, V73, P3131, DOI 10.1073/pnas.73.9.3131; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; RINE J, 1987, GENETICS, V116, P9; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; SPRAGUE G F JR, 1991, P77; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73	41	331	348	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					735	745		10.1016/S0092-8674(00)81671-2	http://dx.doi.org/10.1016/S0092-8674(00)81671-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619427	Bronze			2022-12-28	WOS:000084488200007
J	Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F				Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F			Atomic scale movement of the voltage-sensing region in a potassium channel measured via spectroscopy	NATURE			English	Article							SHAKER K+ CHANNEL; RESONANCE ENERGY-TRANSFER; SODIUM-CHANNELS; FLUORESCENCE; S4; ACTIVATION; CURRENTS; SEQUENCE; CHELATE	Voltage-gated ion channels are transmembrane proteins that are essential for nerve impulses and regulate ion flow across cell membranes in response to changes in membrane potential. They are made up of four homologous domains or subunits, each of which contains six transmembrane segments(1,2). Studies of potassium channels have shown that the second (S2) and fourth (S4) segments contain several charged residues, which sense changes in voltage and form part of the voltage sensor(3-5). Although these regions clearly undergo conformational changes in response to voltage(6-10), little is known about the nature of these changes because voltage-dependent distance changes have not been measured. Here we use lanthanide-based resonance energy transfer(11,12) to measure distances between Shaker potassium channel subunits at specific residues. Voltage-dependent distance changes of up to 3.2 Angstrom were measured at several sites near the S4 segment. These movements directly correlated with electrical measurements of the voltage sensor, establishing the link between physical changes and electrical charge movement. Measured distance changes suggest that the region associated with the S4 segment undergoes a rotation and possible tilt, rather than a large transmembrane movement, in response to voltage. These results demonstrate the first in situ measurement of atomic scale movement in a transmembrane protein.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Anesthesiol, Sch Med, Los Angeles, CA 90095 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bezanilla, F (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.							Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; BEZANILLA F, IN PRESS PHYSL REV; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen JY, 1999, BIOCONJUGATE CHEM, V10, P311, DOI 10.1021/bc980113w; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURRELL SR, 1992, BIOPHYS J, V62, P238; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Scholz F, 1998, J SOLID STATE ELECTR, V2, P1, DOI 10.1007/s100080050056; SCOH SA, 1996, NEURON, V16, P1159; Selvin PR, 1996, INORG CHEM, V35, P700, DOI 10.1021/ic950840s; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Xiao M, 1998, P NATL ACAD SCI USA, V95, P15309, DOI 10.1073/pnas.95.26.15309; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	25	426	443	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					809	813		10.1038/45552	http://dx.doi.org/10.1038/45552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617201	Bronze			2022-12-28	WOS:000084330500065
J	Parsonnet, J; Shmuely, H; Haggerty, T				Parsonnet, J; Shmuely, H; Haggerty, T			Fecal and oral shedding of Helicobacter pylori from healthy infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNOMAGNETIC SEPARATION; GASTRIC BIOPSY; DENTAL PLAQUE; TRANSMISSION; SALIVA; FECES; PCR; DNA; SPECIMENS; SEQUENCE	Context Helicobacter pylori commonly infects humans; however, its mode of transmission remains unknown. Objective To determine how humans-the primary host for H pylori-shed the organism into the environment. Design Controlled clinical experimental study conducted from February through December 1998. Setting Clinical research unit of a hospital in northern California. Patients Sixteen asymptomatic H pylori-infected and 10 uninfected adults. Intervention A cathartic (sodium phosphate) and an emetic (ipecac) were given to all infected subjects and an emetic was given to 1 uninfected subject. Main Outcome Measure Confirmed H pylori isolates cultured from stool, air, or saliva before and after catharsis and emesis and from vomitus during emesis. Isolates were fingerprinted using repetitive extragenic palindromic (REP) polymerase chain reaction and species identity was confirmed by sequencing the 16s ribosomal RNA gene. Results All vomitus samples from infected subjects grew H pylori, often in high quantities. Air sampled during vomiting grew H pylori from 6 (37.5%) of the 16 subjects. Saliva before and after emesis grew low quantities of H pylori in 3 (18.8%) and 9 (56.3%) subjects, respectively. No normal stools and only 22 (21.8%) of 101 induced stools grew the organism, although 7 (50.0%) of 14 subjects had at least 1 positive culture (2 stool culture samples were contaminated by fungus and were not included). Fingerprints of isolates within subjects were identical to one another but differed among subjects. No samples from uninfected subjects yielded H pylori. Conclusions Helicobacter pylori can be cultivated uniformly from vomitus and, occasionally, from saliva and cathartic stools. The organism is potentially transmissible during episodes of gastrointestinal tract illness, particularly with vomiting.	Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Parsonnet, J (corresponding author), Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, HRP Bldg,Room T225, Stanford, CA 94305 USA.	parsonnt@leland.stanford.edu		Parsonnet, Julie/0000-0001-7342-5366	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053689] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NIDDK NIH HHS [R01 DK053689, R01 DK/CA53689] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axon ATR, 1996, EUR J GASTROEN HEPAT, V8, P1, DOI 10.1097/00042737-199601000-00001; Black Robert E., 1995, P13; *BOARD DIR AM SOC, 1997, AM HOSP FORM SERV DR; CAUL EO, 1994, LANCET, V343, P1240, DOI 10.1016/S0140-6736(94)92146-6; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P505; ENROTH H, 1995, J CLIN MICROBIOL, V33, P2162, DOI 10.1128/JCM.33.8.2162-2165.1995; FERGUSON DA, 1993, J CLIN MICROBIOL, V31, P2802, DOI 10.1128/JCM.31.10.2802-2804.1993; Figura N, 1996, LANCET, V347, P1342, DOI 10.1016/S0140-6736(96)90996-4; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Georgopoulos SD, 1996, GUT, V39, P634, DOI 10.1136/gut.39.5.634; GO MF, 1995, SCAND J GASTROENTERO, V30, P640, DOI 10.3109/00365529509096306; Grove DI, 1998, PATHOLOGY, V30, P183, DOI 10.1080/00313029800169206; KELLY SM, 1994, GASTROENTEROLOGY, V107, P1671, DOI 10.1016/0016-5085(94)90806-0; KRAJDEN S, 1989, J CLIN MICROBIOL, V27, P1397, DOI 10.1128/JCM.27.6.1397-1398.1989; Lau D, 1998, GASTROENTEROLOGY, V114, pA196, DOI 10.1016/S0016-5085(98)80798-1; Li CF, 1996, DIGEST DIS SCI, V41, P2142, DOI 10.1007/BF02071393; LOFFELD RJLF, 1991, J PATHOL, V165, P69, DOI 10.1002/path.1711650111; LUDWIG W, 1994, FEMS MICROBIOL REV, V15, P155, DOI 10.1111/j.1574-6976.1994.tb00132.x; Luman W, 1996, EUR J GASTROEN HEPAT, V8, P11, DOI 10.1097/00042737-199601000-00004; Madinier IM, 1997, J PERIODONTOL, V68, P2, DOI 10.1902/jop.1997.68.1.2; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, AM J GASTROENTEROL, V87, P1728; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; MEGRAUD F, 1995, ALIMENT PHARM THERAP, V9, P85; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; Parsonnet J, 1998, GUT, V43, pS6, DOI 10.1136/gut.43.2008.S6; PEREZPEREZ GI, 1991, J CLIN MICROBIOL, V29, P642, DOI 10.1128/JCM.29.3.642-644.1991; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; Tauxe Robert V., 1995, P37; Taylor David N., 1995, P551; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; Watanabe T, 1998, SCAND J GASTROENTERO, V33, P1140, DOI 10.1080/00365529850172476; WEISS J, 1994, J CLIN MICROBIOL, V32, P1663, DOI 10.1128/JCM.32.7.1663-1668.1994; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685	38	244	260	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2240	2245		10.1001/jama.282.23.2240	http://dx.doi.org/10.1001/jama.282.23.2240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605976	Bronze			2022-12-28	WOS:000084138600032
J	Cho, MK; Magnus, D; Caplan, AL; McGee, D				Cho, MK; Magnus, D; Caplan, AL; McGee, D		Ethics Genomics Grp	Genetics - Ethical considerations in synthesizing a minimal genome	SCIENCE			English	Editorial Material							LIFE		Stanford Univ, Ctr Biomed Eth, Stanford, CA 94304 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Baylor Univ, Dept Relig, Waco, TX 76798 USA	Stanford University; University of Pennsylvania; Pennsylvania Medicine; Baylor University	Cho, MK (corresponding author), Stanford Univ, Ctr Biomed Eth, Stanford, CA 94304 USA.							BEGLEY S, 1999, NEWSWEEK        0222, V133, P50; BENTLEY P, 1985, JUDALSM, V34, P301; Bono H, 1998, GENOME RES, V8, P203, DOI 10.1101/gr.8.3.203; CAPLAN A, 1998, HUMAN CLONING DEBATE, P83; CAPLAN A, 1998, AM MED WRITERS ASS J, V13, P17; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gilbert S., 1997, DEV BIOL; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Margulis Lynn, 1995, WHAT IS LIFE; MCGEE G, 1998, HUMAN CLONING DEBATE, P98; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Rizzotti M, 1996, DEFINING LIFE; STACKHOUSE M, 1974, ANDOVER NEWTON Q, V14, P245; 1997, SCI WATCH        SEP, P3; 1995, J MED PHILOS, V20	17	83	97	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2087	+		10.1126/science.286.5447.2087	http://dx.doi.org/10.1126/science.286.5447.2087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617419				2022-12-28	WOS:000084157300032
J	Bastian, H				Bastian, H			Commentary: "health has become secondary to a sexually attractive body"	BRITISH MEDICAL JOURNAL			English	Editorial Material											Bastian, H (corresponding author), POB 569, Blackwood, SA 5051, Australia.							ALMUFTI R, 1996, LANCET, V347, P55; DEMELLO E, 1994, CAMB Q HEALTHC ETHIC, V3, P358; JANOWITZ B, 1982, SOC SCI MED, V16, P19, DOI 10.1016/0277-9536(82)90419-1	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1402	1402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10610166				2022-12-28	WOS:000083995200026
J	Sorenson, SB				Sorenson, SB			Public health - Regulating firearms as a consumer product	SCIENCE			English	Article							SUICIDES		Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Sorenson, SB (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA.							Bonnie RJ, 1999, REDUCING BURDEN INJU; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; Fox JA., 1999, HOMICIDE TRENDS US; Hargarten SW, 1996, JAMA-J AM MED ASSOC, V275, P42, DOI 10.1001/jama.275.1.42; Hoyert DL, 1999, NATL VITAL STAT REP, V47; JINKS R, 1977, HIST SMITH WESSON; KAHANE CJ, 1996, 808537NRD31 NHTSA DO; KAHANE CJ, 1981, 805705 DOT HS NHTSA; KUBY AM, 1999, FALL 1998 NATL GUN P; ROBINSON KD, 1998, PERSONALIZED GUNS RE; Sheley J.F., 1995, LINE FIRE YOUTH GUNS; *SMITHS I NAT MUS, 1895, 002043 SMITHS I NAT; SORENSON SB, IN PRESS INJURY PREV; Teret S P, 1995, Inj Prev, V1, P139, DOI 10.1136/ip.1.3.139; Teret SP, 1998, NEW ENGL J MED, V339, P813, DOI 10.1056/NEJM199809173391206; Wachtel J., 1998, POLICING INT J POLIC, V21, P220; WINTEMUTE GJ, 1988, AM J PUBLIC HEALTH, V78, P824, DOI 10.2105/AJPH.78.7.824; WRIGHT JD, 1994, ARMED CONSIDERED DAN	18	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1481	1482		10.1126/science.286.5444.1481	http://dx.doi.org/10.1126/science.286.5444.1481			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	257DZ	10610547				2022-12-28	WOS:000083768300027
J	Velculescu, VE				Velculescu, VE			Essay: Amersham Pharmacia Biotech & Science Prize - Tantalizing transcriptomes - SAGE and its use in global gene expression analysis	SCIENCE			English	Editorial Material							SERIAL ANALYSIS; PATTERNS; CANCER		Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Velculescu, VE (corresponding author), Johns Hopkins Oncol Ctr, 424 N Bond St, Baltimore, MD 21231 USA.		Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X				ADAMS MD, 1995, NATURE, V377, P3; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERMEKING H, 1997, MOL CELL, V1; Hibi K, 1998, CANCER RES, V58, P5690; LEWIN B, 1980, GENE EXPRESSION; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; VELCULESCU VE, IN PRESS NATURE GENE; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	16	35	44	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1491	1492		10.1126/science.286.5444.1491	http://dx.doi.org/10.1126/science.286.5444.1491			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610550				2022-12-28	WOS:000083768300034
J	Rothwell, PM				Rothwell, PM			Interpretation of variations in outcome in audit of clinical interventions	LANCET			English	Editorial Material							CASE-MIX; STROKE		Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England	Radcliffe Infirmary	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Berlowitz DR, 1996, ANN INTERN MED, V124, P557, DOI 10.7326/0003-4819-124-6-199603150-00003; Bower H, 1998, BRIT MED J, V317, P1101; CARGILL V, 1986, HEALTH SERV RES, V21, P663; COLLINS R, 1996, OXFORD TXB MED; Davenport RJ, 1996, BRIT MED J, V312, P1503, DOI 10.1136/bmj.312.7045.1503; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Horton R, 1998, LANCET, V351, P1900; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; ROTHWELL P, 1995, LANCET, V346, P1623, DOI 10.1016/S0140-6736(95)91953-8; Rothwell PM, 1999, LANCET, V353, P1325, DOI 10.1016/S0140-6736(99)01000-4; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151	13	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					4	5		10.1016/S0140-6736(99)00349-9	http://dx.doi.org/10.1016/S0140-6736(99)00349-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615879				2022-12-28	WOS:000085049200004
J	Firth-Cozens, J; Midgley, SJ; Burges, C				Firth-Cozens, J; Midgley, SJ; Burges, C			Questionnaire survey of post-traumatic stress disorder in doctors involved in the Omagh bombing	BRITISH MEDICAL JOURNAL			English	Article									Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Erne Hosp, Sperrin Lake Hlth & Social Care Trust, Enniskillen, North Ireland	Northumbria University	Firth-Cozens, J (corresponding author), Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England.							Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Bamber M, 1994, Nurs Times, V90, P32; FIRTHCOZENS J, 1995, YORKSHIRE MED, V7, P10; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353	5	35	35	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1609	1609		10.1136/bmj.319.7225.1609	http://dx.doi.org/10.1136/bmj.319.7225.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600958	Bronze, Green Published			2022-12-28	WOS:000084562600012
J	Isaacs, D; Fitzgerald, D				Isaacs, D; Fitzgerald, D			Seven alternatives to evidence based medicine	BRITISH MEDICAL JOURNAL			English	Article									New Childrens Hosp, Dept Educ & Med, Westmead, NSW 2145, Australia	University of Sydney	Isaacs, D (corresponding author), New Childrens Hosp, Dept Educ & Med, Westmead, NSW 2145, Australia.							*EBM IMF, 1999, J EXPONENTIAL SALARI, V99, P1; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; McClarey M, 1998, Nurs Manag (Harrow), V5, P16; O'Donnell M., 1997, SCEPTICS MED DICT; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Solomon MJ, 1998, MED J AUSTRALIA, V169, P380, DOI 10.5694/j.1326-5377.1998.tb126809.x	7	167	172	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1618	1618		10.1136/bmj.319.7225.1618	http://dx.doi.org/10.1136/bmj.319.7225.1618			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600968	Bronze, Green Published			2022-12-28	WOS:000084562600020
J	Bastani, B; Nahass, G				Bastani, B; Nahass, G			Type I primary hyperoxaluria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Louis Univ, Hlth Sci Ctr, St Louis, MO 63110 USA	Saint Louis University	Bastani, B (corresponding author), St Louis Univ, Hlth Sci Ctr, St Louis, MO 63110 USA.			Bastani, Bahar/0000-0002-2138-4248					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1979	1979		10.1056/NEJM199912233412605	http://dx.doi.org/10.1056/NEJM199912233412605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607815				2022-12-28	WOS:000084399400005
J	Diede, SJ; Gottschling, DE				Diede, SJ; Gottschling, DE			Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta	CELL			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; SINGLE-STRANDED-DNA; LENGTH REGULATION; BINDING PROTEIN; REPLICATION FORK; GENE DISRUPTION; YEAST KU; ATAXIA-TELANGIECTASIA; REVERSE-TRANSCRIPTASE; EST GENES	To better understand the requirements for telomerase-mediated telomere addition in vivo, we developed an assay in S. cerevisiae that creates a chromosome end immediately adjacent to a short telomeric DNA tract. The de novo end acts as a telomere: it is protected from degradation in a CDC13-dependent manner, telomeric sequences are added efficiently, and addition occurs at a faster rate in mutant strains that have long telomeres. Telomere addition was detected in M phase arrested cells, which permitted us to determine that the essential DNA polymerases alpha and delta and DNA primase were required. This indicates that telomeric DNA synthesis by telomerase is tightly coregulated with the production of the opposite strand. Such coordination prevents telomerase from generating excessively long single-stranded tails, which may be deleterious to chromosome stability in S. cerevisiae.	Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Fred Hutchinson Cancer Center; University of Chicago	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA.		Diede, Scott/G-2288-2012	Diede, Scott/0000-0001-5422-549X	NIGMS NIH HHS [GM43893, GM07281] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AK, 1996, MOL CELL BIOL, V16, P4614; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Brachmann CB, 1998, YEAST, V14, P115; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHATTOO BB, 1979, GENETICS, V93, P51; CONRAD MN, 1983, MOL CELL BIOL, V3, P1000, DOI 10.1128/MCB.3.6.1000; Dionne I, 1998, NUCLEIC ACIDS RES, V26, P5365, DOI 10.1093/nar/26.23.5365; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; Formosa T, 1999, GENETICS, V151, P1459; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARTWELL LH, 1985, GENETICS, V110, P381; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1991, P132; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Maniatis T., 1982, MOL CLONING LAB MANU; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Marcand S, 1997, CIBA F SYMP, V211, P76; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Price CM, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1216; Ray A, 1999, MOL CELL BIOL, V19, P31; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	85	313	317	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					723	733		10.1016/S0092-8674(00)81670-0	http://dx.doi.org/10.1016/S0092-8674(00)81670-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619426	Bronze			2022-12-28	WOS:000084488200006
J	McAlister, FA; Clark, HD; van Walraven, C; Straus, SE; Lawson, FME; Moher, D; Mulrow, CD				McAlister, FA; Clark, HD; van Walraven, C; Straus, SE; Lawson, FME; Moher, D; Mulrow, CD			The medical review article revisited: Has the science improved?	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROL TRIALS; METAANALYSES; QUALITY; BIAS	Background: The validity of a review depends on its methodologic quality. Objective: To determine the methodologic quality of recently published review articles. Design: Critical appraisal. Setting: All reviews of clinical topics published in six general medical journals in 1996. Measurements: Explicit criteria that have been published and validated were used. Results: Of 158 review articles, only 2 satisfied all 10 methodologic criteria (median number of criteria satisfied, 1), Less than a quarter of the articles described how evidence was identified, evaluated, or integrated; 34% addressed a focused clinical question; and 39% identified gaps in existing knowledge. Of the 111 reviews that made treatment recommendations, 48% provided an estimate of the magnitude of potential benefits (and 34%, the potential adverse effects) of the treatment options, 45% cited randomized clinical trials to support their recommendations, and only 6% made any reference to costs. Conclusions: The methodologic quality of clinical review articles is highly variable, and many of these articles do not specify systematic methods.	Univ Oxford, Oxford, England; Univ Alberta, Edmonton, AB, Canada; Univ Ottawa, Loeb Hlth Res Inst, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON K1H 8L1, Canada; Univ Toronto, Toronto, ON, Canada; Audie L Murphy Vet Affairs Hosp, San Antonio, TX USA	University of Oxford; University of Alberta; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; University of Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E3-24 WMC,8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341; Moher, David/0000-0003-2434-4206				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Bramwell VHC, 1997, ANN ONCOL, V8, P1185, DOI 10.1023/A:1008269422459; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; COOPER HM, 1980, PSYCHOL BULL, V87, P442, DOI 10.1037/0033-2909.87.3.442; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; Haynes R.B., 1993, ACP J CLUB, V119, pA22; HAYNES RB, 1992, BRIT MED J, V304, P330, DOI 10.1136/bmj.304.6823.330; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; McAlister FA, 1999, J GEN INTERN MED, V14, P236, DOI 10.1046/j.1525-1497.1999.00323.x; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; *PHIL INST SCI INF, 1995, J CIT REP, V26; Sacks HS, 1996, MT SINAI J MED, V63, P216; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	20	101	105	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					947	951		10.7326/0003-4819-131-12-199912210-00007	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610646				2022-12-28	WOS:000084374400006
J	Cogoni, C; Macino, G				Cogoni, C; Macino, G			Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase	SCIENCE			English	Article							TRANSGENIC PLANTS; BLOOMS-SYNDROME; TOPOISOMERASE; RNA; SUPPRESSION; SENSITIVITY; INDUCTION; CRASSA	The phenomenon of posttranscriptional gene silencing (PTGS), which occurs when a transgene is introduced into a cell, is poorly understood. Here, the qde-3 gene, which is required for the activation and maintenance of gene silencing in the fungus Neurospora crassa, was isolated. Sequence analysis revealed that the qde-3 gene belongs to the RecQ DNA helicase family. The QDE3 protein may function in the DNA-DNA interaction between introduced transgenes or with an endogenous gene required for gene-silencing activation. In animals, genes that are homologous to RecQ protein, such as the human genes for Bloom's syndrome and Werner's syndrome, may also function in PTGS.	Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy	Sapienza University Rome	Cogoni, C (corresponding author), Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Viale Regina Elena 324, I-00161 Rome, Italy.							Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Duguet M, 1997, J CELL SCI, V110, P1345; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; INOUE H, 1981, MUTAT RES, V80, P27, DOI 10.1016/0027-5107(81)90175-5; ISHII C, 1991, MOL GEN GENET, V228, P33, DOI 10.1007/BF00282444; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Matzke MA, 1998, CELL MOL LIFE SCI, V54, P94, DOI 10.1007/s000180050128; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; PICKFORD A, UNPUB; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; YU EE, 1996, SCIENCE, V272, P258	25	203	244	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2342	2344		10.1126/science.286.5448.2342	http://dx.doi.org/10.1126/science.286.5448.2342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600745				2022-12-28	WOS:000084318500062
J	Mora, CI; Riciputi, LR; Cole, DR				Mora, CI; Riciputi, LR; Cole, DR			Short-lived oxygen diffusion during hot, deep-seated meteoric alteration of anorthosite	SCIENCE			English	Article							REGIONAL METAMORPHISM; HYDROTHERMAL SYSTEMS; WATER FUGACITY; ION MICROPROBE; ISOTOPE RATIOS; STABLE-ISOTOPE; NEW-ZEALAND; IDAHO; EQUILIBRIA; BATHOLITH	Heterogeneous oxygen isotope compositions of plagioclase from the Boehls Butte anorthosite include some of the most oxygen-18-depleted values (to -16 per mil) reported for plagioclase in meta-igneous rocks and indicate high-temperature (T > 500 degrees C) isotopic exchange between plagioclase and nearly pristine meteoric fluid. Retrograde reaction-enhanced permeability assisted influx of meteoric-hydrothermal fluids into the deep-seated anorthosite. Isotopic gradients of about 14 per mil over 600 micrometers in single crystals require short-lived (about 10(4) years) diffusional exchange of oxygen and Locally Large effective water:rock ratios, followed by rapid Loss of water and cessation of oxygen diffusion in the anorthosite.	Univ Tennessee, Dept Geol Sci, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Div Chem & Analyt Sci, Oak Ridge, TN 37831 USA	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory	Mora, CI (corresponding author), Univ Tennessee, Dept Geol Sci, Knoxville, TN 37996 USA.		Mora, Claudia/B-5511-2017	Mora, Claudia/0000-0003-2042-0208				CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; CRISS RE, 1986, REV MINERAL, V16, P373; CRISS RE, 1983, GEOL SOC AM BULL, V94, P640, DOI 10.1130/0016-7606(1983)94<640:AOADSO>2.0.CO;2; Edwards KJ, 1998, GEOCHIM COSMOCHIM AC, V62, P2265, DOI 10.1016/S0016-7037(98)00120-3; ELPHICK SC, 1988, CONTRIB MINERAL PETR, V100, P690; FARVER JR, 1990, GEOCHIM COSMOCHIM AC, V54, P2953, DOI 10.1016/0016-7037(90)90113-Y; GILETTI BJ, 1978, GEOCHIM COSMOCHIM AC, V42, P45, DOI 10.1016/0016-7037(78)90215-6; Graham CM, 1998, CONTRIB MINERAL PETR, V132, P371, DOI 10.1007/s004100050430; GROVER TW, 1992, AM J SCI, V292, P474, DOI 10.2475/ajs.292.7.474; Hanson RB, 1997, ECON GEOL BULL SOC, V92, P880, DOI 10.2113/gsecongeo.92.7-8.880; HIETANEN A, 1963, US GEOL SURV PROF B, V344; House MA, 1997, J METAMORPH GEOL, V15, P753, DOI 10.1111/j.1525-1314.1997.00052.x; HOUSE MA, 1994, GEOLOGY, V22, P1007, DOI 10.1130/0091-7613(1994)022<1007:LOTTSO>2.3.CO;2; JENKIN GRT, 1994, J METAMORPH GEOL, V12, P429, DOI 10.1111/j.1525-1314.1994.tb00033.x; Kohn MJ, 1999, AM MINERAL, V84, P570; Larson PB, 1998, AM J SCI, V298, P572, DOI 10.2475/ajs.298.7.572; Losh S, 1997, GEOL SOC AM BULL, V109, P300, DOI 10.1130/0016-7606(1997)109<0300:SIAMSO>2.3.CO;2; MATSUHISA Y, 1979, GEOCHIM COSMOCHIM AC, V43, P1131, DOI 10.1016/0016-7037(79)90099-1; MORA CI, 1992, AM MINERAL, V77, P1258; Morrison J, 1998, SCIENCE, V279, P63, DOI 10.1126/science.279.5347.63; ORVILLE PM, 1972, AM J SCI, V272, P234, DOI 10.2475/ajs.272.3.234; REYNOLDS SJ, 1987, GEOLOGY, V15, P362, DOI 10.1130/0091-7613(1987)15<362:SAOFII>2.0.CO;2; Riciputi LR, 1998, INT J MASS SPECTROM, V178, P81, DOI 10.1016/S1387-3806(98)14088-5; TAYLOR HP, 1969, NEW YORK ST MUS SCI, V18, P111; Templeton AS, 1998, EARTH PLANET SC LETT, V154, P73, DOI 10.1016/S0012-821X(97)00143-X; Zheng YF, 1996, EUR J MINERAL, V8, P317; [No title captured]	27	10	10	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2323	2325		10.1126/science.286.5448.2323	http://dx.doi.org/10.1126/science.286.5448.2323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600738				2022-12-28	WOS:000084318500055
J	Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A				Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A			Cognitive modularity and genetic disorders	SCIENCE			English	Article							INFANT; NEUROPSYCHOLOGY	This study challenges the use of adult neuropsychological models for explaining developmental disorders of genetic origin. When uneven cognitive profiles are found in childhood or adulthood, it is assumed that such phenotypic outcomes characterize infant starting states, and it has been claimed that modules subserving these abilities start out either intact or impaired. Findings from two experiments with infants with Williams syndrome (a phenotype selected to bolster innate modularity claims) indicate a within-syndrome double dissociation: For numerosity judgments, they do well in infancy but poorly in adulthood, whereas for Language, they perform poorly in infancy but well in adulthood. The theoretical and clinical implications of these results could Lead to a shift in focus for studies of genetic disorders.	UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England; Univ London Univ Coll, Dept Psychol, London WC1E 6BT, England; Birkbeck Coll, Ctr Brain & Cognit Dev, London WC1E 7JL, England	University of London; University College London; University of London; University College London; University of London; Birkbeck University London	Karmiloff-Smith, A (corresponding author), UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England.	a.karmiloff-smith@ich.ucl.ac.uk	Karmiloff-Smith, Annette/N-4535-2014	Karmiloff-Smith, Annette/0000-0002-2470-5609; Johnson, Mark/0000-0003-4229-2585				BARONCOHEN S, 1998, HDB MENTAL RETARDATI, P335; Bayley N, 1993, BAYLEY SCALES INFANT; Bellugi U., 1994, ATYPICAL COGNITIVE D, P23; Bishop DVM, 1997, Q J EXP PSYCHOL-A, V50, P899, DOI 10.1080/027249897391946; Clearfield MW, 1999, PSYCHOL SCI, V10, P408, DOI 10.1111/1467-9280.00177; Eisenberg Daniel, 2015, J MENT HEALTH, V20, P222, DOI [10.3109/10673229.2012.712839, DOI 10.3109/09638237.2014.954693, 10.3109/08039481003777484]; Elman JL, 1996, RETHINKING INNATENES; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GOLINKOFF RM, 1987, J CHILD LANG, V14, P23, DOI 10.1017/S030500090001271X; HAAF RA, 1989, INFANT BEHAV DEV, V12, P211, DOI 10.1016/0163-6383(89)90007-6; Karmiloff-Smith A, 1998, TRENDS COGN SCI, V2, P389, DOI 10.1016/S1364-6613(98)01230-3; KINNEAR PR, 1999, SPSS WINDOWS MADE SI, P98; Leslie A.M., 1992, CURRENT DIRECTIONS P, V1, P18, DOI DOI 10.1111/1467-8721; ONEILL JM, 1994, INFANT BEHAV DEV, V17, P465, DOI 10.1016/0163-6383(94)90039-6; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Schafer G, 1998, CHILD DEV, V69, P309, DOI 10.2307/1132166; STARKEY P, 1990, COGNITION, V36, P97, DOI 10.1016/0010-0277(90)90001-Z; STRAUSS MS, 1981, CHILD DEV, V52, P1146, DOI 10.2307/1129500; Tassabehji M, 1999, AM J HUM GENET, V64, P118, DOI 10.1086/302214; Temple CM, 1997, J CHILD PSYCHOL PSYC, V38, P27, DOI 10.1111/j.1469-7610.1997.tb01504.x	21	187	188	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2355	2358		10.1126/science.286.5448.2355	http://dx.doi.org/10.1126/science.286.5448.2355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	266UK	10600749				2022-12-28	WOS:000084318500066
J	Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA				Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA			CNS myelin and Sertoli cell tight junction strands are absent in Osp/Claudin-11 null mice	CELL			English	Article							OLIGODENDROCYTE-SPECIFIC PROTEIN; ZONULA OCCLUDENS; NERVOUS-SYSTEM; EXPRESSION; GENE; BARRIER; TESTIS; PERMEABILITY; ARCHITECTURE; MUTATION	Oligodendrocyte-specific protein (OSP)/claudin-11 is a recently identified transmembrane protein found in CNS myelin and testis with unknown function. Herein we demonstrate that Osp null mice exhibit both neurological and reproductive deficits: CNS nerve conduction is slowed, hindlimb weakness is conspicuous, and males are sterile. Freeze fracture reveals that tight junction intramembranous strands are absent in CNS myelin and between Sertoli cells of mutant mice. Our results demonstrate that OSP is the mediator of parallel-array tight junction strands and distinguishes this protein from other intrinsic membrane proteins in tight junctions. These novel results provide direct evidence of the pivotal role of the claudin family in generating the paracellular physical barrier of tight junctions necessary for spermatogenesis and normal CNS function.	CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Dept Ophthalmol, New York, NY 10029 USA; NICHHD, Sect Struct Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lazzarini, RA (corresponding author), CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.			gow, alexander/0000-0001-7446-8990	NEI NIH HHS [1K08 EY 00390-01A1] Funding Source: Medline; NINDS NIH HHS [NS01596, NS33165] Funding Source: Medline; NATIONAL EYE INSTITUTE [K08EY000390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033165, K08NS001596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000002, Z01DC000002] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AUMULLER G, 1986, INT J ANDROL, V9, P99, DOI 10.1111/j.1365-2605.1986.tb00872.x; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BLAKEMORE WF, 1969, J ULTRA MOL STRUCT R, V29, P496, DOI 10.1016/S0022-5320(69)90069-0; Bronstein JM, 1996, NEUROLOGY, V47, P772, DOI 10.1212/WNL.47.3.772; Bronstein JM, 1997, J NEUROSCI RES, V50, P713, DOI 10.1002/(SICI)1097-4547(19971201)50:5<713::AID-JNR8>3.3.CO;2-Q; Dym M, 1970, Biology Reprod., V3, P308; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FANNON AM, 1995, J CELL BIOL, V129, P189, DOI 10.1083/jcb.129.1.189; FRIEDRICH VL, 1981, HDB NEUROANATOMICAL, P345; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; GILULA NB, 1976, DEV BIOL, V50, P142, DOI 10.1016/0012-1606(76)90074-9; Gondre M, 1998, J CELL BIOL, V141, P493, DOI 10.1083/jcb.141.2.493; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Gow A, 1998, J CELL BIOL, V140, P925, DOI 10.1083/jcb.140.4.925; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRIFFITHS IR, 1995, NEUROPATH APPL NEURO, V21, P97, DOI 10.1111/j.1365-2990.1995.tb01035.x; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HILDEBRAND C, 1971, ACTA PHYSIOL SCAND, P43; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Mori Seiji, 1998, American Journal of Physiology, V274, pC1708; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; MUGNAINI E, 1974, NATURE, V251, P725, DOI 10.1038/251725a0; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; PLYMATE S, 1994, ENDOCRIN METAB CLIN, V23, P749, DOI 10.1016/S0889-8529(18)30065-3; Ruio-Hortega, 1928, MEM REL SOC ESPAN HI, V14, P5; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Scherer SS, 1995, J NEUROSCI, V15, P8281; SCHNAPP B, 1978, PHYSL PATHOBIOLOGY A, P83; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STRAIN GM, 1993, BRAIN RES BULL, V32, P57, DOI 10.1016/0361-9230(93)90319-7; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; TABIRA T, 1978, J NEUROCYTOL, V7, P489, DOI 10.1007/BF01173993; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; YULE TD, 1990, J REPROD IMMUNOL, V18, P89, DOI 10.1016/0165-0378(90)90026-3	47	552	562	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					649	659		10.1016/S0092-8674(00)81553-6	http://dx.doi.org/10.1016/S0092-8674(00)81553-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612400	Bronze			2022-12-28	WOS:000084278700011
J	Kim, P; Lieber, CM				Kim, P; Lieber, CM			Nanotube nanotweezers	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; INDIVIDUAL CARBON NANOTUBES; MICROELECTROMECHANICAL STRUCTURES; TRANSPORT; PROBES; MANIPULATION; SURFACE; FILMS; WIRES; TIP	Nanoscale electromechanical systems-nanotweezers-based on carbon nanotubes have been developed for manipulation and interrogation of nanostructures. Electrically conducting and mechanically robust carbon nanotubes were attached to independent electrodes fabricated on pulled glass micropipettes. Voltages applied to the electrodes closed and opened the free ends of the nanotubes, and this electromechanical response was simulated quantitatively using known nanotweezer structure and nanotube properties. The mechanical capabilities of the nanotweezers were demonstrated by grabbing and manipulating submicron clusters and nanowires. The conducting nanotube arms of the tweezers were also used for measuring the electrical properties of silicon carbide nanoclusters and gallium arsenide nanowires.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.		Chu, Yung-Ming/C-6318-2009; Kim, Philip/N-1886-2013	Kim, Philip/0000-0002-8255-0086				Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; DUAN X, IN PRESS ADV MAT; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; Flatte ME, 1996, PHYS REV B, V53, P10536, DOI 10.1103/PhysRevB.53.R10536; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Hafner JH, 1999, NATURE, V398, P761, DOI 10.1038/19658; HELLMICH W, 1995, APPL PHYS A-MATER, V61, P193, DOI 10.1007/BF01538389; Hertel T, 1998, J PHYS CHEM B, V102, P910, DOI 10.1021/jp9734686; Kim Philip, UNPUB; KIM Y, 1992, SCIENCE, V257, P375, DOI 10.1126/science.257.5068.375; MACDONALD NC, 1989, SENSOR ACTUATOR, V20, P123, DOI 10.1016/0250-6874(89)87110-0; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; NIU Q, 1995, PHYS REV B, V51, P5502, DOI 10.1103/PhysRevB.51.5502; RUCKES T, UNPUB; SHI F, 1995, COMPUT STRUCT, V56, P769, DOI 10.1016/0045-7949(95)00007-4; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Wolf E.L., 1985, PRINCIPLES ELECT TUN; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; Wong SS, 1998, APPL PHYS LETT, V73, P3465, DOI 10.1063/1.122798; YAO JJ, 1992, SCANNING MICROSCOPY, V6, P937; Yazdani A, 1996, SCIENCE, V272, P1921, DOI 10.1126/science.272.5270.1921	28	1050	1100	10	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2148	2150		10.1126/science.286.5447.2148	http://dx.doi.org/10.1126/science.286.5447.2148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591644				2022-12-28	WOS:000084157300049
J	Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A				Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A			Systemic amyloidosis presenting with angina pectoris	ANNALS OF INTERNAL MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; CARDIAC AMYLOIDOSIS; CHEST PAIN; CORONARY; ARTERIES	Background: Manifestations of cardiac amyloidosis may include congestive heart failure and sudden cardiac death. Although vascular involvement in patients with amyloidosis is common, systemic amyloidosis presenting with angina is rare. Objectives: To report on patients with systemic amyloidosis presenting with angina pectoris. Design: Case series. Setting: Academic medical center. Patients: Five patients who presented with angina pectoris and normal coronary angiogram as the initial manifestation of systemic amyloidosis. Measurements: Endothelial-dependent and endothelialin-dependent coronary flow reserve. Results: All patients had coronary flow reserve abnormalities and subsequently developed congestive heart failure and systemic manifestations of amyloidosis. Histologic evaluation revealed amyloid deposition in the intramyocardial coronary vessels. Conclusions: Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormalities despite normal coronary angiograms. This finding may have major therapeutic and prognostic implications in this patient population.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA; NHLBI, NIH, Cardiol Branch, Bethesda, MD 20892 USA	Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lerman.amir@mayo.edu	Gertz, Morie/K-2873-2019	al suwaidi, MB, ChB, FACC, FESC, FSCAI, jassim/0000-0002-5299-9106				BRANDT K, 1968, AM J MED, V44, P955, DOI 10.1016/0002-9343(68)90095-8; BUJA LM, 1970, AM J CARDIOL, V26, P394, DOI 10.1016/0002-9149(70)90736-8; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CROTTY TB, 1994, CARDIOVASC PATHOL, V5, P39; CUETOGARCIA L, 1985, AM J CARDIOL, V55, P606, DOI 10.1016/0002-9149(85)90268-1; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; Hasdai D, 1998, MAYO CLIN PROC, V73, P1133, DOI 10.4065/73.12.1133; Hasdai D, 1997, CIRCULATION, V96, P3390; LICHTLEN PR, 1995, J AM COLL CARDIOL, V25, P1013, DOI 10.1016/0735-1097(94)00519-V; NARANG R, 1993, CARDIOLOGY, V82, P294, DOI 10.1159/000175878; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SAFFITZ JE, 1983, AM J CARDIOL, V51, P1234, DOI 10.1016/0002-9149(83)90379-X; Schafer S, 1996, CIRCULATION, V94, P3376, DOI 10.1161/01.CIR.94.12.3376; SMITH RRL, 1979, AM J CARDIOL, V44, P413, DOI 10.1016/0002-9149(79)90389-8; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; THIBAULT GE, 1992, NEW ENGL J MED, V327, P714, DOI 10.1056/NEJM199209033271008; WRIGHT JR, 1981, MEDICINE, V60, P429, DOI 10.1097/00005792-198111000-00004	18	55	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					838	841		10.7326/0003-4819-131-11-199912070-00007	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610629				2022-12-28	WOS:000084053200006
J	Bergqvist, D				Bergqvist, D			Salvage of critically ischaemic limbs	LANCET			English	Editorial Material							RANDOMIZED TRIAL; PATENCY; BYPASS; ANGIOPLASTY; GRAFTS		Uppsala Univ, Univ Hosp, Dept Surg, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Bergqvist, D (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg, SE-75185 Uppsala, Sweden.							Becquemin JP, 1997, NEW ENGL J MED, V337, P1726, DOI 10.1056/NEJM199712113372404; Bergqvist D, 1998, EUR J SURG, V164, P3; BOLIA A, 1994, EUR J VASCULAR SURG, V8, P214, DOI 10.1016/S0950-821X(05)80463-3; Hamsho A, 1999, EUR J VASC ENDOVASC, V17, P197, DOI 10.1053/ejvs.1998.0671; KARACAGIL S, 1990, ARCH SURG-CHICAGO, V125, P1055; Labs KH, 1999, EUR J VASC ENDOVASC, V18, P253, DOI 10.1053/ejvs.1999.0931; MOODY AP, 1992, BRIT J SURG, V79, P750, DOI 10.1002/bjs.1800790809; Nydahl S, 1997, EUR J VASC ENDOVASC, V14, P212, DOI 10.1016/S1078-5884(97)80194-3; RUTHERFORD RB, 1988, J VASC SURG, V8, P236, DOI 10.1067/mva.1988.avs0080236; Stonebridge PA, 1997, J VASC SURG, V26, P543, DOI 10.1016/S0741-5214(97)70051-X	10	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1920	1921		10.1016/S0140-6736(99)00307-4	http://dx.doi.org/10.1016/S0140-6736(99)00307-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622290				2022-12-28	WOS:000084034700004
J	Strasser, BJ				Strasser, BJ			Molecular medicine - "Sickle cell anemia, a molecular disease"	SCIENCE			English	Editorial Material									Univ Geneva, CMU, Louis Jeantet Inst Hist Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Strasser, BJ (corresponding author), Univ Geneva, CMU, Louis Jeantet Inst Hist Med, CH-1211 Geneva 4, Switzerland.		Strasser, Bruno J/E-9337-2012	Strasser, Bruno J./0000-0002-2773-6670				Conley CL, 1980, BLOOD PURE ELOQUENT, P319; De Chadarevian S, 1998, MOL BIOL MED NEW PRA, P171; HAGER T, 1995, FORCE NATURE, P332; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KAY LE, 1993, MOL VISION LIFE, P256; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; Wailoo Keith, 1997, DRAWING BLOOD	7	35	37	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1488	1490		10.1126/science.286.5444.1488	http://dx.doi.org/10.1126/science.286.5444.1488			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610548				2022-12-28	WOS:000083768300032
J	Clark, JP				Clark, JP			Babes and boobs? Analysis of JAMA cover art	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL JOURNALS	Objective To determine the representation of die sexes in JAMA cover art Design Review of 50 consecutive issues. Setting JAMA, March 1997-March 1998. Main outcome measures Numbers and nature of covers portraying men and women. Results Of the 50 covers, 34 depicted humans. 15 depicted women, 13 men, and 6 were of mixed or indeterminate sex. 11 pictures of women included a child and five included nudity. One cover showed a man with a child (not as a father) and none depicted nudity Men were depicted exclusively in authoritative roles. Conclusions Much of the cover art gives strong messages about sexual stereotypes chat are inappropriate in modern society. JAMA should consider reviewing its policy for choosing cover art.	Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5S 1A8, Canada	University of Toronto	Clark, JP (corresponding author), Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada.			Clark, Jocalyn/0000-0002-8014-3989				Bickel J, 1997, JAMA, V277, P1407, DOI 10.1001/jama.277.17.1405; Fletcher RH, 1998, LANCET, V352, P30; Fried LP, 1996, JAMA-J AM MED ASSOC, V276, P898, DOI 10.1001/jama.276.11.898; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; ITZIN C, 1986, FEMINIST SOCIAL PSYC; Kandela P, 1998, LANCET, V352, P7; Kassirer JP, 1999, NEW ENGL J MED, V340, P466, DOI 10.1056/NEJM199902113400609; LUNDBERG GD, 1996, SCI NEWS UPDATE 1030, P1; Meryn S, 1998, BRIT MED J, V316, P1922, DOI 10.1136/bmj.316.7149.1922; O'Kelly C.G., 1983, QUAL SOCIOL, V6, P136, DOI [10.1007/BF00987084, DOI 10.1007/BF00987084]; Smith R, 1998, BRIT MED J, V316, P1622, DOI 10.1136/bmj.316.7145.1622; Waalen J, 1997, JAMA, V277, P1404, DOI 10.1001/jama.277.17.1404	12	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1603	1604		10.1136/bmj.319.7225.1603	http://dx.doi.org/10.1136/bmj.319.7225.1603			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600956	Bronze, Green Published			2022-12-28	WOS:000084562600009
J	Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY				Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY			Spectroscopic mapping of voltage sensor movement in the Shaker potassium channel	NATURE			English	Article							K+ CHANNEL; SODIUM-CHANNELS; ENERGY-TRANSFER; MOLECULAR-BASIS; S4 SEGMENT; CONFORMATIONS; FLUORESCENCE; CHARGE	Voltage-gated ion channels underlie the generation of action potentials and trigger neurosecretion and muscle contraction. These channels consist of an inner pore-forming domain, which contains the ion permeation pathway and elements of its gates, together with four voltage-sensing domains, which regulate the gates(1-6). To understand the mechanism of voltage sensing it is necessary to define the structure and motion of the S4 segment, the portion of each voltage-sensing domain that moves charged residues across the membrane in response to voltage change(7-14) We have addressed this problem by using fluorescence resonance energy transfer as a spectroscopic ruler(15-17) to determine distances between S4s in the Shaker K+ channel in different gating states. Here we provide evidence consistent with S4 being a tilted helix that twists during activation. We propose that helical twist contributes to the movement of charged side chains across the membrane electric field and that it is involved in coupling voltage sensing to gating.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 271 Life Sci Addit, Berkeley, CA 94720 USA.		isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Cantor, 1980, BIOPHYS CHEM; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; FRETCH GC, 1989, NATURE, V340, P642; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jovin T.M, 1989, CELL STRUCT FUNCT, P99; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	26	243	255	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					813	817		10.1038/45561	http://dx.doi.org/10.1038/45561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617202				2022-12-28	WOS:000084330500066
J	Philipp, M; Kohnen, R; Hiller, KO				Philipp, M; Kohnen, R; Hiller, KO			Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks	BRITISH MEDICAL JOURNAL			English	Article							ANTIDEPRESSANT; TERM; WORT	Objectives To assess the efficacy and safety of hypericum extract (STEI 300, Steiner Arzneimittel, Berlin) compared with imipramine and placebo in patients in primary care with a current episode of moderate depression. Design Randomised, double blind, multicentre, parallel group trial for 8 weeks. Setting Trained panel of IS general practitioners from four German states: Bavaria Berlin, Rhineland Palatinate, and Saxony. Participants 263 patients (66 men, 197 women) with moderate depression according to ICD-10 (international classification of diseases, 10th revision) codes F32.1 and F33.1. Interventions 1050 mg hypericum extract (350 mg three times daily), 100 mg imipramine (50 mg, 25 mg, and 25 mg daily), or placebo three times daily Main outcome measures Change from baseline score on the It item version of the Hamilton depression scale, the Hamilton anxiety scale, the clinical global impressions scale, Zung's self rating depression scale, and SF-YB, and adverse events profile. Results Hypericum extract was more effective at reducing Hamilton depression scores than placebo and as effective as imipramine (mean - 15.4 (SD 8.1), -12.1 (7.4). and -14.2 (7.3) respectively). Comparable results were found for Hamilton anxiety and clinical global impressions scales and were most pronounced for the Zung self rating depression scale. Quality of life was more improved in the standardised mental component scale of the SF-36 with both active treatments than with placebo but in the physical component scale was improved only by hypericum extract compared with placebo. The rate of adverse events with hypericum extract was in the range of the placebo group but lower than that of the imipramine group (0.5, 0.6, and 1.2 events per patient respectively). Conclusions At an average dose of 350 mg three times daily hypericum extract was more effective than placebo and at least as effective as 100 mg imipramine daily in the treatment of moderate depression. Treatment with hypericum extract is safe and improves quality of life.	Steiner Arzneimittel, D-12207 Berlin, Germany; Bezirkskrankenhaus Landshut, D-84034 Landstuhl, Germany; Imerem Inst Med Res Management & Biometr, D-90478 Nurnberg, Germany		Hiller, KO (corresponding author), Steiner Arzneimittel, D-12207 Berlin, Germany.							Angst J, 1997, BMJ-BRIT MED J, V315, P1143; Bollini P, 1999, BRIT J PSYCHIAT, V174, P297, DOI 10.1192/bjp.174.4.297; DeSmet PAGM, 1996, BMJ-BRIT MED J, V313, P241, DOI 10.1136/bmj.313.7052.241; Ernst E, 1998, EUR J CLIN PHARMACOL, V54, P589, DOI 10.1007/s002280050519; *EUR COMM, 1998, CPMPICH36396 EUR COM; *EUR COMM, 1990, NOT GUID MED PROD TR; *EUR COMM, 1997, CPMPICH13595 EUR COM; *GERM COMM, 1992, BUNDESANZEIGER  0808; Heiligenstein J H, 1995, Int Psychogeriatr, V7 Suppl, P125, DOI 10.1017/S1041610295002407; LEHMACHER W, 1993, EUROPAISCHE PERSPEKT, P152; Lepine JP, 1997, INT CLIN PSYCHOPHARM, V12, P19, DOI 10.1097/00004850-199701000-00003; LINDE K, 1999, COCHRANE LIB; Linden M, 1996, NERVENARZT, V67, P205; Montgomery SA., 1994, EUROPEAN NEUROPSYCHO, V4, P283, DOI [DOI 10.1016/0924-977X(94)90093-0, 10.1016/0924-977X(94)90093-0]; PRESKORN SH, 1992, J CLIN PSYCHIAT, V53, P5; Rohmel J, 1998, STAT MED, V17, P1703; Volz HP, 1997, PHARMACOPSYCHIATRY, V30, P72, DOI 10.1055/s-2007-979522	17	156	158	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1534	1538		10.1136/bmj.319.7224.1534	http://dx.doi.org/10.1136/bmj.319.7224.1534			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591711	Green Published, Bronze			2022-12-28	WOS:000084245600021
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine and the doctor	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England		Zollman, C (corresponding author), Res Council Complementary Med, London, England.							LEWITH G, 1996, OXFORD GEN PRACTICE; *RES COUNC COMPL M, 1998, MED ATT COMPL MED RE; SHARMA U, 1995, COMPLEMENTARY MED TO; 1993, COMPLEMENTARY MED NE	4	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1558	1561		10.1136/bmj.319.7224.1558	http://dx.doi.org/10.1136/bmj.319.7224.1558			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591724	Green Published			2022-12-28	WOS:000084245600029
J	Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC				Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC			Global transposon mutagenesis and a minimal mycoplasma genome	SCIENCE			English	Article							SEQUENCE; GENITALIUM; SPIROCHETE; PNEUMONIAE; ARCHAEON; COPIES; IS256	Mycoplasma genitalium with 517 genes has the smallest gene complement of any independently replicating cell so far identified. Global transposon mutagenesis was used to identify nonessential genes in an effort to Learn whether the naturally occurring gene complement is a true minimal genome under Laboratory growth conditions. The positions of 2209 transposon insertions in the completely sequenced genomes of M. genitalium and its close relative M. pneumoniae were determined by sequencing across the junction of the transposon and the genomic DNA. These junctions defined 1354 distinct sites of insertion that were not Lethal. The analysis suggests that 265 to 350 of the 480 protein-coding genes of M. genitalium are essential under Laboratory growth conditions, including about 100 genes of unknown function.	Inst Gen Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Venter, JC (corresponding author), Celera Gen, 45 W Gude Dr, Rockville, MD 20850 USA.			Fraser, Claire/0000-0003-1462-2428				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cho MK, 1999, SCIENCE, V286, P2087, DOI 10.1126/science.286.5447.2087; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; DYKE KGH, 1992, PLASMID, V28, P235, DOI 10.1016/0147-619X(92)90055-F; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOFFEAU A, 1997, NATURE, V387; Himmelreich R, 1997, NUCLEIC ACIDS RES, V25, P701, DOI 10.1093/nar/25.4.701; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; Kaneko T, 1996, DNA Res, V3, P109; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNUDTSON KL, 1993, GENE, V137, P217, DOI 10.1016/0378-1119(93)90009-R; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P128, DOI 10.1016/S0968-0004(96)80165-4; Krause DC, 1996, MOL MICROBIOL, V20, P247, DOI 10.1111/j.1365-2958.1996.tb02613.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MOROWITZ HJ, 1984, ISRAEL J MED SCI, V20, P750; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Reddy SP, 1996, FEMS IMMUNOL MED MIC, V15, P199, DOI 10.1016/0928-8244(96)00060-0; RICE LB, 1995, ANTIMICROB AGENTS CH, V39, P1147, DOI 10.1128/AAC.39.5.1147; Romero-Arroyo CE, 1999, J BACTERIOL, V181, P1079, DOI 10.1128/JB.181.4.1079-1087.1999; Saurin W, 1996, MOL MICROBIOL, V22, P389; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	29	662	710	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2165	2169		10.1126/science.286.5447.2165	http://dx.doi.org/10.1126/science.286.5447.2165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591650				2022-12-28	WOS:000084157300055
J	Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J				Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J			Golgi membranes are absorbed into and reemerge from the ER during mitosis	CELL			English	Article							ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; LIVING CELLS; BREFELDIN-A; HELA-CELLS; MATRIX PROTEIN; APPARATUS; FRAGMENTATION; DYNAMICS; COMPLEX	Quantitative imaging and photobleaching were used to measure ER/Golgi recycling of GFP-tagged Golgi proteins in interphase cells and to monitor the dissolution and reformation of the Golgi during mitosis. In interphase, recycling occurred every 1.5 hr, and blocking ER egress trapped cycling Golgi enzymes in the ER with loss of Golgi structure. In mitosis, when ER export stops, Golgi proteins redistributed into the ER as shown by quantitative imaging in vivo and immuno-EM. Comparison of the mobilities of Golgi proteins and lipids ruled out the persistence of a separate mitotic Golgi vesicle population and supported the idea that all Golgi components are absorbed into the ER. Moreover, reassembly of the Golgi complex after mitosis failed to occur when ER export was blocked. These results demonstrate that in mitosis the Golgi disperses and reforms through the intermediary of the ER, exploiting constitutive recycling pathways. They thus define a novel paradigm for Golgi genesis and inheritance.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; BioInformat Serv, Rockville, MD 20854 USA; NINCDS, Light Imaging Facil, NIH, Bethesda, MD 20892 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Mol Neurobiol Lab, I-66030 Santa Maria Imbaro, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.		Ward, Theresa H./E-9650-2013; Hirschberg, Koret/AAF-4566-2019; Ellenberg, Jan/I-4688-2014	Ward, Theresa H./0000-0002-9881-8649; Ellenberg, Jan/0000-0001-5909-701X; Polishchuk, Roman/0000-0002-7698-1955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059018] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59018-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Edidin M., 1994, MOBILITY PROXIMITY B, P109; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Farmaki T, 1999, J CELL SCI, V112, P589; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FOSTER DM, 1994, BMES BULL, V18, P19; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACQUEZ JA, 1996, COMPARTMENTAL ANAL B; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1992, J CELL SCI, V103, P875; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Polishchuk RS, 1999, EUR J CELL BIOL, V78, P170, DOI 10.1016/S0171-9335(99)80096-X; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; WADSWORTH P, 1983, J CELL BIOL, V97, P1249, DOI 10.1083/jcb.97.4.1249; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	48	265	274	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					589	601		10.1016/S0092-8674(00)81548-2	http://dx.doi.org/10.1016/S0092-8674(00)81548-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612395	Bronze			2022-12-28	WOS:000084278700006
J	Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR				Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR			A novel nuclear export activity in HIV-1 matrix protein required for viral replication	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INTRACELLULAR-TRANSPORT; LOCALIZATION SIGNAL; NONDIVIDING CELLS; RNA DIMERIZATION; MESSENGER-RNA; LEPTOMYCIN-B; INFECTION; CRM1; ENCAPSIDATION	An important aspect of the pathophysiology of human immunodeficiency virus type-1 (HIV-1) infection is the ability of the virus to replicate in non-dividing cells(1-3). HIV-1 matrix (MA), the amino-terminal domain of the Pr55 gag polyprotein (Pr55), bears a nuclear localization signal that promotes localization of the viral preintegration complex to the nucleus of non-dividing cells following virus entry(3-5). However, late during infection, MA, as part of Pr55, directs unspliced viral RNA to the plasma membrane(6), the site of virus assembly. How MA can mediate these two opposing targeting functions is not understood. Here we demonstrate that MA has a previously undescribed nuclear export activity. Although MA lacks the canonical leucine-rich nuclear export signal, nuclear export is mediated through the conserved Crmlp pathway and functions in both mammalian cells and yeast. A mutation that disrupts the MA nuclear export signal (MA-M4) mislocalizes Pr55 and genomic viral RNA to the nucleus, thereby severely impairing viral replication. Furthermore, we show that MA-M4 can act in a dominant-negative fashion to mislocalize genomic viral RNA even in the presence of wild-type MA, We conclude that the MA nuclear export signal is required to counteract the MA nuclear localization signal, thus ensuring the cytoplasmic availability of the components required for virion assembly.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Fornerod M, 1997, CELL, V90, P1051; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Krausslich HG, 1996, CURR TOP MICROBIOL, V214, P25; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Sakuragi J, 1997, J VIROL, V71, P3250, DOI 10.1128/JVI.71.4.3250-3254.1997; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	26	102	105	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					681	685		10.1038/45272	http://dx.doi.org/10.1038/45272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604476				2022-12-28	WOS:000084189800070
J	Thommes, EW; Duncan, MJ; Levison, HF				Thommes, EW; Duncan, MJ; Levison, HF			The formation of Uranus and Neptune in the Jupiter-Saturn region of the Solar System	NATURE			English	Article							GIANT PLANETS; FAMILY COMETS; KUIPER BELT; ORIGIN; ACCRETION	Planets are believed to have formed through the accumulation of a large number of small bodies(1-4). In the case of the gas-giant planets Jupiter and Saturn, they accreted a significant amount of gas directly from the protosolar nebula after accumulating solid cores of about 5-15 Earth masses(5,6). Such models, however, have been unable to produce the smaller ice giants(7,8) Uranus and Neptune at their present locations, because in that region of the Solar System the small planetary bodies will have been more widely spaced, and less tightly bound gravitationally to the Sun. When applied to the current Jupiter-Saturn zone, a recent theory predicts that, in addition to the solid cores of Jupiter and Saturn, two or three other solid bodies of comparable mass are likely to have formed(9). Here we report the results of model calculations that demonstrate that such cores will have been gravitationally scattered outwards as Jupiter, and perhaps Saturn, accreted nebular gas. The orbits of these cores then evolve into orbits that resemble those of Uranus and Neptune, as a result of gravitational interactions with the small bodies in the outer disk of the protosolar nebula.	Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada; SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA	Queens University - Canada	Duncan, MJ (corresponding author), Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				BODENHEIMER P, 1986, ICARUS, V67, P391, DOI 10.1016/0019-1035(86)90122-3; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Duncan MJ, 1998, ASTRON J, V116, P2067, DOI 10.1086/300541; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Levison HF, 1998, ASTRON J, V116, P1998, DOI 10.1086/300557; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; LISSAUER JJ, 1996, NEPTUNE TRITON, P37; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; Morbidelli A, 1998, ASTR SOC P, V149, P83; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Safronov V S., 1969, EVOLUTION PROTOPLANE; STEWART G, 1998, P LUN PLAN SCI C 29; Weidenschilling SJ, 1996, NATURE, V384, P619, DOI 10.1038/384619a0; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E	21	207	210	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					635	638		10.1038/45185	http://dx.doi.org/10.1038/45185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604469				2022-12-28	WOS:000084189800057
J	Taylor, RS; Belli, AM; Jacob, S				Taylor, RS; Belli, AM; Jacob, S			Distal venous arterialisation for salvage of critically ischaemic inoperable limbs	LANCET			English	Article								Background Amputation remains the only option in patients with extensive arterial disease in whom conventional bypass operations are not feasible. Up to 10 000 amputations for vascular disease are estimated to be done annually. We investigated the use of venous perfusion as an alternative method of limb salvage. Methods Over 28 months, 18 patients with critical-limb ischaemia underwent bypass procedures to the venous bed of the foot with vein, synthetic graft, or a combination of these as the conduit. Various methods were used to destroy the valves of the venous system. We followed up patients for a mean of 17 months. Findings Three grafts failed immediately after surgery and necessitated major amputation, with orie death. One late failure did not necessitate amputation. 15 patients had relief of symptoms and retained a useful pain-free limb with healing of ulcers and gangrene. Two patients with functioning grafts died at 5 months and 13 months, respectively. Three patients had successful further radiological intervention. The overall limb-salvage rate was 83% and 1-year limb-salvage rate was 75%. Interpretation Distal venous arterialisation is a unique procedure that has exciting possibilities for limb salvage and merits further investigation. Increased use of this procedure may help to lower the number of limbs amputated for vascular disease.	Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England	St Georges University London	Taylor, RS (corresponding author), Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England.							BAFFOUR R, 1988, SURG GYNECOL OBSTET, V166, P28; Bernheim BM, 1912, ANN SURG, V55, P195, DOI 10.1097/00000658-191202000-00002; BLAISDELL FW, 1966, AM J SURG, V112, P166, DOI 10.1016/0002-9610(66)90005-5; CARREL A, 1902, LYON MED, V99, P153; CUTTINO JT, 1975, BASIC RES CARDIOL, V70, P568, DOI 10.1007/BF01906387; DORMANDY JA, 1995, VASC MED REV, V5, P331; Francois-Franck M, 1896, COMPT REND HEBD SOC, V48, P150; GERARD DF, 1981, SURGERY, V89, P485; GOLDSMITH HS, 1984, JAMA-J AM MED ASSOC, V252, P2034, DOI 10.1001/jama.252.15.2034; Halstead AE, 1912, SURG GYNECOL OBSTET, V14, P1; KUMAR S, 1983, LANCET, V2, P364; LENGUA F, 1993, J CHIR-PARIS, V130, P12; Lengua F, 1975, NOUV PRESSE MED, V4, P1039; MATOLO NM, 1976, ANN SURG, V184, P622, DOI 10.1097/00000658-197611000-00016; Pokrovsky AV, 1996, ANN VASC SURG, V4, P73; ROBERTSON RL, 1950, SURGERY, V27, P1; ROOT HD, 1965, J AMER MED ASSOC, V191, P645, DOI 10.1001/jama.1965.03080080035008; SANMARTIN Y, 1902, JURADO MED FARMACOL, V12, P1641; SHEIL AGR, 1977, BRIT J SURG, V64, P197, DOI 10.1002/bjs.1800640314; SZILAGYI DE, 1951, AMA ARCH SURG, V63, P435, DOI 10.1001/archsurg.1951.01250040445003; WOLFE JHN, 1986, BRIT J SURG, V73, P321	21	35	44	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1962	1965		10.1016/S0140-6736(99)03164-5	http://dx.doi.org/10.1016/S0140-6736(99)03164-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622299				2022-12-28	WOS:000084034700013
J	Krummel, T; Dimitrov, Y; Moulin, B; Hannedouche, T				Krummel, T; Dimitrov, Y; Moulin, B; Hannedouche, T			Acute renal failure induced by topical ketoprofen	BRITISH MEDICAL JOURNAL			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DISEASE							MOULIN, Bruno/0000-0001-6772-7165				FERNANDO AHN, 1994, BRIT MED J, V308, P533, DOI 10.1136/bmj.308.6927.533; OCALLAGHAN CA, 1994, BRIT MED J, V308, P110, DOI 10.1136/bmj.308.6921.110; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; Shah AK, 1996, PHARMACEUT RES, V13, P168, DOI 10.1023/A:1016014308638; Skeith KJ, 1996, BRIT J CLIN PHARMACO, V42, P163, DOI 10.1046/j.1365-2125.1996.03864.x	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					93	93		10.1136/bmj.320.7227.93	http://dx.doi.org/10.1136/bmj.320.7227.93			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625264	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000084746600019
J	Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG				Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG			Structural basis of Smad2 recognition by the Smad anchor for receptor activation	SCIENCE			English	Article							TGF-BETA RECEPTOR; PROTEINS; COMPLEX; SPECIFICITY	The Smad proteins mediate transforming growth factor-beta (TGF beta) signaling from the transmembrane serine-threonine receptor kinases to the nucleus. The Smad anchor for receptor activation (SARA) recruits Smad2 to the TGF beta receptors for phosphorylation. The crystal structure of a Smad2 MH2 domain in complex with the Smad-binding domain (SBD) of SARA has been determined at 2.2 angstrom resolution. SARA SBD, in an extended conformation comprising a rigid coil, an alpha helix, and a beta strand, interacts with the beta sheet and the three-helix bundle of Smad2 Recognition between the SARA rigid coil and the Smad2 beta sheet is essential for specificity, whereas interactions between the SARA beta strand and the Smad2 three-helix bundle contribute significantly to binding affinity. Comparison of the structures between Smad2 and a comediator Smad suggests a model for how receptor-regulated Smads are recognized by the type I receptors.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst,Dept Med Genet & Microb, Program Mol Biol & Microbiol, Toronto, ON M5G 1X5, Canada	Princeton University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu	Wrana, Jeffrey/F-8857-2013	Shi, Yigong/0000-0003-2030-168X; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA85171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA085171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Liu B, 1999, MOL CELL BIOL, V19, P424; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	19	225	249	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					92	97		10.1126/science.287.5450.92	http://dx.doi.org/10.1126/science.287.5450.92			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615055				2022-12-28	WOS:000084578400041
J	Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A				Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A			Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; INFECTION; MENINGITIS; STRATEGIES	Background: Group B streptococcal infections are a leading cause of neonatal mortality, and they also affect pregnant women and the elderly. Many cases of the disease in newborns can be prevented by the administration of prophylactic intrapartum antibiotics. In the 1990s, prevention efforts increased. In 1996, consensus guidelines recommended use of either a risk-based or a screening-based approach to identify candidates for intrapartum antibiotics. To assess the effects of the preventive efforts, we analyzed trends in the incidence of group B streptococcal disease from 1993 to 1998. Methods: Active, population-based surveillance was conducted in selected counties of eight states. A case was defined by the isolation of group B streptococci from a normally sterile site. Census and live-birth data were used to calculate the race-specific incidence of disease; national projections were adjusted for race. Results: Disease in infants less than seven days old accounted for 20 percent of all 7867 group B streptococcal infections. The incidence of early-onset neonatal infections decreased by 65 percent, from 1.7 per 1000 live births in 1993 to 0.6 per 1000 in 1998. The excess incidence of early-onset disease in black infants, as compared with white infants, decreased by 75 percent. Projecting our findings to the entire United States, we estimate that 3900 early-onset infections and 200 neonatal deaths were prevented in 1998 by the use of intrapartum antibiotics. Among pregnant girls and women, the incidence of invasive group B streptococcal disease declined by 21 percent. The incidence among nonpregnant adults did not decline. Conclusions: Over a six-year period, there has been a substantial decline in the incidence of group B streptococcal disease in newborns, including a major reduction in the excess incidence of these infections in black infants. These improvements coincide with the efforts to prevent perinatal disease by the wider use of prophylactic intrapartum antibiotics. (N Engl J Med 2000;342:15-20.).	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Serv, Atlanta, GA USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Johns Hopkins Sch Hyg & Publ Hlth, Baltimore, MD USA; Vanderbilt Med Ctr, Nashville, TN USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Minnesota Dept Hlth, Minneapolis, MN USA; Dept Human Resources, Portland, OR USA	Centers for Disease Control & Prevention - USA; Emory University; University of California System; University of California Berkeley; Johns Hopkins University; Vanderbilt University; Minnesota Department of Health (MHD)	Schrag, SJ (corresponding author), Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, MS-C23,1600 clifton Rd, Atlanta, GA 30333 USA.							Baker CJ, 1999, J INFECT DIS, V179, P142, DOI 10.1086/314574; BAKER CJ, 1973, J PEDIATR-US, V82, P724, DOI 10.1016/S0022-3476(73)80606-7; BARTON LL, 1973, J PEDIATR-US, V82, P719, DOI 10.1016/S0022-3476(73)80605-5; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P679; *COMM OBST PRACT, 173 ACOG COMM OBST P; *DEP HLTH HUM SERV, IN PRESS HLTH PEOPL; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; Fernandez M, 1998, ANTIMICROB AGENTS CH, V42, P1517, DOI 10.1128/AAC.42.6.1517; FRANCIOSI RA, 1973, J PEDIATR-US, V82, P707, DOI 10.1016/S0022-3476(73)80604-3; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Krohn MA, 1999, J INFECT DIS, V179, P1410, DOI 10.1086/314756; Locksmith GJ, 1999, AM J OBSTET GYNECOL, V180, P416, DOI 10.1016/S0002-9378(99)70225-5; MCCRACKEN GH, 1973, J PEDIATR-US, V82, P703, DOI 10.1016/S0022-3476(73)80603-1; Mohle-Boetani JC, 1999, PEDIATRICS, V103, P703, DOI 10.1542/peds.103.4.703; MOHLEBOETANI JC, 1993, JAMA-J AM MED ASSOC, V270, P1442, DOI 10.1001/jama.270.12.1442; Pearlman MD, 1998, OBSTET GYNECOL, V92, P258, DOI 10.1016/S0029-7844(98)00155-0; ROBBINS JB, 1995, ANN NY ACAD SCI, V754, P68, DOI 10.1111/j.1749-6632.1995.tb44439.x; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; Towers CV, 1998, AM J OBSTET GYNECOL, V179, P879, DOI 10.1016/S0002-9378(98)70182-6; YANCEY MK, 1994, OBSTET GYNECOL, V83, P367; YANCEY MK, 1994, OBSTET GYNECOL, V84, P816; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1996, MMWR MORB MORTAL WKL, V45, P1; 1997, MMWR MORB MORTAL WKL, V46, P473; 1998, MMWR MORB MORTAL WKL, V47, P665	28	701	731	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					15	20		10.1056/NEJM200001063420103	http://dx.doi.org/10.1056/NEJM200001063420103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620644				2022-12-28	WOS:000084575600003
J	Mynors-Wallis, LM; Gath, DH; Day, A; Baker, F				Mynors-Wallis, LM; Gath, DH; Day, A; Baker, F			Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EMOTIONAL DISORDERS; PLACEBO	Objectives To determine whether problem solving treatment combined with antidepressant medication is more effective than either treatment alone in the management of major depression in primary care. To assess the effectiveness of problem solving treatment when given by practice nurses compared with general practitioners when both have been trained in the technique. Design Randomised controlled trial with four treatment groups. Setting Primary care in Oxfordshire. Participants Patients aged 18-65 years with major depression on the research diagnostic criteria-a score of 13 or more on the 17 item Hamilton rating scale for depression and a minimum duration of illness of four weeks. Interventions Problem solving treatment by research general practitioner or research practice nurse or antidepressant medication or a combination of problem solving treatment and antidepressant medication. Main outcome measures Hamilton rating scale for depression, Beck depression inventory, clinical interview schedule (revised), and the modified social adjustment schedule assessed at 6, 12, and 52 weeks. Results Patients in all groups showed a dear improvement over 12 weeks. The combination of problem solving treatment and antidepressant medication was no more effective than either treatment alone. There was no difference in outcome irrespective of who delivered the problem solving treatment. Conclusions Problem solving treatment is an effective treatment for depressive disorders in primary care. The treatment can be delivered by suitably trained practice nurses or general practitioners. The combination of this treatment with antidepressant medication is no more effective than either treatment alone.	Univ Oxford, Dept Psychiat, Warneford Hosp, Oxford OX3 7BJ, England	University of Oxford	Mynors-Wallis, LM (corresponding author), Univ Oxford, Dept Psychiat, Warneford Hosp, Oxford OX3 7BJ, England.	lmmw@soton.ac.uk						BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLACKER CVR, 1988, PSYCHOPHARMACOLOGY, V95, pS14; CATALAN J, 1991, PSYCHOL MED, V21, P1013, DOI 10.1017/S0033291700030002; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; *DEPR GUID PAN, 1993, CLIN PRACT GUID, V5; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; GATH DH, 1997, SCI PRACTICE COGNITI; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MynorsWallis L, 1997, PSYCHOL MED, V27, P731, DOI 10.1017/S0033291796004126; MynorsWallis L, 1997, BRIT J PSYCHIAT, V170, P113, DOI 10.1192/bjp.170.2.113; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; PRIEST RG, 1996, BRIT MED J, V313, P838; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013	15	289	291	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2000	320	7226					26	30		10.1136/bmj.320.7226.26	http://dx.doi.org/10.1136/bmj.320.7226.26			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617523	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000084621600019
J	Longo, MJ; Jaffe, CC				Longo, MJ; Jaffe, CC			Electrical alternans.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Virginia Mason Med Ctr, Seattle, WA 98111 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	Virginia Mason Medical Center; Yale University	Longo, MJ (corresponding author), Virginia Mason Med Ctr, Seattle, WA 98111 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2060	2060		10.1056/NEJM199912303412705	http://dx.doi.org/10.1056/NEJM199912303412705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615078				2022-12-28	WOS:000084573300005
J	Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT				Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT			Enhanced morphine analgesia in mice lacking beta-arrestin 2	SCIENCE			English	Article							ADRENERGIC-RECEPTOR KINASE; OPIOID-RECEPTOR; OPIATE RECEPTOR; MU-RECEPTOR; HOT-PLATE; DESENSITIZATION; GENE; INTERNALIZATION; STIMULATION; MECHANISMS	The ability of morphine to alleviate pain is mediated through a heterotrimeric guanine nucleotide binding protein (G protein)-coupled heptahelical receptor (GPCR), the mu opioid receptor (mu OR). The efficiency of GPCR signaling is tightly regulated and ultimately Limited by the coordinated phosphorylation of the receptors by specific GPCR kinases and the subsequent interaction of the phosphorylated receptors with beta-arrestin 1 and beta-arrestin 2. Functional deletion of the beta-arrestin 2 gene in mice resulted in remarkable potentiation and prolongation of the analgesic effect of morphine, suggesting that mu OR desensitization was impaired. These results provide evidence in vivo for the physiological importance of beta-arrestin 2 in regulating the function of a specific GPCR, the mu OR. Moreover, they suggest that inhibition of beta-arrestin 2 function might lead to enhanced analgesic effectiveness of morphine and provide potential new avenues for the study and treatment of pain, narcotic tolerance, and dependence.	Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu; caron002@mc.duke.edu	Bohn, Laura M/A-7483-2014; Lefkowitz, Robert/AAW-2649-2021; Gainetdinov, Raul R/G-5875-2011; Bohn, Laura/A-4412-2008	Bohn, Laura M/0000-0002-6474-8179; Gainetdinov, Raul R/0000-0003-2951-6038; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA006023] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDA NIH HHS [F32 DA006023] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELKNAP JK, 1989, PHYSIOL BEHAV, V46, P69, DOI 10.1016/0031-9384(89)90324-7; BOHN LM, UNPUB; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Conner DA, 1997, CIRC RES, V81, P1021; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; Elmer GI, 1998, PAIN, V75, P129, DOI 10.1016/S0304-3959(97)00215-7; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GAINETDINOV RR, UNPUB; Gardmark M, 1998, PHARMACOL TOXICOL, V83, P252, DOI 10.1111/j.1600-0773.1998.tb01478.x; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LIN FC, UNPUB; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MAYER DJ, 1976, PAIN, V2, P379, DOI 10.1016/0304-3959(76)90080-4; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PORTOGHESE PS, 1990, J MED CHEM, V33, P1547, DOI 10.1021/jm00168a004; PORTOGHESE PS, 1993, HDB EXPT PHARM OPIOI, V1, P279; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; SMITH DJ, 1988, EUR J PHARMACOL, V156, P47, DOI 10.1016/0014-2999(88)90145-8; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Walker JKL, 1999, AM J PHYSIOL-REG I, V276, pR1214, DOI 10.1152/ajpregu.1999.276.4.R1214; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YAKSH TL, 1988, PROG BRAIN RES, V77, P371; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	39	752	771	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2495	2498		10.1126/science.286.5449.2495	http://dx.doi.org/10.1126/science.286.5449.2495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617462				2022-12-28	WOS:000084429700045
J	Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F				Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F			Pharmacological rescue of mutant p53 conformation and function	SCIENCE			English	Article							DNA-BINDING; CELL-LINES; WILD-TYPE; PROTEIN; MUTATIONS; INVITRO; DOMAIN	Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.	Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Groton, CT 06340 USA	Pfizer	Rastinejad, F (corresponding author), Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Eastern Point Rd, Groton, CT 06340 USA.							BARTEK J, 1990, ONCOGENE, V5, P893; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DANIELS DA, 1994, J MOL BIOL, V243, P639, DOI 10.1016/0022-2836(94)90038-8; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEGROS Y, 1994, ONCOGENE, V9, P3689; MILNER J, 1990, ONCOGENE, V5, P1683; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Nielsen LL, 1997, CANCER GENE THER, V4, P129; OConnor PM, 1997, CANCER RES, V57, P4285; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRUSINER SB, 1997, SCIENCE, V278, P243; ROSENFELD MR, 1995, NEUROLOGY, V45, P1533, DOI 10.1212/WNL.45.8.1533; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	24	652	690	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2507	2510		10.1126/science.286.5449.2507	http://dx.doi.org/10.1126/science.286.5449.2507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617466				2022-12-28	WOS:000084429700049
J	Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM				Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM			Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; ANGIOGENESIS; SKIN; INFLAMMATION; VENULES; TIE2	Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) are endothelial cell-specific growth factors. Direct comparison of transgenic mice overexpressing these factors in the skin revealed that the VEGF-induced blood vessels were Leaky, whereas those induced by Ang1 were nonleaky. Moreover, vessels in Ang1-overexpressing mice were resistant to Leaks caused by inflammatory agents. Coexpression of Ang1 and VEGF had an additive effect on angiogenesis but resulted in Leakage-resistant vessels typical of Ang1. Ang1 therefore may be useful for reducing microvascular Leakage in diseases in which the Leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Regeneron	Thurston, G (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.			Thurston, Gavin/0000-0002-4105-5919	NHLBI NIH HHS [HL-24136, HL-59157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baluk P, 1999, BRIT J PHARMACOL, V126, P522, DOI 10.1038/sj.bjp.0702323; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BERGMAN RK, 1975, J ALLERGY CLIN IMMUN, V55, P378, DOI 10.1016/0091-6749(75)90076-7; Cunha-Vaz J, 1998, EUR J OPHTHALMOL, V8, P127, DOI 10.1177/112067219800800301; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Erjefalt JS, 1998, CLIN EXP ALLERGY, V28, P1013; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FUJII E, 1994, N-S ARCH PHARMACOL, V350, P361; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Inoue H, 1997, EUR J PHARMACOL, V333, P231, DOI 10.1016/S0014-2999(97)01040-6; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P607, DOI 10.1083/jcb.11.3.607; MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; OHRUI T, 1992, J ALLERGY CLIN IMMUN, V89, P933, DOI 10.1016/0091-6749(92)90215-N; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Schainfeld RM, 1999, ANN INTERN MED, V130, P442, DOI 10.7326/0003-4819-130-5-199903020-00017; Shiels IA, 1998, MED HYPOTHESES, V50, P113, DOI 10.1016/S0306-9877(98)90195-5; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; SVENSJO E, 1986, FASEB J, V45, P89; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; WADSWORTH JDF, 1993, BIOCHEM J, V295, P537, DOI 10.1042/bj2950537; ZWEIFACH BW, 1973, ANNU REV PHYSIOL, V35, P117, DOI 10.1146/annurev.ph.35.030173.001001	31	1087	1167	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2511	2514		10.1126/science.286.5449.2511	http://dx.doi.org/10.1126/science.286.5449.2511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617467				2022-12-28	WOS:000084429700050
J	Whitty, CJM				Whitty, CJM			Erasmus, syphilis, and the abuse of stigma	LANCET			English	Editorial Material									Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi	University of Malawi	Whitty, CJM (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England.		Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027				ERASMUS D, OPERA OMNIA, V5; TEMKIN I, 1977, DOUBLE FACE JANUS OT, P475	2	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2147	2148		10.1016/S0140-6736(99)11155-3	http://dx.doi.org/10.1016/S0140-6736(99)11155-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609831				2022-12-28	WOS:000084318200042
J	Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B				Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B			Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic	SCIENCE			English	Article							C-TERMINAL PART; ANTIMICROBIAL PEPTIDE; BACTERIAL-MEMBRANES; NISIN; TRANSLOCATION; VANCOMYCIN; VESICLES; BILAYERS	Resistance to antibiotics is increasing in some groups of clinically important pathogens. For instance, high vancomycin resistance has emerged in enterococci. Promising alternative antibiotics are the peptide antibiotics, abundant in host defense systems, which kill their targets by permeabilizing the plasma membrane, These peptides generally do not act via specific receptors and are active in the micromolar range. Here it is shown that vancomycin and the antibacterial peptide nisin Z use the same target: the membrane-anchored cell wall precursor Lipid II, Nisin combines high affinity for Lipid II with its pore-forming ability, thus causing the peptide to be highly active (in the nanomolar range).	Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53105 Bonn, Germany; NIZO, Food Res Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	Utrecht University; University of Bonn; NIZO Food Research; University of Groningen	Breukink, E (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	e.j.breukink@chem.uu.nl	Breukink, Eefjan/I-3039-2016; Kuipers, Oscar/B-6752-2009	Breukink, Eefjan/0000-0002-7311-0660; Kuipers, Oscar/0000-0001-5596-7735				Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STONE KJ, 1973, J BIOL CHEM, V249, P1823; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VanKraaij C, 1997, EUR J BIOCHEM, V247, P114; WILLIAMS DH, 1988, BIOCHEM PHARMACOL, V37, P133, DOI 10.1016/0006-2952(88)90765-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	17	614	634	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2361	2364		10.1126/science.286.5448.2361	http://dx.doi.org/10.1126/science.286.5448.2361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600751	Green Submitted			2022-12-28	WOS:000084318500068
J	Apfeld, J; Kenyon, C				Apfeld, J; Kenyon, C			Regulation of lifespan by sensory perception in Caenorhabditis elegans	NATURE			English	Article							NUCLEOTIDE-GATED CHANNEL; DAUER LARVA FORMATION; C-ELEGANS; NERVOUS-SYSTEM; LONGEVITY; DAF-2; GENES; SPAN; DIAPAUSE; PATHWAY	Caenorhabditis elegans senses environmental signals through ciliated sensory neurons located primarily in sensory organs in the head and tail. Cilia function as sensory receptors, and mutants with defective sensory cilia have impaired sensory perception(1,2) Cilia are membrane-bound microtubule-based structures and in C. elegans are only found at the dendritic endings of sensory neurons(3). Here we show that mutations that cause defects in sensory cilia or their support cells, or in sensory signal transduction, extend lifespan. Our findings imply that sensory perception regulates the lifespan of this animal, and suggest that in nature, its Lifespan may be regulated by environmental cues.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu		Apfeld, Javier/0000-0001-9897-5671				Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Coburn CM, 1998, DEVELOPMENT, V125, P249; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Collet J, 1998, GENETICS, V148, P187; DORMAN JB, 1995, GENETICS, V141, P1399; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Komatsu H, 1999, BRAIN RES, V821, P160, DOI 10.1016/S0006-8993(99)01111-7; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; LARSEN PL, 1995, GENETICS, V139, P1567; LAWLESS JF, 1982, MODELS METHODS LIFET; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Peckol EL, 1999, DEVELOPMENT, V126, P1891; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	27	394	438	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					804	809		10.1038/45544	http://dx.doi.org/10.1038/45544			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617200				2022-12-28	WOS:000084330500064
J	Forbes, RB; Lees, A; Waugh, N; Swingler, RJ				Forbes, RB; Lees, A; Waugh, N; Swingler, RJ			Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; GUIDELINES; CARE	Objective To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. Design Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey Local and published costs were used. Effectiveness was modelled using data on relative risk reductions from a randomised trial of interferon beta-lb. Setting Tayside region, 1993-5. Subjects 132 ambulatory people with secondary; progressive multiple sclerosis. Main outcome measures Cost per quality adjusted life lear (QALY) gained. Rate of relapse and proportion becoming wheelchair dependent ol:er three years. Results The number needed to treat for 30 months to delay time to wheelchair dependence in one per-son by nine months was 18 (95% confidence interval 5 to 26), For every 18 people treated for 30 months, sh relapses would be prevented, gaining 0.397 discounted QALYs. The cost per QALY gained was pound 1 024 667 (pound 276 466 to pound 1 485 499). If treatment was restricted to patients attending neurology services, the number needed to treat was 14 (cost per QALY gained pound 833 514 (pound 161 358 to infinity)). The cost per QALY gained was not sensitive to changes in cost which took account of a societal perspective. Conclusions The cost per QALY; gained from interferon beta is high because of the high drug cost and modest clinical effect Resources could be used more efficiently elsewhere.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurol, Dundee DD1 9SY, Scotland; Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland; Scottish Hlth Purchasing Informat Ctr, Aberdeen AB15 6RE, Scotland	University of Dundee	Forbes, RB (corresponding author), Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland.	raeburn.forbes@royalhospitals.n-i-nhs.uk		Forbes, Raeburn/0000-0002-1444-7909				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Auty A, 1998, CAN J NEUROL SCI, V25, P23; Blumhardt L., 1996, BR J MED EC, V10, P99; *BRIT MED ASS, 1995, BRIT NAT FORM; BROWN MG, 1996, THERAPEUTIC EC ASSES; Busch MP, 1997, TRANSFUSION, V37, P1003, DOI 10.1046/j.1537-2995.1997.371098016437.x; Carton H, 1998, J NEUROL NEUROSUR PS, V64, P444, DOI 10.1136/jnnp.64.4.444; Dolan P, 1995, SOCIAL TARIFF EUROQO; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Forbes RB, 1999, AM J EPIDEMIOL, V149, P1016; FREEMAN J, 1997, STANDARDS HEALTHCARE; Gardner MJ, 1989, STAT CONFIDENCE, P28; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; Goodkin DE, 1998, LANCET, V352, P1486, DOI 10.1016/S0140-6736(98)00057-9; Graham B, 1997, BRIT J GEN PRACT, V47, P170; Holmes J, 1997, BRIT MED J, V314, P601; HOLMES J, 1998, J NEUROL NEUROSUR PS, V64, P420; Holmes J., 1995, BR J MED EC, V8, P181; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MCALPINE D, 1952, Q J MED, V21, P135; MOONEY C, 1992, EC MED HLTH CARE, P5; OBRIEN B, 1997, MULT SCLER, V47, P170; PARKIN D, 1998, HLTH TECHNOL ASSESSM, V2; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Richards RG, 1996, BRIT MED J, V313, P1159, DOI 10.1136/bmj.313.7066.1159; SACKETT DL, 1996, PRACTICE TEACH EVIDE; Stolp-Smith KA, 1998, NEUROLOGY, V50, P1594, DOI 10.1212/WNL.50.6.1594; Tolley KH, 1997, PHARMACOECONOMICS, V11, P210, DOI 10.2165/00019053-199711030-00002; Tremlett HL, 1998, J NEUROL NEUROSUR PS, V65, P362, DOI 10.1136/jnnp.65.3.362; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; Vickrey BG, 1997, J CLIN EPIDEMIOL, V50, P557, DOI 10.1016/S0895-4356(97)00001-2; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1998, MS MATTERS       NOV	39	69	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1529	1533		10.1136/bmj.319.7224.1529	http://dx.doi.org/10.1136/bmj.319.7224.1529			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591710	Green Published, Bronze			2022-12-28	WOS:000084245600020
J	Michel, H				Michel, H			Bioenergetics - Proton pumping by cytochrome c oxidase	NATURE			English	Article									Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60528 Frankfurt, Germany	Max Planck Society	Michel, H (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.							Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; MICHEL H, IN PRESS BIOCHEMISTR; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; Verkhovsky MI, 1999, BBA-BIOENERGETICS, V1412, P184, DOI 10.1016/S0005-2728(99)00053-5; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0	7	31	32	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					602	603		10.1038/45133	http://dx.doi.org/10.1038/45133			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604465				2022-12-28	WOS:000084189800046
J	Stopfer, M; Laurent, G				Stopfer, M; Laurent, G			Short-term memory in olfactory network dynamics	NATURE			English	Article							OSCILLATING NEURAL ASSEMBLIES; VISUAL-CORTEX; INFORMATION; SYNCHRONIZATION; INSECTS; BULB; CAT	Neural assemblies in a number of animal species display self-organized, synchronized oscillations in response to sensory stimuli in a variety of brain areas.(1-5). In the olfactory system of insects, odour-evoked oscillatory synchronization of antennal lobe projection neurons (PNs) is superimposed on slower and stimulus-specific temporal activity patterns. Hence, each odour activates a specific and dynamic projection neuron assembly whose evolution during a stimulus is locked to the oscillation clock(6,7). Here we examine, using locusts, the changes in population dynamics of projection-neuron assemblies over repeated odour stimulations, as would occur when an animal first encounters and then repeatedly samples an odour for identification or localization. We find that the responses of these assemblies rapidly decrease in intensity, while they show a marked increase in spike time precision and inter-neuronal oscillatory coherence. Once established, this enhanced precision in the representation endures for several minutes. This change is stimulus-specific, and depends on events within the antennal lobe circuits, independent of olfactory receptor adaptation: it may thus constitute a form of sensory memory. Our results suggest that this progressive change in olfactory network dynamics serves to converge, over repeated odour samplings, on a more precise and readily classifiable odour representation, using relational information contained across neural assemblies.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.		Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1978, ELECTROEN CLIN NEURO, V44, P586, DOI 10.1016/0013-4694(78)90126-8; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Kay S. M., 1988, MODERN SPECTRAL ESTI; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; LAWLESS H, 1997, TASTING SMELLING; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; MASSON C, 1990, PHYSIOL REV, V70, P199, DOI 10.1152/physrev.1990.70.1.199; Mellon D, 1997, J COMP PHYSIOL A, V180, P553, DOI 10.1007/s003590050072; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; PRECHTL JC, 1994, P NATL ACAD SCI USA, V91, P12467, DOI 10.1073/pnas.91.26.12467; SLIFER EH, 1965, J MORPHOL, V114, P393; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WEHT M, 1999, J NEUROSCI, V19, P381	21	191	193	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					664	668		10.1038/45244	http://dx.doi.org/10.1038/45244			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604472				2022-12-28	WOS:000084189800066
J	Lucas, A; Stafford, M; Morley, R; Abbott, R; Stephenson, T; MacFadyen, U; Elias-Jones, A; Clements, H				Lucas, A; Stafford, M; Morley, R; Abbott, R; Stephenson, T; MacFadyen, U; Elias-Jones, A; Clements, H			Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial	LANCET			English	Article							1ST YEAR GROWTH; PRETERM INFANTS; VISUAL-ACUITY; TERM INFANTS; COGNITIVE-DEVELOPMENT; ARACHIDONIC-ACID; DOCOSAHEXAENOIC ACID; DIETARY-FAT; QUOTIENT; BRAIN	Background We tested whether addition of n-3 and n-6 long-chain polyunsaturated fatty acids (LCPUFA) to infant-formula milk during the first 6 months promotes long-term cognitive and motor development, without adverse consequences. Methods We did a double-blind, randomised, controlled, efficacy and safety trial of formula with and without LCPUFAs, with an additional breastfed reference group, in four hospitals in two cities in the UK. The participants were 447 healthy full-term babies. 309 were fed formula (155 without LCPUFAs) and 138 were breastfed for at least 6 weeks. The main outcome measures were: Bayley Mental and Psychomotor Development Indices (MDI, PDI) at 18 months (primary efficacy outcome) and Knobloch, Passamanick, and Sherrards test at 9 months (secondary outcome). Principal safety outcomes were: infection, atopy, growth, and gastrointestinal tolerance. Findings Babies fed formula with and without LCPUFA did not differ in cognitive or motor development, growth, infection, atopy or tolerance. The mean (95% CI) MDI was 0.5 (-2.7 to 3.8) units and the PDI 0.6 (-1.8 to 3.0) units higher in the supplementation group. Formula-fed infants had similar developmental scores to the breastfed reference group after adjustment for higher social class and maternal education in the latter. Interpretation There was no evidence of a beneficial or adverse effect on cognitive and motor development or growth up to 18 months. Although no significant differences in safety outcomes were observed, we suggest such data should be collected in future LCPUFA trials. Our trial does not provide support for addition of LCPUFA to standard infant formula but we are now doing further follow-up of this cohort.	MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; UCL Med Sch, Dept Epidemiol & Publ Hlth, London, England; Menzies Ctr Populat Hlth Res, Hobart, Tas, Australia; Univ Melbourne, Clin Epidemiol & Biostat Unit, Parkville, Vic 3052, Australia; Queensland Univ Technol, Fac Hlth, Dept Human Movement Studies, Brisbane, Qld, Australia; Nottingham Univ NHS Trust, Queens Med Ctr, Dept Child Hlth, Nottingham, England; Stirling Royal Infirm, Stirling, Scotland; Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England; Nottingham City Hosp NHS Trust, Nottingham, England	University of London; University College London; University of London; University College London; University of Melbourne; Queensland University of Technology (QUT); Nottingham University Hospital NHS Trust; University of Nottingham; University of Leicester; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Lucas, A (corresponding author), MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.		Abbott, Rebecca/I-3186-2012	Abbott, Rebecca/0000-0003-4165-4484; Stephenson, Terence/0000-0001-8871-7847				AGOSTONI C, 1995, PEDIATR RES, V38, P262, DOI 10.1203/00006450-199508000-00021; AGOSTONI C, 1996, P 17 INT S NEON INT, pA25; Auestad N, 1997, PEDIATR RES, V41, P1, DOI 10.1203/00006450-199701000-00001; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BENNETT M, 1987, AM J PATHOL, V126, P103; Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; BOURRE JM, 1989, J NUTR, V119, P15, DOI 10.1093/jn/119.1.15; *CAN PAED SOC, 1998, DIET CAN HLTH CAN NU; CARLSON SE, 1992, LIPIDS, V27, P901, DOI 10.1007/BF02535870; CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073; Carlson SE, 1996, AM J CLIN NUTR, V63, P687, DOI 10.1093/ajcn/63.5.687; CARLSON SE, 1994, EUR J CLIN NUTR, V48, pS27; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; Fritsche KL, 1997, CLIN SCI, V92, P95, DOI 10.1042/cs0920095; GALLI E, 1994, BRIT J DERMATOL, V130, P752, DOI 10.1111/j.1365-2133.1994.tb03413.x; HARTMANN EE, 1995, INVEST OPHTH VIS SCI, V36, pS869; INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q; INNIS SM, 1992, J PEDIATR-US, V120, pS56, DOI 10.1016/S0022-3476(05)81237-5; Innis SM, 1996, AM J CLIN NUTR, V64, P40, DOI 10.1093/ajcn/64.1.40; INNIS SM, 1994, NUTRITION, V10, P72; KNBLOCH H, 1966, PEDIATRICS, V38, P1095; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCAS A, 1997, DEV BRAIN BEHAV ROLE, P1; LUCAS A, 1994, ARCH DIS CHILD, V70, P141; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MAKRIDES M, 1994, AM J CLIN NUTR, V60, P180; Montalto Michael B., 1996, Pediatric Research, V39, p316A; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; Paul KP, 1997, METABOLISM, V46, P619, DOI 10.1016/S0026-0495(97)90003-2; Pleisler S. J, 1983, PROG LIPID RES, V22, P79; Prosser R. J, 1991, ML3 SOFTWARE 3 LEVEL; RAITEN DJ, 1998, J NUTR, V115, P2089; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; ROGAN WJ, 1993, EARLY HUM DEV, V31, P181, DOI 10.1016/0378-3782(93)90194-Y; SACK J, 1980, HUMAN MILK ITS BIOL, P56; SAGHER FA, 1991, J PEDIATR GASTR NUTR, V13, P83, DOI 10.1097/00005176-199107000-00015; Scott DT, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e59; SIMMER K, 1998, COCHRANE LIB COCHRAN; UAUY RD, 1990, PEDIATR RES, V28, P485, DOI 10.1203/00006450-199011000-00014; Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5	42	165	177	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1948	1954		10.1016/S0140-6736(99)02314-4	http://dx.doi.org/10.1016/S0140-6736(99)02314-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622297				2022-12-28	WOS:000084034700011
J	Nebreda, AR; Gavin, AC				Nebreda, AR; Gavin, AC			Signal transduction - Cell survival demands some Rsk	SCIENCE			English	Editorial Material									European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Basel, Inst Physiol, CH-4051 Basel, Switzerland	European Molecular Biology Laboratory (EMBL); University of Basel	Nebreda, AR (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Nebreda, Angel Rodriguez/R-9594-2019	Gavin, Anne-Claude/0000-0003-4917-2340				Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335	13	70	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1309	1310		10.1126/science.286.5443.1309	http://dx.doi.org/10.1126/science.286.5443.1309			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10610536				2022-12-28	WOS:000083675500029
J	Beecham, L				Beecham, L			Consultants reach agreement on 50m pound award	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					62	62						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617549				2022-12-28	WOS:000084621600061
J	Razavi, M; Aul, EA; Razavi, B; Fincham, RW				Razavi, M; Aul, EA; Razavi, B; Fincham, RW			Exclusion criteria	LANCET			English	Article							POLYNEUROPATHY		Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Razavi, M (corresponding author), Univ Iowa Hosp & Clin, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Aul, Edward/0000-0002-6366-4512				Barohn RJ, 1998, SEMIN NEUROL, V18, P49, DOI 10.1055/s-2008-1040861; BEGHI E, 1989, J NEUROL NEUROSUR PS, V52, P1420, DOI 10.1136/jnnp.52.12.1420; FINCHAM RW, 1968, ARCH NEUROL-CHICAGO, V19, P464, DOI 10.1001/archneur.1968.00480050034002; Nystrom E, 1997, ACTA NEUROL SCAND, V95, P311, DOI 10.1111/j.1600-0404.1997.tb00216.x; Uncini A, 1996, MUSCLE NERVE, V19, P365, DOI 10.1002/(SICI)1097-4598(199603)19:3<365::AID-MUS14>3.0.CO;2-R	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					38	38		10.1016/S0140-6736(99)09326-5	http://dx.doi.org/10.1016/S0140-6736(99)09326-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615890				2022-12-28	WOS:000085049200015
J	Langford, NJ; Marshall, T; Ferner, RE				Langford, NJ; Marshall, T; Ferner, RE			The lacing defence: double blind study of thresholds for detecting addition of ethanol to drinks	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Dept Gen Med & Clin Pharmacol, Birmingham B18 7QH, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Ferner, RE (corresponding author), City Hosp, Dept Gen Med & Clin Pharmacol, Birmingham B18 7QH, W Midlands, England.		Langford, Nigel/P-3308-2019	Ferner, Robin/0000-0003-3769-1346				Armitage P., 1971, STAT METHODS MED RES, V1; DENNY RC, 1986, N LAW J, V26, P923; JONES AW, 1991, MED SCI LAW, V31, P229, DOI 10.1177/002580249103100307; LEY NJ, 1993, DRINK DRIVING LAW PR; MARLATT GA, 1973, J ABNORM PSYCHOL, V81, P233, DOI 10.1037/h0034532	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1610	1610		10.1136/bmj.319.7225.1610	http://dx.doi.org/10.1136/bmj.319.7225.1610			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600959	Green Published, Bronze			2022-12-28	WOS:000084562600013
J	Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA				Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA			Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; PROTEIN-KINASE; HUMAN CANCERS; CELL-CYCLE; S-PHASE; ANTICANCER AGENTS; MISMATCH REPAIR; P53 MUTATIONS; PATHWAY	The hCHK2 gene encodes the human homolog of the yeast Cds1 and Rad53 G(2) checkpoint kinases, whose activation in response to DNA damage prevents cellular entry into mitosis. Here, it is shown that heterozygous germ Line mutations in hCHK2 occur in Li-Fraumeni syndrome, a highly penetrant Familiar cancer phenotype usually associated with inherited mutations in the TP53 gene. These observations suggest that hCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and they also provide a link between the central role of p53 inactivation in human cancer and the well-defined G(2) checkpoint in yeast.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA; Paterson Inst Canc Res, Canc Res Campaign, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Harvard Univ, Sch Med, Boston, MA 02114 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02114 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; Royal Manchester Childrens Hosp, Canc Res Campaign, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England	Harvard University; Massachusetts General Hospital; Harvard University; Paterson Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Manchester Children's Hospital	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Bldg 149, Charlestown, MA 02139 USA.	Haber@helix.mgh.harvard.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; BIRCH JM, 1994, CANCER RES, V54, P1298; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eng C, 1997, CANCER EPIDEM BIOMAR, V6, P379; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GARBER JE, 1991, CANCER RES, V51, P6094; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OConnor PM, 1997, CANCER RES, V57, P4285; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prives C, 1999, J PATHOL, V187, P112; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1909, TRENDS BIOCHEM SCI, V23, P399; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P261; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	55	696	714	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2528	2531		10.1126/science.286.5449.2528	http://dx.doi.org/10.1126/science.286.5449.2528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617473				2022-12-28	WOS:000084429700056
J	Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ				Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ			Photic induction of mPer1 and mPer2 in Cry-deficient mice lacking a biological clock	SCIENCE			English	Article							BLUE-LIGHT PHOTORECEPTORS; HUMAN PHOTOLYASE HOMOLOG; DROSOPHILA PERIOD GENE; CIRCADIAN CLOCK; EXPRESSION; SIMILARITY; ORTHOLOG; MAMMALS; RHYTHMS; OPSIN	Mice Lacking mCry1 and mCry2 are behaviorally arrhythmic. As shown here, cyclic expression of the clock genes mPer1 and mPer2 (mammalian Period genes 1 and 2) in the suprachiasmatic nucleus and peripheral tissues is abolished and mPer1 and mPer2 mRNA Levels are constitutively high. These findings indicate that the biological clock is eliminated in the absence of both mCRY1 and mCRY2 (mammalian cryptochromes 1 and 2) and support the idea that mammalian CRY proteins act in the negative Limb of the circadian feedback Loop. The mCry double-mutant mice retain the ability to have mPer1 and mPer2 expression induced by a brief Light stimulus known to phase-shift the biological clock in wild-type animals. Thus, mCRY1 and mCRY2 are dispensable for Light-induced phase shifting of the biological clock.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands	Kobe University; Tohoku University; Erasmus University Rotterdam	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	van der Horst, Gijsbertus TJ/E-3661-2015; Hoeijmakers, Jan/AAX-6972-2021; Jansen, Heiko T./A-5770-2008	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; KURNE K, 1999, CELL, V98, P193; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Soni BG, 1997, FEBS LETT, V406, P279, DOI 10.1016/S0014-5793(97)00287-1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; YAMAGUCHI S, UNPUB; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	35	307	319	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2531	2534		10.1126/science.286.5449.2531	http://dx.doi.org/10.1126/science.286.5449.2531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617474				2022-12-28	WOS:000084429700057
J	Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW				Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW			Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-DOSE METHOTREXATE; CULDOCENTESIS; DIAGNOSIS	Background: The use of methotrexate for the treatment of women with tubal ectopic pregnancies is now common practice. However, the clinical and hormonal determinants of the success of this treatment are not known. Methods: We studied 350 women with tubal ectopic pregnancies who were treated with methotrexate intramuscularly according to a single-dose protocol. Pretreatment serum concentrations of human chorionic gonadotropin and progesterone, the size and volume of the gestational mass, fetal cardiac activity, and the presence of fluid (presumably blood) in the peritoneal cavity were correlated with the efficacy of therapy, as defined by resolution of the ectopic pregnancy without the need for surgical intervention. Results: There was no relation between the women's age or parity, the size or volume of the conceptus, or the presence of fluid in the peritoneal cavity and the efficacy of treatment. Among the 320 women in whom treatment was successful (91 percent), the mean (+/-SD) serum chorionic gonadotropin and progesterone concentrations were 4019+/-6362 mIU per milliliter and 6.9+/-6.7 ng per milliliter (21.9+/-21.3 nmol per liter), respectively, as compared with 13,420+/-16,590 mIU per milliliter and 10.2+/-5.5 ng per milliliter (32.4+/-17.5 nmol per liter) (P<0.001 and P=0.02) in the 30 women in whom treatment was not successful. Fetal cardiac activity was present in 12 percent of the successfully treated cases and 30 percent of those in which treatment was not successful (P=0.01). Regression analysis revealed the pretreatment serum chorionic gonadotropin concentration to be the only factor that contributed to the failure rate. Conclusions: Among women with tubal ectopic pregnancies, a high serum chorionic gonadotropin concentration is the most important factor associated with failure of treatment with a single-dose methotrexate protocol. (N Engl J Med 1999;341:1974-8.) (C)1999, Massachusetts Medical Society.	Univ Tennessee, Div Gynecol, Dept Obstet & Gynecol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lipscomb, GH (corresponding author), Rm E102,853 Jefferson Ave, Memphis, TN 38103 USA.							CARTWRIGHT PS, 1984, J REPROD MED, V29, P88; CORSAN GH, 1995, HUM REPROD, V10, P2719, DOI 10.1093/oxfordjournals.humrep.a135774; FERNANDEZ H, 1995, FERTIL STERIL, V63, P25, DOI 10.1016/S0015-0282(16)57291-4; GLOCK JL, 1994, FERTIL STERIL, V62, P716; Kooi S, 1992, Obstet Gynecol Surv, V47, P739, DOI 10.1097/00006254-199211000-00001; Lipscomb GH, 1998, AM J OBSTET GYNECOL, V178, P1354, DOI 10.1016/S0002-9378(98)70343-6; RANSOM MX, 1994, OBSTET GYNECOL, V83, P1033, DOI 10.1097/00006250-199406000-00026; ROMERO R, 1985, OBSTET GYNECOL, V65, P519; SHALEV E, 1995, FERTIL STERIL, V63, P20, DOI 10.1016/S0015-0282(16)57290-2; Stika CS, 1996, AM J OBSTET GYNECOL, V174, P1840, DOI 10.1016/S0002-9378(96)70219-3; STORRING PL, 1980, J ENDOCRINOL, V84, P295, DOI 10.1677/joe.0.0840295; STOVALL TG, 1991, OBSTET GYNECOL, V77, P754; STOVALL TG, 1990, FERTIL STERIL, V54, P537; VERMESH M, 1990, AM J OBSTET GYNECOL, V162, P411, DOI 10.1016/0002-9378(90)90397-P	14	216	230	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1974	1978		10.1056/NEJM199912233412604	http://dx.doi.org/10.1056/NEJM199912233412604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607814				2022-12-28	WOS:000084399400004
J	LaRosa, JC; He, J; Vupputuri, S				LaRosa, JC; He, J; Vupputuri, S			Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EVENTS CARE TRIAL; CHOLESTEROL LEVELS; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; ARTERY DISEASE; HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; CAROTID ATHEROSCLEROSIS; POSTMENOPAUSAL WOMEN; ELDERLY PATIENTS	Context Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women. Objective To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women. Data Sources Trials published in English-language journals were retrieved by searching MEDLINE (1966-December 1998), bibliographies, and authors' reference files. Study Selection Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified). Data Extraction information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus. Data Synthesis Data from the 5 trials, with 30 817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Statin drug treatment was associated with a 20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol, Overall, statin drug treatment reduced risk 31% in major coronary events (95% confidence interval [CI], 26%-36%) and 21% in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%;95% CI, 13%-42%) and men (31%; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31%; 95% CI, 24%-36%). Conclusions Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.	SUNY Hlth Sci Ctr, Off President, Brooklyn, NY 11203 USA; Tulane Univ, Med Ctr, Dept Epidemiol, New Orleans, LA USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Tulane University	LaRosa, JC (corresponding author), SUNY Hlth Sci Ctr, Off President, 450 Clarkson Ave,Box 01, Brooklyn, NY 11203 USA.	jclarosa@netmail.hscbklyn.edu						[Anonymous], 1993, Am J Cardiol, V72, P1031; Bertrand ME, 1997, J AM COLL CARDIOL, V30, P863, DOI 10.1016/S0735-1097(97)00259-3; Bestehorn HP, 1997, EUR HEART J, V18, P226; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; Campeau L, 1997, NEW ENGL J MED, V336, P153; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Davidson M, 1997, AM J CARDIOL, V79, P1475, DOI 10.1016/S0002-9149(97)00174-4; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DOWNS JR, 1995, AM J CARDIOL, V75, P1130; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Fleiss J.L., 1994, HDB RES SYNTHESIS, P245; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; GAW A, 1998, INT C VASC PREV MAY; Gould AL, 1998, CIRCULATION, V97, P946; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JONES PH, 1991, CLIN CARDIOL, V14, P146, DOI 10.1002/clc.4960140211; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; LaRosa JC, 1997, ARCH INTERN MED, V157, P961, DOI 10.1001/archinte.157.9.961; LAROSA JC, 1994, ARCH INTERN MED, V154, P529, DOI 10.1001/archinte.154.5.529; LAROSA JC, 1998, 20 C EUR SOC CARD AU; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Lewis SJ, 1998, J AM COLL CARDIOL, V32, P140, DOI 10.1016/S0735-1097(98)00202-2; Lindholm LH, 1996, J INTERN MED, V240, P13, DOI 10.1046/j.1365-2796.1996.492831000.x; Mercuri M, 1996, AM J MED, V101, P627, DOI 10.1016/S0002-9343(96)00333-6; Miettinen TA, 1997, CIRCULATION, V96, P4211; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Qizilbash N, 1995, LANCET, V346, P1647; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SANTINGA JT, 1994, AM J MED, V96, P509, DOI 10.1016/0002-9343(94)90090-6; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tamura A, 1997, AM J CARDIOL, V79, P893, DOI 10.1016/S0002-9149(97)00010-6; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	45	956	989	0	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2340	2346		10.1001/jama.282.24.2340	http://dx.doi.org/10.1001/jama.282.24.2340			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612322				2022-12-28	WOS:000084261700028
J	Diepolder, HM; Scholz, S; Papa, GR				Diepolder, HM; Scholz, S; Papa, GR			Influence of HLA alleles on outcome of hepatitis C virus infection	LANCET			English	Editorial Material							NONSTRUCTURAL PROTEIN-3; CLEARANCE		Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81337 Munich, Germany; Univ Munich, Inst Immunol, D-81337 Munich, Germany; Univ Munich, Immunogenet Lab, Kinderpoliklin, D-80539 Munich, Germany	University of Munich; University of Munich; University of Munich	Diepolder, HM (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81337 Munich, Germany.							Alric L, 1997, GASTROENTEROLOGY, V113, P1675, DOI 10.1053/gast.1997.v113.pm9352872; Barrett S, 1999, J HEPATOL, V30, P979, DOI 10.1016/S0168-8278(99)80249-9; Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Lamonaca V, 1999, HEPATOLOGY, V30, P1088, DOI 10.1002/hep.510300435; Minton EJ, 1998, J INFECT DIS, V178, P39, DOI 10.1086/514258; MISSALE G, 1996, J CLIN INVEST, V98, P716; Tibbs C, 1996, HEPATOLOGY, V24, P1342, DOI 10.1002/hep.510240604	8	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2094	2095		10.1016/S0140-6736(99)00327-X	http://dx.doi.org/10.1016/S0140-6736(99)00327-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609808				2022-12-28	WOS:000084318200002
J	Hill, AP; Baeza, J				Hill, AP; Baeza, J			Dealing with things that go wrong	LANCET			English	Editorial Material									Kings Fund, Effect Practice Programme, London W1M 0AN, England		Hill, AP (corresponding author), Kings Fund, Effect Practice Programme, London W1M 0AN, England.							DEPARTMENT OF HEALTH, 1999, SUPP DOCT PROT PAT C; ENNIS M, 1999, MED MISHAPS PIECES P, P168; FALLBERG L, 1999, MED MISHAPS, P86; *HC HLTH COMM, 1999, PROC REL ADV CLIN IN; Lloyd-Bostok S.M., 1999, MED MISHAPS, P109; MARINKER M, 1998, CLIN FUTURES; MUDUR G, 1998, BRIT MED J, V316, P1558; Mulcahy Linda, 1999, CAUSE COMPLAINT EVAL; TURONE F, 1998, BRIT MED J, V316, P1261; Williams B, 1998, SOC SCI MED, V47, P1351, DOI 10.1016/S0277-9536(98)00213-5	10	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2099	2100		10.1016/S0140-6736(99)00443-2	http://dx.doi.org/10.1016/S0140-6736(99)00443-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609813				2022-12-28	WOS:000084318200007
J	Kozuma, M; Suzuki, Y; Torii, Y; Sugiura, T; Kuga, T; Hagley, EW; Deng, L				Kozuma, M; Suzuki, Y; Torii, Y; Sugiura, T; Kuga, T; Hagley, EW; Deng, L			Phase-coherent amplification of matter waves	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATION; BRAGG SCATTERING; ATOMS; TRAP	Phase-coherent matter-wave amplification was demonstrated using Bose-Einstein-condensed rubidium-87 atoms. A small seed matter wave was created with coherent optical Bragg diffraction. Amplification of this seed matter wave was achieved by using the initial condensate as a gain medium through the superradiance effect. The coherence properties of the amplified matter wave, studied with a matter-wave interferometer, were shown to be locked to those of the initial seed wave. The active matter-wave device demonstrated here has great potential in the fields of atom optics, atom Lithography, and precision measurements.	Univ Tokyo, Inst Phys, Meguro Ku, Tokyo 1538902, Japan; Gakushuin Univ, Dept Phys, Toshima Ku, Tokyo 1718588, Japan; NIST, Phys Lab, Gaithersburg, MD 20899 USA	University of Tokyo; Gakushuin University; National Institute of Standards & Technology (NIST) - USA	Kozuma, M (corresponding author), Univ Tokyo, Inst Phys, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.		Deng, Lu/B-3997-2012; Hagley, Edward/B-4285-2012					Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Bloch I, 1999, PHYS REV LETT, V82, P3008, DOI 10.1103/PhysRevLett.82.3008; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; GILTNER DM, 1995, PHYS REV LETT, V75, P2638, DOI 10.1103/PhysRevLett.75.2638; Hagley EW, 1999, SCIENCE, V283, P1706, DOI 10.1126/science.283.5408.1706; HUTH BG, 1970, APPL PHYS LETT, V16, P185, DOI 10.1063/1.1653154; Inouye S, 1999, SCIENCE, V285, P571, DOI 10.1126/science.285.5427.571; Kozuma M, 1999, PHYS REV LETT, V82, P871, DOI 10.1103/PhysRevLett.82.871; Law CK, 1998, PHYS REV A, V58, P4791, DOI 10.1103/PhysRevA.58.4791; MARTIN PJ, 1988, PHYS REV LETT, V60, P515, DOI 10.1103/PhysRevLett.60.515; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; Myatt CJ, 1996, OPT LETT, V21, P290, DOI 10.1364/OL.21.000290; PETERS GI, 1971, J PHYS PT A GEN, V4, P238, DOI 10.1088/0305-4470/4/2/009; TORII Y, 1999, UNPUB	17	176	183	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2309	2312		10.1126/science.286.5448.2309	http://dx.doi.org/10.1126/science.286.5448.2309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600733				2022-12-28	WOS:000084318500050
J	Shlim, DR				Shlim, DR			Into thin air: Deaths on Everest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		HAWLEY RJ, 1999, JAMA-J AM MED ASSOC, V281, P1341; HAWLEY RJ, 1997, THIN AIR PERSONAL AC; SHLIM DR, 1989, JAMA-J AM MED ASSOC, V261, P1017, DOI 10.1001/jama.261.7.1017; Terray L., 1963, CONQUISTADORS USELES	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2212	2212		10.1001/jama.282.23.2212	http://dx.doi.org/10.1001/jama.282.23.2212			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605970				2022-12-28	WOS:000084138600023
J	Aithal, GP; Rawlins, MD; Day, CP				Aithal, GP; Rawlins, MD; Day, CP			Accuracy of hepatic adverse drug reaction reporting in one English health region	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Day, CP (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Day, Christopher/Z-3305-2019	Aithal, Guruprasad/0000-0003-3924-4830				Aithal PG, 1999, GUT, V44, P731, DOI 10.1136/gut.44.5.731; BENICHOU C, 1990, J HEPATOL, V11, P272; DANAN G, 1988, J HEPATOL, V7, P132, DOI 10.1016/S0168-8278(88)80517-8; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41	5	94	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1541	1541		10.1136/bmj.319.7224.1541	http://dx.doi.org/10.1136/bmj.319.7224.1541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591713	Green Published, Bronze			2022-12-28	WOS:000084245600024
J	Rimm, EB; Williams, P; Fosher, K; Criqui, M; Stampfer, MJ				Rimm, EB; Williams, P; Fosher, K; Criqui, M; Stampfer, MJ			Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RANDOMIZED CONTROLLED TRIAL; RED WINE CONSUMPTION; MYOCARDIAL-INFARCTION; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; CARDIOVASCULAR RISK; ETHANOL INGESTION; PLASMINOGEN-ACTIVATOR	Objective To summarise quantitatively the association between moderate alcohol intake and biological markers of risk of coronary heart disease and to predict how these changes would lower the risk. Design Meta-analysis of all experimental studies that assessed the effects of moderate alcohol intake on concentrations of high density lipoprotein cholesterol, apolipoprotein A I, fibrinogen, triglycerides, and other biological markers previously found to be associated with risk of coronary heart disease. Participants Men and woman free of previous chronic disease and who were not dependent on alcohol. Studies were included in which biomarkers were assessed before and after participants consumed up to 100 g of alcohol a dal: Interventions Alcohol as ethanol, beer, wine, or spirits. Main outcome measures Changes in concentrations of high density lipoprotein cholesterol, apolipoprotein A I, Lp(a) lipoprotein, triglycerides, tissue type plasminogen activator activity, tissue type plasminogen activator antigen, insulin, and glucose after consuming an experimental dose of alcohol for 1 to 9 weeks; a shelter period was accepted for studies of change in concentrations of fibrinogen, factor VIT, von Willebrand factor, tissue type plasminogen activator activity and tissue type plasminogen activator antigen. Results 61 data records were abstracted from 42 eligible studies with information on change in biological markers of risk of coronary heart disease. An experimental dose of 30 g of ethanol a day increased concentrations of high density lipoprotein cholesterol by 3.99 mg/dl (95% confidence interval 3.25 to 4.73), apolipoprotein A I by 8.82 mg/dl (7.79 to 9.86), and triglyceride by 5.69 mg/dl (2.49 to 8.89). Several haemostatic factors related to a thrombolytic profile were modestly affected by alcohol. On the basis of published associations between these biomarkers and risk of coronary heart disease 30 g of alcohol a day would cause an estimated reduction of 24.7% in risk of coronary heart disease. Conclusions Alcohol intake is causally related to lower risk of coronary heart disease through changes in lipids and. haemostatic factors.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Calif San Diego, San Diego Sch Med & Family & Prevent Med, La Jolla, CA 92093 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Diego	Rimm, EB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.	eric.rimm@channing.harvard.edu		Fosher, Kerry/0000-0002-9421-9243				ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; BARBORIAK JJ, 1976, ATHEROSCLEROSIS, V24, P323, DOI 10.1016/0021-9150(76)90087-3; BELFRAGE P, 1977, EUR J CLIN INVEST, V7, P127, DOI 10.1111/j.1365-2362.1977.tb01584.x; Belfrage P, 1973, Acta Med Scand Suppl, V552, P1; BERG B, 1973, ACTA MED SCAND, P13; BERTIERE MC, 1986, ATHEROSCLEROSIS, V61, P7, DOI 10.1016/0021-9150(86)90108-5; Branchi A, 1997, EUR J CLIN NUTR, V51, P362, DOI 10.1038/sj.ejcn.1600408; BURR ML, 1986, BRIT J NUTR, V56, P81, DOI 10.1079/BJN19860087; CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; CAMARGO CA, 1996, RES MONOGRAPHYS NATL, V31, P25; Carbonneau MA, 1997, EUR J CLIN NUTR, V51, P682, DOI 10.1038/sj.ejcn.1600464; CLEVIDENCE BA, 1995, ARTERIOSCL THROM VAS, V15, P179, DOI 10.1161/01.ATV.15.2.179; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; COUZIGOU P, 1984, ANN NUTR METAB, V28, P377, DOI 10.1159/000176849; COX KL, 1993, J HYPERTENS, V11, P191, DOI 10.1097/00004872-199302000-00012; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; Criqui MH, 1997, J STUD ALCOHOL, V58, P453, DOI 10.15288/jsa.1997.58.453; CROUSE JR, 1984, J LIPID RES, V25, P486; *DEP HLTHINT WORK, 1995, SENS DRINK; deRijke YB, 1996, AM J CLIN NUTR, V63, P329, DOI 10.1093/ajcn/63.3.329; Doll R, 1997, BRIT MED J, V315, P1664, DOI 10.1136/bmj.315.7123.1664; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; ELMER O, 1984, HAEMOSTASIS, V14, P223; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; FRASER GE, 1983, ATHEROSCLEROSIS, V46, P275, DOI 10.1016/0021-9150(83)90178-8; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; FRIMPONG NA, 1989, AM J CLIN NUTR, V50, P987, DOI 10.1093/ajcn/50.5.987; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; Furman MI, 1998, J AM COLL CARDIOL, V31, P352, DOI 10.1016/S0735-1097(97)00510-X; GALLI C, 1984, Drug-Nutrient Interactions, V3, P61; Gaziano JM, 1999, AM J CARDIOL, V83, P52, DOI 10.1016/S0002-9149(98)00782-6; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GINSBERG H, 1974, ANN INTERN MED, V80, P143, DOI 10.7326/0003-4819-80-2-143; GLUECK CJ, 1980, AM J CLIN NUTR, V33, P2287, DOI 10.1093/ajcn/33.11.2287; HAGIAGE M, 1992, METABOLISM, V41, P856, DOI 10.1016/0026-0495(92)90167-9; HANNUKSELA M, 1992, J LIPID RES, V33, P737; HANNUKSELA ML, 1992, CIRCULATION S4, V86, P2756; HARTUNG GH, 1986, AM J CARDIOL, V58, P148, DOI 10.1016/0002-9149(86)90259-6; HARTUNG GH, 1993, ATHEROSCLEROSIS, V100, P33, DOI 10.1016/0021-9150(93)90065-3; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HARTUNG GH, 1990, METABOLISM, V39, P81, DOI 10.1016/0026-0495(90)90152-3; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HILLBOM M, 1987, EUR J CLIN INVEST, V17, P68, DOI 10.1111/j.1365-2362.1987.tb01228.x; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HULLEY SB, 1981, CIRCULATION, V64, P57; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; Kiechl S, 1996, BRIT MED J, V313, P1040; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; KLUFT C, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90363-O; KONDO K, 1994, LANCET, V344, P1152, DOI 10.1016/S0140-6736(94)90656-4; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MALMENDIER CL, 1985, CLIN CHIM ACTA, V152, P281, DOI 10.1016/0009-8981(85)90103-2; MARCKMANN P, 1992, ATHEROSCLEROSIS, V96, P235, DOI 10.1016/0021-9150(92)90070-W; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MarquesVidal P, 1996, AM J EPIDEMIOL, V143, P1089, DOI 10.1093/oxfordjournals.aje.a008683; MASAREI JRL, 1986, ATHEROSCLEROSIS, V60, P79, DOI 10.1016/0021-9150(86)90090-0; McConnell MV, 1997, AM J CARDIOL, V80, P1226, DOI 10.1016/S0002-9149(97)00647-4; MCKENZIE CR, 1996, ALCOHOL CARDIOVASCUL, V3; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIKHAILIDIS DP, 1987, AM J CLIN PATHOL, V88, P342, DOI 10.1093/ajcp/88.3.342; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOSTELLER F, 1992, STAT SCI, V7, P227; NEIMAN J, 1987, ALCOHOL ALCOHOLISM, V22, P265; NUMMINEN H, 1991, METABOLISM, V40, P695, DOI 10.1016/0026-0495(91)90086-C; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P209; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; PUCHOIS P, 1990, ARCH INTERN MED, V150, P1638, DOI 10.1001/archinte.150.8.1638; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; Rakic V, 1998, ATHEROSCLEROSIS, V137, P243, DOI 10.1016/S0021-9150(97)00269-4; RAND ML, 1989, THROMB HAEMOSTASIS, V61, P254; REEDER VC, 1996, ALCOHOL CARDIOVASCUL, V31; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; RENAUD S, 1993, HLTH ISSUES RELATED, P18; Renaud SC, 1996, CLIN CHIM ACTA, V246, P77, DOI 10.1016/0009-8981(96)06228-6; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; ROSENSON RS, 1994, ARTERIOSCLER THROMB, V14, P1928, DOI 10.1161/01.ATV.14.12.1928; ROSNER B, 1992, AM J EPIDEMIOL, V136, P1400, DOI 10.1093/oxfordjournals.aje.a116453; SAVOLAINEN MJ, 1995, CURR OPIN LIPIDOL, V6, P243, DOI 10.1097/00041433-199508000-00009; SHARPE PC, 1995, QJM-INT J MED, V88, P101; Sharpe PC, 1998, BRIT MED J, V316, P1675, DOI 10.1136/bmj.316.7145.1675; SMITH SJ, 1995, STAT MED, V14, P531, DOI 10.1002/sim.4780140513; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STUBBS CD, 1992, LIPIDS, V27, P255, DOI 10.1007/BF02536471; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; SUMI H, 1988, ALCOHOL ALCOHOLISM, V23, P33; Sumi Hiroyuki, 1998, Japanese Journal of Alcohol Studies and Drug Dependence, V33, P263; SUZUKAWA M, 1994, J AM COLL NUTR, V13, P237, DOI 10.1080/07315724.1994.10718403; THORNTON J, 1983, LANCET, V2, P819; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; VALIMAKI M, 1988, EUR J CLIN INVEST, V18, P472, DOI 10.1111/j.1365-2362.1988.tb01042.x; VALIMAKI M, 1991, METABOLISM, V40, P1168, DOI 10.1016/0026-0495(91)90211-E; van Tol A, 1998, ATHEROSCLEROSIS, V141, pS101, DOI 10.1016/S0021-9150(98)00226-3; VEENSTRA J, 1990, THROMB HAEMOSTASIS, V63, P345; VEENSTRA J, 1990, ALCOHOL, V7, P547, DOI 10.1016/0741-8329(90)90046-F; VERSCHUREN PME, 1993, HLTH ISSUES RELATED, P329; Vitelli LL, 1996, NUTR METAB CARDIOVAS, V6, P194; Willett W., 1990, NUTR EPIDEMIOLOGY	115	957	978	1	80	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1523	1528D		10.1136/bmj.319.7224.1523	http://dx.doi.org/10.1136/bmj.319.7224.1523			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591709	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000084245600019
J	Anderson, D; Walter, P				Anderson, D; Walter, P			Blobel's nobel: A vision validated	CELL			English	Editorial Material									CALTECH, Howard Hughes Med Inst, Div Biol 216 76, Pasadena, CA 91125 USA; Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Anderson, D (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol 216 76, Pasadena, CA 91125 USA.								0	4	4	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					557	558		10.1016/S0092-8674(00)81543-3	http://dx.doi.org/10.1016/S0092-8674(00)81543-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612390	Bronze			2022-12-28	WOS:000084278700001
J	Cyster, JG				Cyster, JG			Chemokines - Chemokines and cell migration in secondary lymphoid organs	SCIENCE			English	Review							ACTIVATED T-CELLS; C-C CHEMOKINE; B-CELL; DENDRITIC CELLS; EBI1-LIGAND CHEMOKINE; MOLECULAR-CLONING; TISSUE CHEMOKINE; FUNCTIONAL LIGAND; IMMUNE-RESPONSE; BETA-CHEMOKINE	As few as one in 100,000 B and T Lymphocytes are specific for a single protein antigen, such as tetanus toxin, yet these cells must come together if an antibody response is to occur. Bringing antigen-presenting cells and rare antigen-specific B and T lymphocytes into physical contact is a principal function of secondary lymphoid organs. In the last few years, details have begun to emerge on the cues that guide cell movements inside lymphoid organs, and a central role for the chemokine family of molecules has been uncovered. Here, current understanding of the roles played by chemokines in the functional biology of secondary lymphoid organs will be reviewed.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.		Calabrese, Massimiliano/I-6195-2012					Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Alcami A, 1998, J IMMUNOL, V160, P624; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Brocker T, 1999, EUR J IMMUNOL, V29, P1610, DOI 10.1002/(SICI)1521-4141(199905)29:05<1610::AID-IMMU1610>3.0.CO;2-8; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chan VWF, 1999, BLOOD, V93, P3610, DOI 10.1182/blood.V93.11.3610.411a48_3610_3616; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Cyster JG, 1997, IMMUNOL REV, V156, P87, DOI 10.1111/j.1600-065X.1997.tb00961.x; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dixon B, 1998, IMMUNOL REV, V166, P341, DOI 10.1111/j.1600-065X.1998.tb01274.x; Flynn S, 1998, J EXP MED, V188, P297, DOI 10.1084/jem.188.2.297; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; Gretz JE, 1997, IMMUNOL REV, V156, P11, DOI 10.1111/j.1600-065X.1997.tb00955.x; Guan P, 1999, GENOMICS, V56, P296, DOI 10.1006/geno.1998.5635; Guinamard R, 1999, J EXP MED, V189, P1461, DOI 10.1084/jem.189.9.1461; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; GYSTER JG, 1999, J EXP MED, V189, P447; Hedrick JA, 1997, J IMMUNOL, V159, P1589; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Hromas R, 1997, J IMMUNOL, V159, P2554; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Kim CH, 1998, J IMMUNOL, V160, P2418; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kodelja V, 1998, J IMMUNOL, V160, P1411; Krzysiek R, 1999, J IMMUNOL, V162, P4455; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MCMASTER PD, 1935, J EXP MED, V51, P783; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Nagira M, 1998, EUR J IMMUNOL, V28, P1516, DOI 10.1002/(SICI)1521-4141(199805)28:05<1516::AID-IMMU1516>3.0.CO;2-J; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; O'Garra A, 1998, CURR BIOL, V8, pR646, DOI 10.1016/S0960-9822(07)00413-7; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; Reape TJ, 1999, AM J PATHOL, V154, P365, DOI 10.1016/S0002-9440(10)65283-2; Rossi DL, 1997, J IMMUNOL, V158, P1033; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanabe S, 1997, J IMMUNOL, V159, P5671; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Tangemann K, 1998, J IMMUNOL, V161, P6330; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tew JG, 1997, IMMUNOL REV, V156, P39, DOI 10.1111/j.1600-065X.1997.tb00957.x; WEINER OD, 1999, CELL POLARITY FRONTI; WILLIMAN K, EUR J IMMUNOL, V28, P2025; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Yoshida R, 1998, INT IMMUNOL, V10, P901, DOI 10.1093/intimm/10.7.901; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634; Zhou YH, 1998, J IMMUNOL, V160, P4018; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	88	800	840	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2098	2102		10.1126/science.286.5447.2098	http://dx.doi.org/10.1126/science.286.5447.2098			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617422				2022-12-28	WOS:000084157300038
J	Vincent, WF				Vincent, WF			Antarctic biogeochemistry - Icy life on a hidden lake	SCIENCE			English	Editorial Material									Univ Laval, Ctr Etud Nord, St Foy, PQ G1K 7P4, Canada	Laval University	Vincent, WF (corresponding author), Univ Laval, Ctr Etud Nord, St Foy, PQ G1K 7P4, Canada.		Vincent, Warwick F/C-9522-2009; Vincent, Warwick/AAH-6152-2019	Vincent, Warwick/0000-0001-9055-1938				ABYZOV SS, 1993, ANTARCTIC MICROBIOLO, P265; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; Dowdeswell JA, 1999, GEOL SOC AM BULL, V111, P254, DOI 10.1130/0016-7606(1999)111<0254:TDATSO>2.3.CO;2; FRIEDMANN EI, 1993, ANTARCTIC MICROBIOLO; Hiscox J, 1999, ASTRON GEOPHYS, V40, P22, DOI 10.1093/astrog/40.2.2.22; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; Siegert MJ, 1999, AM SCI, V87, P510; Stone R, 1999, SCIENCE, V286, P36; VINCENT WF, 1988, MICROBIAL ECOSYSTEMS; WUEST A, UNPUB OCEAN MODELLIN; 1999, 23 CONS M	15	10	10	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2094	2095		10.1126/science.286.5447.2094	http://dx.doi.org/10.1126/science.286.5447.2094			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617420				2022-12-28	WOS:000084157300035
J	Denschlag, J; Simsarian, JE; Feder, DL; Clark, CW; Collins, LA; Cubizolles, J; Deng, L; Hagley, EW; Helmerson, K; Reinhardt, WP; Rolston, SL; Schneider, BI; Phillips, WD				Denschlag, J; Simsarian, JE; Feder, DL; Clark, CW; Collins, LA; Cubizolles, J; Deng, L; Hagley, EW; Helmerson, K; Reinhardt, WP; Rolston, SL; Schneider, BI; Phillips, WD			Generating solitons by phase engineering of a Bose-Einstein condensate	SCIENCE			English	Article							BRAGG SCATTERING; ATOMS; COLLISIONS; WAVES	Quantum phase engineering is demonstrated with two techniques that allow the spatial phase distribution of a Bose-Einstein condensate (BEC) to be written and read out. A quantum state was designed and produced by optically imprinting a phase pattern onto a BEC of sodium atoms, and matter-wave interferometry with spatially resolved imaging was used to analyze the resultant phase distribution. An appropriate phase imprint created solitons, the first experimental realization of this nonlinear phenomenon in a BEC. The subsequent evolution of these excitations was investigated both experimentally and theoretically.	Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA; Univ Oxford, Oxford OX1 3PU, England; Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; Ecole Normale Super, F-75231 Paris, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Natl Sci Fdn, Div Phys, Arlington, VA 22230 USA	National Institute of Standards & Technology (NIST) - USA; University of Oxford; United States Department of Energy (DOE); Los Alamos National Laboratory; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Washington; University of Washington Seattle; National Science Foundation (NSF); NSF - Directorate for Mathematical & Physical Sciences (MPS); NSF - Division of Physics (PHY)	Denschlag, J (corresponding author), Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA.		Clark, Charles W/A-8594-2009; Deng, Lu/B-3997-2012; Hagley, Edward/B-4285-2012; Denschlag, Johannes P Hecker/B-6047-2008; rolston, steven l/L-5175-2013; Helmerson, Kristian/E-3683-2013	Clark, Charles W/0000-0001-8724-9885; Denschlag, Johannes P Hecker/0000-0003-1984-4994; rolston, steven l/0000-0003-1671-4190; 				ADAMS CS, 1994, PHYS REP, V240, P143, DOI 10.1016/0370-1573(94)90066-3; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1997, PHYS REV LETT, V79, P553, DOI 10.1103/PhysRevLett.79.553; Berman P., 1997, ATOM INTERFEROMETRY; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; BRADLEY CC, 1995, PHYS REV LETT, V75, P985; Bullough R.K., 1988, SPRINGER SERIES NONL, P150; BUSCH T, 1998, CONDMAT9809408; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Deng L, 1999, NATURE, V398, P218, DOI 10.1038/18395; Dobrek L, 1999, PHYS REV A, V60, pR3381, DOI 10.1103/PhysRevA.60.R3381; Dum R, 1998, PHYS REV LETT, V80, P2972, DOI 10.1103/PhysRevLett.80.2972; Fedichev PO, 1999, PHYS REV A, V60, P3220, DOI 10.1103/PhysRevA.60.3220; GILTNER DM, 1995, PHYS REV LETT, V75, P2638, DOI 10.1103/PhysRevLett.75.2638; Hagley EW, 1999, PHYS REV LETT, V83, P3112, DOI 10.1103/PhysRevLett.83.3112; Hasegawa A., 1990, OPTICAL SOLITONS FIB; Jackson AD, 1998, PHYS REV A, V58, P2417, DOI 10.1103/PhysRevA.58.2417; Kozuma M, 1999, PHYS REV LETT, V82, P871, DOI 10.1103/PhysRevLett.82.871; LENS G, 1993, PHYS REV LETT, V71, P3271; MARTIN PJ, 1988, PHYS REV LETT, V60, P515, DOI 10.1103/PhysRevLett.60.515; Matthews MR, 1999, PHYS REV LETT, V83, P3358, DOI 10.1103/PhysRevLett.83.3358; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; Muryshev AE, 1999, PHYS REV A, V60, pR2665, DOI 10.1103/PhysRevA.60.R2665; Perez-Garcia VM, 1998, PHYS REV A, V57, P3837, DOI 10.1103/PhysRevA.57.3837; PEYRARD M, 1995, MOL EXCITATIONS BIOM; Reinhardt WP, 1997, J PHYS B-AT MOL OPT, V30, pL785, DOI 10.1088/0953-4075/30/22/001; REINHARDT WP, 1998, TUNNELING COMPLEX SY, P277; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; TAYLOR JR, 1992, OPTICAL SOLITONS; Tiesinga E, 1996, J RES NATL INST STAN, V101, P505, DOI 10.6028/jres.101.051; TORIL Y, 1999, CONDMAT9908160; Williams JE, 1999, NATURE, V401, P568, DOI 10.1038/44095; Zobay O, 1999, PHYS REV A, V59, P643, DOI 10.1103/PhysRevA.59.643	34	1097	1109	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					97	101		10.1126/science.287.5450.97	http://dx.doi.org/10.1126/science.287.5450.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615056				2022-12-28	WOS:000084578400042
J	Callen, JP				Callen, JP			Dermatomyositis	LANCET			English	Review							JUVENILE DERMATOMYOSITIS; CUTANEOUS CHANGES; CONTROLLED TRIAL; MUSCLE WEAKNESS; SINE MYOSITIS; POLYMYOSITIS; MANIFESTATIONS; METHOTREXATE; INVOLVEMENT; CALCINOSIS	Dermatomyositis is one of the idiopathic inflammatory myopathies with characteristic cutaneous manifestations including the heliotrope rash, Gottron's papules, cuticular changes including periungual telangiectasia, a photodistributed erythema or poikiloderma, and a scaly alopecia. Dermatomyositis has been linked to cancer, particularly ovarian cancer. Cancer-associated disease is more commonly found in older patients, and when present, is associated with a poor prognosis. A childhood form of the disease exists and is frequently complicated by the development of calcinosis. Dermatomyositis is a systemic disorder and whereas the skin and muscles are the most commonly affected organs, patients may have arthralgias, arthritis, oesophageal disease, or cardiopulmonary dysfunction. Recently described serological abnormalities, known as myositis-specific antibodies, add credence to the notion that this disorder is distinct from all other collagen-vascular diseases, and may lead to important discoveries about the pathogenesis of the inflammatory myopathies, which are not currently of practical use in the clinic or office. Management of the patient with myositis usually includes systemic corticosteroids with or without an immunosuppressive agent. Cutaneous disease is more difficult to manage, but antimalarials, methotrexate, and intravenous immunoglobulin are effective in small, often open-label, studies.	Univ Louisville, Div Dermatol, Louisville, KY 40202 USA	University of Louisville	Callen, JP (corresponding author), Univ Louisville, Div Dermatol, 310 E Broadway,Suite 200, Louisville, KY 40202 USA.							AIRIO A, 1995, J RHEUMATOL, V22, P1300; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; CALLEN AM, 1994, ARTHRITIS RHEUM, V37, pR10; CALLEN JP, 1982, J AM ACAD DERMATOL, V6, P253, DOI 10.1016/S0190-9622(82)70018-0; CHEONG WK, 1994, BRIT J DERMATOL, V131, P205; CHOW WH, 1995, CANCER CAUSE CONTROL, V5, P9; COSNES A, 1995, ARCH DERMATOL, V131, P1381, DOI 10.1001/archderm.131.12.1381; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Daoud MS, 1997, J AM ACAD DERMATOL, V36, P178, DOI 10.1016/S0190-9622(97)70276-7; EUWER RL, 1991, J AM ACAD DERMATOL, V24, P959, DOI 10.1016/0190-9622(91)70153-S; GonzalezLopez L, 1996, CLIN EXP RHEUMATOL, V14, P373; GROB JJ, 1989, DERMATOLOGICA, V178, P58, DOI 10.1159/000248390; Kasteler JS, 1997, J AM ACAD DERMATOL, V36, P67, DOI 10.1016/S0190-9622(97)70327-X; KASTELER JS, 1994, JAMA-J AM MED ASSOC, V272, P1939, DOI 10.1001/jama.272.24.1939; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; Lundberg Ingrid E., 1998, Current Opinion in Rheumatology, V10, P521, DOI 10.1097/00002281-199811000-00004; Marie I, 1998, J RHEUMATOL, V25, P1336; Marie I, 1999, MEDICINE, V78, P139, DOI 10.1097/00005792-199905000-00001; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; Oliveri MB, 1996, J RHEUMATOL, V23, P2152; Pachman Lauren M., 1995, Current Opinion in Rheumatology, V7, P437, DOI 10.1097/00002281-199509000-00013; PENG JC, 1995, ARCH OTOLARYNGOL, V121, P1298; ROCKERBIE NR, 1989, J AM ACAD DERMATOL, V20, P629, DOI 10.1016/S0190-9622(89)70074-8; SAYERS ME, 1992, J RHEUMATOL, V19, P1385; SIGUREGEIRSSON B, 1992, NEW ENGL J MED, V325, P363; Spiera Robert, 1998, Current Opinion in Rheumatology, V10, P556, DOI 10.1097/00002281-199811000-00008; STONECIPHER MR, 1993, J AM ACAD DERMATOL, V28, P951, DOI 10.1016/0190-9622(93)70136-H; TARGOFF IN, 1991, CURR PROBL DERMATOL, V3, P131; Villalba L, 1998, ARTHRITIS RHEUM-US, V41, P392, DOI 10.1002/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X; Villalba Lourdes, 1996, Current Opinion in Rheumatology, V8, P544, DOI 10.1097/00002281-199611000-00008; WHITMORE SE, 1994, MEDICINE, V73, P153, DOI 10.1097/00005792-199405000-00004; WOO TY, 1984, J AM ACAD DERMATOL, V10, P592, DOI 10.1016/S0190-9622(84)80263-7; WORTMAN RL, 1999, CURR PRACT MED, V2, P167; ZIEGLSCHMIDADAMS ME, 1995, J AM ACAD DERMATOL, V32, P754, DOI 10.1016/0190-9622(95)91455-2	36	247	257	0	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					53	57		10.1016/S0140-6736(99)05157-0	http://dx.doi.org/10.1016/S0140-6736(99)05157-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615903				2022-12-28	WOS:000085049200040
J	Chiswick, ML				Chiswick, ML			Assessment of pain in neonates	LANCET			English	Editorial Material							SKIN		St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England		Chiswick, ML (corresponding author), St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England.							ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; Andrews K, 1999, DEV MED CHILD NEUROL, V41, P696, DOI 10.1017/S0012162299001425; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; CONSTANTINOU J, 1994, NEUROREPORT, V5, P2281, DOI 10.1097/00001756-199411000-00019; Johnston CC, 1996, PEDIATRICS, V98, P925; Porter FL, 1998, PEDIATRICS, V102, P1383, DOI 10.1542/peds.102.6.1383; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0	10	18	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					6	8		10.1016/S0140-6736(99)00392-X	http://dx.doi.org/10.1016/S0140-6736(99)00392-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615882				2022-12-28	WOS:000085049200007
J	Garrow, J				Garrow, J			Christmas factor and snacking	LANCET			English	Editorial Material							WEIGHT; WOMEN		Dial House, Rickmansworth WD3 2DQ, England		Garrow, J (corresponding author), Dial House, Rickmansworth WD3 2DQ, England.							ANDERSSON I, 1992, INT J OBESITY, V16, P1013; Friedman JM, 1999, PROG OBES R, P307; Marmonier C, 1999, AM J CLIN NUTR, V70, P854; RODIN J, 1977, J COMP PHYSIOL PSYCH, V91, P586, DOI 10.1037/h0077354; SMITH S, 1855, LADY HOLLAND MEMOIR, P376; Stock M, 1982, OBESITY LEANNESS BAS; Tuomisto T, 1998, APPETITE, V30, P211, DOI 10.1006/appe.1997.0142; VANSTAVEREN WA, 1986, INT J OBESITY, V10, P133; WOOLEY OW, 1972, J COMP PHYSIOL PSYCH, V80, P250, DOI 10.1037/h0033069; ZAHORSKAMARKIEWICZ B, 1980, INT J OBESITY, V4, P139	10	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2000	355	9197					8	8		10.1016/S0140-6736(99)90449-X	http://dx.doi.org/10.1016/S0140-6736(99)90449-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615883				2022-12-28	WOS:000085049200008
J	Petrie, KJ; White, GR; Cameron, LD; Collins, JP				Petrie, KJ; White, GR; Cameron, LD; Collins, JP			Photographic memory, money, and liposuction: survey of medical students' wish lists	BRITISH MEDICAL JOURNAL			English	Article								Objectives To examine whether medical students made fewer altruistic wishes and more money oriented wishes in later years of the medical course than students in earlier years. Design Anonymous questionnaire survey Setting Auckland University School of Medicine. Participants 520 medical students from 6 years of the course responded to the questionnaire item "If you had three wishes what would you wish for?" Main outcome measures Proportion of wishes in various categories. Results The three most popular categories of wishes were happiness (34%, of students), money (32%), and altruistic wishes (31%). Rates of altruistic wishes (odds ratio = 1.05, 95%, confidence interval 0.94 to 1.18; P = 0.36) and wishes for money (odds ratio = 0.96, 0.86 to 1.08; P = 0.52) did nor vary over the years of the course. Female medical students were more likely tl-lan males to make altruistic wishes (36% v 26%; chi(2) = 5.68, P = 0.02), intimacy wishes (25% v 18%; chi(2) = 3.74, P = 0.05), and happiness wishes (42% v 26%; chi(2) = 18.82, P = 0.0001), Men were more likely than women to make sexual wishes (5% v 0.8%; chi(2) = 7.34, P = 0.01), Conclusions We found no evidence that students were less altruistic and more money oriented in the later years of the medical course.	Univ Auckland, Fac Med & Hlth Sci, Hlth Psychol Res Grp, Auckland, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Ctr Med Educ, Auckland, New Zealand	University of Auckland; University of Auckland	Petrie, KJ (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Hlth Psychol Res Grp, Private Bag 92019, Auckland, New Zealand.							BUSS DM, 1995, AM PSYCHOL, V50, P164, DOI 10.1037/0003-066X.50.3.164; KAY J, 1990, JAMA-J AM MED ASSOC, V263, P572, DOI 10.1001/jama.263.4.572; King LA, 1997, J PERS, V65, P49, DOI 10.1111/j.1467-6494.1997.tb00529.x; KING LA, 1995, J PERS, V63, P985, DOI 10.1111/j.1467-6494.1995.tb00323.x; WOLF TM, 1989, MED EDUC, V23, P19, DOI 10.1111/j.1365-2923.1989.tb00807.x; ZELDOW PB, 1987, MED EDUC, V21, P353, DOI 10.1111/j.1365-2923.1987.tb00375.x	6	8	8	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1593	1595		10.1136/bmj.319.7225.1593	http://dx.doi.org/10.1136/bmj.319.7225.1593			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600951	Green Published, Bronze			2022-12-28	WOS:000084562600006
J	Awadalla, P; Eyre-Walker, A; Smith, JM				Awadalla, P; Eyre-Walker, A; Smith, JM			Linkage disequilibrium and recombination in hominid mitochondrial DNA	SCIENCE			English	Article							HEREDITARY OPTIC NEUROPATHY; HUMAN-EVOLUTION; MTDNA; GENE; MUTATION; POPULATIONS; GENOME; ENCEPHALOMYOPATHY; CARDIOMYOPATHY; SEQUENCE	The assumption that human mitochondrial DNA is inherited from one parent only and therefore does not recombine is questionable, Linkage disequilibrium in human and chimpanzee mitochondrial DNA declines as a function of the distance between sites, This pattern can be attributed to one mechanism only: recombination.	Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 1JT, Midlothian, Scotland	University of Sussex; University of Sussex; University of Edinburgh	Eyre-Walker, A (corresponding author), Univ Sussex, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England.		Weinstock, George M/C-6314-2013; Eyre-Walker, Adam/G-6216-2011; Awadalla, Philip/AAC-4896-2021	Weinstock, George M/0000-0002-2997-4592; Eyre-Walker, Adam/0000-0001-5527-8729; 				ANDREWS RM, IN PRESS NATURE GENE; AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859; Awadalla P, 1999, GENETICS, V152, P413; BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041; BROWN MD, 1992, GENETICS, V130, P163; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; Excoffier L, 1999, MOL BIOL EVOL, V16, P1357, DOI 10.1093/oxfordjournals.molbev.a026046; Eyre-Walker A, 1999, P ROY SOC B-BIOL SCI, V266, P2041, DOI 10.1098/rspb.1999.0884; Eyre-Walker A, 1999, P ROY SOC B-BIOL SCI, V266, P477, DOI 10.1098/rspb.1999.0662; Hagelberg E, 1999, P ROY SOC B-BIOL SCI, V266, P485, DOI 10.1098/rspb.1999.0663; HASEGAWA M, 1993, J MOL EVOL, V37, P347, DOI 10.1007/BF00178865; HILL WG, 1968, THEOR APPL GENET, V31, P881; HOWELL N, 1992, AM J HUM GENET, V50, P1333; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; Macaulay V, 1999, P ROY SOC B-BIOL SCI, V266, P2037, DOI 10.1098/rspb.1999.0883; MARZUKI S, 1991, HUM GENET, V88, P139; Meyer S, 1999, GENETICS, V152, P1103; MIYASHITA N, 1988, GENETICS, V120, P199; Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150; OHTA T, 1969, GENET RES, V13, P47, DOI 10.1017/S001667230000272X; OHTA T, 1982, P NATL ACAD SCI-BIOL, V79, P1940, DOI 10.1073/pnas.79.6.1940; OZAWA T, 1995, BIOCHEM BIOPH RES CO, V207, P613, DOI 10.1006/bbrc.1995.1232; OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; REID FM, 1994, HUM MOL GENET, V3, P1435; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; SCHAEFFER SW, 1993, GENETICS, V135, P541; Shitara H, 1998, GENETICS, V148, P851; Smith JM, 1999, GENETICS, V153, P1021; THYGARAN B, 1996, J BIOL CHEM, V271, P27536; Torroni A, 1996, GENETICS, V144, P1835; TORRONI A, 1993, AM J HUM GENET, V53, P591; TORRONI A, 1992, GENETICS, V130, P153; WAKELEY J, 1993, J MOL EVOL, V37, P613; Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WEIR BS, 1986, AM J HUM GENET, V38, P776; Wise CA, 1998, GENETICS, V148, P409; YONEDA M, 1990, BIOCHEM INT, V21, P789	41	207	217	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2524	2525		10.1126/science.286.5449.2524	http://dx.doi.org/10.1126/science.286.5449.2524			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617471				2022-12-28	WOS:000084429700054
J	Sachs, JP; Repeta, DJ				Sachs, JP; Repeta, DJ			Oligotrophy and nitrogen fixation during eastern Mediterranean sapropel events	SCIENCE			English	Article							ARABIAN SEA; CYANOBACTERIUM TRICHODESMIUM; NATURAL ABUNDANCE; ISOTOPE RATIOS; CARBON; PRODUCTIVITY; PHOSPHORUS; SEDIMENTS; PACIFIC; DENITRIFICATION	Nitrogen isotopic measurements in fossil chlorophyll from Late Pleistocene organic-rich sediments (sapropels) in the eastern Mediterranean Sea provide geochemical evidence for stratified, nutrient-depleted surface water and extensive nitrogen fixation. This evidence is reconciled with previous indications of high productivity by invoking a model of sapropel formation in which increased river discharge facilitates development of a specialized phytoplankton population whose annual mass sinking provides the organic flux to generate sapropels. This interpretation is consistent with the widespread occurrence of mat-forming diatoms that thrive in stratified water and can harbor diazotrophic bacterial symbionts, but does not support eutrophication of surface waters by enhanced river runoff ora circulation reversal.	Columbia Univ Barnard Coll, Dept Environm Sci, New York, NY 10027 USA; Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Columbia University; Woods Hole Oceanographic Institution	Sachs, JP (corresponding author), Columbia Univ Barnard Coll, Dept Environm Sci, 3009 Broadway, New York, NY 10027 USA.							Altabet M.A., 1996, PARTICLE FLUX OCEAN, P155; ALTABET MA, 1995, NATURE, V373, P506, DOI 10.1038/373506a0; Aly IM, 1982, P 4 INT C STABL IS J, P475; [Anonymous], 1978, P OCEAN DRILLING PRO, DOI [DOI 10.2973/DSDP.PROC.42-1.113.1978, DOI 10.2973/DSDP.PROC.42-1.113-1]; BETHOUX JP, 1981, MAR CHEM, V10, P141, DOI 10.1016/0304-4203(81)90029-3; BETHOUX JP, 1986, LIMNOL OCEANOGR, V31, P1353, DOI 10.4319/lo.1986.31.6.1353; BETHOUX JP, 1990, NATURE, V347, P660, DOI 10.1038/347660a0; BETHOUX JP, 1992, DEEP-SEA RES, V39, P1641, DOI 10.1016/0198-0149(92)90053-V; BONIN DJ, 1989, AQUAT SCI, V21, P131; CALVERT SE, 1992, NATURE, V359, P223, DOI 10.1038/359223a0; CALVERT SE, 1983, OCEANOL ACTA, V6, P255; Capone DG, 1998, MAR ECOL PROG SER, V172, P281, DOI 10.3354/meps172281; Carpenter E. J., 1983, NITROGEN MARINE ENV, P65; Carpenter EJ, 1997, DEEP-SEA RES PT I, V44, P27, DOI 10.1016/S0967-0637(96)00091-X; CASTRADORI D, 1993, PALEOCEANOGRAPHY, V8, P459, DOI 10.1029/93PA00756; CHEDDADI R, 1995, PALEOCEANOGRAPHY, V10, P301, DOI 10.1029/94PA02673; CITA MB, 1977, QUATERNARY RES, V8, P205, DOI 10.1016/0033-5894(77)90046-1; CLINE J D, 1975, Marine Chemistry, V3, P271, DOI 10.1016/0304-4203(75)90009-2; DELANGE GJ, 1983, NATURE, V305, P797, DOI 10.1038/305797a0; DELWICHE CC, 1970, ENVIRON SCI TECHNOL, V4, P929, DOI 10.1021/es60046a004; FRY B, 1991, DEEP-SEA RES, V38, pS1003, DOI 10.1016/S0198-0149(10)80021-4; GANESHRAM RS, 1995, NATURE, V376, P755, DOI 10.1038/376755a0; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; Guillard R.R.L., 1978, BOTANICAL MONOGRAPHS, V13, P372; Hartnett HE, 1998, NATURE, V391, P572, DOI 10.1038/35351; HOERING TC, 1960, J AM CHEM SOC, V82, P376, DOI 10.1021/ja01487a031; HOWELL MW, 1992, MAR GEOL, V103, P461, DOI 10.1016/0025-3227(92)90032-D; JENKINS JA, 1983, MAR MICROPALEONTOL, V8, P521; Jickells TD, 1998, SCIENCE, V281, P217, DOI 10.1126/science.281.5374.217; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; Kemp AES, 1999, NATURE, V398, P57, DOI 10.1038/18001; KROM MD, 1991, LIMNOL OCEANOGR, V36, P424, DOI 10.4319/lo.1991.36.3.0424; LIBES SM, 1988, DEEP-SEA RES, V35, P517, DOI 10.1016/0198-0149(88)90129-X; LIU KK, 1989, LIMNOL OCEANOGR, V34, P820, DOI 10.4319/lo.1989.34.5.0820; MACKO SA, 1987, CHEM GEOL, V65, P79, DOI 10.1016/0168-9622(87)90064-9; MACKO SA, 1984, NATURWISSENSCHAFTEN, V71, P374, DOI 10.1007/BF00410746; MANGINI A, 1979, SEDIMENT GEOL, V23, P113, DOI 10.1016/0037-0738(79)90009-5; MEYBECK M, 1982, AM J SCI, V282, P401, DOI 10.2475/ajs.282.4.401; MINAGAWA M, 1986, MAR CHEM, V19, P245, DOI 10.1016/0304-4203(86)90026-5; Myers PG, 1998, PALEOCEANOGRAPHY, V13, P586, DOI 10.1029/98PA02736; OWENS NJP, 1987, ADV MAR BIOL, V24, P390; Passier HF, 1999, NATURE, V397, P146, DOI 10.1038/16441; REPETA D, UNPUB; RICHARDS FA, 1961, DEEP-SEA RES, V7, P254, DOI 10.1016/0146-6313(61)90043-0; Rohling EJ, 1989, PALEOCEANOGRAPHY, V4, P531, DOI 10.1029/PA004i005p00531; ROHLING EJ, 1993, MAR MICROPALEONTOL, V21, P191, DOI 10.1016/0377-8398(93)90015-P; ROHLING EJ, 1994, MAR GEOL, V122, P1, DOI 10.1016/0025-3227(94)90202-X; Rossignol-Strick M, 1987, PALEOCEANOGRAPHY, V2, P333, DOI 10.1029/PA002i003p00333; ROSSIGNOLSTRICK M, 1985, PALAEOGEOGR PALAEOCL, V49, P237, DOI 10.1016/0031-0182(85)90056-2; ROSSIGNOLSTRICK M, 1982, NATURE, V295, P105, DOI 10.1038/295105a0; Sachs JP, 1999, GEOCHIM COSMOCHIM AC, V63, P1431, DOI 10.1016/S0016-7037(99)00097-6; SACHS JP, IN PRESS ORG GEOCHEM; SAINO T, 1987, DEEP-SEA RES, V34, P807, DOI 10.1016/0198-0149(87)90038-0; SCHAFER P, 1993, NATURWISSENSCHAFTEN, V80, P511, DOI 10.1007/BF01140806; SCHLITZER R, 1991, DEEP-SEA RES, V38, P1531, DOI 10.1016/0198-0149(91)90088-W; SHAW HF, 1984, MAR GEOL, V61, P1, DOI 10.1016/0025-3227(84)90104-X; Sigman DM, 1997, MAR CHEM, V57, P227, DOI 10.1016/S0304-4203(97)00009-1; THUNELL RC, 1989, NATURE, V338, P493, DOI 10.1038/338493a0; VANOS BJH, 1994, PALEOCEANOGRAPHY, V9, P601, DOI 10.1029/94PA00597; VELINSKY DJ, MAR CHEM, V67, P161; VILLAREAL TA, 1991, MAR ECOL PROG SER, V76, P201, DOI 10.3354/meps076201; WADA E, 1987, DEEP-SEA RES, V34, P829, DOI 10.1016/0198-0149(87)90039-2; WADA E, 1978, GEOMICROBIOL J, V1, P85, DOI 10.1080/01490457809377725; WADIE W F, 1984, Acta Adriatica, V25, P29; Wilkerson FP., 1988, OCEANOL ACTA, V9, P179; Zahn R, 1987, PALEOCEANOGRAPHY, V2, P543, DOI 10.1029/PA002i006p00543	66	207	216	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2485	2488		10.1126/science.286.5449.2485	http://dx.doi.org/10.1126/science.286.5449.2485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617458				2022-12-28	WOS:000084429700041
J	Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E				Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E			Three-dimensional structure of the human TFIID-IIA-IIB complex	SCIENCE			English	Article							RNA-POLYMERASE-II; TATA-BINDING-PROTEIN; MEDIATE TRANSCRIPTIONAL ACTIVATION; YEAST TFIIA/TBP/DNA COMPLEX; CRYSTAL-STRUCTURE; PROMOTER SELECTIVITY; IN-VITRO; COACTIVATOR; INITIATION; DROSOPHILA	The multisubunit transcription factor IID (TFIID) is an essential component of the eukaryotic RNA polymerase II machinery that works in concert with TFIIA (IIA) and TFIIB (IIB) to assemble initiation complexes at core eukaryotic promoters. Here the structures of human TFIID and the TFIID-IIA-IIB complex that were obtained by electron microscopy and image analysis to 35 angstrom resolution are presented. TFIID is a trilobed, horseshoe-shaped structure, with TFIIA and TFIIB bound on opposite Lobes and flanking a central cavity. Antibody studies Locate the TATA-binding protein (TBP) between TFIIA and TFIIB at the top of the cavity that most Likely encompasses the TATA DNA binding region of the supramolecular complex.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	enogales@lbl.gov		Ladurner, Andreas/0000-0003-3835-232X				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ANDEL F, UNPUB; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen JL, 1996, METHOD ENZYMOL, V273, P208; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HARAUZ G, 1986, OPTIK, V73, P146; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	47	110	112	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2153	2156		10.1126/science.286.5447.2153	http://dx.doi.org/10.1126/science.286.5447.2153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591646				2022-12-28	WOS:000084157300051
J	Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T				Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T			Mouse models of tumor development in neurofibromatosis type 1	SCIENCE			English	Article							NF1 GENE; SUPPRESSOR GENE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CELLS; MUTATIONS; DELETIONS; SCHWANN; PRODUCT; ALLELES; CANCER	Neurofibromatosis type 1 (NF1) is a prevalent familiar cancer syndrome resulting from germ Line mutations in the NF1 tumor suppressor gene. Hallmark features of the disease are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress to malignancy. Unlike humans, mice that are heterozygous for a mutation in Nf1 do not develop neurofibromas. However, as described here, chimeric mice composed in part of Nf1(-/-) cells do, which demonstrates that loss of the wild-type Nf1 allele is rate-limiting in tumor formation. In addition, mice that carry Linked germ line mutations in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperative and causal role for p53 mutations in MPNST development. These two mouse models provide the means to address fundamental aspects of disease development and to test: therapeutic strategies.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Merck & Company; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Tufts University; Tufts University	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu	Reilly, Karlyne/V-4475-2019	Reilly, Karlyne/0000-0001-9109-4409				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BADER JL, 1986, ANN NY ACAD SCI, V486, P57, DOI 10.1111/j.1749-6632.1986.tb48062.x; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1992, MAMM GENOME, V3, pS162, DOI 10.1007/BF00648429; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; Daschner K, 1997, BIOCHEM BIOPH RES CO, V234, P346, DOI 10.1006/bbrc.1997.6645; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hope D G, 1981, Adv Neurol, V29, P33; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOTHE RA, 1995, J NEUROPATH EXP NEUR, V54, P65, DOI 10.1097/00005072-199501000-00008; LUONGO C, 1994, CANCER RES, V54, P5947; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STARK M, 1995, HUM GENET, V96, P619; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WICK MR, 1987, AM J CLIN PATHOL, V87, P425, DOI 10.1093/ajcp/87.4.425; WOODRUFF JM, 1996, SOFT TISSUE TUMORS; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	42	322	329	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2172	2176		10.1126/science.286.5447.2172	http://dx.doi.org/10.1126/science.286.5447.2172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591652				2022-12-28	WOS:000084157300057
J	Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD				Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD			The role of CCR7 in T(H)1 and T(H)2 cell localization and delivery of B cell help in vivo	SCIENCE			English	Article							INDUCER LYMPHOCYTES-T; CHEMOKINE RECEPTOR; LYMPHOID-TISSUES; PERTUSSIS TOXIN; DENDRITIC CELLS; EXPRESSION; MIGRATION; RESPONSES; SUBSETS; CLONES	Subsets of murine CD4(+) T cells Localize to different areas of the spleen after adoptive transfer. Naive and T helper 1 (T(H)1) cells, which express the chemokine receptor CCR7, are home to the periarteriolar Lymphoid sheath, whereas activated T(H)2 cells, which lack CCR7, form rings at the periphery of the T cell zones near B cell follicles. Retroviral transduction of T(H)2 cells with CCR7 forces them to localize in a T(H)1-like pattern and inhibits their participation in B cell help in vivo but not in vitro. Thus, differential expression of chemokine receptors results in unique cellular migration patterns that are important for effective Immune responses.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Chaplin, DD (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.			Chaplin, David/0000-0002-1354-3069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034580, U01AI034580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34580] Funding Source: Medline; NIGMS NIH HHS [T32 GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas A K, 1993, Semin Immunol, V5, P441, DOI 10.1006/smim.1993.1050; ABBAS AK, 1990, J IMMUNOL, V144, P2031; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; DELPRETE GF, 1991, J EXP MED, V174, P809, DOI 10.1084/jem.174.4.809; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KILLAR L, 1987, J IMMUNOL, V138, P1674; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PABST R, 1991, SCANNING MICROSCOPY, V5, P1075; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pulendran B, 1997, J IMMUNOL, V159, P2222; RANDOLPH D, UNPUB; Randolph DA, 1999, J IMMUNOL, V162, P2375; Ranganath S, 1998, J IMMUNOL, V161, P3822; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; van den Eertwegh A J, 1994, Semin Immunol, V6, P327, DOI 10.1006/smim.1994.1041; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WILLFUHR KU, 1990, EUR J IMMUNOL, V20, P903, DOI 10.1002/eji.1830200428; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	40	153	160	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2159	2162		10.1126/science.286.5447.2159	http://dx.doi.org/10.1126/science.286.5447.2159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591648				2022-12-28	WOS:000084157300053
J	White, KP; Rifkin, SA; Hurban, P; Hogness, DS				White, KP; Rifkin, SA; Hurban, P; Hogness, DS			Microarray analysis of Drosophila development during metamorphosis	SCIENCE			English	Article							STEROID-RECEPTOR SUPERFAMILY; GENE-EXPRESSION PATTERNS; ECDYSONE-INDUCIBLE GENE; CELL-DEATH; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHATASE; DNA MICROARRAY; EARLY PUFF; ENCODES 2; MELANOGASTER	Metamorphosis is an integrated set of developmental processes controlled by a transcriptional hierarchy that coordinates the action of hundreds of genes. In order to identify and analyze the expression of these genes, high-density DNA microarrays containing several thousand Drosophila melanogaster gene sequences were constructed. Many differentially expressed genes can be assigned to developmental pathways known to be active during metamorphosis, whereas others can be assigned to pathways not previously associated with metamorphosis. Additionally, many genes of unknown function were identified that may be involved in the control and execution of metamorphosis. The utility of this genome-based approach is demonstrated for studying a set of complex biological processes in a multicellular organism.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	White, KP (corresponding author), Stanford Univ, Med Ctr, Beckman Ctr B400, Dept Biochem, Stanford, CA 94305 USA.			Rifkin, Scott/0000-0001-8476-3256				Allard JD, 1996, DEVELOPMENT, V122, P1137; Artero R, 1998, DEV BIOL, V195, P131, DOI 10.1006/dbio.1997.8833; Ashburner M, 1999, GENETICS, V153, P179; BARNETT SW, 1990, DEV BIOL, V140, P362, DOI 10.1016/0012-1606(90)90086-X; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; BODMER R, 1993, DEVELOPMENT, V118, P719; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FINELLI L, 1995, GENETICS, V141, P271; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; GARBE JC, 1993, DEVELOPMENT, V119, P1237; GUILD GM, 1984, J MOL BIOL, V179, P289, DOI 10.1016/0022-2836(84)90067-6; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MARONI G, 1983, DROS INFORM SERV, V59, P142; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MURTHA MT, 1989, DEV BIOL, V135, P66, DOI 10.1016/0012-1606(89)90158-9; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROGULSKI KR, 1995, J MOL BIOL, V249, P298, DOI 10.1006/jmbi.1995.0298; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Speicher S, 1998, NEURON, V20, P221, DOI 10.1016/S0896-6273(00)80451-1; Stryer L., 1988, BIOCHEMISTRY-US; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Truman James W., 1993, P1245; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; Weaver TA, 1995, DEVELOPMENT, V121, P4149; WHITE K, UNPUB; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; Wright LG, 1996, J MOL BIOL, V255, P387, DOI 10.1006/jmbi.1996.0032	54	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2179	2184		10.1126/science.286.5447.2179	http://dx.doi.org/10.1126/science.286.5447.2179			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591654				2022-12-28	WOS:000084157300059
J	Brahams, D				Brahams, D			End of compensation for unwanted healthy children	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Sq Chambers, London WC1R 5LQ, England.							JOHNSTONE H, 1999, TIMES           1126; 1999, TIMES           1126	2	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1924	1924		10.1016/S0140-6736(99)00434-1	http://dx.doi.org/10.1016/S0140-6736(99)00434-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622293				2022-12-28	WOS:000084034700007
J	Lieb, K; Maiwald, M; Berger, M; Voderholzer, U				Lieb, K; Maiwald, M; Berger, M; Voderholzer, U			Insomnia for 5 years	LANCET			English	Article							WHIPPLES-DISEASE		Univ Freiburg, Dept Psychiat, Freiburg, Germany; Univ Heidelberg, Dept Microbiol, Heidelberg, Germany	University of Freiburg; Ruprecht Karls University Heidelberg	Lieb, K (corresponding author), Univ Freiburg, Dept Psychiat & Psychotherapy, Hauptstr 5, D-79104 Freiburg, Germany.			Maiwald, Matthias/0000-0001-5448-8417				Cortelli P, 1999, J SLEEP RES, V8, P23; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; Louis ED, 1996, ANN NEUROL, V40, P561, DOI 10.1002/ana.410400404; SIERACKI JC, 1960, J NEUROPATH EXP NEUR, V19, P70, DOI 10.1097/00005072-196001000-00006; vonHerbay A, 1997, GASTROENTEROLOGY, V113, P434, DOI 10.1053/gast.1997.v113.pm9247461	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1966	1966		10.1016/S0140-6736(99)08400-7	http://dx.doi.org/10.1016/S0140-6736(99)08400-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622300				2022-12-28	WOS:000084034700014
J	Mangus, RS; Dipiero, A; Hawkins, CE				Mangus, RS; Dipiero, A; Hawkins, CE			Medical students' attitudes toward physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUTHANASIA	Context In November 1994, Oregon became the first US state to legalize physician-assisted suicide (PAS) as an option for end-of-life care. Objective This study compares the attitudes and experiences of medical students in Oregon regarding PAS to those of fourth-year medical students in the United States outside Oregon. Design A survey of all students at the Oregon Health Sciences University and fourth-year medical students at 3 non-Oregonian US medical schools. Participants Oregon medical students returned 227 questionnaires (58%), and 113 were returned from control schools (33%). Results A similar percentage of both study groups favored the legalization of PAS (64% vs 66%; P=.74). If the practice were legal, 55% of the total surveyed reported they "might be willing to write a lethal prescription," (50% Oregon students vs 60% control; P=.13 and 44% fourth-year Oregon students vs 60% control; P=.04). Among fourth-year students, 20% reported a request by a patient to the student or a preceptor for a lethal prescription in the past year (26% vs 16%; P=.09). Conclusions This study demonstrates support for and willingness by many medical students to participate in PAS. Some medical students reported observation of PAS during their training experience. Fourth-year Oregon students reported significantly less willingness than other students to provide a patient with a lethal prescription, perhaps indicating hesitancy to include PAS in clinical practice.	Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Mangus, RS (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.		Mangus, Richard S/M-1446-2018	Mangus, Richard S/0000-0003-4300-2594				Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Muller MT, 1996, MED EDUC, V30, P428, DOI 10.1111/j.1365-2923.1996.tb00863.x; *MULTN COUNT EL DI, 1994, OR VOT PAMPHL BALL M, V16; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P967, DOI 10.1001/jama.278.12.967; Steinberg MA, 1997, MED J AUSTRALIA, V166, P131, DOI 10.5694/j.1326-5377.1997.tb140042.x; Verhoef MJ, 1996, CAN MED ASSOC J, V155, P885	10	20	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2080	2081		10.1001/jama.282.21.2080	http://dx.doi.org/10.1001/jama.282.21.2080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591396	hybrid			2022-12-28	WOS:000083908700033
J	Fillingame, RH				Fillingame, RH			Protein structure - Molecular rotary motors	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI F1-ATPASE; ATP SYNTHASE; EPSILON-SUBUNIT		Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@facstaff.wisc.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961	15	51	52	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1687	1688		10.1126/science.286.5445.1687	http://dx.doi.org/10.1126/science.286.5445.1687			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10610565				2022-12-28	WOS:000083912200022
J	Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS				Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS			Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy	LANCET			English	Article							HEPATIC METASTASES; LIVER METASTASES; COLON-CANCER; FLUOROURACIL; THERAPY; FLOW; SONOGRAPHY; CARCINOMA; TUMOR	Background As yet there is no established method of accurately identifying patients with colorectal cancer who, despite undergoing apparently curative resection, are at high risk of recurrence. We assessed whether the doppler perfusion index (DPI; ratio of hepatic arterial to total liver blood flow) could be used to select patients who should receive adjuvant chemotherapy. Methods We studied 120 patients undergoing curative surgery for colorectal cancer. DPI was measured before surgery with colour duplex doppler ultrasonography. A DPI value of at least 0.3 was defined as abnormal. All patients were followed up until death or for at least 5 years. Results At 5 years, patients with Dukes' stage A or B tumours (n=61) had recurrence-free survival of 57% and overall survival of 64%, compared with 39% and 42% for patients with Dukes' stage C tumours (n=59; p=0.016 and p=0.008, respectively). 47 patients had normal DPI values and 73 patients had abnormal values. Patients with normal DPI had recurrence-free survival of 89% and overall survival of 91%, compared with 22% and 29% for those with abnormal DPI values (both p<0.0001). Conclusions DPI can be used to identify patients with colorectal cancer at high risk of recurrence who are in need of adjuvant treatment. However, further studies with larger numbers of patients are needed to confirm these findings.	Royal Infirm, Dept Radiol, Glasgow G31 2ER, Lanark, Scotland; Hairmyres Hosp, Dept Surg, E Kilbride, Lanark, Scotland; Royal Infirm, Univ Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Royal Infirmary of Edinburgh; University Hospital Hairmyres; Royal Infirmary of Edinburgh; University of Glasgow	Leen, E (corresponding author), Royal Infirm, Dept Radiol, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							CARTER R, 1994, BRIT J CANCER, V69, P1025, DOI 10.1038/bjc.1994.201; FINLAY IG, 1986, BRIT J SURG, V73, P732, DOI 10.1002/bjs.1800730918; GILBERT JM, 1984, BRIT J SURG, V71, P203, DOI 10.1002/bjs.1800710311; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; LABIANCA R, 1995, LANCET, V345, P939; LEEN E, 1993, GUT, V34, P554, DOI 10.1136/gut.34.4.554; LEEN E, 1991, ANN SURG, V214, P599, DOI 10.1097/00000658-199111000-00010; LEEN E, 1994, ANN SURG, V220, P663, DOI 10.1097/00000658-199411000-00010; LEEN E, 1995, RADIOLOGY, V195, P113, DOI 10.1148/radiology.195.1.7892449; LEEN E, 1991, BRIT J CANCER, V63, P323, DOI 10.1038/bjc.1991.76; LEVESON SH, 1985, BRIT J SURG, V72, P128, DOI 10.1002/bjs.1800720220; MCARDLE CS, 1990, BRIT J SURG, V77, P206; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; OBRIEN MJ, 1988, BR J MED SCI, V157, P5; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Oppo K, 1998, RADIOLOGY, V208, P453, DOI 10.1148/radiology.208.2.9680575; RIDGE JA, 1987, CANCER, V59, P1547, DOI 10.1002/1097-0142(19870501)59:9<1547::AID-CNCR2820590903>3.0.CO;2-6; Warren HW, 1993, BRIT J SURG, V80, P1461	18	66	71	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					34	37		10.1016/S0140-6736(99)06322-9	http://dx.doi.org/10.1016/S0140-6736(99)06322-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615889				2022-12-28	WOS:000085049200014
J	Peltola, H				Peltola, H			Emergency or routine vaccination against meningococcal disease in Africa?	LANCET			English	Editorial Material									Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.							Abbasi K, 1999, BMJ-BRIT MED J, V318, P1568, DOI 10.1136/bmj.318.7198.1568; Centers for Disease C, 1995, MMWR-MORBID MORTAL W, V44, P121; GREENWOOD BM, 1980, LANCET, V1, P729; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; LAPEYSSONNIE L, 1963, Bull World Health Organ, V28 Suppl, P1; Peltola H, 1998, DRUGS, V55, P347, DOI 10.2165/00003495-199855030-00003; PELTOLA H, 1982, LANCET, V2, P595; TORRES EM, 1987, REV CUB PEDIAT, V59, P773; *WHO WORK GROUP, 1995, CONTR MEN DIS WHO PR	9	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					3	3		10.1016/S0140-6736(99)00389-X	http://dx.doi.org/10.1016/S0140-6736(99)00389-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615878				2022-12-28	WOS:000085049200003
J	Albert, LJ; Inman, RD				Albert, LJ; Inman, RD			Mechanisms of disease: Molecular mimicry and autoimmunity.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEPENDENT DIABETES-MELLITUS; PANCREATIC BETA-CELLS; T-CELL; GLUTAMATE-DECARBOXYLASE; KLEBSIELLA-PNEUMONIAE; COXSACKIE-VIRUS; ANKYLOSING-SPONDYLITIS; POSITIVE SELECTION; REACTIVE ARTHRITIS; SEQUENCE HOMOLOGY		Univ Hlth Network, Toronto Western Hosp, Arthrit Ctr Excellence,Dept Med, Div Rheumatol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Inman, RD (corresponding author), Univ Hlth Network, Toronto Western Hosp, Arthrit Ctr Excellence,Dept Med, Div Rheumatol, FP 1-221,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	rinman@torhosp.toronto.on.ca		Inman, Robert/0000-0002-4750-1422				Adderson EE, 1998, J IMMUNOL, V161, P2020; ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; Amsen D, 1998, IMMUNOL REV, V165, P209, DOI 10.1111/j.1600-065X.1998.tb01241.x; ANDERSEN O, 1993, J NEUROL, V240, P417, DOI 10.1007/BF00867354; ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; BEHAR SM, 1995, ARTHRITIS RHEUM-US, V38, P458, DOI 10.1002/art.1780380403; COHEN IR, 1985, ARTHRITIS RHEUM, V28, P841, DOI 10.1002/art.1780280802; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; DAMIAN RT, 1964, AM NAT, V98, P129, DOI 10.1086/282313; Endl J, 1997, J CLIN INVEST, V99, P2405, DOI 10.1172/JCI119423; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Hausmann S, 1997, CURR OPIN IMMUNOL, V9, P831, DOI 10.1016/S0952-7915(97)80186-0; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hemmer B, 1998, J IMMUNOL, V160, P3631; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Huber SA, 1996, J IMMUNOL, V156, P3528; JONES DB, 1995, NAT MED, V1, P284, DOI 10.1038/nm0495-284; KAPLAN MH, 1961, J EXP MED, V113, P1, DOI 10.1084/jem.113.1.1; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LIPTON HL, 1975, INFECT IMMUN, V11, P1147, DOI 10.1128/IAI.11.5.1147-1155.1975; LOCHT H, 1993, J RHEUMATOL, V20, P845; LUO CY, 1994, J IMMUNOL, V152, P2555; LUO GY, 1993, J IMMUNOL, V151, P922; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MOON RY, 1995, J RHEUMATOL, V22, P529; Motyka B, 1998, J IMMUNOL, V160, P77; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; RICHTER W, 1994, J EXP MED, V180, P721, DOI 10.1084/jem.180.2.721; Roudier C, 1996, IMMUNOL TODAY, V17, P357, DOI 10.1016/0167-5699(96)30021-2; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1998, NEW ENGL J MED, V339, P571; SINGH B, 1994, J RHEUMATOL, V21, P670; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TSUCHIYA N, 1989, CLIN EXP IMMUNOL, V76, P354; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; Wang RF, 1998, P NATL ACAD SCI USA, V95, P3804, DOI 10.1073/pnas.95.7.3804; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YONG Z, 1989, CLIN EXP RHEUMATOL, V7, P513; ZABRISKIE JB, 1966, J EXP MED, V124, P661, DOI 10.1084/jem.124.4.661; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	55	338	353	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2068	2074		10.1056/NEJM199912303412707	http://dx.doi.org/10.1056/NEJM199912303412707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615080				2022-12-28	WOS:000084573300007
J	Cooke, FJ; Richards, DB; Kellett, CF; Morse, RE				Cooke, FJ; Richards, DB; Kellett, CF; Morse, RE			Bangers and cash: multicentre survey of what doctors are driving	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Integrated Med, Cardiff CF4 4XW, S Glam, Wales; Univ London St Georges Hosp, London SW17 0QT, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; Nuffield Orthopaed Ctr, Oxford OX3 7LD, England	Cardiff University; St Georges University London; Radcliffe Infirmary; Nuffield Orthopaedic Centre	Morse, RE (corresponding author), Univ Wales Hosp, Dept Integrated Med, Cardiff CF4 4XW, S Glam, Wales.			Richards, Duncan/0000-0002-8093-7084					0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1616	1617		10.1136/bmj.319.7225.1616	http://dx.doi.org/10.1136/bmj.319.7225.1616			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600964	Bronze, Green Published			2022-12-28	WOS:000084562600018
J	Palazzo, FF; Warner, OJ				Palazzo, FF; Warner, OJ			Surgeons swear when operating: fact or myth?	BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews Hosp, Sch Med, Dept Immunol, London EC1A 7BE, England; Royal London Hosp, Sch Med, Dept Immunol, London EC1A 7BE, England; Oxford Deanery, Oxford OX2 0AU, England	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Palazzo, FF (corresponding author), St Bartholomews Hosp, Sch Med, Dept Immunol, London EC1A 7BE, England.								0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1611	1611		10.1136/bmj.319.7225.1611	http://dx.doi.org/10.1136/bmj.319.7225.1611			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600960	Green Published, Bronze			2022-12-28	WOS:000084562600014
J	Smil, V				Smil, V			China's great famine: 40 years later	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY		Univ Manitoba, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Smil, V (corresponding author), Univ Manitoba, Winnipeg, MB R3T 2N2, Canada.	vsmil@cc.umanitoba.ca						AIRD JS, 1982, POPUL DEV REV, V8, P85; ASHTON B, 1984, POPUL DEV REV, V10, P613, DOI 10.2307/1973284; Banister J., 1987, CHINAS CHANGING POPU; Becker Jasper, 1996, HUNGRY GHOSTS; BOSS LP, 1994, JAMA-J AM MED ASSOC, V272, P371, DOI 10.1001/jama.272.5.371; Chang GH, 1997, ECON DEV CULT CHANGE, V46, P1, DOI 10.1086/452319; *ENCY BRIT, 1997, NEW ENCY BRIT MICR, V4, P674; Lopez GA, 1998, B ATOM SCI, V54, P39, DOI 10.1080/00963402.1998.11456844; MACRAE J, 1995, WAR HUNGER, V52, P217; PENG XZ, 1987, POPUL DEV REV, V13, P639, DOI 10.2307/1973026; POLLITT E, 1995, J NUTR, V125, pS2211, DOI 10.1093/jn/125.suppl_8.2211S; RHODES R, 1988, JAMA-J AM MED ASSOC, V260, P686, DOI 10.1001/jama.260.5.686; SEN A, 1995, GRANTA, V52, P217; SMIL V, 1981, FOOD POLICY, V6, P67, DOI 10.1016/0306-9192(81)90016-6; SMIL V, 1985, SCI AM, V253, P116, DOI 10.1038/scientificamerican1285-116; State Statistical Bureau, 1978, CHIN STAT YB; YANG DL, 1996, CATASTROPHE REFORM C	17	116	116	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1619	1621		10.1136/bmj.319.7225.1619	http://dx.doi.org/10.1136/bmj.319.7225.1619			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600969	Green Published			2022-12-28	WOS:000084562600021
J	Rescigno, TN; Baertschy, M; Isaacs, WA; McCurdy, CW				Rescigno, TN; Baertschy, M; Isaacs, WA; McCurdy, CW			Collisional breakup in a quantum system of three charged particles	SCIENCE			English	Article							DIFFERENTIAL CROSS-SECTIONS; ELECTRON-IMPACT IONIZATION; HYDROGEN SCATTERING; FORM	Since the invention of quantum mechanics, even the simplest example of the collisional breakup of a system of charged particles, e(-) + H --> H+ + e(-) + e(-) (where e(-) is an electron and H is hydrogen), has resisted solution and is now one of the Last unsolved fundamental problems in atomic physics. A complete solution requires calculation of the energies and directions for a final state in which all three particles are moving away from each other. Even with supercomputers, the correct mathematical description of this state has proved difficult to apply, A framework for solving ionization problems in many areas of chemistry and physics is finally provided by a mathematical transformation of the Schrodinger equation that makes the final state tractable, providing the key to a numerical solution of this problem that reveals its full dynamics.	Lawrence Livermore Natl Lab, Phys Directorate, Livermore, CA 94551 USA; Lawrence Livermore Natl Lab, Dept Appl Sci, Livermore, CA 94550 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Rescigno, TN (corresponding author), Lawrence Livermore Natl Lab, Phys Directorate, POB 5508, Livermore, CA 94551 USA.		MCCURDY, CLYDE/GRE-7874-2022					Baertschy M, 1999, PHYS REV A, V60, pR13, DOI 10.1103/PhysRevA.60.R13; BALSLEV E, 1971, COMMUN MATH PHYS, V22, P280, DOI 10.1007/BF01877511; BRAUNER M, 1989, J PHYS B-AT MOL OPT, V22, P2265, DOI 10.1088/0953-4075/22/14/010; BRAY I, 1993, PHYS REV LETT, V70, P746, DOI 10.1103/PhysRevLett.70.746; BURKE PG, 1962, REV MOD PHYS, V34, P458, DOI 10.1103/RevModPhys.34.458; KOHN W, 1948, PHYS REV, V74, P1763, DOI 10.1103/PhysRev.74.1763; Lucey SP, 1999, P ROY SOC A-MATH PHY, V455, P349, DOI 10.1098/rspa.1999.0317; McCurdy CW, 1997, PHYS REV A, V56, P1958, DOI 10.1103/PhysRevA.56.1958; MCCURDY CW, 1997, PHYS REV A, V56, pR4346; PEKERIS CL, 1958, PHYS REV, V112, P1649, DOI 10.1103/PhysRev.112.1649; PERCIVAL IC, 1957, P CAMBRIDGE PHIL SOC, V53, P654; PETERKOP RK, 1963, B ACAD SCI USSR PHYS, V27, P987; PETERKOP RK, 1962, OPT SPECTROSC, V13, P87; Pindzola MS, 1996, PHYS REV A, V54, P2142, DOI 10.1103/PhysRevA.54.2142; Pindzola MS, 1997, PHYS REV A, V55, P4617, DOI 10.1103/PhysRevA.55.4617; Rader J, 1996, PHYS REV A, V53, P225, DOI 10.1103/PhysRevA.53.225; RESCIGNO TN, IN PRESS PHYS REV A; Roder J, 1997, J PHYS B-AT MOL OPT, V30, P1309, DOI 10.1088/0953-4075/30/5/022; Roder J, 1997, PHYS REV LETT, V79, P1666, DOI 10.1103/PhysRevLett.79.1666; RUDGE MRH, 1965, PROC R SOC LON SER-A, V283, P262, DOI 10.1098/rspa.1965.0020; Schiff L.I., 1968, QUANTUM MECH; SCHWARTZ C, 1961, PHYS REV, V124, P1468, DOI 10.1103/PhysRev.124.1468; SHYN TW, 1992, PHYS REV A, V45, P2951, DOI 10.1103/PhysRevA.45.2951; SIMON B, 1972, COMMUN MATH PHYS, V27, P1, DOI 10.1007/BF01649654; SIMON B, 1979, PHYS LETT A, V71, P211, DOI 10.1016/0375-9601(79)90165-8	26	445	453	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2474	2479		10.1126/science.286.5449.2474	http://dx.doi.org/10.1126/science.286.5449.2474			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617455				2022-12-28	WOS:000084429700038
J	St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D				St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D			Changes in the scope of care provided by primary care physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES; MANAGED-CARE; CONSULTATION	Background: Strategies to control medical costs and improve the quality of care often translate into decisions affecting the range of services primary care physicians provide to patients, which patients are referred for specialty care, and the points in disease processes at which referrals are made. This study focused on physicians' assessments of changes in the scope of care provided by primary care physicians and their assessments of the appropriateness of the scope of the care that primary care physicians are expected to provide. Methods: We analyzed data from the 1996-1997 Community Tracking Study Physician Survey. Telephone interviews were conducted with 12,385 physicians (reflecting a response rate of 65 percent) who were drawn from a representative random sample of physicians providing direct patient care in the continental United States and not employed by the federal government. The analysis was based on responses from the 7015 primary care physicians and 5092 specialists who had been in practice for at least two years. Results: Thirty percent of the primary care physicians and 50 percent of the specialists reported that the scope of care provided by primary care physicians had increased during the previous two years. Twenty-four percent of the primary care physicians and 38 percent of the specialists reported that the scope of care expected to be provided by primary care physicians was greater than it should be. According to multivariate analysis, primary care physicians other than general or family practitioners (i.e., pediatricians and general internists), those who were in one- or two-physician practices, those who received revenues from capitation, and those who served as gatekeepers for their patients' care were significantly more likely to report that the scope of care they were expected to provide was greater than it should be. Conclusions: The finding that nearly one in four primary care physicians reported that the scope of care they were expected to provide was greater than it should be arouses concern about the potential impact of changes in the delivery of health care. The associations we found between financial and administrative aspects of managed care and physicians' concern about the scope of care they provide to their patients deserve careful consideration. (N Engl J Med 1999;341:1980-5.) (C)1999, Massachusetts Medical Society.	Kansas Hlth Inst, Topeka, KS 66612 USA; Ctr Study Hlth Syst Change, Washington, DC USA; Massachusetts Gen Hosp, Partners Healthcare Syst, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	St Peter, RF (corresponding author), Kansas Hlth Inst, 100 SE 9th St,3rd Fl, Topeka, KS 66612 USA.							EISENBERG J, 1986, DOCTORS DECISIONS CO; Grembowski DE, 1998, MED CARE RES REV, V55, P3, DOI 10.1177/107755879805500101; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; Hirth RA, 1996, MED CARE, V34, P1199, DOI 10.1097/00005650-199612000-00005; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1535; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; KEIL L, 1998, TECHNICAL PUBLICATIO, V9; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuo D, 1998, JAMA-J AM MED ASSOC, V280, P905, DOI 10.1001/jama.280.10.905; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; METCALF CE, 1996, TECHNICAL PUBLICATIO, V1; RESCHOVSKY JD, 1998, TECHNICAL PUBLICATIO, V10; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Rosser WW, 1996, J FAM PRACTICE, V42, P139; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136	20	92	94	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1980	1985		10.1056/NEJM199912233412606	http://dx.doi.org/10.1056/NEJM199912233412606			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607816				2022-12-28	WOS:000084399400006
J	Goodlin, SJ; Zhong, ZS; Lynn, J; Teno, JM; Fago, JP; Desbiens, N; Connors, AF; Wenger, NS; Phillips, RS				Goodlin, SJ; Zhong, ZS; Lynn, J; Teno, JM; Fago, JP; Desbiens, N; Connors, AF; Wenger, NS; Phillips, RS			Factors associated with use of cardiopulmonary resuscitation in seriously ill hospitalized adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-SUSTAINING TREATMENT; SUPPORT PROGNOSTIC MODEL; CONGESTIVE-HEART-FAILURE; INTENSIVE-CARE UNIT; CRITICALLY ILL; FUNCTIONAL STATUS; PHYSICIANS; ORDERS; SURVIVAL; PREFERENCES	Context The epidemiology of do-not-resuscitate (DNR) orders for hospitalized patients has been reported, but little is known about factors associated with the use of cardiopulmonary resuscitation (CPR). Objective To identify factors associated with an attempt at CPR for patients who experienced cardiopulmonary arrest. Design Secondary analysis of data collected in 2 prospective cohort studies: the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT, 1989-1994) and the Hospitalized Elderly Longitudinal Project (HELP, 1994). Setting Five teaching hospitals across the United States. Participants A total of 2505 seriously ill hospitalized patients and nonelectively admitted persons aged 80 years or older who experienced cardiopulmonary arrest. Main Outcome Measures Medical records data on CPR efforts, DNR orders, disease severity, age, race, sex, length of stay, and survival; functional status and preferences concerning CPR obtained by interviews with patients or surrogates; and 2-month survival estimates provided by physicians. Results Five hundred fourteen study subjects (21%) received CPR during their index hospitalization. Among them, 327 (63.6%) had CPR within 2 days of death and 93 (18.1%) had resuscitation and survived their index hospitalization. Use of CPR was more likely in men (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.12-1.73), younger patients (OR per 10-year increase, 0.90; 95% CI, 0.84-0.96), African Americans (OR, 1.76; 95% CI, 1.33-2.34), patients whose reported preferences were for CPR (OR, 2.60; 95% CI, 1.91-3.55), who reported better quality of life (OR, 1.49; 95% CI, 1.10-2.03), or who had higher physician estimates for 2-month survival (OR per 10% increase, 1.14; 95% CI, 1.09-1.19). Rates varied significantly with geographic location and diagnosis; the adjusted OR for patients with congestive heart failure was 3.31 (95% CI, 2.12-5.15) compared with patients with acute respiratory failure or multiple organ system failure. Conclusions Our data suggest that a resuscitation attempt is more likely when preferred by patients and when death is least expected. Further study is required to understand variation in use of CPR among sites and for patients with different diagnoses, race,sex, or age.	Latter Day St Hosp, Div Geriatr, Salt Lake City, UT 84143 USA; George Washington Univ, Ctr Improve Care Dying, Washington, DC USA; Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Univ Tennessee, Coll Med, Chattanooga Unit, Chattanooga, TN USA; Univ Virginia, Dept Med, Charlottesville, VA USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; Open Soc Inst, Project Death Amer, New York, NY USA	George Washington University; Brown University; Dartmouth College; University of Tennessee System; University of Tennessee Health Science Center; University of Virginia; University of California System; University of California Los Angeles; Harvard University; Beth Israel Deaconess Medical Center	Goodlin, SJ (corresponding author), Latter Day St Hosp, Div Geriatr, 8th Ave & C St, Salt Lake City, UT 84143 USA.			Connors, Alfred F./0000-0001-7123-3360				[Anonymous], 1999, DEATH FORETOLD PROPH; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BERGER R, 1994, CHEST, V106, P872, DOI 10.1378/chest.106.3.872; CALLAHAN D, 1987, HASTINGS CENT REP, V17, P21, DOI 10.2307/3562666; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Emergency Cardiac Care Committee and Subcommittees American Heart Association, 1992, JAMA-J AM MED ASSOC, V268, P2282; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; HANSON LC, 1991, J AM GERIATR SOC, V39, P772, DOI 10.1111/j.1532-5415.1991.tb02699.x; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Jayes RL, 1996, CHEST, V110, P1332, DOI 10.1378/chest.110.5.1332; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOCH KA, 1994, CRIT CARE MED, V22, P233, DOI 10.1097/00003246-199402000-00013; KOENIG BA, 1995, WESTERN J MED, V163, P244; Krumholz HM, 1998, CIRCULATION, V98, P648, DOI 10.1161/01.CIR.98.7.648; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 1997, New Horiz, V5, P56; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; National Conference on Cardiopulmonary Resuscitation and Emergency Cardiac Care, 1974, JAMA-J AM MED ASSOC, V227, P864; Oppenheim A, 1998, CRIT CARE MED, V26, P423, DOI 10.1097/00003246-199803000-00003; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; PETERSON MW, 1991, CHEST, V100, P168, DOI 10.1378/chest.100.1.168; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Poses RM, 1997, ARCH INTERN MED, V157, P1001, DOI 10.1001/archinte.157.9.1001; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; SCHEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004	43	82	82	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2333	2339		10.1001/jama.282.24.2333	http://dx.doi.org/10.1001/jama.282.24.2333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612321	Bronze			2022-12-28	WOS:000084261700027
J	Ravn, P; Bidstrup, M; Wasnich, RD; Davis, JW; McClung, MR; Balske, A; Coupland, C; Sahota, O; Kaur, A; Daley, M; Cizza, G				Ravn, P; Bidstrup, M; Wasnich, RD; Davis, JW; McClung, MR; Balske, A; Coupland, C; Sahota, O; Kaur, A; Daley, M; Cizza, G		Early Postmenopausal Intervention	Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							REPLACEMENT THERAPY; REMODELING TRANSIENT; BIOCHEMICAL MARKERS; ORAL ALENDRONATE; MINERAL DENSITY; ELDERLY WOMEN; DOUBLE-BLIND; OSTEOPOROSIS; FRACTURES; MASS	Background: Up to 3 years of treatment with alendronate, 5 mg/d, prevents postmenopausal bone loss. Objective: To determine whether the effect of alendronate is sustained at 4 years of treatment and persists after treatment is discontinued. Design: Randomized, controlled trial. Setting: United States and Europe. Participants: 1609 postmenopausal women 45 to 59 years of age. Intervention: Participants were randomly assigned to receive oral alendronate, 5 mg/d or 2.5 mg/d; placebo; or open-label estrogen-progestin, Women in the alendronate groups received alendronate for the first 2 years of the study. Treatment was then continued without change or replaced with placebo for the last 2 years of the study. Measurements: Annual measurement of bone mineral density. Results: By year 4, the bone mineral density of participants in the placebo group had decreased by 1% to 6% (P < 0.001). Four years of treatment with 5 mg of alendronate per day increased bone mineral density at the spine (mean change [+/- SE], 3.8% +/- 0.3%), hip (mean, 2.9% +/- 0.2%), and total body (mean, 0.9% +/- 0.2%) (P < 0.001 overall). By year 4, bone mineral density at most skeletal sites was greater in participants who switched from alendronate to placebo than in those who continuously received placebo. In years 3 and 4, bone loss in participants who switched from alendronate to placebo was similar to that seen during years 1 and 2 in those who continuously received placebo. Compared with 5 mg of alendronate per day, estrogen-medroxyprogesterone acetate produced similar increases in bone mineral density and estradiol-norethisterone acetate produced increases that were substantially greater. Conclusions: Four years of treatment with alendronate or estrogen-progestin prevented postmenopausal bone loss. A residual effect was seen Z years after alendronate therapy was stopped; however, continuous alendronate treatment was more effective in preventing postmenopausal bone loss than 2 years of alendronate followed by Z years of placebo.	Ctr Clin & Basic Res, DK-2750 Ballerup, Denmark; Hawaii Osteoporosis Ctr, Honolulu, HI USA; Oregon Osteoporosis Ctr, Portland, OR USA; City Hosp, Nottingham NG5 1PB, England; Merck & Co Inc, Rahway, NJ 07065 USA	Center Clinical & Basic Research; Oregon Osteoporosis Center; University of Nottingham; Merck & Company	Ravn, P (corresponding author), Ctr Clin & Basic Res, Ballerup Byvej 22, DK-2750 Ballerup, Denmark.		Ravn, Pernillle/AAT-9761-2020; McClung, Michael/ABA-4100-2021	Ravn, Pernillle/0000-0001-8752-1121; McClung, Michael/0000-0002-7827-0778; Coupland, Carol/0000-0002-2327-3306; Sahota, Opinder/0000-0003-0055-7637				ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; BERG RL, 1990, 2ND 50 YEARS PROMOTI, P76; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; CHRISCHILLES EA, 1998, J BONE MINER RES S, V5, pS182; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1981, LANCET, V1, P459; CUMMINGS SR, 1990, CLIN ORTHOP RELAT R, P163; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; Devogelaer JP, 1996, BONE, V18, P141, DOI 10.1016/8756-3282(95)00436-X; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; FULEIHAN GE, 1997, J BONE MINER RES  S1, V11, pS143; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GARNERO P, 1995, BONE, V16, P499, DOI 10.1016/8756-3282(95)00075-O; HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jcem.76.6.8501142; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; Heaney RP, 1997, J BONE MINER RES, V12, P1143, DOI 10.1359/jbmr.1997.12.8.1143; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1980, LANCET, V2, P1151; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002-9343(97)00130-7; WREN BG, 1991, MATURITAS, V13, P17, DOI 10.1016/0378-5122(91)90281-T	32	142	142	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					935	+		10.7326/0003-4819-131-12-199912210-00005	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610644				2022-12-28	WOS:000084374400004
J	Woeber, KA				Woeber, KA			The year in review: The thyroid	ANNALS OF INTERNAL MEDICINE			English	Review							NEEDLE ASPIRATION BIOPSY; TREATED GRAVES-DISEASE; HYPERTHYROIDISM; THYROXINE; OPHTHALMOPATHY; THERAPY; NODULES; MANAGEMENT; METHIMAZOLE; RECURRENCE	Several studies that have important implications for the management of patients with various thyroid disorders were recently published. These studies concern screening for thyroid disease, thyroid eye disease and treatment with iodine-131, antithyroid drug treatment, treatment of hypothyroidism, and management of thyroid nodules. For each topic, the results of the studies are presented and recommendations for their translation into clinical practice are offered.	Univ Calif San Francisco, Dept Med, Mt Zion Med Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Woeber, KA (corresponding author), Univ Calif San Francisco, Dept Med, Mt Zion Med Ctr, Box 1640, San Francisco, CA 94143 USA.							Bartalena L, 1998, ANN INTERN MED, V129, P632, DOI 10.7326/0003-4819-129-8-199810150-00010; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; Bunevicius R, 1999, NEW ENGL J MED, V340, P424, DOI 10.1056/NEJM199902113400603; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; DIEKMAN T, 1995, ARCH INTERN MED, V155, P1490, DOI 10.1001/archinte.155.14.1490; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Hagag P, 1998, THYROID, V8, P989, DOI 10.1089/thy.1998.8.989; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; Helfand M, 1998, ANN INTERN MED, V129, P141, DOI 10.7326/0003-4819-129-2-199807150-00020; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; Imseis RE, 1998, J CLIN ENDOCR METAB, V83, P685, DOI 10.1210/jc.83.2.685; Khurana KK, 1998, THYROID, V8, P511, DOI 10.1089/thy.1998.8.511; Lucas A, 1997, J CLIN ENDOCR METAB, V82, P2410, DOI 10.1210/jc.82.8.2410; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; Rittmaster RS, 1998, J CLIN ENDOCR METAB, V83, P814, DOI 10.1210/jc.83.3.814; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TAMAI H, 1995, J CLIN ENDOCR METAB, V80, P1481, DOI 10.1210/jc.80.5.1481; Tan GH, 1997, ANN INTERN MED, V126, P226, DOI 10.7326/0003-4819-126-3-199702010-00009; Toft AD, 1999, NEW ENGL J MED, V340, P469, DOI 10.1056/NEJM199902113400611; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; VESTERGAARD H, 1989, LANCET, V2, P47; Zelmanovitz F, 1998, J CLIN ENDOCR METAB, V83, P3881, DOI 10.1210/jc.83.11.3881	23	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					959	962		10.7326/0003-4819-131-12-199912210-00009	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610648				2022-12-28	WOS:000084374400008
J	Carpenter, CF; Subramanian, AK				Carpenter, CF; Subramanian, AK			Cutaneous zygomycosis (mucormycosis)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Johns Hopkins Univ, Baltimore, MD 21287 USA	Johns Hopkins University	Carpenter, CF (corresponding author), Johns Hopkins Univ, Baltimore, MD 21287 USA.			Carpenter, Christopher/0000-0001-5708-5381; Subramanian, Aruna/0000-0002-1373-6768					0	14	15	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1891	1891		10.1056/NEJM199912163412504	http://dx.doi.org/10.1056/NEJM199912163412504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601508				2022-12-28	WOS:000084210200004
J	Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC				Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC			Crystal structure of the vinculin tail suggests a pathway for activation	CELL			English	Article							F-ACTIN-BINDING; CYTOSKELETAL PROTEIN VINCULIN; INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; TALIN-BINDING; ALPHA-ACTININ; DOMAIN; SITE; MEMBRANE; SEQUENCE	Vinculin plays a dynamic role in the assembly of the actin cytoskeleton. A strong interaction between its head and tail domains that regulates binding to other cytoskeletal components is disrupted by acidic phospholipids. Here, we present the crystal structure of the vinculin tail, residues 879-1066. Five amphipathic helices form an antiparallel bundle that resembles exchangeable apolipoproteins. A C-terminal arm wraps across the base of the bundle and emerges as a hydrophobic hairpin surrounded by a collar of basic residues, adjacent to the N terminus. We show that the C-terminal arm is required for binding to acidic phospholipids but not to actin, and that binding either ligand induces conformational changes that may represent the first step in activation.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham-inst.org	Bagshaw, Clive R./L-5484-2019; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	Bagshaw, Clive R./0000-0002-5396-153X; de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739; Bakolitsa, Constantina/0000-0002-6980-9831				Adams PD, 1999, ACTA CRYSTALLOGR D, V55, P181, DOI 10.1107/S0907444998006635; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1992, J CELL SCI, V103, P719; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Goldmann WH, 1998, EUR J BIOCHEM, V254, P413, DOI 10.1046/j.1432-1327.1998.2540413.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hemmings L, 1996, J CELL SCI, V109, P2715; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls A., 1992, GRASP GRAPHICAL REPR; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WELLER PA, 1990, P NATL ACAD SCI USA, V87, P5667, DOI 10.1073/pnas.87.15.5667; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327	60	153	156	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					603	613		10.1016/S0092-8674(00)81549-4	http://dx.doi.org/10.1016/S0092-8674(00)81549-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612396	Bronze			2022-12-28	WOS:000084278700007
J	Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA				Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA			Functional human corneal equivalents constructed from cell lines	SCIENCE			English	Article							HUMAN EPITHELIAL-CELLS; GROWTH-FACTOR; FIBROBLAST GROWTH; IMMORTALIZATION; EXPRESSION; CULTURE; GENE; EYE	Human corneal equivalents comprising the three main Layers of the cornea (epithelium, stroma, and endothelium) were constructed. Each cellular layer was fabricated from immortalized human corneal cells that were screened for use on the basis of morphological, biochemical, and electrophysiological similarity to their natural counterparts. The resulting corneal equivalents mimicked human corneas in key physical and physiological functions, including morphology, biochemical marker expression, transparency, ion and fluid transport, and gene expression. Morphological and functional equivalents to human corneas that can be produced in vitro have immediate applications in toxicity and drug efficacy testing, and form the basis for future development of implantable tissues.	Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Hosp, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Procter & Gamble Co, Miami Valley Labs, Div Human & Environm Safety, Cincinnati, OH 45253 USA; Ctr Hosp Univ Quebec, Biomat Inst Quebec, Quebec City, PQ G1L 3L5, Canada; Univ Tennessee, Coll Med, Dept Physiol, Memphis, TN 38163 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Procter & Gamble; Laval University; University of Tennessee System; University of Tennessee Health Science Center	Griffith, M (corresponding author), Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada.		Mantovani, Diego/J-2457-2012	Mantovani, Diego/0000-0001-9672-895X; Griffith, May/0000-0003-1222-6720; Watsky, Mitchell/0000-0003-2079-9887				Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bockman CS, 1998, INVEST OPHTH VIS SCI, V39, P1143; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; DOILLON CJ, 1987, BIOMATERIALS, V8, P195, DOI 10.1016/0142-9612(87)90063-9; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Gause WC, 1995, PCR PRIMER LAB MANUA; Germain L, 1999, PATHOBIOLOGY, V67, P140, DOI 10.1159/000028064; GEROSKI DH, 1984, CURR EYE RES, V3, P331, DOI 10.3109/02713688408997217; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH JF, 1980, TOXICOL APPL PHARM, V55, P501, DOI 10.1016/0041-008X(80)90052-6; Griffith M., UNPUB; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; *INT LIF SCI I, 1996, J TOXICOL CUTANEOUS, V15, P211; JAGER MJ, 1995, EYE, V9, P241, DOI 10.1038/eye.1995.47; Janvier R, 1997, ANTICANCER RES, V17, P1551; KAHN CR, 1993, INVEST OPHTH VIS SCI, V34, P1983; KAO WWY, 1975, BIOCHIM BIOPHYS ACTA, V411, P202, DOI 10.1016/0304-4165(75)90300-1; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; MINAMI Y, 1993, INVEST OPHTH VIS SCI, V34, P2316; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; Okada Y, 1998, GRAEF ARCH CLIN EXP, V236, P853, DOI 10.1007/s004170050170; Pettenati MJ, 1997, HUM GENET, V101, P26, DOI 10.1007/s004390050580; PITTS DG, 1994, ENV VISION, pCH6; POWER WJ, 1995, CURR EYE RES, V14, P879, DOI 10.3109/02713689508995127; Priest D., 1998, IOVS, V39, pS352; QUINLAN MP, 1994, ONCOGENE, V9, P2639; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Shoichet M. S., 1998, POLYM TISSUE ENG; Sotozono C, 1997, CURR EYE RES, V16, P670, DOI 10.1076/ceyr.16.7.670.5057; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WATSKY MA, 1995, DUANES FDN CLIN OPHT, V2, pCH4; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	37	377	451	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2169	2172		10.1126/science.286.5447.2169	http://dx.doi.org/10.1126/science.286.5447.2169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591651				2022-12-28	WOS:000084157300056
J	Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH				Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH			Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; NEURONAL-SPECIFIC ACTIVATOR; GLYCOGEN-SYNTHASE KINASE-3; DIRECTED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; TAU-PROTEIN; ALZHEIMERS-DISEASE; REGULATORY SUBUNIT; CEREBRAL-CORTEX	Cyclin-dependent kinase 5 (Cdk5) is required for proper development of the mammalian central nervous system. To be activated, Cdk5 has to associate with its regulatory subunit, p35, We have found that p25, a truncated form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease. This accumulation correlates with an increase in Cdk5 kinase activity. Unlike p35, p25 is not readily degraded, and binding of p25 to Cdk5 constitutively activates Cdk5, changes its cellular location and alters its substrate specificity, In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules, Moreover, expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis, These findings indicate that cleavage of p35, followed by accumulation of p25, may be involved in the pathogenesis of cytoskeletal abnormalities and neuronal death in neurodegenerative diseases.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp E, Ctr Canc, Charlestown, MA 02119 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306				Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gilmore EC, 1998, J NEUROSCI, V18, P6370; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Guidato S, 1996, J NEUROCHEM, V66, P1698; Henchcliffe C, 1997, NEUROSCI LETT, V230, P41, DOI 10.1016/S0304-3940(97)00472-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANAKA T, 1995, FEBS LETT, V360, P5, DOI 10.1016/0014-5793(95)00061-D; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	49	1246	1335	0	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					615	622		10.1038/45159	http://dx.doi.org/10.1038/45159			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604467				2022-12-28	WOS:000084189800054
J	DeMets, DL; Pocock, SJ; Julian, DG				DeMets, DL; Pocock, SJ; Julian, DG			The agonising negative trend in monitoring of clinical trials	LANCET			English	Review							HEART-FAILURE; MORTALITY; VESNARINONE; DISEASE; DESIGN	Randomised clinical trials are undertaken in the hope of showing positive benefits of a new treatment, but on occasion quite the opposite trend can occur, if the interim data suggest possible negative (harmful) effects of a new treatment. The handling of such emerging negative trends is among the most complicated and ethically challenging scenarios in monitoring clinical trials through repeated interim analyses. Statistical methods are helpful to detect the point of no likely beneficial effect, and the point that separates neutral results from harmful results. However, in practice the decision whether land exactly when) to stop such a trial involves a complex of other issues that depends on the context of the disease, the treatment being assessed, and the current practice of medicine. Owing to this complexity, an independent Data and Safety Monitoring Board (DSMB) is best suited to deal with such a situation. Prediction of whether a negative trend will emerge in any trial is not possible. Negative trends were not anticipated in the cardiovascular trials and the trials of lung-cancer prevention described here. In the light of these experiences, all trials and their DSMBs should consider ahead of time the possibility of unexpectedly harmful results, and should document appropriately the statistical guidelines and the decision-making process required to cope with such undesirable events.	Univ Wisconsin, Dept Biostat, Madison, WI USA; London Sch Hyg & Trop Med, Med Stat Unit, London, England; Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Wisconsin System; University of Wisconsin Madison; University of London; London School of Hygiene & Tropical Medicine; Newcastle University - UK	DeMets, DL (corresponding author), Univ Wisconsin, Dept Biostat & Med Informat, 600 Highland Ave,Room K6-446-4675, Madison, WI 53792 USA.	demets@biostat.wisc.edu						Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1988, CONTROL CLIN TRIALS, V9, P137; [Anonymous], 1986, Lancet, V2, P57; CANNER PL, 1981, CONTROL CLIN TRIALS, V1, P363; *CARD ARRH SUPPR T, 1989, NEW ENGL J MED, V312, P406; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; DEMETS DL, 1982, BIOMETRIKA, V69, P661; DEMETS DL, 1999, CLIN TRIALS CARDIOVA, P31; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FLEMING TR, 1993, CONTROL CLIN TRIALS, V14, P183, DOI 10.1016/0197-2456(93)90002-U; FREEDMAN LS, 1994, STAT MED, V13, P1371, DOI 10.1002/sim.4780131312; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hjalmarson A, 1999, LANCET, V353, P2001; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JENNISON C, 1989, J R STAT SOC B, V51, P305; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; *PREV ATH COMPL KE, 1998, BMJ-BRIT MED J, V298, P424; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SCHWARTZ PJ, 1994, CIRCULATION, V89, P2892; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	30	90	92	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1983	1988		10.1016/S0140-6736(99)03464-9	http://dx.doi.org/10.1016/S0140-6736(99)03464-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622312				2022-12-28	WOS:000084034700042
J	Stenseth, NC				Stenseth, NC			Evolutionary biology - The evolutionary synthesis	SCIENCE			English	Editorial Material									Univ Oslo, Dept Biol, N-0316 Oslo, Norway	University of Oslo	Stenseth, NC (corresponding author), Univ Oslo, Dept Biol, POB 1050 Blindern, N-0316 Oslo, Norway.	n.c.stenseth@bio.uio.no	Stenseth, Nils Chr./G-5212-2016	Stenseth, Nils Chr./0000-0002-1591-5399				[Anonymous], 1861, ORIGIN SPECIES MEANS; DOBZHANSKY T, 1973, AM BIOL TEACH, V35, P125, DOI 10.2307/4444260; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Maynard Smith J., 1982, pi; Maynard Smith J., 1986, PROBLEMS BIOL; Maynard Smith J., 1999, ORIGINS LIFE BIRTH L; MAYR E, 1995, P AM PHILOS SOC, V139, P317; Mayr E, 1997, THIS IS BIOL; Mayr E., 1963, ANIMAL SPECIES EVOLU; Mayr E, 1942, SYSTEMATICS ORIGIN S; Mayr Ernst, 1991, ONE LONG ARGUMENT C; Mayr W., 1969, PRINCIPLES SYSTEMATI; Nesse RM, 1995, WHY WE GET SICK; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; Szathmary E, 1995, MAJOR TRANSITIONS EV; Williams G. C., 1966, P307; Williams G. C, 1996, PLAN PURPOSE NATURE; Williams G. C, 1992, NATURAL SELECTION DO; Wynne-Edwards V. C., 1962, pUnpaginated	19	1	1	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1490	1490		10.1126/science.286.5444.1490	http://dx.doi.org/10.1126/science.286.5444.1490			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610549				2022-12-28	WOS:000083768300033
J	Beecham, L				Beecham, L			BMA will review healthcare funding	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					62	63						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617549				2022-12-28	WOS:000084621600062
J	Jones, J				Jones, J			Doctors suspended in child health inquiry	BRITISH MEDICAL JOURNAL			English	News Item																		Samuels MP, 1996, PEDIATRICS, V98, P1154; SOUTHALL, 1999, BRIT MED J, V318, P553	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					9	9						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617514				2022-12-28	WOS:000084621600011
J	McKiernan, PJ; Baker, AJ; Kelly, DA				McKiernan, PJ; Baker, AJ; Kelly, DA			The frequency and outcome of biliary atresia in the UK and Ireland	LANCET			English	Article							LIVER-TRANSPLANTATION; SURGERY; EXPERIENCE; CHILDREN; SURVIVAL	Background Biliary atresia is an obliterative cholangiopathy of infancy that is fatal if untreated, Surgical treatment, the Kasai portoenterostomy, may restore bile flow and clear jaundice, and, if successful, achieve a 10-year survival of 90% with a native liver. The outcome of a 2-year cohort of children with biliary atresia in the UK and Ireland was assessed to find the current frequency, the factors influencing outcome, and the medium-term need for liver transplantation. Methods Cases diagnosed between March, 1993, and February, 1995, were notified by paediatricians to the British Paediatric Surveillance Unit via a monthly reporting system. Confirmed cases were followed up by postal questionnaires to notifying paediatricians. Findings 93 cases were confirmed, a frequency of 1/16 700 livebirths, Primary surgery was done in 91 children in 15 surgical centres with an early success rate for clearing jaundice of 55% overall. Centres were grouped according to caseload; group A had more than 5 cases/year and group B fewer than 5 cases/year. Early success was higher in group-A centres, odds ratio 2.02 (95% CI 0.86-4.73), but this did not reach statistical significance. Of 41 children in whom surgery was unsuccessful in clearing jaundice 9 (22%) died and 30 (73%) underwent liver transplantation. Survival without liver transplantation and overall survival were both significantly greater in group-A centres, rate ratios 0.48 (95% CI 0.27-0.86) and 0.32 (0.11-0.94). Actuarial 5-year survival without transplantation was 61.3% in group-A centres and 13.7% in group-B centres. Actuarial 5-year overall survival was 91.2% in group A and 75% in group B, Once centre size was taken into account, no other factor, including age at surgery, was predictive of survival without transplantation or overall survival. Interpretation The outcome of children with biliary atresia is related to the caseload of the surgical centre where they have their primary surgery. Children with biliary atresia should be managed in surgical centres with a caseload of more than five cases annually.	Birmingham Childrens Hosp NHS Trust, Liver Unit, Birmingham B4 6NH, W Midlands, England; Kings Coll Hosp London, Paediat Liver Unit, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	McKiernan, PJ (corresponding author), Birmingham Childrens Hosp NHS Trust, Liver Unit, Birmingham B4 6NH, W Midlands, England.	Pat.Mckiernan@bhamchildrens.wmids.nhs.uk						Altman RP, 1997, ANN SURG, V226, P348, DOI 10.1097/00000658-199709000-00014; Arul GS, 1998, ARCH DIS CHILD, V79, P65, DOI 10.1136/adc.79.1.65; ATWELL JD, 1992, ARCH DIS CHILD, V67, P345, DOI 10.1136/adc.67.3.345; Balistreri WF, 1996, HEPATOLOGY, V23, P1682, DOI 10.1002/hep.510230652; BEATH S, 1993, J PEDIATR SURG, V28, P1044, DOI 10.1016/0022-3468(93)90515-M; BLOOMFIELD S, 1990, ARCH DIS CHILD, V65, P139, DOI 10.1136/adc.65.1.139; British Association of Paediatric Surgeons, 1995, GUID PURCH PROV PAED; CHANDRA RS, 1978, J PEDIATR-US, V93, P196, DOI 10.1016/S0022-3476(78)80495-8; CHANDRA RS, 1974, J PEDIATR-US, V85, P649, DOI 10.1016/S0022-3476(74)80508-1; DANKS DM, 1977, ARCH DIS CHILD, V52, P360, DOI 10.1136/adc.52.5.360; Davenport M, 1997, J PEDIATR SURG, V32, P479, DOI 10.1016/S0022-3468(97)90611-4; FIELD D, 1991, ARCH DIS CHILD-FETAL, V66, P408, DOI 10.1136/adc.66.4_Spec_No.408; HENRIKSEN NT, 1981, ARCH DIS CHILD, V56, P622, DOI 10.1136/adc.56.8.622; HOUWEN RHJ, 1989, ARCH DIS CHILD, V64, P214, DOI 10.1136/adc.64.2.214; KARRER FM, 1990, J PEDIATR SURG, V25, P1076, DOI 10.1016/0022-3468(90)90222-U; KASAI M, 1989, J PEDIATR SURG, V24, P851, DOI 10.1016/S0022-3468(89)80580-9; KASAI M, 1968, Journal of Pediatric Surgery, V3, P665, DOI 10.1016/0022-3468(68)90897-X; LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793, DOI 10.1016/0016-5085(90)90489-N; LYNN R, 1998, BRIT PAEDIAT SURVEIL; MCCLEMENT JW, 1985, BRIT MED J, V290, P345, DOI 10.1136/bmj.290.6465.345; MIELIVERGANI G, 1989, LANCET, V1, P421; OHI R, 1991, SURG LIVER DIS CHILD, P60; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Shim W K, 1974, Prog Pediatr Surg, V6, P53; STRINGER MD, 1992, BRIT MED J, V304, P737, DOI 10.1136/bmj.304.6829.737; TAN CEL, 1994, J PEDIATR SURG, V29, P1459, DOI 10.1016/0022-3468(94)90144-9	26	278	295	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					25	29		10.1016/S0140-6736(99)03492-3	http://dx.doi.org/10.1016/S0140-6736(99)03492-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615887				2022-12-28	WOS:000085049200012
J	Lohr, F				Lohr, F			On losing your molecular privacy	BRITISH MEDICAL JOURNAL			English	Editorial Material													Lohr, Frank/AAC-2528-2022	Lohr, Frank/0000-0003-1014-5556					0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1651	1652		10.1136/bmj.319.7225.1651	http://dx.doi.org/10.1136/bmj.319.7225.1651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600984	Green Published			2022-12-28	WOS:000084562600035
J	Wu, K; Iedema, MJ; Cowin, JP				Wu, K; Iedema, MJ; Cowin, JP			Ion penetration of the water-oil interface	SCIENCE			English	Article							DYNAMICS	Ions typically pass with difficulty from water into organic phases because of water's superior solvation power. This inhibits such processes as ion transport in batteries or in Lipid bilayers of cells. ion penetration across such an interface was studied with unusual structural control. Hydronium ions were soft-landed at 1 electron volt on cold films of 3-methylpentane ("oil") on a metal substrate. The field produced by these ions drove them through the films when warmed. Coadsorption of water (0.14 to 35 bilayers) inhibited the ion penetration by creating a solvation energy trap. A Born solvation model successfully predicted the trapping energies (0 to 38 kilojoules per mole).	Pacific NW Natl Lab, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Cowin, JP (corresponding author), Pacific NW Natl Lab, Box 999,Mail Stop K8-88, Richland, WA 99352 USA.		Rudich, Yinon/K-1498-2012; Wu, Kai/A-4903-2011; zinc, spinel/C-4011-2008	Rudich, Yinon/0000-0003-3149-0201; Wu, Kai/0000-0002-5016-0251; 				ALLEN HE, 1995, METAL CONTAMINATED A; Benjamin I, 1997, ANNU REV PHYS CHEM, V48, P407, DOI 10.1146/annurev.physchem.48.1.407; BENJAMIN I, 1993, SCIENCE, V261, P1558, DOI 10.1126/science.261.5128.1558; Biesecker JP, 1998, REV SCI INSTRUM, V69, P485, DOI 10.1063/1.1148459; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; CONWAY BE, 1975, J ELECTROANAL CHEM, V65, P491, DOI 10.1016/0368-1874(75)85139-2; Cowin JP, 1999, NATURE, V398, P405, DOI 10.1038/18848; Dang LX, 1999, J PHYS CHEM B, V103, P8195, DOI 10.1021/jp991824+; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Iedema MJ, 1998, J PHYS CHEM B, V102, P9203, DOI 10.1021/jp982549e; Lide DR, 1997, CRC HDB CHEM PHYSICS, P6; LING AC, 1968, J PHYS CHEM-US, V72, P1918, DOI 10.1021/j100852a010; Materer N, 1997, SURF SCI, V381, P190, DOI 10.1016/S0039-6028(97)00090-3; Mitchell W, 1963, FUEL CELLS; Noyes Robert, 1995, NUCL WASTE CLEANUP T; SEN RK, 1975, ANNU REV PHYS CHEM, V26, P287, DOI 10.1146/annurev.pc.26.100175.001443; Smith RS, 1997, PHYS REV LETT, V79, P909, DOI 10.1103/PhysRevLett.79.909; Starks C.M., 1994, PHASE TRANSFER CATAL; Tsekouras AA, 1999, J CHEM PHYS, V111, P2222, DOI 10.1063/1.479494; Tsekouras AA, 1998, PHYS REV LETT, V80, P5798, DOI 10.1103/PhysRevLett.80.5798	20	26	26	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2482	2485		10.1126/science.286.5449.2482	http://dx.doi.org/10.1126/science.286.5449.2482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617457				2022-12-28	WOS:000084429700040
J	Randall, A				Randall, A			Millennium pay	BRITISH MEDICAL JOURNAL			English	Editorial Material									Worthing & Southland Hosp NHS Trust, Worthing, England		Randall, A (corresponding author), Worthing & Southland Hosp NHS Trust, Worthing, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1585	1585		10.1136/bmj.319.7224.1585	http://dx.doi.org/10.1136/bmj.319.7224.1585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591747	Green Published			2022-12-28	WOS:000084245600073
J	Ross, SE				Ross, SE			"Memes" as infectious agents in psychosomatic illness	ANNALS OF INTERNAL MEDICINE			English	Article							ANOREXIA-NERVOSA; CHRONIC FATIGUE; FIBROMYALGIA; EPIDEMIC; DISORDERS; NEURASTHENIA; LABEL		Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ross, SE (corresponding author), Univ Colorado, Hlth Sci Ctr, Box F414,4200 E 9th Ave, Denver, CO 80262 USA.	steve.ross@uchsc.edu						ACOCELLA J, 1998, POLITICS HYSTERIA, P64; ANGELL M, 1996, CLASH MED EVIDENCE L; [Anonymous], 1999, LANCET, V354, P173; ARONOWITZ RA, 1992, STUDIES CULTURAL HIS; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; BARSKY AJ, 1979, ANN INTERN MED, V91, P63, DOI 10.7326/0003-4819-91-1-63; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; Boss LP, 1997, EPIDEMIOL REV, V19, P233, DOI 10.1093/oxfordjournals.epirev.a017955; BRODSKY CM, 1988, OCCUP MED, V3, P653; BRUMBERG JJ, 1988, EMERGENCE ANOREXIA N; CHEW P K, 1976, SMJ Singapore Medical Journal, V17, P10; CLELAND LG, 1987, MED J AUSTRALIA, V147, P236, DOI 10.5694/j.1326-5377.1987.tb133417.x; COLLIGAN M, 1982, MASS PSYCHOGENIC ILL; Dawkins Richard, 1976, SELFISH GENE; FAVA M, 1989, AM J PSYCHIAT, V146, P963; GOTHE CJ, 1995, PSYCHOSOMATICS, V36, P1; GREENBERG DB, 1990, PSYCHOSOMATICS, V31, P129, DOI 10.1016/S0033-3182(90)72185-8; HADLER NM, 1990, J OCCUP ENVIRON MED, V32, P38; Hadler NM, 1997, POSTGRAD MED, V102, P161, DOI 10.3810/pgm.1997.08.284; Hadler NM, 1996, CLEV CLIN J MED, V63, P85, DOI 10.3949/ccjm.63.2.85; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; HALL W, 1988, SOC SCI MED, V27, P645, DOI 10.1016/0277-9536(88)90013-5; Mehler PS, 1996, HOSP PRACT, V31, P109; Nemery B, 1999, LANCET, V354, P77, DOI 10.1016/S0140-6736(05)75348-4; Osterweis M., 1987, PAIN DISABILITY CLIN; Riley JL, 1998, PAIN, V74, P181, DOI 10.1016/S0304-3959(97)00199-1; Showalter E., 1997, HYSTORIES; SIROIS F, 1982, MASS PSYCHOGENIC ILL; WELCH MS, 1971, LADIES HOME J    NOV, P98; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; Wilke WS, 1996, CLEV CLIN J MED, V63, P87, DOI 10.3949/ccjm.63.2.87; YAGER J, 1974, NEW ENGL J MED, V291, P907, DOI 10.1056/NEJM197410242911713; YASSI A, 1989, CAN MED ASSOC J, V140, P816; 1981, AM HER DICT ENGLISH, P834; 1990, MMWR MORB MORTAL WKL, V39, P301; 1996, MMWR MORB MORTAL WKL, V45, P6	36	16	16	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					867	871		10.7326/0003-4819-131-11-199912070-00019	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262ET	10610639				2022-12-28	WOS:000084053200018
J	Gibson, RA				Gibson, RA			Long-chain polyunsaturated fatty acids and infant development	LANCET			English	Editorial Material							RHESUS-MONKEYS; VISUAL-ACUITY; TERM INFANTS; DEFICIENCY; GROWTH		Flinders Med Ctr, Child Nutr Res Ctr, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Child Hlth Res Inst, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Dept Paediat & Child Hlth, Bedford Pk, SA 5042, Australia	Flinders Medical Centre; Flinders Medical Centre; Flinders Medical Centre	Gibson, RA (corresponding author), Flinders Med Ctr, Child Nutr Res Ctr, Bedford Pk, SA 5042, Australia.		Gibson, Robert Alan/E-7546-2012	Gibson, Robert Alan/0000-0002-8750-525X				Anderson JW, 1999, AM J CLIN NUTR, V70, P525; Auestad N, 1997, PEDIATR RES, V41, P1, DOI 10.1203/00006450-199701000-00001; Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; CARLSON SE, 1992, LIPIDS, V27, P901, DOI 10.1007/BF02535870; Columbo J, 1997, DEV BRAIN BEHAV ROLE, P339; GIBSON RA, 1999, IN PRESS AM J CLIN N; Kurlak LO, 1999, ARCH DIS CHILD-FETAL, V80, pF148, DOI 10.1136/fn.80.2.F148; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; Makrides M, 1999, PEDIATRICS, V104, P468, DOI 10.1542/peds.104.3.468; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; SIMMER K, 1998, COCHRANE LIB; UAUY RD, 1990, PEDIATR RES, V28, P485, DOI 10.1203/00006450-199011000-00014; Vanderhoof J, 1999, J PEDIATR GASTR NUTR, V29, P318, DOI 10.1097/00005176-199909000-00015; [No title captured]	15	16	16	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1919	1920		10.1016/S0140-6736(99)00300-1	http://dx.doi.org/10.1016/S0140-6736(99)00300-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622289				2022-12-28	WOS:000084034700003
J	Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA				Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA			Selection of metastatic tumour phenotypes by host immune systems	LANCET			English	Article							E-CADHERIN; FAS COUNTERATTACK; TAP-1 EXPRESSION; T-CELLS; CANCER; INTEGRIN; CARCINOMA; LIGAND; LYMPHOCYTES; MECHANISMS	Metastasis and the processes underlying this phenomenon make epithelial cancers so malignant. Local control of cancers by surgery is sometimes possible but locoregional and distant recurrence commonly lead to the failure of treatment with ensuing morbidity and mortality. Tumour cells express a range of new antigens during growth and there are opportunities for the host immune system to interact with these antigens. This immune interaction eliminates the tumour or allows selection of phenotypic variants. Cell phenotypes selected by an incomplete immune response resemble the cell type commonly associated with metastases. Thus we propose that the host immune system may be responsible for selection of this phenotype and progression of the disease.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Gastrointestinal Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK	Seymour, K (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Kirby, John/0000-0003-2543-4131; Seymour, Keith/0000-0003-0850-2745				Aizawa K, 1999, INT J ONCOL, V14, P85; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; Dudley ME, 1996, INT J CANCER, V65, P249, DOI 10.1002/(SICI)1097-0215(19960117)65:2<249::AID-IJC20>3.0.CO;2-7; Fey MF, 1996, ANN ONCOL, V7, P121; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; Hadley GA, 1997, J IMMUNOL, V159, P3748; Hedger M P, 1997, Rev Reprod, V2, P38, DOI 10.1530/ror.0.0020038; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kuwabara K, 1998, JPN J CANCER RES, V89, P40, DOI 10.1111/j.1349-7006.1998.tb00477.x; LEHMANN F, 1995, EUR J IMMUNOL, V25, P340, DOI 10.1002/eji.1830250206; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Pang M, 1998, ARTHRITIS RHEUM, V41, P1456, DOI 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Svane IM, 1996, EUR J IMMUNOL, V26, P1844, DOI 10.1002/eji.1830260827; TaylorPapadimitriou J, 1997, IMMUNOL TODAY, V18, P105, DOI 10.1016/S0167-5699(97)01028-1; YAMAMOTO K, 1995, J IMMUNOL, V154, P1804; YOUNG D, 1989, DRUG RESISTANCE CANC; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085	31	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1989	1991		10.1016/S0140-6736(99)04435-9	http://dx.doi.org/10.1016/S0140-6736(99)04435-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622313				2022-12-28	WOS:000084034700043
J	Dickinson, H				Dickinson, H			Plant biology - No stigma attached to male rejection	SCIENCE			English	Editorial Material							SELF-INCOMPATIBILITY; FLOWERING PLANTS; BRASSICA; POLLEN; PROTEIN		Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Dickinson, H (corresponding author), Univ Oxford, Dept Plant Sci, Rodney Porter Bldg,S Parks Rd, Oxford OX1 3RB, England.							ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; DICKINSON HG, 1994, NATURE, V364, P573; DICKINSON HG, 1998, KEW S SER, V15; FRANKLIN FCH, 1995, INT REV CYTOL, V158, P1; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; Hiscock SJ, 1999, INT REV CYTOL, V193, P165; HODGKIN T, 1988, NEW PHYTOL, V110, P557, DOI 10.1111/j.1469-8137.1988.tb00296.x; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; SARKER RH, 1988, P NATL ACAD SCI USA, V85, P4340, DOI 10.1073/pnas.85.12.4340; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Whitehouse H.L.K., 1950, ANN BOT, V54, P198	16	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1690	1691		10.1126/science.286.5445.1690	http://dx.doi.org/10.1126/science.286.5445.1690			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10610566				2022-12-28	WOS:000083912200024
J	Dalrymple, J; Appleby, J				Dalrymple, J; Appleby, J			Cross sectional study of reporting of epileptic seizures to general practitioners	BRITISH MEDICAL JOURNAL			English	Article							POPULATION; ACCIDENTS; COMMUNITY; STIGMA; RATES	Objective Comparison of reporting of recent epileptic seizures by patients to a doctor and anonymously. Design Cross sectional study of patients with epilepsy by comparison of paired questionnaires. Setting Rural and urban general practices in Norfolk. Participants 122 patients aged over 16 years and able to self complete a questionnaire who were recruited by 31 general practitioners when attending for review of their epilepsy. Main outcome measure The difference in reported occurrence of seizure to general practitioners and in a linked anonymous questionnaire. Results 18 patients failed to report a seizure in the past year to their general practitioner (uncontrolled epilepsy). 40% (24/60) of people with epilepsy who anonymously reported a seizure in the past year held a driving licence, but only six revealed this to their general practitioner. The unemployment rate was 34%, substantially higher than the 9% in the general population. Measures of anxiety, depression and stigmatisation were higher in patients with uncontrolled epilepsy. Conclusions A significant proportion of patients with epilepsy underreport their seizures. Recognition of underreporting is important if patients are to benefit from adequate and appropriate treatment. General practitioners' ability to treat epilepsy is hampered by their role in regulating the rights of epileptic patients to hold a driving licence or access certain occupations.	Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England; Kings Fund, Policy & Dev Directorate, Hlth Syst Programme, London W1M 0AN, England	University of East Anglia	Dalrymple, J (corresponding author), Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England.							Beaussart M, 1997, Med Law, V16, P295; Black A B, 1997, Med Law, V16, P253; Brown S, 1993, Seizure, V2, P91, DOI 10.1016/S1059-1311(05)80111-6; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Collings J A, 1994, Seizure, V3, P255, DOI 10.1016/S1059-1311(05)80172-4; Gilliam F, 1997, EPILEPSIA, V38, P233, DOI 10.1111/j.1528-1157.1997.tb01102.x; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HANSOTIA P, 1991, NEW ENGL J MED, V324, P1511; HOPKINS A, 1977, LANCET, V1, P183; HOPKINS AP, 1996, OXFORD TXB MED, P3924; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KRUMHOLZ A, 1994, EPILEPSIA, V35, P668, DOI 10.1111/j.1528-1157.1994.tb02490.x; Ridsdale L, 1996, BRIT J GEN PRACT, V46, P365; SALINSKY MC, 1992, EPILEPSIA, V33, P469, DOI 10.1111/j.1528-1157.1992.tb01693.x; SCAMBLER G, 1986, SOCIOL HEALTH ILL, V8, P26, DOI 10.1111/1467-9566.ep11346455; SCAMBLER G, 1989, EXPERIENCE ILLNESS, P52; Scheinder JW, 1981, SOC SCI MED A, V15A, P211; TAYLOR J, 1995, QJM-MON J ASSOC PHYS, V88, P733; Thapar AK, 1996, BRIT J GEN PRACT, V46, P37; Troster H, 1997, EPILEPSIA, V38, P1227, DOI 10.1111/j.1528-1157.1997.tb01221.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P747, DOI 10.1111/j.1528-1157.1975.tb04760.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P743; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	63	64	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					94	97		10.1136/bmj.320.7227.94	http://dx.doi.org/10.1136/bmj.320.7227.94			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625265	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000084746600020
J	Lumb, AB; Vail, A				Lumb, AB; Vail, A			Difficulties with anonymous shortlisting of medical school applications and its effects on candidates with non-European names: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ETHNIC-MINORITY GROUPS; UNITED-KINGDOM; DISCRIMINATION; APPLICANTS	Objective To assess the feasibility of anonymous shortlisting of applications for medical school and its effect on those with non-European names. Design Prospective cohort study. Setting Leeds school of medicine, United Kingdom. Subjects 2047 applications for 1998 entry from the United Kingdom and the European Union. Intervention Deletion of all references to name and nationality from the application form. Main outcome measures Scoring by two admissions tutors at shortlisting. Results Deleting names was cumbersome as some were repeated up to 15 times. Anonymising application forms was ineffective as one admissions tutor was able to identify nearly 50% of candidates classed as being from an ethnic minority group. Although scores were lower for applicants with non-European names, anonymity did not improve scores. Applicants with non-European names who were identified as such by tutors were significantly less likely to drop marks in one particular non-academic area (the career insight component) than their European counterparts. Conclusions There was no evidence of benefit to candidates with non-European names of attempting to blind assessment. Anonymising application forms cannot be recommended.	Univ Leeds, Sch Med, Leeds LS2 9NL, W Yorkshire, England	University of Leeds	Lumb, AB (corresponding author), Univ Leeds, Sch Med, Worsley Med & Dent Bldg, Leeds LS2 9NL, W Yorkshire, England.			Lumb, Andrew/0000-0002-6684-9205; Vail, Andy/0000-0001-8274-2726				COLLIER J, 1986, MED EDUC, V20, P86, DOI 10.1111/j.1365-2923.1986.tb01052.x; ESMAIL A, 1995, BRIT MED J, V310, P501, DOI 10.1136/bmj.310.6978.501; Gillborn D., 1996, RECENT RES ACHIEVEME; MCMANUS IC, 1985, BRIT MED J, V290, P319, DOI 10.1136/bmj.290.6464.319-c; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; McManus IC, 1998, BRIT MED J, V317, P1111; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; McManus IC, 1997, CHOOSING TOMORROWS D, P60	8	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					82	85		10.1136/bmj.320.7227.82	http://dx.doi.org/10.1136/bmj.320.7227.82			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625258	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000084746600015
J	Paul, REL; Coulson, TN; Raibaud, A; Brey, PT				Paul, REL; Coulson, TN; Raibaud, A; Brey, PT			Sex determination in malaria parasites	SCIENCE			English	Article							TRANSMISSION-BLOCKING IMMUNITY; LOCAL MATE COMPETITION; PLASMODIUM-GALLINACEUM; ERYTHROPOIETIN; ANTIBODIES; CHICKENS; BIOLOGY; RATIOS	A century ago, W. G. MacCallum identified distinct male and female forms in malaria parasites of both birds and humans. Since then, scientists have been punted by the high female-to-male ratios of parasites in Plasmodium infections and by the mechanism of sex determination. The sex ratio of malaria parasites was shown to become progressively more male as conditions that allow motility and subsequent fertilization by the male parasites become adverse. This resulted from an increased immune response against male gametes, which coincides with intense host erythropoietic activity. Natural and artificial induction of erythropoiesis in vertebrate hosts provoked a shift toward male parasite production. This change in parasite sex ratio led to reduced reproductive success in the parasite, which suggests that sex determination is adaptive and is regulated by the hematologic state of the host.	Inst Pasteur, Lab Biochim & Biol Mol Insectes, F-75724 Paris 15, France; Zool Soc London, Inst Zool, London NW1 4RY, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Zoological Society of London	Paul, REL (corresponding author), Inst Pasteur, Lab Biochim & Biol Mol Insectes, 25 Rue Dr Roux, F-75724 Paris 15, France.	topotito@pasteur.fr						CARTER R, 1979, EXP PARASITOL, V47, P194, DOI 10.1016/0014-4894(79)90073-0; CARTER R, 1979, EXP PARASITOL, V47, P185, DOI 10.1016/0014-4894(79)90072-9; Carter R., 1988, MALARIA PRINCIPLES P, P253; CHARNOV E L, 1982; CRAWLEY MJ, 1993, GUM ECOLOGISTS; Day KP, 1998, PARASITOLOGY, V116, pS95, DOI 10.1017/S0031182000084985; ElHassan AMA, 1997, EUR J HAEMATOL, V59, P299, DOI 10.1111/j.1600-0609.1997.tb01690.x; Garnham PCC., 1966, MALARIA PARASITES OT; GEIRINGER E, 1961, P SOC EXP BIOL MED, V106, P752, DOI 10.3181/00379727-106-26464; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HAWKING F, 1972, PARASITOLOGY, V65, P189, DOI 10.1017/S003118200004498X; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; MCGUIRE MJ, 1993, FUNDAMENTALS CLIN HE, P117; MILLEDGE JS, 1985, J APPL PHYSIOL, V59, P360, DOI 10.1152/jappl.1985.59.2.360; PAGEL H, 1992, ADV EXP MED BIOL, V317, P515; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Paul REL, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P153; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; READ AF, 1995, P ROY SOC B-BIOL SCI, V260, P359, DOI 10.1098/rspb.1995.0105; ROSSE WF, 1966, BLOOD-J HEMATOL, V27, P654, DOI 10.1182/blood.V27.5.654.654; SCHALL JJ, 1989, PARASITOLOGY, V98, P343, DOI 10.1017/S0031182000061412; SCHINDLER SL, 1987, COMP BIOCHEM PHYS A, V87, P533, DOI 10.1016/0300-9629(87)90356-2; SHUTLER D, 1995, P NATL ACAD SCI USA, V92, P6748, DOI 10.1073/pnas.92.15.6748; Shutler D, 1998, OIKOS, V82, P417, DOI 10.2307/3546363; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; Wilson K, 1996, FUNCT ECOL, V10, P592, DOI 10.2307/2390169	27	101	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					128	131		10.1126/science.287.5450.128	http://dx.doi.org/10.1126/science.287.5450.128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615046				2022-12-28	WOS:000084578400051
J	Szalai, C; Bojszko, A; Beko, G; Falus, A				Szalai, C; Bojszko, A; Beko, G; Falus, A			Prevalence of CCR5 Delta 32 in allergic diseases	LANCET			English	Letter							ASTHMA		Hungarian Acad Sci, Sect Mol Immunol, Budapest, Hungary; Heim Pal Paediat Hosp, H-1958 Budapest, Hungary	Hungarian Academy of Sciences	Szalai, C (corresponding author), Hungarian Acad Sci, Sect Mol Immunol, Budapest, Hungary.		Szalai, Csaba/A-2041-2008					CORNE J, 1994, LANCET, V344, P344, DOI 10.1016/S0140-6736(94)91388-9; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Szalai C, 1999, PEDIATR RES, V46, P82, DOI 10.1203/00006450-199907000-00014; Thomas NS, 1997, AM J RESP CRIT CARE, V156, pS144, DOI 10.1164/ajrccm.156.4.12-tac-13	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					66	66		10.1016/S0140-6736(05)72005-5	http://dx.doi.org/10.1016/S0140-6736(05)72005-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615909				2022-12-28	WOS:000085049200047
J	Towler, HMA				Towler, HMA			Medical retina CD Rom	BRITISH MEDICAL JOURNAL			English	Software Review									Whipps Cross Hosp & Chest Clin, NE London Eye Partnership, London, England	University of London; Queen Mary University London	Towler, HMA (corresponding author), Whipps Cross Hosp & Chest Clin, NE London Eye Partnership, London, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					65	65		10.1136/bmj.320.7226.65	http://dx.doi.org/10.1136/bmj.320.7226.65			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617551	Green Published			2022-12-28	WOS:000084621600067
J	Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL				Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL			Are there excess Sharons in genitourinary clinics?	BRITISH MEDICAL JOURNAL			English	Article									Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Med Stat & Comp, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Foley, E (corresponding author), Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England.							Merry E., 1995, 1 NAMES DEFINITIVE G	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1615	1615		10.1136/bmj.319.7225.1615	http://dx.doi.org/10.1136/bmj.319.7225.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600963	Green Published, Bronze			2022-12-28	WOS:000084562600017
J	Howard, MR				Howard, MR			Walcheren 1809: a medical catastrophe	BRITISH MEDICAL JOURNAL			English	Article																		Bond G. C., 1979, GRAND EXPEDITION BRI; Borland J, 1810, Med Phys J, V23, P183; BRETTJAMES A, 1963, HIST TODAY, V13, P811; CHAPLIN A, 1919, MED ENGLAND REIGN GE, V3, P92; CHAPLIN A, 1919, MED ENGLAND REIGN GE, V3, P86; CODRINGTON E, 1873, MEMOIR E CODRINGTON, V1, P154; Crowe K E, 1973, Engl Hist Rev, V88, P770; CURLING H, 1928, RECOLLECTIONS R HARR, P179; DAVIS JB, 1810, SCI POPULAR VIEW FEV; DAWSON GP, 1810, OBSERVATIONS WALCHER; Feibel R M, 1968, Bull Hist Med, V42, P62; FLETCHER I, 1997, SERVICE KING LETT W; FORTESCUE J, 1930, HIST BRIT ARMY, V7, P1899; GREEN J, 1827, VICISSITUDES SOLDIER, P38; HARGROVE G, 1812, ACCOUNT ISLANDS WALC; HODGE WB, 1856, Q J STAT SOC, V19, P219; HOWARD MR, 1991, J ROY SOC MED, V84, P299, DOI 10.1177/014107689108400517; JEFFREY RW, 1907, DYOTTS DIARY 1781 18, V1, P288; KEMPTHORNE GA, 1934, J ROY ARMY MED CORPS, V62, P133; McGuffie T. H., 1947, ENGL HIST REV, V62, P191; Pringle John, 1752, OBSERVATIONS DIS ARM; Swellengrebel NH, 1938, MALARIA NETHERLANDS; TRESAL JB, 1915, ESSAI FIEVRE ADYNAMI; WRIGHT T, 1811, HIST WALCHEREN REMIT	24	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1642	1645		10.1136/bmj.319.7225.1642	http://dx.doi.org/10.1136/bmj.319.7225.1642			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600979	Green Published			2022-12-28	WOS:000084562600030
J	Dauphas, N; Marty, B				Dauphas, N; Marty, B			Heavy nitrogen in carbonatites of the Kola Peninsula: A possible signature of the deep mantle	SCIENCE			English	Article							ALKALINE PROVINCE; SEISMIC EVIDENCE; OCEANIC BASALTS; DIAMONDS; SYSTEMATICS; ISOTOPES; NEON; GEOCHEMISTRY; CONSTRAINTS; COMPONENTS	Nitrogen and argon isotopes were measured in carbonatites and associated rocks from the Kola Peninsula in Russia. The Kola mantle source, which is thought to be Located in the deep mantle, is enriched in heavy nitrogen (+3 per mil relative to air) as compared to Earth's surface (atmosphere and crust, +2 per mit) and the shallow mantle (-4 per mil). Recycling of oceanic crust (+6 per mil) or metal-silicate partitioning may account for the nitrogen isotopic composition of the deep mantle.	Ctr Rech Petrog & Geochim, CNRS, UPR 9046, F-54501 Vandoeuvre Nancy, France; Ecole Natl Super Geol, F-54501 Vandoeuvre Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Lorraine	Dauphas, N (corresponding author), Ctr Rech Petrog & Geochim, CNRS, UPR 9046, 15 Rue Notre Dame des Pauvres,Boite Postale 20, F-54501 Vandoeuvre Nancy, France.		Dauphas, Nicolas/E-4568-2011					Beaumont V, 1999, PRECAMBRIAN RES, V96, P63, DOI 10.1016/S0301-9268(99)00005-4; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; Bijwaard H, 1999, EARTH PLANET SC LETT, V166, P121, DOI 10.1016/S0012-821X(99)00004-7; Bird JM, 1999, EARTH PLANET SC LETT, V170, P83, DOI 10.1016/S0012-821X(99)00101-6; Bowman AW, 1997, APPL SMOOTHING TECHN; BOYD SR, 1994, CHEM GEOL, V116, P43, DOI 10.1016/0009-2541(94)90157-0; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; Breger L, 1998, SCIENCE, V282, P718, DOI 10.1126/science.282.5389.718; Cartigny P, 1998, SCIENCE, V280, P1421, DOI 10.1126/science.280.5368.1421; Cartigny P, 1998, CHEM GEOL, V147, P147, DOI 10.1016/S0009-2541(97)00178-2; Cartigny P, 1997, TERRA NOVA, V9, P175, DOI 10.1046/j.1365-3121.1997.d01-26.x; Dauphas N, 1998, METEORIT PLANET SCI, V33, pA38; EXLEY RA, 1987, EARTH PLANET SC LETT, V81, P163, DOI 10.1016/0012-821X(87)90153-1; Hashizume K., 1997, KAZAN, V42, pS293; Helmberger DV, 1998, NATURE, V396, P251, DOI 10.1038/24357; Hirose K, 1999, NATURE, V397, P53, DOI 10.1038/16225; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; HUMBERT F, 1999, LUNAR PLANET SCI, V30, P1955; JAVOY M, 1986, CHEM GEOL, V57, P41, DOI 10.1016/0009-2541(86)90093-8; Javoy M, 1997, GEOPHYS RES LETT, V24, P177, DOI 10.1029/96GL03931; Javoy M, 1998, CHEM GEOL, V147, P11, DOI 10.1016/S0009-2541(97)00169-1; JAVOY M, 1984, EARTH PLANET SC LETT, V68, P399, DOI 10.1016/0012-821X(84)90125-0; JUNGCK MHA, 1979, METEORITICS, V14, P439; KRAMM U, 1993, LITHOS, V30, P33, DOI 10.1016/0024-4937(93)90004-V; KRAMM U, 1993, EUR J MINERAL, V5, P985; Kukharenko A.A., 1965, CALEDONIAN COMPLEX U; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; Marty B, 1999, GEOCHIM COSMOCHIM AC, V63, P3619, DOI 10.1016/S0016-7037(99)00169-6; Marty B, 1997, EARTH PLANET SC LETT, V152, P101, DOI 10.1016/S0012-821X(97)00153-2; MARTY B, 1995, NATURE, V377, P326, DOI 10.1038/377326a0; Marty B, 1998, EARTH PLANET SC LETT, V164, P179, DOI 10.1016/S0012-821X(98)00202-7; MATSUDA J, 1993, SCIENCE, V259, P788, DOI 10.1126/science.259.5096.788; MAZOR E, 1970, GEOCHIM COSMOCHIM AC, V34, P781, DOI 10.1016/0016-7037(70)90031-1; Moreira M, 1998, SCIENCE, V279, P1178, DOI 10.1126/science.279.5354.1178; OZIMA M, 1988, GEOCHIM COSMOCHIM AC, V52, P19, DOI 10.1016/0016-7037(88)90052-X; PETERS KE, 1978, LIMNOL OCEANOGR, V23, P598, DOI 10.4319/lo.1978.23.4.0598; RICHET P, 1977, ANNU REV EARTH PL SC, V5, P65, DOI 10.1146/annurev.ea.05.050177.000433; Russell SA, 1998, NATURE, V396, P255, DOI 10.1038/24364; Sarda P, 1999, SCIENCE, V283, P666, DOI 10.1126/science.283.5402.666; SHEATHER SJ, 1991, J ROY STAT SOC B MET, V53, P683; Snow JE, 1998, NATURE, V391, P166, DOI 10.1038/34396; TANG M, 1988, GEOCHIM COSMOCHIM AC, V52, P1245; Tolstikhin IN, 1998, CHEM GEOL, V147, P27, DOI 10.1016/S0009-2541(97)00170-8; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; WADA E, 1975, Geochemical Journal, V9, P139; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; Widom E, 1996, EARTH PLANET SC LETT, V142, P451, DOI 10.1016/0012-821X(96)00111-2; WIELER R, 1992, GEOCHIM COSMOCHIM AC, V56, P2907, DOI 10.1016/0016-7037(92)90367-R	50	80	80	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2488	2490		10.1126/science.286.5449.2488	http://dx.doi.org/10.1126/science.286.5449.2488			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617459				2022-12-28	WOS:000084429700042
J	Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L				Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L			A mutation in the C-elegans EXP-2 potassium channel that alters feeding behavior	SCIENCE			English	Article							GATED K+ CHANNEL; CAENORHABDITIS-ELEGANS; ION PERMEATION; INACTIVATION; GENE	The nematode pharynx has a potassium channel with unusual properties, which allows the muscles to repolarize quickly and with the proper delay. Here, the Caenorhabditis elegans exp-2 gene is shown to encode this channel. EXP-2 is a Kv-type (voltage-activated) potassium channel that has inward-rectifying properties resembling those of the structurally dissimilar human ether-a-go-go-related gene (HERG) channel. Null and gain-of-function mutations affect pharyngeal muscle excitability in ways that are consistent with the electrophysiological behavior of the channel, and thereby demonstrate a direct Link between the kinetics of this unusual channel and behavior.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Davis, MW (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	wdavis@biology.utah.edu		Davis, Mikel/0000-0003-1867-1593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL046154, R01HL046154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46154, R37 HL046154, R01 HL046154] Funding Source: Medline; NINDS NIH HHS [NS28407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], COMMUNICATION; AVERY L, 1993, GENETICS, V133, P897; BYERLY L, 1979, J PHYSIOL-LONDON, V288, P263; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARY RB, 1994, J CELL SCI, V107, P1609; Davis MW, 1995, J NEUROSCI, V15, P8408; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FLEISCHHAUER R, IN PRESS J NEUROSCI; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; MALONE C, COMMUNICATION; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OWENS S, COMMUNICATION; PANYI G, 1995, BIOPHYS J, V69, P896, DOI 10.1016/S0006-3495(95)79963-5; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1990, GENETICS, V124, P855; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Williams BD, 1995, METHOD CELL BIOL, V48, P81; ZUHLKE RD, 1994, RECEPTOR CHANNEL, V2, P237	22	44	47	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2501	2504		10.1126/science.286.5449.2501	http://dx.doi.org/10.1126/science.286.5449.2501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617464	Green Accepted			2022-12-28	WOS:000084429700047
J	Adamson, GD				Adamson, GD			A 36-year-old woman with endometriosis, pelvic pain, and infertility	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MILD ENDOMETRIOSIS; FOLLOW-UP; UNEXPLAINED INFERTILITY; OVARIAN-CANCER; UNITED-STATES; WOMEN; NAFARELIN; TRIAL; LAPAROSCOPY; DIAGNOSIS		Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Fertil Phys No Calif, Palo Alto, CA USA; Fertil Phys No Calif, San Jose, CA USA; Stanford Univ, Dept Gynecol & Obstet, Sch Med, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	Harvard University; Beth Israel Deaconess Medical Center; Stanford University; University of California System; University of California San Francisco	Adamson, GD (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ADAMSON GD, 1992, FERTIL STERIL, V57, P965; ADAMSON GD, 1990, AM J OBSTET GYNECOL, V162, P568, DOI 10.1016/0002-9378(90)90431-6; Adamson GD, 1997, AM J OBSTET GYNECOL, V177, P1413, DOI 10.1016/S0002-9378(97)70084-X; ADAMSON GD, 1994, AM J OBSTET GYNECOL, V171, P1488, DOI 10.1016/0002-9378(94)90392-1; ADAMSON GD, 1993, FERTIL STERIL, V59, P35; Adamson GD, 1996, ENDOSCOPIC MANAGEMEN, P147; *AM COLL OBST GYN, 1996, ACOG TECHN B, V223; *AM SOC REPR MED, 1999, PRACT COMM REP GUID; BARBIERI RL, 1992, AM J OBSTET GYNECOL, V166, P740, DOI 10.1016/0002-9378(92)91706-G; BERNSTEIN SJ, 1998, PUBLICATION RAND; Berube S, 1998, FERTIL STERIL, V69, P1034, DOI 10.1016/S0015-0282(98)00081-8; Berube S, 1998, EPIDEMIOLOGY, V9, P504, DOI 10.1097/00001648-199809000-00006; Buck GM, 1997, EPIDEMIOLOGY, V8, P435, DOI 10.1097/00001648-199707000-00015; BURNS LH, 1999, INFERTILITY COUNSELI, P513; BURNS LH, 1999, INFERTILITY COUNSELI, P179; Busacca M, 1999, AM J OBSTET GYNECOL, V180, P519, DOI 10.1016/S0002-9378(99)70247-4; COLLINS JA, 1995, FERTIL STERIL, V64, P538, DOI 10.1016/S0015-0282(16)57789-9; CRAMER D, 1999, CONTEMP OBSTET GYNEC, V44, P75; DLUGI AM, 1990, FERTIL STERIL, V54, P419; Guzick DS, 1998, FERTIL STERIL, V70, P207, DOI 10.1016/S0015-0282(98)00177-0; HANEY AF, 1993, BAILLIERE CLIN OB GY, V7, P791, DOI 10.1016/S0950-3552(05)80464-X; HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805; HORNSTEIN MD, 1995, FERTIL STERIL, V63, P955, DOI 10.1016/S0015-0282(16)57530-X; HUGHES EG, 1993, FERTIL STERIL, V59, P963; HURD SJ, 1992, ADOLESCENT PEDIAT G, V5, P3, DOI 10.1016/S0932-8610(12)80099-5; Jensen TK, 1998, BRIT MED J, V317, P505, DOI 10.1136/bmj.317.7157.505; Kaufman S, 1995, J WOMENS HEALTH, V4, P247; KIM AH, 1997, INFERT REPROD MED CL, V8, P623; Koninckx PR, 1999, GYNECOL OBSTET INVES, V47, P23, DOI 10.1159/000052856; Koninckx PR, 1999, GYNECOL OBSTET INVES, V47, P3, DOI 10.1159/000052853; Koninckx PR, 1999, GYNECOL OBSTET INVES, V47, P47, DOI 10.1159/000052859; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; MARCUS SF, 1994, AM J OBSTET GYNECOL, V171, P812, DOI 10.1016/0002-9378(94)90103-1; Mosgaard BJ, 1998, FERTIL STERIL, V70, P1049, DOI 10.1016/S0015-0282(98)00337-9; Mosgaard BJ, 1997, FERTIL STERIL, V67, P1005, DOI 10.1016/S0015-0282(97)81431-8; Olive DL, 1998, CHRONIC PELVIC PAIN, P61; Panidis DK, 1998, J REPROD MED, V43, P1034; Potashnik G, 1999, FERTIL STERIL, V71, P853, DOI 10.1016/S0015-0282(99)00085-0; Redwine DB, 1992, INFERTIL REPROD MED, V3, P683; Silva PD, 1999, J REPROD MED, V44, P288; *SOC ASS REPR TECH, 1999, 1996 ASS REPR TECHN; SPEROFF L, 1997, SEM REPR END END NEW, V15, P235; SPEROFF L, 1997, SEM REPR END END NEW, V15, P285; SPEROFF L, 1997, SEM REPR END END NEW, V15, P301; SPEROFF L, 1997, SEM REPR END END NEW, V15, P273; SPEROFF L, 1997, SEM REPR END END NEW, V15, P309; SPEROFF L, 1997, SEM REPR END END NEW, V15, P263; SPEROFF L, 1997, SEM REPR END END NEW, V15, P319; SPEROFF L, 1997, SEM REPR END END NEW, V15, P291; SPEROFF L, 1997, SEM REPR END END NEW, V15, P229; SPEROFF L, 1997, SEM REPR END END NEW, V15, P251; SPEROFF L, 1997, SEM REPR END END NEW, V15, P209; SPEROFF L, 1997, SEM REPR END END NEW, V15, P199; STEEGE JF, 1998, CHRONIC PELVIC PAIN, P126; Surrey ES, 1999, FERTIL STERIL, V71, P420, DOI 10.1016/S0015-0282(98)00500-7; Sutton CJG, 1997, FERTIL STERIL, V68, P1070, DOI 10.1016/S0015-0282(97)00403-2; WALLER KG, 1993, FERTIL STERIL, V59, P511; WHEELER JM, 1989, J REPROD MED, V34, P41; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	59	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2347	2354		10.1001/jama.282.24.2347	http://dx.doi.org/10.1001/jama.282.24.2347			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612323				2022-12-28	WOS:000084261700029
J	Ferraccioli, G; Di Poi, E; Di Gregorio, F; Giacomuzzi, F; Guerra, U				Ferraccioli, G; Di Poi, E; Di Gregorio, F; Giacomuzzi, F; Guerra, U			Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome	LANCET			English	Article								The appearance of vasospastic features in the central nervous system (CNS) after a cold stressor test was investigated through single photon emission computed tomography (SPECT) of regional cerebral blood flow in patients with systemic lupus erythematosus, with and without Raynaud's syndrome, and in scleroderma patients. We have shown that Raynaud's syndrome may occur in the CNS and that anticardiolipin or lupus anticoagulant positivity may favour perfusion defects.	Univ Udine, Rheumatol Unit, DPMSC, I-33100 Udine, Italy; Hosp Udine, Nucl Med Serv, I-33100 Udine, Italy	University of Udine	Ferraccioli, G (corresponding author), Univ Udine, Rheumatol Unit, DPMSC, I-33100 Udine, Italy.			Ferraccioli, Gianfranco/0000-0002-6884-4301				ATKINSON RA, 1976, HEADACHE, V16, P1, DOI 10.1111/j.1526-4610.1976.hed1601001.x; Kao CH, 1999, EUR J NUCL MED, V26, P129, DOI 10.1007/s002590050368; RUPPERT A, 1993, ARTHRITIS RHEUM, V36, P1253; San Pedro EC, 1998, CLIN NUCL MED, V23, P709, DOI 10.1097/00003072-199810000-00019	4	26	26	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2135	2136		10.1016/S0140-6736(99)03788-5	http://dx.doi.org/10.1016/S0140-6736(99)03788-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609825				2022-12-28	WOS:000084318200021
J	Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M				Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M			Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; CD40 LIGAND; FUNCTIONAL CD40; SMOOTH-MUSCLE; A-BETA; PROTEIN; EXPRESSION; MICE; PRECURSOR	Alzheimer's disease (AD) has a substantial inflammatory component, and activated microglia may play a central role in neuronal degeneration, CD40 expression was increased on cultured microglia treated with freshly solublized amyloid-beta (A beta, 500 nanomolar) and on microglia from a transgenic murine model of AD (Tg APP(sw)). Increased tumor necrosis factor alpha production and induction of neuronal injury occurred when A beta-stimulated microglia were treated with CD40 ligand (CD40L), Microglia from Tg APP(sw) mice deficient for CD4OL demonstrated reduction in activation, suggesting that the CD40-CD40L interaction is necessary for A beta-induced microglial activation. Finally, abnormal tau phosphorylation was reduced in Tg APP(sw) animals deficient for CD40L, suggesting that the CD40-CD40L interaction is an early event in AD pathogenesis.	Univ S Florida, Roskamp Inst, Tampa, FL 33613 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	State University System of Florida; University of South Florida; University of Kentucky; University of Kentucky; Howard Hughes Medical Institute; Yale University	Mullan, M (corresponding author), Univ S Florida, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.		Mattson, Mark P/F-6038-2012; Tan, Jun/I-5339-2012	Paris, Daniel/0000-0002-9622-0846; Mullan, Michael/0000-0002-1473-7527				Castillo GM, 1997, J NEUROCHEM, V69, P2452; Combs CK, 1999, J NEUROSCI, V19, P928; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; Ellis RJ, 1996, NEUROLOGY, V46, P1592, DOI 10.1212/WNL.46.6.1592; Genis I, 1999, J NEUROCHEM, V72, P206, DOI 10.1046/j.1471-4159.1999.0720206.x; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUBERMAN M, 1994, J NEUROIMMUNOL, V52, P147, DOI 10.1016/0165-5728(94)90108-2; James ND, 1996, NEUROBIOL AGING, V17, P235, DOI 10.1016/0197-4580(95)02068-3; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Oleana VH, 1998, NEUROREPORT, V9, P1451, DOI 10.1097/00001756-199805110-00037; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Sempowski GD, 1997, J IMMUNOL, V158, P4670; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	307	322	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2352	2355		10.1126/science.286.5448.2352	http://dx.doi.org/10.1126/science.286.5448.2352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600748				2022-12-28	WOS:000084318500065
J	Joshi, N; Caputo, GM; Weitekamp, MR; Karchmer, AW				Joshi, N; Caputo, GM; Weitekamp, MR; Karchmer, AW			Primary care: Infections in patients with diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MALIGNANT EXTERNAL OTITIS; SOFT-TISSUE INFECTIONS; URINARY-TRACT INFECTIONS; PERINEPHRIC ABSCESS; AMPHOTERICIN-B; EMPHYSEMATOUS PYELONEPHRITIS; ELDERLY PATIENTS; PNEUMONIA; MANAGEMENT; COMMUNITY		Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Joshi, N (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Suite UPC 4100,POB 850, Hershey, PA 17033 USA.							ABENGOWE CU, 1974, CAN MED ASSOC J, V111, P1112; AHRENHOLZ DH, 1988, SURG CLIN N AM, V68, P199; *AM COLL PHYS TASK, 1990, GUID AD IMM; Banyai AL., 1931, AM REV TUBERC, V24, P650; BOUTER KP, 1991, DIABETES RES CLIN PR, V12, P61, DOI 10.1016/0168-8227(91)90131-V; BREEN JD, 1995, INFECT DIS CLIN N AM, V9, P11; CANOSO JJ, 1993, RHEUM DIS CLIN N AM, V19, P293; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Chee S. P., 1995, Annals Academy of Medicine Singapore, V24, P473; COOPER G, 1982, AM J MED, V73, P658, DOI 10.1016/0002-9343(82)90407-7; Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V; EAGLE H, 1952, AM J MED, V13, P389, DOI 10.1016/0002-9343(52)90293-3; EDELSTEIN H, 1988, MEDICINE, V67, P118, DOI 10.1097/00005792-198803000-00005; ELLENBOGEN P H, 1976, Urology, V8, P413, DOI 10.1016/0090-4295(76)90505-7; EVANOFF GV, 1987, AM J MED, V83, P149, DOI 10.1016/0002-9343(87)90511-0; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FISHER JF, 1987, J INFECT DIS, V156, P685, DOI 10.1093/infdis/156.4.685; FISHER JF, 1995, CLIN INFECT DIS, V20, P183, DOI 10.1093/clinids/20.1.183; FORLAND M, 1977, JAMA-J AM MED ASSOC, V238, P1924, DOI 10.1001/jama.238.18.1924; FRYE KR, 1988, J UROLOGY, V139, P1245, DOI 10.1016/S0022-5347(17)42880-1; GALE GR, 1961, AM J MED SCI, V241, P604; GALLACHER SJ, 1995, DIABETIC MED, V12, P916, DOI 10.1111/j.1464-5491.1995.tb00396.x; GOZAL D, 1986, ARCH SURG-CHICAGO, V121, P233; HANSEN RO, 1964, ACTA MED SCAND, V176, P721; HENDY M, 1983, BRIT J DIS CHEST, V77, P87, DOI 10.1016/0007-0971(83)90010-4; HIGH KP, 1992, CLIN INFECT DIS, V15, P128, DOI 10.1093/clinids/15.1.128; Houston MS, 1997, ARCH INTERN MED, V157, P2190, DOI 10.1001/archinte.157.19.2190; Jacobs LG, 1996, CLIN INFECT DIS, V22, P30, DOI 10.1093/clinids/22.1.30; KASS EH, 1957, ARCH INTERN MED, V100, P709, DOI 10.1001/archinte.1957.00260110025004; KOZIEL H, 1995, INFECT DIS CLIN N AM, V9, P65; Langford JD, 1997, AM J OPHTHALMOL, V124, P265, DOI 10.1016/S0002-9394(14)70804-9; LAUCKS SS, 1994, SURG CLIN N AM, V74, P1339; LEIBOVICI L, 1991, DIABETES CARE, V14, P89, DOI 10.2337/diacare.14.2.89; LEU HS, 1995, CLIN INFECT DIS, V20, P1152, DOI 10.1093/clinids/20.5.1152; LI CC, 1997, CHIN MED J TAIPEI, V59, P59; MARRIE TJ, 1992, J INFECTION, V24, P247, DOI 10.1016/S0163-4453(05)80029-5; MCMAHON MM, 1995, INFECT DIS CLIN N AM, V9, P1; MCMILLIN K, 1985, J COMPUT ASSIST TOMO, V9, P330, DOI 10.1097/00004728-198503000-00019; MENTZER RM, 1975, AM J SURG, V129, P10, DOI 10.1016/0002-9610(75)90159-2; MICHAELI J, 1984, J UROLOGY, V131, P203, DOI 10.1016/S0022-5347(17)50309-2; Muchova J, 1999, DIABETIC MED, V16, P74, DOI 10.1046/j.1464-5491.1999.00015.x; PESSA ME, 1985, SURG GYNECOL OBSTET, V161, P357; POMETTA D, 1967, NEW ENGL J MED, V276, P1118, DOI 10.1056/NEJM196705182762004; Rassias AJ, 1999, ANESTH ANALG, V88, P1011, DOI 10.1097/00000539-199905000-00008; SCHAINUCK LI, 1968, AM J MED, V44, P134, DOI 10.1016/0002-9343(68)90245-3; SENTOCHNIK DE, 1995, INFECT DIS CLIN N AM, V9, P53; SILWER H, 1958, Acta Med Scand Suppl, V335, P1; SINGH CR, 1983, J UROLOGY, V130, P1171, DOI 10.1016/S0022-5347(17)51740-1; Slattery WH, 1996, OTOLARYNG CLIN N AM, V29, P795; SMITH HW, 1958, ARCHIV OTOLARYNGOL, V68, P715; SMITHERMAN KO, 1995, MED CLIN N AM, V79, P53, DOI 10.1016/S0025-7125(16)30084-0; STEVENS DL, 1988, J INFECT DIS, V158, P23, DOI 10.1093/infdis/158.1.23; Stokkel MPM, 1997, EUR J NUCL MED, V24, P1429, DOI 10.1007/s002590050172; Stokkel MPM, 1996, LARYNGOSCOPE, V106, P338, DOI 10.1097/00005537-199603000-00018; TELZAK EE, 1991, J INFECT DIS, V164, P538, DOI 10.1093/infdis/164.3.538; THORLEY JD, 1974, MEDICINE, V53, P441, DOI 10.1097/00005792-197411000-00004; THORNTON GF, 1971, MED CLIN N AM, V55, P931, DOI 10.1016/S0025-7125(16)32487-7; TIERNEY MR, 1995, INFECT DIS CLIN N AM, V9, P195; VALERIUS NH, 1982, ACTA MED SCAND, V211, P463; VAZQUEZ JA, 1995, INFECT DIS CLIN N AM, V9, P97; VEJLSGAARD R, 1966, ACTA MED SCAND, V179, P173; Wang JH, 1998, CLIN INFECT DIS, V26, P1434, DOI 10.1086/516369; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187; WISE GJ, 1982, J UROLOGY, V128, P82, DOI 10.1016/S0022-5347(17)52765-2; WONGBERINGER A, 1992, JAMA-J AM MED ASSOC, V20, P2780; WOODHEAD MA, 1987, LANCET, V1, P671; Zagoria R J, 1991, J Vasc Interv Radiol, V2, P156, DOI 10.1016/S1051-0443(91)72491-3; ZAKY DA, 1976, AM J MED, V61, P298, DOI 10.1016/0002-9343(76)90181-9	69	655	691	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1906	1912		10.1056/NEJM199912163412507	http://dx.doi.org/10.1056/NEJM199912163412507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601511				2022-12-28	WOS:000084210200007
J	Wald, NJ; Hackshaw, AK; Frost, CD				Wald, NJ; Hackshaw, AK; Frost, CD			When can a risk factor be used as a worthwhile screening test?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews Hosp, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England; Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine	Wald, NJ (corresponding author), St Bartholomews Hosp, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.	n.j.wald@mds.qmw.ac.uk	Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Armitage P, 1991, STAT METHODS MED RES; Chatfield C., 1980, INTRO MULTIVARIATE A; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1996, EMERY RIMOINS PRINCI, P545	5	269	272	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1562	1565		10.1136/bmj.319.7224.1562	http://dx.doi.org/10.1136/bmj.319.7224.1562			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591726	Green Published			2022-12-28	WOS:000084245600030
J	Vogt, TF; Duboule, D				Vogt, TF; Duboule, D			Antagonists Go out on a limb	CELL			English	Review							HOMEODOMAIN PROTEIN; LEG DEVELOPMENT; EXTRADENTICLE; DROSOPHILA; FGFS		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	Princeton University; University of Geneva	Vogt, TF (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			duboule, denis/0000-0001-9961-2960				Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Goff DJ, 1997, DEVELOPMENT, V124, P627; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Merino R, 1999, DEVELOPMENT, V126, P5515; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pizette S, 1999, DEVELOPMENT, V126, P883; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; Strigini M, 1999, SEMIN CELL DEV BIOL, V10, P335, DOI 10.1006/scdb.1999.0293; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157; ZWILLING E, 1956, J EXP ZOOL, V132, P219, DOI 10.1002/jez.1401320203	22	39	40	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					563	566		10.1016/S0092-8674(00)81545-7	http://dx.doi.org/10.1016/S0092-8674(00)81545-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612392	Bronze			2022-12-28	WOS:000084278700003
J	Povar, GJ; Snyder, L				Povar, GJ; Snyder, L		Ethics & Human Rights Comm	Selling products out of the office	ANNALS OF INTERNAL MEDICINE			English	Article								The sale of products from the physician's office raises several ethical issues and may affect the trust necessary to sustain the patient-physician relationship. When deciding whether to sell products out of the office and, if so, which ones, physicians should carefully consider such criteria as the urgency of the patient's need, the clinical relevance to the patient's condition, the adequacy of evidence to support, use of the product, and geographic and time constraints for the patient in otherwise obtaining the product. Physicians should make full disclosure about their financial interests in selling the product and inform patients about alternatives for purchasing the product. Charges for products sold through the office should be limited to the reasonable costs incurred in making them available.	Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, Philadelphia, PA USA; Cameron Med Grp, Silver Spring, MD 20910 USA		Snyder, L (corresponding author), Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA USA.							[Anonymous], 1990, NEW MED OLD ETHICS; BRODY H, 1992, HEALERS POWER; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012	4	7	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					863	864		10.7326/0003-4819-131-11-199912070-00012	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610634				2022-12-28	WOS:000084053200011
J	Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T				Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T			Tbx5 and the retinotectum projection	SCIENCE			English	Article							T-BOX GENES; TYROSINE KINASE; VISUAL-SYSTEM; EXPRESSION; RETINA; CHICK; FAMILY; DIFFERENTIATION; ARBORIZATION; EVOLUTION	Dorsal and ventral aspects of the eye are distinct from the early stages of development. The developing eye cup grows dorsally, and the choroidal fissure is formed on its ventral side. Retinal axone from the dorsal and ventral retina project to the ventral and dorsal tectum, respectively. Misexpression of the Tbx5 gene induced dorsalization of the ventral side of the eye and altered projections of retinal ganglion cell axons. Thus, Tbx5 is involved in eye morphogenesis and is a topographic determinant of the visual projections between retina and tectum.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Tohoku Univ, Dept Mol Neurobiol, Sendai, Miyagi 98077, Japan	Nara Institute of Science & Technology; University of California System; University of California San Diego; Tohoku University	Ogura, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		MOMOSE, Tsuyoshi/D-2257-2011	Momose, Tsuyoshi/0000-0002-3806-3408				Agulnik SI, 1996, GENETICS, V144, P249; Barbieri AM, 1999, P NATL ACAD SCI USA, V96, P10729, DOI 10.1073/pnas.96.19.10729; Braisted JE, 1997, DEV BIOL, V191, P14, DOI 10.1006/dbio.1997.8706; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CROSSLAND WJ, 1979, J COMP NEUROL, V185, P87, DOI 10.1002/cne.901850106; Dudley AT, 1997, DEV DYNAM, V208, P349; DUDLEY AT, 1997, GENE DEV, V11, P3254; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GIBSONBROWN JJ, 1998, MECH DEVELOP, V74, P65; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; JACOBSON M, 1967, SCIENCE, V155, P1106, DOI 10.1126/science.155.3766.1106; KOSHIBATAKEUCHI K, UNPUB; MEY J, 1992, J HIRNFORSCH, V33, P673; Momose T, 1999, DEV GROWTH DIFFER, V41, P335; MOTGAN BA, 1996, METHOD CELL BIOL, V51, P185; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NORNES HO, 1990, DEVELOPMENT, V109, P797; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Ohsaki K, 1999, GENES CELLS, V4, P267, DOI 10.1046/j.1365-2443.1999.00257.x; Ohuchi H, 1998, DEVELOPMENT, V125, P51; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; Schmitt EA, 1996, J COMP NEUROL, V371, P222, DOI 10.1002/(SICI)1096-9861(19960722)371:2<222::AID-CNE3>3.0.CO;2-4; Szel A, 1996, MICROSC RES TECHNIQ, V35, P445; SZEL A, 1992, J COMP NEUROL, V325, P327, DOI 10.1002/cne.903250302; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	35	202	207	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					134	137		10.1126/science.287.5450.134	http://dx.doi.org/10.1126/science.287.5450.134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615048				2022-12-28	WOS:000084578400053
J	Gale, EAM; Clark, A				Gale, EAM; Clark, A			A drug on the market?	LANCET			English	Editorial Material							ISLET AMYLOID POLYPEPTIDE; GENE-RELATED PEPTIDE; DIABETES-MELLITUS; AMYLIN; PROTEIN; HORMONE; INSULIN		Univ Bristol, Southmead Hosp, Div Med, Bristol BS10 5NB, Avon, England; Radcliffe Infirm, Diabet Res Labs, Oxford OX2 6HE, England	Southmead Hospital; University of Bristol; Radcliffe Infirmary; University of Oxford	Gale, EAM (corresponding author), Univ Bristol, Southmead Hosp, Div Med, Bristol BS10 5NB, Avon, England.							AMIEL S, 1993, LANCET, V341, P1249, DOI 10.1016/0140-6736(93)91153-D; BIENZTADMOR B, 1992, BIO-TECHNOL, V10, P521, DOI 10.1038/nbt0592-521; BRETHERTONWATT D, 1990, DIABETOLOGIA, V33, P115, DOI 10.1007/BF00401050; CLARK A, 1987, LANCET, V2, P231; CLARK A, 1992, DIABETES METAB REV, V8, P117, DOI 10.1002/dmr.5610080204; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DEKONING EJP, 1993, DIABETOLOGIA, V36, P378, DOI 10.1007/BF00402271; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; DIMASI JA, 1994, CLIN PHARMACOL THER, V55, P609, DOI 10.1038/clpt.1994.78; GAETA LSL, 1994, MED CHEM RES, V3, P483; JOHNSON KH, 1991, DIABETES, V40, P310, DOI 10.2337/diabetes.40.3.310; KOLTERMAN OG, 1995, DIABETES CARE, V18, P1179, DOI 10.2337/diacare.18.8.1179; LASAGNA L, 1989, PERSPECT BIOL MED, V32, P322; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; Macdonald IA, 1997, DIABETIC MED, V14, pS24, DOI 10.1002/(SICI)1096-9136(199706)14:2+<S24::AID-DIA399>3.3.CO;2-D; Mitchell P, 1997, LANCET, V350, P270, DOI 10.1016/S0140-6736(05)62238-6; Navarro M, 1996, J NEUROCHEM, V67, P1982; NISHI M, 1989, MOL ENDOCRINOL, V3, P1775, DOI 10.1210/mend-3-11-1775; OPIE EL, 1900, J EXP MED, V5, P527; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1973, ACTA PATH MICRO IM A, VA 81, P291; WESTERMARK P, 1986, BIOCHEM BIOPH RES CO, V140, P827, DOI 10.1016/0006-291X(86)90708-4; WESTERMARK P, 1994, AMYLOID, V1, P47, DOI 10.3109/13506129409148624; WILDING JPH, 1994, DIABETOLOGIA, V37, P166, DOI 10.1007/s001250050088; 1989, WALL STREET J   0517	26	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					61	63		10.1016/S0140-6736(99)07304-3	http://dx.doi.org/10.1016/S0140-6736(99)07304-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615905				2022-12-28	WOS:000085049200042
J	Leibovici, L				Leibovici, L			Alternative (complementary) medicine: a cuckoo in the nest of empiricist reed warblers	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Rabin Med Ctr, Dept Internal Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Internal Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	leibovic@post.tau.ac.il						Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Mock DW, 1999, NATURE, V397, P647, DOI 10.1038/17679; Rigas B, 1999, LANCET, V354, P1634, DOI 10.1016/S0140-6736(99)06034-1; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P836, DOI 10.1136/bmj.319.7213.836; Zollman C, 1999, BRIT MED J, V319, P1558, DOI 10.1136/bmj.319.7224.1558; ZOLLMAN C, 1999, BRIT MED J, V319, P1254; ZOLLMAN C, 1999, BRIT MED J, V319, P1176; ZOLLMAN C, 1999, BRIT MED J, V319, P973; ZOLLMAN C, 1999, BRIT MED J, V319, P1419; ZOLLMAN C, 1999, BRIT MED J, V319, P1115	16	15	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1629	1631		10.1136/bmj.319.7225.1629	http://dx.doi.org/10.1136/bmj.319.7225.1629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600974	Green Published			2022-12-28	WOS:000084562600025
J	Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P				Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P			A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSFER-RNA LIGASE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; MISSENSE MUTATIONS; PATHWAY; KINASE	The unfolded protein response (UPR) mediates signaling from the endoplasmic reticulum to the nucleus. In yeast, a key regulatory step in the UPR is the spliceosome-independent splicing of HAC1 mRNA encoding a UPR-specific transcription factor, which is initiated by the transmembrane kinase/endoribonuclease Ire1. We show that yeast HAC1 mRNA is correctly spliced in mammalian cells upon UPR induction and that mammalian Ire1 can precisely cleave both splice junctions. Surprisingly, UPR induction leads to proteolytic cleavage of Ire1, releasing fragments containing the kinase and nuclease domains that accumulate in the nucleus. Nuclear localization and UPR induction are reduced in presenilin-1 knockout cells. These results suggest that the salient features of the UPR are conserved among eukaryotic cells and that presenilin-1 controls Ire1 proteolysis in mammalian cells.	Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HAZE K, 1999, IN PRESS MOL BIOL CE; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	42	237	250	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					691	702		10.1016/S0092-8674(00)81667-0	http://dx.doi.org/10.1016/S0092-8674(00)81667-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619423	Bronze			2022-12-28	WOS:000084488200003
J	Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH				Benson, BW; Mohtadi, NGH; Rose, MS; Meeuwisse, WH			Head and neck injuries among ice hockey players wearing full face shields vs half face shields	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL-INJURIES	Context Speculation exists that use of a full face shield by ice hockey players may increase their risk of concussions and neck injuries, offsetting the benefits of protection from dental, facial, and ocular injuries, but, to our knowledge, no data exist regarding this possibility. Objective To determine the risk of sustaining a head or neck injury among intercollegiate ice hockey players wearing full face shields compared with those wearing half shields. Design, Setting, and Participants Prospective cohort study conducted during the 1997-1998 Canadian Inter-University Athletics Union hockey season of 642 male hockey players (mean age, 22 years) from 22 teams. Athletes from 11 teams wore full face shields and athletes from 11 teams wore half face shields during play. Main Outcome Measure Reportable injury, defined as any event requiring assessment or treatment by a team therapist or physician or any mild traumatic brain injury or brachial plexus stretch, categorized by time lost from subsequent participation and compared by type of face shield. Results Of 379 athletes who wore full face shields, 195 (61.6%) had at least 1 injury during the study season, whereas of 323 who wore half lace shields, 204 (63.2%) were injured. The risk of sustaining a facial laceration and dental injury was 2.31 (95% confidence interval [CI], 1.53-3.48; P < .001) and 9.90 (95% CI, 1.88-52.1; P = .007) times greater, respectively, for players wearing half vs full face shields. No statistically significant risk differences were found for neck injuries, concussion, or other injuries, although time lost from participation because of concussion was significantly greater in the half shield group (P < .001), than in the group wearing full shields. Conclusions These data provide evidence that the use of full face shields is associated with significantly reduced risk of sustaining facial and dental injuries without an increase in the risk of neck injuries, concussions, or other injuries.	Univ Calgary, Ctr Sports Med, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB T2N 1N4, Canada	University of Calgary; University of Calgary	Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	meeuwiss@ucalgary.ca						Bishop P J, 1983, Can J Appl Sport Sci, V8, P19; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brukner P, 1996, Aust Fam Physician, V25, P1445; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Deady B, 1996, J Emerg Med, V14, P645, DOI 10.1016/S0736-4679(96)00134-5; GOODWINGERBERIC.S, 1987, CHILD NERV SYST, V3, P59; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONTELPARE WJ, 1996, EPIDEMIOLOGY SPORTS, P247; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY T, 1985, CAN J OPHTHALMOL, V20, P2; PASHBY T, 1993, SAFETY ICE HOCKEY, P159; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; REILLY M, 1982, ATHL TRAIN, V17, P88; SIM FH, 1987, AM J SPORT MED, V15, P30, DOI 10.1177/036354658701500105; Smith A W, 1985, Can J Appl Sport Sci, V10, P68; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1984, CAN J NEUROL SCI, V11, P34, DOI 10.1017/S0317167100045297; TATOR CH, 1991, CAN J SURG, V34, P63; TATOR CH, 1982, CAN MED ASSOC J, V127, P1077; Voaklander DC, 1996, CLIN J SPORT MED, V6, P15, DOI 10.1097/00042752-199601000-00005; WALSH S, 1989, SAFETY ICE HOCKEY, P55; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	27	111	111	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2328	2332		10.1001/jama.282.24.2328	http://dx.doi.org/10.1001/jama.282.24.2328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612320	Bronze			2022-12-28	WOS:000084261700026
J	Kahn, J; Lagakos, S; Wulfsohn, M; Cherng, D; Miller, M; Cherrington, J; Hardy, D; Beall, G; Cooper, R; Murphy, R; Basgoz, N; Ng, E; Deeks, S; Winslow, D; Toole, JJ; Coakley, D				Kahn, J; Lagakos, S; Wulfsohn, M; Cherng, D; Miller, M; Cherrington, J; Hardy, D; Beall, G; Cooper, R; Murphy, R; Basgoz, N; Ng, E; Deeks, S; Winslow, D; Toole, JJ; Coakley, D		GS-408 Study Team	Efficacy and safety of adefovir dipivoxil with antiretroviral therapy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-LEVEL RESISTANCE; HIV-INFECTED ADULTS; CD4 CELL COUNTS; COMBINATION THERAPY; ANTIVIRAL ACTIVITY; CUBIC MILLIMETER; ZIDOVUDINE; ANALOGS; LYMPHOCYTES	Context Adefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration. Objective To determine if adefovir confers antiretroviral or immunologic benefit when added to stable antiretroviral therapy. Design Multicenter, 24-week, randomized, double-blind, placebo-controlled study. Enrollment was conducted from June 3, 1996, through May 6, 1997. Setting Thirty-three US HIV treatment centers. Participants Of 1171 patients screened, 442 patients infected with HIV receiving stable antiretroviral therapy for at least 8 weeks with plasma HIV RNA greater than 2500 copies/mL and CD4(+) cell count above 0.20 x 10(9)/L were randomized. Intervention Patients were randomized to receive either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable placebo (n = 223), All patients received L-carnitine, 500 mg/d, Open-label adefovir was offered after 24 weeks and was continued until the end of the study. Main Outcome Measures Changes in HIV RNA from baseline, based on area under the curve and CD4(+) cell levels, adverse events, and effect of baseline genotypic resistance on response to adefovir, Results Patients assigned to adefovir demonstrated a 0.4-log(10) decline from baseline in HIV RNA compared with no change in the placebo group (P < .001), which continued through 48 weeks. CD4(+) cell counts did not change. During the initial 24 weeks, elevated hepatic enzyme levels (P < .001), gastrointestinal tract complaints (P < .001), and weight loss (P < .001) were associated with use of adefovir, Between 24 weeks and 48 weeks elevations in serum creatinine occurred in 60% of patients, usually returning to baseline after discontinuation of adefovir. Patients with lamivudine or lamivudine and zidovudine resistance mutations demonstrated anti-HIV effects with adefovir(P less than or equal to.01 vs placebo group). Conclusions This study suggests that once-daily adefovir therapy reduces HIV RNA and is active against isolates resistant to lamivudine or lamivudine and zidovudine, Nephrotoxicity occurred when treatment extended beyond 24 weeks but was reversible.	Gilead Sci Inc, Foster City, CA 94404 USA; Pacific Oak Res, Beverly Hills, CA USA; Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA; Kraus Med Partners, Los Angeles, CA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA	Gilead Sciences; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Northwestern University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Kahn, J (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, 995 Potrero Ave, San Francisco, CA 94110 USA.	jkahn@php.ucsf.edu		Murphy, Robert/0000-0003-3936-2052				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bailar JC., 1992, MED USES STAT; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BarditchCrovo P, 1997, J INFECT DIS, V176, P406, DOI 10.1086/514057; Bradley JV., 1968, DISTRIBUTION FREE ST; Brettle RP, 1998, INT J STD AIDS, V9, P80, DOI 10.1258/0956462981921729; BRONSON JJ, 1989, ACS SYM SER, V401, P72; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DECLERCQ E, 1987, ANTIVIR RES, V8, P261; Deeks SG, 1997, J INFECT DIS, V176, P1517, DOI 10.1086/514150; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fleming P L, 1998, AIDS, V12 Suppl A, pS55; GALLANT J, 1999, 39 INT C ANT AG CHEM; Gazzard B, 1998, LANCET, V352, P314, DOI 10.1016/S0140-6736(98)04084-7; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HOLME E, 1989, LANCET, V2, P469; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KATLARNA C, 1998, 4 INT C DRUG THER HI; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kramata P, 1996, MOL PHARMACOL, V49, P1005; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Miller MD, 1999, J INFECT DIS, V179, P92, DOI 10.1086/314560; NEYTS J, 1993, EUR J CLIN MICROBIOL, V12, P437, DOI 10.1007/BF01967438; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301	32	161	176	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2305	2312		10.1001/jama.282.24.2305	http://dx.doi.org/10.1001/jama.282.24.2305			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612317	Bronze			2022-12-28	WOS:000084261700023
J	Smith, DM; Tabin, CJ				Smith, DM; Tabin, CJ			Developmental biology - BMP signalling specifies the pyloric sphincter	NATURE			English	Article							GUT		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Smith, DM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Natsume T, 1997, J BIOL CHEM, V272, P11535; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; Zakany J, 1999, NATURE, V401, P761, DOI 10.1038/44511; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	11	34	36	2	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					748	749		10.1038/45439	http://dx.doi.org/10.1038/45439			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617196				2022-12-28	WOS:000084330500044
J	Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH				Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH			Binding of paxillin to alpha(4) integrins modifies integrin-dependent biological responses	NATURE			English	Article							SUBUNIT CYTOPLASMIC DOMAINS; FOCAL ADHESION KINASE; CELL-MIGRATION; PROTEIN; SRC; ASSOCIATION; ROLES; FYN	The alpha(4) integrins are indispensable for embryogenesis, haematopoiesis and immune responses(1,2), possibly because a4 regulates cellular functions differently from other integrins through its cytoplasmic tail(3). We used novel mimics(4) of the alpha(4) tail to identify molecules that could account for alpha(4)-specific signalling. Here we report that the alpha(4) tail, but not several other alpha-subunit tails, binds tightly to the signalling adaptor paxillin, Paxillin physically associated with alpha(4) integrins in Jurkat T cells at high stoichiometry, and joining the alpha(4) tail to alpha(IIb) resulted in a complex of integrin alpha(IIb)beta(3) With paxillin. This association markedly enhanced the rates of alpha(IIb)beta(3)-dependent phosphorylation of focal adhesion kinase and cell migration. It also reduced cell spreading, focal adhesion and stress fibre formation. A point mutation within the alpha(4) tail that disrupts paxillin binding reversed all of these effects. Furthermore, alpha(4)beta(1)-dependent adhesion to VCAM-1 led to spreading of mouse embryonic fibroblasts derived from paxillin-null but not from wild-type mice. Thus, the tight association of paxillin with the alpha(4) tail leads to distinct biochemical and biological responses to integrin-mediated cell adhesion.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN YP, 1994, BLOOD, V84, P1857; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Hagmann J, 1998, J CELL SCI, V111, P2181; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	29	278	291	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					676	681		10.1038/45264	http://dx.doi.org/10.1038/45264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604475				2022-12-28	WOS:000084189800069
J	Repacholi, MH; Ahlbom, A				Repacholi, MH; Ahlbom, A			Link between electromagnetic fields and childhood cancer unresolved	LANCET			English	Editorial Material							MAGNETIC-FIELDS; LEUKEMIA		WHO, Div Occupat & Environm Hlth, CH-1211 Geneva 27, Switzerland; Karolinska Inst, Natl Inst Environm Med, S-10401 Stockholm, Sweden	World Health Organization; Karolinska Institutet	Repacholi, MH (corresponding author), WHO, Div Occupat & Environm Hlth, CH-1211 Geneva 27, Switzerland.							Dockerty JD, 1999, CANCER CAUSE CONTROL, V10, P641; Dockerty JD, 1998, CANCER CAUSE CONTROL, V9, P299, DOI 10.1023/A:1008825220759; *EL POW RES I, 1994, TR103470 EPRI; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; McBride ML, 1999, AM J EPIDEMIOL, V149, P831, DOI 10.1093/oxfordjournals.aje.a009899; MCKINLAY AF, 1999, RADIAT PROT DOSIM, V83, P1; Michaelis J, 1998, EPIDEMIOLOGY, V9, P92, DOI 10.1097/00001648-199801000-00018; *NAT RES COUNC, 1996, POSS HLTH EFF EXP RE; Portier C. J., 1998, NIH PUBLICATION; Repacholi MH, 1999, BIOELECTROMAGNETICS, V20, P133, DOI 10.1002/(SICI)1521-186X(1999)20:3<133::AID-BEM1>3.0.CO;2-O	10	17	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1918	1919		10.1016/S0140-6736(99)00433-X	http://dx.doi.org/10.1016/S0140-6736(99)00433-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622288				2022-12-28	WOS:000084034700002
J	Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT				Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT			Midline episiotomy and anal incontinence: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FECAL INCONTINENCE; PELVIC FLOOR; SPHINCTER DAMAGE; VAGINAL DELIVERY; PERINEAL TRAUMA; FOLLOW-UP; CHILDBIRTH; REPAIR; RISK	Objective To evaluate the relation between midline episiotomy and postpartum anal incontinence. Design Retrospective cohort study with three study arms and six months of follow up. Setting University teaching hospital. Participants Primiparous women who vaginally delivered a live full term, singleton baby between 1 August 1996 and 8 February 1997: 209 who received an episiotomy; 206 who did not receive an episiotomy but experienced a second, third, or fourth degree spontaneous perineal laceration; and 211 who experienced either no laceration or a first degree perineal laceration. Main outcome measures Self reported faecal and natus incontinence at three and six months postpartum. Results Women who had episiotomies bad a higher risk of faecal incontinence at three (odds ratio 5.5, 95% confidence interval 1.8 to 16.2) and six (3.7, 0.9 to 15.6) months postpartum compared with women with an intact perineum. Compared with women with a spontaneous laceration, episiotomy tripled the risk of faecal incontinence at three months (95%, confidence interval 1.3 to 7.9) and six months (0.7 to 11.2) postpartum, and doubled the risk of flatus incontinence at three months (1.3 to 3.4) and six months (1.2 to 3.7) postpartum. A non-extending episiotomy (that is, second degree surgical incision) tripled the risk of faecal incontinence (1.1 to 9.0) and nearly doubled the risk of flatus incontinence (1.0 to 3.0) at three months postpartum compared with women who had a second degree spontaneous tear. The effect of episiotomy was independent of maternal age, infant birth weight, duration of second stage of labour, use of obstetric instrumentation during delivery, and complications of labour. Conclusions Midline episiotomy is not effective in protecting the perineum and sphincters during childbirth and may impair anal continence.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Signorello, LB (corresponding author), Int Epidemiol Inst, 1450 Res Blvd,Suite 550, Rockville, MD 20850 USA.			Harlow, Bernard/0000-0002-6735-8862				BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; DEEN KI, 1993, GUT, V34, P685, DOI 10.1136/gut.34.5.685; Frudinger A, 1997, BRIT J OBSTET GYNAEC, V104, P1009, DOI 10.1111/j.1471-0528.1997.tb12058.x; HELWIG JT, 1993, OBSTET GYNECOL, V82, P276; ISAGERSALLY L, 1986, BRIT J OBSTET GYNAEC, V93, P420; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; NIELSEN MB, 1992, BRIT J SURG, V79, P104, DOI 10.1002/bjs.1800790204; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; SORENSEN M, 1993, BRIT J SURG, V80, P392, DOI 10.1002/bjs.1800800343; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; Sultan AH, 1997, BRIT J OBSTET GYNAEC, V104, P979; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THORP JM, 1987, OBSTET GYNECOL, V70, P260; THORP JM, 1989, AM J OBSTET GYNECOL, V160, P1027, DOI 10.1016/0002-9378(89)90152-X; WALKER MPR, 1991, OBSTET GYNECOL, V77, P668	21	121	124	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					86	90		10.1136/bmj.320.7227.86	http://dx.doi.org/10.1136/bmj.320.7227.86			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625261	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000084746600016
J	Yamey, G				Yamey, G			Suicide rate is decreasing in England and Wales	BRITISH MEDICAL JOURNAL			English	News Item																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					75	75						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625249				2022-12-28	WOS:000084746600007
J	Edwards, EB; Roberts, JP; McBride, MA; Schulak, JA; Hunsicker, LG				Edwards, EB; Roberts, JP; McBride, MA; Schulak, JA; Hunsicker, LG			The effect of the volume of procedures at transplantation centers on mortality after liver transplantation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background: For many complex surgical procedures there is an association between a low volume of procedures and an increased risk of death for the patients who undergo the procedures. Methods: We examined the effect of the volume of procedures at transplantation centers on the risk of death after liver transplantation. We analyzed all liver transplantations performed in the United States between October 1, 1987, and April 30, 1994. Because the results for 1987 to 1991 were largely similar to those from 1992 to 1994, we focused on the more recent period. Results: Between January 1, 1992, and April 30, 1994, 47 centers performed 20 or fewer liver transplantations each per year (total, 837 transplantations) and were designated low-volume centers, and 52 centers performed more than 20 transplantations each per year (total, 6526) and were designated high-volume centers. The one-year mortality rate for the low-volume centers was 25.9 percent, as compared with 20.0 percent for the high-volume centers. Thirteen centers, all of which had low volumes, had one-year mortality rates of more than 40 percent. Low-volume centers that were affiliated with high-volume centers, such as pediatric transplantation programs, had results similar to those of the high-volume centers. The one-year mortality rate at unaffiliated low-volume centers was 28.3 percent, as compared with a rate of 20.1 percent for the group of all high-volume centers plus affiliated low-volume centers (P < 0.001). Conclusions: As a group, liver-transplantation centers in the United States that perform 20 or fewer transplantations per year have mortality rates that are significantly higher than those at centers that perform more than 20 transplantations per year. Information regarding the outcome of liver transplantation at transplantation centers should be made widely available to the public. (N Engl J Med 1999;341:2049-53.) (C)1999, Massachusetts Medical Society.	United Network Organ Sharing, Richmond, VA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Iowa, Coll Med, Iowa City, IA USA	United Network for Organ Sharing; University of California System; University of California San Francisco; University Hospitals of Cleveland; University of Iowa	Edwards, EB (corresponding author), United Network Organ Sharing, Richmond, VA USA.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Bhattacharyya GK, 1977, STAT CONCEPTS METHOD; GORDON TA, 1995, ANN SURG, V221, P43, DOI 10.1097/00000658-199501000-00005; Hastie TJ., 2017, GEN ADDITIVE MODELS; HOSENPUD JD, 1994, JAMA-J AM MED ASSOC, V271, P1844, DOI 10.1001/jama.271.23.1844; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kazmers A, 1996, J VASC SURG, V23, P191, DOI 10.1016/S0741-5214(96)70263-X; *UN NETW ORG SHAR, 1996, 1996 ANN REP US SCI; *UN NETW ORG SHAR, 1997, 1997 REP CTR SPEC GR	10	202	203	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2049	2053		10.1056/NEJM199912303412703	http://dx.doi.org/10.1056/NEJM199912303412703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615076				2022-12-28	WOS:000084573300003
J	Jenkinson, S				Jenkinson, S			Childhood: a public health issue	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1653	1653		10.1136/bmj.319.7225.1653	http://dx.doi.org/10.1136/bmj.319.7225.1653			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600986	Green Published			2022-12-28	WOS:000084562600037
J	Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D				Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D			Genetic definition and sequence analysis of Arabidopsis centromeres	SCIENCE			English	Article							REPETITIVE DNA; RNA GENES; THALIANA; RECOMBINATION; PROTEINS; REGIONS; RETROTRANSPOSONS; HETEROCHROMATIN; CONSTRUCTION; EUKARYOTES	High-precision genetic mapping was used to define the regions that contain centromere functions on each natural chromosome in Arabidopsis thaliana. These regions exhibited dramatic recombinational repression and contained complex DNA surrounding large arrays of 180-base pair repeats. Unexpectedly, the DNA within the centromeres was not merely structural but also encoded several expressed genes. The regions flanking the centromeres were densely populated by repetitive elements yet experienced normal levels of recombination. The genetically defined centromeres were well conserved among Arabidopsis ecotypes but displayed Limited sequence homology between different chromosomes, excluding repetitive DNA. This investigation provides a platform for dissecting the role of individual sequences in centromeres in higher eukaryotes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Inst Genom Res, Rockville, MD 20850 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UJ, Norfolk, England; Sanger Ctr, Cambridge CB10 1SA, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA	University of Chicago; J. Craig Venter Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Wellcome Trust Sanger Institute; Cold Spring Harbor Laboratory; Washington University (WUSTL)	Preuss, D (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57 St, Chicago, IL 60637 USA.	dpreuss@midway.uchicago.edu	Kuromori, Takashi/G-7862-2013; Copenhaver, Gregory/AFL-9831-2022; Copenhaver, Gregory P/A-7549-2014; Copenhaver, Gregory/AAH-2031-2022; Marra, Marco A/B-5987-2008	Kuromori, Takashi/0000-0003-3232-7262; Copenhaver, Gregory/0000-0002-7962-3862; Copenhaver, Gregory P/0000-0002-7962-3862; Copenhaver, Gregory/0000-0002-7962-3862; Marra, Marco A/0000-0001-7146-7175; McCombie, W. Richard/0000-0003-1899-0682				BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bevan M, 1999, BIOESSAYS, V21, P110, DOI 10.1002/(SICI)1521-1878(199902)21:2&lt;110::AID-BIES5&gt;3.0.CO;2-V; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; CALLIS J, 1995, GENETICS, V139, P921; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; CHARLESWORTH B, 1986, GENETICS, V112, P947, DOI 10.1093/genetics/112.4.947; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Choo KHA, 1998, GENOME RES, V8, P81, DOI 10.1101/gr.8.2.81; Chye ML, 1997, PLANT MOL BIOL, V35, P893, DOI 10.1023/A:1005947804227; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Copenhaver GP, 1999, CURR OPIN PLANT BIOL, V2, P104, DOI 10.1016/S1369-5266(99)80021-1; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; FLEIG U, 1995, NUCLEIC ACIDS RES, V23, P922, DOI 10.1093/nar/23.6.922; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heslop-Harrison JS, 1999, PLANT CELL, V11, P31, DOI 10.1105/tpc.11.1.31; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; INOHARA N, 1991, J BIOL CHEM, V266, P7333; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kaszas E, 1996, EMBO J, V15, P5246, DOI 10.1002/j.1460-2075.1996.tb00910.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KONIECZNY A, 1991, GENETICS, V127, P801; KUHN RM, 1991, P NATL ACAD SCI USA, V88, P1306, DOI 10.1073/pnas.88.4.1306; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; LIN X, IN PRESS NATURE; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Murata M, 1997, PLANT J, V12, P31, DOI 10.1046/j.1365-313X.1997.12010031.x; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Pelissier T, 1996, GENETICA, V97, P141, DOI 10.1007/BF00054621; PREUSS D, 1994, SCIENCE, V264, P1458, DOI 10.1126/science.8197459; Puechberty J, 1999, GENOMICS, V56, P274, DOI 10.1006/geno.1999.5742; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TSAY YF, 1993, SCIENCE, V260, P342, DOI 10.1126/science.8385803; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; WAMBUTT R, IN PRESS NATURE; Wright DA, 1996, GENETICS, V142, P569	46	348	380	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2468	2474		10.1126/science.286.5449.2468	http://dx.doi.org/10.1126/science.286.5449.2468			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617454				2022-12-28	WOS:000084429700037
J	Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH				Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH			Emergency department triage strategies for acute chest pain using creatine Kinase-MB and troponin I assays: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN; ROOM	Background: Evaluation of acute chest pain is highly variable. Objective: To evaluate the cost-effectiveness of strategies using cardiac markers and noninvasive tests for myocardial ischemia. Design: Cost-effectiveness analysis. Data Sources: Prospective data from 1066 patients with chest pain and from the published literature. Target Population: Patients admitted with acute chest pain. Time Horizon: Lifetime. Perspective: Societal. Interventions: Creatine kinase (CK)-MB mass assay alone; CK-MB mass assay followed by cardiac troponin assay if the CK-MB value is normal; CK-MB mass assay followed by troponin I assay if the CK-MB value is normal and electrocardiography shows ischemic changes; both CK-MB mass and troponin I assays; and troponin I assay alone. These strategies were evaluated alone or in combination with early exercise testing. Outcome Measures: Lifetime cost, life expectancy (in years), and incremental cost-effectiveness. Results of Base-Case Analysis: For patients 55 to 64 years of age, measurement of CK-MB mass followed by exercise testing in appropriate patients was the most competitive strategy ($43000 per year of life saved). Measurement of CK-MB mass followed by troponin I measurement had an incremental cost-effectiveness ratio of $47400 per year of life saved for patients 65 to 74 years of age; it was also the most cost-effective strategy when early exercise testing could not be performed, CK-MB values were normal, and ischemic changes were seen on electrocardiography. Results of Sensitivity Analysis: Results were influenced by age, probability of myocardial infarction, and medical costs. Conclusions: Measurement of CK-MB mass plus early exercise testing is a cost-effective initial strategy for younger patients and those with a low to moderate probability of myocardial infarction. Troponin I measurement can be a cost-effective second test in higher-risk subsets of patients if the CK-MB level is normal and early exercise testing is not an option.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Lee, TH (corresponding author), Partners Community Healthcare Inc, Suite 1150,Prudential Tower, Boston, MA 02119 USA.	thlee@partners.org	Polanczyk, Carisi CAP/D-6208-2013	Sacks, David/0000-0003-3100-0735				Anderson F P, 1998, Clin Lab Manage Rev, V12, P63; APPLE FS, 1995, CLIN CHIM ACTA, V237, P59, DOI 10.1016/0009-8981(95)06064-K; BODOR GS, 1992, CLIN CHEM, V38, P2203; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Green GB, 1998, ANN EMERG MED, V31, P19, DOI 10.1016/S0196-0644(98)70276-8; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Johnson PA, 1999, AM HEART J, V137, P1137, DOI 10.1016/S0002-8703(99)70374-1; Keffer JH, 1997, AM J CLIN PATHOL, V107, P398; Kirk JD, 1998, ANN EMERG MED, V32, P1, DOI 10.1016/S0196-0644(98)70091-5; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Krumholz HM, 1998, AM HEART J, V135, P523, DOI 10.1016/S0002-8703(98)70331-X; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; LAVE JR, 1994, MED CARE, V32, pJS77; LEE T, 1990, COMMON DIAGNOSTIC TE, P36; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; Mair J, 1997, CLIN CHIM ACTA, V257, P99, DOI 10.1016/S0009-8981(96)06436-4; Mair J, 1996, CLIN CHIM ACTA, V245, P19, DOI 10.1016/0009-8981(95)06168-1; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; O'Brien JA, 1998, DIABETES CARE, V21, P1122, DOI 10.2337/diacare.21.7.1122; Polanczyk CA, 1999, AM J CARDIOL, V83, P1175, DOI 10.1016/S0002-9149(99)00055-7; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; Polanczyk CA, 1998, J AM COLL CARDIOL, V32, P8, DOI 10.1016/S0735-1097(98)00176-4; Stinett AA, 1996, COST EFFECTIVENESS H, P349; Tosteson ANA, 1996, CIRCULATION, V94, P143, DOI 10.1161/01.CIR.94.2.143; Tucker JF, 1997, ACAD EMERG MED, V4, P13, DOI 10.1111/j.1553-2712.1997.tb03637.x; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; *US BUR CENS, 1997, STAT ABSTR US, P89; Wu AHB, 1996, CLIN CHEM, V42, P651	32	36	37	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					909	+		10.7326/0003-4819-131-12-199912210-00002	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610641				2022-12-28	WOS:000084374400001
J	Kopans, DB				Kopans, DB			Breast-cancer screening with ultrasonography	LANCET			English	Editorial Material							US; WOMEN		Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kopans, DB (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.							BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Buchberger W, 1999, AM J ROENTGENOL, V173, P921, DOI 10.2214/ajr.173.4.10511149; FEIG SA, 1995, CANCER, V75, P2412, DOI 10.1002/1097-0142(19950515)75:10<2412::AID-CNCR2820751005>3.0.CO;2-4; GORDON PB, 1993, RADIOLOGY, V189, P573, DOI 10.1148/radiology.189.2.8210392; GORDON PB, 1995, CANCER, V76, P626, DOI 10.1002/1097-0142(19950815)76:4<626::AID-CNCR2820760413>3.0.CO;2-Z; Kolb TM, 1998, RADIOLOGY, V207, P191, DOI 10.1148/radiology.207.1.9530316; KOPANS DB, 1985, RADIOLOGY, V157, P505, DOI 10.1148/radiology.157.2.3901112; Shapiro S, 1988, PERIODIC SCREENING B	9	33	38	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2096	2097		10.1016/S0140-6736(99)90400-2	http://dx.doi.org/10.1016/S0140-6736(99)90400-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609810				2022-12-28	WOS:000084318200004
J	Lundstrom, T; Schoenfeld, W; Lee, H; Petroff, PM				Lundstrom, T; Schoenfeld, W; Lee, H; Petroff, PM			Exciton storage in semiconductor self-assembled quantum dots	SCIENCE			English	Article							WELL	Storage and retrieval of excitons were demonstrated with semiconductor self-assembled quantum dots (QDs). The optically generated excitons were dissociated and stored as separated electron-hole pairs in coupled QD pairs. A bias voltage restored the excitons, which recombined radiatively to provide a readout optical signal. The Localization of the spatially separated electron-hole pair in QDs was responsible for the ultralong storage times, which were on the order of several seconds. The present limits of this optical storage medium are discussed.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Petroff, PM (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Petroff, Pierre/M-9840-2019					Abstreiter G, 1999, JPN J APPL PHYS 1, V38, P449, DOI 10.1143/JJAP.38.449; Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991; DOHLER GH, 1996, PROPERTIES 3 5 SUPER, V15, P11; FELDMANN J, 1992, SOLID STATE COMMUN, V83, P245, DOI 10.1016/0038-1098(92)90846-2; Finley JJ, 1998, APPL PHYS LETT, V73, P2618, DOI 10.1063/1.122524; Fricke M, 1996, EUROPHYS LETT, V36, P197, DOI 10.1209/epl/i1996-00210-x; LEONARD D, 1993, APPL PHYS LETT, V63, P3203, DOI 10.1063/1.110199; REHM W, 1983, PHYS REV B, V28, P5937, DOI 10.1103/PhysRevB.28.5937; Rocke C, 1997, PHYS REV LETT, V78, P4099, DOI 10.1103/PhysRevLett.78.4099; Schoenfeld WV, 1999, APPL PHYS LETT, V74, P2194, DOI 10.1063/1.123798; Yusa G, 1997, APPL PHYS LETT, V70, P345, DOI 10.1063/1.119068; Zimmermann S, 1999, SCIENCE, V283, P1292, DOI 10.1126/science.283.5406.1292	12	265	269	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2312	2314		10.1126/science.286.5448.2312	http://dx.doi.org/10.1126/science.286.5448.2312			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600734				2022-12-28	WOS:000084318500051
J	Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A				Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A			Crystal structure of Thermotoga maritima ribosome recycling factor: A tRNA mimic	SCIENCE			English	Article							ELONGATION-FACTOR-G; COMPLETE GENOME SEQUENCE; RELEASE FACTOR RF3; PROTEIN-BIOSYNTHESIS; TERMINATION COMPLEX; FACTOR RRF; GUANOSINE TRIPHOSPHATE; TRANSFER-RNAS; DISSOCIATION; RESOLUTION	Ribosome recycling factor (RRF), together with elongation factor G (EF-G), catalyzes recycling of ribosomes after one round of protein synthesis. The crystal structure of RRF was determined at 2.55 angstrom resolution. The protein has an unusual fold where domain I is a Long three-helix bundle and domain II is a three-layer beta/alpha/beta sandwich. The molecule superimposes almost perfectly with a transfer RNA (tRNA) except that the amino acid-binding 3' end is missing. The mimicry suggests that RRF interacts with the posttermination ribosomal complex in a similar manner to a tRNA, leading to disassembly of the complex. The structural arrangement of this mimicry is entirely different from that of other cases of Less pronounced mimicry of tRNA so far described.	Lund Univ, Ctr Chem & Chem Engn, SE-22100 Lund, Sweden; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	Lund University; University of Pennsylvania	Liljas, A (corresponding author), Lund Univ, Ctr Chem & Chem Engn, POB 124, SE-22100 Lund, Sweden.	anders.liljas@mbfys.ln.se	Al-karadaghi, Salam/F-1492-2011	Al-karadaghi, Salam/0000-0001-8608-0635; Selmer, Maria/0000-0001-9079-2774				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Grentzmann G, 1998, RNA, V4, P973, DOI 10.1017/S1355838298971576; GUALERZI C, 1971, BIOCHEM BIOPH RES CO, V45, P1312, DOI 10.1016/0006-291X(71)90162-8; Heurgue-Hamard V, 1998, EMBO J, V17, P808, DOI 10.1093/emboj/17.3.808; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; ISHITSUKA H, 1970, J BIOL CHEM, V245, P3346; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; Janosi L, 1996, BIOCHIMIE, V78, P959, DOI 10.1016/S0300-9084(97)86718-1; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; JANOSI L, IN PRESS J MOL BIOL; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaji A, 1998, BIOCHEM BIOPH RES CO, V250, P1, DOI 10.1006/bbrc.1998.9168; KAJI A, 1999, ACTA CRYSTALLOGR D, V55, P2049; Kanai T, 1998, EUR J BIOCHEM, V256, P212, DOI 10.1046/j.1432-1327.1998.2560212.x; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURBERG M, COMMUNICATION; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OGAWA K, 1975, EUR J BIOCHEM, V58, P411, DOI 10.1111/j.1432-1033.1975.tb02388.x; OUZOUNIS C, 1995, PROTEIN SCI, V4, P2424, DOI 10.1002/pro.5560041121; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; RYOJI M, 1981, P NATL ACAD SCI-BIOL, V78, P5973, DOI 10.1073/pnas.78.10.5973; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1	53	146	151	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2349	2352		10.1126/science.286.5448.2349	http://dx.doi.org/10.1126/science.286.5448.2349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600747				2022-12-28	WOS:000084318500064
J	Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J				Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J			Inhibition of msl-2 splicing by Sex-lethal reveals interaction between U2AF(35) and the 3 ' splice site AG	NATURE			English	Article							DOSAGE COMPENSATION GENE; PRE-MESSENGER-RNA; MAMMALIAN INTRONS; CATALYTIC STEP; DROSOPHILA; PROTEIN; EXPRESSION; SELECTION; ENCODES	The protein Sex-lethal (SXL) controls dosage compensation in Drosophila by inhibiting the splicing and translation of male-specific-lethal-2 (msl-2) transcripts(1-6) Here we report that splicing inhibition of msl-2 requires a binding site for SXL at the polypyrimidine (poly(Y)) tract associated with the 3' splice site, and an unusually long distance between the poly(Y) tract and the conserved AG dinucleotide at the 3' end of the intron, Only this combination allows efficient blockage of U2 small nuclear ribonucleoprotein particle binding and displacement of the large subunit of the U2 auxiliary factor (U2AF(65)) from the poly(Y) tract by SXL, Crosslinking experiments with ultraviolet light indicate that the small subunit of U2AF (U2AF(35)) contacts the AG dinucleotide only when located in proximity to the poly(Y) tract. This interaction stabilizes U2AF65 binding such that SXL can no longer displace it from the poly(Y) tract. Our results reveal a novel function for U2AF35, a critical role for the 3' splice site AG at the earliest steps of spliceosome assembly and the need for a weakened U2AF(35)-AG interaction to regulate intron removal.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Valcarcel, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Bilbao Cortes, Daniel/0000-0003-1630-8811; Guth-Gundel, Sabine/0000-0001-9115-1397				BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; Gebauer F, 1998, RNA, V4, P142; GREENFIELD BH, 1991, ISOKINET EXERC SCI, V1, P207; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Umen JG, 1995, RNA, V1, P869; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	22	225	234	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					838	841		10.1038/45602	http://dx.doi.org/10.1038/45602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617208				2022-12-28	WOS:000084330500072
J	Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Jones, J; Parker, G				Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Jones, J; Parker, G			Randomised controlled trial of effectiveness of Leicester hospital at home scheme compared with hospital care	BRITISH MEDICAL JOURNAL			English	Article							SICKNESS IMPACT PROFILE; SHORT GENERIC VERSION; EARLY DISCHARGE; STATE	Objective To compare effectiveness of patient care in hospital at home scheme with hospital care. Design Pragmatic randomised controlled trial. Setting Leicester hospital at home scheme and the city's three acute hospitals Participants 199 consecutive patients referred to hospital at home bu their general practitioner and assessed as being suitable for admission. Six of 102 patients randomised to hospital at home refused admission, as did 23 of 97 allocated to hospital. Intervention Hospital at home or hospital inpatient care. Main outcome measures Mortality and change in health status (Barthel index, sickness impact profile 68, EuroQol, Philadelphia geriatric morale scale) assessed at 2 weeks and 3 months after randomisation. The main process measures were service inputs, discharge destination, readmission rates, length of initial stay, and total days of care. Results Hospital at home group and hospital group showed no significant differences in health status (median scores on sickness impact profile 68 were 29 and 30 respectively at 2 weeks. and 24 and 26 at 3 months) or in dependency; (Barthel scores 15 and 14 at 2 weeks and 16 for both groups at 3 months). At 3 months' follow up. 26 (25%) of hospital at home group had died compared with 30 (31%) of hospital group (relative risk 0.82 (95% confidence interval 0.52 to 1.28)). Hospital at home group required fewer days of treatment than hospital group, both in terms of initial stay (median 8 days v 14.5 days, P = 0.026) and total days of care at 3 months (median 9 days v 16 days, P = 0.031). Conclusions Hospital at home scheme delivered care as effectively as hospital, with no clinically important differences in health status. Hospital at home resulted in significantly shorter lengths of stay, which did not lead to a higher rate of subsequent admission. Objective To compare effectiveness of patient care in hospital at home scheme with hospital care. Design Pragmatic randomised controlled trial. Setting Leicester hospital at home scheme and the city's three acute hospitals.	Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Nuffield Community Care Studies Unit, Leicester LE1 6TP, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester	Wilson, A (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England.			Jagger, Carol/0000-0002-6377-9926; Parker, Gillian Mary/0000-0002-2221-6748				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1998, BRIT MED J, V316, P1761, DOI 10.1136/bmj.316.7147.1761; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; MAHONEY F I, 1965, Md State Med J, V14, P61; MORRIS JN, 1975, J GERONTOL, V30, P77, DOI 10.1093/geronj/30.1.77; PATTIE AH, 1976, BRIT J PSYCHIAT, V129, P68, DOI 10.1192/bjp.129.1.68; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; SHEPPERD S, 1998, COCHRANE LIB; WILSON A, 1997, BR J COMMUNITY HLTH, V2, P234	15	75	75	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1542	1546		10.1136/bmj.319.7224.1542	http://dx.doi.org/10.1136/bmj.319.7224.1542			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	265LK	10591717	Bronze, Green Published			2022-12-28	WOS:000084245600025
J	Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM				Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM			Eukaryotic type II chaperonin CCT interacts with actin through specific subunits	NATURE			English	Article							COMPLEX POLYPEPTIDE-1 TCP-1; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; THERMOSOME; PROTEIN; IMAGES	Chaperonins assist the folding of other proteins(1). Type II chaperonins, such as chaperonin containing TCP-1(CCT), are found in archaea and in the eukaryotic cytosol(2). They are hexadecameric or nonadecameric oligomers composed of one to eight different polypeptides. Whereas type I chaperonins like GroEL are promiscuous, assisting in the folding of many other proteins(1) only a small number of proteins, mainly actin and tubulin, have been described as natural substrates of CCT, This specificity may be related to the divergence of the eight CCT subunits(3). Here we have obtained a three-dimensional reconstruction of the complex between CCT and alpha-actin by cryo-electron microscopy and image processing. This shows that cr-actin interacts with the apical domains of either of two CCT subunits. Immunolabelling of CCT-substrate complexes with antibodies against two specific CCT subunits showed that actin binds to CCT using two specific and distinct interactions: the small domain of actin binds to CCT delta and the large domain to CCT beta or CCT epsilon (both in position 1,4 with respect to delta). These results indicate that the binding of actin to CCT is both subunit-specific and geometry-dependent, Thus, the substrate recognition mechanism of eukaryotic CCT may differ from that of prokaryotic GroEL.	CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Almeria, Dept Arquitectura Comp & Elect, Almeria 04120, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Universidad de Almeria	Valpuesta, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.		Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019; Fernandez, Jose-Jesus/A-5084-2008; Llorca, Oscar/K-1144-2014; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009	Valpuesta, José M/0000-0001-7468-8053; Fernandez, Jose-Jesus/0000-0003-2222-3355; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; 				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; Marabini R, 1998, ULTRAMICROSCOPY, V72, P53, DOI 10.1016/S0304-3991(97)00127-7; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Rommelaere H, 1999, BIOCHEMISTRY-US, V38, P3246, DOI 10.1021/bi9815905; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1999, MOL CHAPERONES FOLDI, P555	19	224	226	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					693	696		10.1038/45294	http://dx.doi.org/10.1038/45294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604479				2022-12-28	WOS:000084189800073
J	Bang, AT; Bang, RA; Baitule, SB; Reddy, MH; Deshmukh, MD				Bang, AT; Bang, RA; Baitule, SB; Reddy, MH; Deshmukh, MD			Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India	LANCET			English	Article							COMMUNITY; PNEUMONIA; REDUCTION; DISEASES	Background Neonatal care is not available to most neonates in developing countries because hospitals are inaccessible and costly. We developed a package of home-based neonatal care, including management of sepsis (septicaemia, meningitis, pneumonia), and tested it in the field, with the hypothesis that it would reduce the neonatal mortality rate by at least 25% in 3 years. Methods We chose 39 intervention and 47 control villages in the Gadchiroli district in India, collected baseline data for 2 years (1993-95), and then introduced neonatal care in the intervention villages (1995-98). Village hearth workers trained in neonatal care made home visits and managed birth asphyxia, premature birth or low birthweigbt, hypothermia, and breast-feeding problems. They diagnosed and treated neonatal sepsis. Assistance by trained traditional birth attendants, health education, and fortnightly supervisory visits were also provided. Other workers recorded all births and deaths in the intervention and the control area (1993-98) to estimate mortality rates. Findings Population characteristics in the intervention and control areas, and the baseline mortality rates (1993-95) were similar. Baseline (1993-95) neonatal mortality rate in the intervention and the control areas was 62 and 58 per 1000 live births, respectively. In the third year of intervention 93% of neonates received home-based care. Neonatal, infant, and perinatal mortality rates in the intervention area (net percentage reduction) compared with the control area, were 25.5 (62.2%), 38.8 (45.7%), and 47.8 (71.0%), respectively (p<0.001). Case fatality in neonatal sepsis declined from 16.6% (163 cases) before treatment, to 2.8% (71 cases) after treatment by village health workers (p<0.01). Home-based neonatal care cost US$5.3 per neonate, and in 1997-98 such care averted one death (fetal or neonatal) per 18 neonates cared for. Interpretation Home-based neonatal care, including management of sepsis, is acceptable, feasible, and reduced neonatal and infant mortality by nearly 50% among our malnourished, illiterate, rural study population. Our approach could reduce neonatal mortality substantially in developing countries.	Soc Educ Act & Res Community Hlth, Gadchiroli 442605, Maharashtra, India		Bang, AT (corresponding author), Soc Educ Act & Res Community Hlth, Gadchiroli 442605, Maharashtra, India.							BANG AT, 1993, ARCH DIS CHILD-FETAL, V68, P550, DOI 10.1136/adc.68.5_Spec_No.550; BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; BANG R, 1989, INT J GYNECOL OBST S, V3, P125; BANG RA, 1989, LANCET, V1, P85; BARTLETT AV, 1991, PEDIATR INFECT DIS J, V10, P752, DOI 10.1097/00006454-199110000-00007; BEHRMAN RE, 1992, NELSON TXB PEDIAT, P501; BERGMAN NJ, 1994, TROP DOCT, V24, P57, DOI 10.1177/004947559402400205; BHANDARI N, 1996, LANCET, V347, P1174; DAGA SR, 1989, J TROP PEDIATRICS, V35, P191, DOI 10.1093/tropej/35.4.191; *GOV IND, 1994, NAT CHILD SURV SAF M, P59; *INT I POP STUD, 1995, NAT FAM HLTH SURV IN, P237; KUMAR R, 1995, TROP DOCT, V25, P29, DOI 10.1177/004947559502500109; MODI N, 1995, J TROP PEDIATRICS, V41, P99, DOI 10.1093/tropej/41.2.99; *NAT NAON FOR, 1996, NAT NEON PER DAT BAS; PRATINIDHI A, 1986, B WORLD HEALTH ORGAN, V64, P291; Registrar General of India, 1994, SAMPL REG SYST FERT; REMINGTON JS, 1990, INFECT DIS FETUS NEW, P641; SESSIONS CF, 1991, DIS NEWBORN, P350; Shanmugasundaram R, 1998, Indian J Pediatr, V65, P249, DOI 10.1007/BF02752301; SINGH M, 1989, NEONATAL NOMENCLATUR, P63; Solomon R, 1999, Indian Pediatr, V36, P133; SUTRISNA B, 1993, LANCET, V342, P887; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; WHO, 1996, WORLD HLTH REP 1996, P14; *WHO, 1998, WORLD HLTH REP 1998, P63; World Health 0rganization, 1995, MAN AC RESP INF CHIL; World Health Organization, 1996, ESS NEWB CAR REP TEC; World Health Organization, 1977, INT CLASS DIS	28	501	516	0	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1955	1961		10.1016/S0140-6736(99)03046-9	http://dx.doi.org/10.1016/S0140-6736(99)03046-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622298				2022-12-28	WOS:000084034700012
J	Smith, O				Smith, O			Development - Whirling derivshes	SCIENCE			English	Editorial Material																		Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1311	1311		10.1126/science.286.5443.1311	http://dx.doi.org/10.1126/science.286.5443.1311			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10610537				2022-12-28	WOS:000083675500031
J	Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M				Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M			Prevalence of antibody to human T cell leukaemia/lymphoma virus in women attending antenatal clinic in southeast London: retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England; Kings Healthcare Trust, Dept Obstet & Gynaecol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Zuckerman, M (corresponding author), Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England.	mark.zuckerman@kcl.ac.uk						Department of Health, 1998, PREV HIV ENGL WAL 19; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; *INT WORK PART ENH, 1998, RED MOTH CHILD TRANS; NIGHTINGALE S, 1993, EPIDEMIOL INFECT, V110, P370; Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60	5	10	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	2000	320	7227					92	93		10.1136/bmj.320.7227.92	http://dx.doi.org/10.1136/bmj.320.7227.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625263	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000084746600018
J	Bland-Hawthorn, J; Freeman, K				Bland-Hawthorn, J; Freeman, K			The baryon halo of the Milky Way: A fossil record of its formation	SCIENCE			English	Review							GLOBULAR-CLUSTER SYSTEMS; METAL-POOR STARS; GALACTIC HALO; FIELD STARS; SPACE DENSITY; THICK-DISK; GALAXIES; BULGES; PHOTOMETRY; DWARF	Astronomers believe that the baryon (stellar) halo of the Milky Way retains a fossil imprint of how it was formed. But a vast Literature shows that the struggle to interpret the observations within a consistent framework continues. The evidence indicates that the halo has built up through a process of accretion and merging over billions of years, which is still going on at a Low Level. Future satellite missions to derive three-dimensional space motions and heavy element (metal) abundances for a billion stars will disentangle the existing web and elucidate how galaxies Like our own came into existence.	Anglo Australian Observ, Epping, NSW 2121, Australia; Australian Natl Univ, Mt Stromlo & Siding Spring Observ, Weston, ACT 2611, Australia	Australian National University	Bland-Hawthorn, J (corresponding author), Anglo Australian Observ, POB 296, Epping, NSW 2121, Australia.	jbh@aaoepp.aao.gov.au	bland-hawthorn, joss/ABE-7646-2020	bland-hawthorn, joss/0000-0001-7516-4016				ALARD C, 1996, THESIS OBSERVATOIRE; Alcock C, 2000, SCIENCE, V287, P74, DOI 10.1126/science.287.5450.74; Arras P, 1999, MON NOT R ASTRON SOC, V306, P257, DOI 10.1046/j.1365-8711.1999.02367.x; ASHMAN KM, 1992, ASTROPHYS J, V384, P50, DOI 10.1086/170850; Beers TC, 1996, ASTR SOC P, V92, P130; BINGGELI B, 1985, ASTRON J, V90, P1681, DOI 10.1086/113874; Binney J, 1997, MON NOT R ASTRON SOC, V288, P365, DOI 10.1093/mnras/288.2.365; Binney J., 1998, PR S ASTROP; Bland-Hawthorn J, 1998, MON NOT R ASTRON SOC, V299, P611, DOI 10.1046/j.1365-8711.1998.01902.x; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; Braun R, 1999, ASTRON ASTROPHYS, V341, P437; Burgarella D, 1997, SCIENCE, V276, P1370, DOI 10.1126/science.276.5317.1370; Buser R, 2000, SCIENCE, V287, P69, DOI 10.1126/science.287.5450.69; CARLBERG RG, 1986, ASTROPHYS J, V310, P593, DOI 10.1086/164711; Carney BW, 1996, ASTRON J, V112, P668, DOI 10.1086/118042; CARNEY BW, 1993, ASTR SOC P, V48, P234; COMBES F, 1990, ASTRON ASTROPHYS, V233, P82; Courteau S, 1996, ASTROPHYS J, V457, pL73, DOI 10.1086/309906; COUTURE J, 1995, ASTRON J, V109, P2050, DOI 10.1086/117430; CUISINIER F, IN PRESS ASTRON ASTR; Da Costa GS, 1999, ASTR SOC P, V165, P153; de Bruijne JHJ, 1999, MON NOT R ASTRON SOC, V306, P381, DOI 10.1046/j.1365-8711.1999.02643.x; de Zeeuw PT, 1999, ASTRON J, V117, P354, DOI 10.1086/300682; DURRELL PR, 1994, ASTRON J, V108, P2114, DOI 10.1086/117223; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; EGGEN OJ, 1959, MON NOT R ASTRON SOC, V119, P255, DOI 10.1093/mnras/119.3.255; EGGEN OJ, 1962, ASTROPHYS J, V136, P748, DOI 10.1086/147433; FELTZING S, IN PRESS ASTRON ASTR; Frayer DT, 1997, ASTROPHYS J SUPPL S, V113, P221, DOI 10.1086/313056; FREEMAN KC, 1992, MORIOND AST, P201; FREEMAN KC, IN PRESS NEW MILLENN; Gnedin OY, 1999, ASTROPHYS J, V522, P935, DOI 10.1086/307659; HARRIS WE, 1994, ASTROPHYS J, V429, P177, DOI 10.1086/174310; Harris WE, 1997, ASTRON J, V114, P1030, DOI 10.1086/118533; HARRIS WE, 1991, ANNU REV ASTRON ASTR, V29, P543, DOI 10.1146/annurev.aa.29.090191.002551; HAWKINS MRS, 1984, MON NOT R ASTRON SOC, V206, P433, DOI 10.1093/mnras/206.3.433; Helmi A, 1999, NATURE, V402, P53, DOI 10.1038/46980; HERNQUIST L, 1988, ASTROPHYS J, V331, P682, DOI 10.1086/166592; HOLTZMAN JA, 1992, ASTRON J, V103, P691, DOI 10.1086/116094; Ibata RA, 1997, ASTRON J, V113, P634, DOI 10.1086/118283; IBATA RA, 1994, NATURE, V370, P194, DOI 10.1038/370194a0; Jablonka P, 1996, ASTRON J, V112, P1415, DOI 10.1086/118109; Jimenez R, 1998, MON NOT R ASTRON SOC, V299, P515, DOI 10.1046/j.1365-8711.1998.01787.x; Johnston KV, 1996, ASTROPHYS J, V465, P278, DOI 10.1086/177418; Klypin A, 1999, ASTROPHYS J, V522, P82, DOI 10.1086/307643; KORMENDY J, UNPUB; KUIJKEN K, 1995, ASTROPHYS J, V443, pL13, DOI 10.1086/187824; Lee YW, 1999, NATURE, V402, P55, DOI 10.1038/46985; LYNDENBELL D, 1995, MON NOT R ASTRON SOC, V275, P429, DOI 10.1093/mnras/275.2.429; Majewski SR, 1996, ASTR SOC P, V92, P119; MAJEWSKI SR, 1994, ASTROPHYS J, V427, pL37, DOI 10.1086/187359; MARQUEZ A, 1994, ASTRON ASTROPHYS SUP, V108, P341; Mather J. C., 1991, ADV SPACE RES, V11, P181; MATTHEWS LD, IN PRESS BUILDING GA; MATTHEWSON DS, 1992, APJS, V81, P413; MCWILLIAM A, 1994, ASTROPHYS J SUPPL S, V91, P749, DOI 10.1086/191954; Moore B, 1999, ASTROPHYS J, V524, pL19, DOI 10.1086/312287; MOULD J, 1998, NATURE, V395, P20; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Norris JE, 1996, IAU SYMP, P353; NORRIS JE, 1989, ASTROPHYS J, V336, pL17, DOI 10.1086/185351; Oort J.H., 1965, GALACTIC STRUCT, P455; OORT JH, 1966, B ASTRON I NETH, V18, P421; Oswalt TD, 1996, NATURE, V382, P692, DOI 10.1038/382692a0; PEEBLES PJE, 1968, ASTROPHYS J, V154, P891, DOI 10.1086/149811; Peletier RF, 1996, ASTRON J, V111, P2238, DOI 10.1086/117958; PRESTON GW, 1994, ASTRON J, V108, P538, DOI 10.1086/117089; QUINN PJ, 1986, ASTROPHYS J, V309, P472, DOI 10.1086/164619; RATNATUNGA KU, 1989, ASTROPHYS J, V339, P126, DOI 10.1086/167282; RODGERS AW, 1981, ASTROPHYS J, V244, P912, DOI 10.1086/158766; RODGERS AW, 1984, ASTROPHYS J, V283, pL5, DOI 10.1086/184320; Roman N.G., 1955, AP J SUPPL, V2, P195, DOI 10.1086/190021; Ryan SG, 1996, ASTROPHYS J, V471, P254, DOI 10.1086/177967; Sandage A., 1994, CARNEGIE ATLAS GALAX; SCHWEIZER F, 1987, NEARLY NORMAL GALAXI, P18; SEARLE L, 1978, ASTROPHYS J, V225, P357, DOI 10.1086/156499; Searle L., 1977, EVOLUTION GALAXIES S, P219; SIMIEN F, 1986, ASTROPHYS J, V302, P564, DOI 10.1086/164015; Sneden C, 1996, ASTROPHYS J, V467, P819, DOI 10.1086/177656; SommerLarsen J, 1997, ASTROPHYS J, V481, P775, DOI 10.1086/304081; Tremaine S, 1999, MON NOT R ASTRON SOC, V307, P877, DOI 10.1046/j.1365-8711.1999.02690.x; TREMAINE SD, 1976, ASTROPHYS J, V203, P72, DOI 10.1086/154049; TULLY RB, 1977, ASTRON ASTROPHYS, V54, P661; van den Bergh S., 1998, GALAXY MORPHOLOGY CL, V1st; Weil ML, 1997, ASTROPHYS J, V490, P664, DOI 10.1086/304886; White SDM, 1996, LES HOUCH S, V60, P349; WHITMORE BC, 1993, ASTRON J, V106, P1354, DOI 10.1086/116732; WHITMORE BC, 1995, ASTRON J, V109, P960, DOI 10.1086/117334; Williams RE, 1996, ASTRON J, V112, P1335, DOI 10.1086/118105; Wyse RFG, 1997, ANNU REV ASTRON ASTR, V35, P637, DOI 10.1146/annurev.astro.35.1.637; YUN MS, IN PRESS ASTROPHYS J; Yusef-Zadeh F, 2000, SCIENCE, V287, P85, DOI 10.1126/science.287.5450.85	95	22	22	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					79	84		10.1126/science.287.5450.79	http://dx.doi.org/10.1126/science.287.5450.79			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615053				2022-12-28	WOS:000084578400039
J	Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE				Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE			A short Fe-Fe distance in peroxodiferric ferritin: Control of Fe substrate versus cofactor decay?	SCIENCE			English	Article							X-RAY ABSORPTION; DINUCLEAR IRON CENTER; METHANE MONOOXYGENASE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; MODEL COMPLEXES; O-2 ACTIVATION; DIAMOND CORE; INTERMEDIATE; ENZYMES	The reaction of oxygen with protein diiron sites is important in bioorganic syntheses and biomineralization. An unusually short Fe-Fe distance of 2.53 angstroms was found in the diiron (mu-1,2 peroxodiferric) intermediate that forms in the early steps of ferritin biomineralization. This distance suggests the presence of a unique triply bridged structure. The Fe-Fe distances in the mu-1,2 peroxodiferric complexes that were characterized previously are much longer (3.1 to 4.0 angstroms). The 2.53 angstrom Fe-Fe distance requires a small Fe-O-O angle (similar to 106 degrees to 107 degrees). This geometry should favor decay of the peroxodiferric complex by the release of H2O2 and mu-oxo or mu-hydroxo diferric biomineral precursors rather than by oxidation of the organic substrate. Geometrical differences may thus explain how diiron sites can function either as a substrate (in ferritin biomineralization) or as a cofactor (in O-2 activation).	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Michigan System; University of Michigan; Emory University; Emory University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Penner-Hahn, JE (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	jeph@umidh.edu	Krebs, Carsten/D-4773-2009; Penner-Hahn, James/GYD-3750-2022	Krebs, Carsten/0000-0002-3302-7053; Penner-Hahn, James/0000-0003-0314-1274	NIGMS NIH HHS [GM-45205, GM-58778, GM-47295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM058778, R01GM045205] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; Bollinger JM, 1998, J AM CHEM SOC, V120, P1094, DOI 10.1021/ja973651c; BOSSEK U, 1990, J AM CHEM SOC, V112, P6387, DOI 10.1021/ja00173a031; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Brunold TC, 1998, J AM CHEM SOC, V120, P5674, DOI 10.1021/ja980129x; Caudle MT, 1996, INORG CHEM, V35, P3577, DOI 10.1021/ic951462u; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; Dong YH, 1997, J AM CHEM SOC, V119, P12683, DOI 10.1021/ja973115k; Dong YH, 1996, ANGEW CHEM INT EDIT, V35, P618, DOI 10.1002/anie.199606181; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Ha Y, 1999, J BIOL INORG CHEM, V4, P243, DOI 10.1007/s007750050310; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; LARSON E, 1992, INORG CHEM, V31, P373, DOI 10.1021/ic00029a008; LING JS, 1994, J AM CHEM SOC, V116, P7682, DOI 10.1021/ja00096a027; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU WT, 1993, INORG CHEM, V32, P4102, DOI 10.1021/ic00071a023; Moenne-Loccoz P, 1999, BIOCHEMISTRY-US, V38, P5290, DOI 10.1021/bi990095l; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; Ookubo T, 1996, J AM CHEM SOC, V118, P701, DOI 10.1021/ja953705n; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Riggs-Gelasco PJ, 1998, J AM CHEM SOC, V120, P849, DOI 10.1021/ja9718230; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; RIGGSGELASCO PJ, 1994, THESIS U MICHIGAN; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Treffry A, 1998, FEBS LETT, V432, P213, DOI 10.1016/S0014-5793(98)00867-9; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; Valentine AM, 1999, J AM CHEM SOC, V121, P3876, DOI 10.1021/ja9839522; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	39	157	162	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					122	125		10.1126/science.287.5450.122	http://dx.doi.org/10.1126/science.287.5450.122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615044				2022-12-28	WOS:000084578400049
J	Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M				Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M			Protein interaction mapping in C-elegans using proteins involved in vulval development	SCIENCE			English	Article							PAPILLOMAVIRUS TYPE-16 E1; CELL-CYCLE REGULATORS; MAP KINASE CASCADE; CAENORHABDITIS-ELEGANS; GENOME; EXPRESSION; PATHWAY; MEMBERS; LIN-15; FAMILY	Protein interaction mapping using large-scale two-hybrid analysis has been proposed as a way to functionally annotate large numbers of uncharacterized proteins predicted by complete genome sequences. This approach was examined in Caenorhabditis elegans, starting with 27 proteins involved in vulval development. The resulting map reveals both known and new potential interactions and provides a functional annotation for approximately 100 uncharacterized gene products. A protein interaction mapping project is now feasible for C. elegans on a genome-wide scale and should contribute to the understanding of molecular mechanisms in this organism and in human diseases.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Life Technol Inc, Rockville, MD 20850 USA; Lab LSR IMAG, F-38402 St Martin Dheres, France	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Thermo Fisher Scientific	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, 44 Binney St, Boston, MA 02115 USA.	Marc_Vidal@DFCI.Harvard.edu	Thierry-Mieg, Nicolas/M-6007-2014	Thierry-Mieg, Nicolas/0000-0002-7667-2853	NATIONAL CANCER INSTITUTE [R21CA081658] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715] Funding Source: NIH RePORTER; NCI NIH HHS [1 R21 CA81658 A 01] Funding Source: Medline; NHGRI NIH HHS [1 RO1 HG01715-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		[Anonymous], 1997, NATURE, V387, pS; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHOI KY, 1994, CELL, V78, P499; CLARK SG, 1994, GENETICS, V137, P987; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURBIN R, 1994, COMPUTATIONAL METHOD; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FERGUSON EL, 1989, GENETICS, V123, P109; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; HARTLEY JL, UNPUB; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu X., UNPUB; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; PRINTEN JA, 1994, GENETICS, V138, P609; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RHODES MA, UNPUB; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Solari F, 1999, DEVELOPMENT, V126, P2483; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thomas JH, 1999, DEVELOPMENT, V126, P3449; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1997, ADV MOLEC BIOL, P109; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; WALHOUT AJM, IN PRESS METHODS ENZ; WALHOUT ALJM, UNPUB; Walhout M, 1998, AM J HUM GENET, V63, P955, DOI 10.1086/302078; Wood WB, 1988, NEMATODE CAENORHABDI; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yasugi T, 1997, J VIROL, V71, P5942, DOI 10.1128/JVI.71.8.5942-5951.1997; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	58	567	645	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					116	122		10.1126/science.287.5450.116	http://dx.doi.org/10.1126/science.287.5450.116			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615043				2022-12-28	WOS:000084578400048
J	Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC				Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC			DNA topoisomerase II beta and neural development	SCIENCE			English	Article							HUMAN FIBROBLASTS; INHIBITORS; REPAIR; RECOMBINATION; CEREVISIAE; EXCISION; SOMITE; MUSCLE; YEAST; RDNA	DNA topoisomerase II beta is shown to have an unsuspected and critical role in neural development. Neurogenesis was normal in II beta mutant mice, but motor axons failed to contact skeletal muscles, and sensory axons failed to enter the spinal cord. Despite an absence of innervation, clusters of acetylcholine receptors were concentrated in the central region of skeletal muscles, thereby revealing patterning mechanisms that are autonomous to skeletal muscle. The defects in motor axon growth in II beta mutant mice resulted in a breathing impairment and death of the pups shortly after birth.	NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	New York University; Harvard University	Yang, X (corresponding author), NYU, Sch Med, Skirball Inst Mol Med, 540 1st Ave, New York, NY 10016 USA.				NINDS NIH HHS [NS27963, NS36193, R01 NS036193, R01 NS041311-03, NS10537, R01 NS041311, R01 NS036193-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010537, R01NS041311, R37NS036193, R01NS027963, R01NS036193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; CHEN M, 1995, ONCOL RES, V7, P103; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Dereuddre S, 1997, CANCER RES, V57, P4301; Dietrich S, 1998, DEVELOPMENT, V125, P2235; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODEMENT P, 1987, DEVELOPMENT, V101, P697; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hogan B, 1994, MANIPULATING MOUSE E; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Kablar B, 1999, DEV BIOL, V208, P93, DOI 10.1006/dbio.1998.9184; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kobayashi M, 1998, MOL CELL BIOL, V18, P6737, DOI 10.1128/MCB.18.11.6737; LEWIS J, 1981, J EMBRYOL EXP MORPH, V64, P211; Ordahl CP, 1998, BIOESSAYS, V20, P357, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;357::AID-BIES1&gt;3.0.CO;2-L; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; POPANDA O, 1992, CARCINOGENESIS, V13, P2321, DOI 10.1093/carcin/13.12.2321; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLIAMS PE, 1971, J CELL SCI, V9, P751; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; Yang X., UNPUB	32	289	296	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					131	134		10.1126/science.287.5450.131	http://dx.doi.org/10.1126/science.287.5450.131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615047				2022-12-28	WOS:000084578400052
J	Gulati, M; Saint, S; Tierney, LM				Gulati, M; Saint, S; Tierney, LM			Impatient inpatient care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISSEMINATED HISTOPLASMOSIS; INDIANAPOLIS; SARCOIDOSIS; OUTBREAKS; DIAGNOSIS; ANTIGEN		Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Hlth Serv Res & Dev Field Program, Ann Arbor, MI USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of California System; University of California San Francisco	Saint, S (corresponding author), Univ Michigan, Dept Internal Med, 3116 Taubman Ctr,Box 0376, Ann Arbor, MI 48109 USA.	saint@umich.edu	Saint, Sanjay/AAF-5126-2019					DEREMEE RA, 1995, MAYO CLIN PROC, V70, P177, DOI 10.4065/70.2.177; GOODWIN RA, 1980, MEDICINE, V59, P1, DOI 10.1097/00005792-198001000-00001; Kopelman RI, 1999, NEW ENGL J MED, V341, P435, DOI 10.1056/NEJM199908053410608; Lynch J P 3rd, 1998, Semin Respir Infect, V13, P229; Newman LS, 1997, NEW ENGL J MED, V337, P139; REDDY P, 1970, AM J MED, V48, P629, DOI 10.1016/0002-9343(70)90014-8; SATHAPATAYAVONGS B, 1983, MEDICINE, V62, P263, DOI 10.1097/00005792-198309000-00001; WHEAT J, 1982, ANN INTERN MED, V97, P680, DOI 10.7326/0003-4819-97-5-680; Wheat J, 1997, MEDICINE, V76, P339, DOI 10.1097/00005792-199709000-00002; WHEAT LJ, 1989, ARCH INTERN MED, V149, P2421, DOI 10.1001/archinte.149.11.2421; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WILLIAMS B, 1994, ARCH PATHOL LAB MED, V118, P1205; Yaseen Z, 1997, AM J MED SCI, V313, P187, DOI 10.1097/00000441-199703000-00011	13	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					37	40		10.1056/NEJM200001063420107	http://dx.doi.org/10.1056/NEJM200001063420107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620648				2022-12-28	WOS:000084575600007
J	Diggory, P; Judd, M				Diggory, P; Judd, M			Advance directives: questionnaire survey of NHS trusts	BRITISH MEDICAL JOURNAL			English	Article							LIVING WILLS; LEGAL				Judd, M (corresponding author), 2 Torrington Gardens, London N11 2AB, England.							Bowker L, 1998, J ROY COLL PHYS LOND, V32, P351; General Medical Council, 1999, SEEK PAT CONS ETH CO; Luttrell S, 1996, BRIT MED J, V313, P1148, DOI 10.1136/bmj.313.7065.1148a; *NHS EX, 1999, 1999031 NHSE	4	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					24	25		10.1136/bmj.320.7226.24	http://dx.doi.org/10.1136/bmj.320.7226.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617519	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000084621600018
J	Strube, G; Rudolf, M				Strube, G; Rudolf, M			For and against - Should steroids be the first line treatment for asthma?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Ealing Hosp NHS Trust, Dept Resp Med, Southall UB1 3HW, Middx, England		Strube, G (corresponding author), 33 Goffs Pk Rd, Crawley RH11 8AX, W Sussex, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					47	47		10.1136/bmj.320.7226.47	http://dx.doi.org/10.1136/bmj.320.7226.47			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617533	Green Published			2022-12-28	WOS:000084621600029
J	Chen, LL; Sigler, PB				Chen, LL; Sigler, PB			The crystal structure of a GroEL/peptide complex: Plasticity as a basis for substrate diversity	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; POLYPEPTIDE BINDING; VIRAL PEPTIDES; CENTRAL CAVITY; PROTEIN; CONFORMATIONS; 2.8-ANGSTROM; INTERMEDIATE; RESOLUTION; MECHANISM	The chaperonin GroEL is a double toriodal assembly that with its cochaperonin GroES facilitates protein folding with an ATP-dependent mechanism. Nonnative conformations of diverse protein substrates bind to the apical domains surrounding the opening of the double toroid's central cavity. Using phage display, we have selected peptides with high affinity for the isolated apical domain. We have determined the crystal structures of the complexes formed by the most strongly bound peptide with the isolated apical domain, and with GroEL. The peptide interacts with the groove between paired or helices in a manner similar to that of the GroES mobile loop. Our structural analysis, combined with other results, suggests that various modes of molecular plasticity are responsible for tight promiscuous binding of nonnative substrates and their release into the shielded cis assembly.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06511 USA.				NIGMS NIH HHS [GM15225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015225, R37GM015225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chatellier J, 1999, J MOL BIOL, V292, P163, DOI 10.1006/jmbi.1999.3040; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1996, CHAPERONINS; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; Ma JP, 1998, P NATL ACAD SCI USA, V95, P8502, DOI 10.1073/pnas.95.15.8502; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	47	200	204	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					757	768		10.1016/S0092-8674(00)81673-6	http://dx.doi.org/10.1016/S0092-8674(00)81673-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619429	hybrid			2022-12-28	WOS:000084488200009
J	Buxton, AE; Lee, KL; Fisher, JD; Josephson, ME; Prystowsky, EN; Hafley, G				Buxton, AE; Lee, KL; Fisher, JD; Josephson, ME; Prystowsky, EN; Hafley, G		Multicenter Unsustained Tachycardi	A randomized study of the prevention of sudden death in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NONSUSTAINED VENTRICULAR-TACHYCARDIA; PROGRAMMED ELECTRICAL-STIMULATION; ARRHYTHMIA SUPPRESSION TRIAL; HOSPITAL CARDIAC-ARREST; FOLLOW-UP; PROGNOSTIC-SIGNIFICANCE; CLINICAL-TRIALS; SURVIVAL; THERAPY	Background: Empirical antiarrhythmic therapy has not reduced mortality among patients with coronary artery disease and asymptomatic ventricular arrhythmias. Previous studies have suggested that antiarrhythmic therapy guided by electrophysiologic testing might reduce the risk of sudden death. Methods: We conducted a randomized, controlled trial to test the hypothesis that electrophysiologically guided antiarrhythmic therapy would reduce the risk of sudden death among patients with coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and asymptomatic, unsustained ventricular tachycardia. Patients in whom sustained ventricular tachyarrhythmias were induced by programmed stimulation were randomly assigned to receive either antiarrhythmic therapy, including drugs and implantable defibrillators, as indicated by the results of electrophysiologic testing, or no antiarrhythmic therapy. Angiotensin-converting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the patients could tolerate them. Results: A total of 704 patients with inducible, sustained ventricular tachyarrhythmias were randomly assigned to treatment groups. Five-year Kaplan-Meier estimates of the incidence of the primary end point of cardiac arrest or death from arrhythmia were 25 percent among those receiving electrophysiologically guided therapy and 32 percent among the patients assigned to no antiarrhythmic therapy (relative risk, 0.73; 95 percent confidence interval, 0.53 to 0.99), representing a reduction in risk of 27 percent. The five-year estimates of overall mortality were 42 percent and 48 percent, respectively (relative risk, 0.80; 95 percent confidence interval, 0.64 to 1.01). The risk of cardiac arrest or death from arrhythmia among the patients who received treatment with defibrillators was significantly lower than that among the patients discharged without receiving defibrillator treatment (relative risk, 0.24; 95 percent confidence interval, 0.13 to 0.45; P<0.001). Neither the rate of cardiac arrest or death from arrhythmia nor the overall mortality rate was lower among the patients assigned to electrophysiologically guided therapy and treated with antiarrhythmic drugs than among the patients assigned to no antiarrhythmic therapy. Conclusions: Electrophysiologically guided antiarrhythmic therapy with implantable defibrillators, but not with antiarrhythmic drugs, reduces the risk of sudden death in high-risk patients with coronary disease. (N Engl J Med 1999;341:1882-90.) (C)1999, Massachusetts Medical Society.	Brown Univ, Sch Med, Providence, RI 02912 USA; Rhode Isl Hosp, Div Cardiol, Providence, RI 02905 USA; Duke Univ, Clin Res Inst, Durham, NC USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; Care Grp, Indianapolis, IN USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Duke University; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	Buxton, AE (corresponding author), Rhode Isl Hosp, Div Cardiol, 2 Dudley St,Suite 360, Providence, RI 02905 USA.		Tang, Anthony S/E-6203-2014	Fisher, John/0000-0003-2748-8715	NHLBI NIH HHS [UO1 HL45726, UO1 HL45700] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL045726, U01HL045700] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; Buxton AE, 1999, CIRCULATION, V99, P1843, DOI 10.1161/01.CIR.99.14.1843; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; Buxton AE, 1996, ANN INTERN MED, V125, P35, DOI 10.7326/0003-4819-125-1-199607010-00006; BUXTON AE, 1987, CIRCULATION, V75, P1178, DOI 10.1161/01.CIR.75.6.1178; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Cairns JA, 1997, LANCET, V349, P1776; CERQUEIRA MD, 1992, J AM COLL CARDIOL, V20, P1452, DOI 10.1016/0735-1097(92)90436-Q; COX DR, 1972, J R STAT SOC B, V34, P187; DENES P, 1991, AM J CARDIOL, V68, P887, DOI 10.1016/0002-9149(91)90404-9; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GOMES JAC, 1984, CIRCULATION, V70, P43, DOI 10.1161/01.CIR.70.1.43; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; IESAKA Y, 1990, AM J CARDIOL, V65, P1057, DOI 10.1016/0002-9149(90)90314-Q; JULIAN DG, 1997, LANCET, V349, P1180; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN RC, 1989, J AM COLL CARDIOL, V14, P155, DOI 10.1016/0735-1097(89)90066-1; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Mitchell LB, 1997, J AM COLL CARDIOL, V30, P1346, DOI 10.1016/S0735-1097(97)00294-5; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RICHARDS D, 1987, CARDIAC ARRHYTHMIAS, P329; Rouleau JL, 1996, J AM COLL CARDIOL, V27, P1119, DOI 10.1016/0735-1097(95)00599-4; ROY D, 1985, CIRCULATION, V72, P487, DOI 10.1161/01.CIR.72.3.487; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; Tavazzi L, 1997, CIRCULATION, V95, P1341; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350	35	1736	1796	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1999	341	25					1882	1890		10.1056/NEJM199912163412503	http://dx.doi.org/10.1056/NEJM199912163412503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264XZ	10601507				2022-12-28	WOS:000084210200003
J	Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L				Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L			Microorganisms in the accreted ice of Lake Vostok, Antarctica	SCIENCE			English	Article							MICROBIAL ECOLOGY; ORGANIC-CARBON; EUROPA; SEAWATER; BACTERIA; OCEAN; WATER	Analysis of a portion of Vostok ice core number 5G, which is thought to contain frozen water derived from Lake Vostok, Antarctica (a body of liquid water located beneath about 4 kilometers of glacial ice), revealed between 2 x 10(2) and 3 x 10(2) bacterial cells per milliliter and Low concentrations of potential growth nutrients, Lipopolysaccharide (a Gram-negative bacterial cell biomarker) was also detected at concentrations consistent with the cell enumeration data, which suggests a predominance of Gram-negative bacteria. At Least a portion of the microbial assemblage was viable, as determined by the respiration of carbon-14-labeled acetate and glutose substrates during incubations at 3 degrees C and 1 atmosphere. These accreted ice data suggest that Lake Vostok may contain viable microorganisms.	Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	University of Hawaii System; University of Hawaii Manoa; University of Quebec; University of Quebec Montreal	Karl, DM (corresponding author), Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				Abyzov SS, 1998, MICROBIOLOGY+, V67, P451; AZAM F, 1979, SCIENCE, V203, P451, DOI 10.1126/science.203.4379.451; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Chapman CR, 1999, SCIENCE, V283, P338, DOI 10.1126/science.283.5400.338; CHRISTIAN JR, 1994, J GEOPHYS RES-OCEANS, V99, P14269, DOI 10.1029/94JC00681; DALZIEL I, 1999, LAK VOST WORKSH FIN, P17; Fukuda R, 1998, APPL ENVIRON MICROB, V64, P3352; HOBBIE JE, 1969, LIMNOL OCEANOGR, V14, P528, DOI 10.4319/lo.1969.14.4.0528; HOLMHANSEN O, 1975, NASA, P75; JANNASCH HW, 1979, BIOSCIENCE, V29, P592, DOI 10.2307/1307765; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl David M., 1998, P29; KARL DM, 1982, APPL ENVIRON MICROB, V44, P891, DOI 10.1128/AEM.44.4.891-902.1982; KARL DM, 1980, MICROBIOL REV, V44, P739, DOI 10.1128/MMBR.44.4.739-796.1980; KARL DM, 1980, SCIENCE, V207, P1345, DOI 10.1126/science.207.4437.1345; Karl DM, 1995, MICR EXTREM UNUSUAL, P35; KENNICUTT MC, 1999, LAK VOST WORKSH FIN, P26; Legrand M, 1997, REV GEOPHYS, V35, P219, DOI 10.1029/96RG03527; MAEDA M, 1979, J APPL BACTERIOL, V47, P175, DOI 10.1111/j.1365-2672.1979.tb01182.x; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MONGER BC, 1993, APPL ENVIRON MICROB, V59, P905, DOI 10.1128/AEM.59.3.905-911.1993; Noble RT, 1998, AQUAT MICROB ECOL, V14, P113, DOI 10.3354/ame014113; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PETIT JR, 1999, LAK VOST WORKSH FIN, P16; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; Qian JG, 1996, ANAL CHEM, V68, P3090, DOI 10.1021/ac960370z; SHACKELFORD RP, 1998, THESIS U HAWAII; SHARP JH, 1995, MAR CHEM, V48, P91, DOI 10.1016/0304-4203(94)00040-K; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Takacs CD, 1998, MICROBIAL ECOL, V36, P239, DOI 10.1007/s002489900111; WATSON SW, 1977, APPL ENVIRON MICROB, V33, P940, DOI 10.1128/AEM.33.4.940-946.1977; WATSON SW, 1979, NATIVE AQUATIC BACTE, P82	35	235	252	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2144	2147		10.1126/science.286.5447.2144	http://dx.doi.org/10.1126/science.286.5447.2144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591643				2022-12-28	WOS:000084157300048
J	Maechler, P; Wollheim, CB				Maechler, P; Wollheim, CB			Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis	NATURE			English	Article							BRAIN SYNAPTIC VESICLES; PANCREATIC BETA-CELLS; SECRETORY VESICLE; RAT-BRAIN; CA2+; DEHYDROGENASE; TRANSPORT; FORMS	The hormone insulin is stored in secretory granules and released from the pancreatic beta-cells by exocytosis(1). In the consensus model of glucose-stimulated insulin secretion, ATP is generated by mitochondrial metabolism, promoting closure of ATP-sensitive potassium (K-ATP) channels, which depolarizes the plasma membrane(2,3). Subsequently, opening of voltage-sensitive Ca2+ channels increases the cytosolic Ca2+ concentration ([Ca2+](c)) which constitutes the main trigger initiating insulin exocytosis(1,3.4), Nevertheless, the Ca2+ signal alone is not sufficient for sustained secretion. Furthermore, glucose elicits a secretory response under conditions of damped, elevated [Ca2+](c) (refs 5, 6), A mitochondrial messenger must therefore exist which is distinct from ATP(7,8). We have identified this as glutamate, We show that glucose generates glutamate from beta-cell mitochondria, A membrane-permeant glutamate analogue sensitizes the glucose-evoked secretory response, acting downstream of mitochondrial metabolism. In permeabilized cells, under conditions of fixed [Ca2+](c), added glutamate directly stimulates insulin exocytosis, independently of mitochondrial function. Glutamate uptake by the secretory granules is likely to be involved, as inhibitors of vesicular glutamate transport suppress the glutamate-evoked exocytosis. These results demonstrate that glutamate acts as an intracellular messenger that couples glucose metabolism to insulin secretion.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Maechler, P (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.	pierre.maechler@medecine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; Janjic D, 1996, PANCREAS, V13, P166, DOI 10.1097/00006676-199608000-00008; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Ozkan ED, 1998, JPN J PHARMACOL, V77, P1, DOI 10.1254/jjp.77.1; ROISIN MP, 1980, FEBS LETT, V115, P143, DOI 10.1016/0014-5793(80)80745-9; ROSETH S, 1995, J NEUROCHEM, V65, P96; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SENER A, 1994, AM J PHYSIOL-ENDOC M, V267, pE573, DOI 10.1152/ajpendo.1994.267.4.E573; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	29	412	418	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					685	689		10.1038/45280	http://dx.doi.org/10.1038/45280			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604477	Green Published			2022-12-28	WOS:000084189800071
J	Kumar, S				Kumar, S			Resisting revolution: generalism and the new genetics	LANCET			English	Editorial Material							PRIMARY-CARE; OPPORTUNITIES; SERVICES; THREATS		Univ Southampton, Aldermoor Hlth Ctr, Primary Med Care Grp, Southampton SO16 5ST, Hants, England	University of Southampton	Kumar, S (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Primary Med Care Grp, Aldermoor Close, Southampton SO16 5ST, Hants, England.							BAIRD PA, 1990, PERSPECT BIOL MED, V33, P203; CLARKE A, 1995, BMJ-BRIT MED J, V311, P35, DOI 10.1136/bmj.311.6996.35; Fugelli P, 1996, BRIT MED J, V312, P456, DOI 10.1136/bmj.312.7029.456; Horton R, 1999, LANCET, V353, P609, DOI 10.1016/S0140-6736(99)00056-2; *HOUS COMM SCI TEC, 1995, HUM GEN SCI ITS CONS; Kendrick T, 1997, BRIT MED J, V314, P672, DOI 10.1136/bmj.314.7081.672; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; KUMARS S, IN PRESS BMJ; LENAGHAN J, 1998, BRAVE NEW NHS IMPACT; Mant D, 1999, LANCET, V353, P743, DOI 10.1016/S0140-6736(98)09102-8; NEIGHBOUR R, 1992, INNER CONSULTATION D; Olsen NDL, 1996, BRIT MED J, V312, P525, DOI 10.1136/bmj.312.7030.525; PENDLETON D, 1992, CONSULTATION; Petersen A.R, 1997, FOUCAULT HLTH MED; Pringle M, 1997, BRIT MED J, V314, P595; Roland M, 1996, BRIT MED J, V313, P704; ROSE S, 1990, NOT OUR GENES; *ROYAL COLL GEN PR, 1999, ROYAL COLL PHYS CONS; *ROYAL COLL GEN PR, 1998, 77 ROYAL COLL GEN PR; STOTT N, 1996, RCGP REPORT GEN PRAC; SWEENEY B, 1997, J R COLL GEN PRACT, V44, P544	21	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1992	1993		10.1016/S0140-6736(99)04073-8	http://dx.doi.org/10.1016/S0140-6736(99)04073-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622314				2022-12-28	WOS:000084034700044
J	Niklason, LE				Niklason, LE			Medical technology - Replacement arteries made to order	SCIENCE			English	Article							CULTURED VASCULAR CELLS; HUMAN BLOOD-VESSEL		Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA	Duke University; Duke University	Niklason, LE (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.							BREGMAN D, 1974, J SURG RES, V16, P624, DOI 10.1016/0022-4804(74)90095-X; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kim SS, 1999, J PEDIATR SURG, V34, P124, DOI 10.1016/S0022-3468(99)90241-5; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Liu SQ, 1998, ATHEROSCLEROSIS, V140, P365, DOI 10.1016/S0021-9150(98)00143-9; Liu SQ, 1999, CRIT REV BIOMED ENG, V27, P75, DOI 10.1615/CritRevBiomedEng.v27.i1-2.30; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	14	74	82	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1493	1494		10.1126/science.286.5444.1493	http://dx.doi.org/10.1126/science.286.5444.1493			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610551				2022-12-28	WOS:000083768300035
J	Yusef-Zadeh, F; Melia, F; Wardle, M				Yusef-Zadeh, F; Melia, F; Wardle, M			The Galactic center: An interacting system of unusual sources	SCIENCE			English	Review							SAGITTARIUS-A-ASTERISK; STELLAR PROPER MOTIONS; ACCRETING BLACK-HOLE; IONIZED-GAS; SUPERGIANT IRS-7; SGR-A; CENTRAL PARSEC; CENTER REGION; NEUTRAL-GAS; RADIO	The region bounded by the inner tens of light-years at the center of the Milky Way Galaxy contains five principal components that coexist within the central deep well of gravitational potential These constituents are a black hole candidate (Sgr A*) with a mass equivalent to 2.6 +/- 0.2 x 10(6) solar masses, a surrounding cluster of evolved stars, a complex of young stars, molecular and ionized gas clouds. and a powerful supernova-like remnant. The interaction of these components is responsible for many of the phenomena occurring in this complex and unique portion of the Galaxy. Developing a consistent picture of the primary interactions between the components at the Galactic center will improve our understanding of the nature of galactic nuclei in general, and will provide us with a better-defined set of characteristics of black holes. For example, the accretion of stellar winds by Sgr A* appears to produce far Less radiation than indicated by estimates based on models of galactic nuclei.	Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA; Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; Univ Arizona, Dept Phys, Tucson, AZ 85721 USA; Univ Sydney, Special Res Ctr Theoret Astrophys, Sydney, NSW 2006, Australia	Northwestern University; University of Arizona; University of Arizona; University of Sydney	Yusef-Zadeh, F (corresponding author), Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA.		Melia, Fulvio/V-4197-2018	Melia, Fulvio/0000-0002-8014-0593; Wardle, Mark/0000-0002-1737-0871				ALLEN DA, 1990, MON NOT R ASTRON SOC, V244, P706; ANTONUCCI R, 1993, ANNU REV ASTRON ASTR, V31, P473, DOI 10.1146/annurev.aa.31.090193.002353; Backer DC, 1999, ASTROPHYS J, V524, P805, DOI 10.1086/307857; BALICK B, 1974, ASTROPHYS J, V194, P265, DOI 10.1086/153242; Beckert T, 1997, ASTRON ASTROPHYS, V328, P95; BECKLIN EE, 1982, ASTROPHYS J, V258, pB135; Bower GC, 1999, ASTR SOC P, V186, P80; BUCKLEY JH, 1997, P 25 INT COSM RAY C, V3, P233; Coil AL, 1999, ASTROPHYS J, V513, P752, DOI 10.1086/306875; Coker RF, 1997, ASTROPHYS J, V488, pL149, DOI 10.1086/310925; Cotera A, 1999, ASTR SOC P, V186, P240; DAVIDSON JA, 1992, ASTROPHYS J, V387, P189, DOI 10.1086/171071; DYSON JE, 1993, MON NOT R ASTRON SOC, V261, P430, DOI 10.1093/mnras/261.2.430; DYSON JE, 1994, MON NOT R ASTRON SOC, V269, P1117; Eckart A, 1997, MON NOT R ASTRON SOC, V284, P576, DOI 10.1093/mnras/284.3.576; Eckart A, 1996, NATURE, V383, P415, DOI 10.1038/383415a0; EKERS RD, 1983, ASTRON ASTROPHYS, V122, P143; ELITZUR M, 1976, ASTROPHYS J, V203, P124, DOI 10.1086/154054; FALCKE H, 1993, ASTRON ASTROPHYS, V278, P1; FRAIL DA, 1994, ASTROPHYS J, V424, pL111, DOI 10.1086/187287; GEBALLE TR, 1987, ASTROPHYS J, V320, P562, DOI 10.1086/165573; GENZEL R, 1985, ASTROPHYS J, V297, P766, DOI 10.1086/163574; Genzel R, 1996, ASTROPHYS J, V472, P153, DOI 10.1086/178051; Genzel R, 1999, ASTR SOC P, V186, P3; Ghez AM, 1998, ASTROPHYS J, V509, P678, DOI 10.1086/306528; Ghez AM, 1999, ASTR SOC P, V186, P18; GUSTEN R, 1987, ASTROPHYS J, V318, P124, DOI 10.1086/165355; HALL DNB, 1982, APJ, V260, pL63; Haller JW, 1996, ASTROPHYS J, V456, P194, DOI 10.1086/176640; HARTMAN RC, 1999, ASTROPHYS J, V79, P202; HERBST TM, 1993, ASTROPHYS J, V411, pL21, DOI 10.1086/186902; JACKSON JM, 1993, ASTROPHYS J, V402, P173, DOI 10.1086/172120; Khokhlov A, 1996, ASTROPHYS J, V457, pL61, DOI 10.1086/309895; KOWALENKO V, IN PRESS MON NOT R A; Koyama K, 1996, PUBL ASTRON SOC JPN, V48, P249, DOI 10.1093/pasj/48.2.249; KRABBE A, 1991, ASTROPHYS J, V382, pL19, DOI 10.1086/186204; LACY JH, 1979, ASTROPHYS J, V227, pL17, DOI 10.1086/182858; LACY JH, 1991, ASTROPHYS J, V380, pL71, DOI 10.1086/186176; LASENBY J, 1989, IAU S, V136, P365; LEBOFSKY MJ, 1982, ASTROPHYS J, V263, P736, DOI 10.1086/160545; LISZT HS, 1995, ASTROPHYS J SUPPL S, V98, P679, DOI 10.1086/192174; Lockett P, 1999, ASTROPHYS J, V511, P235, DOI 10.1086/306667; LUTZ D, 1993, ASTROPHYS J, V418, P244, DOI 10.1086/173386; LYNDENBELL D, 1971, MON NOT R ASTRON SOC, V152, P461, DOI 10.1093/mnras/152.4.461; Maeda Y, 1996, PUBL ASTRON SOC JPN, V48, P417, DOI 10.1093/pasj/48.3.417; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; MARR JM, 1992, ASTROPHYS J, V400, pL29, DOI 10.1086/186641; MCGINN MT, 1989, ASTROPHYS J, V338, P824, DOI 10.1086/167239; MELIA F, 1994, ASTROPHYS J, V426, P577, DOI 10.1086/174094; Melia F, 1998, ASTROPHYS J, V508, P676, DOI 10.1086/306456; Melia F, 1996, ASTROPHYS J, V460, pL33, DOI 10.1086/309964; Melia F, 1998, ASTROPHYS J, V508, pL65, DOI 10.1086/311713; MELIA F, 1999, ASP C SERIES, V186, P214; Menten KM, 1997, ASTROPHYS J, V475, pL111, DOI 10.1086/310472; MEZGER PG, 1989, ASTRON ASTROPHYS, V209, P337; MEZGER PG, 1986, ASTRON ASTROPHYS, V157, P252; Morris M, 1996, ANNU REV ASTRON ASTR, V34, P645, DOI 10.1146/annurev.astro.34.1.645; MYOSHI M, 1995, NATURE, V374, P623; NARAYAN R, 1995, NATURE, V374, P623, DOI 10.1038/374623a0; Narayan R, 1998, ASTROPHYS J, V492, P554, DOI 10.1086/305070; PAULS T, 1993, ASTROPHYS J, V403, pL13, DOI 10.1086/186710; PEDLAR A, 1989, ASTROPHYS J, V342, P769, DOI 10.1086/167635; Reid MJ, 1999, ASTROPHYS J, V524, P816, DOI 10.1086/307855; RIEKE GH, 1989, ASTROPHYS J, V344, pL5, DOI 10.1086/185517; Roberts DA, 1996, ASTROPHYS J, V459, P627, DOI 10.1086/176927; ROBERTS DA, 1993, ASTROPHYS J SUPPL S, V86, P133, DOI 10.1086/191773; Sanders RH, 1998, MON NOT R ASTRON SOC, V294, P35, DOI 10.1046/j.1365-8711.1998.01127.x; SANDQVIST A, 1989, ASTRON ASTROPHYS, V223, P293; SANDQVIST A, 1974, ASTRON ASTROPHYS, V33, P413; SANDQVIST A, 1985, ASTRON ASTROPHYS, V152, P25; SCHWARZ UJ, 1989, ASTRON ASTROPHYS, V215, P33; SELLGREN K, 1987, ASTROPHYS J, V317, P881, DOI 10.1086/165338; SELLGREN K, 1990, ASTROPHYS J, V359, P112, DOI 10.1086/169039; SERABYN E, 1986, ASTRON ASTROPHYS, V169, P85; SERABYN E, 1992, ASTROPHYS J, V395, P166, DOI 10.1086/171640; SERABYN E, 1991, ASTROPHYS J, V378, P557, DOI 10.1086/170457; SERABYN E, 1988, ASTROPHYS J, V326, P171, DOI 10.1086/166078; Wardle M, 1999, ASTROPHYS J, V525, pL101, DOI 10.1086/312351; WARDLE M, 1992, NATURE, V357, P308, DOI 10.1038/357308a0; Wardle M, 1999, ASTR SOC P, V186, P432; WOLLMAN ER, 1977, ASTROPHYS J, V218, pL103, DOI 10.1086/182585; WRIGHT MCH, 1987, GALACTIC CTR, P133; Yusef-Zadeh F, 1999, ASTROPHYS J, V512, P230, DOI 10.1086/306769; Yusef-Zadeh F, 1998, ASTROPHYS J, V499, pL159, DOI 10.1086/311364; Yusef-Zadeh F, 1999, ASTR SOC P, V186, P197; YUSEFZADEH F, 1987, ASTROPHYS J, V320, P545, DOI 10.1086/165572; YusefZadeh F, 1996, ASTROPHYS J, V466, pL25, DOI 10.1086/310165; YUSEFZADEH F, 1995, ASTROPHYS J, V442, P646, DOI 10.1086/175468; YUSEFZADEH F, 1993, ASTROPHYS J, V410, pL27, DOI 10.1086/186871; YUSEFZADEH F, 1991, ASTROPHYS J, V371, pL59, DOI 10.1086/186002; YUSEFZADEH F, 1990, NATURE, V348, P45, DOI 10.1038/348045a0; YUSEFZADEH F, 1992, ASTROPHYS J, V385, pL41, DOI 10.1086/186273; YUSEFZADEH F, 1989, IAU S, V136, P443; Zhao JH, 1998, ASTROPHYS J, V499, pL163, DOI 10.1086/311374; ZHAO JH, 1995, ASTROPHYS J, V450, P122, DOI 10.1086/176124; ZHAO JH, 1991, NATURE, V354, P46, DOI 10.1038/354046a0; ZYLKA R, 1990, ASTRON ASTROPHYS, V234, P133	98	51	52	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					85	91		10.1126/science.287.5450.85	http://dx.doi.org/10.1126/science.287.5450.85			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615054	Green Submitted			2022-12-28	WOS:000084578400040
J	George, CFP; Singh, SM				George, CFP; Singh, SM			Hypocretin (orexin) pathway to sleep	LANCET			English	Editorial Material							NARCOLEPSY		Univ Western Ontario, Dept Med, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Zool, London, ON N6A 4G5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	George, CFP (corresponding author), Univ Western Ontario, Dept Med, London, ON N6A 4G5, Canada.							Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; BAKER TL, 1982, EXP NEUROL, V75, P729, DOI 10.1016/0014-4886(82)90038-3; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; GUILLEMINAULT C, 1989, LANCET, V2, P1376; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; SINGH SM, 1990, LANCET, V335, P726, DOI 10.1016/0140-6736(90)90842-S	9	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					6	6		10.1016/S0140-6736(99)90468-3	http://dx.doi.org/10.1016/S0140-6736(99)90468-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615881				2022-12-28	WOS:000085049200006
J	Moradi, P; Rowe, J; Washington, S				Moradi, P; Rowe, J; Washington, S			Whither hospital linen? Two centre observational study of alien hospital linen	BRITISH MEDICAL JOURNAL			English	Article									Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England; Withington Hosp, Manchester M20 8LE, Lancs, England		Rowe, J (corresponding author), Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England.							HOLT JL, 1978, HOSPITALS, V52, P183; RAJECKI R, 1992, CONT LONGTERM CARE, V15, P42	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1614	1614		10.1136/bmj.319.7225.1614	http://dx.doi.org/10.1136/bmj.319.7225.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600962	Bronze, Green Published			2022-12-28	WOS:000084562600016
J	Ramanan, SV				Ramanan, SV			The bottlewasher and the ambassador	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Connecticut, Sch Med, Hartford, CT 06105 USA	University of Connecticut	Ramanan, SV (corresponding author), Univ Connecticut, Sch Med, Hartford, CT 06105 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1650	1651		10.1136/bmj.319.7225.1650	http://dx.doi.org/10.1136/bmj.319.7225.1650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600983	Green Published			2022-12-28	WOS:000084562600034
J	Braddock, CH; Edwards, KA; Hasenberg, NM; Laidley, TL; Levinson, W				Braddock, CH; Edwards, KA; Hasenberg, NM; Laidley, TL; Levinson, W			Informed decision making in outpatient practice - Time to get back to basics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL DECISIONS; PRIMARY-CARE; CONSENT; DISCLOSURE; PHYSICIANS	Context Many clinicians have called for an increased emphasis on the patient's role in clinical decision making. However, little is known about the extent to which physicians foster patient involvement in decision making, particularly in routine office practice. Objective To characterize the nature and completeness of informed decision making in routine office visits of both primary care physicians and surgeons. Design Cross-sectional descriptive evaluation of audiotaped office visits during 1993, Setting and Participants A total of 1057 encounters among 59 primary care physicians (general internists and family practitioners) and 65 general and orthopedic surgeons; 2 to 12 patients were recruited from each physician's community-based private office. Main Outcome Measures Analysis of audiotaped patient-physician discussions for elements of informed decision making, using criteria that varied with the level of decision complexity: basic (eg, laboratory test), intermediate (eg, new medication), or complex (eg, procedure), Criteria for basic decisions included discussion of the nature of the decision and asking the patient to voice a preference; other categories had criteria that were progressively more stringent, Results The 1057 audiotaped encounters contained 3552 clinical decisions. Overall, 9.0% of decisions met our definition of completeness for informed decision making, Basic decisions were most often completely informed (17.2%), while no intermediate decisions were completely informed, and only 1 (0.5%) complex decision was completely informed. Among the elements of informed decision making, discussion of the nature of the intervention occurred most frequently (71%) and assessment of patient understanding least frequently (1.5%). Conclusions Informed decision making among this group of primary care physicians and surgeons was often incomplete. This deficit was present even when criteria for informed decision making were tailored to expect less extensive discussion for decisions of lower complexity. These findings signal the need for efforts to encourage informed decision making in clinical practice.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Hlth Serv Res & Dev Field Program, Seattle, WA 98108 USA; Cascade Physicians, Portland, OR USA; Univ Chicago, Div Gen Internal Med & Geriatr, Chicago, IL 60637 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Chicago	Braddock, CH (corresponding author), VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Hlth Serv Res & Dev Field Program, 1660 S Columbian Way, Seattle, WA 98108 USA.				AHRQ HHS [R01-HS0728 9] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALDIFI R, 1971, JAMA-J AM MED ASSOC, V216, P1325; ALFIDI RJ, 1975, RADIOLOGY, V114, P231, DOI 10.1148/114.1.231; [Anonymous], 1986, HIST THEORY INFORM C; APPELBAUM P, 1987, INFORMED CONSENT LEG; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Braddock CH, 1997, J GEN INTERN MED, V12, P339, DOI 10.1046/j.1525-1497.1997.00057.x; Braddock CH, 1998, AM J MED, V105, P354; BRODY H, 1989, HASTINGS CENT REP, V19, P5, DOI 10.2307/3562634; Deber RB, 1996, ARCH INTERN MED, V156, P1414, DOI 10.1001/archinte.156.13.1414; Diem SJ, 1997, J GEN INTERN MED, V12, P397; FADEN RR, 1981, MED CARE, V19, P718, DOI 10.1097/00005650-198107000-00003; FADEN RR, 1977, HEALTH EDUC QUART, V5, P198, DOI 10.1177/109019817700500302; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Jonsen A. R., 1992, CLIN ETHICS; Katz J., 1984, SILENT WORLD DOCTOR; KATZ JN, 1992, ARTHRITIS RHEUM-US, V35, P1257, DOI 10.1002/art.1780351103; Levinson W, 1999, SURGERY, V125, P127, DOI 10.1067/msy.2099.94990; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; LIDZ CW, 1982, MAKING HLTH CARE DEC; MORRIS LA, 1982, J BEHAV MED, V5, P363, DOI 10.1007/BF00846163; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; RAMSEY P, 1970, PATIENTS PERSON EXPL; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; SULMASY DP, 1994, J CLIN ETHIC, V5, P189; WU WC, 1988, J GEN INTERN MED, V3, P9, DOI 10.1007/BF02595749	26	860	866	1	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2313	2320		10.1001/jama.282.24.2313	http://dx.doi.org/10.1001/jama.282.24.2313			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	265TK	10612318	Bronze			2022-12-28	WOS:000084261700024
J	Tsutakawa, SE; Jingami, H; Morikawa, K				Tsutakawa, SE; Jingami, H; Morikawa, K			Recognition of a TG mismatch: The crystal structure of very short patch repair endonuclease in complex with a DNA duplex	CELL			English	Article							ESCHERICHIA-COLI K-12; POLYMERASE-I; MINOR-GROOVE; BASE-PAIRS; PROTEIN; BINDING; MECHANISM; GENE; VSR; TRANSCRIPTION	The crystal structure of very short patch repair (Vsr) endonuclease, in complex with Mg2+ and with duplex DNA containing a TG mismatch, has been determined at 2.3 Angstrom resolution. In E. coli, the enzyme recognizes a TG mismatched base pair, generated after spontaneous deamination of methylated cytosines, and cleaves the phosphate backbone on the 5' side of the thymine. Extensive interactions between the DNA and the protein characterize a novel recognition mechanism, where three aromatic residues intercalate from the major groove into the DNA to strikingly deform the base pair stacking. With the presence of a cleaved DNA intermediate in the active center, the structure of the Vsr/DNA complex provides detailed insights into the catalytic mechanism for endonuclease activity.	Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 565, Japan; Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 565, Japan		Morikawa, K (corresponding author), Biomol Engn Res Inst, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 565, Japan.	morikawa@beri.co.jp		Tsutakawa, Susan/0000-0002-4918-4571				Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P4925, DOI 10.1093/nar/26.21.4925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1998, NAT STRUCT BIOL, V5, P697, DOI 10.1038/1394; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; GLASNER W, 1995, J MOL BIOL, V245, P1; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, J MOL BIOL, V190, P605, DOI 10.1016/0022-2836(86)90246-9; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Miller MD, 1999, J MOL BIOL, V288, P975, DOI 10.1006/jmbi.1999.2729; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Rasmussen LJ, 1998, CONT CANC RES, P205; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOHAIL A, 1990, J BACTERIOL, V172, P4214, DOI 10.1128/jb.172.8.4214-4221.1990; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	48	87	90	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					615	623		10.1016/S0092-8674(00)81550-0	http://dx.doi.org/10.1016/S0092-8674(00)81550-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612397	Bronze			2022-12-28	WOS:000084278700008
J	Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B				Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B			Induction of autophagy and inhibition of tumorigenesis by beclin 1	NATURE			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; CELLS; MECHANISMS; BRCA1; YEAST; FIBROBLASTS; VACUOLE	The process of autophagy, or bulk degradation of cellular proteins through an autophagosomic-lysosomal pathway(1), is important in normal growth control and may be defective in tumour cells(2) However, little is known about the genetic mediators of autophagy in mammalian cells or their role in tumour development. The mammalian gene encoding Beclin 1 (ref. 3), a novel Bcl-2-interacting, coiled-coil protein, has structural similarity to the yeast autophagy gene, apg6/vps30 (refs 4, 5), and is mono-allelically deleted in 40-75% of sporadic human breast cancers and ovarian cancers(6). Here we show using gene-transfer techniques, that beclin 1 promotes autophagy in autophagy-defective yeast with a targeted disruption of agp6/vps30, and in human MCF7 breast carcinoma cells. The autophagy-promoting activity of beclin 1 in MCF7 cells is associated with inhibition of MCF7 cellular proliferation, in vitro clonigenicity and tumorigenesis in nude mice. Furthermore, endogenous Beclin 1 protein expression is frequently low in human breast epithelial carcinoma cell lines and tissue, but is expressed ubiquitously at high levels in normal breast epithelia. Thus, beclin 1 is a mammalian autophagy gene that can inhibit tumorigenesis and is expressed at decreased levels in human breast carcinoma. These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Clin Mol Biol, D-81377 Munich, Germany	Columbia University; Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Levine, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	levine@cuccfa.ccc.columbia.edu	Kempkes, Bettina/B-3322-2013					Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADLEY MO, 1977, J BIOL CHEM, V252, P5310; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; EBLE R, 1992, BIOTECHNIQUES, V13, P18; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; GRONOSTAJSKI RM, 1984, J CELL PHYSIOL, V119, P127, DOI 10.1002/jcp.1041190120; GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JIANG W, 1993, ONCOGENE, V8, P3447; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501; KNECHT E, 1984, EXP CELL RES, V154, P224, DOI 10.1016/0014-4827(84)90682-7; LEE HK, 1992, ARCH BIOCHEM BIOPHYS, V296, P271, DOI 10.1016/0003-9861(92)90572-E; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; MITCHENER JS, 1976, AM J PATHOL, V83, P485; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; OTSUKA H, 1978, EXP CELL RES, V112, P127, DOI 10.1016/0014-4827(78)90533-5; ROMMENS JM, 1995, GENOMICS, V28, P530, DOI 10.1006/geno.1995.1185; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	27	2601	2802	4	416	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					672	676		10.1038/45257	http://dx.doi.org/10.1038/45257			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604474				2022-12-28	WOS:000084189800068
J	Hackman, R; Kapur, B; Koren, G				Hackman, R; Kapur, B; Koren, G			Use of the nicotine patch by pregnant women	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hackman, R (corresponding author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BENOWITZ NL, 1991, JAMA-J AM MED ASSOC, V266, P3174, DOI 10.1001/jama.266.22.3174; Lambers DS, 1996, SEMIN PERINATOL, V20, P115, DOI 10.1016/S0146-0005(96)80079-6; Reid RD, 1999, CAN MED ASSOC J, V160, P1577; *US PHARM CONV, 1915, DRUG INF HLTH CAR PR, V1, P1995	4	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1700	1700		10.1056/NEJM199911253412216	http://dx.doi.org/10.1056/NEJM199911253412216			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10610440				2022-12-28	WOS:000083847500020
J	Fulton, S; Woodside, B; Shizgal, P				Fulton, S; Woodside, B; Shizgal, P			Modulation of brain reward circuitry by leptin	SCIENCE			English	Article							MELANIN-CONCENTRATING HORMONE; HYPOTHALAMIC SELF-STIMULATION; RECEPTOR MESSENGER-RNA; FOOD-RESTRICTED RATS; OBESE GENE; LATERAL HYPOTHALAMUS; FEEDING-BEHAVIOR; NEUROPEPTIDE-Y; BODY-WEIGHT; PROTEIN	Leptin, a hormone secreted by fat cells, suppresses food intake and promotes weight Loss, To assess the action of this hormone on brain reward circuitry, changes in the rewarding effect of Lateral hypothalamic stimulation were measured after leptin administration. At five stimulation sites near the fornix, the effectiveness of the rewarding electrical stimulation was enhanced by chronic food restriction and attenuated by intracerebroventricular infusion of leptin. In contrast, the rewarding effect of stimulating neighboring sites was insensitive to chronic food restriction and was enhanced by leptin in three of four cases. These opposing effects of Leptin may mirror complementary changes in the rewarding effects of feeding and of competing behaviors.	Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Shizgal, P (corresponding author), Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.	shizgal@CSBN.concordia.ca	Shizgal, Peter/V-5602-2019; Shizgal, Peter/H-9823-2013	Shizgal, Peter/0000-0003-4265-0792; 				ABRAHAMSEN GC, 1995, BRAIN RES, V695, P186, DOI 10.1016/0006-8993(95)00764-H; Arvanitogiannis A, 1999, PHYSIOL BEHAV, V65, P805; Arvanitogiannis A, 1996, PHYSIOL BEHAV, V59, P795, DOI 10.1016/0031-9384(95)02157-4; BLUNDELL JE, 1968, NATURE, V219, P627, DOI 10.1038/219627a0; Broberger C, 1998, J COMP NEUROL, V402, P460; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CARR KD, 1993, BRAIN RES, V607, P141, DOI 10.1016/0006-8993(93)91499-I; CONOVER KL, 1994, BEHAV NEUROSCI, V108, P559; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; De Vaca SC, 1998, PHYSIOL BEHAV, V64, P251, DOI 10.1016/S0031-9384(98)00050-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Elmquist JK, 1998, J COMP NEUROL, V395, P535; FULTON S, UNPUB; GALLISTEL CR, 1987, PHARMACOL BIOCHEM BE, V26, P731, DOI 10.1016/0091-3057(87)90605-8; Gillard ER, 1998, J NEUROSCI, V18, P2646; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Horvath TL, 1999, J NEUROSCI, V19, P1072; LEIBOWITZ SF, 1979, BRAIN RES, V172, P115, DOI 10.1016/0006-8993(79)90899-0; LEIBOWITZ SF, 1975, BRAIN RES, V98, P529, DOI 10.1016/0006-8993(75)90371-6; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; OLDS ME, 1963, J COMP NEUROL, V120, P259, DOI 10.1002/cne.901200206; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; STANLEY BG, 1993, BRAIN RES, V604, P304; Watts AG, 1999, J NEUROSCI, V19, P6111, DOI 10.1523/JNEUROSCI.19-14-06111.1999; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	33	316	317	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					125	128		10.1126/science.287.5450.125	http://dx.doi.org/10.1126/science.287.5450.125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615045				2022-12-28	WOS:000084578400050
J	Edlow, JA; Caplan, LR				Edlow, JA; Caplan, LR			Primary care: Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THUNDERCLAP HEADACHE; COMPUTED-TOMOGRAPHY; LUMBAR PUNCTURE; INTRACRANIAL ANEURYSM; WARNING LEAK; CEREBROSPINAL-FLUID; SENTINEL HEADACHE; CEREBRAL ANEURYSM; DELAYED DIAGNOSIS; MINOR LEAK		Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Edlow, JA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, Finard 202,330 Brookline Ave, Boston, MA 02215 USA.	jonathan_edlow@hms.harvard.edu	Edlow, Jonathan A/F-7128-2016					ADAMS HP, 1980, JAMA-J AM MED ASSOC, V244, P794, DOI 10.1001/jama.244.8.794; ADAMS HP, 1983, NEUROLOGY, V33, P981, DOI 10.1212/WNL.33.8.981; ANDREOLI A, 1987, STROKE, V18, P558, DOI 10.1161/01.STR.18.3.558; Atlas SW, 1997, NEUROIMAG CLIN N AM, V7, P709; BALL MJ, 1975, CAN MED ASSOC J, V112, P78; BASSI P, 1991, ACTA NEUROL SCAND, V84, P277, DOI 10.1111/j.1600-0404.1991.tb04954.x; BURUMA OJS, 1981, J NEUROL NEUROSUR PS, V44, P144, DOI 10.1136/jnnp.44.2.144; DAY JW, 1986, LANCET, V2, P1247; deBruijn SFTM, 1996, LANCET, V348, P1623, DOI 10.1016/S0140-6736(96)07294-7; DHOPESH V, 1979, HEADACHE, V19, P37, DOI 10.1111/j.1526-4610.1979.hed1901037.x; DUFFY GP, 1983, MED J AUSTRALIA, V1, P514, DOI 10.5694/j.1326-5377.1983.tb136193.x; DUFFY GP, 1982, BRIT MED J, V285, P1163, DOI 10.1136/bmj.285.6349.1163; Evans RW, 1996, NEUROL CLIN, V14, P1, DOI 10.1016/S0733-8619(05)70240-1; FERRO JM, 1991, CEREBROVASC DIS, V1, P160, DOI 10.1159/000108834; Findlay JM, 1997, CAN J NEUROL SCI, V24, P161; FISHMAN RA, 1992, CEREBROSPINAL FLUID, P183; FRISHBERG BM, 1994, NEUROLOGY, V44, P1191, DOI 10.1212/WNL.44.7.1191; Fujii Y, 1996, J NEUROSURG, V84, P35, DOI 10.3171/jns.1996.84.1.0035; HARLING DW, 1989, CEPHALALGIA, V9, P87, DOI 10.1046/j.1468-2982.1989.0902087.x; HAUERBERG J, 1991, ACTA NEUROL SCAND, V83, P61; HILLMAN J, 1986, SURG NEUROL, V26, P547, DOI 10.1016/0090-3019(86)90337-X; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jakobsson KE, 1996, J NEUROSURG, V85, P995, DOI 10.3171/jns.1996.85.6.0995; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; KARCZ A, 1993, ANN EMERG MED, V22, P553, DOI 10.1016/S0196-0644(05)81941-9; Kasner SE, 1997, NEUROIMAG CLIN N AM, V7, P679; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1985, STROKE, V16, P587, DOI 10.1161/01.STR.16.4.587; LANG DT, 1990, AM J CLIN PATHOL, V93, P403, DOI 10.1093/ajcp/93.3.403; Latchaw RE, 1997, NEUROIMAG CLIN N AM, V7, P693; LEBLANC R, 1987, J NEUROSURG, V66, P35, DOI 10.3171/jns.1987.66.1.0035; LEICHT MJ, 1980, ANN EMERG MED, V9, P404, DOI 10.1016/S0196-0644(80)80152-1; LINN FHH, 1994, LANCET, V344, P590, DOI 10.1016/S0140-6736(94)91970-4; Linn FHH, 1998, J NEUROL NEUROSUR PS, V65, P791, DOI 10.1136/jnnp.65.5.791; MACDONALD A, 1988, J NEUROL NEUROSUR PS, V51, P342, DOI 10.1136/jnnp.51.3.342; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Mayer PL, 1996, STROKE, V27, P1558, DOI 10.1161/01.STR.27.9.1558; Morgenstern LB, 1998, ANN EMERG MED, V32, P297; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; NOGUCHI K, 1995, RADIOLOGY, V196, P773, DOI 10.1148/radiology.196.3.7644642; OKAWARA SH, 1973, J NEUROSURG, V38, P575, DOI 10.3171/jns.1973.38.5.0575; PAGE KB, 1994, J CLIN PATHOL, V47, P986, DOI 10.1136/jcp.47.11.986; Pascual J, 1996, NEUROLOGY, V46, P1520, DOI 10.1212/WNL.46.6.1520; RamirezLassepas M, 1997, ARCH NEUROL-CHICAGO, V54, P1506, DOI 10.1001/archneur.1997.00550240058013; RAPS EC, 1993, ARCH NEUROL-CHICAGO, V50, P265, DOI 10.1001/archneur.1993.00540030031010; ROOST KT, 1972, NEUROLOGY, V22, P973, DOI 10.1212/WNL.22.9.973; Rosenorn J, 1987, Br J Neurosurg, V1, P33, DOI 10.3109/02688698709034339; SAKAS DE, 1995, BRIT MED J, V310, P1186, DOI 10.1136/bmj.310.6988.1186; Sames TA, 1996, ACAD EMERG MED, V3, P16, DOI 10.1111/j.1553-2712.1996.tb03296.x; Schattner A, 1996, LANCET, V348, P411, DOI 10.1016/S0140-6736(05)65036-2; SCHIEVINK WI, 1988, SURG NEUROL, V29, P367, DOI 10.1016/0090-3019(88)90045-6; Schievink WI, 1997, NEW ENGL J MED, V336, P1267; SCHIEVINK WI, 1989, SURG NEUROL, V32, P266, DOI 10.1016/0090-3019(89)90228-0; Schriger DL, 1998, JAMA-J AM MED ASSOC, V279, P1293, DOI 10.1001/jama.279.16.1293; Schull MJ, 1999, ACAD EMERG MED, V6, P131, DOI 10.1111/j.1553-2712.1999.tb01051.x; SEYMOUR JJ, 1995, AM J EMERG MED, V13, P43, DOI 10.1016/0735-6757(95)90240-6; Sidman R, 1996, ACAD EMERG MED, V3, P827, DOI 10.1111/j.1553-2712.1996.tb03526.x; SMITH WP, 1981, AM J ROENTGENOL, V136, P543, DOI 10.2214/ajr.136.3.543; SODERSTROM C E, 1977, Stroke, V8, P606; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SVED PD, 1995, MED J AUSTRALIA, V162, P310, DOI 10.5694/j.1326-5377.1995.tb139907.x; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VANGIJN J, 1982, NEURORADIOLOGY, V23, P153, DOI 10.1007/BF00347559; VanGijn J, 1997, LANCET, V349, P1492, DOI 10.1016/S0140-6736(05)62095-8; Vermeulen M, 1996, J NEUROL, V243, P496, DOI 10.1007/BF00886869; VERMEULEN M, 1989, J NEUROL NEUROSUR PS, V52, P826, DOI 10.1136/jnnp.52.7.826; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; WEIR B, 1994, CEPHALALGIA, V14, P79, DOI 10.1046/j.1468-2982.1994.1402079.x; Weir B, 1998, SUBARACHNOID HEMORRH, P144; WIJDICKS EFM, 1988, LANCET, V2, P68; 1989, LANCET, V2, P658	73	315	320	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					29	36		10.1056/NEJM200001063420106	http://dx.doi.org/10.1056/NEJM200001063420106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620647				2022-12-28	WOS:000084575600006
J	Almond, DS; Green, CJ; Geurin, DM; Evans, S				Almond, DS; Green, CJ; Geurin, DM; Evans, S			Lesson of the week - Norwegian scabies misdiagnosed as an adverse drug reaction	BRITISH MEDICAL JOURNAL			English	Review							IVERMECTIN		Univ Liverpool, Dept Clin Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England; Liverpool John Moores Univ, Sch Pharm, Liverpool L3 3AF, Merseyside, England; Royal Liverpool Univ Hosp NHS Trust, Dept Pathol, Liverpool L7 8XP, Merseyside, England; Royal Liverpool Univ Hosp NHS Trust, Dept Dermatol, Liverpool L7 8XP, Merseyside, England; Broad Green Univ Hosp NHS Trust, Dept Pathol, Liverpool L7 8XP, Merseyside, England; Broad Green Univ Hosp NHS Trust, Dept Dermatol, Liverpool L7 8XP, Merseyside, England	University of Liverpool; Liverpool John Moores University; University of Liverpool; University of Liverpool	Almond, DS (corresponding author), Univ Liverpool, Dept Clin Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England.							Barkwell R, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63020-6; Bonomo RA, 1998, CLIN INFECT DIS, V27, P645, DOI 10.1086/517139; BURGESS IF, 1996, PRACTITIONER, V240, P739; HOPPER AH, 1990, AGE AGEING, V19, P125, DOI 10.1093/ageing/19.2.125; KOLAR KA, 1991, AM FAM PHYSICIAN, V44, P1317; MEINKING TL, 1995, NEW ENGL J MED, V333, P26, DOI 10.1056/NEJM199507063330105; SCLESINGER I, 1994, SO MED J, V87, P352; SHELLEY WB, 1988, J AM ACAD DERMATOL, V19, P673, DOI 10.1016/S0190-9622(88)70221-2	8	18	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					35	36		10.1136/bmj.320.7226.35	http://dx.doi.org/10.1136/bmj.320.7226.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617527	Green Published			2022-12-28	WOS:000084621600024
J	Fong, YM				Fong, YM			Doppler perfusion index in colorectal cancer	LANCET			English	Editorial Material							ADJUVANT THERAPY; FLUOROURACIL; LEVAMISOLE; CARCINOMA		Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.							DALY JM, 1984, ARCH SURG-CHICAGO, V119, P936; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Oppo K, 1998, RADIOLOGY, V208, P453, DOI 10.1148/radiology.208.2.9680575; Rosenberg SA., CANC PRINCIPLES PRAC, Ved, P895	5	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					5	6		10.1016/S0140-6736(99)00334-7	http://dx.doi.org/10.1016/S0140-6736(99)00334-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615880				2022-12-28	WOS:000085049200005
J	Marian, AJ				Marian, AJ			Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy	LANCET			English	Article							EXPRESSION; MUTATIONS; DEATH	Myocardial contractility is generally believed to be increased in hypertrophic cardiomyopathy. I propose the opposite-that cardiac myocyte contractility Is decreased in this disorder. Accordingly, the contractile deficit provides the primary stimulus for increased expression of trophic factors in the heart, which leads to hypertrophy, interstitial fibrosis, and other phenotypes. Variation among individuals in expression of trophic factors would account for the variability of phenotypes. Gene transfer studies in cardiac myocytes showing impaired contractility and increased expression of trophic factors in the myocardium of patients with hypertrophic cardiomyopathy support this hypothesis. Testing of the hypothesis would require measurement of contractility of cardiac myocytes isolated from patients with hypertrophic cardiomyopathy, identification of the main trophic factors in the hearts of these patients, and investigation of whether their inhibition can prevent or lead to regression of the cardiac phenotypes.	Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA	Baylor College of Medicine	Marian, AJ (corresponding author), Baylor Coll Med, Dept Med, Cardiol Sect, 1 Baylor Plaza,543E, Houston, TX 77030 USA.			Marian, AJ/0000-0002-1252-7120	NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abchee A, 1997, J INVEST MED, V45, P191; Brugada R, 1997, J INVEST MED, V45, P542; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; Hasegawa K, 1996, HYPERTENSION, V27, P259, DOI 10.1161/01.HYP.27.2.259; HIROTA Y, 1982, AM J CARDIOL, V50, P990, DOI 10.1016/0002-9149(82)90407-6; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; Li RK, 1997, CIRCULATION, V96, P874; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; MARIAN AJ, 1993, LANCET, V342, P1073; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; Tesson F, 1997, J MOL CELL CARDIOL, V29, P831, DOI 10.1006/jmcc.1996.0332; WYNNE J, 1992, HEART DISEASE TXB CA, P1394	15	168	197	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					58	60		10.1016/S0140-6736(99)06187-5	http://dx.doi.org/10.1016/S0140-6736(99)06187-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615904				2022-12-28	WOS:000085049200041
J	Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM				Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM			Effect of socioeconomic deprivation on waiting time for cardiac surgery: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article						a	REVASCULARIZATION RATES; CORONARY; ACCESS	Objective To determine whether the priority given to patients referred for cardiac surgery is associated with socioeconomic status. Design Retrospective study with multivariate logistic regression analysis of the association between deprivation and classification of urgency with allowance for age, sex, and type of operation. Multivariate linear regression analysis was used to determine association between deprivation and waiting time within each category of urgency, with allowance for age, sex, and type of operation. Setting NHS waiting lists in Scotland. Participants 26 642 patients waiting for cardiac surgery, 1 January 1986 to 31 December 1997. Main outcome measures Deprivation as measured by Carstairs deprivation category. Time spent on NHS waiting list. Results Patients who were most deprived tended to be younger and were more likely to be female. Patients in deprivation categories 6 and 7 (most deprived) waited about three weeks longer for surgery than those in category 1 (mean difference 24 days, 95% confidence interval 15 to 32), Deprived patients had an odds ratio of 0.5 (0.46 to 0.61) for having their operations classified as urgent compared with the least deprived, after allowance for age, sex, and type of operation. When urgent and routine cases were considered separately, there was no significant difference in waiting times between the most and least deprived categories. Conclusions Socioeconomically deprived patients are thought to be more likely to develop coronary heart disease but are less likely to be investigated and offered surgery once it has developed. Such patients may be further disadvantaged by having to wait longer for surgery because of being given lower priority.	Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland; Monklands Hosp, Dept Cardiol, Airdrie ML6 0JS, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	Royal Infirmary of Edinburgh; Monklands Hospital; University of Glasgow	Pell, JP (corresponding author), Greater Glasgow Hlth Board, Dalian House,350 St Vincents St, Glasgow G3 8YU, Lanark, Scotland.		Ford, Ian/ABE-6145-2020	Pell, Jill/0000-0002-8898-7035				BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; Carstairs V., 1991, DEPRIVATION HLTH SCO; DREVER F, 1996, POPUL TRENDS, V86, P15; DREVER F, 1997, HLTH INEQUALITIES; FINDLAY IN, 1990, BRIT HEART J, V64, P43; FINDLAY IN, 1991, BRIT HEART J, V66, pA70; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; KAGUSKAR S, 1997, CORONARY HEART DIS S; Keskimaki I, 1997, EUR J PUBLIC HEALTH, V7, P392, DOI 10.1093/eurpub/7.4.392; MacLeod MCM, 1999, HEART, V81, P252, DOI 10.1136/hrt.81.3.252; Manson-Siddle CJ, 1998, J EPIDEMIOL COMMUN H, V52, P507, DOI 10.1136/jech.52.8.507; *OFF POP CENS SURV, 1995, 1991 CENS; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3	14	84	84	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					15	18		10.1136/bmj.320.7226.15	http://dx.doi.org/10.1136/bmj.320.7226.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617517	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000084621600014
J	Watkins, SJ				Watkins, SJ			Conviction by mathematical error? Doctors and lawyers should get probability theory right	BRITISH MEDICAL JOURNAL			English	Editorial Material							INFANT-DEATH-SYNDROME; SUBSEQUENT SIBLINGS; RECURRENCE RISK; SUDDEN		Stockport Hlth Author, Stockport SK7 5BY, England		Watkins, SJ (corresponding author), Stockport Hlth Author, Stockport SK7 5BY, England.							BEAL SM, 1988, ARCH DIS CHILD, V63, P924, DOI 10.1136/adc.63.8.924; EMERY JL, 1986, LANCET, V1, P313; GUNTHEROTH WG, 1990, J PEDIATR-US, V116, P520, DOI 10.1016/S0022-3476(05)81596-3; IRGENS LM, 1984, J PEDIATR-US, V104, P349, DOI 10.1016/S0022-3476(84)81093-8; McKenzie G, 1984, BR J SOC PREV MED, V25, P119; Oyen N, 1996, AM J EPIDEMIOL, V144, P300, DOI 10.1093/oxfordjournals.aje.a008925; PETERSON DR, 1986, J PEDIATR-US, V108, P911, DOI 10.1016/S0022-3476(86)80926-X; REESE A, 1999, STAT JUSTICE; WOLKIND S, 1993, ACTA PAEDIATR, V82, P873, DOI 10.1111/j.1651-2227.1993.tb12583.x	9	30	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					2	3		10.1136/bmj.320.7226.2	http://dx.doi.org/10.1136/bmj.320.7226.2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617504	Green Published			2022-12-28	WOS:000084621600002
J	Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE				Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE			Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa	LANCET			English	Article							FAILURE	Background Recurrent epidemics of meningococcal disease have been reported throughout the African meningitis belt since description of the disease in 1912, Meningococcal polysaccharide vaccines can effectively prevent disease but the optimum strategy for their use in this setting has been controversial. We used data from an outbreak of meningococcal disease in northern Ghana in 1997 to assess the potential effect of different vaccination strategies. Methods We identified all reported cases of meningococcal meningitis and estimated the number of cases and deaths that could have been prevented by vaccination through use of a simple mathematical model. We then assessed the potential effect of different vaccination strategies and the burden of these strategies on the public-health system. Findings In the three affected regions in northern Ghana there were 18 703 cases and 1356 deaths reported between November, 1996, and May, 1997. Vaccination began in the third week of February and continued to April, reaching 72% of the at-risk population and preventing an estimated 23% of cases and 18% of deaths. A strategy of routine childhood and adult immunisation would have prevented 61% of cases had this same rate of vaccine coverage been achieved and maintained before the epidemic. If vaccination had started after the onset of the epidemic in January, as currently advocated by WHO guidelines, a similar proportion (61%) of cases could have been prevented. Interpretation Prevention of epidemics of meningococal disease in west Africa will be difficult until long-lasting conjugate vaccines capable of interrupting transmission of Neisseria meningitidis can be incorporated into routine infant-immunisation schedules, Until then, the strategy of surveillance and response advocated by WHO is as effective and more practical than a strategy of routine childhood and adult vaccination with currently available polysaccharide vaccines.	Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Surveillance, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ghana Minist Hlth, Accra, Ghana	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Rosenstein, NE (corresponding author), Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS-C23, Atlanta, GA 30333 USA.		Sackey, Samuel Oko/I-9207-2019					ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297; CAMPAGNE G, 1997, INT C ANT AG CHEM SA; *COMM DIS CTR, 1999, MMWR-MORBID MORTAL W, V48, P513; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Kaninda AV, 1997, LANCET, V350, P1708, DOI 10.1016/S0140-6736(05)64315-2; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; Lapeyssonnie L., 1963, B WHO              S, V28, P3; LEAKE JAD, 1998, INT C EM INF DIS ATL; MOORE PS, 1992, INT J EPIDEMIOL, V21, P155, DOI 10.1093/ije/21.1.155; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; REIDO FX, 1995, PEDIATR INFECT DIS J, V14, P643; REINGOLD AL, 1985, LANCET, V2, P114; Robbins JB, 1997, LANCET, V350, P880, DOI 10.1016/S0140-6736(97)03227-3; SMITH AW, 1988, T ROY SOC TROP MED H, V82, P312, DOI 10.1016/0035-9203(88)90459-2; SPIEGEL A, 1993, B WORLD HEALTH ORGAN, V71, P311; TWUMASI PA, 1995, J INFECT DIS, V171, P632, DOI 10.1093/infdis/171.3.632; VARAINE F, 1997, T R SOC TROP MED HYG, V51, P3; Veeken H, 1998, B WORLD HEALTH ORGAN, V76, P135; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; Wenger J, 1997, LANCET, V350, P1709, DOI 10.1016/S0140-6736(05)64316-4; *WHO, 1995, CONTR MEN DIS WHO PR; WILKINS J, 1979, PEDIATRICS, V94, P828; World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P313	26	58	59	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					30	33		10.1016/S0140-6736(99)03366-8	http://dx.doi.org/10.1016/S0140-6736(99)03366-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615888				2022-12-28	WOS:000085049200013
J	Carter, AJ				Carter, AJ			Dwale: an anaesthetic from old England	BRITISH MEDICAL JOURNAL			English	Article									N Staffordshire Hosp, Dept Anaesthet, Stoke On Trent ST4 6QG, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Carter, AJ (corresponding author), N Staffordshire Hosp, Dept Anaesthet, Stoke On Trent ST4 6QG, Staffs, England.							BOWMAN WC, 1963, J PHARM PHARMACOL, V15, pI25; CAMERON ML, 1993, ANGLOSAXON MED, P12; Carter AJ, 1996, BRIT MED J, V313, P1630, DOI 10.1136/bmj.313.7072.1630; CONNOR RD, 1987, WEIGHTS MEASURES ENG, P125; DREISBACH RH, 1987, HDB POISONING, P499; DRUMMER OH, 1995, MED J AUSTRALIA, V162, P592, DOI 10.5694/j.1326-5377.1995.tb138553.x; ELLIS ES, 1946, ANCIENT ANODYNES, P82; GRIEVE M, 1931, MODERN HERBAL, V2, P476; HUSON P, 1970, MASTERING WITCHCRAFT, P146; KEYS TE, 1945, HIST SURG ANAESTHESI, P104; MANN J, 1992, MURDER MAGIC MED, P76; MURRAY JAH, 1897, NEW ENGLISH DICT, P488; RAWCLIFFE C, 1997, MED SOC LATER MEDIEV, P184; VICARY R, 1995, DIST PLANT LORE, P393; VOIGTS LE, 1992, HEALTH, DISEASE AND HEALING IN MEDIEVAL CULTURE, P34; 1981, READERS DIGEST, P157	16	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1623	1626		10.1136/bmj.319.7225.1623	http://dx.doi.org/10.1136/bmj.319.7225.1623			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600971	Green Published			2022-12-28	WOS:000084562600023
J	Cheetham, GMT; Steitz, TA				Cheetham, GMT; Steitz, TA			Structure of a transcribing T7 RNA polymerase initiation complex	SCIENCE			English	Article							DNA-POLYMERASE; T7-RNA POLYMERASE; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; BINDING-SITES; PROMOTER; BACTERIOPHAGE-T7; REPLICATION; MITOCHONDRIAL	The structure of a T7 RNA polymerase (T7 RNAP) initiation complex captured transcribing a trinucleotide of RNA from a 17-base pair promoter DNA containing a 5-nucleotide single-strand template extension was determined at a resolution of 2.4 angstroms, Binding of the upstream duplex portion of the promoter occurs in the same manner as that in the open promoter complex. but the single-stranded template is repositioned to place the +4 base at the catalytic active site. Thus, synthesis of RNA in the initiation phase Leads to accumulation or "scrunching" of the template in the enclosed active site pocket of T7 RNAP, Only three base pairs of heteroduplex are formed before the RNA peels off the template.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lykke-Andersen J, 1998, NUCLEIC ACIDS RES, V26, P5630, DOI 10.1093/nar/26.24.5630; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; RECHINSKY VO, 1992, FEBS LETT, V306, P129, DOI 10.1016/0014-5793(92)80983-N; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2	37	277	290	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2305	2309		10.1126/science.286.5448.2305	http://dx.doi.org/10.1126/science.286.5448.2305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600732				2022-12-28	WOS:000084318500049
J	Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ				Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ			Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGENIC DETERMINANTS; MAXIMUM-LIKELIHOOD; E-GLYCOPROTEIN; DNA-SEQUENCES; IDENTIFICATION; EVOLUTION; TREES; KUNJIN; GENE	In Late summer 1999, an outbreak of human encephalitis occurred in the northeastern United States that was concurrent with extensive mortality in crows (Corvus species) as well as the deaths of several exotic birds at a zoological park in the same area. Complete genome sequencing of a flavivirus isolated from the brain of a dead Chilean flamingo (Phoenicopterus chilensis), together with partial sequence analysis of envelope glycoprotein (E-glycoprotein) genes amplified from several other species including mosquitoes and two fatal human cases, revealed that West Nile (WN) virus circulated in natural transmission cycles and was responsible for the human disease. Antigenic mapping with E-glycoprotein-specific monoclonal antibodies and E-glycoprotein phylogenetic analysis confirmed these viruses as WN. This North American WN virus was most closely related to a WN virus isolated from a dead goose in Israel in 1998.	Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA; Inst Pasteur, Unite Arbovirus & Virus Fievres Hemorragiques, F-75724 Paris 15, France; USA, Med Res Inst Infect Dis, Div Virol & Pathol, Frederick, MD 21701 USA; USA, Med Res Inst Infect Dis, Div Virol, Frederick, MD 21701 USA; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; USDA, Natl Vet Serv Labs, Anim & Plant Hlth Inspect Serv, Ames, IA 50010 USA; Minist Agr & Rural Dev, Kimron Vet Inst, Div Avian Dis, IL-50250 Bet Dagan, Israel; New York State Dept Environm Conservat, Div Fish Wildlife & Marine Resources, Wildlife Pathol Unit, Delmar, NY 12054 USA; Wildlife Conservat Soc, Bronx, NY 10460 USA	Centers for Disease Control & Prevention - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Queensland; United States Department of Agriculture (USDA); Kimron Veterinary Institute; Wildlife Conservation Society	Lanciotti, RS (corresponding author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA.		/S-4986-2019; Smith, Jane/B-6254-2009	/0000-0002-5918-2190; Roehrig, John/0000-0001-7581-0479				ADAMS SC, 1995, VIROLOGY, V206, P49, DOI 10.1016/S0042-6822(95)80018-2; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548; GOULD EA, 1990, ARCH VIROL, V1, P137; HALL RA, 1991, IMMUNOL CELL BIOL, V69, P47, DOI 10.1038/icb.1991.7; HAWKES RA, 1988, J GEN VIROL, V69, P1105, DOI 10.1099/0022-1317-69-5-1105; HENCHAL EA, 1985, AM J TROP MED HYG, V34, P162, DOI 10.4269/ajtmh.1985.34.162; Kumar S., 1993, MEGA MOL EVOLUTIONAR; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1983, VIROLOGY, V128, P118, DOI 10.1016/0042-6822(83)90323-9; ROEHRIG JT, 1990, AM J TROP MED HYG, V42, P394, DOI 10.4269/ajtmh.1990.42.394; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; RZHETSKY A, 1993, MOL BIOL EVOL, V10, P1073; SAVAGE HM, IN PRESS AM J TROP M; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872	21	1164	1243	1	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2333	2337		10.1126/science.286.5448.2333	http://dx.doi.org/10.1126/science.286.5448.2333			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600742				2022-12-28	WOS:000084318500059
J	Josefson, D				Josefson, D			COX 2 inhibitors can affect the stomach lining	BRITISH MEDICAL JOURNAL			English	News Item																		Shiff SJ, 1999, NAT MED, V5, P1348, DOI 10.1038/70909; 1999, NATURE MED, V5, P1415	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1518	1518		10.1136/bmj.319.7224.1518	http://dx.doi.org/10.1136/bmj.319.7224.1518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591696	Green Published			2022-12-28	WOS:000084245600007
J	Salama, P; Laurence, B; Nolan, ML				Salama, P; Laurence, B; Nolan, ML			Health and human rights in contemporary humanitarian crises: is Kosovo more important than Sierra Leone?	BRITISH MEDICAL JOURNAL			English	Article									Concern, Dublin 2, Ireland; Med Emergency Relief Int, MERLIN, London W1M 1HW, England		Salama, P (corresponding author), Concern, Lower Camden ST, Dublin 2, Ireland.							*ACT FAIM FRANC, 1999, REP RAP ASS MAK DIST; *AMN INT, 1999, SIERR LEON 1998 YEAR; ANNAN K, 1999, 7 UNSC; ANNAN K, 1999, 7 UNSC, P46; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; GASSER HP, 1993, INT HUM LAW INTRO; GRACA M, 1996, A51306 UN; HAVEL V, 1999, NY REV          0610; *HUM RIGHTS WATCH, 1999, WORLD REP; Human Rights Watch, 1999, SIERR LEON GETT AW M, V11; Iacopino V, 1999, JAMA-J AM MED ASSOC, V282, P479, DOI 10.1001/jama.282.5.479; *MED EM REFL INT, 1999, SIERR LEON NUTR SURV; *MED EM REL INT, 1999, MERLIN REP 2 STAG NU; Meddings D, 1998, BRIT MED J, V317, P1249; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; Onishi N, 1999, NY TIMES INT    0822, P3; PLATTNER D, 1992, INT REV RED CROSS, V291, P567; RICHARDS P, 1996, AFRICAN ISSUES FIGHT; SANTABARBARA J, 1997, WAR PUBLIC HLTH, P168; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; TOOLE MJ, 1997, PUBLIC HLTH CONSEQUE, P419; *UN FAO, 1999, REP FOOD SUPPL SIT C; *US AG INT DEV, 1999, 17 USAID; Vincent, 1996, Health Hum Rights, V2, P25, DOI 10.2307/4065233; Vranic S., 1996, BREAKING WALL SILENC	25	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1569	1571		10.1136/bmj.319.7224.1569	http://dx.doi.org/10.1136/bmj.319.7224.1569			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591728	Green Published			2022-12-28	WOS:000084245600032
J	Lee, SH; Hava, DL; Waldor, MK; Camilli, A				Lee, SH; Hava, DL; Waldor, MK; Camilli, A			Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TOXIN-COREGULATED PILUS; SUICIDE VECTOR; EL-TOR; REGULON; CONSTRUCTION; COLONIZATION; ACTIVATION; IDENTIFY; PROMOTER	The temporal expression patterns of the critical Vibrio cholerae virulence genes, tcpA and ctxA, were determined during infection using a recombinase reporter. TcpA was induced biphasically in two temporally and spatially separable events in the small intestine, whereas ctxA was induced monophasically only after, and remarkably, dependent upon, tcpA expression; however, this dependence was not observed during in vitro growth. The requirements of the virulence regulators, ToxR, TcpP, and ToxT, for expression of tcpA and ctxA were determined and were found to differ significantly during infection versus during growth in vitro. These results illustrate the importance of examining virulence gene expression in the context of bona fide host-pathogen interactions.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA	Tufts University; Tufts University	Camilli, A (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.				NIAID NIH HHS [AI 07422, AI 40262, AI 42347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040262, R01AI042347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angelichio MJ, 1999, INFECT IMMUN, V67, P3733, DOI 10.1128/IAI.67.8.3733-3739.1999; Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CAMILLI A, 1994, P NATL ACAD SCI USA, V91, P2634, DOI 10.1073/pnas.91.7.2634; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; Chakrabarti S, 1999, INFECT IMMUN, V67, P1025, DOI 10.1128/IAI.67.3.1025-1033.1999; Champion GA, 1997, MOL MICROBIOL, V23, P323, DOI 10.1046/j.1365-2958.1997.2191585.x; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Davis BM, 1999, J BACTERIOL, V181, P6779, DOI 10.1128/JB.181.21.6779-6787.1999; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; HIGGINS DE, 1994, MOL MICROBIOL, V14, P17, DOI 10.1111/j.1365-2958.1994.tb01263.x; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; IWANAGA M, 1986, MICROBIOL IMMUNOL, V30, P1075, DOI 10.1111/j.1348-0421.1986.tb03037.x; Klose KE, 1998, J BACTERIOL, V180, P303, DOI 10.1128/JB.180.2.303-316.1998; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Medrano AI, 1999, INFECT IMMUN, V67, P2178, DOI 10.1128/IAI.67.5.2178-2183.1999; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schuhmacher DA, 1999, J BACTERIOL, V181, P1508, DOI 10.1128/JB.181.5.1508-1514.1999; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SUN D, 1991, INFECT IMMUN, V59, P114, DOI 10.1128/IAI.59.1.114-118.1991; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	30	220	232	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					625	634		10.1016/S0092-8674(00)81551-2	http://dx.doi.org/10.1016/S0092-8674(00)81551-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612398	Bronze			2022-12-28	WOS:000084278700009
J	Beck, T; Hall, MN				Beck, T; Hall, MN			The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; KINASE; RAPAMYCIN; PROTEINS; MODULES; STRESS; GROWTH; MSN2P	The rapamycin-sensitive TOR signalling pathway in Saccharomyces cerevisiae activates a cell-growth program in response to nutrients such as nitrogen and carbon(1-4). The TOR1 and TOR2 kinases (TOR) control cytoplasmic protein synthesis and degradation through the conserved TAP42 protein(5-8). Upon phosphorylation by TOR, TAP42 binds and possibly inhibits type 2A and type-2A-related phosphatases(6-8); however, the mechanism by which TOR controls nuclear events such as global repression of starvation-specific transcription is unknown. Here we show that TOR prevents transcription of genes expressed upon nitrogen limitation by promoting the association of the GATA transcription factor GLN3 with the cytoplasmic protein URE2. The binding of GLN3 to URE2 requires TOR-dependent phosphorylation of GLN3, Phosphorylation and cytoplasmic retention of GLN3 are also dependent on the TOR effector TAP42, and are antagonized by the type-2A-related phosphatase SIT4. TOR inhibits expression of carbon-source-regulated genes by stimulating the binding of the transcriptional activators MSN2 and MSN4 to the cytoplasmic 14-3-3 protein BMH2, Thus, the TOR signalling pathway broadly controls nutrient metabolism by sequestering several transcription factors in the cytoplasm.	Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland.			Hall, Michael N/0000-0002-2998-0757				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Hara K, 1998, J BIOL CHEM, V273, P22160; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHERMAN F, 1991, P3; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	26	771	789	3	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					689	692		10.1038/45287	http://dx.doi.org/10.1038/45287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604478				2022-12-28	WOS:000084189800072
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1983: Barbara McClintock (1902-92)	LANCET			English	Article											Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					2007	2007		10.1016/S0140-6736(05)76787-8	http://dx.doi.org/10.1016/S0140-6736(05)76787-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622337				2022-12-28	WOS:000084034700070
J	[Anonymous]				[Anonymous]			Cell surgery	SCIENCE			English	Editorial Material																		Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1498	1498		10.1126/science.286.5444.1498	http://dx.doi.org/10.1126/science.286.5444.1498			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610553				2022-12-28	WOS:000083768300039
J	Bhattacharya, S; Hall, M				Bhattacharya, S; Hall, M			Cost-effective treatment of couples with subfertility	LANCET			English	Editorial Material							INFERTILE		Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Bhattacharya, S (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen AB25 2ZD, Scotland.			Bhattacharya, Siladitya/0000-0002-4588-356X				Botting B, 1990, 3 4 MORE STUDY TRIPL; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; COHLEN BJ, 1999, COCHRANE LIB; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; Hughes EG, 1997, HUM REPROD, V12, P1865, DOI 10.1093/humrep/12.9.1865; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; Van Voorhis BJ, 1998, FERTIL STERIL, V70, P995, DOI 10.1016/S0015-0282(98)00341-0	7	4	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2000	355	9197					2	2		10.1016/S0140-6736(99)00467-5	http://dx.doi.org/10.1016/S0140-6736(99)00467-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615877				2022-12-28	WOS:000085049200002
J	Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G				Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G			Cortical mechanisms of human imitation	SCIENCE			English	Article							AUTOMATED IMAGE REGISTRATION; GRASP REPRESENTATIONS; PREMOTOR CORTEX; AREA 5; MONKEY; BRAIN; CONSCIOUSNESS; LOCALIZATION; RECOGNITION; VALIDATION	How does imitation occur? How can the motor plans necessary for imitating an action derive from the observation of that: action? Imitation may be based on a mechanism directly matching the observed action onto an internal motor representation of that action ("direct matching hypothesis"). To test this hypothesis, normal human participants were asked to observe and imitate a finger movement and to perform the same movement after spatial or symbolic cues. Brain activity was measured with functional magnetic resonance imaging. If the direct matching hypothesis is correct, there should be areas that become active during finger movement; regardless of how it is evoked, and their activation should increase when the same movement is elicited by the observation of an identical movement made by another individual. Two areas with these properties were found in the left; inferior frontal cortex (opercular region) and the rostral-most region of the right superior parietal lobule.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Max Planck Inst Psychol Res, Dept Cognit & Act, D-80802 Munich, Germany; Univ Parma, Inst Human Physiol, I-43100 Parma, Italy	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Max Planck Society; University of Parma	Iacoboni, M (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA.		Brass, Marcel/J-7082-2012; Bekkering, Harold/A-6357-2009; Galantucci, Bruno/E-5770-2010	Brass, Marcel/0000-0002-3364-4019; 				Berlucchi G, 1997, TRENDS NEUROSCI, V20, P560, DOI 10.1016/S0166-2236(97)01136-3; Binkofski F, 1999, EUR J NEUROSCI, V11, P3276, DOI 10.1046/j.1460-9568.1999.00753.x; Binkofski F, 1999, EXP BRAIN RES, V128, P210, DOI 10.1007/s002210050838; BRASS M, IN PRESS ACTA PSYCHO; BRASS M, IN PRESS BRAIN COGN; BRYNE RW, 1995, THINKING APE EVOLUTI; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; De Renzi E., 1990, HDB CLIN NEUROPSYCHO, V2, P245; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; FRITH C, 1995, BEHAV BRAIN SCI, V18, P682, DOI 10.1017/S0140525X00040474; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Georgieff N, 1998, CONSCIOUS COGN, V7, P465, DOI 10.1006/ccog.1998.0367; Gewirtz J.L, 1969, HDB SOCIALIZATION TH, P57; GEWIRTZ JL, 1968, PSYCHOL REV, V75, P374, DOI 10.1037/h0026378; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Goldenberg G, 1997, NEUROPSYCHOLOGIA, V35, P333, DOI 10.1016/S0028-3932(96)00085-1; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Grezes J, 1998, COGN NEUROPSYCHOL, V15, P553, DOI 10.1080/026432998381023; Head H, 1920, BRAIN, V43, P87, DOI 10.1093/brain/43.2.87; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; KEPHART NC, 1971, SLOW LEARNER CLASSRO; Krams M, 1998, EXP BRAIN RES, V120, P386, DOI 10.1007/s002210050412; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MELTZOFF AN, 1983, CHILD DEV, V54, P702, DOI 10.2307/1130058; Menon RS, 1999, TRENDS COGN SCI, V3, P207, DOI 10.1016/S1364-6613(99)01329-7; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pawlby S. J, 1977, STUDIES MOTHER INFAN, P203; Petrides M., 1994, HDB NEUROPSYCHOLOGY, V9, P17; Piaget J., 1962, PLAY DREAMS IMITATIO; Preuss Todd M., 1995, P1227; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1999, ARCH ITAL BIOL, V137, P85; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; SCHOFIELD WN, 1976, Q J EXP PSYCHOL, V28, P571, DOI 10.1080/14640747608400584; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; von Bonin G., 1947, NEOCORTEX MACACA MUL; Woods R. P., 1996, QUANTIFICATION BRAIN, P353, DOI [10.1016/B978-012389760-2/50070-0, DOI 10.1016/B978-012389760-2/50070-0]; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Woods RP, 1999, HUM BRAIN MAPP, V8, P73, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<73::AID-HBM1>3.0.CO;2-7; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Zaidel E, 1996, BRAIN, V119, P2155, DOI 10.1093/brain/119.6.2155-a	47	1848	1895	5	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2526	2528		10.1126/science.286.5449.2526	http://dx.doi.org/10.1126/science.286.5449.2526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617472				2022-12-28	WOS:000084429700055
J	Woolf, SH				Woolf, SH			The need for perspective in evidence-based medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; HEALTH-CARE; COST-EFFECTIVENESS; NATIONAL PATTERNS; PHYSICAL-ACTIVITY; LIFE EXPECTANCY; RISK-FACTORS; MORTALITY	Research advances are generating a growing body of clinical trial and other data on the effects of tests and treatments on outcomes, but there is no information resource within the health care system that systematically puts that information in perspective. Policy makers, clinicians, and individuals lack a ready means to compare the relative effectiveness of various interventions in prolonging survival or preventing the occurrence or complications of a disease: information that is critical in setting priorities. A crude analysis of preventable deaths suggests that evidence-based primary prevention (getting the population to stop smoking, exercise, lower cholesterol levels, and control blood pressure) would prevent considerably more deaths per year than would various evidence-based treatments for cardiovascular disease. Examining evidence from this perspective calls attention to mismatched priorities-most health care expenditures in the United States go toward treatment of diseases and their late-stage complications and relatively few resources are devoted to primary prevention and health promotion. Similar analyses at the individual level can help patients put personal options in perspective. This article proposes a bibliographic evidence-collection center and simulation modeling program to estimate potential benefits and harms of competing interventions for populations and individuals. Such evidence-based projections would enable policy makers, clinicians, and patients to judge whether they give due priority to the interventions most likely to improve health. With the steady growth in research data, the need for a system that enables society and individuals to put evidence in perspective will become progressively more urgent.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Family Practice, Fairfax, VA 22033 USA	Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Family Practice, 3712 Charles Stewart Dr, Fairfax, VA 22033 USA.	shwoolf@aol.com						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *AM HEART ASS, 1999, CHOL OTH LIP; [Anonymous], 1996, JAMA, V276, P241; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P659; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; BUNKER JP, 1994, MILBANK Q, V72, P225, DOI 10.2307/3350295; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P645; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P673; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P825; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P529; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P797; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P633; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P107; Clarke M, 1998, LANCET, V351, P1451; *COCHR COLL, 1999, COCHR REV CD ROM; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cowen ME, 1996, MED CARE, V34, P264, DOI 10.1097/00005650-199603000-00006; *DARTM MED SCH CTR, 1996, DARTM ATL HLTH CAR; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; Frankel, 1996, PRIORITY SETTING HLT; FURBERG CD, 1994, PREV MED, V23, P599, DOI 10.1006/pmed.1994.1096; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GARG R, 1995, JAMA-J AM MED ASSOC, V274, P462; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GORELICK PB, 1994, STROKE, V25, P220, DOI 10.1161/01.STR.25.1.220; Gould AL, 1998, CIRCULATION, V97, P946; GUNNINGSCHEPERS L, 1989, HEALTH POLICY, V12, P1; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Klein R., 1996, MANAGING SCARCITY; KLEIN RW, 1993, MED DECIS MAKING, V13, P347, DOI 10.1177/0272989X9301300411; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Naidoo B, 1997, J EPIDEMIOL COMMUN H, V51, P144, DOI 10.1136/jech.51.2.144; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; *NAT CANC I, 1999, SEER CANC STAT REV 1; *NAT COMM QUAL ASS, 1999, SEL NAT AV; *NAT CTR HLTH STAT, 1998, HLTH US 1998 SOC STA; *NAT CTR HLTH STAT, 1996, PHS PUBL; *NAT I PUBL HLTH E, 1997, PUBL HLTH STAT FOR H; *NCI, 1999, SEER CANC STAT REV 1; *NCI, CANC RAT RISKS; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; Peters K D, 1998, Natl Vital Stat Rep, V47, P1; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Rafferty M, 1998, WESTERN J MED, V169, P269; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Sackett D. L., 1997, EVIDENCE BASED MED P; Schauffler HH, 1998, AM J PREV MED, V14, P161, DOI 10.1016/S0749-3797(97)00029-9; Stafford RS, 1997, ARCH INTERN MED, V157, P2460, DOI 10.1001/archinte.157.21.2460; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Stange KC, 1998, J FAM PRACTICE, V46, P377; STEVENS A, 1997, HLTH CARE NEEDS ASSE; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; TEUTSCH S M, 1992, Morbidity and Mortality Weekly Report, V41, P1; Towler B, 1998, BRIT MED J, V317, P559, DOI 10.1136/bmj.317.7158.559; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WOODWELL DA, 1997, 295 VIT HLTH STAT; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	70	68	70	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2358	2365		10.1001/jama.282.24.2358	http://dx.doi.org/10.1001/jama.282.24.2358			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	265TK	10612327				2022-12-28	WOS:000084261700033
J	Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW				Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW			Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis - A case series	ANNALS OF INTERNAL MEDICINE			English	Article							URSODEOXYCHOLIC ACID; CONTROLLED TRIAL	Background: No established medical therapy alters the progressive course of primary sclerosing cholangitis. Objective: To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis. Design: Case series. Setting: University hospital in Mainz, Germany. Patients: 15 patients with primary sclerosing cholangitis. Intervention: Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day). Measurements: Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a >30% change in stenosis was considered significant). Results: After a median observation period of 41 months (range, 3 to 81 months), liver enzyme levels declined significantly in all patients. Six of 10 patients with follow-up liver biopsies showed histologic improvement. Significant radiographic deterioration was seen in only 1 of 10 patients who had endoscopic retrograde cholangiography. In 7 patients previously treated with UDCA alone, liver enzyme levels declined significantly only after immunosuppressive therapy was added. Adverse drug reactions led to the withdrawal of study medications in 2 patients. Conclusions: Combined immunosuppressive therapy may alter the progression of primary sclerosing cholangitis. Our observations suggest a benefit from adding immunosuppressive drugs to UDCA therapy. A randomized trial is warranted.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Lohse, AW (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, Langenbeckstr 1, D-55131 Mainz, Germany.			Schramm, Christoph/0000-0002-4264-1928				BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; BURGERT SL, 1984, GASTROENTEROLOGY, V86, P1037; CHAPMAN RW, 1991, SEMIN LIVER DIS, V11, P1, DOI 10.1055/s-2008-1040415; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; HAYASHI H, 1990, GASTROENTEROLOGY, V99, P533, DOI 10.1016/0016-5085(90)91038-8; JAVETT SL, 1971, LANCET, V1, P810; Kaplan MM, 1997, NEW ENGL J MED, V336, P719, DOI 10.1056/NEJM199703063361009; KNOX TA, 1994, GASTROENTEROLOGY, V106, P494, DOI 10.1016/0016-5085(94)90610-6; LARUSSO NF, 1988, GASTROENTEROLOGY, V95, P1036, DOI 10.1016/0016-5085(88)90180-1; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; MENDEL R, 1985, RADIOLOGE, V25, P83; MYERS RN, 1970, AM J GASTROENTEROL, V53, P527; OLSSON R, 1995, GASTROENTEROLOGY, V108, P1199, DOI 10.1016/0016-5085(95)90220-1; Stiehl A, 1997, J HEPATOL, V26, P560, DOI 10.1016/S0168-8278(97)80421-7; VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P455; WAGNER A, 1971, LANCET, V2, P663; WIESNER RH, 1994, MAYO CLIN PROC, V69, P969, DOI 10.1016/S0025-6196(12)61822-9; WIESNER RH, 1991, HEPATOLOGY, V14, pA63	20	79	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					943	946		10.7326/0003-4819-131-12-199912210-00006	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610645				2022-12-28	WOS:000084374400005
J	Mindel, A; Tideman, R				Mindel, A; Tideman, R			HPV transmission - still feeling the way	LANCET			English	Editorial Material							CHILDREN; WARTS		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia.			Mindel, Adrian/0000-0002-8780-9982				FAIRLEY CK, 1995, EPIDEMIOL INFECT, V115, P169, DOI 10.1017/S0950268800058234; FERENCZY A, 1989, OBSTET GYNECOL, V74, P950; Handley J, 1997, PEDIATR DERMATOL, V14, P339, DOI 10.1111/j.1525-1470.1997.tb00976.x; Koutsky LA, 1999, SEXUALLY TRANSMITTED, P347; Matters R, 1998, Commun Dis Intell, V22, P52; ORIEL JD, 1992, GENITOURIN MED, V68, P80; ORIEL JD, 1994, SCARS VENUS HIST VEN, P149; SHAH K V, 1990, P1651; Sonnex C, 1999, SEX TRANSM INFECT, V75, P317, DOI 10.1136/sti.75.5.317; Wen LM, 1999, SEX TRANSM INFECT, V75, P312, DOI 10.1136/sti.75.5.312	10	4	5	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2097	2098		10.1016/S0140-6736(99)00367-0	http://dx.doi.org/10.1016/S0140-6736(99)00367-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609811				2022-12-28	WOS:000084318200005
J	Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR			Transmissible and genetic prion diseases share a common pathway of neurodegeneration	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; WILD-TYPE; SCRAPIE; PROTEIN; ENCEPHALOPATHY; PATHOGENESIS; PATHOLOGY; HAMSTERS; RODENTS; BRAINS	Prion diseases can be infectious, sporadic and genetic(1-4). The infectious forms of these diseases, including bovine spongiform encephalopathy and Creutzfeldt-Jakob disease, are usually characterized by the accumulation in the brain of the transmissible pathogen, an abnormally folded isoform of the prion protein (PrP) termed PrPSc. However, certain inherited PrP mutations appear to cause neurodegeneration in the absence of PrPSc (refs 5-8), working instead by favoured synthesis of (PrP)-Pr-Ctm, a transmembrane form of PrP (ref. 9). The relationship between the neurodegeneration seen in transmissible prion diseases involving PrPSc and that associated with (PrP)-Pr-Ctm has remained unclear. Here we find that the effectiveness of accumulated PrPSc in causing neurodegenerative disease depends upon the predilection of host-encoded PrP to be made in the (PrP)-Pr-Ctm form. Furthermore, the time course of PrPSc accumulation in transmissible prion disease is followed closely by increased generation of (PrP)-Pr-Ctm. Thus, the accumulation of PrPSc appears to modulate in trans the events involved in generating or metabolising (PrP)-Pr-Ctm. Together, these data suggest that the events of (PrP)-Pr-Ctm-mediated neurodegeneration may represent a common step in the pathogenesis of genetic and infectious prion diseases.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X				BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; CHANDLER RL, 1961, LANCET, V1, P1378; CZUB M, 1986, J GEN VIROL, V67, P2005, DOI 10.1099/0022-1317-67-9-2005; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Johnston AR, 1998, NEUROBIOL DIS, V5, P188, DOI 10.1006/nbdi.1998.0194; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PATTISON IH, 1968, RES VET SCI, V9, P408; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Wong K, 1996, NEUROLOGY, V47, P741, DOI 10.1212/WNL.47.3.741	30	235	241	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					822	826		10.1038/45574	http://dx.doi.org/10.1038/45574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617204				2022-12-28	WOS:000084330500068
J	Chavez, FP; Strutton, PG; Friederich, CE; Feely, RA; Feldman, GC; Foley, DC; McPhaden, MJ				Chavez, FP; Strutton, PG; Friederich, CE; Feely, RA; Feldman, GC; Foley, DC; McPhaden, MJ			Biological and chemical response of the equatorial Pacific Ocean to the 1997-98 El Nino	SCIENCE			English	Article							SURFACE PARTIAL-PRESSURE; 40-50 DAY OSCILLATION; SOUTHERN OSCILLATION; WARM POOL; TROPICAL PACIFIC; CARBON-DIOXIDE; SEA; CO2; VARIABILITY; 150-DEGREES-W	During the 1997-98 El Nino, the equatorial Pacific Ocean retained 0.7 x 10(15) grams of carbon that normally would have been Lost to the atmosphere as carbon dioxide. The surface ocean became impoverished in plant nutrients, and chlorophyll concentrations were the Lowest on record. A dramatic recovery occurred in mid-1998, the system became highly productive, analogous to coastal environments, and carbon dioxide flux out of the ocean was again high. The spatial extent of the phytoplankton bloom that followed recovery from El Nino was the Largest ever observed for the equatorial Pacific. These chemical and ecological perturbations were linked to changes in the upwelling of nutrient-enriched waters. The description and explanation of these dynamic changes would not have been possible without an observing system that combines biological, chemical, and physical sensors on moorings with remote sensing of chlorophyll.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; NOAA, Natl Marine Fisheries Serv, Honolulu Lab, Honolulu, HI 96822 USA	Monterey Bay Aquarium Research Institute; National Oceanic Atmospheric Admin (NOAA) - USA; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA	Chavez, FP (corresponding author), Monterey Bay Aquarium Res Inst, 7700 Sandholdt Rd, Moss Landing, CA 95039 USA.	chfr@mbari.org	Strutton, Peter G/C-4466-2011; Feely, Richard A./ABI-5740-2020; McPhaden, Michael J/D-9799-2016	Strutton, Peter G/0000-0002-2395-9471; McPhaden, Michael J/0000-0002-8423-5805				Archer DE, 1996, DEEP-SEA RES PT II, V43, P779, DOI 10.1016/0967-0645(96)00017-3; BARBER RT, 1986, NATURE, V319, P279, DOI 10.1038/319279a0; BARBER RT, 1983, SCIENCE, V222, P1203, DOI 10.1126/science.222.4629.1203; BARNETT TP, 1991, J CLIMATE, V4, P487, DOI 10.1175/1520-0442(1991)004<0487:OEP>2.0.CO;2; Brainerd KE, 1997, J GEOPHYS RES-OCEANS, V102, P10437, DOI 10.1029/96JC03864; Chai F, 1996, DEEP-SEA RES PT II, V43, P1031, DOI 10.1016/0967-0645(96)00029-X; CHAVEZ FP, 1987, DEEP-SEA RES, V34, P1229, DOI 10.1016/0198-0149(87)90073-2; Chavez FP, 1998, GEOPHYS RES LETT, V25, P3543, DOI 10.1029/98GL02729; Chavez FP, 1996, DEEP-SEA RES PT II, V43, P835, DOI 10.1016/0967-0645(96)00028-8; Chavez FP, 1995, DAHL WS ENV, V18, P313; Chavez FP, 1995, DAHL WS ENV, V18, P149; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; COCHLAN WP, 1996, EOS, V76, P177; Cronin MF, 1997, J GEOPHYS RES-OCEANS, V102, P8533, DOI 10.1029/97JC00020; DANDONNEAU Y, 1995, DEEP-SEA RES PT II, V42, P349, DOI 10.1016/0967-0645(95)00017-K; EPPLEY RW, 1992, J GEOPHYS RES-OCEANS, V97, P655, DOI 10.1029/91JC01386; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; FEELY RA, 1987, J GEOPHYS RES-OCEANS, V92, P6545, DOI 10.1029/JC092iC06p06545; Foley DG, 1997, DEEP-SEA RES PT II, V44, P1801, DOI 10.1016/S0967-0645(97)00080-5; Godfrey JS, 1998, J GEOPHYS RES-OCEANS, V103, P14395, DOI 10.1029/97JC03120; Gordon RM, 1997, LIMNOL OCEANOGR, V42, P419, DOI 10.4319/lo.1997.42.3.0419; GOYET C, 1994, MAR CHEM, V45, P257, DOI 10.1016/0304-4203(94)90073-6; HALPERN D, 1988, J PHYS OCEANOGR, V18, P1415; INOUE HY, 1992, TELLUS B, V44, P1, DOI 10.1034/j.1600-0889.1992.00001.x; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; Jones C, 1998, J CLIMATE, V11, P1057, DOI 10.1175/1520-0442(1998)011<1057:TIOTMJ>2.0.CO;2; KEELING CD, 1985, METEORITICS, V20, P437; Kerr RA, 1998, SCIENCE, V280, P522, DOI 10.1126/science.280.5363.522; KESSLER WS, 1995, DEEP-SEA RES PT II, V42, P295, DOI 10.1016/0967-0645(95)00041-N; Kolber ZS, 1998, BBA-BIOENERGETICS, V1367, P88, DOI 10.1016/S0005-2728(98)00135-2; LAU KM, 1986, B AM METEOROL SOC, V67, P533, DOI 10.1175/1520-0477(1986)067<0533:TDOATE>2.0.CO;2; LEFEVRE N, 1994, J GEOPHYS RES-OCEANS, V99, P12639, DOI 10.1029/94JC00293; MADDEN RA, 1971, J ATMOS SCI, V28, P702, DOI 10.1175/1520-0469(1971)028<0702:DOADOI>2.0.CO;2; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; McCarthy JJ, 1996, DEEP-SEA RES PT II, V43, P1065, DOI 10.1016/0967-0645(96)00022-7; MCCLAIN CR, 1998, SEA TECHNOL      SEP; MCPHADEN MJ, 1990, SCIENCE, V250, P1385, DOI 10.1126/science.250.4986.1385; McPhaden MJ, 1999, SCIENCE, V283, P950, DOI 10.1126/science.283.5404.950; Meyers S.D., 1995, EOS T AM GEOPHYS UNI, V76, P533, DOI [10.1029/95EO00326, DOI 10.1029/95EO00326]; PICAUT J, 1995, J GEOPHYS RES-OCEANS, V100, P18393, DOI 10.1029/95JC01358; Picaut J, 1996, SCIENCE, V274, P1486, DOI 10.1126/science.274.5292.1486; SMETHIE WM, 1985, J GEOPHYS RES-OCEANS, V90, P7005, DOI 10.1029/JC090iC04p07005; Takahashi T, 1997, P NATL ACAD SCI USA, V94, P8292, DOI 10.1073/pnas.94.16.8292; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; Toggweiler JR, 1995, DAHL WS ENV, V18, P337; Wanninkhof R, 1996, J GEOPHYS RES-OCEANS, V101, P16333, DOI 10.1029/96JC01348; Weller RA, 1996, J CLIMATE, V9, P1959, DOI 10.1175/1520-0442(1996)009<1959:SMAASF>2.0.CO;2; WINGUTH AME, 1994, GLOBAL BIOGEOCHEM CY, V8, P39, DOI 10.1029/93GB03134; WYRTKI K, 1981, J PHYS OCEANOGR, V11, P1205, DOI 10.1175/1520-0485(1981)011<1205:AEOEUI>2.0.CO;2; YODER JA, 1994, NATURE, V371, P689, DOI 10.1038/371689a0	50	482	503	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2126	2131		10.1126/science.286.5447.2126	http://dx.doi.org/10.1126/science.286.5447.2126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591638				2022-12-28	WOS:000084157300043
J	Guenin, LM				Guenin, LM			Expressing a consensus on candour	NATURE			English	Editorial Material									Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Guenin, LM (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Guenin LM, 1996, ACAD MED, V71, P595, DOI 10.1097/00001888-199606000-00010; Guenin LM, 1996, SCIENCE, V271, P1790; Guenin Louis M, 1996, Sci Eng Ethics, V2, P47, DOI 10.1007/BF02639317; *NAT AC SCI, 1992, RESP SCI; 1995, FED REG         0227, V60, P10588; 1999, FED REG         1014, V64, P55723	6	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					577	578		10.1038/45068	http://dx.doi.org/10.1038/45068			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604459				2022-12-28	WOS:000084189800025
J	Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B				Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B			HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus-1; ritonavir; saquinavir; protease inhibitors; genotype	IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; IN-VIVO; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; ZIDOVUDINE RESISTANCE; COMBINATION THERAPY; CONTROLLED TRIAL; PLUS SAQUINAVIR; CELL COUNTS	Background: Tests for resistance to HIV drugs are available for clinical use; however, their predictive Value has not been fully assessed. Objectives: To determine HIV-1 genotypic predictors of a virologic response to saquinavir-ritonavir therapy in patients in whom at least one previous protease inhibitor-containing regimen had failed and to compare the predictive value of baseline genotype with that of standard clinical evaluation. Design: Retrospective clinical cohort study. Setting: University-based HIV clinic. Patients: 54 H.IV-1-infected adults treated with saquinavir-ritonavir who had experienced virologic failure while receiving a protease inhibitor-containing regimen for at least 3 months. Measurements: HIV-1 reverse transcriptase and protease gene sequences, CD4 cell counts, clinical characteristics, detailed antiretroviral treatment history, and plasma HIV-1 RNA levels at baseline and at three follow-up time points (median, 4, 12, and 26 weeks). Virologic failure was defined as a plasma HIV RNA level greater than 1000 copies/mL. Results: In 22 patients (41%), a plasma HIV-1 RNA level less than 500 copies/mL was achieved by week 12; in 15 patients (28%), this response was maintained through week 26. Clinical characteristics predicting a poorer response included a diagnosis of AIDS, Tower CD4 cell count, and higher plasma HIV RNA level (P < 0.03). Number of previous nucleoside reverse transcriptase inhibitors, previous protease inhibitor therapy, and duration of previous protease inhibitor therapy were predictors of poorer response (P < 0.01). Multivariate regression models revealed that protease mutations present at the initiation of saquinavir-ritonavir therapy were the strongest predictors of virologic response. A model of clinical features explained up to 45% of the variation in virologic outcomes by week 12, whereas the explained variance was 71% when genotypic predictors were included. Conclusions: In patients in whom protease inhibitor-containing antiretroviral therapy fails, HIV-1 genotype is predictive of virologic response to subsequent therapy. This predictive capacity adds to that of standard clinical evaluation.	Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University	Zolopa, AR (corresponding author), Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Grant Bldg,Room S-156, Stanford, CA 94305 USA.	azolopa@stanford.edu	Merigan, Thomas/AGQ-7464-2022	Montoya, Jose G/0000-0002-3378-8071; katzenstein, david/0000-0002-8593-4560	NIAID NIH HHS [R01 AI046148, R01 AI046148-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAXTER JD, 1999, P 6 C RETR OPP INF C; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHATTERJEE S, 1988, SENSITIVITY REGRESSI, P117; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1997, 1 INT WORKSH HIV RES, P31; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1997, LANCET, V349, P1489, DOI 10.1016/S0140-6736(05)62092-2; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; EASTMAN PS, 1995, J CLIN MICROBIOL, V33, P2777, DOI 10.1128/JCM.33.10.2777-2780.1995; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIGAN PR, IN PRESS AID; Hazuda D, 1997, NAT MED, V3, P836, DOI 10.1038/nm0897-836; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LANIER ER, 1999, ANTIVIR THER S, V4, P56; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; *LOS AL NAT LAB, 1997, HUM RETR AIDS COMP A; MAYERS DL, 1997, 1 INT WORKSH HIV RES, P52; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; PATRICK AK, 1998, 2 INT WORKSH HIV DRU, P39; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; SHAFER RW, 1995, J INFECT DIS, V172, P70, DOI 10.1093/infdis/172.1.70; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Vella S, 1998, AIDS Clin Care, V10, P17; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; 1998, ANN INT MED, V128, P1079	56	174	179	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					813	+		10.7326/0003-4819-131-11-199912070-00003	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610625	Green Accepted			2022-12-28	WOS:000084053200002
J	Showalter, E; Griffin, A				Showalter, E; Griffin, A			Commentary: all women should have a choice	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Princeton Univ, Dept English, Princeton, NJ 08544 USA	Princeton University	Showalter, E (corresponding author), Princeton Univ, Dept English, Princeton, NJ 08544 USA.	112075.445@compuserve.com						BOSELEY S, 1999, GUARDIAN        0607, P7; de Costa C, 1998, LANCET, V351, P1202, DOI 10.1016/S0140-6736(97)12035-9	2	15	15	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1401	1401						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10610164				2022-12-28	WOS:000083995200024
J	Kessel, A; Watts, C; Weiss, HA				Kessel, A; Watts, C; Weiss, HA			Bad blood? Survey of public's views on unlinked anonymous testing of blood for HIV and other diseases	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Epidemiol Unit, London WC1E 7HT, England; Barking & Havering Hlth Author, Directorate Publ Hlth, Barking IG11 8EY, England; Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kessel, A (corresponding author), Univ London London Sch Hyg & Trop Med, Epidemiol Unit, Keppel St, London WC1E 7HT, England.		weiss, helen/ABC-7823-2021	weiss, helen/0000-0003-3547-7936				Berridge V., 1996, AIDS UK MAKING POLIC; *DEP HLTH HUM SERV, 1997, CHILD MALTR 1995 REP, P2; GILL ON, 1989, BRIT MED J, V299, P1297; Kessel Anthony S, 1997, Sci Eng Ethics, V3, P297, DOI 10.1007/s11948-997-0036-0; KOPELMAN LM, 1994, J MED PHILOS, V19, P525, DOI 10.1093/jmp/19.6.525	5	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					90	91		10.1136/bmj.320.7227.90	http://dx.doi.org/10.1136/bmj.320.7227.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625262	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000084746600017
J	Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH				Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH			Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission	CELL			English	Article							AMINO-ACID TRANSPORTER; VESICULAR GABA TRANSPORTER; GLUTAMINE TRANSPORT; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; CEREBRAL-CORTEX; GLIAL-CELLS; RAT-LIVER; ARABIDOPSIS; IMMUNOCYTOCHEMISTRY	The amino acid glutamine has a central role in nitrogen metabolism. Although the molecular mechanisms responsible for its transport across cell membranes remain poorly understood, classical amino acid transport system N appears particularly important. Using intracellular pH measurements, we have now identified an orphan protein related to a vesicular neurotransmitter transporter as system N. Functional analysis shows that this protein (SN1) involves H+ exchange as well as Na+ cotransport and, under physiological conditions, mediates glutamine efflux as well as uptake. Together with the pattern of SN1 expression, these unusual properties suggest novel physiological roles for system N in nitrogen metabolism and synaptic transmission.	Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Cell Biol, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Biomed Sci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oslo	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA.		Krrr, Daa/ABG-2688-2020	Krrr, Daa/0000-0003-4468-3029; Storm-Mathisen, Jon/0000-0002-2930-3262				ALBRECHT J, 1989, NEUROPHARMACOLOGY, V28, P885, DOI 10.1016/0028-3908(89)90183-4; Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Bender D.A., 1975, AMINO ACID METABOLIS; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; CONTI F, 1994, J HISTOCHEM CYTOCHEM, V42, P717, DOI 10.1177/42.6.7910617; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Fishman RA., 1992, CEREBROSPINAL FLUID; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; Gundersen V, 1996, EUR J NEUROSCI, V8, P758, DOI 10.1111/j.1460-9568.1996.tb01261.x; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HUNDAL HS, 1987, J PHYSIOL-LONDON, V393, P283, DOI 10.1113/jphysiol.1987.sp016824; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KANNER BI, 1994, J EXP BIOL, V196, P237; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pouyssegur J, 1987, Methods Enzymol, V151, P131, DOI 10.1016/S0076-6879(87)51014-X; RAMAHAROBANDRO N, 1982, BRAIN RES, V244, P113, DOI 10.1016/0006-8993(82)90909-X; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Rose CR, 1998, J NEUROSCI, V18, P3554; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1984, J NEUROCHEM, V43, P1438, DOI 10.1111/j.1471-4159.1984.tb05406.x; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORMMATHISEN J, 1986, MED BIOL, V64, P127; Tamarappoo BK, 1997, J NEUROCHEM, V68, P954; TATE SS, 1973, ENZYMES GLUTAMINE ME, P77; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Xiang JM, 1998, BRAIN RES, V783, P37, DOI 10.1016/S0006-8993(97)01194-3; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	52	260	266	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					769	780		10.1016/S0092-8674(00)81674-8	http://dx.doi.org/10.1016/S0092-8674(00)81674-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619430	Bronze			2022-12-28	WOS:000084488200010
J	Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G				Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G			Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis	CELL			English	Article							NMR STRUCTURE; CELL-DEATH; PROTEIN; ACTIVATION; MITOCHONDRIA; MUTAGENESIS; RESONANCE; INHIBITOR; CASPASE-3; DYNAMICS	Apoptotic DNA fragmentation and chromatin condensation are mediated by the caspase-activated DFF40/ CAD nuclease, which is chaperoned and inhibited by DFF45/ICAD. CIDE proteins share a homologous regulatory CIDE-N domain with DFF40/CAD and DFF45/ ICAD. Here we report the solution structure of CIDE-N of human CIDE-B. We show that the CIDE-N of CIDE-B interacts with CIDE-N domains of both DFF40 and DFF45. The binding epitopes are similar and map to a highly charged bipolar surface region of CIDE-B. Furthermore, we demonstrate that the CIDE-N of CIDE-B regulates enzymatic activity of the DFF40/ DFF45 complex in vitro. Based on these results and mutagenesis data, we propose a model for the CIDE-N/ CIDE-N complex and discuss the role of this novel bipolar interaction in mediating downstream events of apoptosis.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Inst Mol & Cell Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Harvard University; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu	Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Zhou, Pei/O-6704-2019	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; Zhou, Pei/0000-0002-7823-3416	NIGMS NIH HHS [GM 38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BRUNGER AT, 1994, XPLOR MANUAL 3 851 S; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	95	97	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					747	755		10.1016/S0092-8674(00)81672-4	http://dx.doi.org/10.1016/S0092-8674(00)81672-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619428	Bronze			2022-12-28	WOS:000084488200008
J	Nakielny, S; Dreyfuss, G				Nakielny, S; Dreyfuss, G			Transport of proteins and RNAs in and out of the nucleus	CELL			English	Review							PORE-TARGETING COMPLEX; BINDING-PROTEIN; EXPORT PATHWAYS; POLY(A)(+) RNA; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; SUMO-1 MODIFICATION; IMPORT RECEPTOR; HNRNP PROTEINS; RAN		Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; Bear J, 1999, MOL CELL BIOL, V19, P6306; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Daneholt B, 1999, CURR BIOL, V9, pR412, DOI 10.1016/S0960-9822(99)80256-5; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Feldherr C, 1998, J CELL SCI, V111, P1889; FELDHERR CM, 1994, INT REV CYTOL, V151, P183, DOI 10.1016/S0074-7696(08)62633-9; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1998, RNA, V4, P351; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Jullien D, 1999, EMBO J, V18, P4348, DOI 10.1093/emboj/18.15.4348; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Keminer O, 1999, P NATL ACAD SCI USA, V96, P11842, DOI 10.1073/pnas.96.21.11842; Kiseleva E, 1998, J CELL SCI, V111, P223; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Macara LG, 1999, CURR BIOL, V9, pR436, DOI 10.1016/S0960-9822(99)80275-9; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mattaj IW, 1999, NATURE, V399, P208, DOI 10.1038/20322; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MICHAEL WM, 1995, CELL, V83, P415; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ohno M, 1999, CURR BIOL, V9, pR66, DOI 10.1016/S0960-9822(99)80013-X; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Sun X, 1998, J CELL BIOL, V142, P1181, DOI 10.1083/jcb.142.5.1181; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	118	638	648	3	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					677	690		10.1016/S0092-8674(00)81666-9	http://dx.doi.org/10.1016/S0092-8674(00)81666-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619422	hybrid			2022-12-28	WOS:000084488200002
J	Espinel, CH				Espinel, CH			Michelangelo's gout in a fresco by Raphael	LANCET			English	Editorial Material									Georgetown Univ, Blood Pressure Ctr, Washington, DC 20057 USA; Ctr Clin Bioeth, Dept Med, Washington, DC USA	Georgetown University	Espinel, CH (corresponding author), 1715 N George Mason Dr,Suite 401, Arlington, VA 22205 USA.							AESCHYLUS, 1989, TRILOGY ORESTEIA; COPERMAN WSC, 1964, SHORT HIST GOUT; De Vecchi P., 1994, SISTINE CHAPEL GLORI; DELACROIX H, 1987, HIGH RENAISSANCE GAR, V2, P645; ESPINEL CH, 1994, LANCET, V344, P1750, DOI 10.1016/S0140-6736(94)92891-6; Espinel CH, 1995, LANCET, V346, P1684, DOI 10.1016/S0140-6736(95)92846-4; Espinel CH, 1998, LANCET, V352, P2007, DOI 10.1016/S0140-6736(98)10102-2; ESPINEL CH, 1993, CLIN LAB MED, V13, P89, DOI 10.1016/S0272-2712(18)30462-1; HIPPOCRATES, 1886, GENUINE WORKS HIPPOC, V2; HIPPOCRATES, 1886, GENUINE WORKS HIPPOC, V1; Jones R, 1983, RAPHAEL, P1; KELLEY WN, 1998, TXB RHEUMATOLOGY, V2, P1313; KOKKO J, 1996, CECILS TXB MED, P511; LUCKI E, 1965, HIST RENAISSANCE 135; PLATO, 1985, COLLECTED DIALOGUES; RODNAN GP, ARTHRITIS RHEUM, V4, P27; SCMITT CB, 1988, CAMBRIDGE HIST RENAI; TUSIANAI J, 1960, COMPLETE POEMS MICHE; VASARI G, 1986, GREAT MASTERS, P127; 1963, LETT MICHELANGELO, V1	20	14	15	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2149	2151		10.1016/S0140-6736(99)09070-4	http://dx.doi.org/10.1016/S0140-6736(99)09070-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609832	hybrid			2022-12-28	WOS:000084318200043
J	Grassi, W; Farina, A; Cervini, C				Grassi, W; Farina, A; Cervini, C			The foot of Philoctetes	LANCET			English	Editorial Material									Univ Ancona, Dept Rheumatol, I-60035 Jesi, AN, Italy	Marche Polytechnic University	Grassi, W (corresponding author), Univ Ancona, Dept Rheumatol, Via Colli 52, I-60035 Jesi, AN, Italy.							SOPHOCLES, 1953, ELECT OTHER PLAYS; STEFANATO C, 1989, J ROY COLL PHYS LOND, V23, P176	2	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2156	2157		10.1016/S0140-6736(99)06567-8	http://dx.doi.org/10.1016/S0140-6736(99)06567-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609835				2022-12-28	WOS:000084318200046
J	Schott, GD				Schott, GD			Mirror writing: Allen's self observations, Lewis Carroll's "looking-glass" letters, and Leonardo da Vinci's maps	LANCET			English	Editorial Material									UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Schott, GD (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.							Allen F. J, 1896, BRAIN, V19, P385, DOI [10.1093/brain/19.2-3.385, DOI 10.1093/BRAIN/19.2-3.385]; BUXBAUM LJ, 1993, NEUROPSYCHOLOGIA, V31, P1417, DOI 10.1016/0028-3932(93)90108-C; CHAN JL, 1988, NEUROLOGY, V38, P59, DOI 10.1212/WNL.38.1.59; CHIA LG, 1987, J NEUROL NEUROSUR PS, V50, P786, DOI 10.1136/jnnp.50.6.786; CLARK K, 1968, DRAWINGS L DAVINCI C, V1, P4; COHEN MN, 1979, LETT L CARROLL, V2; Cohen Morton N, 1837, LETT L CARROLL, V1; Critchley M., 1928, MIRROR WRITING; Fuller J. K., 1916, U CALIFORNIA PUBLICA, V2, P199; HEILMAN KM, 1980, J NEUROL NEUROSUR PS, V43, P774, DOI 10.1136/jnnp.43.9.774; Orton ST, 1928, J AMER MED ASSOC, V90, P1095, DOI 10.1001/jama.1928.02690410007003; PARADOWSKI W, 1971, PERCEPT MOTOR SKILL, V32, P617, DOI 10.2466/pms.1971.32.2.617; RODRIGUEZ R, 1991, NEUROPSYCHOLOGIA, V29, P1191, DOI 10.1016/0028-3932(91)90033-5; Schott G D, 1979, J Neurol Sci, V42, P321, DOI 10.1016/0022-510X(79)90165-5; SCHOTT GD, 1980, J NEUROL NEUROSUR PS, V43, P768, DOI 10.1136/jnnp.43.9.768; SMETACEK V, 1992, NATURE, V355, P118, DOI 10.1038/355118b0; STREIFLER M, 1976, CORTEX, V12, P356, DOI 10.1016/S0010-9452(76)80039-1; TASHIRO K, 1987, J NEUROL NEUROSUR PS, V50, P1572, DOI 10.1136/jnnp.50.12.1572; WADE JB, 1991, J CLIN EXP NEUROPSYC, V13, P299, DOI 10.1080/01688639108401045; Yang MJ, 1997, NEUROPSYCHOLOGIA, V35, P1491, DOI 10.1016/S0028-3932(97)00071-7	20	18	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2158	2161		10.1016/S0140-6736(99)07016-6	http://dx.doi.org/10.1016/S0140-6736(99)07016-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	266UG	10609837				2022-12-28	WOS:000084318200048
J	Golden, RL				Golden, RL			William Osler at 150 - An overview of a life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Biographical-Item								Sir William Osler is one of the most admired and honored physicians in the history of medicine. He influenced the development of medicine in Canada, the United States, and Great Britain, where he held professorships at McGill University, the University of Pennsylvania, Johns Hopkins University, and Oxford University. Through his textbook, The Principles and Practice of Medicine, and other clinical and philosophical writings, he exercised a truly global influence. In this sesquicentennial of his birth, William Osler continues to serve as a model of excellence for the medical profession. This examination of the reasons for his enduring impact reveals a legacy of clinical, scientific, literary, educational, and intraprofessional accomplishments linked to a remarkable personality, and bound together by an extraordinary humanism.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Golden, RL (corresponding author), 56 Laurel Hill Rd, Centerport, NY 11721 USA.							Barondess J A, 1975, Trans Am Clin Climatol Assoc, V86, P59; BEAN RB, 1961, W OSLER APHORISMS BE; BEAN WB, 1966, CAN MED ASSOC J, V95, P1031; Bensley E H, 1976, Bull Hist Med, V50, P596; Bett WR, 1951, OSLER MAN LEGEND; BROWNE T, 1967, PROSE T BROWN, V282; CHRISTIAN HA, 1949, ARCH INTERN MED, V84, P77, DOI 10.1001/archinte.1949.00230010087016; CUSHING H, 1925, LIFE W OSLER, P2; CUSHING H, 1925, LIFE W OSLER, V1; DAVIS EY, 1999, WORKS EGERTON YORRIC, P93; DELAVAN DB, 1926, INT ASSOC MED MUS, V9, P202; DEWEY N, 1969, J AMER MED ASSOC, V210, P2245, DOI 10.1001/jama.210.12.2245; FINNEY JTM, 1926, INT ASSOC MED MUS B, V9, P273; GARRISON FH, 1929, INTRODUCTION HIST ME, P631; Garrison FH, 1926, INT ASSOC MED MUS B, V9, P29; Golden R.L., 1988, W OSLER ANNOTATED BI; GOLDEN RL, 1992, ANN INTERN MED, V116, P255, DOI 10.7326/0003-4819-116-3-255; Gwyn N B, 1920, Can Med Assoc J, V10, P24; HOWARD RP, 1983, CHIEF W OSLER; HURD HM, 1926, INT ASSOC MED B, V9, P262; HUTCHISON R, 1949, Q J MED, V18, P275; Kimbrough R C 3rd, 1995, J S C Med Assoc, V91, P350; KNIGHT JA, 1983, W OSLERS CALL MED JO; LEIDY J, 1926, INT ASSOC MED MUS B, V9, P218; LUDMERER KM, 1985, DEV AM MED ED, P173; Nation E F, 1973, Urology, V2, P468, DOI 10.1016/0090-4295(73)90031-9; Osboume M, 1926, INT ASS MED MUSEUMS, V9, P171; PENFIELD W, 1949, ARCH INTERN MED, V84, P104, DOI 10.1001/archinte.1949.00230010114020; Penfield W, 1926, INT ASSOC MED MUS B, V9, P385; Reid Edith Gittings, 1931, GREAT PHYSICIAN SHOR; ROLAND CG, 1984, PERSPECT BIOL MED, V27, P299; SINGER C, 1949, BRIT MED J, V2, P46; STRAUSS MB, 1968, FAMILIAR MED QUOTATI, P406; THAYER WS, 1926, INT ASSOS MED MUS B, V9, P286; Thayer WS, 1931, OSLER OTHER PAPERS, P1; Welch William H., 1914, J HOPKINS HOSP B, V25, P363	36	25	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2252	2258		10.1001/jama.282.23.2252	http://dx.doi.org/10.1001/jama.282.23.2252			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605978				2022-12-28	WOS:000084138600034
J	Koenig, RE				Koenig, RE			AIDS in paradise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		GOMEZ E, 1996, ESTIMACIONES PROYECC	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2195	2196		10.1001/jama.282.23.2195	http://dx.doi.org/10.1001/jama.282.23.2195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605958				2022-12-28	WOS:000084138600001
J	Senzaki, K; Ogawa, M; Yagi, T				Senzaki, K; Ogawa, M; Yagi, T			Proteins of the CNR family are multiple receptors for reelin	CELL			English	Article							DEVELOPING CEREBELLAR CORTEX; CAJAL-RETZIUS CELLS; HIPPOCAMPAL DEVELOPMENT; EXPRESSION; MOUSE; ORGANIZATION; MIGRATION; NEURONS; BRAIN; MICE	Layering and positioning of neurons require Reelin-and Src family-associated mammalian Disabled (mDab1). Cadherin-related neuronal receptor (CNR) genes are expressed in neurons of the cortical layer, but not in Cajal-Retzius cells expressing Reelin. This leads us to hypothesize that CNRs bound to Fyn of the Src family are receptors for Reelin. Herein we confirm the association and colocalization of CNR proteins with Reelin. This binding is blocked by CR-50 antibody against Reelin, as well as by monoclonal antibodies produced against CNRs. Both disturb the signaling pathway from Reelin to mDab1 and the positioning of cortical neurons in vitro. These results strongly suggest that the CNR family proteins are multiple Reelin receptors. In addition, differential conservation of the Reelin-binding domain among terrestrial vertebrates may be pertinent to the diversity or complexity of brains.	Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan; RIKEN, Lab Cell Culture Dev, Brain Sci Inst, Wako, Saitama 35101, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); RIKEN	Yagi, T (corresponding author), Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan.	yagi@nips.ac.jp						Alcantara S, 1998, J NEUROSCI, V18, P7779; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DELONG GR, 1970, DEV BIOL, V22, P563, DOI 10.1016/0012-1606(70)90169-7; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Komuro H, 1998, J NEUROSCI, V18, P1478; Marin-Padilla M, 1998, TRENDS NEUROSCI, V21, P64, DOI 10.1016/S0166-2236(97)01164-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; Prince VE, 1998, DEVELOPMENT, V125, P407; Rakic P, 1996, P NATL ACAD SCI USA, V93, P9218, DOI 10.1073/pnas.93.17.9218; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RIVAS RJ, 1995, J NEUROSCI, V15, P981; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; YAGI T, 1993, ONCOGENE, V8, P3343; Yagi T, 1999, BIOCHEM PHARMACOL, V57, P845; [No title captured]	42	242	245	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					635	647		10.1016/S0092-8674(00)81552-4	http://dx.doi.org/10.1016/S0092-8674(00)81552-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612399	Bronze			2022-12-28	WOS:000084278700010
J	Brown, JB; Boles, M; Mullooly, JP; Levinson, W				Brown, JB; Boles, M; Mullooly, JP; Levinson, W			Effect of clinician communication skills training on patient satisfaction - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE PHYSICIANS; GENERAL-PRACTICE; OUTCOMES; INTERVENTION; PERFORMANCE; INFORMATION; PROVIDER; BEHAVIOR	Background: Although substantial resources have been invested in communication skills training for clinicians, little research has been done to test the actual effect of such training on patient satisfaction. Objective: To determine whether clinicians' exposure to a widely used communication skills training program increased patient satisfaction with ambulatory medical care visits. Design: Randomized, controlled trial. Setting: A not-for-profit group-model health maintenance organization in Portland, Oregon. Participants: 69 primary care physicians, surgeons, medical subspecialists, physician assistants, and nurse practitioners from the Permanente Medical Group of the Northwest. Intervention: "Thriving in a Busy Practice: Physician-Patient Communication," a communication skills training program consisting of two 4-hour interactive workshops. Between workshops, participants audiotaped office visits and studied the audiotapes. Measurements: Change in mean overall score on the Art of Medicine survey (HealthCare Research, Inc., Denver, Colorado), which measures patients' satisfaction with clinicians' communication behaviors, and global visit satisfaction. Results: Although participating clinicians' self-reported ratings of their communication skills moderately improved, communication skills training did not improve patient satisfaction scores. The mean score on the Art of Medicine survey improved more in the control group (0.072 [95% Cl, -0.010 to 0.154]) than in the intervention group (0.030 [Cl, -0.060 to 0.120]). Conclusions: "Thriving in a Busy Practice: Physician-Patient Communication," a typical continuing medical education program geared toward developing clinicians' communication skills, is not effective in improving general patient satisfaction. To improve global visit satisfaction, communication skills training programs may need to be longer and more intensive, teach a broader range of skills, and provide ongoing performance feedback.	Ctr Hlth Res, Portland, OR 97227 USA; Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Brown, JB (corresponding author), Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.	jonathan.brown@kp.org						Aharony L, 1993, Med Care Rev, V50, P49, DOI 10.1177/002570879305000104; BENSING JM, 1985, SOC SCI MED, V20, P737, DOI 10.1016/0277-9536(85)90064-4; BRODY DS, 1980, J CHRON DIS, V33, P57, DOI 10.1016/0021-9681(80)90086-7; CARTER WB, 1982, MED CARE, V20, P550, DOI 10.1097/00005650-198206000-00002; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; CRECO PJ, 1993, NEW ENGL J MED, V329, P1271; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Doering E R, 1983, QRB Qual Rev Bull, V9, P291; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; FAULKNER A, 1995, MED EDUC, V29, P303, DOI 10.1111/j.1365-2923.1995.tb02853.x; FREDERIKSON LG, 1995, PATIENT EDUC COUNS, V25, P237, DOI 10.1016/0738-3991(95)00801-6; Freeborn DK, 1997, J GEN INTERN MED, V12, P619, DOI 10.1046/j.1525-1497.1997.07122.x; GASK L, 1988, MED EDUC, V22, P132, DOI 10.1111/j.1365-2923.1988.tb00423.x; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HALL JA, 1994, MED CARE, V32, P1216, DOI 10.1097/00005650-199412000-00005; Joos SK, 1996, J GEN INTERN MED, V11, P147, DOI 10.1007/BF02600266; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEVINSON W, 1993, MED CARE, V31, P285, DOI 10.1097/00005650-199304000-00001; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LEWIS CC, 1991, PEDIATRICS, V88, P351; Maguire P, 1996, EUR J CANCER, V32A, P1486, DOI 10.1016/0959-8049(96)00059-7; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; MAIMAN LA, 1988, AM J DIS CHILD, V142, P773, DOI 10.1001/archpedi.1988.02150070087033; MISHLER EG, 1989, J GEN INTERN MED, V4, P325, DOI 10.1007/BF02597407; Newcomer R, 1996, INQUIRY-J HEALTH CAR, V33, P144; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; ROWLANDMORIN PA, 1990, EVAL HEALTH PROF, V13, P168, DOI 10.1177/016327879001300202; RUBIN HR, 1990, MED CARE, V28, pS3, DOI 10.1097/00005650-199009001-00002; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; Stein T S, 1999, Eff Clin Pract, V2, P63; VERBY J, 1980, PATIENT COUNS HEALTH, V2, P68, DOI 10.1016/S0738-3991(80)80004-8; VERBY JE, 1979, BRIT MED J, V1, P1686, DOI 10.1136/bmj.1.6179.1686; Verve, 2021, PAT JOURN FIN UNPUB; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	37	219	223	1	35	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					822	+		10.7326/0003-4819-131-11-199912070-00004	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262ET	10610626				2022-12-28	WOS:000084053200003
